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	Introduction 
Coronary artery disease (CAD) and Percutaneous coronary intervention (PCI) 
CAD and relative morbidity are the leading cause of mortality in western countries. Since its birth in 1977, PCI 
has developed a central role to treat stable and unstable CAD and improve its prognosis. Today PCI is a 
milestone for CAD treatment and, accordingly, the number of procedures across Europe, both for stable and 
unstable CAD, increasingly growth in the last decade1-3. The implementation of refined treatment strategies, 
better devices and more efficacious pharmacological treatment to reduce the occurrence of ischemic 
complications early and late after PCI, reduced the burden of cardiovascular mortality. The inhibition of 
coagulation and platelet activity is essential to maintain the immediate results of PCI and prevent complications 
and recurrence of ischemic/thrombotic events; therefore, both anticoagulant and antiplatelet agents represent the 
mainstay of pharmacotherapy in patient undergoing PCI1-3. Even after PCI, it is crucial to prevent ischemic 
complications, and dual antiplatelet therapy (DAPT), constituted by the association of aspirin and an inhibitor of 
the platelet receptor P2Y12, became a pivotal pharmacological treatment after PCI, preventing both stent and 
non-stent related ischemic events4. On the other hand, the strengthening of antithrombotic therapy and the 
development of more potent drugs warranted special interest to the balance between the desirable 
antithrombotic effects and the increased risk of bleeding, a balance which has become a matter of great 
discussion and a topic of relevant scientific research5,6. Indeed, while these therapies prevent from ischemic 
events, they carry a risk of major and clinically relevant bleeding complications, which have been clearly found 
to affect morbidity and mortality at least as much as ischemic recurrences5,6. 
For years unfractionated heparin (UFH) has been the unique anticoagulant to be used before and during PCI, but 
some limitations, such as the need for ACT monitoring (related to its variable dose-response relationship with 
nonlinear pharmacokinetics and poor predictable effects), a narrow therapeutic window, platelet activation, and 
the potential for inducing thrombocytopenia (HIT) and HIT-thrombosis syndrome. For these reasons, during the 
last decades, studies have been conducted to test new anticoagulants with more pharmacologic and clinical 
advantages. Among them, the most studied is bivalirudin, a 20-amino acid synthetic polypeptide with a short 
half-life, which binds directly to circulating and fibrin-bound thrombin, blocking its enzymatic activity. Many 
studies have been conducted so far, and there is still great interest into such a comparison due to the potential to 
reduce bleeding events compared with UFH, despite some concerns have been raised in terms of stent 
thrombosis risks7-12. 
DAPT type and duration has been the focus of several trials in the last twenty years4. Evidence from multiple 
trials demonstrated that the beneficial anti-ischemic effect of P2Y12-inhibitors implemented on top of aspirin is 
linearly related to the pharmacological potency and the overall duration of treatment13-16. Nevertheless, the 
implementation of more potent or prolonged treatments raised the issue of a proportional increase of bleeding 
complications13-17. Bleedings are far from being innocent bystanders, and such complications both during and 
after PCI have been shown to significantly impact mortality in a similar or even greater magnitude than 
coronary ischemic events5,6.  
Important lines of research during last years have been focused to reduce ischemic and bleeding events. The use 
of the radial approach for coronary angiography and /or PCI, as compared to the more traumatic femoral 
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	approach, has demonstrated a significant reduction of peri-procedural bleeding1,18. This holds particularly true in 
patients with ACS, when more potent antithrombotic drugs are used, increasing bleeding liability1,18.  
Stent type selection, and subsequent antiplatelet treatment, has also been considered an important factor for the 
ischemia/bleeding balance after PCI. Since the introduction of first-generation drug-eluting stents (DES), which 
were developed to reduce in-stent restenosis, concern was raised about their higher thrombogenicity, especially 
for late or very late events (>12 months after intervention)19. As a reaction to this preliminary data, the 
community and international guidelines took position for prolonging DAPT in patients treated with DES to at 
least 12 months. This practice, initially advocated for first generation DES, has been automatically translated 
also to second-generation DES despite their technical improvements (i.e. reduced strut-thickness, more 
biocompatible or resorbable drug carriers). Hence, since longer DAPT was recommended after DES 
implantation, it was common practice to use bare-metal stents (BMS) in patients deemed at high bleeding risk, 
despite no direct comparison between these two strategies was available. However, during last few years, 
important evidence has supported the use of DES over BMS even in patients at high bleeding risk20-23, and stent 
type is not recommended to be a driver of the decision-making on the optimal DAPT duration4. 
 
Aortic stenosis (AS) and Transcatheter aortic valve implantation (TAVI) 
AS has become the most frequent type of VHD in Europe and North America24. It primarily presents as calcific 
AS in adults of advanced age (2–7% of the population >65 years). The second most frequent aetiology, which 
dominates in the younger age group, is congenital, whereas rheumatic AS has become rare. Calcific AS is a 
chronic, progressive disease24. During a long latent period, patients remain asymptomatic. The duration of the 
asymptomatic phase varies widely between individuals. Sudden cardiac death is a frequent cause of death in 
symptomatic patients but appears to be rare in the truly asymptomatic (<1% per year), even in very severe AS24. 
As soon as symptoms occur, the prognosis of severe AS is dismal, with survival rates of only 15–50% at 5 
years. Early therapy should be strongly recommended in all symptomatic patients with severe aortic stenosis 
because of their dismal spontaneous prognosis24. The only exceptions are patients with severe comorbidities 
indicating a survival of <1 year and patients in whom severe comorbidities or their general condition at an 
advanced age make it unlikely that the intervention will improve quality of life or survival. For more than 50 
years, surgical aortic valve replacement (SAVR) has been the standard of care for patients with severe 
symptomatic AS, improving outcomes and prolonging the lives of these patients. The first human implantation 
of a percutaneous implantable prosthetic heart valve composed of 3 bovine pericardial leaflets mounted within a 
balloon-expandable stent was performed in Rouen on 16 April 2002 in a 57-year-old desperately ill man in 
cardiogenic shock, with critical aortic stenosis, subacute leg ischemia deemed inoperable due to multiple 
comorbidities (valve replacement had been declined for this patient, and balloon valvuloplasty had been 
performed with nonsustained results) 25. Since then, TAVI has dramatically evolved, devices and procedural 
techniques have rapidly improved and results of randomized clinical trials have revolutionized the current 
treatment of severe aortic stenosis leading today to more than 300,000 procedures performed worldwide in more 
than 1,000 centres and 65 countries25,26. Fifteen years after the first-in-man case, we can consider TAVI, with its 
explosive potential, as one of the major medical breakthroughs of the past decade in cardiology25,26. A large 
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	body of studies have addressed the issue of the optimization of risk stratification and clinical outcomes in 
patients undergoing TAVI, and explored the comparison of TAVI with SAVR25,26. Technological improvements 
and favourable clinical outcomes allowed to clearly establish the role of TAVI as the recommended strategy 
compared with medical therapy for inoperable patients, and alternative to surgery for high-risk patients, 
reaching more recently also the appropriate scientific evidence to recommend this procedure in patients at 
intermediate risk24. Furthermore, trials among low-risk patients are ongoing and evidence on feasibility and 
safety of TAVI in other clinical settings (treatment of patients with bicuspid aortic valve, pure native aortic 
regurgitation, degenerated surgical bioprosthetic valves or those with symptomatic moderate aortic stenosis or 
asymptomatic severe AS) is being accumulated25,26. However, ischemic and bleeding events soon after or at 
long-term after TAVI remain high, advocating dedicated investigations on optimal antithrombotic therapy even 
in this clinical setting 25-27. For the post-procedural antithrombotic therapy, based on the increased thrombotic 
risks related to TAVI valve structure, DAPT with aspirin (indefinitely) and clopidogrel (1 to 6 months)—in the 
absence of a specific indication for anticoagulation—has been a widely accepted empirical treatment, which was 
incorporated into practice guidelines24-28. However, the limited evidence available has not clearly supported 
benefits of DAPT over aspirin alone, rather showed potential risks in terms of increased risk of bleeding 
complications28. Additionally, there are arguments supporting the preferential use of oral anticoagulation (OAC) 
instead of antiplatelet agents, including the uncertainties about the exact mechanisms causing thrombotic events 
after TAVI, the high rates of pre-existing and new-onset atrial fibrillation and the evidence that leaflet 
thrombosis, even subclinical, is not rare and might require OAC. However, while preventing such thrombotic 
complications, OAC therapy also increases the bleeding risks, so, again, as for patients undergoing PCI, 
clinicians have to face with the difficult decision-making to select the optimal approach to balance ischemia and 
bleeding in order to offer the most appropriate prevention of thrombotic events while minimizing bleeding 
complications. 
 
Like Bellerophon searching for and fighting with the Chimera, clinicians should be aware of the trade-off of 
both bleeding and ischemia and their impact on patients’ health, thus, should search for the optimal therapy 
which has not to face with a single animal (ischemia or bleeding), rather must account and balance for the 
effects on both these entities. 
 
In light of the evidence produced by several observational and randomized clinical trials in patients undergoing 
PCI or TAVI, growing importance has been given to the selection of the right patient population for specific 
treatment strategies (including different types and duration of antithrombotic drugs, vascular approaches, stent 
types, type of revascularization or aortic valve replacement used, etc.). Hence, the individualization of the 
treatment type and duration based on the single-patient risk profile appears a promising approach in order to 
deliver the proper treatment to the right recipient, in line with the principles of precision medicine. 
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Bivalirudin versus heparin with 
or without glycoprotein IIb/IIIa 
inhibitors in patients with STEMI 
undergoing primary PCI: An 
updated meta-analysis of 10,350 
patients from five randomized 
clinical trials
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Abstract
Aims: To evaluate the impact of bivalirudin versus heparin on efficacy and safety outcomes of ST-segment elevation 
myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) and to explore the 
impact of differential use (bailout vs. routine) of glycoprotein IIb/IIIa inhibitors (GPI).
Methods and Results:  Five randomized controlled trials encompassing 10,350 patients were included. Primary efficacy 
and safety endpoints were all-cause death and major bleeding, respectively. All-cause death at 30 days did not significantly 
differ with bivalirudin compared to heparin (odds ratio (OR) 0.97, 95% confidence interval (CI) 0.74–1.28; P=0.84). Major 
bleeding was significantly reduced by bivalirudin compared to heparin (OR 0.58, 95% CI 0.40–0.85; P=0.005). Bivalirudin 
use was associated with non-significantly different rates of 30-day definite stent thrombosis (ST) (OR 1.71, 95% CI 
0.84–3.49; P=0.14), albeit with higher rates of acute ST (OR 3.55, 95% CI 1.67–7.56; P=0.001) and non-significantly 
different rates of subacute ST (OR 0.86, 95% CI 0.46–1.61; P=0.64). There were non-significant differences in the 30-day 
rates of reinfarction (OR 1.47, 95% CI 0.94–2.30; P=0.10) and cardiovascular death (OR 0.76, 95% CI 0.56–1.02; P=0.07). 
There were no significant interactions between bailout versus routine GPI use in the heparin arm for any of the safety 
or efficacy outcomes (all Pinteraction>0.10).
Conclusions: Bivalirudin compared with heparin was associated with comparable 30-day rates of mortality with reduced 
major bleeding, at the price of an increased risk of acute ST, with non-significant differences in the overall 30-day rates of 
ST and reinfarction. Intended use of GPI in the heparin arm did not significantly modify the treatment effects of bivalirudin. 
Given the important differences between trials, as well as evolution in technique and adjunct pharmacotherapy, further 
randomized trials are warranted to discriminate whether there are substantial safety and efficacy differences between 
these agents during primary PCI in STEMI.
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Introduction
According to European and US guidelines, primary percu-
taneous coronary intervention (PCI) is the standard of care 
for patients with ST-segment elevation myocardial infarc-
tion (STEMI).1,2 Among anticoagulation alternatives to 
support PCI, the direct antithrombin inhibitor bivalirudin 
was provided with a class I recommendation with level of 
evidence B based on data from the Harmonizing Outcomes 
with Revascularization and Stents in Acute Myocardial 
Infarction (HORIZONS-AMI) trial.3,4 In HORIZONS-
AMI, bivalirudin reduced major bleeding at 30 days and 
cardiovascular mortality at 3 years compared with unfrac-
tionated heparin and routine use of a glycoprotein IIb/IIIa 
inhibitor (GPI), but increased the rates of acute stent throm-
bosis (ST).
PCI practice for STEMI has evolved in recent years, 
with more frequent pre-hospital initiation of antithrombotic 
treatment, widespread use of radial access, introduction of 
potent platelet P2Y12 inhibitors (prasugrel, ticagrelor), and 
use of GPI restricted to bailout situations at selected cent-
ers. These changes were incorporated in the European 
Ambulance Acute Coronary Syndrome Angiography; 
(EUROMAX) trial, which demonstrated consistent results 
with HORIZONS-AMI.5–8 Subsequently, conflicting results 
from three additional randomized controlled trials (RCTs) 
of bivalirudin versus heparin in STEMI have been pub-
lished and/or presented at major cardiovascular con-
gresses,9–11 with one single-center trial11 raising concerns 
regarding the risk–benefit profile of bivalirudin compared 
with heparin monotherapy, leading to a downgrade of the 
recommendation for bivalirudin in primary PCI (from I to 
IIa) in the recently published European guidelines for myo-
cardial revascularization.12 Following these events, con-
trary results were reported from a large multicenter trial 
reconfirming the safety benefit of bivalirudin compared to 
heparin monotherapy, with similar rates of adverse ischemic 
events at 30 days and 1 year.9
The manner in which GPI were used in the heparin arm 
(whether routine and/or for bailout only) may be an impor-
tant modifying factor when interpreting the risk–benefit 
ratio of bivalirudin. Two meta-analyses of RCTs conducted 
across the broad spectrum of PCI (elective and acute coro-
nary syndromes) concluded that bivalirudin, as compared to 
heparin without planned GPI use, reduces the risk of major 
bleeding at the expense of a higher risk of acute ST.13,14 
However, those meta-analyses did not have STEMI as a pri-
mary focus and did not include the full dataset from the 
recently presented large-scale Bivalirudin in Acute 
Myocardial Infarction vs. Glycoprotein IIb/IIIa and Heparin: 
a Randomised Controlled Trial (BRIGHT),9 including ST 
and long-term outcomes. In addition, the potential modify-
ing effect of different GPI use strategies in primary PCI 
RCTs of bivalirudin has not fully been examined. We there-
fore performed an updated meta-analysis of RCTs to evalu-
ate the impact of bivalirudin on efficacy and safety outcomes 
of patients with STEMI undergoing primary PCI compared 
to heparin with or without routine GPI use.
Methods
The study was designed in compliance with PRISMA 
(Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) standards.15 Full description of the study 
methodology is provided in the Online Supplement. Briefly, 
the analysis was restricted to studies published or presented 
at a major cardiovascular meeting through September 2014 
that met all the following inclusion criteria: randomized 
trial of bivalirudin versus heparin; study population of 
patients with acute myocardial infarction (at least 85% 
STEMI) undergoing PCI; follow-up outcomes reported for 
at least 30 days. The primary efficacy and safety endpoints 
were the 30-day incidences of all-cause death and protocol-
defined major bleeding, respectively.
Results
Search results and study details
The initial search strategy identified 300 citations, of which 
12 were retrieved for full text review. Five trials encom-
passing a total of 10,350 patients met all inclusion criteria 
and had no exclusion criteria (Figure 1). Study details and 
related interventions are provided in the Online Supplement 
and in Supplementary Table S1. The mean age of patients 
was 61 years. Seventy-seven per cent were men, 16% pre-
sented with diabetes mellitus and 44% were treated with 
radial access (Supplementary Table S2).
Thirty-day results
All trials reported 30-day all-cause death, reinfarction, 
stroke, revascularization, definite ST and major bleeding 
rates. Four trials reported 30-day cardiovascular mortality 
and definite or probable ST (which was further classified as 
acute (<24 hours) and subacute (1–30 days)).
The pooled data showed no significant differences in all-
cause mortality (primary efficacy outcome) with bivalirudin 
versus heparin (2.8% vs. 2.7%, odds ratio (OR) 0.97 (0.74–
1.28); P=0.84; Supplementary Table S3, Figure 2), with low 
heterogeneity (I2=18%), no asymmetry in the funnel plot, 
and no systematic bias apparent across studies (Begg’s test 
P=0.62). Removal of individual studies did not significantly 
influence the point estimate (Supplementary Table S4). 
There was no significant difference in 30-day cardiovascu-
lar mortality with bivalirudin compared to heparin (2.0% vs. 
2.5%, OR 0.76 (0.56–1.02); P=0.07; Supplementary Table 
S3, Figure 3), nor heterogeneity (I2=0), evidence of 
asymmetry in the funnel plot, or systematic bias across stud-
ies (Begg’s test P=0.17). The magnitude of the point esti-
mate for cardiovascular mortality was influenced by the 
HORIZONS-AMI trial (Supplementary Table S4).
 by guest on March 7, 2015acc.sagepub.comDownloaded from 
Capodanno et al. 3
Definitions of reinfarction used across studies are 
described in Supplementary Table S5. There was no signifi-
cant difference in 30-day reinfarction with bivalirudin com-
pared to heparin (1.9% vs. 1.2%, OR 1.47 (0.94–2.30); 
P=0.10; Supplementary Table S3, Figure 3), with mild heter-
ogeneity (I2=37%) and no evidence of asymmetry in the fun-
nel plot or systematic bias across studies (Begg’s test P=0.62). 
Removal of HEAT-PPCI or EUROMAX reduced the magni-
tude of the point estimate (Supplementary Table S4).
There was no significant difference in 30-day stroke 
with bivalirudin compared to heparin (0.8% vs. 0.9%, OR 
0.87 (0.56–1.37); P=0.55; Supplementary Table S3, Figure 
3), with no evidence of heterogeneity (I2=0), asymmetry in 
the funnel plot, or systematic bias apparent across studies 
(Begg’s test P=0.14). None of the studies unduly influ-
enced the point estimate (Supplementary Table S4).
There was no significant difference in 30-day revascu-
larization with bivalirudin compared to heparin (2.4% vs. 
1.6%, OR 1.46 (0.95–2.25); P=0.09; Supplementary Table 
S3, Figure 2), with mild heterogeneity (I2=45%) and no 
evidence of asymmetry in the funnel plot or systematic bias 
across studies (Begg’s test P=0.62). Removal of HEAT-
PPCI reduced the magnitude of the point estimate 
(Supplementary Table S4).
There was no significant difference in 30-day definite 
(1.9% vs. 1.0%, OR 1.71 (0.84–3.46); P=0.14; Supplementary 
Table S3, Figure 4) and definite or probable ST (2.1% vs. 
1.2%, OR 1.77 (0.84–2.73); P=0.13; Supplementary Table 
S3, Figure 4) with bivalirudin compared to heparin. The risk 
of acute ST was significantly higher with bivalirudin (1.4% 
vs. 0.4%, OR 3.55 (1.67–7.56); P=0.001; Supplementary 
Table S3, Figure 4), with no significant differences in the risk 
Figure 1. Flow diagram. Studies included in the meta-analysis. P-PCI: primary percutaneous coronary intervention; RCT: 
randomized controlled trial; STEMIL ST-elevation myocardial infarction.
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of subacute ST (0.8% vs. 0.8%, OR 0.86 (0.46–1.61); P=0.64; 
Supplementary Table S3, Figure 4). Moderate heterogeneity 
was observed for definite ST and definite or probable ST and 
mild heterogeneity for acute and subacute ST. There was no 
asymmetry in the funnel plot for any of the ST endpoints or 
systematic bias across studies (Begg’s test P=NS for all end-
points). The point estimates of definite ST and definite or 
probable ST became significant after the exclusion of 
BRIGHT, whereas the point estimate of acute ST became 
non-significant after the exclusion of HORIZONS-AMI or 
HEAT-PPCI. None of the studies was found to influence the 
point estimate for subacute ST (Supplementary Table S4). 
The OR for acute ST was 1.98 (0.17–23.50; P=0.59) in analy-
ses restricted to studies with routine post-PCI bivalirudin 
infusion and 4.04 (2.01–8.11; P<0.0001) in analyses restricted 
to studies with no routine post-PCI bivalirudin infusion 
(Pinteraction=0.59; Table 1).
Definitions of protocol-defined major bleeding used 
across studies are described in Supplementary Table S6. The 
pooled data showed a significant reduction in major bleed-
ing with bivalirudin (3.9% vs. 7.2%, OR 0.58 (0.40–0.85); 
P=0.005; Supplementary Table S3, Figure 5), with moder-
ate heterogeneity (I2=64%), and no evidence of asymmetry 
in the funnel plot or systematic bias across studies (Begg’s 
test P=1.00). The reduction in major bleeding with bivaliru-
din persisted if BARC 1–5 bleeding in BRIGHT (the study 
definition) was replaced with BARC 2–5 bleeding (OR 0.57 
(0.37–0.88); P=0.01) or BARC 3–5 bleeding (OR 0.61 
(0.40–0.92); P=0.02). Although the risk of major bleeding 
remained numerically lower with bivalirudin, removal of 
HORIZONS-AMI, EUROMAX or BRIGHT one at a time 
resulted in loss of significance for the point estimate, and 
removal of HEAT-PPCI substantially strengthened the point 
estimate (Supplementary Table S4).
GPI interaction
There were no significant interactions between the pooled 
point estimate for any safety or efficacy endpoint of the 
meta-analysis and the modality of GPI use in the heparin 
arm (all Pinteraction>0.10; Figure 6). The OR for major bleed-
ing was 0.64 (0.33–1.23) in analyses restricted to studies 
with bailout GPI use and 0.49 (0.36–0.67) in analyses 
restricted to studies with routine GPI use (Pinteraction=0.49; 
Figure 6).
Long-term results
BRIGHT reported 1-year event rates and HORIZONS-
AMI reported 3-year event rates. The outcomes of the 
pooled analysis of the two trials at the longest available fol-
low up are illustrated in Supplementary Table S7. 
Bivalirudin was associated with a reduced risk of all-cause 
mortality compared with heparin (OR 0.77 (0.61–0.99); 
P=0.04), with no heterogeneity (I2=0). Conversely, there 
were no significant differences in reinfarction (OR 0.81 
(0.62–1.06); P=0.12; I2=5), stroke (OR 0.78 (0.51–1.22); 
P=0.28; I2=0), revascularization (OR 1.21 (1.00–1.47); 
P=0.09; I2=0), and definite or probable ST (OR 0.88 (0.65–
1.20); P=0.43; I2=0). There was a trend towards less bleed-
ing with bivalirudin (OR 0.50 (0.24–1.03); P=0.06), with 
moderate heterogeneity (I2=54).
Discussion
The major findings from this meta-analysis of five rand-
omized trials are summarized as follows. First, in patients 
with STEMI undergoing primary PCI, bivalirudin reduced 
the 30-day risk of major bleeding with similar mortality 
compared with heparin. Second, bivalirudin was associated 
with a greater rate of ST within the first 24 hours of the 
procedure. Third, these results were consistent whether the 
control arm was heparin with the routine use of GPI or hep-
arin alone with provisional GPI reserved for bailout. Fourth, 
mild-to-moderate heterogeneity was observed for many of 
the endpoints and the point estimates for several of the 
major outcomes were sensitive to the removal of single 
studies. The results of this meta-analysis should therefore 
Figure 2. All-cause death. Thirty-day random-effects odds ratio and 95% confidence interval for all-cause death.
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Figure 3. Cardiovascular death, reinfarction, stroke and revascularization. Thirty-day random-effects odds ratios and 95% 
confidence intervals for cardiovascular death (a), reinfarction (b), stroke (c) and revascularization (d).
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Figure 4. Stent thrombosis. Thirty-day random-effects odds ratios and 95% confidence intervals for 30-day definite (a), 30-day 
definite or probable (b), acute (c) and subacute (d) stent thrombosis.
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be interpreted with caution given the differences between 
the included trials.
In the HORIZONS-AMI trial, bivalirudin resulted in 
reduced rates of major and minor bleeding compared to hepa-
rin plus routine GPI in STEMI, with reduced cardiovascular 
and all-cause mortality at 30 days and 3 years.3,4 HORIZONS-
AMI was also the first trial to report increased rates of acute 
ST with bivalirudin, a finding subsequently observed in 
EUROMAX and HEAT-PPCI, but not in BRIGHT or 
BRAVE-4. In no trial was ST increased with bivalirudin after 
24 hours. Differences between trials may explain the inter-
study variability in acute ST risk with bivalirudin. Bivalirudin 
has a short half-life, and the rapid door-to-balloon and proce-
dure times achieved in contemporary trials may have offered 
minimal anti-thrombin exposure from bivalirudin if the drug 
was used during the procedure only. In this regard the use of 
a post-PCI bivalirudin infusion varied across studies, from 
being not routinely used in HORIZONS-AMI, HEAT-PPCI 
and BRAVE-4, to being used in most or all patients in 
EUROMAX (4:1 low-dose:high-dose at operator discretion) 
and BRIGHT (low-dose). In a post-hoc observation from 
EUROMAX, the use of a post-procedure bivalirudin infusion 
for median 4.5 hours at the PCI dose eliminated the acute ST 
risk after primary PCI.16 In BRIGHT,9 the use of a routine 
low-dose bivalirudin infusion for 4 hours was also associated 
with the absence of acute ST risk. In the present meta-analysis 
a significant interaction was not present between the use of a 
post-PCI bivalirudin infusion and the risk of acute ST, 
although the risk of acute ST with bivalirudin was significant 
in analyses restricted to studies in which routine infusion was 
used, and non-significant in analyses restricted to studies 
without routine infusion. The routine use of prasugrel may 
also have reduced the rate of acute ST in BRAVE-4, although 
given the delayed absorption of P2Y12 inhibitors in STEMI17,18 
and the lack of a similar effect in EUROMAX and HEAT-
PPCI, this finding may be due to chance. Pending further 
studies on the association with newer P2Y12 inhibitors in 
STEMI, a 4-hour post-PCI infusion of bivalirudin seems pru-
dent, and was not associated with increased bleeding in either 
BRIGHT or EUROMAX. Extending the bivalirudin infusion 
Table 1. Stent thrombosis stratified by use of post-procedural bivalirudin infusion.
Outcome Trials Patients OR (95% CI) P level Chi2 I2, % Pinteraction*
Definite ST
 Routine post-PCI infusion 2 4056 1.17 (0.16, 8.39) 0.88 4.92 80 0.65
 No routine post-PCI infusion 3 5047 1.94 (0.81, 4.63) 0.14 5.09 61
Definite or probable ST**
 Routine post-PCI infusion 2 4056 1.32 (0.25, 6.98) 0.74 4.44 77 0.64
 No routine post-PCI infusion 2 4503 2.13 (0.70, 6.47) 0.18 4.79 79
Acute (0–24 hours) ST**
 Routine post-PCI infusion 2 4056 1.98 (0.17, 23.50) 0.59 3.51 71 0.59
 No routine post-PCI infusion 2 4503 4.04 (2.01, 8.11) <0.0001 0.40 0
Subacute (24 hours-30 days) ST**
 Routine post-PCI infusion 2 4056 0.91 (0.33, 2.49) 0.85 0.63 0 0.64
 No routine post-PCI infusion 2 4503 1.68 (0.16, 17.93) 0.67 2.82 65
*Test for subgroup differences between studies with routine post-procedural bivalirudin infusion and studies without.
CI: confidence interval; OR: odds ratio; PCI: percutaneous coronary intervention; ST: stent thrombosis.
**Not reported in BRAVE-4.
Figure 5. Major bleeding. Thirty-day random-effects odds ratio and 95% confidence interval for protocol-defined major bleeding.
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post-procedure may overcome the theoretical treatment gap 
between the rapid offset of antithrombin therapy with bivali-
rudin and the slow onset of therapeutic efficacy of antiplatelet 
drugs in the setting of STEMI.19 The impact of a prolonged 
low-dose bivalirudin infusion on the risk–benefit profile of 
bivalirudin is under further investigation in the Minimizing 
Adverse Haemorrhagic Events by TRansradial Access Site 
and Systemic Implementation of angioX (MATRIX) trial.20
Other important differences were present between the tri-
als in the present (and previous) meta-analyses that may 
affect their interpretation. First, radial intervention, which 
may reduce major bleeding rates, was frequent in 
EUROMAX, BRIGHT and HEAT-PPCI, but uncommon in 
HORIZONS-AMI and BRAVE-4. Second, the potent P2Y12 
inhibitors prasugrel or ticagrelor were frequently used in 
EUROMAX, HEAT-PPCI and BRAVE-4, but not in 
HORIZONS-AMI or BRIGHT. Third, in EUROMAX, GPI 
use in the heparin arm was left to the operator’s discretion, 
but no interaction was present between the treatment effect 
of bivalirudin and routine versus provisional GPI use.5–7 
Fourth, patients were randomly assigned early during trans-
fer for primary PCI in EUROMAX, which avoided a possi-
ble confounding effect of pre-randomization heparin as 
noted in HORIZONS-AMI. Fifth, in the three-arm rand-
omized BRIGHT trial, bivalirudin was found to reduce the 
risk of bleeding compared with heparin monotherapy or 
heparin plus routine GPI,9 while in HEAT-PPCI, GPI was 
restricted to bailout use in both the bivalirudin and heparin 
groups, and an increased risk of acute ST was observed with 
bivalirudin without a reduction in bleeding.11 In this regard 
it should be highlighted that the heparin dose used in hepa-
rin monotherapy-treated patients ranged from 70 U/kg in 
HEAT-PPCI to 100 U/kg in EUROMAX and BRIGHT. 
Bivalirudin was associated with reduced major bleeding in 
Figure 6. Outcomes of the meta-analysis stratified by GPI use in the heparin arm. Random-effects odds ratio and 95% confidence 
interval are reported according to GPI use (bailout vs. routine) in the heparin arm. Interaction values for subgroup differences 
between studies with routine GPI use in the heparin arm and studies with bailout GPI use in the heparin arm are reported. For the 
purpose of this analysis, the heparin arms of the BRIGHT trial were considered separately in the comparison versus the bivalirudin 
group.
CV: cardiovascular; GPI: glycoprotein IIb/IIIa inhibitors; OR: odds ratio; RE: random effects; ST: stent thrombosis.
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EUROMAX and BRIGHT (the studies using a high dose in 
patients on heparin monotherapy), but not in HEAT-PPCI 
(which used a lower dose). Sixth, the BRAVE-4 trial was 
stopped prematurely and showed no differences in bleeding 
and ischemic endpoints between patients allocated to bivali-
rudin plus prasugrel compared to heparin plus clopidogrel.10 
The fact that both the antithrombin and P2Y12 antagonist 
were randomized in this trial makes the findings difficult to 
interpret. Finally, all the trials were multicenter except 
HEAT-PPCI, which was unique in randomly assigning a 
near all-comers population, although lacking the external 
validity and generalizability of multicenter trials.21
In our analysis bivalirudin decreased major bleeding. 
Although this benefit was numerically greater in trials in 
which GPI use was routine rather than reserved for bailout, 
the interaction term for GPI use and treatment effect was not 
statistically significant, consistent with the BRIGHT results 
and the post-hoc analysis from EUROMAX.7 These data 
thus suggest that bivalirudin reduces major bleeding in 
patients with STEMI undergoing primary PCI compared to 
heparin alone or heparin plus routine GPI. The significantly 
higher risk of acute ST with bivalirudin, with no difference in 
subacute ST, was also independent of GPI use (routine vs. 
provisional) in the heparin arm. The increased risk of acute 
ST likely drove trends toward increased 30-day rates of rein-
farction and revascularization with bivalirudin treatment as 
well. No such trends were observed in BRIGHT or BRAVE-
4, however, given the absence of an acute ST risk with bivali-
rudin. Mitigating the acute ST propensity with bivalirudin 
(e.g. with a 4-hour post-PCI infusion, if proved to be effec-
tive) would clearly improve its overall risk–benefit ratio.
Considering the net effects of ischemic and bleeding 
complications is important. In this regard, the use of bivali-
rudin rather than heparin (with or without GPI) was associ-
ated with a trend towards reduced 30-day cardiovascular 
mortality, with comparable all-cause mortality. A signifi-
cant reduction in all-cause mortality was found at long term 
in the pooled analysis of HORIZONS-AMI and BRIGHT, 
the only studies reporting a 1-year or longer follow-up. 
Given the differences in study design and adjunctive thera-
pies between trials it is clear that additional large-scale, 
adequately powered RCTs (with long-term follow-up) are 
required to resolve remaining uncertainties.
The definition of reinfarction varied substantially between 
trials, and the non-significant trend for greater reinfarction 
seen with bivalirudin was decreased after individually 
removing EUROMAX or HEAT-PPCI. In this regard these 
trials stand out in that the bailout rates of GPI were particu-
larly high in the heparin-only arms (25.4% and 13.5%, 
respectively) compared to the others, a practice of uncertain 
clinical utility. In addition, door-to-balloon times in HEAT-
PPCI were less than 30 minutes (leading to a very short biva-
lirudin infusion) and the activated clotting times were 
substantially lower than usually seen with bivalirudin, but 
not with heparin (a finding difficult to interpret, however, 
given the use of a non-standard assay). The definitions of 
protocol-defined major bleeding also varied substantially 
between trials, with BRIGHT pre-specifying all bleeding as 
the major safety endpoint. However, bivalirudin use was still 
associated with reduced rates of major bleeding when only 
BARC 2–5 or 3–5 bleeding rates from BRIGHT were con-
sidered in the meta-analysis.
Study limitations
The results of this meta-analysis are subject to the limitations 
and differences of the original included studies themselves. 
Variation in study design (Supplementary Tables S1 and S2), 
endpoint definitions (Supplementary Tables S5, S6 and S8) 
and publication bias are limitations of all meta-analyses. All 
included studies share the limitation of an open-label design. 
Randomization in EUROMAX was not stratified by intended 
routine versus bailout GPI use, introducing the possibility of 
imbalances between groups, although in a pre-specified mul-
tivariable analysis the relative effects of bivalirudin were not 
affected by GPI use pattern. The BRIGHT trial included 12% 
of patients with non-STEMI; outcomes of the STEMI cohort 
have not been separately presented, with the exception of ST. 
Moreover, data from BRIGHT are currently unpublished. 
The limitations inherent in the single-center HEAT-PPCI 
design have been discussed, as have the implications of the 
randomization scheme and early termination of BRAVE-4. 
In this regard several of the results were sensitive to the 
HEAT-PPCI results, whereas omitting BRAVE-4 did not sig-
nificantly change any of the point estimates in our meta-anal-
ysis. In addition, the trials varied markedly in the use of 
pre-randomization heparin and study drug, radial artery 
access, potent P2Y12 inhibitors, post-PCI bivalirudin and 
heparin infusions or low molecular-weight heparin use, and 
other factors that could not be completely accounted for in 
the present analysis (Online Supplement). Finally, follow-up 
beyond 30 days was available for only two of the studies. 
The 1–3 year data from HORIZONS-AMI and BRIGHT 
suggest a sustained or improving risk–benefit profile of biva-
lirudin over time, but more data are needed in this regard.
Conclusions
In this updated meta-analysis from five RCTs, bivalirudin 
was found to reduce the 30-day rates of major bleeding with 
similar survival compared to heparin monotherapy or heparin 
plus GPI in patients with STEMI undergoing primary PCI. 
Bivalirudin was associated with an increased risk of acute ST, 
but not subacute or total ST. Non-significant trends were pre-
sent for an increased risk of reinfarction and repeat revascu-
larization with bivalirudin, but also of reduced cardiovascular 
mortality, compared with heparin. Routine versus bailout GPI 
use in the heparin arm did not significantly modify the risk–
benefit ratio of bivalirudin compared with heparin for any of 
these safety and efficacy endpoints. Bivalirudin was 
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associated with improved long-term survival based on the 
available data from two studies. Given differences between 
the included trials, however, and evolution in technique and 
adjunct pharmacotherapy, additional large-scale randomized 
trials (including embedded cost-effectiveness assessment) 
with long-term follow-up are warranted to determine whether 
there are clinically relevant differences between bivalirudin 
and heparin with or without routine GPI in patients with 
STEMI undergoing primary PCI.
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ABSTRACT
Introduction: Percutaneous coronary intervention (PCI) is a milestone for treating coronary artery
disease (CAD). Antithrombotic therapy is essential to prevent ischemic complications, including
the microvascular no-reflow, while minimizing bleeding events.
Areas covered: This overview discusses available and developing drugs for PCI including antic-
oagulants, antiplatelets and treatment of no-reflow.
Expert opinion: For years unfractionated heparin (UFH) has been the unique anticoagulant to be
used before and during PCI. Enoxaparin showed similar efficacy and safety, yet, based on recent trials,
bivalirudin has been shown to have some benefits, particularly for patients with ST-segment elevation
myocardial infarction (STEMI). The evidence concerning new anticoagulants is still preliminary, except
for new oral anticoagulants, particularly rivaroxaban that showed intriguing findings and is currently
under investigation. Dual antiplatelet therapy (DAPT) is the standard of care after PCI, but new
developments have recently emerged. Indeed, ticagrelor and prasugrel are currently recommended
over clopidogrel due to their significant reduction of ischemic events in acute coronary syndrome
(ACS) whereas clopidogrel remains the choice in stable CAD. Among new agents, vorapaxar and
cangrelor showed positive but limited evidence and might be considered at least in selected patients.
Conversely, evidence on effective treatments for no-reflow remains limited and would require future
dedicated research.
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1. Introduction
Coronary artery disease (CAD) is the leading cause of
morbidity and mortality in western countries and percu-
taneous coronary interventions (PCIs) have developed a
central role in the management of patients with stable or
unstable CAD. The inhibition of coagulation and platelet
activity is essential to maintain the immediate results of
PCI and prevent complications and recurrence of
ischemic/thrombotic events; therefore, both anticoagu-
lant and antiplatelet agents represent the mainstay of
catheterization-laboratory pharmacotherapy. Conversely,
the development of potent drugs warranted special
interest to the balance between the desirable antithrom-
botic effects and the increased risk of bleeding.
Pharmacologic therapy also plays a crucial role in the
management of no-reflow phenomenon, one of the
most important complications during PCI (especially
primary PCI).
Until the year 2000, few pharmacologic agents were
available for the cath-lab use, but in the last decade, new
antithrombotics have been developed for PCI and others
are currently under evaluation. This has revolutionized
the pharmacopeia for the treatment of patients under-
going PCI. When the dual antiplatelet therapy (DAPT)
concept had been consolidated, clopidogrel became
the most popular second antiplatelet to be added to
low-dose aspirin, but in recent years, different new
P2Y12 inhibitors have emerged, changing the common
clinical practice. At the same time, the role of glycopro-
tein IIb/IIIa inhibitors (GPIs) has been redefined and also
anticoagulant alternatives to the commonly used unfrac-
tionated heparin (UFH) have emerged, such as enoxa-
parin, bivalirudin and fondaparinux, including other
drugs. This study provides a comprehensive yet concise
overview of multiple treatment options for patients
undergoing PCI. Currently available and developing
drugs for the cath-lab use during PCI will be discussed,
including anticoagulants, antiplatelets, and therapies for
the prevention and treatment of no-reflow.
The MEDLINE database was primarily explored via
PubMed to analyze clinical trials, studies, meta-analyses,
and reviews relevant to this topic. The registry
ClinicalTrials.gov was also referred to evaluate the var-
ious recent ongoing clinical trials. All the relevant
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studies were identified using the following keywords and
their combination: ‘percutaneous coronary intervention’,
‘drugs’, ‘antithrombotic’, ‘antiplatelet’, ‘anticoagulant’,
‘no-reflow’, ‘heparin’, ‘bivalirudin’, ‘fondaparinux’, ‘dabi-
gatran’, ‘rivaroxaban’, ‘apixaban’, ‘edoxaban’, ‘otamixa-
ban’, ‘argatroban’, ‘M118’, ‘aptamer’, ‘clopidogrel’,
‘prasugrel’, ‘ticagrelor’, ‘cangrelor’, ‘elinogrel’, ‘P2Y12 inhi-
bitors or antagonists’, ‘vorapaxar’, ‘glycoprotein IIb/IIIa
inhibitor’, ‘abciximab’, ‘tirofiban’, and ‘eptifibatide’.
2. Anticoagulant therapy
2.1. Unfractionated heparin
UFH is a sulfated glycosaminoglycan composed of
alternating uronate and glucosamine units containing
straight-chain mucopolysaccharides of highly variable
length. This complex heterogeneous substance has a
molecular weight ranging from 3000 to 30,000 Da
(with a mean of 15,000 Da). UFH acts as an indirect
thrombin inhibitor, exerting its effects through the
endogenous serine protease antithrombin (AT) III. As
AT complexes with heparin, it undergoes a conforma-
tional change, accelerating its enzymatic activity and
rapidly inhibiting factor IIa (thrombin), factor Xa, and,
to a lesser extent, factors IXa, XIa, and VIIa (Table 1).
During PCI, UFH is administered intravenously, and the
generally recommended dose is 70–100 U/kg as bolus,
to achieve a target activated clotting time (ACT) of
250–350 s (50–70 U/kg bolus to achieve an ACT of
200–250 s is recommended if GPIs are used). ACT
should be <180 s when the femoral sheath is removed
to minimize bleeding complications. ACT monitoring is
crucial to guide UFH dosing during PCI, because it is a
predictor of thrombotic complications (ACT < 300 s),
as recently demonstrated in the FUTURA/OASIS-8 (fon-
daparinux with unfractionated heparin during revascu-
larization in ACS/optimal antiplatelet strategy for
interventions) trial.[1]
Before cath-lab, UFH can be initiated with a bolus
of 60–70 IU/kg (maximum of 5000 IU), followed by an
initial infusion of 12–15 IU/kg/h (maximum 1000 IU/h),
maintaining an activated partial thromboplastin time
(aPTT) level of 50–75 s, corresponding to 1.5–2.5 times
the upper limit of normal. This narrow therapeutic
window is due to the increased risk of bleeding with-
out further antithrombotic benefits at the higher aPTT
values. In patients receiving prior UFH, at the time of
Article highlights
● A large body of evidence supports the recommendations on
the currently used drugs during PCI.
● Several new pharmacologic options have recently emerged, but
further studies are needed to support their benefits and to
drive new recommendations.
● The evidence for new parenteral anticoagulants (i.e. argatro-
ban, otamixaban, M118, pegnivacogin/anivamersen) is still pre-
liminary, while new oral anticoagulants, particularly
rivaroxaban, showed promising findings to be confirmed.
● Among the new antiplatelets, vorapaxar and cangrelor showed
positive but limited evidence and might be considered at least
in selected patients.
● No-reflow still remains a critical complication of PCI and further
dedicated research is warranted.
This box summarizes key points contained in the article
Table 1. Characteristics of the main anticoagulants.
UFH LMWH Bivalirudin Fondaparinux
Target of
anticoagulation
IIa, Xa, IXa, XIa, VIIa IIA and Xa IIa Xa
Administration Intravenous Subcutaneous Intravenous Subcutaneous
Half-life 30–60 min 3–6 h 25 min 17–21 h
Clearance Cellular mechanisms and renal Renal Renal (20%) Renal
Monitoring
needed
Yes Yes No No
Monitoring test ACT AntiXa level ACT (not ideal) AntiXa level
Reversibility Yes Yes (partial) No No
Antidote Protamine Protamine - -
1 mg/100 IU of UFH 1 mg/1 mg of LMWH
Dosage Prior to coronary angiography: 60–70 IU/kg IV (max 5000 IU) and
infusion (12–15 IU/kg/h) (max 1000 IU/h), target aPTT 1.5–2.5×
control
1 mg/kg s.c. twice a
day
Bolus 0.75 mg/kg i.
v., infusion 1.75 mg/
kg/h
Prior to coronary
angiography: 2.5 mg
s.c. once a day
During PCI: 70–100 IU/kg IV with ACT target of 250–350 s (50–
70 IU/kg with ACT target of 200–250 s if GPIs are used)
During PCI: an
additional bolus of
UFH is needed
Dose adjustment
in CKD
No adjustment No adjustment2 No adjustment of No adjustment
Not recommended for
eGFR < 15 ml/min/
1.73 m
bolus, reduce
infusion
rate to 1 mg/kg/h
and to 0.25 for
dialysis
Not recommended for
eGFR < 20 ml/min/
1.73 m2
Abbreviations: ACT = activated clotting time; aPTT = activated partial thromboplastin time; CKD = chronic kidney disease; eGFR = estimated glomerular
filtration rate; IU = international units; GPIs = glycoprotein IIb/IIIa inhibitors; LMWH = low-molecular weight heparin; PCI = percutaneous coronary
intervention; UFH = unfractionated heparin.
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PCI, an additional UFH bolus is administered as
needed to achieve the ACT target level.
An important advantage of using UFH is that it can
be antagonized with intravenous protamine sulfate
(1 mg for each 100 UFH units). However, UFH has
some limitations, such as the need for ACT monitoring
that is related to its bound to cells and plasma proteins
determining a variable dose-response relationship with
nonlinear pharmacokinetics and poor predictable
effects. Other limitations of UFH include a narrow ther-
apeutic window, platelet activation, the potential for
inducing thrombocytopenia (HIT) and HIT-thrombosis
syndrome. For these reasons, during the last decades,
studies have been conducted to test new anticoagu-
lants with more pharmacologic and clinical advantages
than UFH, despite the fact that it still remains the
standard of care for thrombosis prevention during PCI.
[2–4]
2.2. Low-molecular weight heparin (LMWH)
Low-molecular weight heparin (LMWH) is produced
from enzymatic or chemical degradation of UFH, result-
ing in a lower molecular weight (5000 Da) with reduced
binding capacity to proteins, yielding a predictable
anticoagulant effect and less need for procedural mon-
itoring. LMWH still acts through ATIII, but cannot form a
ternary complex with AT and thrombin because of its
smaller monosaccharide chains; therefore, LMWH has
preferential anti-Xa as opposed to AT activity. LMWH
incurs much less nonspecific binding, thus presenting a
lower risk of HIT and less platelet activation compared
with UFH. Among LMWHs, enoxaparin is the most stu-
died in the setting of PCI. It is recommended as an
alternative to UFH during elective PCI on the basis of
the STEEPLE (safety and efficacy of enoxaparin in PCI
patients, an international randomized evaluation) trial,
in which 3528 patients were randomized to either intra-
venous enoxaparin 0.5 or 0.75 mg/kg or UFH.[5] The
primary end point (noncoronary artery bypass graft
(CABG)-related bleeding over 48 h) was significantly
reduced with the lower but not the higher dose.
Major bleeding was significantly reduced in both enox-
aparin groups, with similar efficacy to UFH. Enoxaparin
provided more predictable anticoagulation. However,
the trial was not large enough to provide a definitive
comparison of efficacy in the prevention of ischemic
events.[5] The superior yield of the new strategy of
enoxaparin, revascularization and glycoprotein IIb/IIIa
inhibitors trial enrolled 10,027 high-risk patients with
NSTE-acute coronary syndrome (ACS) to an early inva-
sive strategy with either UFH or enoxaparin, showing
that enoxaparin was non-inferior to UFH.[6] Enoxaparin
was associated with increased risk of bleeding, but
mainly in patients who switched from UFH to enoxa-
parin and vice versa.[6] Based on this trial, recommen-
dations state that enoxaparin may be considered as an
alternative to UFH in NSTE-ACS (with no additional drug
given during PCI if the last enoxaparin dose was given
<8 h prior to the procedure, while an additional enox-
aparin bolus of 0.3 mg/kg administered prior to PCI if
the last enoxaparin dose was given >8 h) and discou-
rage the cross-overs between heparins. In the setting of
ST-segment elevation myocardial infarction (STEMI),
enoxaparin could be considered as an alternative to
UFH based on the ATOLL (acute STEMI treated with
primary PCI and intravenous enoxaparin or UFH to
lower ischaemic and bleeding events at short- and
long-term follow-up) trial, which randomized 910
patients.[7] The 30-day primary composite end point
of death, myocardial infarction (MI), procedural failure,
or major bleeding was reduced nonsignificantly in the
enoxaparin arm (0.5 mg/kg IV) compared with UFH in
the absence of bleeding difference.[7] However, LMWHs
have little activity against thrombin, are not completely
reversible (protamine may reverse only the anti-IIa
effect but does not completely reverse the anti-Xa
activity), cannot be monitored by point-of-care assays,
need dose adjustment (not clearly defined) in case of
obese patients or those with renal insufficiency.
2.3. Bivalirudin
Bivalirudin is a 20-amino acid synthetic polypeptide
with a short half-life, which binds directly to circulating
and fibrin-bound thrombin, blocking its enzymatic
activity (Table 1). In contrast to UFH, bivalirudin does
not have any natural inhibitors such as platelet factor 4
and does not require ACT monitoring of anticoagula-
tion in the cath-lab, but assessing the ACT 5 min after
dosing is a safety reminder to verify its effect. Moreover,
not interacting with plasma proteins or cells, it does not
activate platelets and does not cause HIT. Also, bivalir-
udin exerts some degree of antiplatelet effect by block-
ing platelet protease-activated 1 and 4 receptors
(protease-activated receptor [PAR]-1 and -4), which are
typically activated by thrombin.[8,9]
In stable CAD, bivalirudin was compared with UFH in
the ISAR-REACT (intracoronary stenting and antithrom-
botic regimenrapid early action for coronary treatment)
3 trial, which showed a trend of increased risk of MI but
significantly lower major bleeding with bivalirudin.
[10,11]
Bivalirudin has emerged as a viable option for antic-
oagulation in ACS too. The efficacy and safety of biva-
lirudin in NSTE-ACS were demonstrated by ACUITY
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(acute catheterization and urgent intervention triage
strategy) and ISAR-REACT4 trials,[12–14] which both
observed a consistently reduced bleeding rate in
patients treated with bivalirudin and a comparable effi-
cacy profile.
However, arguments on its safety and efficacy profile
have been marked by intense controversy and debate
in STEMI patients.[15] In the first trial, HORIZONS-AMI
(harmonizing outcomes with revascularization and
stents-acute myocardial infarction), bivalirudin reduced
major bleeding at 30 days and cardiovascular mortality
at 3 years compared with UFH and routine use of a GPI,
but increased the rates of acute stent thrombosis (ST).
[16] However, from that study, primary PCI practice has
evolved, with more frequent prehospital initiation of
antithrombotic treatment, widespread use of radial
access, introduction of potent antiplatelet agents (pra-
sugrel and ticagrelor), and use of GPI restricted to bail-
out situations. The EUROMAX (european ambulance
acute coronary syndrome angiography) trial incorpo-
rated these changes and demonstrated results consis-
tent with those of HORIZONS-AMI.[17] However,
contrasting evidence from three additional randomized
trials of bivalirudin versus UFH in STEMI (bavarian reper-
fusion alternatives evaluation [BRAVE] 4, bivalirudin in
acute myocardial infarction vs. glycoprotein IIb/IIIa and
heparin: a randomized controlled trial, how effective are
antithrombotic therapies in primary-PCI) has subse-
quently emerged.[18–20] In particular, the HEAT-PPCI
trial raised concerns on the risk–benefit profile of biva-
lirudin compared with heparin monotherapy, leading to
a downgrade in the recent European guidelines of the
recommendation for bivalirudin in primary PCI (from I
to IIa).[2] A pooled analysis from these five trials
showed that compared to UFH, bivalirudin was asso-
ciated with similar 30-day mortality with reduced major
bleeding, at the price of increased acute ST, with non-
significant differences in the overall 30-day rates of ST
and reinfarction. Interestingly, the use of GPIs in the
heparin arm did not significantly modify the treatment
effects of bivalirudin.[15]
Importantly, the results of the MATRIX (minimizing
adverse haemorrhagic events by transradial access
site and systemic implementation of angiox) trial
have been recently published (Figure 1). This trial
randomly assigned either bivalirudin or UFH to 7213
ACS patients for whom PCI was anticipated.[21,22]
Patients in the bivalirudin group were subsequently
randomly assigned to receive or not a post-PCI biva-
lirudin infusion. Primary outcomes were the occur-
rence of major adverse cardiovascular events (MACE)
(a composite of death, MI, or stroke) and net adverse
clinical events (NACE) (a composite of major bleeding
or a major adverse cardiovascular event). The primary
outcome for the comparison of a post-PCI bivalirudin
infusion with no post-PCI infusion was a composite of
urgent target-vessel revascularization, definite ST, or
NACE. The rates of MACE and NACE were not signifi-
cantly different between bivalirudin and UFH, but
bivalirudin was associated with reduced bleeding
and also lower all-cause death, lower cardiovascular
death at the price of higher definite ST (borderline p-
values). Post-PCI bivalirudin infusion, as compared
with no infusion, did not significantly decrease the
rates of urgent target-vessel revascularization, definite
ST, or NACE.[21,22] However, at explorative analysis,
Figure 1. Clinical outcomes in the MATRIX Antithrombin-type trial. Cumulative incidence, risk ratios (RR) and confidence intervals
(95% CI) are reported for ischemic and bleeding events in the bivalirudin and unfractionated heparin groups.
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prolongation of PCI bivalirudin dose was associated
with low ischemic and bleeding risk when compared
to both low post-PCI regimen and UFH. The consis-
tency of these results across the types of ACS remains
to be seen.
2.4. Fondaparinux
This drug indirectly inhibits factor Xa. Currently, this is
not a drug to be used in the cath-lab during PCI but in
the pre-PCI period, being the recommended drug for
patients with NSTE-ACS due to the most favorable effi-
cacy/safety profile. In this case, an additional bolus of
anticoagulant with anti-IIa activity (UFH, enoxaparin, or
bivalirudin) at the time of PCI will be necessary due to
the increased risk of catheter-related thrombosis. For
this reason, in the setting of STEMI, fondaparinux is not
recommended; indeed, the OASIS 6 trial enrolling STEMI
patients showed a significantly higher rate of guiding
catheter-related thrombosis.[23]
2.5. New developments in anticoagulation therapy
2.5.1. Non-vitamin-K oral anticoagulants
Rivaroxaban and dabigatran have been investigated for
anticoagulation during PCI. Dabigatran was studied in
the D-fine clinical trial, a phase IIa prospective, rando-
mized, exploratory study conducted in four hospitals in
The Netherlands.[24] This study included 50 stable
patients undergoing elective PCI. Patients on standard
DAPT were randomized (2:2:1) to either pre-procedural
dabigatran 110 mg b.i.d. (n = 19) or 150 mg b.i.d.
(n = 21), as compared to standard intraprocedural
UFH (n = 10). Following PCI, a significant increase in
the levels of the prothrombin fragment 1 + 2 (F1 + 2) in
the combined dabigatran group was observed com-
pared to the level just before PCI. Also, thrombin-AT
(TAT) complexes were increased significantly in the
combined dabigatran group compared to pre-PCI
levels. Conversely, in the UFH control group, no
increase was observed in F1 + 2 and TAT complexes
during PCI. Five out of 40 patients required bailout
anticoagulation in the dabigatran group, of whom
four experienced a procedural MI. One minor access-
site bleeding occurred in the dabigatran group.
Therefore, this exploratory study showed that dabiga-
tran did not provide a sufficient anticoagulation during
PCI.[24] Contrarily, the X-PLORER (evaluating optimal
concomitant anticoagulation in rivaroxaban treated
patients, an oral direct factor Xa inhibitor, during per-
cutaneous coronary revascularization) trial showed that
rivaroxaban effectively suppressed coagulation
activation for elective PCI and stenting.[25] Stable
patients (n = 108) undergoing elective PCI and on
DAPT were randomized (2:2:2:1) to a short treatment
course of rivaroxaban 10 mg (n = 30), rivaroxaban
20 mg (n = 32), rivaroxaban 10 mg plus UFH (n = 30),
or standard periprocedural UFH (n = 16). Blood samples
for markers of thrombin generation and coagulation
activation were drawn prior to and after start of PCI,
confirming the efficacy of rivaroxaban.[25]
Some studies have also investigated on the long-
term role for rivaroxaban, apixaban, and dabigatran in
addition to DAPT in patients with recent ACS, but none
of them is currently recommended because the results
have been poorly encouraging, except for the 2.5 mg
twice-daily dose of rivaroxaban. In the apixaban for
prevention of acute ischemic and safety events-2, apix-
aban (5 mg twice daily) was compared with placebo, in
addition to standard antiplatelet therapy, in patients
with a recent ACS and at least two additional risk
factors for recurrent ischemic events.[26] It was prema-
turely terminated after recruitment of 7392 patients
due to an increase in major bleeding events with apix-
aban in the absence of a counterbalancing reduction in
recurrent ischemic events.[26]
The RE-DEEM (dabigatran vs. placebo in patients
with acute coronary syndromes on dual antiplatelet
therapy: a randomized, double-blind, phase II trial)
trial enrolled patients with recent ACS and randomized
them to receive various doses of dabigatran (50, 75,
110, and 150 mg) or placebo; however, a dose-depen-
dent increase in major or minor bleeding was observed
with dabigatran, while no significant decrease of
ischemic events with dabigatran was observed.[27]
In the recent ATLAS-ACS-2 TIMI 51 trial (anti-Xa ther-
apy to lower cardiovascular events in addition to stan-
dard therapy in subjects with ACS 2-TIMI 51 trial),
15,526 patients with a recent ACS were randomized to
receive rivaroxaban 2.5 or 5 mg twice daily or placebo.
[28] Only the dose of 2.5 mg provided promising
results; indeed, the twice-daily 2.5 mg, but not the
5 mg, dose of rivaroxaban reduced the rates of death
from cardiovascular causes and from any cause. As
compared with placebo, rivaroxaban increased the
rates of major bleeding not related to CABG and intra-
cranial hemorrhage, without a significant increase in
fatal bleeding or other adverse events, but the twice-
daily 2.5 mg dose resulted in fewer fatal bleeding
events than the twice-daily 5 mg dose.[28] Based on
these study results, rivaroxaban 2.5 mg b.i.d. is
approved in Europe for the secondary prevention of
ACS patients on top of aspirin and clopidogrel or aspirin
only. However, it remains unclear how this triple
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therapy treatment strategy compares with aspirin and
ticagrelor or aspirin and prasugrel, which are the first-
line, recommended P2Y12 inhibitors in ACS patients by
European and American guidelines.
2.5.2. Argatroban
Argatroban is a synthetic arginine-derived direct throm-
bin inhibitor and is an attractive anticoagulant for PCI
due to its rapid onset and offset and its hepatic elim-
ination. It was approved for PCI in patients with HIT.
The argatroban-E04 open-label, multiple-dose, con-
trolled study examined the safety and efficacy of arga-
troban in non-HIT patients undergoing elective PCI.[29]
A total of 140 patients were randomized to three arga-
troban doses (ARG250, ARG300, and ARG350 with 250,
300, or 350 μg/kg bolus, followed by 15, 20, or 25 μg/
kg/min infusion) or UFH (70–100 IU/kg bolus).
Argatroban prolonged ACT in a dose-dependent man-
ner, with more patients reaching the minimum target
ACT after the initial bolus injection (ARG250: 86.1%,
ARG300: 89.5%, and ARG350: 96.8%) compared to
45.5% in UFH (p < 0.001). A significantly higher propor-
tion of patients did not require additional bolus injec-
tions to start PCI in the argatroban arm when compared
to the UFH arm (p ≤ 0.002). Consequently, the time to
start of PCI was shortened in the argatroban groups.
Composite incidences of death, MI, and urgent revascu-
larization until day 30 were not significantly different
between the groups. Major bleeding was observed only
in UFH (3.0%), while minor bleeding occurred in
ARG350 (3.2%) and UFH (6.1%, n.s.).[29] Argatroban is
currently recommended for HIT patients and does not
appear to be an attractive treatment option beyond this
niche patient population, in which, however, bivalirudin
is also a recommended option.
2.5.3. Otamixaban
Otamixaban is a novel intravenous direct factor Xa inhi-
bitor. In the SEPIA (study to evaluate the pharmacody-
namics, the safety and tolerability, and the
pharmacokinetics of several intravenous regimens of
the Factor Xa inhibitor otamixaban in comparison to
intravenous unfractionated heparin in subjects under-
going non-urgent percutaneous coronary intervention)-
PCI double-blind, double-dummy, parallel-group, dose-
ranging trial, 947 patients were randomly assigned to
either one of five weight-adjusted otamixaban regimens
or weight-adjusted UFH before PCI.[30] Otamixaban
reduced F1 + 2 significantly more than UFH at the high-
est dose regimen, while no significant difference in the
incidence of thrombolysis in MI (TIMI) bleeding was
observed between the otamixaban and UFH groups.
These results were the basis for further adequately
powered clinical outcome trials in patients with ACS.
Then, otamixaban was tested in 3241 patients with
NSTE-ACS in a double-blind phase 2 trial (SEPIA-ACS1
TIMI42), which demonstrated that infusions of 0.100–
0.140 mg/kg/h might reduce ischemic events and have
a safety profile similar to UFH plus eptifibatide, support-
ing the need for a phase 3 trial.[31] Finally, in the phase 3
TAO (treatment of acute coronary syndromes with ota-
mixaban trial, the clinical efficacy and safety of otamix-
aban) were compared with those of UFH plus
downstream eptifibatide in patients with NSTE-ACS
undergoing a planned early invasive strategy.[32] A
total of 13,229 patients with NSTE-ACS were enrolled,
and the otamixaban dose selected at interim-analysis
was an intravenous bolus of 0.080 mg/kg followed by
an infusion of 0.140 mg/kg/h. However, otamixaban did
not reduce the rate of ischemic events but increased
bleeding, thereby not supporting its use for patients
with NSTE-ACS undergoing planned early PCI.[32]
2.5.4. M118
M118 is a novel LMWH that combines the beneficial
properties of UFH and enoxaparin while addressing
their respective limitations. It is produced by depoly-
merization of UFH that is derived from porcine intest-
inal mucosa, significantly reducing molecular weight
(range from 5500 to 9000 Da). It is characterized by a
broad anticoagulant activity, including potent activity
against factor Xa and thrombin, low polydispersity, sub-
cutaneous bioavailability (around 70% in humans), and
predictable subcutaneous and intravenous pharmacoki-
netics. The anti-Xa to anti-IIa ratio of approximately
1.4:1 remains constant over time in vivo. The plasma
half-life of M118 is approximately 1 h after intravenous
bolus injection and 2–3 h after subcutaneous injection.
Importantly, M118 does not activate platelets, and its
anticoagulant activity can be monitored by standard
coagulation assays such as ACT and aPTT. Additionally,
owing to its charge, it is reversible to subtherapeutic
levels with protamine sulfate (1 mg per 100-IU dose). In
the Phase II EMINENCE (evaluation of M118 in percuta-
neous coronary intervention) multicenter trial (43 cen-
ters in the United States and Canada), 503 patients
undergoing elective PCI were randomized in an open-
label fashion to one of four arms: UFH 70 U/kg, M118
50 IU/kg IV, M118 75 IU/kg IV, or M118 100 IU/kg IV.[33]
The rates of the primary end point between the pooled
M118 groups versus UFH demonstrated that M118 was
non-inferior to UFH at preventing PCI-related complica-
tions (28.4% pooled M118 arms versus 31.1% UFH), and
the adverse event profiles of M118 and UFH were
comparable.
6 G. GARGIULO ET AL.
2.5.5. RNA aptamers
RNA aptamers are single-stranded oligonucleotide
sequences that bind with high specificity to some pro-
tein sequences. An important advantage of this strategy
is related to the fact that they are nucleotides; there-
fore, it is possible to engineer complementary
sequences to be used as very effective antidotes. The
REG1 system (pegnivacogin/anivamersen) is an exam-
ple of this anticoagulation system. Pegnivacogin repre-
sents an extremely potent, chemically unique
anticoagulant that inhibits factor IXa and can be
reversed by anivamersen. This system is being investi-
gated for use in PCI. A recent Phase II trial, REVERSAL
(feasibility and safety study comparing REG1 anticoagu-
lation system with unfractionated heparin in elective)-
PCI, compared the REG1 system (n = 20) with UFH
(n = 4).[34] Anticoagulation was partially reversed after
PCI (n = 10) and fully reversed 4 h later (n = 10). This
study preliminarily demonstrated the adequate intra-
procedural anticoagulation, with rapid and effective
reversal after PCI using the REG1 system.
Subsequently, the RADAR (randomized, partially-
blinded, multicenter, active-controlled, dose-ranging
study assessing the safety, efficacy, and pharmacody-
namics of the REG1 anticoagulation system compared
to unfractionated heparin or low molecular heparin in
subjects with ACS)-PCI phase II trial was conducted by
randomizing ACS patients to pegnivacogin 1 mg/kg with
25%, 50%, 75%, or 100% anivamersen reversal or UFH. Of
the 640 patients randomized, 388 (61%) underwent PCI.
[35] The inhibition with at least 50% reversal had a
favorable bleeding profile and appeared effective at sup-
pressing ischemic events and thrombotic complications,
supporting the need for larger phase trials in PCI.
The phase III trial REGULATE (a study to determine
the efficacy and safety of REG1 compared to bivalirudin
in patients undergoing)-PCI (NCT01848106) was started
in 2013 to test the hypothesis of whether pegnivacogin
could result in fewer ischemic events than bivalirudin
while active control with anivamersen could preserve
the benefit of reduced bleeding.[36] This trial compared
REG1 with bivalirudin in preventing periprocedural
ischemic complications and major bleeding in patients
undergoing PCI (in stable and ACS [non ST-elevation
myocardial infarction, NSTEMI and unstable angina, UA]
patients). The study was terminated after enrollment of
3232 patients due to severe allergic reactions in 10 of
1605 (0.6%) patients receiving pegnivacogen, including
one fatal event and nine anaphylactic reactions.[36]
There were no differences in rates of the primary end
point between REG1 and bivalirudin groups (6.7% vs.
6.4%; OR: 1.05; 95% CI: 0.80–1.39; p = 0.72). REG1 was
associated with a numerically higher rate of major
bleeding (0.4% vs. 0.1%; OR: 3.49; 95% CI: 0.73–16.82;
p = 0.09) and a significantly higher rate of major or
minor bleeding (6.5% vs. 4.1%; OR: 1.65; 95% CI: 1.19–
2.25; p = 0.002). However, the incidence of ST trended
lower in the REG-arm (<0.1 vs. 0.4%: OR: 0.17; 95% CI:
0.12–1.38; p = 0.06). We can speculate that these aller-
gic reactions may have arisen from preexisting antibo-
dies to polyethylene glycol, although the mechanism
remains undefined at this time; future analyses using
demographic information and stored immunologic
blood samples are planned. While the concept of
high-level anticoagulation with active reversal is pro-
mising, its clinical role requires additional studies.
3. Oral antiplatelet therapy
3.1. Standard of care
For several years, oral antiplatelet therapy with clopido-
grel and low-dose aspirin has been the standard of care
after PCI. During the last decade, important trials have
demonstrated that new oral P2Y12 inhibitors, prasugrel
and ticagrelor (Table 2), are more potent and effective in
preventing ischemic events than clopidogrel in the set-
ting of DAPT in patients with ACS, despite an increased
risk of bleeding being observed with both agents. Indeed,
current guidelines support the use of these two agents
over clopidogrel. An ongoing trial is comparing prasugrel
and ticagrelor in ACS patients undergoing planned PCI
(ISAR-REACT5).[37] However, the optimal duration of
DAPT after PCI, with the aim of balancing ischemic and
bleeding complications, still remains a great matter of
debate.[38–43] Recently, the PEGASUS (prevention of car-
diovascular events in patients with prior heart attack
using ticagrelor compared to placebo on a background
of aspirin) trial demonstrated that adding ticagrelor to
aspirin in patients with prior MI (1–3 years earlier) was
associated with significant benefits compared with aspirin
alone.[44] Both dosages tested (60 mg or 90 mg twice
daily) reduced the primary end point and rates of MI, with
the 60 mg ticagrelor regimen also associated with lower
stroke and cardiovascular mortality.
3.2. Vorapaxar
Vorapaxar acts by inhibiting PAR-1 and leading to
prevention of thrombin-mediated platelet activation.
It was approved in May 2014 on the basis of TRA2P-
TIMI50 trial.[45] This study tested the hypothesis that
adding a platelet-activated receptor 1 inhibitor to the
current standard of DAPT may provide benefits by a
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more comprehensive platelet inhibition. Patients with
prior MI on maintenance antiplatelet therapy were
randomized 1:1 to vorapaxar (8898) or placebo (8881)
and maintenance therapy with vorapaxar (2.5 mg
daily) at a median follow-up of 2.5 years. A reduction
of cardiovascular death, MI, or stroke at the expense of
increased risk of moderate to severe bleeding was
observed with vorapaxar.[45] However, the thrombin
receptor antagonist for clinical event reduction trial in
acute coronary syndrome, which randomized 12,944
patients with ACS (NSTEMI and UA but not STEMI) to
vorapaxar or placebo, highlighted safety risks related
to this treatment strategy.[46] Indeed, follow-up of the
trial was prematurely interrupted due to safety con-
cerns; in particular, the addition of vorapaxar to stan-
dard therapy did not significantly reduce the primary
composite end point (death from cardiovascular
causes, MI, stroke, recurrent ischemia with rehospitali-
zation, or urgent coronary revascularization) but sig-
nificantly increased the risk of major bleeding,
including intracranial hemorrhage.[46]
4. Parenteral antiplatelet therapy
4.1. GPI
Currently three different GPIs are commercially avail-
able. These drugs are able to abrogate the effects of
the IIb/IIIa receptor on platelet aggregation and adhe-
sion through reversible or irreversible inhibition
(Table 3).
Today, GPIs are not routinely recommended during
PCI.[2] In elective PCI, some benefits have been demon-
strated. The 3T/2R trial (3T/2R = tailoring treatment with
tirofiban in patients showing resistance to aspirin and/
or resistance to clopidogrel) showed reduction of MACE
without increase of bleeding using high-bolus tirofiban
in poor responders to aspirin or clopidogrel or both
[47], while the additive value of tirofiban administered
with the high-dose bolus in the prevention of ischemic
complications during high-risk coronary angioplasty
trial demonstrated a reduction of thrombotic complica-
tions, mainly MI, during high-risk PCI in patients pre-
treated with thienopyridines.[48] However, in elective
PCI, GPIs are currently restricted to bailout situations
(intra-procedural thrombus formation, slow-flow, threa-
tened vessel closure), although suggested benefits
emerged from anecdotal experiences.[2] Similarly, in
patients with NSTE-ACS undergoing PCI, most recent
trials (ISAR-REACT4, early glycoprotein IIb/IIIa inhibition
in non-ST-segment elevation-ACS) did not support an
important role for GPIs, particularly if administered
before PCI (upstream); hence, European guidelines
state that GPIs should not be used routinely in this
setting, while they should be considered in bailout or
thrombotic complications (class IIa, level C).[2]
Conversely, American guidelines support GPI use in
the case of NSTE-ACS with high-risk features (e.g. ele-
vated troponin) but without adequate pretreatment
with clopidogrel or ticagrelor (Class I, level A), as
upstream therapy in case of patients treated with an
early invasive strategy and DAPT with intermediate/
Table 2. Principal characteristics of P2Y12 inhibitors.
Clopidogrel Prasugrel Ticagrelor Cangrelor
Chemical class Thienopyridine Thienopyridine Cyclopentyl-
triazolopyrimidine
Stabilized ATP analogue
Administration Oral Oral Oral Intravenous
Dose 300–600 mg then 75 mg a day 60 mg then 10 mg
a day
180 mg then 90 mg
twice a day
30 μg/kg bolus then 4 μg/kg/
min infusion
Dose in CKD
eGFR 15–60 ml/min/1.73 m2 No adjustment No adjustment No adjustment No adjustment
eGFR < 15 ml/min/1.73 m2 Use only for selected indications (e.g. ST
prevention)
Not recommended Not recommended No adjustment
Binding to P2Y12 Irreversible Irreversible Reversible Reversible
Activation Prodrug, with variable Prodrug, with
predictable
Active drug, with
additional
Active drug
liver metabolism liver metabolism active metabolite
Onset of loading dose effecta 2–6 hb 30 minb 30 minb 2 minb
Duration effect 3–10 days 7–10 days 3–5 days 1–2 h
Withdrawal before surgery 5 days 7 days 5 days 1 h
Plasma half-life of active P2Y12
inhibitor
30–60 min 30–60 minc 6–12 h 5–10 min
Inhibition of adenosine
reuptake
No No Yes Yes (the inactive metabolite
only)
Abbreviations: ATP = adenosine triphosphate; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; ST = stent thrombosis.
a50% inhibition of ADP-induced platelet aggregation.
bOnset of effect may be delayed if intestinal absorption is delayed (e.g. by opiate).
cThe distribution phase half-life is reported since it most likely reflects duration of clinically relevant plasma levels, while the corresponding elimination phase
half-life is approximately 7 h.
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high-risk features (e.g. positive troponin) (Class IIb, level
B) and at the time of PCI in patients with NSTE-ACS and
high-risk features treated with UFH and adequately
pretreated with clopidogrel (class IIa, level B), but this
latter recommendation should be reserved to patients
without high risk of bleeding complications and does
not include prasugrel or ticagrelor because the data are
still insufficient to make specific recommendations.[3]
The most relevant clinical setting for the use of GPIs
remains that of STEMI.[49] In the era before preloading
with thienopyridines, several studies have shown that
GPI, mainly abciximab, added to UFH in STEMI patients
treated with primary PCI was associated with improved
outcomes, but also high-dose tirofiban showed to be
non-inferior to abciximab in this setting (multicentre
evaluation of single high-dose bolus tirofiban vs abcix-
imab with sirolimus-eluting stent or bare metal stent in
acute myocardial infarction study trial).[50] Also, in the
era of routine use of thienopyridines, GPIs could be
useful, indeed the FABOLUS-PRO (facilitation through
aggrastat by dropping or shortening infusion line in
patients with ST-segment elevation myocardial infarc-
tion compared to or on top of prasugrel given at load-
ing dose) showed that better platelet inhibition in
STEMI patients was reached by adding tirofiban bolus
to pretreatment with prasugrel and that a bolus fol-
lowed by 2 h infusion was necessary in patients pre-
treated with clopidogrel.[51]
However, subsequent trials (FINESSE [facilitated
intervention with enhanced reperfusion speed to stop
events], On-TIME2 [continuing tirofiban in myocardial
infarction evaluation], BRAVE 3, intracoronary abciximab
and aspiration thrombectomy in patients with large
anterior-myocardial infarction) provided contrasting
results on clinical benefits; thus, there is no definitive
answer regarding routine use of GPIs in primary PCI,
particularly when prasugrel or ticagrelor is used, and
the value of starting upstream of PCI remains uncer-
tain.[2]
Several studies have assessed the administration of
abciximab as intracoronary instead of an intravenous
bolus. Small studies suggested potential benefits of the
intracoronary route, but they were not confirmed in
large randomized trials and in a recent meta-analysis
of five randomized trials.[49,52,53]
The main concern related to GPI use is the increase
of bleeding complications, but to reduce this risk and
provide similar efficacy, abciximab could be adminis-
tered as only bolus without post-PCI infusion, as
shown in the facilitation through abciximab by drop-
ping infusion line in patients undergoing coronary
stenting-synergy with clopidogrel at high loading dose
regimen.[54]
Currently, European STEMI guidelines [2] state that:
(1) the upstream use of GPIs (versus in-lab use) may be
considered only in high-risk patients undergoing trans-
fer for primary PCI (class IIb, level B); (2) in-lab use is
reasonable for angiographic evidence of large throm-
bus, slow- or no-reflow, and other thrombotic compli-
cations as bailout therapy (class IIa, level C), although
this has not been tested in randomized trials. American
guidelines [4] recommend that: (1) it is reasonable to
begin treatment with an intravenous GPI such as abcix-
imab (level of evidence A), high-bolus-dose tirofiban
(level of evidence B), or double-bolus eptifibatide
(level of evidence B) at the time of primary PCI (with
Table 3. Principal characteristics of GPI.
Abciximab Eptifibatide Tirofiban
Type Fab fragment of chimeric human-murine
monoclonal antibody
Synthetic cyclic heptapeptide Synthetic nonpeptide
Molecular
weight
Large molecule Small molecule Small molecule
(47,515 Da) (832 Da) (496 Da)
Antigenicity Present Absent Absent
Inhibition Noncompetitive Competitive Competitive
Binding Irreversible Competitive Competitive
Plasma half-life 10–30 min 2.5–2.8 h 1.2–2 h
Receptor binding Minutes Seconds Seconds
Recovery of
platelet
function
24–48 h ≈4 h ≈4 h
Elimination
route
Spleen Renal 60–75% Renal 65–75%
Dosage
recommended
Bolus of 0.25 mg/kg IV followed by 0.125 µg/
kg/min infusion (maximum 10 µg/min) and
can be continued for 12 h after PCI.
Bolus of 180 µg/kg IV over 1–2 min, a
second bolus of 180 µg/kg 10 min later,
and an infusion of 2 µg/kg/min.
High-bolus dose 25 µg/kg IV, then 0.15 µg/
kg/min
Dose adjustment
in CKD
No dose adjustment is needed Infusion should be reduced by half if
eGFR < 50 ml/min/1.73 m2. Not
recommended if <30 or on hemodialysis
Bolus and infusion should be reduced by
50% with eGFR 15–30 ml/min/1.73 m2. Not
recommended if <15 ml/min/1.73 m2.
Abbreviations: CKD = chronic kidney disease; Da = dalton; eGFR = estimated glomerular filtration rate; IU = international units; GPI = glycoprotein IIb/IIIa
inhibitor; PCI = percutaneous coronary intervention.
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or without stenting or clopidogrel pretreatment) in
selected patients with STEMI who are receiving UFH
(class IIa); (2) it may be reasonable to administer an
intravenous GPI in the pre-catheterization laboratory
setting (e.g. ambulance, emergency department) to
patients with STEMI for whom primary PCI is intended
(class IIb, level B of recommendation); (3) it may be
reasonable to administer intracoronary abciximab to
patients with STEMI undergoing primary PCI (class IIb,
level B of recommendation).
4.2. Cangrelor
Cangrelor is an intravenous reversible P2Y12 inhibitor. It is
chemically known as N-2-methylthio-ethyl-2-(3,3,3-trilflour-
oprpylthiol)-5ʹ-adenyl acid, being this an analogue of ade-
nosine triphosphate (ATP), the natural antagonist of the
P2Y12 receptor (Table 2). It is dephosphorylated to the
nucleoside and its primary metabolite is essentially inac-
tive. It is characterized by a potent, predictable inhibition of
ADP-induced inhibition of platelet aggregation that is
virtually immediate (when administered as a bolus) and
rapidly reversible. Cangrelor achieves almost complete and
immediate inhibition of ADP-induced platelet aggregation
when administered as a bolus of 30 μg/kg, and continuous
infusion sustains the high degree of inhibition. The plasma
half-life is approximately 3–5 min, and platelet function is
restored within 1 h after cessation of infusion. In contrast to
other P2Y12 inhibitors, cangrelor is not characterized by a
significant renal or hepatic metabolism. Pivotal trials
showed a satisfactory rate of major bleeding events, but
no significant decrease of adverse cardiac events. Based on
phase II studies, the cangrelor phase III program
CHAMPION (cangrelor versus standard therapy to achieve
optimal management of platelet inhibition) was designed.
This program originally consisted of two randomized 1:1,
double-blind, double-dummy trials, CHAMPION PCI and
CHAMPION PLATFORM (Table 4).[55,56] The hypothesis
tested in these trials was that cangrelor, given during PCI,
could reduce thrombotic events compared with clopido-
grel administered at the beginning or at the end of PCI,
respectively, with an acceptable safety profile. The phase III
Table 4. Cangrelor phase III trials.
CHAMPION
PLATFORM
CHAMPION
PCI
CHAMPION
PHOENIX BRIDGE
Number of
patients
5295 (modified ITT) 8877 (ITT) 10,942 (modified ITT) 210
Patients
included
Requiring PCI (with or
without stent) in elective or ACS
excluding STEMI and P2Y12-naive
Requiring PCI (with or
without stent) in
patients with ACS. Previous daily
use of clopidogrel 75 mg allowed
Requiring either urgent or
elective PCI and P2Y12-
naive
ACS or treated with a coronary stent
and receiving a thienopyridine
Awaiting CABG
Cangrelor
protocol
30 μg/kg IV bolus and 4 μg/kg/min
IV infusion
30 μg/kg IV bolus and 4 μg/kg/min
IV infusion
30 μg/kg IV bolus and
4 μg/kg/min IV infusion
Infusion of 0.75 μg/kg/min IV on the
basis of a stage I dose-finding study
in 10 patients
Duration of
treatment
Minimum infusion of 2 h and a
maximum of 4 h, followed by
clopidogrel 600 mg
Infusion for at least 2 h or for the
duration of PCI, and a maximum of
4 h followed by clopidogrel 600 mg
Infusion for at least 2 h or
for the duration of PCI,
and a maximum of 4 h
followed by clopidogrel
600 mg
Thienopyridines were stopped
(clopidogrel 5 days before CABG,
prasugrel 7 days) and cangrelor or
placebo was administered for at
least 48 h, which was discontinued
1–6 h before CABG.
Comparator Clopidogrel 600 mg loading dose
(end of PCI)
Clopidogrel 600 mg loading dose
(before PCI)
Clopidogrel 300 or 600 mg
loading dose (before PCI)
Placebo
Primary end
point
Composite of death, MI, or IDR at
48 h
Composite of death from any
cause, MI, or IDR
at 48 h
Composite of death, MI,
IDR, or ST at 48 h
Platelet reactivity (PRU) assessed
daily
Safety
endpoint
Bleeding events at 48 h (single
events and categorized events
[ACUITY, GUSTO, TIMI criteria]
Bleeding events at 48 h (single
events and categorized events
[ACUITY, GUSTO, TIMI criteria]
Major/minor non-CABG-
related hemorrhage by
clinically relevant criteria
at 48 h (TIMI, GUSTO,
others);
Incidence of blood
product transfusion until
48 h, categorized
according to relationship
with CABG
Excessive CABG surgery-related
bleeding
Notes Enrollment was stopped when a
70% interim analysis concluded
that the trial would be unlikely to
show superiority for the primary
end point
Enrollment was stopped when a
70% interim analysis concluded
that the trial would be unlikely to
show superiority for the primary
end point
Abbreviations: ACS = acute coronary syndrome; ACUITY = acute catheterization and urgent intervention triage strategy; CABG = coronary artery bypass graft;
GUSTO = global use of strategies to open occluded coronary arteries; IDR = ischemia-driven revascularization; ITT = intention-to-treat; MI = myocardial
infarction; PCI = percutaneous coronary interventions; PRU = P2Y12 reaction unit; ST = stent thrombosis; STEMI = ST-segment elevation myocardial
infarction; TIMI = thrombolysis in myocardial infarction.
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CHAMPION-PCI and CHAMPION-PLATFORM trials com-
pared cangrelor with clopidogrel 600 mg in ACS patients
scheduled for PCI, but they were different with regard to
the timing of the clopidogrel dose administration.
Unfortunately, due to insufficient evidence of the cangrelor
clinical effectiveness, both trials were prematurely discon-
tinued. However, a further trial was subsequently planned
(CHAMPION-PHOENIX) [57] on the basis of important con-
siderations: (1) the reduction of ST and death from any
cause was observed in CHAMPION-PCI and CHAMPION-
PLATFORM trials; (2) the absence of expected overall ben-
efit of cangrelormay be related to the definition ofMI used,
which was considered inappropriate. Therefore, in the new
CHAMPION-PHOENIX trial, different from the two previous
studies, the following characteristics were included: (1) the
definition of MI as end point; (2) the comparator arm was
clopidogrel 300 or 600 mg, at the investigator discretion;
(3) the primary end point was the composite of death, MI,
ischemia-driven revascularization, or ST (including intrapro-
cedural) at 48 h; (4) the population of interest was restricted
to clopidogrel-naïve patients. The definition of MI used in
PHOENIX was based on the Second Universal definition of
MI for all types ofMI but PCI-related (type 4a) MI, where this
definition was expanded to include some elements (like
angiographic complications) that were later included in the
Third Universal MI definition.[57] In PHOENIX, PCI-related
MI could be assessed using cardiac biomarkers only if
troponin pre-PCI was normal or elevated but stable or
falling according to at least two samples over 6 h. A great
relevance was placed on the accurate assessment of base-
line status, in fact 98% of the enrolled patients had at least
two troponin values before PCI. Patients with NSTE-ACS,
with one or no biomarker assessment available, or increas-
ing biomarkers before PCI, required additional evidence of
MI, while in STEMI patients PCI-related MI was not adjudi-
cated by definition.
CHAMPION-PHOENIX (Table 4) randomized to can-
grelor or clopidogrel 11,145 patients who had not pre-
viously received a P2Y12 antagonist and required PCI,
including patients with stable angina and ACS (with or
without ST-segment elevation).[57] The primary efficacy
end point (composite of death, MI, ischemia-driven
revascularization or ST at 48 h after randomization)
was lower with cangrelor compared to clopidogrel
(4.7% vs. 5.9%, respectively, p = 0.005), driven by
decrease of acute periprocedural MI and ST. The benefit
from cangrelor was consistent across several prespeci-
fied subgroups, except for diabetic patients, who repre-
sented 27.8% of the global population (p = 0.26). No
differences were observed in the primary safety end
point (0.16% vs. 0.11%; p = 0.44). Overall, the data
suggest a promising role for cangrelor, particularly for
patients with ACS who could benefit from its
pharmacologic rapidity in the onset/offset of action.
Future studies are needed, however, to determine the
optimal way to transition ACS-PCI patients from can-
grelor to prasugrel or ticagrelor; such patients repre-
sented only 43% of patients recruited in the
CHAMPION-PHOENIX trial. The prespecified pooled ana-
lysis of patient-level data from the three cangrelor trials
confirmed the lower rates of PCI periprocedural throm-
botic complications (3.8% vs. 4.7%; p = 0.0007) and ST
(0.5% vs. 0.8%, p = 0.0008), with no difference in major
bleeding.[58]
Due to its rapid on/off effect, cangrelor also has
potential as a bridging agent in patients requiring sur-
gery, by adequately preventing ischemic events while
allowing rapid restoration of platelet function on ther-
apy discontinuation in the event of bleeding. The
BRIDGE (bridging anticoagulation in patients who
require temporary interruption of warfarin therapy for
an elective invasive procedure or surgery) study evalu-
ated the efficacy of this strategy for patients taking
clopidogrel who are scheduled for surgery (Table 4).
[59] A total of 210 patients taking thienopyridines for
ACS or after stent placement, who were awaiting CABG,
had their thienopyridine stopped and were then rando-
mized to either cangrelor (0.75 µg/kg/min) or placebo
for at least 48 h. The study drug was discontinued 1–6 h
before CABG surgery. Patients randomized to cangrelor
had lower levels of platelet reactivity throughout the
treatment period compared with placebo. There was no
significant difference in major bleeding prior to CABG
surgery, although minor bleeding episodes were
numerically higher with cangrelor.[59] These findings
demonstrate the potential role of cangrelor in this
common clinical setting; however, due to the use of a
surrogate end point (platelet reactivity as the primary
end point), this trial must be interpreted with caution.
Cangrelor has been approved in Europe and United
States for the reduction of thrombotic cardiovascular
events in adult patients with CAD undergoing PCI who
have not received an oral P2Y12 inhibitor prior to the
PCI procedure and in whom oral therapy with P2Y12
inhibitors is not feasible or desirable. Current European
guidelines on NSTE-ACS state that its use may be con-
sidered in P2Y12 inhibitor-naive patients undergoing
PCI (Class IIb level of evidence A).[60]
4.3. Elinogrel
Elinogrel has the unique advantage of being the only
P2Y12 inhibitor to be administered both orally and
intravenously. This could provide a rapid effect like
cangrelor, but without the need of shifting after PCI to
another oral P2Y12 inhibitor. However, elinogrel is not
EXPERT OPINION ON PHARMACOTHERAPY 11
currently approved due to absence of phase 3 trials
supporting its safety and effectiveness. The phase 2A
trial ERASE-MI (early rapid reversal of platelet thrombo-
sis with intravenous elinogrel before PCI to optimize
reperfusion in acute myocardial infarction) was
designed to investigate the safety and tolerability of
escalating doses (10, 20, 40, and 60 mg) as a single
intravenous bolus before diagnostic coronary angiogra-
phy (except primary PCI).[61] Seventy patients were
randomized in the dose-escalation study, but the dose
confirmation phase was not started because the trial
was prematurely terminated for administrative reasons.
No differences in serious adverse events, bleeding,
laboratory values, corrected TIMI frame count, or ST-
resolution were demonstrated between elinogrel and
placebo.[61] The phase 2B trial INNOVATE (intravenous
and oral administration of elinogrel to evaluate toler-
ability and efficacy)-PCI randomized 652 patients to
receive clopidogrel (300 or 600 mg loading dose before
PCI followed by 75 mg daily) or elinogrel (80 or 120 mg
IV followed by 50 or 100 or 150 mg twice daily).[62]
Elinogrel was found to be associated with increased
TIMI combined bleeding (largely related to increased
bleeding requiring medical attention), nonsignificant
increase of periprocedural MI, significant increase of
dyspnea and transaminase elevation, but there were
no cases of heart block, bradycardia, hypotension, or
liver failure.[62]
5. No-reflow treatment
During the last decades, the use of new pharmacolo-
gical and mechanical therapies allowing recanalization
of the infarct-related epicardial coronary artery (IRA)
has determined a significant improvement of the
acute MI prognosis. Many efforts have been made in
order to achieve a more rapid and effective IRA reca-
nalization and myocardial reperfusion, particularly
through primary PCI in the setting of STEMI.
However, mortality still remains considerable and
‘no-reflow’ phenomenon is responsible, at least in
part, for worse outcomes.[63,64] It is described as
the inability to effectively restore myocardial reperfu-
sion in a previously ischemic region in the IRA terri-
tory despite its successful recanalization.[63,64] The
rate of no-reflow widely ranges (5–50%) on the basis
of the method used for its assessment. Its pathogen-
esis is mainly related to ischemia damage (particularly
when >45 min), distal embolization, and reperfusion
injury.[63,64] Therefore, the reduction of time from
ischemia onset and the use of strategies reducing
ischemia and micro-thromboemboli could be able to
reduce no-reflow. A chronic therapy with statins also
seems to reduce no-reflow by reducing the suscept-
ibility of microcirculation to injury.[65,66]
Among the pharmacologic approaches to treat no-
reflow, the most studied include:
GPIs, particularly abciximab, have shown to provide
benefits in case of no-reflow.[67,68] Their use seems to
reduce thrombus burden, improving microvascular per-
fusion. Intracoronary administration of abciximab could
be considered for this indication.[52,67]
Adenosine induces coronary vasodilation and acti-
vates intracellular cardioprotective signaling pathways
and can be administered either intracoronarily or intra-
venously. It has demonstrated benefits on reduction of
no-reflow and improvement of outcomes.[69–72]
Generally, an intracoronary dose of 30–60 µg or more
is recommended during primary PCI in case of no-
reflow, particularly if a microvascular spasm is sup-
posed. Also, an investigational product (GP-531), able
to increase adenosine levels during ischemia, was
shown to reduce the ‘no-reflow’ and the infarct size in
an animal model.[73]
Other vasodilators such as verapamil, nitroprusside,
and nicardipine have also been investigated to
improve microvascular perfusion through counterba-
lancing coronary spasm and regulating endothelial
function.[74–77] Although initial benefits were
observed with nitroprusside, the intracoronary injec-
tion of 60 µg compared with placebo in a rando-
mized trial failed to improve coronary flow and
myocardial reperfusion.[74] The intracoronary admin-
istration of verapamil has been studied in several
studies and a meta-analysis of 539 patients has
shown benefits in reducing no-reflow/slow-reflow,
corrected TIMI frame count, wall motion index, and
also the 2-month rate of MACE.[77]
Nicorandil has been supposed to be useful for no-
reflow due to its anti-ischemia and antianginal benefits.
[78,79] Although some benefits have been described,
no firm data support its use and it is not widely used for
no-reflow during primary PCI.
6. Conclusions
The pharmacologic strategies to be used in the peripro-
cedural period in order to prevent and treat PCI com-
plications have increased in the last few years. New
interesting options have been recently developed, but
they need to be further studied in the near future to
demonstrate their beneficial efficacy and safety profiles
compared with the currently available drugs.
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7. Expert opinion
In the last decade, several efforts have been made in the
research regarding drugs to be used before, during, and
after PCI, with several important new developments cur-
rently available as compared with 10–20 years ago.
Further new drugs are hoped to be available in the next
years in order to minimize ischemic and bleeding events
and to improve patients’ prognosis during and after PCI.
The anticoagulation therapy has achieved a satisfy-
ing balance between benefits and risks, because bivalir-
udin has demonstrated to have similar ischemic
complications compared to heparin, but a lower rate
of bleeding events.
The evidence concerning other anticoagulants (i.e.
argatroban, otamixaban, M118, pegnivacogin/aniva-
mersen) is still preliminary and none of them could be
currently considered as a potential alternative to UFH,
LMWH, or bivalirudin.
Also, the pharmacopeia of antiplatelet agents has been
greatly expanded in the last few years. The addition of
clopidogrel to aspirin was clearly demonstrated to be
beneficial for all patients undergoing PCI, particularly
those with ACS in whom the duration of the DAPT should
be longer that those patients undergoing PCI for stable
CAD. Indeed, DAPT has become the cornerstone of all
patients treated with PCI. Prasugrel and ticagrelor have
clearly demonstrated to be associated with better out-
comes compared with clopidogrel in the setting of ACS
patients. Moreover, ticagrelor has recently demonstrated
to improve prognosis when given well beyond 1 year in
post-MI patients with stable CAD, in addition to aspirin
therapy.[44] All these findings have open the door for a
present and a future changing approach to patients with
CAD compared to the previous standard of clopidogrel
plus aspirin. Moreover, other new drugs have been devel-
oped with other potential implications for the future
management of these patients. Whereas elinogrel did
not provide encouraging results, vorapaxar and cangrelor
seem to be a reasonable treatment option in selected
patient subsets. In particular, cangrelor has the unique
characteristic of being immediately active/inactive
through its venous administration and might become a
precious support for therapy before and during PCI, parti-
cularly for those with ACS in whom a more rapid antipla-
telet effect is desired. As concerned GPIs, although their
role has been downsized in the last years, they are still
important for interventional cardiologists during the PCI
and probably will continue to be precious in the future
particularly in the setting of STEMI patients and in the case
of PCI complications (thrombosis, no-reflow).
Finally, the no-reflow still remains a crucial complica-
tion during PCI because it negatively affects the
patient’s prognosis despite the vessel patency being
properly achieved by stenting. In this field, the research
has been focused mainly on the complex pathophysio-
logical mechanisms and on the use of old drugs rather
than designing or studying new drugs. The future per-
spective on the no-reflow phenomenon would be that
of reducing its incidence (by improving antithrombotic
therapy, reducing timing to PCI in ACS patients, and
implementing PCI procedures) and trying to find more
effective strategies to reverse it when occurs.
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The most effective antithrombotic therapy for preventing
ischemic complications while limiting bleeding risk in patients
with an acute coronary syndrome (ACS) who are undergoing a
percutaneous coronary intervention (PCI) is strongly debated.1,2
Bivalirudin and unfractionated heparin (UFH) are 2 of the most
commonly used treatment regimens and have been compared in
different trials.1 Unfractionated heparin used to be the only
anticoagulant drug used before and during PCI in ACS patients. The
main advantage of using UFH is that it can be antagonized with
intravenous protamine sulfate. However, UFH has some limita-
tions including: a) the need for activated clotting time monitoring
due to its variable dose-response relationship with poor predict-
able effects, b) platelet activation, and c) risk of heparin-induced
thrombocytopenia (HIT) and HIT-thrombosis syndrome. Conse-
quently, in the last few years, new anticoagulants with more
pharmacologic and clinical advantages than UFH have been tested,
although UFH still remains the standard of care for thrombosis
prevention during PCI.1
Bivalirudin is a 20 amino-acid synthetic polypeptide that binds
directly to thrombin thus inhibiting its enzymatic activity.
Bivalirudin cannot be antagonized, but due to its short half-life,
its effects are limited by stopping its infusion, and activated
clotting time monitoring is not mandatory to verify the effects.
Furthermore, bivalirudin does not activate platelets and does not
cause HIT given that it does not interact with plasma proteins or
cells.1 In recent years, bivalirudin has emerged as an intriguing
alternative to UFH, with the main advantage being the lower rates
of major bleeding in patients with ACS, particularly in those with
ST-segment elevation myocardial infarction (STEMI).3–6 However,
some concerns about bivalirudin use have been raised in terms of
stent thrombosis (ST).3,5,7,8
Recently, interest in comparing these 2 drugs has been further
increased due to the publication of the MATRIX trial.9 This is
the latest and largest study comparing bivalirudin and UFH in the
setting of ACS. In a contemporary clinical practice (high percentage
of revascularization, patients equally balanced to radial and
femoral approach, UFH arm without routine use of glycoprotein
IIb/IIIa inhibitors (GPI), prehospital antithrombotic treatment,
inclusion of new platelet P2Y12 antagonists), this trial showed that
the rates of major adverse cardiovascular events and net adverse
clinical events were not significantly lower in ACS patients treated
with bivalirudin compared with those treated with UFH at
30-days. Notably, bivalirudin was associated with lower rates of
major bleeding and mortality but higher rates of ST as previously
shown in some of the other trials, although these observations
are limited by statistical considerations since the trial was not
powered to explore these single endpoints. However, given the
previous results of HORIZONS-AMI3 and BRIGHT4 trials, it will be
interesting to see if the results of MATRIX will be confirmed or not
during a longer follow-up.
In the article published in Revista Espan˜ola de Cardiologı´a,
Verdoia et al10 report the results of a systematic review and meta-
analysis of randomized clinical trials comparing bivalirudin and
UFH in patients with ACS. The study included 12 randomized
clinical trials and 32 746 patients. The 12 trials were categorized as
subgroups for clinical presentation (5 for STEMI and 6 for non—ST-
segment elevation acute coronary syndrome [NSTEACS] and 1,
MATRIX, divided the subgroups into both). Outcomes were
analyzed at 30 days, although 1 trial provided in-hospital (SWITCH
III) data and 1 at 48 hours after discharge (PROTECT-TIMI30). At
30 days, there were no significant differences in all-cause mortality
(odds ratio [OR] = 0.91; 95% confidence interval [95%CI], 0.77-1.08;
P = .28) without significant overall heterogeneity (I2 = 4%). This
result was consistent between subgroups of STEMI and NSTEACS
(interaction P = .12), although a significant heterogeneity was
observed (I2 = 58%) with an opposite trend: NSTEACS OR 1.13 (95%
CI, 0.82-1.55); STEMI OR 0.84 (95% CI 0.69-1.02). Stent thrombosis
was higher in the bivalirudin treated patients (OR = 1.42; 95% CI
1.09-1.83; P = .008), although this result was calculated from only
8 of 12 trials and it is not clear if it referred to definite or to definite/
probable ST. Interestingly, some heterogeneity emerged between
subgroups (I2 = 45%) with ST being significantly increased only in
the 5 STEMI trials analyzed (MATRIX data are missing) but not
in the 3 NSTEACS trials. Bivalirudin was found to be associated
with lower rates of major bleeding (OR = 0.60; 95% CI, 0.54-0.67;
P < .0001), consistently in STEMI and NSTEACS trials. However, a
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high heterogeneity emerged in the latter analysis (I2 = 71%) and the
meta-regression analysis demonstrated that this finding was
significantly driven by the differential use of GPI with bivalirudin
benefits observed in trials with higher use of GPI (P = .02). The
study did not explore whether the use of GPI might have influenced
mortality or ST. Similarly, there was no exploration of other
outcomes (ie, cardiac mortality, myocardial infarction or compos-
ite endpoints) as well as the impact of other relevant differential
factors (ie, access site or use on new P2Y12 inhibitors).
Systematic reviews and meta-analyses identify, appraise and
synthesize all evidence on a specific research question. They allow
an increase in the statistical power of treatment comparisons
beyond that of individual studies. Thus, meta-analyses are
considered the highest level of evidence and could contribute to
help physicians stay up to date and to guide healthcare decisions in
daily clinical practice.
However, the increasing popularity of these studies has led to
duplicate meta-analyses on the same topic, sometimes with
different results, which make their interpretation difficult for
readers.11 Notably, a recent study showed that more than half of
meta-analyses have at least 1 overlapping meta-analysis, and some
topics had up to 13 overlapping meta-analyses.12 This is exactly
what has happened in the comparison between bivalirudin and
UFH. When making a search in PubMed, in which we restricted the
search to publications from 2014 onward, we found that 24 meta-
analyses have been published on this topic (Table).7,8,10,13–33
Although there were some differences among these 24 studies, this
is probably one of the more appropriate examples of overlapping
meta-analysis on the same clinical question, which significantly
contributes to confusion among readers.
A further relevant consideration on the performance of a meta-
analysis concerns its methodology. The main principle to pool
different studies in a single analysis is that the data/studies
included should be similar (study design, eligibility criteria, type of
patients and procedures, type of outcomes and their definitions,
etc). Are we seeing an analysis of apples and oranges in the
comparison of bivalirudin and UFH in ACS or PCI?34 When
considering the studies included, one could argue that clinical
characteristics and clinical practice differ strongly among them.
Trials including different clinical presentations (STEMI, NSTEMI,
unstable angina) are pooled together and this is per se a relevant
confounding factor. Nevertheless, the TENACITY trial was included
in the meta-analysis, even though a quarter of patients underwent
elective PCI. If we focus on the 5 trials on STEMI patients and the
MATRIX subgroup of STEMI patients, important differences should
be considered when pooling these studies together and interpret-
ing the overall results: a) the bivalirudin regimen of post-PCI
infusion significantly varied across trials, from being not routinely
adopted in the HORIZONS-AMI, BRAVE-4 (Bavarian Reperfusion
Alternatives Evaluation-4)35 and HEAT-PPCI,36 to being used in
most of the patients in the EUROMAX trial5 (low-dose or high-dose
left at the operator’s discretion, being finally used in 77.5% and
Table
Meta-analyses on Bivalirudin vs UFH Appearing in PubMed From 2014 to 1st April 2016
First author Journal Year Setting Studies included
Verdoia et al10 Rev Esp Cardiol 2016 ACS 12
Barria Perez et al13 Am J Cardiol 2016 PCI 30 (12 RCTs)
Zhang et al14 Int J Cardiol 2016 PCI 17
Shah et al15 Am Heart J 2016 STEMI 6
Farag et al16 Open Heart 2015 ACS 19
Li et al17 Medicine 2015 PCI 17
Navarese et al18,a Thromb Haemost 2015 ACS 16
Kianoush et al19,b Thromb Res 2015 PCI 25
Bavry et al20 PloS One 2015 PCI 15
Nairooz et al21,c Catheter Cardiovasc Interv 2015 PCI 4
Ferrante et al22 Catheter Cardiovasc Interv 2015 STEMI 3
Ibebuogu er al23,c Am J Cardiovasc Drugs 2015 PCI 6
Verdoia et al24 Thromb Res 2015 PCI 22
Capodanno et al7 Eur Heart J Acute Cardiovasc Care 2015 STEMI 5
Piccolo et al25,d Thromb Haemost 2015 PCI 11
Huang et al26 Angiology 2015 PCI 20
Navarese et al8 J Am Coll Cardiol Intv 2015 ACS 13
Stone GW et al27,e J Am Coll Cardiol 2015 STEMI 2 (patient-level)
Cassese et al28 Eurointervention 2015 PCI 10
Lipinski et al29 Cardiovasc Revasc Med 2014 PCI 14
Bangalore et al30,f BMJ 2014 STEMI 5
Cavender et al31 Lancet 2014 PCI 16
Nairooz et al32 Am J Cardiol 2014 PCI/STEMI 7/2
Tarantini et al33 Am Heart J 2014 PCI 12
ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; RCTs, randomized clinical trials; STEMI; ST-segment elevation myocardial infarction; UFH,
unfractionated heparin.
a This is a network meta-analysis including various antithrombotic regimens for a total of 42 trials, but 16 were those comparing bivalirudin vs UFH with or without GPI.
b This meta-analysis includes RCTs comparing bivalirudin and an active control.
c This meta-analysis is focused on diabetic patients.
d This meta-analysis is focused on stent thrombosis as outcome.
e This is a patient-level meta-analysis of HORIZONS-AMI and EUROMAX trials.
f This is a network meta-analysis including various antithrombotic regimens for a total of 22 trials, but 5 were those comparing bivalirudin vs UFH with or without GPI.
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22.5%, respectively) and BRIGHT (only high-dose allowed) or
randomized in the MATRIX to post-PCI infusion or no infusion
(low-dose or high-dose left at the operator’s discretion, being used
in approximately 63% and 37% respectively); b) GPI use differed
markedly across trials (HORIZONS-AMI: 7.5% and 97.7% in the
bivalirudin and UFH groups; EUROMAX: 11.5% and 69.1%; BRIGHT:
4.4% and 52.9%; HEAT-PPCI: 13.5% and 15.5%; BRAVE-4: 3.0% and
6.1%; MATRIX: 4.6% and 25.9%); c) access site for PCI (almost all
femoral access in HORIZONS-AMI and BRAVE-4; three-quarters
radial access in BRIGHT and HEAT-PPCI; well balanced in
EUROMAX and MATRIX); d) new potent P2Y12 inhibitors
(prasugrel or ticagrelor) were frequently used in EUROMAX,
HEAT-PPCI, BRAVE-4 (all patients received prasugrel in the
bivalirudin arm while all UFH patients received clopidogrel) and
MATRIX, but not in HORIZONS-AMI or BRIGHT; e) the UFH dose
adopted in heparin monotherapy-treated patients ranged from
70 U/kg in HEAT-PPCI to 100 U/kg in EUROMAX and BRIGHT with
the first trial not showing that bivalirudin reduced major bleeding
compared with the other trials; f) the HEAT-PPCI, which was the
only trial to support UFH advantages over bivalirudin, enrolled
all-comer patients but was the only single-center trial; and
g) EUROMAX also included 8.5% of patients treated with
enoxaparin in the control group. Similarly, substantial differences
also can be found in the 6 trials classified as NSTEACS, such as
clinical practice and definitions (for example the BAS [Bivalirudin
Angioplasty Study] trial was published in 199537 and was
reanalyzed in 200138 and enrolled patients in 1993-1994).
In addition to the obvious limitations related to the different
designs and patient characteristics of the primary trials included, it
should also be considered that pooled data from publications do
not offer the opportunity to adjust, and—most of all—published
data are sometimes managed or pooled differently from the
original design of the trial. In the present analysis, for example,
the BRIGHT trial, which randomized patients to 3 arms, was
considered as 2-arm by pooling the UFH and UFH+GPI arms.
Moreover, the MATRIX trial enrolled all ACS patients and for the
present analysis its results were divided for STEMI and NSTEACS.
Although sensitivity and meta-regression analyses often help to
explore sources of heterogeneity in standard meta-analyses, only
patient-level data overcome common limitations by improving
internal validity and allowing time-to-event, subgroup, and
covariable adjusted analyses.
The results of the present meta-analysis by Verdoia et al seem
to be in line with previous literature regarding the benefits of
bivalirudin on major bleeding and its risks in terms of ST. However,
it is also important to stress that the main increase in ST related to
bivalirudin use has been commonly described in acute rather than
subacute ST5–8 and that the post-PCI infusion of bivalirudin
appears to reduce ST risks.4,5 Future detailed subanalyses from the
MATRIX trial could help to clarify this issue because this trial
randomized patients to receive the bivalirudin post-PCI infusion or
not and also included a large number of patients treated with the
2 different infusion regimens.9 Verdoia et al, however, found no
significant differences between bivalirudin and UFH in terms of
mortality. The major doubt that remains unresolved is exactly the
impact of the drug on mortality: is bivalirudin able to reduce all-
cause and cardiovascular death? Major bleeding is an important
prognostic determinant of mortality, but all-cause death seems
nonsignificantly decreased despite the reduction of major bleeding
events.8,10 Interestingly, bivalirudin seems to offer benefits in
mortality only in patients with STEMI undergoing primary-PCI,
as shown in this and other meta-analyses.7,10,15 However, this
apparent differential impact on STEMI and NSTEACS could also be
related to the characteristics and differences among the trials
included in the analysis. Indeed, the most contemporary MATRIX
trial demonstrated consistent results between ACS subgroups.9
Overall, the absence of mortality benefits here described reinforces
the concept that reducing bleeding, even the most severe bleeding
events, does not necessarily translate into a reduction of major
adverse cardiovascular events. It is possible that the increase of ST,
as well as a trend toward an increase of myocardial infarction and
target vessel revascularization, could mitigate the advantages in
bleeding events, which would help to explain the absence of
differences in composite events and the uncertainties on mortality
benefits.7,9,15
Finally, the cost-effectiveness of choosing bivalirudin rather
than UFH should be considered. Are the overall results sufficient to
justify the use of bivalirudin despite its much more higher cost?
Some important suggestions for readers have been previously
published to aid understanding and to contrast uncertainties when
overlapping meta-analyses obtain discordant conclusions.11
In conclusion, do we finally have a winner between bivalirudin
and UFH? Although well conducted, this meta-analysis does not
provide a definitive conclusion and practitioners still need to use
clinical judgment in deciding between a costly bleeding-saving
treatment strategy and the costless standard of care, consisting of
UFH and limited use of GPI. It remains to be understood whether
the use of bivalirudin translates into a real mortality advantage and
whether prolongation of infusion after PCI in a full PCI regimen
mitigates the risks of ST without trade-offs. While research is still
on-going to tease out these outstanding questions, the market
penetration of bivalirudin will be probably more affected by the
affordability of generic bivalirudin formulations than by its
scientific merits.
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EDITORIAL COMMENT
Bivalirudin in Current Practice
Melius Abundare Quam Deficere?*
Marco Valgimigli, MD, PHD, Giuseppe Gargiulo, MD
T he optimal antithrombotic therapy forpreventing ischemic complications whilelimiting bleeding risk in patients with acute
coronary syndrome (ACS) who are undergoing
primary percutaneous coronary intervention (pPCI)
remains an area of great controversy (1). The quest
for an ideal parenteral anticoagulant agent able to
replace unfractionated heparin (UFH) has remained
an ongoing topic for investigation since the 1990s.
Bivalirudin was compared with UFH first in experi-
mental models and then in patients with coronary
artery disease (CAD). During this long-lasting
journey, contrasting evidence has been accumulated
on bivalirudin efficacy and safety profile compared
with UFH. After initial promising findings in the early
1990s, HAS/BAS (Hirulog/Bivalirudin Angioplasty
Study) published in 1995 (conducted in 1993 to 1994)
showed that bivalirudin (bolus of 1.0 mg/kg followed
by infusion of 2.5 mg/kg/h for 4 h, then 0.2 mg/kg/h
for 14 to 20 h) had similar efficacy but lower bleeding
risk than high and prolonged regimen of UFH (bolus
of 175 U/kg followed by infusion of 15 U/kg/h for 18
to 24 h). However, the sponsor interpreted these find-
ings as insufficient to warrant further investment,
which led to terminate further clinical studies with
bivalirudin, including the ongoing TIMI-8 (Thrombo-
lysis In Myocardial Infarction-8) trial. Bivalirudin
was then acquired by The Medicines Company, which
profoundly invested in a new era of clinical studies. A
meta-analysis of randomized trials by Kong et al. (2)
in 1999 suggested that bivalirudin was as effective
as UFH but safer in patients with CAD. The results
of HAS/BAS study were also reanalyzed updating
the primary endpoint definition and modifying its
time point, which generated new evidence suggesting
that bivalirudin was superior for both efficacy and
safety at 7 and 90 days (3). Multiple trials were then
conducted with bivalirudin at a revised bolus and
post-bolus infusion regimen in patients with Non-
ST-segment elevation-acute coronary syndrome
(NSTE-ACS), ST-segment elevation myocardial infarc-
tion (STEMI), or both (Online Table 1) against various
comparator arms (UFH with or without glycoprotein
IIb/IIIa inhibitors [GPI] and on top of various oral
P2Y12 inhibitors), which resulted in a large body of
evidence for bivalirudin in PCI patients.
Across studies and regimens, bivalirudin has
consistently shown to mitigate the bleeding risk (4).
This benefit has been observed against all possible
comparator arms, including UFH plus routine use of
GPI, UFH plus liberal or restricted use of GPI and UFH
alone. Importantly, not only access site bleeding
was attenuated by bivalirudin but also those not
access site–related, which are at least as frequent in
ACS patients and most likely more detrimental on
prognosis.
Yet, in STEMI patients undergoing pPCI, all major
studies so far conducted have identified a sizable risk
of acute stent thrombosis (ST) across all compactors,
including UFHþGPI, UFH"GPI, or UFH alone (4).
This observation fueled an ongoing debate on the
value of this anticoagulant option in current practice,
where, despite growing awareness on the impor-
tance of bleeding on patient outcomes, the avoid-
ance of ST remains the number 1 obsession by all
interventionists.
To mitigate that risk, 2 studies have protocol
mandated and 1 study randomly allocated bivalirudin
patients to continue the treatment well after PCI.
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Results were mixed as in only 1 of the 3 trials no
excess of ST risk was observed in patients receiving
post-intervention bivalirudin infusion. Yet, focusing
on the post-PCI bivalirudin regimen, results are
apparently concordant in suggesting that only a full
PCI regimen after intervention can mitigate that
risk excess to null.
In this issue of JACC: Cardiovascular Interventions,
Shah et al. (5) should be commended for the comple-
tion of a traditional and network meta-analysis,
apparently restricted to patients with STEMI under-
going pPCI, with a specific focus to acute ST. This
analysis is timely and provides additional evidence
that the effects of anti-thrombotic drugs are largely
regimen-dependent. Bivalirudin was unsurprisingly
associated to a significantly higher risk of acute ST (4).
Yet, the new finding is that a post-pPCI infusion at full
dose (Biv-Full) (1.75 mg/kg/h) abolished that risk as
compared with the low-dose (Biv-Low) (0.25 mg/kg/h)
or no infusion as well as with UFH. Notably, the sig-
nificant benefit of bivalirudin over UFH in terms of
reduction of major bleeding persisted in studies using
the post-pPCI Biv-Full treatment strategy.
These results are potentially practice changing
and largely consistent with the updated recommen-
dations for use of bivalirudin in the United States.
However, there are numerous limitations to this
analysis, which should raise caution.
Shah et al. (5) aimed at restricting the analysis to
pPCI patients. Yet, they included a sizable proportion
of NSTE-ACS patients. Although the inclusion of all
MATRIX (Minimizing Adverse Hemorrhagic Events by
Transradial Access Site and Systemic Implementation
of Angiox) study patients (i.e., including 3,203 [44%]
NSTE-ACS) was acknowledged, Shah et al. (5) did not
clarify to the readers that 269 NSTE-ACS patients also
included in BRIGHT (Bivalirudin in Acute Myocardial
Infarction vs Heparin and GPI Plus Heparin Trial)
were pooled due to unavailability of individual pa-
tient data. This may have diluted the relative and
absolute risks of ST in bivalirudin-treated patients.
The main limitation to this analysis however is
its largely nonrandomized and unadjusted nature.
Network meta-analyses are very powerful and
increasingly accepted tools to enhance study power
and artificially create comparator arm(s) levering on
the relative risk reductions observed within ran-
domized arms. Yet, its use for observational findings
may amplify the biases known to occur when treat-
ment is not randomly allocated.
The MATRIX trial remains today the only
study where patients treated with bivalirudin were
randomized to receive post-PCI infusion or no infu-
sion of bivalirudin (6). Hence, the data comparing
post-PCI versus no post-PCI bivalirudin infusion (Biv-
No) are largely indirect since HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) and HEAT-
PPCI (How Effective Are Antithrombotic Therapies
in Primary Percutaneous Coronary Intervention)
studies provided only data on Biv-No strategy,
whereas BRIGHT and EUROMAX (European Ambu-
lance Acute Coronary Syndrome Angiography Trial)
provided only data on Biv-Full. Even more worrisome
is the comparison between low versus full post-PCI
regimen.
No study so far has randomized the post-PCI
bivalirudin regimen. A full bivalirudin regimen was
protocol mandated in BRIGHT, whereas both the
EUROMAX and MATRIX studies left post-PCI regi-
mens to the discretion of the treating physicians,
which was consistent with current and previous
European or North American bivalirudin label,
respectively.
Consequently, the Biv-Full population is a mixture
of patients derived from BRIGHT, EUROMAX, and
MATRIX studies, whereas Biv-Low is a smaller
population that was derived exclusively from the
EUROMAX and MATRIX trials. In both trials, the
2 populations were imbalanced in number with a
majority of patients receiving Biv-Low rather than
Biv-Full (63% vs. 37% in MATRIX and 77.5% vs. 22.5%
in EUROMAX, respectively). Operators have probably
applied a clinical selection in using a regimen over
the other, administering Biv-Low to patients with
higher bleeding risk whereas Biv-Full to those at
increased risk of acute ST.
Additionally, the heterogeneity in the duration of
post-PCI infusion should be considered as further
potential source of bias. In EUROMAX, bivalirudin
had to be prolonged per protocol for at least 4 h after
PCI and overall the median duration was 268 min
(interquartile range [IQR]: 250 to 292 min). In
BRIGHT, the protocol stated that Biv-Full was at least
30 min, but maximum 4 h and that a supplementary
infusion at low dose (0.2 mg/kg/h) was allowed up to
20 h at operator’s discretion. All patients received a
post-PCI infusion of Biv-Full for a median duration
of 180 min (IQR: 148 to 240) but 115 patients (15.6%)
thereafter also received the optional 0.2 mg/kg/h dose
for a median duration of 400 min (IQR: 375 to 410
min). Finally, MATRIX patients assigned to post-PCI
infusion were to receive Biv-Full for up to 4 h or
Biv-Low for at least 6 h and, overall the average du-
rations were 264 " 209.8 min and 433 " 248 min,
respectively.
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Hence, these results would need prospective vali-
dation. Currently, the SWEDEHEART (Bivalirudin vs
Heparin in NSTEMI and STEMI in Patients on Modern
Antiplatelet Therapy in SWEDEHEART A Multicenter,
Prospective, Randomized Controlled Clinical Trial
Based on the SWEDEHEART Platform; NCT02311231)
trial is ongoing. Although it will contribute to the
evidence in the long-lasting journey of bivalirudin
versus UFH comparison, the protocol mandates the
use of post-PCI bivalirudin at full regimen only.
Should bivalirudin be used from now on in STEMI
patients with post-PCI full dose infusion? An
individual patient meta-analysis is planned which
shall at least try to adjust for measurable and
measured confounders given the largely non-
randomized nature of this comparison. Whether
prolonging bivalirudin at full PCI regimen after PCI
mitigates ST while not increasing bleeding risks re-
mains to be ascertained.
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ABSTRACT
BACKGROUND Contrasting evidence exists on the comparative efficacy and safety of bivalirudin and unfractionated
heparin (UFH) in relation to the planned use of glycoprotein IIb/IIIa inhibitors (GPIs).
OBJECTIVES This study assessed the efficacy and safety of bivalirudin compared with UFH with or without GPIs in
patients with acute coronary syndrome (ACS) who underwent invasive management.
METHODS In the MATRIX (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic
Implementation of AngioX) program, 7,213 patients were randomly assigned to receive either bivalirudin or UFH with or
without GPIs at discretion of the operator. The 30-day coprimary outcomes were major adverse cardiovascular events
(MACEs) (a composite of death, myocardial infarction, or stroke), and net adverse clinical events (NACEs) (a composite of
MACEs or major bleeding).
RESULTS Among 3,603 patients assigned to receive UFH, 781 (21.7%) underwent planned treatment with GPI before
coronary intervention. Bailout use of GPIs was similar between the bivalirudin and UFH groups (4.5% and 5.4%)
(p ¼ 0.11). At 30 days, the 2 coprimary endpoints of MACEs and NACEs, as well as individual endpoints of mortality,
myocardial infarction, stent thrombosis or stroke did not differ among the 3 groups after adjustment. Compared with the
UFH and UFHþGPI groups, bivalirudin reduced bleeding, mainly the most severe bleeds, including fatal and nonaccess
site#related events, as well as transfusion rates and the need for surgical access site repair. These findings were not
influenced by the administered intraprocedural dose of UFH and were confirmed at multiple sensitivity analyses,
including the randomly allocated access site.
CONCLUSIONS In patients with ACS, the rates of MACEs and NACEs were not significantly lower with bivalirudin
than with UFH, irrespective of planned GPI use. However, bivalirudin significantly reduced bleeding complications,
mainly those not related to access site, irrespective of planned use of GPIs. (Minimizing Adverse Haemorrhagic
Events by Transradial Access Site and Systemic Implementation of AngioX [MATRIX]; NCT01433627)
(J Am Coll Cardiol 2018;71:1231–42) © 2018 by the American College of Cardiology Foundation.
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T he most effective antithrombotictherapy in patients with an acutecoronary syndrome (ACS) who are
undergoing a percutaneous coronary inter-
vention (PCI) remains strongly debated
(1–3). Unfractionated heparin (UFH) (with
or without planned glycoprotein IIb/IIIa
inhibitors [GPIs]) and bivalirudin are 2 of the
most commonly used antithrombotic strate-
gies and have been compared in different
trials since the 1990s (4). Conflicting data
have accumulated since then, so that the
comparative safety and effectiveness profile
of bivalirudin compared with UFH alone in
current practice remains unclear.
Although some trials, including EURO-
MAX (European Ambulance Acute Coronary
Syndrome Angiography Trial) (5,6) and
BRIGHT (Bivalirudin in Acute Myocardial
Infarction vs Heparin and GPI Plus Heparin
Trial) (7), have shown benefits in terms
of major bleeding reduction related to bivalirudin
use, irrespective of GPI use in the UFH arm, the
HEAT-PPCI (How Effective are Antithrombotic Ther-
apies in Primary Percutaneous Coronary
Intervention) and the most recent VALIDATE-
SWEDEHEART (Bivalirudin versus Heparin in
ST-Segment and Non–ST-Segment Elevation Myocar-
dial Infarction in Patients on Modern Antiplatelet
Therapy in the Swedish Web System for Enhancement
and Development of Evidence-based Care in Heart
Disease Evaluated according to Recommended Ther-
apies Registry Trial) studies showed that heparin
alone did not increase bleeding events compared with
bivalirudin (8,9). Because planned use of GPIs in pa-
tients who receive UFH has been reduced, this
discrepancy is notable.
Therefore, we pre-specified to examine the
comparative efficacy and safety profile of bivalirudin
compared with UFH alone or with UFHþGPI in the
context of the largest contemporary trial to assess the
value of bivalirudin in an all-comer ACS population
and the only study that allocated access site by
random selection.
METHODS
STUDY DESIGN. The MATRIX (Minimizing Adverse
Haemorrhagic Events by Transradial Access Site and
Systemic Implementation of AngioX) antithrombin
study is a randomized, multicenter trial that
compared bivalirudin (the use of GPIs was restricted
SEE PAGE 1243
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Myocardial Infarction
UFH = unfractionated heparin
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to bailout conditions) with UFH (use of GPI was left to
the discretion of the investigator) in 7,213 patients
with ACS with or without ST-segment elevation, in
whom PCI was planned. This was 1 of 3 trials of
the MATRIX program (NCT01433627), as previously
described (1,10).
STUDY PATIENTS. Patients with non#ST-segment
elevation acute coronary syndrome (NSTE-ACS) were
eligible if they had a history consistent with new or
worsening cardiac ischemia that occurred while they
were at rest or with minimal activity within 7 days
before randomization, and met at least 2 high-risk
criteria among the following: 1) age of 60 years or
older, elevation of cardiac biomarkers, or electrocar-
diographic changes compatible with ischemia; and 2) if
they were considered to be candidates for PCI after
completion of coronary angiography. Patients with ST-
segment elevation myocardial infarction (STEMI)
were eligible if they presented within 12 h of the onset
of symptoms or between 12 and 24 h after symptom
onset if there was evidence of continued ischemia or
previous fibrinolytic treatment. The main inclusion
and exclusion criteria were previously reported (1,10).
All patients provided written informed consent.
STUDY PROTOCOL AND RANDOMIZATION. Using a
computer-generated random sequence, we random-
ized patients in a 1:1 ratio to receive bivalirudin or
UFH, with a random block size stratified by the type
of ACS (i.e., with ST-segment elevation vs. without
ST-segment elevation) intended for or ongoing use of
a P2Y12 inhibitor (clopidogrel vs. ticagrelor or prasu-
grel), and study site. Patients with STEMI underwent
randomization before coronary angiography; patients
with NSTE-ACS underwent randomization immedi-
ately after completion of angiography but before the
start of PCI.
All interventions were administered in an open-
label fashion. Bivalirudin was given according to the
product labeling, with a bolus of 0.75 mg/kg of body
weight, followed immediately by an infusion of
1.75 mg/kg/h until completion of PCI. Receiving a post-
PCI bivalirudin infusion or no post-PCI infusion was
randomly determined (MATRIX treatment duration).
In those assigned to bivalirudin prolongation, the
choice between 2 regimens (full dose for up to 4 h or
reduced dose of 0.25mg/kg/h for at least 6 h) wasmade
at the discretion of the treating physicians. UFH was
administered at a dose of 70 to 100 U or 50 to 70 U/kg
in patients who did not receive or received GPI,
respectively. Subsequent UFH dose adjustment
based on the activated clotting time was left to the
discretion of the treating physicians. A GPI could be
administered before PCI in all patients in the UFH
group based on judgment of the treating physician,
but the drug was to be administered in the bivalirudin
group only to patients who had periprocedural
ischemic complications (i.e., no-reflow or giant
thrombus) after PCI. The use of other medications
was allowed according to professional guidelines.
FOLLOW-UP AND STUDY OUTCOMES. Clinical
follow-up was performed at 30 days. Two coprimary
30-day composite outcomes were pre-specified: major
adverse cardiovascular events (MACEs), defined as the
composite of all-cause mortality, myocardial infarc-
tion (MI), or stroke; and net adverse clinical events
(NACEs), defined as the composite of MACEs or major
bleeding not related to coronary artery bypass graft
(CABG) (Bleeding Academic Research Consortium
type 3 or 5). Secondary outcomes included each
component of the composite outcomes, cardiovascu-
lar mortality, and stent thrombosis (ST). Bleeding was
also assessed and adjudicated on the basis of the TIMI
(Thrombolysis In Myocardial Infarction) and GUSTO
(Global Utilization of Streptokinase and Tissue Plas-
minogen Activator) scales. Stent thrombosis was
defined as the definite or probable occurrence of a
stent-related thrombotic event according to the Aca-
demic Research Consortium classification. All out-
comes were pre-specified. An independent clinical
events committee blinded to treatment allocation
adjudicated all suspected events.
STATISTICAL ANALYSIS. The trial was powered for
superiority on the 2 coprimary composite outcomes
at 30 days, expecting a rate reduction of 30% that
corresponded to a rate ratio of 0.70.
All analyses were performed per intention-to-treat
principle, including all patients in the analysis
based on the allocated access. Events up to 30 days
post-randomization were considered. We analyzed
primary and secondary outcomes as time to first
event using the Mantel-Cox method, accompanied by
log-rank tests to calculate corresponding 2-sided
p values. We did not perform any adjustments
for multiple comparisons but set the alpha error at
2.5% to correct for the 2 coprimary outcomes.
We analyzed secondary outcomes with a 2-sided
alpha set at 5% to allow conventional interpretation
of results. Survival curves were constructed using
Kaplan-Meier estimates. We performed stratified an-
alyses according to the dosage of heparin used or to
access site (radial or femoral) and we estimated
possible interaction terms across comparisons.
Whether the attribution to bivalirudin and UFH
arms was randomized, the planned use of GPI was
only allowed in the UFH arm and was left to the
discretion of the physician. Because of the
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nonrandomized nature of the planned GPI use in
the UFH arm, clinical outcomes were adjusted for
confounders. A multivariable logistic model was used
to obtain adjusted analyses, and the variables
included were age, sex, body mass index, type of ACS,
center, diabetes, smoking, hypertension, previous
MI, previous CABG, previous stroke and/or transient
ischemic attack (TIA), peripheral vascular disease,
Killip class, previous lytic therapy, creatinine, intra-
aortic balloon pump, heparin use before arrival at the
catheterization laboratory, full procedural success,
duration of the procedure, treated vessel, SYNTAX
(Synergy Between Percutaneous Coronary Interven-
tion with Taxus and Cardiac Surgery) score, proximal
location of lesion, large vessel caliber (defined
by using a stent $3 mm or post-dilatation
balloon $3.5 mm), $1 complex lesion, thrombus in
the treated lesion, TIMI flow 0 to 1 before PCI, and
clopidogrel at discharge.
As a sensitivity analysis, a propensity score was
calculated to minimize any selection bias due to the
differences in clinical characteristics between the
2 treatment groups (i.e., UFH alone and UFH þ GPI).
For each patient in the UFH arm, a propensity score
that indicated the likelihood of receiving GPI was
calculated by the use of a nonparsimonious multi-
variable logistic regression. A propensity score that
indicated the predicted probability of receiving a
specific treatment conditional on the observed cova-
riates was then calculated from the logistic equation
for each patient. Then, the formula was also applied
for patients in the bivalirudin arm (in which
per-protocol planned GPI was not allowed). The
following variables were included: age, sex, body
mass index, type of ACS, center, diabetes, smoking,
family history of coronary artery disease, hyperten-
sion, hypercholesterolemia, previous MI, previous
PCI, previous stroke and/or TIA, peripheral vascular
disease, chronic obstructive pulmonary disease,
Killip class, cardiac arrest, left ventricular ejection
fraction, creatinine, treated vessel, SYNTAX score,
proximal location of the lesion, large and/or small
vessel caliber, $1 complex lesion, thrombus in the
treated lesion, TIMI flow 0 to 1 before PCI, medication
in the catheterization laboratory (fondaparinux,
enoxaparin, beta-blockers, ticagrelor, clopidogrel),
and lesions treated and stented per patients. The
individual propensity score was incorporated into the
adjustment model to compare outcomes. In addition,
to reduce the effect of treatment selection bias and
potential confounding related to these observational
comparisons, we performed rigorous adjustment for
significant differences in the baseline characteristics
of patients with propensity score matching using the
following algorithm: 1:1 optimal match with a 0.1 SD
caliper and no replacement. All analyses were
performed using the STATA version 14.1 (StataCorp,
College Station, Texas) and R (R Foundation, Vienna,
Austria) statistical packages.
RESULTS
PATIENTS. The MATRIX-antithrombin trial enrolled
7,213 patients with ACS from 78 centers in Italy, the
Netherlands, Spain, and Sweden between October
2011 and November 2014. Of these patients, 3,610
patients were assigned to receive bivalirudin and
3,603 were assigned to receive UFH, of whom 2,822
received UFH without planned GPI infusion (UFH
alone group) and 781 patients underwent planned
treatment with GPI before coronary intervention
(UFHþGPI group). In the bivalirudin and UFH groups,
a similar proportion of patients received bailout
use of GPIs during treatment (4.5% and 5.4%,
respectively; p ¼ 0.11).
Clinical and procedural characteristics as well
as choice of concomitant medications during hospi-
talization or at discharge were imbalanced among
the 3 groups (Online Tables 1 to 3).
Compared with UFH alone, patients with planned
GPI were younger, more frequently male, smokers,
and had STEMI or cardiac arrest at presentation, but
less frequently had a history of diabetes, hyperten-
sion, MI, PCI, CABG, stroke/TIA, chronic obstructive
pulmonary disease, peripheral vascular disease, or
renal dysfunction (Online Table 1). Patients who
received planned GPI infusion experienced a longer
procedural time, despite more frequently receiving
single-vessel intervention. They more frequently
required intra-aortic balloon pumps; recanalization
of occluded, proximally located, and thrombus-
containing lesion(s); and required larger stent
diameters and longer overall stent length (Online
Table 2).
CLINICAL OUTCOMES. Unadjusted and adjusted
comparisons for the 30-day outcomes across the
groups are shown in Tables 1 to 3. After multivariable
or propensity-score adjustment, the 2 coprimary
endpoints of MACEs and NACEs did not differ among
the 3 groups (Figure 1, Central Illustration, Tables 1 to 3).
Similarly, there were no within-groups differences
with respect to the individual endpoints of mortality,
MI, ST, or stroke (Tables 1 to 3). However, bivalirudin
remained associated with reduced risks of bleeding
due to lower rates of the most severe occurrences,
including fatal and nonaccess site#related, mainly
gastrointestinal events compared with UFH alone
and to lower risks of both gastrointestinal and
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TABLE 1 Clinical Outcomes up to 30 Days in Bivalirudin Versus UFH Alone
All
(N ¼ 7,213)
Bivalirudin
(n ¼ 3,610)
UFH Alone
(n ¼ 2,822)
Unadjusted
Rate Ratio
(95% CI) p Value
Multivariable
Adjusted Rate Ratio
(95% CI) p Value
Propensity
Score Adjusted
Rate Ratio
(95% CI) p Value
Death, MI, stroke 762 (10.6) 371 (10.3) 327 (11.6) 0.89 (0.76#1.03) 0.113 1.02 (0.85#1.22) 0.843 0.96 (0.81#1.13) 0.618
Death, MI, stroke, BARC 3 or 5 845 (11.7) 401 (11.1) 362 (12.8) 0.87 (0.75#1.00) 0.047 0.96 (0.81#1.14) 0.664 0.92 (0.78#1.07) 0.282
Death, MI, stroke,
BARC 3 or 5, TVR, ST
860 (11.9) 410 (11.4) 367 (13.0) 0.87 (0.76#1.01) 0.059 0.97 (0.82#1.15) 0.739 0.92 (0.79#1.08) 0.309
Death 142 (2.0) 59 (1.6) 65 (2.3) 0.71 (0.5#1.01) 0.055 0.91 (0.43#1.94) 0.805 0.71 (0.48#1.04) 0.08
Cardiovascular death 136 (1.9) 56 (1.6) 63 (2.2) 0.69 (0.48#1.00) 0.046 1.01 (0.45#2.28) 0.976 0.69 (0.47#1.03) 0.072
MI 610 (8.5) 307 (8.5) 258 (9.1) 0.93 (0.79#1.1) 0.391 1.03 (0.85#1.24) 0.771 1.03 (0.86#1.23) 0.778
Stroke 29 (0.4) 13 (0.4) 15 (0.5) 0.68 (0.32#1.42) 0.301 0.56 (0.24#1.28) 0.17 0.58 (0.27#1.28) 0.178
TIA 14 (0.2) 5 (0.1) 7 (0.2) 0.56 (0.18#1.76) 0.313 0.91 (0.21#4.02) 0.905 0.73 (0.22#2.42) 0.611
TVR 87 (1.2) 52 (1.4) 25 (0.9) 1.63 (1.01#2.62) 0.044 1.50 (0.90#2.51) 0.118 1.40 (0.85#2.29) 0.186
ST definite 57 (0.8) 36 (1.0) 15 (0.5) 1.88 (1.03#3.43) 0.037 1.77 (0.91#3.41) 0.091 1.56 (0.84#2.91) 0.163
Acute 33 (0.5) 20 (0.6) 9 (0.3) 1.74 (0.79#3.82) 0.164 1.85 (0.76#4.50) 0.178 1.45 (0.64#3.27) 0.369
Subacute 24 (0.3) 16 (0.4) 6 (0.2) 2.08 (0.82#5.33) 0.117 1.56 (0.57#4.25) 0.386 1.72 (0.65#4.54) 0.275
ST definite/probable 80 (1.1) 45 (1.2) 26 (0.9) 1.35 (0.83#2.19) 0.218 1.57 (0.88#2.83) 0.129 1.32 (0.79#2.23) 0.291
Acute 38 (0.5) 22 (0.6) 12 (0.4) 1.43 (0.71#2.90) 0.313 1.93 (0.80#4.68) 0.144 1.25 (0.59#2.66) 0.562
Subacute 42 (0.6) 23 (0.6) 14 (0.5) 1.28 (0.66#2.50) 0.459 1.18 (0.52#2.64) 0.692 1.39 (0.68#2.85) 0.371
Bleeding 873 (12.1) 391 (10.8) 345 (12.2) 0.89 (0.77#1.02) 0.101 0.84 (0.71#1.00) 0.044 0.85 (0.72#1.00) 0.043
BARC 1 427 (5.9) 190 (5.3) 170 (6.0) 0.87 (0.71#1.07) 0.201 0.83 (0.66#1.04) 0.10 0.84 (0.68#1.05) 0.126
BARC 2 304 (4.2) 151 (4.2) 107 (3.8) 1.10 (0.86#1.41) 0.437 1.03 (0.79#1.34) 0.827 1.09 (0.84#1.42) 0.505
BARC 3 116 (1.6) 44 (1.2) 50 (1.8) 0.69 (0.46#1.03) 0.069 0.69 (0.45#1.07) 0.096 0.65 (0.42#0.99) 0.045
BARC 3a 62 (0.9) 24 (0.7) 24 (0.9) 0.78 (0.44#1.38) 0.392 1.03 (0.55#1.90) 0.935 0.76 (0.42#1.37) 0.361
BARC 3b 49 (0.7) 16 (0.4) 25 (0.9) 0.50 (0.27#0.94) 0.027 0.42 (0.22#0.81) 0.01 0.47 (0.24#0.90) 0.024
BARC 3c 5 (0.1) 4 (0.1) 1 (0) 3.13 (0.35#27.98) 0.282 — — 2.17 (0.23-20.59) 0.499
BARC 4 5 (0.1) 1 (0) 4 (0.1) 0.20 (0.02#1.75) 0.104 — — 0.31 (0.03#2.98) 0.31
BARC 5 21 (0.3) 5 (0.1) 14 (0.5) 0.28 (0.10#0.78) 0.009 — — 0.20 (0.06#0.62) 0.006
BARC 5a 15 (0.2) 4 (0.1) 9 (0.3) 0.35 (0.11#1.13) 0.065 0.26 (0.03#2.08) 0.206 0.24 (0.06#0.96) 0.043
BARC 5b 6 (0.1) 1 (0) 5 (0.2) 0.16 (0.02#1.34) 0.051 — — 0.12 (0.01#1.12) 0.063
BARC 3 or 5 137 (1.9) 49 (1.4) 64 (2.3) 0.60 (0.41#0.87) 0.006 0.65 (0.43#0.99) 0.043 0.55 (0.37#0.81) 0.003
BARC 3 or 5 access site 51 (0.7) 19 (0.5) 23 (0.8) 0.65 (0.35#1.19) 0.155 0.65 (0.34#1.24) 0.19 0.66 (0.35#1.26) 0.209
BARC 3 or 5 nonaccess site 86 (1.2) 30 (0.8) 41 (1.5) 0.57 (0.36#0.92) 0.018 0.64 (0.37#1.12) 0.117 0.49 (0.30#0.81) 0.005
BARC 2, 3 or 5 441 (6.1) 200 (5.5) 171 (6.1) 0.91 (0.75#1.12) 0.389 0.90 (0.72#1.13) 0.361 0.88 (0.71#1.10) 0.257
BARC 2, 3 or 5 access site 237 (3.3) 105 (2.9) 98 (3.5) 0.84 (0.64#1.10) 0.206 0.81 (0.61#1.09) 0.165 0.86 (0.65#1.14) 0.298
BARC 2, 3 or 5 nonaccess site 204 (2.8) 95 (2.6) 73 (2.6) 1.02 (0.75#1.38) 0.912 1.04 (0.74#1.46) 0.83 0.92 (0.66#1.27) 0.599
TIMI major 49 (0.7) 16 (0.4) 26 (0.9) 0.48 (0.26#0.9) 0.019 0.39 (0.18#0.83) 0.015 0.38 (0.20#0.74) 0.005
TIMI minor 50 (0.7) 17 (0.5) 20 (0.7) 0.66 (0.35#1.27) 0.212 0.79 (0.40#1.56) 0.492 0.65 (0.33#1.29) 0.216
TIMI major/minor 99 (1.4) 33 (0.9) 46 (1.6) 0.56 (0.36#0.88) 0.010 0.57 (0.34#0.95) 0.03 0.49 (0.30#0.79) 0.004
GUSTO severe 42 (0.6) 16 (0.4) 20 (0.7) 0.63 (0.32#1.21) 0.158 0.67 (0.29#1.54) 0.35 0.47 (0.23#0.95) 0.037
GUSTO moderate 42 (0.6) 16 (0.4) 17 (0.6) 0.74 (0.37#1.46) 0.376 0.92 (0.43#1.96) 0.823 0.79 (0.39#1.62) 0.526
GUSTO mild 784 (10.9) 358 (9.9) 304 (10.8) 0.92 (0.79#1.07) 0.289 0.86 (0.72#1.02) 0.081 0.89 (0.75#1.05) 0.173
GUSTO moderate/severe 84 (1.2) 32 (0.9) 37 (1.3) 0.68 (0.42#1.09) 0.103 0.79 (0.45#1.37) 0.398 0.61 (0.37#1.01) 0.053
Composite of surgical access site
repair and blood transfusion
103 (1.4) 36 (1.0) 51 (1.8) 0.55 (0.36#0.85) 0.006 0.52 (0.32#0.84) 0.008 0.58 (0.37#0.91) 0.018
Surgical access site repair 17 (0.2) 5 (0.1) 8 (0.3) 0.49 (0.16#1.49) 0.199 0.52 (0.15#1.74) 0.289 0.58 (0.18#1.84) 0.354
Blood transfusion 94 (1.3) 31 (0.9) 47 (1.7) 0.52 (0.33#0.81) 0.004 0.47 (0.28#0.79) 0.004 0.54 (0.33#0.87) 0.011
Distribution of BARC 3 or 5
Intracranial bleeding 7 (0.1) 4 (0.1) 3 (0.1) 1.04 (0.23#4.66) 0.957 0.48 (0.06#3.92) 0.496 0.83 (0.18#3.91) 0.815
Pericardial bleeding 28 (0.4) 11 (0.3) 14 (0.5) 0.61 (0.28#1.35) 0.222 0.76 (0.24#2.40) 0.637 0.49 (0.21#1.13) 0.094
Gastrointestinal bleeding 27 (0.4) 6 (0.2) 16 (0.6) 0.29 (0.11#0.75) 0.006 0.31 (0.12#0.85) 0.023 0.26 (0.09#0.71) 0.008
Genito-urinary bleeding 12 (0.2) 5 (0.1) 2 (0.1) 1.95 (0.38#10.07) 0.415 2.80 (0.40#19.41) 0.298 2.04 (0.39#10.64) 0.399
Access site bleeding 49 (0.7) 19 (0.5) 22 (0.8) 0.68 (0.37#1.25) 0.207 0.70 (0.36#1.33) 0.27 0.69 (0.36#1.33) 0.267
Other bleeding 10 (0.1) 3 (0.1) 5 (0.2) 0.47 (0.11#1.96) 0.288 1.17 (0.12#11.52) 0.891 0.37 (0.07#1.90) 0.232
Values are n (%) unless otherwise indicated.
BARC [ Bleeding Academic Research Consortium; CI ¼ confidence interval; GUSTO ¼ Global Utilization of Streptokinase and Tissue Plasminogen Activator; MI ¼ myocardial infarction; ST ¼ stent
thrombosis; TIA ¼ transient ischemic attack; TIMI ¼ Thrombolysis In Myocardial Infarction; TVR ¼ target vessel revascularization; UFH ¼ unfractionated heparin.
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TABLE 2 Clinical Outcomes up to 30 Days in Bivalirudin Versus UFH Plus Planned GPI
All
(N ¼ 7,213)
Bivalirudin
(n ¼ 3,610)
UFH þ GPI
(n ¼ 781)
Unadjusted
Rate Ratio
(95% CI) p Value
Multivariable
Adjusted Rate Ratio
(95% CI) p Value
Propensity
Score Adjusted
Rate Ratio
(95% CI) p Value
Death, MI, stroke 762 (10.6) 371 (10.3) 64 (8.2) 1.25 (0.96#1.64) 0.094 0.99 (0.70#1.39) 0.947 0.95 (0.70#1.29) 0.731
Death, MI, stroke, BARC 3 or 5 845 (11.7) 401 (11.1) 82 (10.5) 1.06 (0.83#1.34) 0.642 0.80 (0.59#1.09) 0.153 0.79 (0.60#1.05) 0.108
Death, MI, stroke,
BARC 3 or 5, TVR, ST
860 (11.9) 410 (11.4) 83 (10.6) 1.07 (0.84#1.35) 0.581 0.81 (0.60#1.10) 0.170 0.81 (0.62#1.07) 0.146
Death 142 (2.0) 59 (1.6) 18 (2.3) 0.71 (0.42#1.2) 0.2 0.60 (0.29#1.27) 0.184 0.75 (0.40#1.41) 0.377
Cardiovascular death 136 (1.9) 56 (1.6) 17 (2.2) 0.71 (0.41#1.23) 0.219 0.60 (0.28#1.29) 0.190 0.76 (0.40#1.45) 0.406
MI 610 (8.5) 307 (8.5) 45 (5.8) 1.48 (1.08#2.02) 0.014 1.05 (0.73#1.50) 0.800 0.97 (0.68#1.38) 0.856
Stroke 29 (0.4) 13 (0.4) 1 (0.1) 2.81 (0.37#21.5) 0.298 2.40 (0.27#21.18) 0.43 4.50 (0.56#35.99) 0.156
TIA 14 (0.2) 5 (0.1) 2 (0.3) 0.54 (0.1#2.79) 0.456 0.57 (0.06#5.46) 0.624 0.45 (0.07#2.77) 0.391
TVR 87 (1.2) 52 (1.4) 10 (1.3) 1.12 (0.57#2.21) 0.733 1.16 (0.57#2.39) 0.678 1.20 (0.58#2.49) 0.619
ST definite 57 (0.8) 36 (1) 6 (0.8) 1.30 (0.55#3.08) 0.553 1.55 (0.63#3.85) 0.341 1.68 (0.67#4.21) 0.265
Acute 33 (0.5) 20 (0.6) 4 (0.5) 1.08 (0.37#3.16) 0.886 1.53 (0.50#4.68) 0.459 1.65 (0.53#5.12) 0.385
Subacute 24 (0.3) 16 (0.4) 2 (0.3) 1.73 (0.4#7.53) 0.459 1.36 (0.28#6.59) 0.699 1.73 (0.36#8.19) 0.492
ST definite/probable 80 (1.1) 45 (1.2) 9 (1.2) 1.08 (0.53#2.21) 0.83 1.28 (0.57#2.86) 0.554 1.33 (0.62#2.87) 0.467
Acute 38 (0.5) 22 (0.6) 4 (0.5) 1.19 (0.41#3.45) 0.749 1.62 (0.53#4.94) 0.394 1.80 (0.58#5.53) 0.306
Subacute 42 (0.6) 23 (0.6) 5 (0.6) 1.00 (0.38#2.62) 0.992 0.78 (0.23#2.65) 0.686 0.97 (0.34#2.77) 0.953
Bleeding 873 (12.1) 391 (10.8) 137 (17.5) 0.62 (0.51#0.75) <0.001 0.64 (0.5#0.83) 0.001 0.64 (0.50#0.80) <0.001
BARC 1 427 (5.9) 190 (5.3) 67 (8.6) 0.61 (0.46#0.81) 0.001 0.72 (0.52#1.00) 0.052 0.70 (0.51#0.96) 0.029
BARC 2 304 (4.2) 151 (4.2) 46 (5.9) 0.71 (0.51#0.99) 0.041 0.75 (0.51#1.10) 0.139 0.72 (0.49#1.04) 0.080
BARC 3 116 (1.6) 44 (1.2) 22 (2.8) 0.43 (0.26#0.72) 0.001 0.46 (0.25#0.85) 0.013 0.43 (0.24#0.77) 0.005
BARC 3a 62 (0.9) 24 (0.7) 14 (1.8) 0.37 (0.19#0.72) 0.002 0.30 (0.13#0.68) 0.004 0.32 (0.15#0.70) 0.004
BARC 3b 49 (0.7) 16 (0.4) 8 (1.0) 0.43 (0.19#1.01) 0.046 0.60 (0.24#1.50) 0.275 0.43 (0.16#1.10) 0.078
BARC 3c 5 (0.1) 4 (0.1) 0 (0) — — — — — —
BARC 4 5 (0.1) 1 (0) 0 (0) — — — — — —
BARC 5 21 (0.3) 5 (0.1) 2 (0.3) 0.54 (0.10#2.79) 0.456 — — 0.57 (0.09#3.63) 0.553
BARC 5a 15 (0.2) 4 (0.1) 2 (0.3) 0.43 (0.08#2.36) 0.319 — — 0.38 (0.05#2.73) 0.336
BARC 5b 6 (0.1) 1 (0) 0 (0) — — — — — —
BARC 3 or 5 137 (1.9) 49 (1.4) 24 (3.1) 0.44 (0.27#0.72) 0.001 0.47 (0.26#0.85) 0.013 0.44 (0.25#0.77) 0.004
BARC 3 or 5 access site 51 (0.7) 19 (0.5) 9 (1.2) 0.46 (0.21#1.01) 0.047 0.57 (0.23#1.37) 0.209 0.44 (0.18#1.07) 0.070
BARC 3 or 5 nonaccess site 86 (1.2) 30 (0.8) 15 (1.9) 0.43 (0.23#0.8) 0.006 0.42 (0.19#0.95) 0.036 0.45 (0.22#0.91) 0.027
BARC 2, 3 or 5 441 (6.1) 200 (5.5) 70 (9.0) 0.62 (0.47#0.81) <0.001 0.64 (0.46#0.89) 0.009 0.61 (0.45#0.84) 0.002
BARC 2, 3 or 5 access site 237 (3.3) 105 (2.9) 34 (4.4) 0.67 (0.45#0.98) 0.04 0.66 (0.42#1.03) 0.067 0.60 (0.39#0.93) 0.021
BARC 2, 3 or 5 nonaccess site 204 (2.8) 95 (2.6) 36 (4.6) 0.57 (0.39#0.84) 0.004 0.65 (0.40#1.03) 0.069 0.65 (0.42#1.00) 0.049
TIMI major 49 (0.7) 16 (0.4) 7 (0.9) 0.49 (0.20#1.20) 0.113 0.47 (0.15#1.43) 0.183 0.68 (0.26#1.79) 0.430
TIMI minor 50 (0.7) 17 (0.5) 13 (1.7) 0.28 (0.14#0.58) <0.001 0.29 (0.11#0.76) 0.012 0.30 (0.13#0.70) 0.006
TIMI major/minor 99 (1.4) 33 (0.9) 20 (2.6) 0.36 (0.20#0.62) <0.001 0.37 (0.18#0.76) 0.007 0.43 (0.23#0.81) 0.009
GUSTO severe 42 (0.6) 16 (0.4) 6 (0.8) 0.58 (0.23#1.47) 0.245 0.67 (0.20#2.20) 0.505 0.75 (0.27#2.11) 0.590
GUSTO moderate 42 (0.6) 16 (0.4) 9 (1.2) 0.38 (0.17#0.87) 0.017 0.29 (0.11#0.80) 0.017 0.29 (0.12#0.74) 0.010
GUSTO mild 784 (10.9) 358 (9.9) 122 (15.6) 0.63 (0.52#0.78) <0.001 0.68 (0.53#0.88) 0.004 0.67 (0.52#0.85) 0.001
GUSTO moderate/severe 84 (1.2) 32 (0.9) 15 (1.9) 0.46 (0.25#0.85) 0.011 0.42 (0.20#0.88) 0.022 0.46 (0.23#0.92) 0.027
Composite of surgical access
site repair and blood transfusion
103 (1.4) 36 (1) 16 (2.0) 0.49 (0.27#0.88) 0.014 0.42 (0.20#0.88) 0.022 0.39 (0.20#0.76) 0.006
Surgical access site repair 17 (0.2) 5 (0.1) 4 (0.5) 0.27 (0.07#1.01) 0.036 0.25 (0.06#1.15) 0.075 0.18 (0.04#0.79) 0.023
Blood transfusion 94 (1.3) 31 (0.9) 16 (2.0) 0.42 (0.23#0.77) 0.004 0.33 (0.15#0.72) 0.005 0.34 (0.17#0.67) 0.002
Distribution of BARC 3 or 5
Intracranial bleeding 7 (0.1) 4 (0.1) 0 (0) — — — — — —
Pericardial bleeding 28 (0.4) 11 (0.3) 3 (0.4) 0.79 (0.22#2.84) 0.722 0.81 (0.16#4.23) 0.807 1.02 (0.26#4.05) 0.976
Gastrointestinal bleeding 27 (0.4) 6 (0.2) 5 (0.6) 0.26 (0.08#0.85) 0.016 0.18 (0.03#0.93) 0.041 0.16 (0.04#0.64) 0.009
Genito-urinary bleeding 12 (0.2) 5 (0.1) 5 (0.6) 0.22 (0.06#0.75) 0.008 0.07 (0.01#0.67) 0.021 0.22 (0.06#0.88) 0.032
Access site bleeding 49 (0.7) 19 (0.5) 8 (1.0) 0.51 (0.22#1.17) 0.108 0.65 (0.26#1.64) 0.36 0.51 (0.20#1.28) 0.150
Other bleeding 10 (0.1) 3 (0.1) 2 (0.3) 0.32 (0.05#1.94) 0.194 — — 0.11 (0.01#1.51) 0.098
Values are n (%) unless otherwise indicated.
GPI ¼ glycoprotein IIb/IIIa inhibitor; other abbreviations as in Table 1.
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TABLE 3 Clinical Outcomes up to 30 Days in UFH Plus Planned GPI Versus UFH Alone
All
(N ¼ 7,213)
UFHþGPI
(n ¼ 781)
UFH Alone
(n ¼ 2822)
Unadjusted
Rate Ratio
(95% CI) p Value
Multivariable
Adjusted Rate Ratio
(95% CI) p Value
Propensity
Score Adjusted
Rate Ratio
(95% CI) p Value
Death, MI, stroke 762 (10.6) 64 (8.2) 327 (11.6) 0.71 (0.54#0.92) 0.011 0.96 (0.66#1.4) 0.827 1.02 (0.73#1.44) 0.888
Death, MI, stroke, BARC 3 or 5 845 (11.7) 82 (10.5) 362 (12.8) 0.82 (0.64#1.04) 0.101 1.09 (0.77#1.52) 0.633 1.15 (0.84#1.57) 0.377
Death, MI, stroke,
BARC 3 or 5, TVR, ST
860 (11.9) 83 (10.6) 367 (13.0) 0.82 (0.64#1.04) 0.096 1.05 (0.75#1.47) 0.785 1.10 (0.81#1.50) 0.526
Death 142 (2.0) 18 (2.3) 65 (2.3) 1.00 (0.59#1.69) 0.998 0.84 (0.22#3.18) 0.799 0.82 (0.41#1.63) 0.565
Cardiovascular death 136 (1.9) 17 (2.2) 63 (2.2) 0.98 (0.57#1.67) 0.926 0.59 (0.12#2.89) 0.515 0.74 (0.36#1.51) 0.401
MI 610 (8.5) 45 (5.8) 258 (9.1) 0.63 (0.46#0.86) 0.004 0.99 (0.66#1.47) 0.959 1.11 (0.76#1.64) 0.581
Stroke 29 (0.4) 1 (0.1) 15 (0.5) 0.24 (0.03#1.82) 0.134 0.11 (0.01#1.50) 0.098 0.15 (0.02#1.37) 0.093
TIA 14 (0.2) 2 (0.3) 7 (0.2) 1.03 (0.21#4.97) 0.968 2.60 (0.32#21.17) 0.372 1.42 (0.20#9.84) 0.725
TVR 87 (1.2) 10 (1.3) 25 (0.9) 1.45 (0.69#3.01) 0.322 1.08 (0.47#2.45) 0.859 0.86 (0.35#2.14) 0.747
ST definite 57 (0.8) 6 (0.8) 15 (0.5) 1.45 (0.56#3.73) 0.443 1.09 (0.38#3.17) 0.871 0.78 (0.24#2.52) 0.683
Acute 33 (0.5) 4 (0.5) 9 (0.3) 1.61 (0.49#5.21) 0.426 1.22 (0.30#5.00) 0.780 0.81 (0.19#3.47) 0.775
Subacute 24 (0.3) 2 (0.3) 6 (0.2) 1.20 (0.24#5.97) 0.820 1.22 (0.20#7.68) 0.829 0.74 (0.11#5.24) 0.766
ST definite/probable 80 (1.1) 9 (1.2) 26 (0.9) 1.25 (0.59#2.67) 0.562 1.13 (0.43#2.93) 0.805 1.02 (0.39#2.65) 0.969
Acute 38 (0.5) 4 (0.5) 12 (0.4) 1.20 (0.39#3.73) 0.747 1.22 (0.30#5.00) 0.780 0.80 (0.2#3.27) 0.757
Subacute 42 (0.6) 5 (0.6) 14 (0.5) 1.29 (0.46#3.58) 0.624 1.22 (0.30#4.95) 0.782 1.26 (0.35#4.59) 0.724
Bleeding 873 (12.1) 137 (17.5) 345 (12.2) 1.43 (1.18#1.75) <0.001 1.27 (0.97#1.68) 0.084 1.27 (0.97#1.66) 0.082
BARC 1 427 (5.9) 67 (8.6) 170 (6.0) 1.42 (1.07#1.89) 0.014 1.14 (0.79#1.65) 0.471 1.08 (0.75#1.55) 0.687
BARC 2 304 (4.2) 46 (5.9) 107 (3.8) 1.55 (1.10#2.19) 0.012 1.45 (0.95#2.20) 0.084 1.48 (0.95#2.30) 0.084
BARC 3 116 (1.6) 22 (2.8) 50 (1.8) 1.59 (0.96#2.63) 0.067 1.66 (0.86#3.18) 0.129 1.84 (0.98#3.46) 0.059
BARC 3a 62 (0.9) 14 (1.8) 24 (0.9) 2.11 (1.09#4.07) 0.023 3.07 (1.20#7.86) 0.019 2.82 (1.24#6.44) 0.014
BARC 3b 49 (0.7) 8 (1.0) 25 (0.9) 1.16 (0.52#2.56) 0.721 0.94 (0.35#2.47) 0.892 1.10 (0.41#2.93) 0.851
BARC 3c 5 (0.1) 0 (0) 1 (0) — — — — — —
BARC 4 5 (0.1) 0 (0) 4 (0.1) — — — — — —
BARC 5 21 (0.3) 2 (0.3) 14 (0.5) 0.52 (0.12#2.27) 0.373 — — 0.25 (0.05#1.34) 0.105
BARC 5a 15 (0.2) 2 (0.3) 9 (0.3) 0.80 (0.17#3.72) 0.778 — — 0.37 (0.06#2.28) 0.284
BARC 5b 6 (0.1) 0 (0) 5 (0.2) — — — — — —
BARC 3 or 5 137 (1.9) 24 (3.1) 64 (2.3) 1.35 (0.85#2.17) 0.203 1.41 (0.74#2.68) 0.293 1.33 (0.74#2.41) 0.342
BARC 3 or 5 access site 51 (0.7) 9 (1.2) 23 (0.8) 1.41 (0.65#3.06) 0.376 1.49 (0.57#3.91) 0.417 1.86 (0.71#4.84) 0.205
BARC 3 or 5 nonaccess site 86 (1.2) 15 (1.9) 41 (1.5) 1.32 (0.73#2.39) 0.353 1.35 (0.58#3.13) 0.482 1.10 (0.52#2.32) 0.805
BARC 2, 3 or 5 441 (6.1) 70 (9.0) 171 (6.1) 1.48 (1.12#1.95) 0.005 1.43 (1.00#2.05) 0.051 1.44 (1.01#2.07) 0.047
BARC 2, 3 or 5 access site 237 (3.3) 34 (4.4) 98 (3.5) 1.25 (0.85#1.85) 0.255 1.31 (0.82#2.12) 0.262 1.53 (0.94#2.49) 0.089
BARC 2, 3 or 5 nonaccess site 204 (2.8) 36 (4.6) 73 (2.6) 1.78 (1.20#2.66) 0.004 1.65 (0.98#2.79) 0.062 1.32 (0.79#2.21) 0.285
TIMI major 49 (0.7) 7 (0.9) 26 (0.9) 0.97 (0.42#2.24) 0.948 0.66 (0.23#1.93) 0.447 0.66 (0.24#1.83) 0.424
TIMI minor 50 (0.7) 13 (1.7) 20 (0.7) 2.35 (1.17#4.72) 0.014 2.61 (0.92#7.43) 0.072 2.66 (1.09#6.51) 0.032
TIMI major/minor 99 (1.4) 20 (2.6) 46 (1.6) 1.57 (0.93#2.66) 0.089 1.37 (0.66#2.84) 0.404 1.38 (0.70#2.70) 0.351
GUSTO severe 42 (0.6) 6 (0.8) 20 (0.7) 1.08 (0.44#2.7) 0.862 0.86 (0.25#2.99) 0.816 0.83 (0.27#2.53) 0.746
GUSTO moderate 42 (0.6) 9 (1.2) 17 (0.6) 1.91 (0.85#4.29) 0.109 3.11 (1.03#9.43) 0.044 3.04 (1.13#8.21) 0.028
GUSTO mild 784 (10.9) 122 (15.6) 304 (10.8) 1.45 (1.18#1.79) <0.001 1.22 (0.92#1.62) 0.167 1.23 (0.92#1.62) 0.158
GUSTO moderate/severe 84 (1.2) 15 (1.9) 37 (1.3) 1.46 (0.80#2.67) 0.21 1.73 (0.76#3.94) 0.192 1.63 (0.77#3.43) 0.199
Composite of surgical access site
repair and blood transfusion
103 (1.4) 16 (2.0) 51 (1.8) 1.13 (0.65#1.99) 0.661 1.29 (0.61#2.72) 0.51 1.52 (0.76#3.05) 0.233
Surgical access site repair 17 (0.2) 4 (0.5) 8 (0.3) 1.81 (0.54#6.00) 0.327 2.54 (0.49#13.23) 0.267 2.91 (0.65#12.95) 0.161
Blood transfusion 94 (1.3) 16 (2.0) 47 (1.7) 1.23 (0.7#2.17) 0.474 1.39 (0.65#2.97) 0.400 1.65 (0.82#3.33) 0.163
Distribution of BARC 3 or 5
Intracranial bleeding 7 (0.1) 0 (0) 3 (0.1) — — — — — —
Pericardial bleeding 28 (0.4) 3 (0.4) 14 (0.5) 0.77 (0.22#2.69) 0.687 0.92 (0.15#5.78) 0.928 0.52 (0.12#2.27) 0.384
Gastrointestinal bleeding 27 (0.4) 5 (0.6) 16 (0.6) 1.13 (0.41#3.08) 0.812 1.30 (0.34#5.05) 0.703 0.99 (0.29#3.36) 0.985
Genito-urinary bleeding 12 (0.2) 5 (0.6) 2 (0.1) 9.03 (1.75#46.56) 0.001 — — 11.14 (1.69#73.65) 0.012
Access site bleeding 49 (0.7) 8 (1.0) 22 (0.8) 1.31 (0.58#2.95) 0.507 1.41 (0.51#3.90) 0.505 1.62 (0.59#4.44) 0.345
Other bleeding 10 (0.1) 2 (0.3) 5 (0.2) 1.45 (0.28#7.45) 0.658 0.87 (0.03#27.51) 0.936 1.88 (0.17#21.24) 0.610
Values are n (%) unless otherwise indicated.
Abbreviations as in Tables 1 and 2.
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genito-urinary hemorrhages compared with UFHþGPI
(Tables 1 and 2).
Transfusion rates and need for surgical access site
repair were also reduced in the bivalirudin group
(Tables 1 and 2). Conversely, bleeding complications,
mainly genito-urinary hemorrhages that fulfilled
Bleeding Academic Research Consortium grade 3A,
TIMI minor, or GUSTO moderate criteria were
FIGURE 1 Coprimary Composite Study Outcomes at 30 Days
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(Left) The cumulative incidence of the coprimary outcome of major adverse cardiovascular events and (right) net adverse clinical events up to 30 days, (top) among
patients who received bivalirudin versus unfractionated heparin (UFH) alone, (middle) bivalirudin versus UFH plus glycoprotein IIb/IIIa inhibitors (GPI), and (bottom)
UFH plus planned GPI versus UFH alone.
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CENTRAL ILLUSTRATION Bivalirudin or Heparin in ACS: Forest Plots of Main Outcomes
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Bivalirudin versus UFH alone
Bivalirudin versus UFH + GPI
A
B
Gargiulo, G. et al. J Am Coll Cardiol. 2018;71(11):1231–42.
Multivariable adjusted rate ratios (RR) of main outcomes at 30 days for (A) bivalirudin versus unfractionated heparin (UFH) alone or (B) bivalirudin versus UFH plus
planned glycoprotein IIb/IIIa inhibitors (GPIs) comparisons. BARC ¼ Bleeding Academic Research Consortium; CI ¼ confidence interval; MI ¼ myocardial infarction;
ST ¼ stent thrombosis.
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increased in the UFHþGPI group compared with UFH
alone (Table 3).
STRATIFIED AND PROPENSITY-MATCHING ANALYSES.
We performed stratified analyses of the main clinical
outcomes in the 3 comparisons, and we observed
that, after adjustment, results remained consistent
across UFH dose subgroups (Online Table 4). We also
stratified major bleeding events by access site and
observed that bivalirudin consistently reduced access
site and nonaccess site bleeding compared with UFH
groups, irrespective of the randomly allocated arterial
access (Online Table 5).
After propensity-score matching was applied
to the MATRIX population, 2,698 matched pairs
of patients were identified for the comparison of
bivalirudin versus UFH alone; there were 747 pairs of
patients for the comparison bivalirudin versus
UFHþGPI group and 578 pairs of patients for the
comparison of UFH alone versus UFHþGPI. This
model, developed to account for the nonrandomized
use of GPI in the UFH arm, showed good discrimi-
nation and calibration (area under the curve: 0.85;
95% confidence interval: 0.83 to 0.87; Hosmer-
Lemeshow: p ¼ 0.352) (Online Figure 1). Post-match
standardized differences for almost all measured
covariates were <10%, which suggested substantial
balance across the groups (Online Figures 2 to 4,
Online Tables 6 to 11). Results of clinical outcomes
at 30 days remained consistent with primary adjusted
analyses (Online Tables 12 to 14), which confirmed a
beneficial effect of bivalirudin versus UFH alone with
respect to fatal and major bleeding across all adopted
bleeding classifications.
DISCUSSION
The salient findings of this pre-specified analysis of
the MATRIX trial can be summarized as follows:
1. The rates of MACEs and NACEs were not signifi-
cantly lower among those who received bivalirudin
compared with among those who received unfrac-
tionated heparin alone or with planned GPI at the
time of PCI.
2. Compared with UFH and UFHþGPI groups, biva-
lirudin consistently reduced major bleeding,
including fatal and nonaccess site#related events,
as well as transfusion rates and need for surgical
access site repair. This observation was consistent
with the multivariable, propensity score#adjusted
and propensity score#matched analyses. Although
ST trended higher and mortality lower with
bivalirudin compared with UFH alone or UFHþGPI,
none of the single components of the primary
composite endpoints, apart from bleeding, differed
at a statistically significant level.
After initial studies, bivalirudin was approved and
used during PCI due to the reduction of bleeding
complications and similar ischemic risks compared
with UFHþGPI. Although an excess of acute ST has
been consistently noted in STEMI patients treated
with bivalirudin compared with UFHþGPI (11), an
early mortality benefit in the bivalirudin arm of the
pivotal HORIZONS-AMI (Harmonizing Outcomes with
Revascularization and Stents in Acute Myocardial
Infarction) trial has reinforced the notion in the
community that bleeding prevention has the poten-
tial to affect mortality endpoints at least as much as
ischemic events (12). However, the routine use of GPI
on top of UFH has been regarded as unwarranted, and
it may have further increased the bleeding risk in the
comparator arms of approval bivalirudin studies.
In the last decade, the introduction of potent oral
P2Y12 inhibitors and the diffusion of the radial access
have reduced the rates of PCI-related ischemic and
bleeding events, respectively, thus, further ques-
tioning the need for routine or even selective use of
GPI in most ACS cases. Most recent trials, including
EUROMAX (6) and BRIGHT (7), have shown benefits
in terms of major bleeding reduction related to biva-
lirudin use, irrespective of GPI use in the UFH arm.
In opposite, the HEAT-PPCI trial showed that heparin
compared with bivalirudin reduced the incidence
of MACEs and ST, with no increase in bleeding
complications (8). The most recent VALIDATE-
SWEDEHEART study aimed at addressing these
uncertainties by comparing bivalirudin versus UFH
alone in ACS patients (matched STEMI and NSTEMI)
who underwent PCI by radial access site and treat-
ment with new P2Y12 inhibitors (9). The trial enrolled
6,006 patients and showed a null effect of bivalirudin
versus UFH with respect to the composite primary
endpoint, including ischemic and bleeding events, as
well as for each individual endpoint at 6 months. The
absence of clear bleeding benefits with bivalirudin
was attributed to the high rate of radial access
(z90%) and negligible use of GPI, which were
restricted to bailout situations (z3%) (9). However,
there were additional factors beyond radial access
and no planned use of GPI that might have contrib-
uted to explaining the lack of bleeding benefit in this
study. A trend in favor of bivalirudin for bleeding
endpoints was noted at 30 days, a time frame that
seems more suitable to capturing the true value of a
purely periprocedural antithrombotic compound. In
addition, the allowance of UFH administration both
before (up to 5,000 U) and in the catheterization
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laboratory (up to 3,000 U) in the bivalirudin arm
might have contributed to bias the results towards
the null. In the MATRIX trial, planned GPI was
allowed in the UFH arm and actually used in less than
one-quarter of patients. Moreover, by study design,
an equal and random proportion of patients were
intervened upon by either radial or femoral access.
We found a consistent effect of bivalirudin in
mitigating the bleeding risk across groups, largely
from nonaccess site#related complications. This
observation suggested that differences in study
design and/or study populations might explain the
apparently inconsistent effect of bivalirudin on
bleeding endpoints beyond the selected access site or
planned GPI use.
However, similar to VALIDATE-SWEDEHEART and
other previous studies, no clear effect of bivalirudin
on the primary composite endpoints was noted,
irrespective of concomitant use of GPI in the UFH
arm. Moreover, no clear effect of bivalirudin on ST or
mortality rates was identified compared with UFH
alone. This might reflect the limited study power to
assess a treatment effect for relatively rare endpoints,
which was further amplified by the need to apply
multivariable analytical tools to account for the
nonrandomized nature of GPI or the lack of a true
treatment effect.
The dose of UFH in the control arms of available
studies is also worth discussing. In the HEAT-PPCI
study, UFH was dosed at 70 U/kg, which might have
contributed to the absence of bleeding advantages
with bivalirudin (8). In contrast, the use of 100 U/kg
UFH might have inflated the risks of bleeding in the
UFH arms of the EUROMAX and BRIGHT studies (5–7).
However, in the MATRIX trial, UFH was administered
at a mean dose of 78 U/kg in the control group, and
our results remained entirely consistent at stratified
analyses by low and high UFH doses. Thus, our
present results did not support the interpretation
that differences across studies might be reconciled
by simply taking the different recommended UFH
doses into account.
The present study added to previous evidence
and supported the concept that bivalirudin does
not provide benefits in terms of composite endpoints,
including ischemic or ischemic and bleeding
events. However, our results suggested benefits for
bivalirudin in terms of bleeding risk mitigation, in
either femoral or radial access. Thus, in addition to
the well-established recommendation for patients
with heparin-induced thrombocytopenia, bivalirudin
should be considered as an alternative to UFH,
particularly in high risk of bleeding patients.
Ultimately, an individual patient data meta-analysis
of all major bivalirudin studies could shed new light
on the merits and limits of bivalirudin versus UFH
with or without GPI in current practice (3).
STUDY LIMITATIONS. Although this was a pre-
specified analysis, use of planned GPI was left to the
discretion of the physician, thus, generating 3 groups
that were imbalanced in number and characteristics.
The use of multivariable adjustment and propensity
score matching successfully eliminated measured
confounders. However, residual unmeasured con-
founding could not be excluded. The value of post-
PCI bivalirudin infusion was not analyzed due to
the need to account for 2 different nonrandomly
allocated post-PCI bivalirudin regimens, which were
seemingly associated with different study results at
univariate analysis (1) and required further dedicated
multivariable investigations.
CONCLUSIONS
Among patients with ACS who underwent invasive
treatment, the planned use of GPIs in the control
group did not affect the comparative effectiveness and
safety profile of bivalirudin versus UFH. Consistent
with the main study results, bivalirudin did not
decrease the rates of the coprimary endpoints
compared with UFH alone, but it did remain associ-
ated with consistent bleeding benefits, largely coming
from major episodes, which were unrelated to the
access site. The effect of bivalirudin versus UFH alone
on more infrequent endpoints, such as ST or fatal
events requires further investigation.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: In patients with ACSs who underwent percutaneous
revascularization, bivalirudin was associated with comparable
efficacy and less bleeding compared with UFH, regardless of
access site or concurrent therapy with GPIs.
TRANSLATIONAL OUTLOOK: Additional investigation is
needed to compare bivalirudin against UFH on other endpoints,
such as stent thrombosis and mortality, and to assess the
cost-effectiveness of these strategies.
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EDITORIAL COMMENT
Activated Clotting Time During
Unfractionated Heparin-Supported
Coronary Intervention
Is Access Site the New Piece of the Puzzle?*
Marco Valgimigli, MD, PHD, Giuseppe Gargiulo, MD
P ercutaneous coronary intervention (PCI) hasdeveloped a pivotal role in the managementof patients with stable or unstable coronary
artery disease (CAD). The inhibition of the coagula-
tion cascade, and platelet activation, adhesion, and
aggregation are key steps to optimize the results of
PCI and prevent periprocedural ischemic complica-
tions; however, the degree of antithrombotic effect
should minimize bleeding risks. Unfractionated hepa-
rin (UFH) has the main advantages of being cheap and
antagonizable by means of intravenous protamine
sulfate, thus it remains the most widely used antico-
agulant agent during PCI. However, UFH has a poorly
predictable effect on the coagulation cascade
and a relatively narrow therapeutic window (1,2).
Consequently, the measurement of activated clotting
time (ACT) at the time of PCI has been advocated to
mitigate both ischemic and bleeding events during
or soon after intervention. The use of ACT was
initially recommended in the mid-1970s to guide
administration and reversal of UFH during cardiopul-
monary bypass, then the diffusion of these interven-
tions led to the development of automated ACT
measurements (3). In 1990s, with the advances
in the field of interventional cardiology, more and
more cardiologists proposed to use in-laboratory
bedside coagulation monitoring to assess heparin
requirements during interventional procedures (3).
Throughout the years, ACT monitoring to adjust
UFH dosing during PCI has been promoted as the
standard practice, although many centers, especially
in Europe, do not assess it routinely. An intravenous
UFH bolus of 70 to 100 U/kg is recommended to
achieve a target ACT of 250 to 300 s (Hemotech
device) or 300 to 350 (Hemochron device) without
planned use of glycoprotein IIb/IIIa inhibitors (GPI)
or 50 to 70 U/kg bolus to achieve an ACT of 200
to 250 s when the concomitant use of GPI is antici-
pated. Interestingly, no study has prospectively
assessed the value of ACT-guided UFH administra-
tion as compared with standard UFH dosing, and
all recommendations concerning optimal ACT values
are based on retrospective and relatively underpow-
ered registry data. What further complicates the
interpretation of available data is that conflicting
data have been reported on the association of
ACT with ischemic or bleeding complications
(Table 1) (4–14).
To date, a large body of evidence supports the
use of transradial (TR) approach over transfemoral
(TF) for PCI, particularly in acute coronary syn-
drome (ACS) patients, due to the lower risk
of access-site–related bleeding complications and
decreased mortality risk (15). However, there is
limited evidence on whether the ACT target to
avoid ischemic and bleeding complications should
vary based on the selected access site. Interest-
ingly, the lack of association between high ACT
values and bleeding outcomes in some recent
studies may be justified by the frequent use of
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radial access site for coronary angiography and
intervention (7,9).
In this issue of JACC: Cardiovascular Interventions,
Louis et al. (16) present the results of a large, 2-center,
retrospective observational study exploring the role
of ACT in patients undergoing PCI and receiving UFH
alone. Overall, unadjusted and adjusted analyses
showed that maximal ACT was associated with higher
rates of major bleeding after TF (ACT value >290 s),
but not TR PCI, whereas there was no clear associa-
tion with the in-hospital ischemic risk, irrespective of
the vascular access site. This finding may suggest that
during TR-PCI, a more intense anticoagulation might
be tolerated compared with TF-PCI as a result of a
much lower access site bleeding risk in the former
over the latter group of patients. This study comes
from data collected in 2 American centers on 9,169
patients (mean age 66 years) who underwent PCI
TABLE 1 Main Studies Exploring the Impact of ACT on Ischemic and Bleeding Outcomes
First Author,
Year, Trial Design Type of Patients N Antithrombotic Treatment Main Findings
Ferguson et al., 1994 Observational
retrospective
Stable or unstable 1,469 UFH alone A diminished ACT response (<250 s) to an initial UFH bolus
was associated with major in-hospital ischemic
complications
Chew et al., 2001,
EPIC, EPILOG,
EPISTENT, IMPACT
II, RAPPORT, HAS
Pool of 6 RCTs Stable or unstable 5,216 UFH alone (control
group of each RCT)
An ACT in the range of 350–375 s provided the lowest
composite ischemic event rate in 7-day ischemic events
compared with rates observed between 171–295 s by
quartile analysis (p ¼ 0.001). The maximum ACT was
correlated with the incidence of major and minor bleeding
(lowest rate for 325–350 s, which progressively increased
with higher ACT values).
Ashby et al., 2003 Observational
retrospective
Stable or unstable 1,020 UFH alone High ACT levels were found to increase hemorrhagic
complications without improving clinical or angiographic
outcomes (these were paradoxically higher with increasing
ACT)
Tolleson et al., 2003,
ESPRIT
RCT analysis Stable or unstable 2,064 UFH alone and UFH þ
eptifibatide groups
Ischemic events did not increase by decreasing ACT levels, at
least to a level of 200s. Bleeding events did increase with
increasing ACT levels and were enhanced with eptifibatide
treatment. An ACT of 200–250 s seemed reasonable in
terms of efficacy and safety.
Pinto et al., 2003,
TACTICTS-TIMI 18
RCT analysis NSTE-ACS 378 UFH þ tirofiban A peak ACT of #250 s was associated with higher ischemic
events. A target ACT >250 was not associated with an
increased risk of major or minor bleeds.
Brener et al., 2004,
TARGET, CREDO,
REPLACE 1 and 2
Pool of 4 RCTs Stable or unstable 9,974 UFH þ GPI (used in
roughly 90%)
ACT did not correlate with ischemic complications and had a
modest association with bleeding complications, driven
mainly by minor bleeding. Lower values did not appear to
compromise efficacy while increasing safety.
Montalescot et al.,
2008, STEEPLE
RCT analysis Stable 1,230 UFH # GPI
(roughly 40%)
Major bleeding increased significantly with an ACT >325 s. A
significant relationship with increasing ischemic events
was observed when ACT was <325 s indicating a narrow
therapeutic window.
Bertrand et al., 2009,
EASY
RCT analysis NSTE-ACS,
transradial PCI
1,234 UFH þ abciximab ACT value of >330 s were protective against peri-PCI
myonecrosis, and this benefit was maintained up to 3 yrs.
Greater ACT values did not correlate with an increased risk
of bleeding.
Rozenman et al., 2012,
HORIZONS-AMI
RCT analysis STEMI 1,624 UFH þ GPI The peak procedural ACT achieved did not have a substantial
effect on major bleeding, mortality, or MACE, although
lower peak ACT was associated with less minor bleeding.
Ducrocq et al., 2015,
FUTURA/OASIS-8
RCT analysis NSTE-ACS 1,882 Fondaparinux followed by
UFH (low or standard
dose) # GPI
(roughly 27%)
An ACT#300 s increased the risk of thrombotic complications
in patients not receiving GPI. ACT, however, did not
predict bleeding complications.
Rajpurohit et al.,
2016
Observational
retrospective
Stable or unstable 12,055 UFH # GPI (roughly 55%) After multivariable adjustment for baseline and procedural
characteristics, ACT was not independently associated
with in-hospital or 1-year ischemic, thrombotic, or
bleeding outcomes.
ACS ¼ acute coronary syndrome(s); ACT ¼ activated clotting time; CREDO ¼ Clopidogrel for the Reduction of Events During Observation; EASY ¼ EArly Discharge after Transradial Stenting of CoronarY
Arteries; EPIC ¼ Evaluation of c7E3 for the Prevention of Ischemic Complications; EPILOG ¼ Evaluation in PTCA to Improve Long-Term Outcome with abciximab Glycoprotein IIb/IIIa blockade; EPISTENT ¼
Evaluation of IIb/IIIa Platelet Inhibitor for Stenting; ESPRIT ¼ Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial; FUTURA/OASIS-8 ¼ Fondaparinux With Unfractionated
Heparin During Revascularization in Acute Coronary Syndromes; GPI ¼ glycoprotein IIb/IIIa inhibitor; HAS ¼ Hirudin Angioplasty Study; HORIZONS-AMI ¼ Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction; IMPACT II ¼ Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II; MACE ¼major adverse cardiovascular event(s); NSTE ¼ non–ST-segment elevation;
PCI¼ percutaneous coronary intervention; RAPPORT¼ Reopro and Primary PTCA Organization and Randomized Trial; RCT ¼ randomized controlled trial; REPLACE 1-2 ¼ Randomized Evaluation in PCI Linking
Angiomax to Reduced Clinical Events; STEEPLE ¼ SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation; STEMI ¼ ST-segment elevation myocardial infarction;
UFH ¼ unfractionated heparin; TARGET ¼ Tirofiban And Reopro Give similar Efficacy outcomes Trial.
SEE PAGE 1036
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without GPI. Two-thirds of the patients were male,
roughly 85% presented with ACS, and the majority
of them received a single-vessel PCI. Only 13% of
patients received new P2Y12 inhibitors, however.
Some important points of this study should be
considered.
1. ACT values were missing in 10.5% of patients
initially screened (1,532 of 14,634).
2. The ACT value at peak is analyzed as a standalone
parameter, irrespective of relevant factors relating
to UFH management (use of pre-PCI bolus and
infusion of UFH, dose and number of intra-
procedural UFH boluses, additional use of UFH
doses guided by prior ACT values, patient body
weight, and duration of the procedure).
3. The definition of bleeding occurrences is not stan-
dardized (i.e., BARC [Bleeding Academic Research
Consortium], TIMI [Thrombolysis In Myocardial
Infarction], or GUSTO [Global Use of Strategies to
OpenOccludedArteries]), and bleeding eventswere
not independently adjudicated. Moreover, the
definition of periprocedural or non–procedural-
related myocardial infarction is missing.
4. TR and TF cohorts were imbalanced (the TR group
comprised roughly one-third of the overall popu-
lation), and the TR cohort experienced a lower rate
of overall bleeding complications, which were
entirely driven by a lower rate of access site
events. As a result, the lower statistical power to
assess an association between ACT and bleeding in
the TR group might explain the null finding in this
group of patients. Moreover, in the TF group,
the majority of bleeding events were access-
related. The bottom line is that this analysis is
largely underpowered to assess a possible associ-
ation between non-access site bleeding and peak
ACT values.
5. Hemochron device was used in all patients,
thus, although this is the most widely used device,
these findings should not be extended to other
devices.
These findings, therefore, should be interpreted
with caution and should not support the misleading
conclusion that radialist operators can dose or over-
dose UFH liberally.
Non–access site bleeding, especially in the context
of prospective randomized studies comparing TR
versus TF intervention in ACS patients (7,15), is not
so rare, is not influenced by the selection of
the access site, and more closely correlates with
mortality outcomes (17,18). On the other hand,
this observation does reinforce the role of radial ar-
tery in current practice and adds to the growing
body of evidence that both technical and pharma-
cological aspects should be regarded as highly
interconnected: It is only then when the puzzle
comes together!
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ABSTRACT 
Aims: To assess whether bivalirudin compared with unfractionated heparin (UFH) is associated with consistent 
outcomes in males and females with acute coronary syndrome (ACS) undergoing invasive management.  
Methods and Results: In the MATRIX program, 7213 patients were randomized to bivalirudin or UFH. Patients in the 
bivalirudin group were subsequently randomly assigned to receive or not a post-PCI bivalirudin infusion. The 30-day 
coprimary outcomes were major adverse cardiovascular and cerebrovascular events (MACE), defined as death, 
myocardial infarction, or stroke, and net adverse clinical events (NACE), defined as MACE or major bleeding. The 
primary outcome for the comparison of a post-PCI bivalirudin infusion with no post-PCI infusion was a composite of 
urgent target-vessel revascularization (TVR), definite stent thrombosis (ST), or NACE. The rate of MACE was not 
significantly lower with bivalirudin than with heparin in male (rate ratio, 0.90; 95% confidence interval [CI], 0.75-1.07; 
P=0.22) and female patients (rate ratio, 1.06; 95% CI, 0.80-1.40; P=0.67) without significant interaction (Pint=0.31), 
nor was the rate of NACE (males: rate ratio, 0.85; 95% CI, 0.72-1.01; P=0.07; females: rate ratio, 0.98; 95% CI, 0.76-
1.28; P=0.91; Pint=0.38). Post-PCI bivalirudin infusion, as compared with no infusion, did not significantly decrease 
the rate of urgent TVR, definite ST, or NACE (males: rate ratio, 0.84; 95% CI, 0.66-1.07; P=0.15; females: rate ratio, 
1.06; 95% CI, 0.74-1.53; P=0.74; Pint=0.28). 
Conclusion: In ACS patients, the rates of MACE and NACE were not significantly lower with bivalirudin than with 
UFH in both sexes. The rate of the composite of urgent TVR, definite ST, or NACE was not significantly lower with a 
post-PCI bivalirudin infusion than with no post-PCI infusion in both sexes. 
 
Keywords: ACS/NSTE-ACS; STEMI; Adjunctive pharmacotherapy 
 
	INTRODUCTION 
Over the past decade, antithrombotic therapies after acute coronary syndrome (ACS) have improved outcomes more in 
men than in women1, 2, raising the question of whether there are sex-specific differences in treatment patterns and 
response to such therapy. However, there is contrasting evidence on the impact of sex on clinical outcomes, particularly 
on overall and cardiovascular mortality, in patients treated for coronary artery disease and differences in presenting 
clinical characteristics, pathophysiologic profile, as well as disparities in treatment may considerably contribute to this 
outcome discrepancy3. A large body of evidence suggests that female patients have increased peri-procedural bleeding 
risk as compared to males4, 5, and recently the radial access showed to be effective in reducing such risk compared to 
femoral access in ACS patients invasively managed6. 
We sought to investigate whether the use of bivalirudin, either continued or discontinued after percutaneous coronary 
intervention (PCI), instead of unfractionated heparin (UFH), might be associated with consistent or differential efficacy 
and safety effects in male and female patients with ACS undergoing invasive management as part of a pre-specified 
analysis in the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of 
Angiox (MATRIX) programme. 
 
METHODS 
Study design, outcomes and statistical analysis 
Design and main results of the MATRIX trial have been previously reported7-9. Details are reported in the supplement.  
 
RESULTS 
Patients 
From October 11, 2011, to November 7, 2014, at 78 centres in Italy, the Netherlands, Spain, and 
Sweden, 3610 patients were assigned to receive bivalirudin (males: 2731, 75.7%; females: 879, 24.3%), either with a 
post-PCI infusion (1799 patients of whom males: 1351, 75.1% and females: 448, 24.9%) or without a post-PCI infusion 
(1811 patients of whom males: 1380, 76.2% and females: 431, 23.8%), and 3603 were assigned to receive UFH (males: 
2764, 76.7%; females: 839, 23.3%). 
Female and male subgroups allocated to bivalirudin versus UFH and to post-PCI bivalirudin infusion versus no post-
PCI infusion were generally well matched in terms of demographics, medical history, clinical presentation, procedural 
aspects and therapy at discharge (Supplementary Tables 1-3). 
Clinical outcomes according to antithrombin type 
MACE occurred in 256 patients (9.4%) in the bivalirudin group and in 287 patients (10.5%) in the UFH group (rate 
ratio, 0.90; 95% confidence interval [CI], 0.75 to 1.07; P=0.22) in males and in 115 (13.1%) and 104 (12.4%) females 
(rate ratio, 1.06; 95% CI, 0.80 to 1.40; P=0.67) without significant interaction (Pint=0.31) (Table 1, Figures 1 and 2). 
A total of 276 patients (10.2%) in the bivalirudin group, as compared with 323 patients (11.8%) in the UFH group, had 
a NACE (rate ratio, 0.85; 95% CI, 0.72 to 1.01; P=0.07) in males and 125 (14.2%) as compared with 121 (14.4%) 
female patients had a NACE (rate ratio, 0.98; 95% CI, 0.76 to 1.28; P=0.91) without significant interaction (Pint=0.38) 
(Table 1, Figures 1 and 2). 
Compared with UFH, bivalirudin was apparently associated with a lower rate of all-cause death in male (1.2% vs. 1.9%; 
rate ratio, 0.63; 95% CI, 0.41 to 0.98; P=0.041) but not in female patients (3.1% vs. 3.8%; rate ratio, 0.80; 95% CI, 0.48 
to 1.34; P=0.40), however there was no detectable signal of heterogeneity across gender (Pint=0.49) (Table 1, Figures 
1 and 3). This was similarly observed for cardiovascular death (males: 1.1% vs. 1.8%; rate ratio, 0.60; 95% CI, 0.38 to 
0.95; P=0.028; females: 3.0% vs. 3.6%; rate ratio, 0.82; 95% CI, 0.49 to 1.40; P=0.47; Pint=0.38; Table 1). There were 
no significant differences between bivalirudin and UFH in both male and female patients for the rates of individual 
endpoints of MI, stroke, TVR, and ST (Table 1, Figures 1 and 3). Bivalirudin consistently reduced rates of major 
bleeding (BARC 3 or 5) compared with UFH across gender (males: 1.2% vs. 2.0%; rate ratio, 0.59; 95% CI, 0.38 to 
0.92; P=0.019; females: 2.0% vs. 4.1%; rate ratio, 0.47; 95% CI, 0.26 to 0.85; P=0.01; Pint=0.53) (Table 1, Figures 1 
and 3). This difference was mainly driven by access-related events in males and by non–access-related bleeding in 
females, with fatal, TIMI major and GUSTO severe bleeding being lower in female patients only (Table 1). 
Clinical outcomes according to bivalirudin treatment duration 
The primary composite outcome was observed in 128 patients (9.6%) who received post-PCI bivalirudin and in 154 
patients (11.2%) who did not receive post-PCI bivalirudin (rate ratio, 0.84; 
95% CI, 0.66 to 1.07; P=0.15) in males and respectively in 67 (15.0%) versus 61 patients (14.2%) (rate ratio, 1.06; 95% 
CI, 0.74 to 1.53; P=0.74) in females (Pint=0.28) (Supplementary Table 4, Figures 4 and 5). No significant differences 
or interactions were observed in terms of MACE, NACE, or individual endpoints of death, MI, stroke, TVR or ST 
(Supplementary Table 4 and Figure 6). 
There was no significant between-group heterogeneity in the rate of bleeding, with BARC 2 events being significantly 
higher male and numerically higher in female patients in the post-PCI bivalirudin arm while BARC 3 or 5 events which 
were not related to the access site being lower in both sexes (Supplementary Table 4). 
Additional analyses 
Supplementary Figures 1-4 list the effect of randomized antithrombin type on MACE and NACE, in male and female 
patients according to pre-specified subgroups. In male patients, the randomized treatment effect appeared consistent 
across most subgroups, with the exception of patients with an increased BMI or those with prior exposure to UFH, in 
	whom bivalirudin, as compared to UFH, lowered MACE and NACE. Treatment effect was also largely consistent in 
female patients.  
Supplementary Figures 5-8 show the effect of randomized bivalirudin treatment duration on MACE and NACE, in 
male and female patients according to pre-specified subgroups.  
 
DISCUSSION 
MATRIX is the largest randomized study on bivalirudin in STEMI, one of the largest in NSTE-ACS patients, and the 
only randomized comparison of post-PCI versus no post-PCI bivalirudin infusion. The study failed to show that 
bivalirudin as compared to UFH±GPI reduces MACE or NACE and post-PCI bivalirudin infusion did not reduce the 
rate of the primary endpoint compared with no post-PCI infusion. At secondary endpoint analyses, bivalirudin 
compared to UFH±GPI decreased the rate of fatalities and the risk of major, mainly non-access-site related, bleeding in 
both randomly allocated access sites.  
The results of the sex-based pre-specified analysis can be summarized as follows: 
1) There was no signal of heterogeneity across sexes for any of the primary endpoints, including MACE and NACE for 
the bivalirudin versus UFH±GPI comparison and the composite of NACE definite ST and urgent TVR for the 
assessment of post-PCI bivalirudin infusion. 
2) In secondary stratified analyses, bivalirudin remained associated to lower risks of mortality and bleeding in both 
sexes, with no signal of a sex-based treatment effect at interaction testing. Mortality was numerically lower with 
bivalirudin in both female and male patients, albeit it reached statistical significance in the latter group only, likely 
reflecting a power issue. BARC 3 or 5 bleeding were significantly reduced in both sexes, interestingly owing to a 
reduction of access site events in males and non-access site related occurrences in females.  
Sex differences in cardiovascular outcomes is a topic of great interest and debate in the cardiology community, with 
data supporting such discrepancy in opposite to others suggesting that women treated for coronary artery disease have 
different clinical, procedural and treatment profiles compared with men which may largely explain the observed 
dissimilarities in prognosis. Indeed, after correcting for sex-based confounders such disparities, particularly in mortality 
and major composite endpoints seem to be no longer demonstrated3, 6. However, female patients have been associated 
with higher rates of peri-procedural bleeding4, 5, and this was also confirmed in a previous pre-specified analysis of 
MATRIX where we observed a greater risk of access-site bleeding and transfusion rates in female as compared with 
male patients after adjusting for confounders6. Additional interest to this topic is related to the fact that women 
represent a limited amount of patients included in the majority of cardiovascular trials. On this background, it seems 
particularly relevant to explore whether there are sex-specific differences in treatment patterns and response to 
antithrombotic therapy.  
In a patient-level pooled analysis of 3 randomized controlled trials (the Randomized Evaluation in PCI Linking 
Angiomax to Reduced Clinical Events, REPLACE-2; Acute Catheterization and Urgent Intervention Triage strategY, 
ACUITY; and Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction, HORIZONS-
AMI) including 14,784 patients (25.6% were women) bivalirudin was compared with UFH plus GPI in ACS patients 
undergoing PCI. Compared with males, females were associated with higher 30-day bleeding events that in turn 
emerged to be the strongest independent predictor of 1-year mortality rather than gender per se. Additionally, both 
sexes experienced similar safety benefits of bivalirudin in reducing bleeding complications, but women experienced a 
more pronounced benefit of bivalirudin in reducing 1-year mortality than men10. Importantly, these results come from 
trials in which UFH was administered with routine use of GPI, there were no use of newer antiplatelet agents and PCI 
procedures were almost exclusively performed by femoral access. In the sex-based analysis of BRIGHT, a trial 
comparing bivalirudin versus heparin versus heparin plus tirofiban in acute MI patients undergoing PCI, female patients 
receiving bivalirudin were associated with significantly lower rates of 30-day bleeding and NACE, but no differences in 
terms of mortality, ST or MACE11. In the sex-based analysis of the ISAR-REACT 4, where patients with NSTEMI 
(n=1,721; 399 women, 23.2%) were randomly allocated to receive bivalirudin or heparin plus abciximab, there were no 
between-groups differences of the main outcome (30-day composite of death, large recurrent MI, urgent TVR or major 
bleeding), but bivalirudin reduced major bleeding in both male and female patients12. 
Our current results are entirely consistent with previous evidence, indicating that bivalirudin provides consistent effect 
in both sexes, resulting in lower risks of bleeding complications across many of the available RCTs. Additionally, in the 
MATRIX we found that reduction of bleeding, mainly most severe episodes, was irrespective of GPI use12. 
Interestingly, however, in the context of the recently reported VALIDATE-SWEDEHAERT trial, where bivaluridin did 
not reduce the primary composite endpoint of NACE or clinically relevant bleeding at 6 months after intervention as 
compared to UFH alone, there was a signal of heterogeneity across sexes (Pint=0.05), with female patients deriving 
apparently a greater benefit from treatment as compared to males2. Therefore, in summary, current evidence shows 
either a consistent or perhaps a slightly greater treatment effect in female patients treated with bivalirudin as compared 
to UFH; a finding which seems to be justifiable by prior observations that females are at increased risk for peri-
procedural bleeding occurrences.  
The inconsistent effect of bivalirudin on the NACE endpoint likely reflects difference in study design, choice of the 
comparator arm, patients’ selection and endpoints definitions across available studies. Similarly, the effect of 
bivalirudin on mortality has been inconsistently observed across trials and some registry data13, which may reflect the 
	fact that this effect, if real, may be small, and likely confounded by the baseline risk status of patients and concomitant 
treatment and medications.  
Prior observations that the use of bivalirudin increases the risks of acute ST have prompted investigations to mitigate 
that risk by prolonging bivalirudin infusion after PCI14, 15. Overall, MATRIX-Treatment-Duration found that post-PCI 
infusion of bivalirudin did not result in lower rates of the primary endpoint or definite ST at 30 days than the rates with 
no post-PCI infusion. This latter finding was also confirmed in the present analysis in both male and female patients. 
In the current practice, when deciding on the anticoagulation strategy to adopt in ACS patients undergoing PCI, it 
should be also considered that bivalirudin remains much more expensive than UFH, however, updated cost-
effectiveness analyses are warranted.  
 
Limitations 
Although this is a pre-specified subgroup analysis, the MATRIX-Antithrombin and Treatment-Duration trials were not 
powered to explore differences between sexes, and randomization was not stratified by sex. We did not adjust for 
multiple comparisons, increasing the risk of type I error. Protocol allowed for discretionary use of GPI in the heparin 
group and two different infusion regimens in the post-PCI bivalirudin infusion group. Although this is consistent with 
clinical practice, it makes the study results more difficult to interpret. 
 
CONCLUSIONS 
Among male and female patients with ACS undergoing invasive treatment, neither the rate of MACE nor the rate of 
NACE was significantly lower with bivalirudin than with unfractionated heparin and discretionary use of glycoprotein 
IIb/IIIa inhibitors. In both sexes, the post-PCI infusion of bivalirudin for at least 4 hours after the intervention did not 
result in a lower rate of the composite outcome of ischemic and bleeding events, including stent thrombosis, than the 
rate with no post-PCI infusion. Our observations of lower risks of bleeding and especially of fatality rates both in male 
and female patients undergoing an invasive management should be interpreted in the context of available evidence, 
which suggests a rather consistent and inconsistent treatment effect of bivalirudin on bleeding and fatal endpoints, 
respectively, both in males and females.  
 
IMPACT ON DAILY PRACTICE 
Current data shows that neither male nor female patients gained significant benefit in terms of composite endpoints by 
receiving bivalirudin compared with heparin with discretionary use of GPI, although a lower rate of bleeding was 
observed. Also the post-PCI infusion of bivalirudin was not superior to no infusion in both sexes. 
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Figure Legend. 
Figure 1. Main Outcomes of Bivalirudin Versus Unfractionated Heparin in Male and Female Patients. 
Bivalirudin and UFH were compared on the basis of sex subgroups, with rate ratios and 95% confidence intervals (CIs), 
for the coprimary endpoints and their components (death, myocardial infarction, stroke, BARC 3 or 5). 
Figure 2. Coprimary Composite Outcomes of Bivalirudin Versus Unfractionated Heparin at 30 Days in Male 
and Female Patients. Panels A and B show the cumulative incidence of the coprimary outcome of MACE and NACE 
respectively. Blue indicates bivalirudin, red indicates UFH, continuous line indicates male, dashed line indicates 
female. 
Figure 3. Components of Coprimary Composite Outcomes of Bivalirudin Versus Unfractionated Heparin at 30 
Days in Male and Female Patients. Panels show the cumulative incidence of the coprimary outcome components of 
all-cause death (A), myocardial infarction (B), stroke (C), and BARC 3 or 5 bleeding (D). Blue indicates bivalirudin, 
red indicates UFH, continuous line indicates male, dashed line indicates female. 
Figure 4. Main Outcomes of Post-PCI Bivalirudin Infusion Versus No Post-PCI Bivalirudin Infusion in Male 
and Female Patients. Bivalirudin infusion and no infusion post-PCI were compared on the basis of sex subgroups, 
with rate ratios and 95% confidence intervals (CIs), for the primary endpoint and its components (death, myocardial 
infarction, stroke, BARC 3 or 5, urgent TVR and definite ST). 
Figure 5. Primary Composite Outcome of Post-PCI Bivalirudin Infusion Versus No Post-PCI Bivalirudin 
Infusion at 30 Days in Male and Female Patients. Figure shows the cumulative incidence of the primary composite 
outcome of urgent target-vessel revascularization (TVR), definite ST, or NACE. Blue indicates prolonged bivalirudin 
infusion, red indicates no post-PCI infusion, continuous line indicates male, dashed line indicates female. 
Figure 6. Components of Primary Composite Outcome of Post-PCI Bivalirudin Infusion Versus No Post-PCI 
Bivalirudin Infusion at 30 Days in Male and Female Patients. Panels show the cumulative incidence of the primary 
outcome components of all-cause death (A), myocardial infarction (B), stroke (C), BARC 3 or 5 bleeding (D), urgent 
TVR (E) and definite ST (F). Blue indicates prolonged bivalirudin infusion, red indicates no post-PCI infusion, 
continuous line indicates male, dashed line indicates female. 
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	ABSTRACT 
Background: The value of prolonged bivalirudin infusion after percutaneous coronary intervention (PCI) in acute 
coronary syndrome (ACS) patients with or without ST-segment elevation remains unclear. 
Objectives: To assess efficacy and safety of a full or low post-PCI bivalirudin regimen in ACS patients with or without 
ST-segment elevation.  
Methods: The MATRIX program assigned bivalirudin to patients without or with a post-PCI infusion at either a full 
(1.75 mg/kg/h) for up to 4 hours, or reduced (0.25 mg/kg/h) for up to 6 hours, regimen at the operator’s discretion. The 
primary endpoint was the 30-day composite of urgent target-vessel revascularization, definite stent thrombosis, or net 
adverse clinical events (composite of all-cause death, myocardial infarction, or stroke [MACE] or major bleeding).  
Results: Among 3610 patients assigned to bivalirudin, 1799 were randomized to receive and 1811 not to receive a post-
PCI bivalirudin infusion. Post-PCI full bivalirudin was administered in 612 (STEMI=399; NSTE-ACS=213) whereas 
1068 (STEMI=519; NSTE-ACS=549) patients received the low regimen. The primary outcome did not differ in STEMI 
or NSTE-ACS patients who received or did not receive post-PCI bivalirudin. However, full as compared to low 
bivalirudin regimen remained associated with a significant reduction of the primary endpoint after multivariable (rate 
ratio 0.21, 95% CI 0.12-0.35; p<0.001) or propensity-score (rate ratio 0.16, 95% CI 0.09-0.26; p<0.001) adjustment. 
Full post-PCI bivalrudin was associated with improved outcomes consistently across ACS types and in comparison with 
the no post-PCI infusion or heparin groups.  
Conclusion: In ACS patients with or without ST-segment elevation, the primary endpoint did not differ with or without 
post-PCI bivalirudin infusion but a post-PCI full dose was associated with improved outcomes when compared with no 
or low-dose post-PCI infusion or heparin (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and 
Systemic Implementation of angioX [MATRIX]; NCT01433627). 
 
Keywords: MATRIX, bivalirudin duration, bivalirudin dose, acute coronary syndrome, STEMI, NSTE-ACS. 
 
CONDENSED ABSTRACT 
The optimal regimen of bivalirudin after percutaneous coronary intervention (PCI) and whether this differs across acute 
coronary syndrome (ACS) with or without ST-segment elevation is unknown. This analysis found no differences 
between post-PCI bivalirudin infusion vs no infusion for the primary endpoint or other outcomes in STEMI and NSTE-
ACS. Yet after adjustment, the full post-PCI bivalirudin dose was associated to improved efficacy and safety outcomes 
when compared to the low post-PCI bivalirudin regimen, no post-PCI infusion or unfractionated heparin groups.  
 
ABBREVIATIONS 
ACS=acute coronary syndrome 
BARC=Bleeding Academic Research Consortium 
CABG=coronary artery bypass grafting  
GPI=glycoprotein IIb/IIIa inhibitor 
GUSTO=Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries 
MACE=major adverse cardiovascular events 
MI=myocardial infarction 
NACE=net adverse clinical events 
NSTE-ACS=non-ST-segment elevation ACS 
PCI=percutaneous coronary intervention 
ST=stent thrombosis 
STEMI=ST-segment elevation myocardial infarction 
TIMI=thrombolysis in myocardial infarction 
UFH=unfractionated heparin 
	INTRODUCTION 
Percutaneous coronary intervention (PCI) in conjunction with periprocedural anticoagulant and antiplatelet therapy 
improves clinical outcomes in patients suffering from either ST-segment elevation myocardial infarction (STEMI) or 
non–ST-segment elevation acute coronary syndromes (NSTE-ACS). Yet, invasively managed ACS patients have an 
increased risk of bleeding, which in turn could be associated with higher mortality (1). Bivalirudin administration at the 
time of PCI has been repeatedly shown to mitigate bleeding complications compared to unfractionated heparin (UFH) 
with or without glycoprotein IIb/IIIa inhibitors (GPI) (2-8). Moreover, while major adverse cardiovascular events 
(MACE) did not differ at 30 days, bivalirudin administration was associated to higher acute stent thrombosis (ST) in 
STEMI (but not NSTE-ACS) and trends towards higher peri-procedural MI in NSTE-ACS patients, especially in those 
in whom administration of oral P2Y12 inhibitors was delayed (5,8-10).  
The prolongation of bivalirudin infusion after PCI has been empirically employed as a potentially safe measure to 
mitigate the ischemic hazards associated to the use of bivalirudin. However, evidence remains limited. 
Data comparing post-PCI versus no post-PCI bivalirudin infusion is largely indirect considering that HORIZONS-AMI 
(2) and HEAT-PPCI (11) studies investigated only a no-post-PCI infusion strategy, BRIGHT (4) and EUROMAX (3) 
mandated the use of a full and a full or low post-PCI bivalirudin dose, respectively, and no other large study prior to 
MATRIX had so far investigated the value of a post-PCI bivalirudin regimen in NSTE-ACS patients.  
Therefore, the aim of this analysis was to assess the role of post-PCI bivalirudin in patients with STEMI and NSTE-
ACS enrolled in the MATRIX Treatment Duration trial, with a focus on the comparative effectiveness of the full versus 
the low post-PCI regimen.  
 
METHODS 
Study Design 
The main results of the MATRIX program including three randomized, multicenter, open-label superiority trials in 
patients with an ACS had been reported previously (6,12,13).  
Here, we report the outcomes stratified by the type of ACS (STEMI and NSTE-ACS) from the MATRIX Treatment 
Duration, whereby 3610 patients were assigned to receive bivalirudin with or without a prolonged post-PCI bivalirudin 
infusion.  
 
Patients 
Detailed inclusion and exclusion criteria were previously reported (6,12,14). Briefly, patients with NSTE-ACS were 
eligible if they had a history consistent with new or worsening cardiac ischemia, occurring while they were at rest or 
with minimal activity within 7 days before randomization, and met at least two high-risk criteria among the following: 
aged 60 years or older, elevated cardiac biomarkers, or electrocardiographic changes compatible with ischemia and if 
they were considered to be candidates for PCI after completion of coronary angiography. Patients with STEMI were 
eligible if presenting within 12 hours after the onset of symptoms or between 12 and 24 hours after symptom onset if 
there was evidence of continuing ischemia or previous fibrinolytic treatment. All patients provided written informed 
consent. 
 
Study Protocol and Randomization 
Patients were randomly assigned, in a 1:1 ratio, to receive bivalirudin or UFH. Patients who were assigned to the 
bivalirudin group were subsequently randomly assigned, in a 1:1 ratio, to receive a post-PCI bivalirudin infusion or no 
post-PCI infusion. Central randomization was concealed with the use of a Web-based system. Randomization sequences 
were computer generated, blocked, and stratified according to type of ACS (STEMI vs troponin positive vs troponin-
negative NSTE-ACS) and intended new or ongoing use of a P2Y12 inhibitor (clopidogrel vs ticagrelor or prasugrel). 
Randomization was performed before coronary angiography for STEMI patients and immediately after completion of 
angiography but before the start of PCI for patients with NSTE-ACS. 
All interventions were administered in an open label fashion. Bivalirudin was given according to the product labeling, 
with a bolus of 0.75 mg per kilogram of body weight, immediately followed by an infusion of 1.75 mg per kilogram per 
hour until completion of the PCI. Bivalirudin was then stopped at the end of PCI or prolonged in accordance with the 
subsequent random assignment. 
Among patients assigned to receive prolonged treatment, bivalirudin could be administered either at the full dose for up 
to 4 hours or at a reduced dose of 0.25 mg per kilogram per hour for at least 6 hours. The choice between the two 
regimens was at the the treating physician’s discretion . A GPI was allowed in the bivalirudin group only in patients 
who had periprocedural ischemic complications (i.e., no reflow or giant thrombus) after PCI (bailout therapy). Other 
medications were allowed according to professional guidelines. The protocol mandated a consistent use of the randomly 
allocated antithrombin regimen in cases of staged procedures.  
 
Follow-up and Outcomes 
Clinical follow-up was performed at 30-day. The primary outcome for MATRIX Treatment Duration was a composite 
of urgent target-vessel revascularization, definite ST, or net adverse clinical events (NACE) up to 30 days. Coprimary 
outcomes for MATRIX Antithrombin and Access site were MACE, defined as a composite of death from any cause, 
myocardial infarction, or stroke, and NACE, defined as a composite of major bleeding that was not related to coronary-
	artery bypass grafting (CABG) (Bleeding Academic Research Consortium [BARC] type 3 or 5) or MACE. Secondary 
outcomes included each component of the composite outcomes, death from cardiovascular causes, and ST. Bleeding 
was also assessed and adjudicated on the basis of the Thrombolysis in Myocardial Infarction (TIMI) and Global 
Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) scales. All 
outcomes were prespecified. 
An independent clinical-events committee whose members were unaware of the study-group assignments adjudicated 
all suspected events. Detailed definitions of outcomes and procedures of the clinical-events committee were previously 
provided (6,12,14).  
 
Statistical analysis 
Details regarding the statistical analysis have been reported previously (6,12,14). Briefly, MATRIX Treatment Duration 
was powered assuming that the incidence of the primary endpoint at 30 days would be 10.0% with short-term 
bivalirudin and 7.0% with prolonged bivalirudin (rate ratio of 0.70), therefore, the enrollment of 1700 patients in each 
study group provided a power of 86% to detect this difference at a two-sided alpha level of 0.05. Analyses were 
performed according to the intention-to-treat principle, including all patients in the analysis according to the allocated 
post-PCI regimen of bivalirudin. Primary and secondary outcomes were analyzed as time-to-first event using the 
Mantel–Cox method, accompanied by log–rank tests to calculate corresponding two-sided p-values. Survival curves 
were constructed using Kaplan–Meier estimates and percentages reported for outcomes are Kaplan–Meier estimates of 
cumulative incidence. 
To compare the two different bivalirudin dosages (full vs low, irrespective of the final treatment duration) in the group 
receiving post-PCI infusion, multivariable and propensity score adjustment models were performed. The multivariable 
model included the following variables: year of randomization, center, access site randomized, diabetes, type of ACS, 
hypertension, previous PCI, previous stroke or TIA, peripheral vascular disease, eGFR, hemoglobin at baseline, TIMI 
flow 0-1 before PCI, P2Y12 inhibitor at discharge, and procedure duration. A propensity score that indicated the 
likelihood of receiving a full or low post-PCI bivalirudin infusion was calculated by using a nonparsimonious 
multivariable logistic regression including the following variables: year of randomization, center, access-site 
randomized, age, sex, body mass index, diabetes, type of ACS, smoking, hypertension, hypercholesterolemia, previous 
MI, previous PCI, previous CABG, previous stroke or TIA, peripheral vascular disease, eGFR, left ventricular ejection 
fraction, hemoglobin at baseline, medications pre-PCI (clopidogrel, fondaparinux, ACE-inhibitors, statins, beta 
blockers, proton pump inhibitors, unfractionated heparin), PCI completed, GPI intraprocedural, ticagrelor 
intraprocedural, ≥2 vessels treated, ≥3 lesions treated, total SYNTAX score, ≥1 BMS, TIMI flow 0-1 before PCI, 
procedural success in all lesions, large and/or small vessel caliber, proximal location of the lesion, presence of thrombus 
in the treated lesion. This score had a very good predictive ability (ROC 0.92; Supplementary Figure 1). The 
individual propensity score was incorporated into the adjustment model to compare outcomes. 
All analyses in the overall study population were stratified by type of ACS and accompanied by χ2 tests for interaction. 
Secondary analyses were also performed separately in STEMI and NSTE-ACS subgroups and were stratified according 
to age, sex, body mass index, type of P2Y12 inhibitor, overall or transradial PCI volume by center, renal function, 
diabetes mellitus, peripheral vascular disease and access site randomization, and accompanied by χ2 tests for interaction 
or tests for trend across ordered groups”. 
Secondary outcomes were analyzed with a two-sided alpha set at 5% to allow conventional interpretation of results. All 
analyses were performed using the STATA version 14.1 (StataCorp, College Station, Texas) and R (R Foundation, 
Vienna, Austria) statistical packages. 
 
 
RESULTS 
Patients 
From October 11, 2011, to November 7, 2014, at 78 centers in Italy, the Netherlands, Spain, and Sweden, 3610 patients 
were assigned to receive bivalirudin as part of the MATRIX program. Of these, 1799 (STEMI=1006; NSTE-ACS=793) 
patients were randomized to receive and 1811 (STEMI=1006; NSTE-ACS=805) to not receive a post-PCI bivalirudin 
infusion. Post-PCI bivalirudin infusion was administered at full or low dose in 612 (STEMI=399; NSTE-ACS=213) and 
1068 (STEMI=519; NSTE-ACS=549) patients respectively, whereas 119 patients did not receive post-PCI infusion. 
The distribution of patients receiving a full or low dose during time is shown in Figure 1. 
Baseline and procedural characteristics, stratified by ACS type, of patients randomized to receive or not to receive post-
PCI bivalirudin infusion were generally well-balanced (Supplementary Tables 1-3). Baseline and procedural 
characteristics stratified by actual post-PCI bivalirudin regimen in those assigned to post-PCI bivalirudin are shown in 
Supplementary Tables 4-6. Compared with patients receiving a low bivalirudin regimen, those treated with a full post-
PCI bivalirudin dose were slightly younger, less frequently affected by cardiovascular risk factors, had a history of MI 
or coronary revascularization or were treated with anti-hypertensive/lipid-lowering agents. Yet, they were more 
frequently smokers or exposed to ticagrelor (as opposed to clopidogrel) or UFH before angiography, more frequently 
presenting TIMI flow 0-1 before PCI, and more frequently treated with ticagrelor or DES implantation 
(Supplementary Tables 4-6). 
 
	Clinical outcomes of post-PCI prolonged vs no infusion of bivalirudin 
The primary composite outcome was similar in patients who either did or did not receive post-PCI bivalirudin in the 
entire population (rate ratio, 0.91, 95% CI 0.74-1.11; p=0.34). When separately appraised in STEMI and NSTEACS 
patients, the results remained consistent in indicating no benefit from post-PCI bivalirudin (Supplementary Results). 
Clinical outcomes of Full vs Low dose of post-PCI prolonged bivalirudin infusion  
At univariate analysis, post-PCI full dose bivalirudin was associated with a significant reduction of the primary 
endpoint consisting of urgent target-vessel revascularization, definite ST, or NACE as compared to low dose bivalirudin 
infusion (rate ratio 0.29, 95% CI 0.19-0.44; p<0.001). After multivariable adjustment, this composite endpoint remained 
lower in the full versus low post-PCI bivalirudin arm (rate ratio 0.21, 95% CI 0.12-0.35; p<0.001). The propensity-
score adjustment provided consistent results (rate ratio 0.16, 95% CI 0.09-0.26; p<0.001) (Table 1; Central 
illustration and Figure 2).  
Similar findings were observed for the MACE (unadjusted rate ratio 0.31, 95% CI 0.2-0.47; p<0.001; multivariable 
adjusted rate ratio 0.23, 95% CI 0.13-0.39; p<0.001; propensity-score adjusted rate ratio 0.17, 95% CI 0.1-0.29; 
p<0.001) or NACE (unadjusted rate ratio 0.30, 95% CI 0.2-0.45; p<0.001; multivariable adjusted rate ratio 0.22, 95% 
CI 0.13-0.36; p<0.001; propensity-score adjusted rate ratio 0.16, 95% CI 0.09-0.27; p<0.001) endpoints favoring the 
full as compared to the low post-PCI bivalirudin regimens (Table 1). The benefit of post-PCI full bivalirudin dose was 
driven by a reduction of MI, ST, TVR and BARC 3 or 5, whereas the rates of all-cause death, cardiovascular mortality 
or stroke did not differ (Table 1; Central illustration and Figures 3-4). Overall, these findings remained consistent 
across the ACS subtypes (Supplementary Tables 8 and 9). 
 
Clinical outcomes of post-PCI Full dose bivalirudin vs no post-PCI infusion or vs heparin  
Compared with the no post-PCI bivalirudin infusion group, full dose post-PCI bivalirudin was associated with a 
significantly lower rate of the primary endpoint, as well as MACE or NACE, and this effect was mainly driven by lower 
rates of MI and BARC 3 or 5 bleeding events (Table 2, Supplementary Tables 10 and 11). When compared with the 
heparin plus provisional GPI group, full dose post-PCI bivalirudin regimen was associated with a significantly lower 
rate of the primary endpoint, as well as MACE or NACE, and this effect was driven by lower rates of all-cause and 
cardiovascular death as well as of MI or BARC 3 or 5 bleeding events (Table 3, Supplementary Tables 12 and 13). 
 
DISCUSSION 
MATRIX was the first trial to explore, in a randomized manner, the differences among post-PCI bivalirudin infusion 
versus no bivalirudin infusion in invasively managed ACS patients. The present analysis sought to further investigate 
the stratified outcomes of post-PCI bivalirudin infusion versus no infusion in STEMI versus NSTE-ACS patients across 
the full spectrum of all pre-defined endpoints as well as the impact of post-PCI bivalirudin dose on outcomes. The main 
findings of this analysis can be summarized as follows: a) there were no differences between post-PCI bivalirudin 
infusion vs no infusion for the primary or other secondary efficacy and safety endpoints in patients either presenting 
STEMI or NSTE-ACS. This observation further reinforces the notion that the type of ACS was not a treatment modifier 
in our study; b) the post-PCI full dose of bivalirudin remained associated after both multivariable or propensity score 
adjusted analyses to beneficial effects in terms of ischemic non-fatal endpoints, including ST and MI as well as 
bleeding events when compared to the low post-PCI bivalirudin dose; c) after multivariable or propensity-score 
adjustment, patients receiving full dose bivalirudin after PCI showed improved outcomes as compared to patients 
receiving only intra-procedural bivalirudin or UFH with provisional GPI. The improved outcome with full dose post-
PCI bivalirudin was driven by lower MI and bleeding rates when the group was compared with bivalirudin without 
post-PCI bivalirudin infusion, whereas all-cause and cardiovascular mortality endpoints also favored the full dose post-
PCI bivalirudin group when it was compared with UFH±GPI.  
 
STEMI and NSTE-ACS patients differ with respect to multiple baseline and procedural characteristics as well as with 
post-procedural risks. Yet, they share the same underlying coronary artery disease characterized by plaque rupture and 
show similar independent association with adverse outcome (15).  
STEMI patients, who are intervened upon as early as possible after symptoms onset, are characterized by having an 
evolving MI with rising cardiac biomarkers, which prevents in many instances the ascertainment of periprocedural 
necrotic injury after coronary intervention. This is at variance with NSTE-ACS patients in whom an invasive 
management is typically performed hours or days after symptoms onset when cardiac biomarkers are declining; a 
setting which allows peri-procedural MI ascertainment. On the other hand, the risk of acute and subacute ST is higher in 
STEMI as compared to NSTE-ACS patients, which is at least in part explained by a slow onset of action from oral 
P2Y12 inhibitors (16). Prolonging bivalirudin infusion after primary PCI completion has therefore been proposed as a 
therapeutic measure to mitigate that risk. At variance with STEMI patients undergoing coronary intervention, no study 
has so far observed a higher risk of acute or subacute ST in patients receiving bivalirduin as compared to UFH with or 
without GPI. This observation may speak against the need to prolong bivalirudin infusion to further optimize outcomes. 
Yet, a small randomized study in 178 patients with stable (58%) or unstable (42%) angina and complex coronary 
anatomy, found that prolonged post-PCI infusion significantly reduced the incidence of periprocedural myocardial 
damage (defined as creatine kinase-MB increase ≥3 times upper limit of normal) compared with no infusion without 
differences in death and other clinical outcomes at 1- and 6-month follow-up (17). 
	In the HORIZONS-AMI, bivalirudin administration was limited, as per protocol, to the procedural period with 
interruption of the infusion at the end of PCI (2). The study showed a significant increase in the acute ST (absolute 1% 
excess that was not extended in ST rates at 30 days) in the bivaluridin arm compared with UFH plus GPI. Subsequently, 
the EUROMAX trial was designed to test whether bivalirudin, initiated during transport for primary PCI in STEMI, 
was superior to UFH in a more contemporary practice of the STEMI patients’ management (3). As opposed to 
HORIZONS-AMI, bivalirudin in the EUROMAX trial was prolonged as per protocol for at least 4 hours after PCI. 
Moreover, the protocol specified that the dosage after PCI had to be 0.25 mg/kg/h, but the full dose (1.75 mg/kg/h) was 
also permitted. In accordance with the HORIZONS-AMI, the EUROMAX confirmed the same 1% absolute increase in 
acute ST as compared with UFH with optional GPI, despite extending bivalirudin infusion for up to 4 hours after PCI, 
but major bleeding was reduced. A specific subanalysis of this trial showed that a high-dose of post-PCI bivalirudin was 
associated to similar rates of acute ST compared with UFH+GPI, while low-dose was independently associated to 
higher rates of acute ST (18). In the BRIGHT trial, bivalirudin was administered during and after the procedure at 1.75 
mg/kg/h (4). The post-procedure infusion was at least 30 minutes and up to 4 hours. At the operator’s discretion, a 
supplementary infusion at low dose (0.2 mg/kg/h) was allowed for up to 20 hours. All patients received a postprocedure 
infusion of the 1.75mg/kg/h bivalirudin PCI dose for a median duration of 180 minutes, and 115 patients (15.6%) 
thereafter received the optional 0.2mg/kg/h dose for a median duration of 400 minutes. Any ST and acute ST were not 
increased, while bleeding and NACE were reduced in the bivalirudin-treated patients. In the HEAT-PPCI, bivalirudin 
was administered without post-PCI prolonged infusion (a re-bolus of 0.3 mg/kg was provided in case of activated 
clotting time <225s at the end of PCI), and was associated with increased ST and MACE rates whereas bleeding did not 
differ (11). ST was observed at a high rate of incidence, at approximately 3.4% at variance with the 1.0% rate in the 
MATRIX Trial (6).   
Most of the evidence in NSTE-ACS patients is outdated and almost exclusively based on bivalirudin administration 
during PCI only (19). Thus, before MATRIX, limited data existed on the value of bivalirudin used at the currently 
suggested regimen versus UFH alone in contemporary practice. Our study explored the benefit of bivalirudin compared 
with UFH across the whole spectrum of ACS patients receiving a concomitant bleeding-avoidance strategy, such as 
trans-radial access and/or UFH alone. An aggregate data network meta-analysis suggested that post-PCI bivalirudin 
given at full regimen decreases the rate of ST and ischemic events (19,20). This analysis was largely based on 
MATRIX study results, but the existence of bias in the analysis was not assessed. The recent VALIDATE-
SWEEDHEART trial contributed to new evidence on bivalirudin versus UFH alone, showing no differences between 
groups (including ST) across ACS types (21). In this study, the protocol mandated the use of post-PCI bivalirudin at full 
regimen. So the MATRIX trial remains today the only study in which STEMI and NSTE-ACS patients treated with 
bivalirudin were randomized to either receive or not to receive post-PCI bivalirudin infusion. 
Our findings altogether lend support to the use of a post-PCI full bivalirudin infusion regimen to further optimize 
outcomes in bivalirudin-treated ACS patients (which is in keeping with the updated FDA label of the product), owing to 
the reduction of ischemic risk without compromising safety, and extend the previous evidence that came from the 
EUROMAX substudy, which focused on ST only (18). Full post-PCI bivalirudin infusion provided consistent 
protection in both STEMI and NSTE-ACS towards ST and periprocedural MI risks. While as expected, the risk of ST 
was in absolute terms greater in STEMI as compared to NSTE-ACS patients, full post-PCI bivalirudin infusion 
decreased that risk consistently across both types of ACS. In addition, full post-PCI bivalirudin decreased the risks of 
MI, mainly periprocedural MI. Interestingly, benefits largely came from a mitigation of the risk during index 
intervention in NSTE-ACS, whereas full post-PCI bivalirudin was associated to lower periprocedural MI risk which 
was mainly during planned staged interventions in STEMI patients. This observation is explained by the difficulties in 
ascertaining additional necrotic injury in patients already suffering from an evolving MI. 
The rates of BARC 3 or 5 bleeding also remained lower after adjustment in the group that received post-PCI full 
bivalirudin regimen as compared to who received a low post-PCI bivalirudin regimen or those who did not receive a 
post-PCI drug infusion. The bleeding risk remained lower in patients treated with the full post-PCI bivalirudin infusion 
also as compared to those assigned to UFH±GPI, owing to lower risks of access-site and non-access site related 
bleeding.  
 
Study limitations  
This study is affected by the protocol limitation which allowed for two different regimens of post-PCI bivalirudin 
infusion. Therefore, even if we had conducted multiple adjustments to account for differences between the groups, all 
these secondary findings should be considered explorative and interpreted with caution.  
This analysis provides important knowledge regarding the role of the bivalirudin regimens during the periprocedural 
period. However, as in previous studies, it is not powered for ST as a primary outcome, and therefore these findings 
should be considered as hypothesis-generating. 
The higher risk of bleeding in patients who received the low post-PCI bivalirudin regimen might have arisen by the 
protocol mandated longer duration of post-PCI bivalirudin infusion in such patients. Conversely, the lower risk of 
bleeding in patients receiving the full post-PCI bivalirudin regimen, when compared to those who did not receive 
infusion -largely attributable to an excess of pericardial bleeding- is counterintuitive. This may reflect a spurious 
finding or be explained by residual confounding not totally corrected by adjustment. Only a large randomized trial of 
bivalirudin with a prolonged post-PCI infusion at full dose versus UFH alone would provide conclusive evidence.  
	CONCLUSION 
In patients with ACS, with or without ST-segment elevation undergoing invasive management, the composite of urgent 
target-vessel revascularization, definite stent thrombosis, or net adverse clinical events, as well as other explored 
endpoints, were not significantly lower with a post-PCI bivalirudin infusion compared with no post-PCI infusion. 
However, a post-PCI bivalirudin infusion at full dose was associated with improved outcomes and was safe when 
compared with other investigated anti-thrombin strategies, including low post-PCI bivalirudin infusion, no infusion or 
unfractionated heparin±GPI. Further studies are needed to confirm these observations. 
 
CLINICAL PERSPECTIVES 
COMPETENCY IN MEDICAL KNOWLEDGE. Multiple data shows that bivalirudin was associated to higher risk 
of acute stent thrombosis (ST) in STEMI (but not NSTE-ACS) patients, suggesting that a prolonged post-PCI infusion 
might reduce such risk. However, the optimal regimen of bivalirudin after percutaneous coronary intervention (PCI), 
and whether this differs across acute coronary syndrome (ACS) with or without ST-segment elevation, is unknown.  
COMPETENCY IN PATIENT CARE. In the MATRIX trial, there were no differences between post-PCI bivalirudin 
infusion vs no infusion for the primary endpoint or other outcomes in STEMI and NSTE-ACS. Additionally, the full 
post-PCI bivalirudin dose was associated to improved efficacy and safety outcomes after an adjustment was 
made/applied, when compared to the low post-PCI bivalirudin regimen, no post-PCI infusion or unfractionated heparin 
groups.  
TRANSLATIONAL OUTLOOK. Additional investigation is needed to assess the effects of bivalirudin at full dose 
post-PCI versus UFH alone in contemporary practice and to assess the cost-effectiveness of these strategies.  
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FIGURE LEGENDS 
Central Illustration. Full or Low post-PCI bivalirudin regimen: Forest Plot of Main Clinical Outcomes. 
Propensity score adjusted rate ratios (RR) of main outcomes at 30 days for Full versus Low post-PCI bivalirudin 
regimen in the overall population and stratified by STEMI and NSTE-ACS. 
BARC=Bleeding Academic Research Consortium; CI=confidence interval; MI=myocardial infarction; ST=stent 
thrombosis; TVR=Target Vessel Revascularization. 
Figure 1. Distribution of patients receiving a Full or a Low post-PCI bivalirudin infusion during time. Bars report 
the proportion per week of Full and Low dose of post-PCI bivalirudin infusion during each month of trial enrollment. 
Vertical dashed lines indicate the publication time of relevant scientific evidence that might have influenced operators’ 
decision. Circles indicate the proportion per week of myocardial infarction (red) and definite stent thrombosis (orange) 
and continuous lines (red and orange) indicate the corresponding regressions. 
Figure 2. Kaplan-Meier curve for the primary endpoint according to the dose (full vs low) of post-PCI 
bivalirudin infusion and ACS type. The cumulative incidence of the primary outcome (composite of all-cause death, 
myocardial infarction, stroke, bleeding BARC 3 or 5, target vessel revascularization or definite stent thrombosis) up to 
30 days, among patients with STEMI or NSTE-ACS who received full or low post-PCI bivalirudin dose. 
Figure 3. Kaplan-Meier curve for individual components of the primary endpoint according to the dose (full vs 
low) of post-PCI bivalirudin infusion and ACS type. The cumulative incidence of the primary outcome components 
including all-cause death (A), myocardial infarction (B), stroke (C), bleeding BARC 3 or 5 (D), target vessel 
revascularization (E) and definite stent thrombosis (F) up to 30 days, among patients with STEMI or NSTE-ACS who 
received full or low post-PCI bivalirudin dose. 
Figure 4. Kaplan-Meier curve for myocardial infarction according to the dose (full vs low) of post-PCI 
bivalirudin infusion and ACS type. The cumulative incidence of myocardial infarction up to 30 days and stratified by 
time (<24h, 2-7 days and 8-30 days) among patients with STEMI or NSTE-ACS who received full or low post-PCI 
bivalirudin dose.  
	Central Illustration. Full or Low post-PCI bivalirudin regimen: Forest Plot of Main Clinical Outcomes. 
 
 
 
 
 
 
Figure 1. Distribution of patients receiving a Full or a Low post-PCI bivalirudin infusion during time. 
 
 
0,01 0,1 1
All
STEMI
NSTE-ACS
All
STEMI
NSTE-ACS
All
STEMI
NSTE-ACS
All
STEMI
NSTE-ACS
All
STEMI
NSTE-ACS
All
STEMI
NSTE-ACS
All
STEMI
NSTE-ACS
Full	dose	better Low dose	better
Definite	ST
TVR
BARC	3	or	5
Stroke
MI
All-cause	death
Primary Endpoint
0.97
0.84
0.84
--
--
--
0.28
0.16	(0.09-0.26)
0.15	(0.07-0.33)
0.18	(0.09-0.35)
0.37	(0.10-1.42)
0.35	(0.07-1.68)
0.41	(0.03-5.53)
Propensity AdjustedRate	Ratio	(95%	CI)						Int P
0.16	(0.09-0.29)
0.16	(0.06-0.45)
0.18	(0.09-0.36)
0.17	(0.01-2.67)
--
0.65	(0.02-21.63)
0.10	(0.02-0.55)
0.08	(0.01-0.81)
0.13	(0.01-1.45)
0.11	(0.03-0.47)
0.11	(0.03-0.51)
--
0.05	(0.01-0.45)
0.05	(0.01-0.47)
--
Full	dose
N=612
Low dose
N=1068
27	(4.4%)													154	(14.4%)
13	(3.3%)													54	(10.4%)
14	(6.6%)													100	(18.2%)
5 (0.8%)															18	(1.7%)
4 (1.0%)															11	(2.1%)
1	(0.5%)															7	(1.3%)
21	(3.4%)													123	(11.5%)
8	(2.0%)															32	(6.2%)
13	(6.1%)													91	(16.6%)
1	(0.2%)															4	(0.4%)
0 (0%)																		3	(0.6%)
1	(0.5%)													 1	(0.2%)
2 (0.3%)															14	(1.3%)
1	(0.3%)															10	(1.9%)
1	(0.5%)													 4	(0.7%)
3	(0.5%)															28	(2.6%)
3 (0.8%)															19	(3.7%)
0 (0%)																		9	(1.6%)
1 (0.2%)															22	(2.1%)
1	(0.3%)															14	(2.7%)
0 (0%)																		8	(1.5%)
Dec
2011
June
2012
Dec
2012
June
2013
Dec
2013
June
2014
Dec
2014
Proportion of Full post−PCI bivalirudin regimen and occurrence of Myocardial infarction and definite Stent Thrombosis
Date of randomisation
pr
op
or
tio
n 
of
 fu
ll b
iva
 re
gim
en
 p
er
 w
ee
k
0
20
40
60
80
10
0
2013 ACCF/AHA 
STEMI guidelines EUROMAX trial
2014 ESC guidelines 
myocardial revascularization
●
● ● ●
●
● ● ● ●
●
●
●
● ●
●
●
● ●
●
●
● ●
●
●
● ● ● ●
● ● ● ●
●
● ●
●
● ● ●
● ST definite proportion
●
● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
●
● ●
●
● ●
●
●
●
●
●
●
●
● ●
● MI proportion
Proportion of M
I and definite ST per week
40%
0%
	Figure 2. Kaplan-Meier curve for the primary endpoint according to the dose (full vs low) of post-PCI 
bivalirudin infusion and ACS type.  
 
 
Figure 3. Kaplan-Meier curve for individual components of the primary endpoint according to the dose (full vs 
low) of post-PCI bivalirudin infusion and ACS type. 
 
 
Figure 4. Kaplan-Meier curve for myocardial infarction according to the dose (full vs low) of post-PCI 
bivalirudin infusion and ACS type.  
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	 T
able 1. C
linical outcom
es at 30 days in post-PC
I bivalirudin prolonged infusion at full versus low
 dose. 
O
U
T
C
O
M
E
 
Post-PC
I 
prolonged 
bivalirudin 
Full dose (n=612) 
Post-PC
I 
prolonged 
bivalirudin 
L
ow
 dose (n=1068) 
U
nadjusted 
R
ate R
atio 
(95%
 C
I) 
P-
value* 
M
ultivariable 
A
djusted R
ate R
atio 
(95%
 C
I) 
P-value 
Propensity Score 
A
djusted  
R
ate R
atio (95%
 
C
I) 
P-value 
D
eath, M
I, Stroke, B
A
R
C
 3 or 5, TV
R
, 
ST 
27 (4.4%
) 
154 (14.4%
) 
0.29 (0.19-0.44) 
<0.001 
0.21 (0.12-0.35) 
<0.001 
0.16 (0.09-0.26) 
<0.001 
D
eath, M
I, Stroke 
26 (4.2%
) 
141 (13.2%
) 
0.31 (0.2-0.47) 
<0.001 
0.23 (0.13-0.39) 
<0.001 
0.17 (0.1-0.29) 
<0.001 
D
eath, M
I, Stroke, B
A
R
C
 3 or 5 
27 (4.4%
) 
149 (14%
) 
0.3 (0.2-0.45) 
<0.001 
0.22 (0.13-0.36) 
<0.001 
0.16 (0.09-0.27) 
<0.001 
D
eath 
5 (0.8%
) 
18 (1.7%
) 
0.48 (0.18-1.3) 
0.141 
--- 
--- 
0.37 (0.1-1.42) 
0.15 
C
ardiovascular death 
5 (0.8%
) 
16 (1.5%
) 
0.54 (0.2-1.48) 
0.227 
--- 
--- 
0.46 (0.11-1.82) 
0.27 
M
I 
21 (3.4%
) 
123 (11.5%
) 
0.29 (0.18-0.45) 
<0.001 
0.24 (0.14-0.41) 
<0.001 
0.16 (0.09-0.29) 
<0.001 
   M
I <24h 
17 (2.8%
) 
91 (8.5%
) 
0.32 (0.19-0.53) 
<0.001 
0.31 (0.17-0.56) 
<0.001 
0.18 (0.04-0.36) 
<0.001 
   M
I 2-7days 
3 (0.5%
) 
24 (2.2%
) 
0.2 (0.06-0.68) 
0.004 
0.22 (0.05-0.90) 
0.035 
0.16 (0.04-0.72) 
0.017 
   M
I 8-30 days 
1 (0.2%
) 
8 (0.7%
) 
0.2 (0.03-1.61) 
0.093 
0.02 (0.0-0.24) 
0.002 
0.04 (0.0-0.39) 
0.005 
Stroke 
1 (0.2%
) 
4 (0.4%
) 
0.44 (0.05-3.9) 
0.444 
--- 
--- 
0.17 (0.01-2.67) 
0.21 
TIA
 
1 (0.2%
) 
2 (0.2%
) 
0.87 (0.08-9.63) 
0.911 
--- 
--- 
1.07 (0.03-35.82) 
0.97 
TV
R
 
3 (0.5%
) 
28 (2.6%
) 
0.19 (0.06-0.61) 
0.002 
0.15 (0.04-0.6) 
0.007 
0.11 (0.03-0.47) 
0.003 
ST definite 
1 (0.2%
) 
22 (2.1%
) 
0.08 (0.01-0.58) 
0.001 
0.05 (0.01-0.47) 
0.008 
0.05 (0.01-0.45) 
0.008 
 A
cute 
1 (0.2%
) 
9 (0.8%
) 
0.19 (0.02-1.53) 
0.082 
0.11 (0.01-1.09) 
0.059 
0.08 (0.01-0.88) 
0.038 
 Subacute 
0 (0%
) 
13 (1.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 ST definite <24h 
1 (0.2%
) 
10 (0.9%
) 
0.17 (0.02-1.36) 
0.059 
0.10 (0.01-1.00) 
0.05 
0.09 (0.01-0.93) 
0.044 
 ST definite 2-7days 
0 (0%
) 
11 (1.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 ST definite 8-30 days 
0 (0%
) 
1 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
ST definite/probable 
1 (0.2%
) 
25 (2.3%
) 
0.07 (0.01-0.51) 
0.001 
0.04 (0.01-0.36) 
0.004 
0.04 (0-0.34) 
0.003 
  A
cute 
1 (0.2%
) 
10 (0.9%
) 
0.17 (0.02-1.36) 
0.059 
0.06 (0.01-0.63) 
0.018 
0.05 (0.01-0.52) 
0.012 
  Subacute 
0 (0%
) 
15 (1.4%
) 
--- 
--- 
--- 
--- 
--- 
--- 
B
leeding 
30 (4.9%
) 
147 (13.8%
) 
0.34 (0.23-0.5) 
<0.001 
0.17 (0.11-0.28) 
<0.001 
0.16 (0.1-0.27) 
<0.001 
 B
A
R
C
 1 
16 (2.6%
) 
71 (6.6%
) 
0.39 (0.22-0.66) 
<0.001 
0.23 (0.12-0.45) 
<0.001 
0.22 (0.11-0.45) 
<0.001 
 B
A
R
C
 2 
12 (2%
) 
62 (5.8%
) 
0.33 (0.18-0.61) 
<0.001 
0.18 (0.09-0.39) 
<0.001 
0.15 (0.07-0.34) 
<0.001 
 B
A
R
C
 3 
2 (0.3%
) 
13 (1.2%
) 
0.27 (0.06-1.19) 
0.062 
0.11 (0.02-0.59) 
0.011 
0.1 (0.02-0.59) 
0.011 
  B
A
R
C
 3a 
0 (0%
) 
8 (0.7%
) 
--- 
--- 
--- 
--- 
--- 
--- 
  B
A
R
C
 3b 
2 (0.3%
) 
3 (0.3%
) 
1.16 (0.19-6.96) 
0.868 
0.49 (0.06-4.09) 
0.51 
0.31 (0.03-3.15) 
0.32 
  B
A
R
C
 3c 
0 (0%
) 
2 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 B
A
R
C
 4 
0 (0%
) 
0 (0%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 B
A
R
C
 5 
0 (0%
) 
1 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
  B
A
R
C
 5a 
0 (0%
) 
1 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
  B
A
R
C
 5b 
0 (0%
) 
0 (0%
) 
--- 
--- 
--- 
--- 
--- 
--- 
	  B
A
R
C
 3 or 5 
2 (0.3%
) 
14 (1.3%
) 
0.25 (0.06-1.09) 
0.046 
0.12 (0.02-0.64) 
0.013 
0.1 (0.02-0.55) 
0.008 
  B
A
R
C
 3 or 5 access site 
2 (0.3%
) 
8 (0.7%
) 
0.44 (0.09-2.05) 
0.279 
0.21 (0.03-1.34) 
0.1 
0.18 (0.03-1.26) 
0.084 
  B
A
R
C
 3 or 5 non-access site 
0 (0%
) 
6 (0.6%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 B
A
R
C
 2, 3 or 5 
14 (2.3%
) 
76 (7.1%
) 
0.31 (0.18-0.55) 
<0.001 
0.16 (0.08-0.32) 
<0.001 
0.13 (0.06-0.28) 
<0.001 
  B
A
R
C
 2, 3 or 5 access site 
10 (1.6%
) 
41 (3.8%
) 
0.42 (0.21-0.84) 
0.011 
0.29 (0.12-0.69) 
0.006 
0.29 (0.11-0.76) 
0.011 
  B
A
R
C
 2, 3 or 5 non-access site 
4 (0.7%
) 
35 (3.3%
) 
0.2 (0.07-0.55) 
0.001 
0.08 (0.03-0.26) 
<0.001 
0.05 (0.01-0.18) 
<0.001 
TIM
I m
ajor 
0 (0%
) 
5 (0.5%
) 
--- 
--- 
--- 
--- 
--- 
--- 
TIM
I m
inor 
0 (0%
) 
7 (0.7%
) 
--- 
--- 
--- 
--- 
--- 
--- 
TIM
I m
ajor/m
inor 
0 (0%
) 
12 (1.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
G
U
STO
 severe 
0 (0%
) 
4 (0.4%
) 
--- 
--- 
--- 
--- 
--- 
--- 
G
U
STO
 m
oderate 
1 (0.2%
) 
4 (0.4%
) 
0.44 (0.05-3.9) 
0.445 
0.5 (0.03-8.27) 
0.63 
0.57 (0.03-11.61) 
0.71 
G
U
STO
 m
ild 
29 (4.7%
) 
139 (13%
) 
0.35 (0.23-0.52) 
<0.001 
0.18 (0.11-0.3) 
<0.001 
0.17 (0.1-0.28) 
<0.001 
G
U
STO
 m
oderate/severe 
1 (0.2%
) 
8 (0.7%
) 
0.22 (0.03-1.74) 
0.114 
0.2 (0.02-2.2) 
0.19 
0.11 (0.01-1.32) 
0.083 
C
om
posite of surgical access site repair 
and blood transfusion 
3 (0.5%
) 
15 (1.4%
) 
0.35 (0.1-1.2) 
0.079 
0.29 (0.05-1.68) 
0.17 
0.37 (0.07-1.91) 
0.23 
 Surgical access site repair 
1 (0.2%
) 
1 (0.1%
) 
1.75 (0.11-27.92) 
0.69 
--- 
--- 
0.84 (0.02-45.33) 
0.93 
 B
lood transfusion 
2 (0.3%
) 
14 (1.3%
) 
0.25 (0.06-1.09) 
0.046 
0.17 (0.02-1.68) 
0.13 
0.3 (0.04-1.98) 
0.21 
D
istribution of B
A
R
C
 3 or 5 
 
 
 
 
 
 
 
 
 Intracranial bleeding 
0 (0%
) 
3 (0.3%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 Pericardial bleeding 
0 (0%
) 
1 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 G
astrointestinal bleeding 
0 (0%
) 
1 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 G
enito-urinary bleeding 
0 (0%
) 
1 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 A
ccess site bleeding 
2 (0.3%
) 
8 (0.7%
) 
0.43 (0.09-2.05) 
0.278 
0.21 (0.03-1.33) 
0.097 
0.18 (0.03-1.25) 
0.083 
 O
ther bleeding 
0 (0%
) 
0 (0%
) 
--- 
--- 
--- 
--- 
--- 
--- 
* Log-rank test 
 
	 T
able 2. C
linical outcom
es at 30 days in post-PC
I bivalirudin prolonged infusion at full dose versus no post-PC
I infusion. 
O
U
T
C
O
M
E
 
Post-PC
I 
prolonged 
bivalirudin 
Full dose (n=612) 
N
o infusion 
(n=1811) 
U
nadjusted 
R
ate R
atio 
(95%
 C
I) 
P-
value* 
M
ultivariable 
A
djusted R
ate R
atio 
(95%
 C
I) 
P-value 
Propensity Score 
A
djusted  
R
ate R
atio (95%
 C
I) 
P-value 
D
eath, M
I, Stroke, B
A
R
C
 3 or 5, TV
R
, 
ST 
27 (4.4%
) 
215 (11.9%
) 
0.36 (0.24-0.53) 
<0.001 
0.36 (0.22-0.56) 
<0.001 
0.4 (0.26-0.62) 
<0.001 
D
eath, M
I, Stroke 
26 (4.2%
) 
190 (10.5%
) 
0.39 (0.26-0.59) 
<0.001 
0.4 (0.25-0.65) 
<0.001 
0.45 (0.29-0.7) 
<0.001 
D
eath, M
I, Stroke, B
A
R
C
 3 or 5 
27 (4.4%
) 
211 (11.7%
) 
0.36 (0.24-0.54) 
<0.001 
0.37 (0.23-0.58) 
<0.001 
0.42 (0.27-0.64) 
<0.001 
D
eath 
5 (0.8%
) 
32 (1.8%
) 
0.46 (0.18-1.18) 
0.098 
--- 
--- 
0.5 (0.18-1.36) 
0.17 
C
ardiovascular death 
5 (0.8%
) 
31 (1.7%
) 
0.47 (0.18-1.22) 
0.114 
--- 
--- 
0.54 (0.2-1.49) 
0.23 
M
I 
21 (3.4%
) 
154 (8.5%
) 
0.39 (0.25-0.62) 
<0.001 
0.43 (0.27-0.7) 
0.001 
0.46 (0.28-0.76) 
0.002 
   M
I <24h 
17 (2.8%
) 
121 (6.7%
) 
0.41 (0.25-0.68) 
<0.001 
0.51 (0.30-0.88) 
0.015 
0.50 (0.29-0.88) 
0.016 
   M
I 2-7days 
3 (0.5%
) 
26 (1.4%
) 
0.33 (0.1-1.08) 
0.053 
0.22 (0.06-0.76) 
0.017 
0.32 (0.09-1.10) 
0.070 
   M
I 8-30 days 
1 (0.2%
) 
7 (0.4%
) 
0.4 (0.05-3.26) 
0.377 
0.36 (0.04-3.10) 
0.36 
0.45 (0.05-4.07) 
0.48 
Stroke 
1 (0.2%
) 
7 (0.4%
) 
0.42 (0.05-3.43) 
0.405 
--- 
--- 
0.39 (0.04-3.41) 
0.39 
TIA
 
1 (0.2%
) 
2 (0.1%
) 
1.48 (0.13-16.33) 
0.747 
0.44 (0.01-14.5) 
0.64 
0.73 (0.07-8.29) 
0.8 
TV
R
 
3 (0.5%
) 
21 (1.2%
) 
0.42 (0.13-1.41) 
0.149 
0.44 (0.12-1.53) 
0.2 
0.45 (0.13-1.62) 
0.22 
ST definite 
1 (0.2%
) 
13 (0.7%
) 
0.23 (0.03-1.74) 
0.118 
0.25 (0.03-2.02) 
0.19 
0.34 (0.04-2.88) 
0.32 
 A
cute 
1 (0.2%
) 
10 (0.6%
) 
0.3 (0.04-2.31) 
0.216 
0.35 (0.04-2.96) 
0.33 
0.52 (0.06-4.76) 
0.57 
 Subacute 
0 (0%
) 
3 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 ST definite <24h 
1 (0.2%
) 
8 (0.4%
) 
0.37 (0.05-2.95) 
0.328 
0.50 (0.06-4.36) 
0.53 
0.57 (0.06-5.24) 
0.62 
 ST definite 2-7days 
0 (0%
) 
4 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 ST definite 8-30 days 
0 (0%
) 
1 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
ST definite/probable 
1 (0.2%
) 
19 (1%
) 
0.16 (0.02-1.16) 
0.037 
0.24 (0.03-1.88) 
0.17 
0.23 (0.03-1.81) 
0.16 
  A
cute 
1 (0.2%
) 
11 (0.6%
) 
0.27 (0.03-2.08) 
0.176 
0.35 (0.04-2.96) 
0.33 
0.52 (0.06-4.76) 
0.57 
  Subacute 
0 (0%
) 
8 (0.4%
) 
--- 
--- 
--- 
--- 
--- 
--- 
B
leeding 
30 (4.9%
) 
192 (10.6%
) 
0.45 (0.31-0.66) 
<0.001 
0.46 (0.3-0.7) 
<0.001 
0.5 (0.33-0.77) 
0.002 
 B
A
R
C
 1 
16 (2.6%
) 
97 (5.4%
) 
0.48 (0.28-0.82) 
0.006 
0.5 (0.27-0.92) 
0.025 
0.66 (0.37-1.19) 
0.17 
 B
A
R
C
 2 
12 (2%
) 
62 (3.4%
) 
0.57 (0.31-1.06) 
0.07 
0.56 (0.28-1.11) 
0.095 
0.5 (0.25-1.02) 
0.058 
 B
A
R
C
 3 
2 (0.3%
) 
28 (1.5%
) 
0.21 (0.05-0.88) 
0.019 
0.21 (0.05-0.92) 
0.038 
0.23 (0.05-1) 
0.05 
  B
A
R
C
 3a 
0 (0%
) 
15 (0.8%
) 
--- 
--- 
--- 
--- 
--- 
--- 
  B
A
R
C
 3b 
2 (0.3%
) 
11 (0.6%
) 
0.54 (0.12-2.43) 
0.412 
0.67 (0.13-3.34) 
0.62 
0.69 (0.14-3.54) 
0.66 
  B
A
R
C
 3c 
0 (0%
) 
2 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 B
A
R
C
 4 
0 (0%
) 
1 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 B
A
R
C
 5 
0 (0%
) 
4 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
  B
A
R
C
 5a 
0 (0%
) 
3 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
  B
A
R
C
 5b 
0 (0%
) 
1 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
	  BA
R
C
 3 or 5 
2 (0.3%
) 
32 (1.8%
) 
0.18 (0.04-0.77) 
0.009 
0.21 (0.05-0.92) 
0.038 
0.19 (0.04-0.81) 
0.025 
  B
A
R
C
 3 or 5 access site 
2 (0.3%
) 
8 (0.4%
) 
0.74 (0.16-3.49) 
0.702 
1.13 (0.21-6.14) 
0.88 
0.91 (0.16-4.99) 
0.91 
  B
A
R
C
 3 or 5 non-access site 
0 (0%
) 
24 (1.3%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 B
A
R
C
 2, 3 or 5 
14 (2.3%
) 
94 (5.2%
) 
0.44 (0.25-0.76) 
0.003 
0.44 (0.24-0.8) 
0.008 
0.39 (0.21-0.74) 
0.004 
  B
A
R
C
 2, 3 or 5 access site 
10 (1.6%
) 
45 (2.5%
) 
0.66 (0.33-1.3) 
0.224 
0.69 (0.32-1.48) 
0.34 
0.69 (0.32-1.5) 
0.35 
  B
A
R
C
 2, 3 or 5 non-access site 
4 (0.7%
) 
49 (2.7%
) 
0.24 (0.09-0.66) 
0.003 
0.25 (0.09-0.72) 
0.01 
0.17 (0.05-0.56) 
0.004 
TIM
I m
ajor 
0 (0%
) 
11 (0.6%
) 
--- 
--- 
--- 
--- 
--- 
--- 
TIM
I m
inor 
0 (0%
) 
9 (0.5%
) 
--- 
--- 
--- 
--- 
--- 
--- 
TIM
I m
ajor/m
inor 
0 (0%
) 
20 (1.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
G
U
STO
 severe 
0 (0%
) 
12 (0.7%
) 
--- 
--- 
--- 
--- 
--- 
--- 
G
U
STO
 m
oderate 
1 (0.2%
) 
11 (0.6%
) 
0.27 (0.03-2.08) 
0.177 
0.33 (0.04-2.7) 
0.3 
0.24 (0.03-1.93) 
0.18 
G
U
STO
 m
ild 
29 (4.7%
) 
168 (9.3%
) 
0.5 (0.34-0.74) 
<0.001 
0.49 (0.32-0.77) 
0.002 
0.58 (0.37-0.9) 
0.015 
G
U
STO
 m
oderate/severe 
1 (0.2%
) 
23 (1.3%
) 
0.13 (0.02-0.95) 
0.017 
0.18 (0.02-1.36) 
0.096 
0.12 (0.02-0.92) 
0.041 
C
om
posite of surgical access site repair 
and blood transfusion 
3 (0.5%
) 
16 (0.9%
) 
0.55 (0.16-1.9) 
0.339 
0.36 (0.08-1.76) 
0.21 
0.48 (0.13-1.75) 
0.27 
 Surgical access site repair 
1 (0.2%
) 
3 (0.2%
) 
0.99 (0.1-9.48) 
0.99 
--- 
--- 
2.28 (0.16-31.8) 
0.54 
 B
lood transfusion 
2 (0.3%
) 
13 (0.7%
) 
0.45 (0.1-2.01) 
0.286 
0.11 (0.01-1.4) 
0.088 
0.34 (0.07-1.57) 
0.17 
D
istribution of B
A
R
C
 3 or 5 
 
 
 
 
 
 
 
 
 Intracranial bleeding 
0 (0%
) 
1 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 Pericardial bleeding 
0 (0%
) 
10 (0.6%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 G
astrointestinal bleeding 
0 (0%
) 
5 (0.3%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 G
enito-urinary bleeding 
0 (0%
) 
4 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 A
ccess site bleeding 
2 (0.3%
) 
8 (0.4%
) 
0.74 (0.16-3.47) 
0.698 
1.13 (0.21-6.12) 
0.89 
0.9 (0.16-4.97) 
0.91 
 O
ther bleeding 
0 (0%
) 
3 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
* Log-rank test 
 
	 T
able 3. C
linical outcom
es at 30 days in post-PC
I bivalirudin prolonged infusion at full dose versus unfractionated heparin. 
O
U
T
C
O
M
E
 
Post-PC
I 
prolonged 
bivalirudin 
Full dose (n=612) 
U
nfractionated 
heparin (n=3603) 
U
nadjusted 
R
ate R
atio 
(95%
 C
I) 
P-
value* 
M
ultivariable 
A
djusted R
ate R
atio 
(95%
 C
I) 
P-value 
Propensity Score 
A
djusted  
R
ate R
atio (95%
 C
I) 
P-value 
D
eath, M
I, Stroke, B
A
R
C
 3 or 5, 
TV
R
, ST 
27 (4.4%
) 
450 (12.5%
) 
0.34 (0.23-0.5) 
<0.001 
0.38 (0.24-0.59) 
<0.001 
0.41 (0.27-0.61) 
<0.001 
D
eath, M
I, Stroke 
26 (4.2%
) 
391 (10.9%
) 
0.38 (0.25-0.56) 
<0.001 
0.44 (0.28-0.69) 
<0.001 
0.47 (0.31-0.72) 
<0.001 
D
eath, M
I, Stroke, B
A
R
C
 3 or 5 
27 (4.4%
) 
444 (12.3%
) 
0.34 (0.23-0.51) 
<0.001 
0.38 (0.25-0.6) 
<0.001 
0.41 (0.27-0.62) 
<0.001 
D
eath 
5 (0.8%
) 
83 (2.3%
) 
0.35 (0.14-0.87) 
0.018 
--- 
--- 
0.39 (0.15-0.98) 
0.046 
C
ardiovascular death 
5 (0.8%
) 
80 (2.2%
) 
0.37 (0.15-0.9) 
0.023 
--- 
--- 
0.41 (0.16-1.03) 
0.059 
M
I 
21 (3.4%
) 
303 (8.4%
) 
0.4 (0.26-0.62) 
<0.001 
0.47 (0.3-0.75) 
0.001 
0.51 (0.32-0.81) 
0.005 
   M
I <24h 
17 (2.8%
) 
239 (6.6%
) 
0.41 (0.25-0.67) 
<0.001 
0.49 (0.29-0.83) 
0.007 
0.54 (0.32-0.92) 
0..023 
   M
I 2-7days 
3 (0.5%
) 
44 (1.2%
) 
0.38 (0.12-1.24) 
0.096 
0.41 (0.12-1.32) 
0.13 
0.37 (0.11-1.25) 
0.11 
   M
I 8-30 days 
1 (0.2%
) 
20 (0.6%
) 
0.28 (0.04-2.09) 
0.184 
0.39 (0.05-3.04) 
0.37 
0.52 (0.06-4.19) 
0.54 
Stroke 
1 (0.2%
) 
16 (0.4%
) 
0.37 (0.05-2.77) 
0.311 
--- 
--- 
0.53 (0.06-4.35) 
0.55 
TIA
 
1 (0.2%
) 
9 (0.2%
) 
0.65 (0.08-5.16) 
0.685 
0.99 (0.1-9.51) 
0.99 
0.86 (0.09-7.84) 
0.89 
TV
R
 
3 (0.5%
) 
35 (1%
) 
0.5 (0.16-1.64) 
0.246 
0.79 (0.23-2.66) 
0.7 
0.84 (0.24-2.95) 
0.79 
ST definite 
1 (0.2%
) 
21 (0.6%
) 
0.28 (0.04-2.08) 
0.183 
0.51 (0.07-3.96) 
0.52 
0.41 (0.05-3.27) 
0.4 
 A
cute 
1 (0.2%
) 
13 (0.4%
) 
0.45 (0.06-3.46) 
0.433 
0.88 (0.11-7.25) 
0.91 
0.66 (0.08-5.57) 
0.7 
 Subacute 
0 (0%
) 
8 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 ST definite <24h 
1 (0.2%
) 
11 (0.3%
) 
0.53 (0.07-4.14) 
0.543 
1.03 (0.12-8.61) 
0.98 
0.67 (0.08-5.78) 
0.72 
 ST definite 2-7days 
0 (0%
) 
7 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 ST definite 8-30 days 
0 (0%
) 
3 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
ST definite/probable 
1 (0.2%
) 
35 (1%
) 
0.17 (0.02-1.22) 
0.045 
0.33 (0.04-2.54) 
0.29 
0.27 (0.03-2.06) 
0.21 
  A
cute 
1 (0.2%
) 
16 (0.4%
) 
0.37 (0.05-2.77) 
0.311 
0.88 (0.11-7.25) 
0.91 
0.63 (0.08-5.29) 
0.67 
  Subacute 
0 (0%
) 
19 (0.5%
) 
--- 
--- 
--- 
--- 
--- 
--- 
B
leeding 
30 (4.9%
) 
482 (13.4%
) 
0.35 (0.24-0.51) 
<0.001 
0.35 (0.23-0.52) 
<0.001 
0.35 (0.24-0.52) 
<0.001 
 B
A
R
C
 1 
16 (2.6%
) 
237 (6.6%
) 
0.39 (0.23-0.65) 
<0.001 
0.38 (0.22-0.66) 
0.001 
0.43 (0.25-0.74) 
0.002 
 B
A
R
C
 2 
12 (2%
) 
153 (4.2%
) 
0.46 (0.25-0.82) 
0.007 
0.44 (0.24-0.83) 
0.011 
0.42 (0.22-0.81) 
0.009 
 B
A
R
C
 3 
2 (0.3%
) 
72 (2%
) 
0.16 (0.04-0.66) 
0.004 
0.18 (0.04-0.74) 
0.018 
0.16 (0.04-0.67) 
0.012 
  B
A
R
C
 3a 
0 (0%
) 
38 (1.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
  B
A
R
C
 3b 
2 (0.3%
) 
33 (0.9%
) 
0.36 (0.09-1.48) 
0.138 
0.36 (0.08-1.57) 
0.17 
0.35 (0.08-1.51) 
0.16 
  B
A
R
C
 3c 
0 (0%
) 
1 (0%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 B
A
R
C
 4 
0 (0%
) 
4 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 B
A
R
C
 5 
0 (0%
) 
16 (0.4%
) 
--- 
--- 
--- 
--- 
--- 
--- 
  B
A
R
C
 5a 
0 (0%
) 
11 (0.3%
) 
--- 
--- 
--- 
--- 
--- 
--- 
  B
A
R
C
 5b 
0 (0%
) 
5 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
	  B
A
R
C
 3 or 5 
2 (0.3%
) 
88 (2.4%
) 
0.13 (0.03-0.54) 
0.001 
0.17 (0.04-0.72) 
0.015 
0.13 (0.03-0.52) 
0.004 
  B
A
R
C
 3 or 5 access site 
2 (0.3%
) 
32 (0.9%
) 
0.37 (0.09-1.53) 
0.152 
0.38 (0.09-1.65) 
0.2 
0.34 (0.08-1.47) 
0.15 
  B
A
R
C
 3 or 5 non-access site 
0 (0%
) 
56 (1.6%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 B
A
R
C
 2, 3 or 5 
14 (2.3%
) 
241 (6.7%
) 
0.33 (0.2-0.57) 
<0.001 
0.35 (0.2-0.62) 
<0.001 
0.3 (0.16-0.54) 
<0.001 
  B
A
R
C
 2, 3 or 5 access site 
10 (1.6%
) 
132 (3.7%
) 
0.44 (0.23-0.84) 
0.01 
0.4 (0.2-0.8) 
0.01 
0.39 (0.2-0.79) 
0.008 
  B
A
R
C
 2, 3 or 5 non-access site 
4 (0.7%
) 
109 (3%
) 
0.21 (0.08-0.58) 
0.001 
0.29 (0.1-0.81) 
0.017 
0.18 (0.06-0.57) 
0.004 
TIM
I m
ajor 
0 (0%
) 
33 (0.9%
) 
--- 
--- 
--- 
--- 
--- 
--- 
TIM
I m
inor 
0 (0%
) 
33 (0.9%
) 
--- 
--- 
--- 
--- 
--- 
--- 
TIM
I m
ajor/m
inor 
0 (0%
) 
66 (1.8%
) 
--- 
--- 
--- 
--- 
--- 
--- 
G
U
STO
 severe 
0 (0%
) 
26 (0.7%
) 
--- 
--- 
--- 
--- 
--- 
--- 
G
U
STO
 m
oderate 
1 (0.2%
) 
26 (0.7%
) 
0.23 (0.03-1.67) 
0.11 
0.26 (0.03-1.97) 
0.19 
0.18 (0.02-1.34) 
0.093 
G
U
STO
 m
ild 
29 (4.7%
) 
426 (11.8%
) 
0.39 (0.27-0.56) 
<0.001 
0.38 (0.25-0.57) 
<0.001 
0.4 (0.27-0.6) 
<0.001 
G
U
STO
 m
oderate/severe 
1 (0.2%
) 
52 (1.4%
) 
0.11 (0.02-0.81) 
0.009 
0.15 (0.02-1.14) 
0.067 
0.09 (0.01-0.69) 
0.02 
C
om
posite of surgical access site 
repair and blood transfusion 
3 (0.5%
) 
67 (1.9%
) 
0.26 (0.08-0.83) 
0.014 
0.25 (0.06-1.07) 
0.061 
0.26 (0.08-0.85) 
0.026 
 Surgical access site repair 
1 (0.2%
) 
12 (0.3%
) 
0.49 (0.06-3.77) 
0.484 
0.56 (0.07-4.65) 
0.59 
0.47 (0.06-3.85) 
0.48 
 B
lood transfusion 
2 (0.3%
) 
63 (1.7%
) 
0.19 (0.05-0.76) 
0.008 
0.13 (0.02-0.99) 
0.048 
0.18 (0.04-0.76) 
0.02 
D
istribution of B
A
R
C
 3 or 5 
 
 
 
 
 
 
 
 
 Intracranial bleeding 
0 (0%
) 
3 (0.1%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 Pericardial bleeding 
0 (0%
) 
17 (0.5%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 G
astrointestinal bleeding 
0 (0%
) 
21 (0.6%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 G
enito-urinary bleeding 
0 (0%
) 
7 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
 A
ccess site bleeding 
2 (0.3%
) 
30 (0.8%
) 
0.39 (0.09-1.63) 
0.181 
0.4 (0.09-1.73) 
0.22 
0.35 (0.08-1.54) 
0.17 
 O
ther bleeding 
0 (0%
) 
7 (0.2%
) 
--- 
--- 
--- 
--- 
--- 
--- 
* Log-rank test 
    
Part 1
Trade-off for ischemia and 
bleeding during and immediately 
after percutaneous coronary 
interventions:
Implementing the Radial approach 
to improve clinical outcomes
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We identifi ed no heterogeneity for 
any of the outcomes addressed in this 
meta-analysis, and results from RIVAL 
and MATRIX are fully compatible, with 
95% CIs of the two trials overlapping 
widely. Rather than focusing on 
subgroup results of an individual trial, 
we advise Dowling and colleagues, 
Brieger and Yong, and Shah and 
Gardner to take the overall body of 
evidence into consideration. If their 
hypotheses were true, some extent 
of between-trial heterogeneity would 
be expected, caused by variation in 
expertise with radial or femoral access 
across included trials.
We are not sure that their 
hypothesis is clinically plausible: 
most interventional cardiologists 
treating patients in MATRIX were 
originally trained to do percutaneous 
coronary intervention through femoral 
access. Most cardiologists who have 
successfully undergone transition 
from femoral to radial access will agree 
that gaining proficiency with radial 
access will not result in loss of the skills 
needed to access the femoral artery for 
diagnostic or interventional purposes. 
We therefore stand by our conclusion 
that radial access emerges as the gold 
standard for coronary intervention, 
providing improved safety and 
eff ectiveness, resulting in lower direct 
and indirect costs,4 and being mostly 
preferred to conventional femoral 
intervention by patients.5
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pay the penalty. Rather than concluding 
that radial access should be the default 
for acute coronary syndromes, we 
believe that clinicians and institutions 
should be careful to retain expertise in 
both procedures.
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We agree that MATRIX requested a fairly 
robust radial expertise for operators 
to qualify, with at least 75 radial 
interventions in the year before the 
start of the study and at least 50% of 
these interventions in patients with 
acute coronary syndrome. By contrast, 
the RIVAL trial2 requested operators 
to have done a minimum of 50 radial 
catheterisations overall to participate. 
However, although interpretation of 
subgroups as if they were properly 
powered trials is well known, it should 
be resisted to avoid over interpretation.3 
Our conclusion that radial access 
should be the default for patients with 
acute coronary syndrome undergoing 
percutaneous coronary intervention 
was not expressed on the basis of a 
subgroup analysis, nor on the basis of 
our study alone, but on a meta-analysis 
of all available clinical trials so far, 
including MATRIX.1
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Impact of Sex on Comparative Outcomes
of Radial Versus Femoral Access in
Patients With Acute Coronary Syndromes
Undergoing Invasive Management
Data From the Randomized MATRIX-Access Trial
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ABSTRACT
OBJECTIVES This study sought to assess whether transradial access (TRA) compared with transfemoral access (TFA)
is associated with consistent outcomes in male and female patients with acute coronary syndrome undergoing
invasive management.
BACKGROUND There are limited and contrasting data about sex disparities for the safety and efficacy of TRA versus
TFA for coronary intervention.
METHODS In the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic
Implementation of angioX) program, 8,404 patients were randomized to TRA or TFA. The 30-day coprimary outcomes
were major adverse cardiovascular and cerebrovascular events (MACCE), defined as death, myocardial infarction, or
stroke, and net adverse clinical events (NACE), defined as MACCE or major bleeding.
RESULTS Among 8,404 patients, 2,232 (26.6%) were women and 6,172 (73.4%) were men. MACCE and NACE were
not significantly different between men and women after adjustment, but women had higher risk of access site
bleeding (male vs. female rate ratio [RR]: 0.64; p ¼ 0.0016), severe bleeding (RR: 0.17; p ¼ 0.0012), and transfusion
(RR: 0.56; p ¼ 0.0089). When comparing radial versus femoral, there was no significant interaction for MACCE and NACE
stratified by sex (pint ¼ 0.15 and 0.18, respectively), although for both coprimary endpoints the benefit with TRA was
relatively greater in women (RR: 0.73; p ¼ 0.019; and RR: 0.73; p ¼ 0.012, respectively). Similarly, there was no
significant interaction between male and female patients for the individual endpoints of all-cause death (pint ¼ 0.79),
myocardial infarction (pint ¼ 0.25), stroke (pint ¼ 0.18), and Bleeding Academic Research Consortium type 3 or 5
(pint ¼ 0.45).
CONCLUSIONS Women showed a higher risk of severe bleeding and access site complications, and radial access
was an effective method to reduce these complications as well as composite ischemic and ischemic or bleeding
endpoints. (J Am Coll Cardiol Intv 2018;11:36–50) © 2018 by the American College of Cardiology Foundation.
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T he advent of combined antithrombotic thera-pies and early invasive management hasreduced the ischemic burden but increased
bleeding risk in patients with acute coronary syn-
drome (ACS) (1–3). The use of radial instead of femoral
access mitigates bleeding while preserving ischemic
risks, thereby providing consistent mortality benefit
across trials (4).
Female patients have increased periprocedural
bleeding risk as compared with men (1,5). However,
female patients have smaller radial arteries that are
more prone to spasm as well as shorter aortic roots
than men, which adds to the operative difficulty and
may undermine the efficacy of radial access in this
population. Previous studies have shown contrasting
evidence about potential sex disparities for the safety
and efficacy of transradial access (TRA) versus trans-
femoral access (TFA) (6,7).
We sought to investigate the comparative efficacy
and safety outcomes across sex of radial versus femoral
access in ACS patients participating in the MATRIX-
Access (Minimizing Adverse Haemorrhagic Events by
TRansradial Access Site and Systemic Implementation
of angioX) trial.
METHODS
STUDY DESIGN. The MATRIX-Access was a
randomized, multicenter, superiority trial
comparing radial with femoral access in pa-
tients with ACS with or without ST-segment
elevation undergoing coronary angiography
and percutaneous coronary intervention
(PCI), if indicated (4,8). This was the first of 3
trials of the MATRIX program (Clinical-
Trials.gov; NCT01433627) and was performed
in all patients with an ACS consenting to
participate in the program. The institutional
review board at each participating center
approved the trial, and all patients gave
written informed consent to participate.
STUDY PATIENTS. Patients were eligible if
they had an ACS with or without ST-segment
elevation, were scheduled to undergo an
invasive approach, and the interventional
cardiologist was willing to proceed with
either radial or femoral access with expertise for
both, including at least 75 coronary interventions
performed and at least 50% of interventions in ACS
via the radial route during the previous year. Patients
SEE PAGE 51
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ACS = acute coronary
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MI = myocardial infarction
NACE = net adverse clinical
event(s)
NSTE-ACS = non–ST-segment
elevation acute coronary
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PCI = percutaneous coronary
intervention
RR = rate ratio
TFA = transfemoral access
TRA = transradial access
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presenting with non–ST-segment elevation ACS
(NSTE-ACS) were eligible if they had a history
consistent with new or worsening ischemia, occur-
ring at rest or with minimal activity within 7 days
before randomization, and fulfilled at least 2 high-
risk criteria (4,8). Patients with ST-segment eleva-
tion myocardial infarction were eligible if they
presented within 12 h of the onset of symptoms or
between 12 and 24 h after symptom onset if there was
evidence of continued ischemia or previous fibrino-
lytic treatment and if they had ST-segment elevation
of at least 1 mm in 2 or more contiguous leads, new
left bundle branch block, or true posterior MI. The
main inclusion and exclusion criteria were previously
reported (4,8).
STUDY PROTOCOL AND RANDOMIZATION. Before
the start of angiography, patients were randomly
assigned 1:1 to radial or femoral access for diagnostic
angiography and PCI, if indicated, using a web-
based system to ensure adequate concealment of
allocation. The randomization sequence was com-
puter generated, blocked, and stratified by site,
intended new or ongoing use of ticagrelor or
prasugrel, type of ACS (ST-segment elevation
myocardial infarction or troponin-positive or
troponin-negative NSTE-ACS), and anticipated use
of immediate PCI. Access site management during
and after the diagnostic or therapeutic procedure
was left to the discretion of the treating physician,
and closure devices were allowed as per local prac-
tice. The use of anticoagulant agents outside the
protocol of the MATRIX program was not allowed.
Bivalirudin administration was consistent with the
approved product labeling, whereas unfractionated
heparin was dosed at 70 to 100 U/kg in patients not
receiving glycoprotein IIb or IIIa inhibitors and at
50 to 70 U/kg in patients receiving glycoprotein IIb
or IIIa inhibitors. Use of all other antithrombotic
medications, including oral antiplatelet agents
and nonantithrombotic medications, such as beta-
blockers, angiotensin-converting enzyme inhibitors,
TABLE 1 Baseline Characteristics According to Access Site and Sex
Male Patients Female Patients
Male
Patients
(n ¼ 6,172)
Female
Patients
(n ¼ 2,232) p Value
Radial
(n ¼ 3,126)
Femoral
(n ¼ 3,046) p Value
Radial
(n ¼ 1,071)
Femoral
(n ¼ 1,161) p Value
Age, yrs 63.8 " 11.6 64.2 " 11.6 0.18 70.7 " 11.2 70.2 " 11.1 0.36 64.0 " 11.6 70.4 " 11.1 <0.0001
Age $75 yrs 623 (19.9) 636 (20.9) 0.35 445 (41.5) 466 (40.1) 0.50 1,259 (20.4) 911 (40.8) <0.0001
STEMI 1,552 (49.6) 1,541 (50.6) 0.46 449 (41.9) 468 (40.3) 0.44 3,093 (50.1) 917 (41.1) <0.0001
NSTE-ACS 1,574 (50.4) 1,505 (49.4) 0.46 622 (58.1) 693 (59.7) 0.44 3,079 (49.9) 1,315 (58.9) <0.0001
Weight, kg 80.7 " 13.1 80.0 " 12.3 0.020 67.8 " 12.7 69.4 " 13.7 0.0042 80.3 " 12.8 68.6 " 13.2 <0.0001
Body mass index, kg/m2 27.3 " 3.9 27.1 " 3.8 0.0083 26.4 " 4.7 27.0 " 5.1 0.0083 27.2 " 3.8 26.7 " 4.9 <0.0001
Diabetes mellitus 687 (22.0) 656 (21.5) 0.018 272 (25.4) 288 (24.8) 0.75 1,343 (21.8) 560 (25.1) 0.0001
Insulin dependent 135 (4.3) 171 (5.6) 0.75 74 (6.9) 86 (7.4) 0.75 306 (5.0) 160 (7.2) 0.0001
Current smoker 1,218 (39.0) 1,141 (37.5) 0.36 241 (22.5) 287 (24.7) 0.42 2,359 (38.2) 528 (23.7) <0.0001
Hypercholesterolemia 1,292 (41.3) 1,340 (44.0) 0.035 507 (47.3) 552 (47.5) 0.92 2,632 (42.6) 1,059 (47.4) 0.0001
Hypertension 1,839 (58.8) 1,830 (60.1) 0.86 786 (73.4) 856 (73.7) 0.86 3,669 (59.4) 1,642 (73.6) <0.0001
Family history of CAD 861 (27.5) 861 (28.3) 0.53 285 (26.6) 286 (24.6) 0.28 1,722 (27.9) 571 (25.6) 0.035
Previous MI 473 (15.1) 486 (16.0) 0.37 112 (10.5) 132 (11.4) 0.49 959 (15.5) 244 (10.9) <0.0001
Previous PCI 501 (16.0) 474 (15.6) 0.62 109 (10.2) 111 (9.6) 0.63 975 (15.8) 220 (9.9) <0.0001
Radial access 94 (3.0) 63 (2.1) 0.019 25 (2.3) 21 (1.8) 0.38 157 (2.5) 46 (2.1) 0.20
Femoral access 225 (7.2) 234 (7.7) 0.47 51 (4.8) 52 (4.5) 0.75 459 (7.4) 103 (4.6) <0.0001
Both radial and femoral access 29 (0.9) 32 (1.1) 0.63 7 (0.7) 3 (0.3) 0.16 61 (1.0) 10 (0.4) 0.017
Access site unknown 153 (4.9) 145 (4.8) 0.81 26 (2.4) 35 (3.0) 0.40 298 (4.8) 61 (2.7) <0.0001
Previous CABG 92 (2.9) 124 (4.1) 0.016 19 (1.8) 22 (1.9) 0.83 216 (3.5) 41 (1.8) 0.0001
Previous TIA or stroke 135 (4.3) 147 (4.8) 0.34 60 (5.6) 83 (7.1) 0.14 282 (4.6) 143 (6.4) 0.0007
Peripheral vascular disease 249 (8.0) 272 (8.9) 0.17 92 (8.6) 100 (8.6) 0.98 521 (8.4) 192 (8.6) 0.82
COPD 182 (5.8) 201 (6.6) 0.21 68 (6.3) 82 (7.1) 0.50 383 (6.2) 150 (6.7) 0.39
History of renal failure 36 (1.2) 36 (1.2) 0.91 10 (0.9) 23 (2.0) 0.041 72 (1.2) 33 (1.5) 0.26
Dialysis 3 (0.1) 3 (0.1) 1.00 1 (0.1) 1 (0.1) 1.00 6 (0.1) 2 (0.1) 0.92
Continued on the next page
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and other antihypertensive agents, were allowed as
per guidelines (9).
STUDY OUTCOMES. Two coprimary 30-day compos-
ite outcomes were pre-specified: major adverse car-
diovascular and cerebrovascular events (MACCE),
defined as the composite of all-cause mortality, MI, or
stroke; and net adverse clinical events (NACE),
defined as the composite of MACCE or noncoronary
artery bypass grafting–related major bleeding
(Bleeding Academic Research Consortium [BARC]
type 3 or 5) (10). Secondary outcomes included
each component of the composite outcomes,
cardiovascular mortality, and stent thrombosis.
Bleeding was also assessed and adjudicated on the
basis of the Thrombolysis In Myocardial Infarction
and GUSTO (Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Coronary
Arteries) scales (11,12). Stent thrombosis was defined
as the definite or probable occurrence of a stent-
related thrombotic event according to the Academic
Research Consortium classification (13). All outcomes
were pre-specified (4,8). An independent clinical
events committee blinded to treatment allocation
adjudicated all suspected outcome events by
reviewing relevant medical records after site
TABLE 1 Continued
Male Patients Female Patients
Male
Patients
(n ¼ 6,172)
Female
Patients
(n ¼ 2,232) p Value
Radial
(n ¼ 3,126)
Femoral
(n ¼ 3,046) p Value
Radial
(n ¼ 1,071)
Femoral
(n ¼ 1,161) p Value
Clinical presentation
Cardiac arrest 59 (1.9) 66 (2.2) 0.44 26 (2.4) 17 (1.5) 0.098 125 (2.0) 43 (1.9) 0.78
Killip class
I 2,845 (91.0) 2,781 (91.3) 0.69 951 (88.8) 1,019 (87.8) 0.45 5,626 (91.2) 1,970 (88.3) 0.0001
II 193 (6.2) 197 (6.5) 0.64 75 (7.0) 104 (9.0) 0.089 390 (6.3) 179 (8.0) 0.0061
III 56 (1.8) 49 (1.6) 0.58 32 (3.0) 30 (2.6) 0.56 105 (1.7) 62 (2.8) 0.0018
IV 32 (1.0) 19 (0.6) 0.083 13 (1.2) 8 (0.7) 0.27 51 (0.8) 21 (0.9) 0.61
Previous lytic therapy 73 (2.3) 83 (2.7) 0.33 21 (2.0) 21 (1.8) 0.88 156 (2.5) 42 (1.9) 0.085
Systolic arterial pressure, mm Hg 138.3 " 25.1 138.1 " 25.4 0.80 139.1 " 26.8 140.7 " 26.3 0.16 138.2 " 25.2 139.9 " 26.6 0.0081
Heart rate, beats/min 75.8 " 16.3 75.3 " 16.4 0.27 77.9 " 17.1 77.9 " 17.7 0.97 75.5 " 16.4 77.9 " 17.4 <0.0001
Left ventricular ejection fraction, % 51.1 " 9.5 51.0 " 9.6 0.48 51.7 " 9.8 50.6 " 10.2 0.0093 51.0 " 9.5 51.1 " 10.0 0.81
eGFR 86.2 " 24.9 85.8 " 24.5 0.54 78.4 " 26.2 76.9 " 27.0 0.19 86.0 " 24.7 77.6 " 26.6 <0.0001
<60 ml/min/1.73 m2 433 (13.9) 399 (13.2) 0.39 267 (25.2) 316 (27.5) 0.23 832 (13.6) 583 (26.4) <0.0001
<30 ml/min/1.73 m2 20 (0.6) 19 (0.6) 0.94 15 (1.4) 30 (2.6) 0.047 39 (0.6) 45 (2.0) <0.0001
Medications before the cath lab
Aspirin 2,960 (94.7) 2,884 (94.7) 0.99 996 (93.0) 1,070 (92.2) 0.45 5,844 (94.7) 2,066 (92.6) 0.0003
Clopidogrel 1,445 (46.2) 1,386 (45.5) 0.57 570 (53.2) 611 (52.6) 0.78 2,831 (45.9) 1,181 (52.9) <0.0001
Prasugrel 411 (13.1) 402 (13.2) 0.95 74 (6.9) 66 (5.7) 0.23 813 (13.2) 140 (6.3) <0.0001
Ticagrelor 754 (24.1) 758 (24.9) 0.48 224 (20.9) 271 (23.3) 0.17 1,512 (24.5) 495 (22.2) 0.028
Enoxaparin 476 (15.2) 488 (16.0) 0.39 211 (19.7) 254 (21.9) 0.21 964 (15.6) 465 (20.8) <0.0001
Fondaparinux 309 (9.9) 332 (10.9) 0.19 119 (11.1) 136 (11.7) 0.65 641 (10.4) 255 (11.4) 0.17
ACE inhibitor 915 (29.3) 899 (29.5) 0.83 338 (31.6) 402 (34.6) 0.12 1,814 (29.4) 740 (33.2) 0.0009
Angiotensin II receptor blocker 290 (9.3) 290 (9.5) 0.74 160 (14.9) 172 (14.8) 0.93 580 (9.4) 332 (14.9) <0.0001
Statins 1,356 (43.4) 1,303 (42.8) 0.63 456 (42.6) 560 (48.2) 0.0073 2,659 (43.1) 1,016 (45.5) 0.047
Beta-blocker 1,216 (38.9) 1,206 (39.6) 0.58 478 (44.6) 569 (49.0) 0.038 2,422 (39.2) 1,047 (46.9) <0.0001
Warfarin 44 (1.4) 39 (1.3) 0.66 28 (2.6) 25 (2.2) 0.47 83 (1.3) 53 (2.4) 0.0010
PPI 1,552 (49.6) 1,546 (50.8) 0.38 606 (56.6) 646 (55.6) 0.65 3,098 (50.2) 1,252 (56.1) <0.0001
Previous unfractionated heparin 991 (31.7) 961 (31.5) 0.90 248 (23.2) 276 (23.8) 0.73 1,952 (31.6) 524 (23.5) <0.0001
Bivalirudin 4 (0.1) 2 (0.1) 0.69 0 (0.0) 0 (0.0) 1.00 6 (0.1) 0 (0.0) 0.35
Values are mean " SD or n (%).
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; eGFR ¼ estimated glomerular filtration rate;
MI ¼ myocardial infarction; NSTE-ACS ¼ non–ST-segment elevation acute coronary syndrome; PCI ¼ percutaneous coronary intervention; PPI ¼ proton pump inhibitor; STEMI ¼ ST-segment elevation
myocardial infarction; TIA ¼ transient ischemic attack.
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monitoring by Trial Form Support (Lund, Sweden) in
Italy and the Netherlands, FLS-Research Support
(Barcelona, Spain) in Spain, and Gothia Forum (Västra
Götaland) in Sweden.
STATISTICAL ANALYSIS. Statistical analyses were
performed by an academic statistical group led by 1 of
the authors (B.R.d.C.), who had access to the full
deidentified data set.
The trial was powered for superiority on the 2
coprimary composite outcomes at 30 days expecting a
rate reduction of 30%, corresponding to rate ratio
(RR) of 0.70.
All analyses were performed per intention-to-treat
principle, including all patients in the analysis based
on the allocated access. Events up to 30 days post-
randomization were considered. We analyzed pri-
mary and secondary outcomes separately for male
and female patients as time to first event using the
Mantel-Cox method, accompanied by log-rank
tests to calculate corresponding 2-sided p values.
We did not perform any adjustments for multiple
TABLE 2 Procedural Characteristics According to Access Site and Sex
Male Patients Female Patients
Male
Patients
(n ¼ 6,172)
Female
Patients
(n ¼ 2,232) p Value
Radial
(n ¼ 3,126)
Femoral
(n ¼ 3,046) p Value
Radial
(n ¼ 1,071)
Femoral
(n ¼ 1,161) p Value
No PCI attempted after coronary angiography 490 (15.7) 501 (16.4) 0.41 337 (31.5) 342 (29.5) 0.30 991 (16.1) 679 (30.4) <0.0001
CABG 130 (4.2) 122 (4.0) 0.76 25 (2.3) 33 (2.8) 0.45 252 (4.1) 58 (2.6) 0.0016
Patient with significant lesion and medical
treatment
246 (7.9) 243 (8.0) 0.87 244 (22.8) 256 (22.0) 0.68 489 (7.9) 500 (22.4) <0.0001
Patient without significant lesion 114 (3.6) 136 (4.5) 0.10 68 (6.3) 53 (4.6) 0.063 250 (4.1) 121 (5.4) 0.0073
PCI attempted 2,634 (84.3) 2,542 (83.5) 0.39 734 (68.5) 816 (70.3) 0.37 5,176 (83.9) 1,550 (69.4) <0.0001
PCI completed 2,634 (84.3) 2,542 (83.5) 0.39 733 (68.4) 815 (70.2) 0.37 5,176 (83.9) 1,548 (69.4) <0.0001
Crossover 162 (5.2) 72 (2.4) <0.0001 81 (7.6) 24 (2.1) <0.0001 234 (3.8) 105 (4.7) 0.037
Medications in the cath lab
Aspirin 161 (5.2) 193 (6.3) 0.045 61 (5.7) 66 (5.7) 0.99 354 (5.7) 127 (5.7) 0.90
Clopidogrel 200 (6.4) 180 (5.9) 0.42 69 (6.4) 74 (6.4) 0.95 380 (6.2) 143 (6.4) 0.66
Prasugrel 281 (9.0) 246 (8.1) 0.20 54 (5.0) 45 (3.9) 0.18 527 (8.5) 99 (4.4) <0.0001
Ticagrelor 283 (9.1) 297 (9.8) 0.35 98 (9.2) 98 (8.4) 0.55 580 (9.4) 196 (8.8) 0.38
Glycoprotein IIb/IIIa inhibitor 473 (15.1) 423 (13.9) 0.17 100 (9.3) 99 (8.5) 0.50 896 (14.5) 199 (8.9) <0.0001
Planned GPI 354 (11.3) 307 (10.1) 0.11 65 (6.1) 65 (5.6) 0.64 661 (10.7) 130 (5.8) <0.0001
Bailout GPI 119 (3.8) 116 (3.8) 1.00 35 (3.3) 34 (2.9) 0.64 235 (3.8) 69 (3.1) 0.12
Unfractionated heparin 1,568 (50.2) 1,415 (46.5) 0.0036 464 (43.3) 449 (38.7) 0.026 2983 (48.3) 913 (40.9) <0.0001
Unfractionated heparin, U/kg 73.6 " 30.1 73.7 " 28.8 0.92 81.9 " 31.8 79.2 " 27.3 0.20 73.7 " 29.5 80.5 " 29.6 <0.0001
Subtherapeutic regimen (<50 U/kg) 356 (11.4) 258 (8.5) 0.00013 106 (9.9) 75 (6.5) 0.0030 614 (9.9) 181 (8.1) 0.015
Therapeutic regimen ($50 U/kg) 1,212 (38.8) 1,157 (38.0) 0.52 358 (33.4) 374 (32.2) 0.54 2,369 (38.4) 732 (32.8) <0.0001
Bivalirudin 1,332 (42.6) 1,300 (42.7) 0.96 387 (36.1) 437 (37.6) 0.46 2,632 (42.6) 824 (36.9) <0.0001
Prolonged infusion post-PCI 672 (21.5) 647 (21.2) 0.81 197 (18.4) 224 (19.3) 0.59 1,319 (21.4) 421 (18.9) 0.012
Average duration of post-PCI bivalirudin
infusion
360.0 " 204.5 372.2 " 269.9 0.35 370.5 " 293.9 403.7 " 286.3 0.24 366.0 " 238.8 388.2 " 290.0 0.13
Full bivalirudin regimen post-PCI 241 (7.7) 225 (7.4) 0.63 82 (7.7) 78 (6.7) 0.39 466 (7.6) 160 (7.2) 0.57
Average duration of full bivalirudin
regimen
249.3 " 64.8 272.3 " 292.1 0.23 288.1 " 267.7 270.7 " 153.7 0.62 260.4 " 208.3 279.6 " 219.1 0.32
Low bivalirudin regimen post-PCI 431 (13.8) 422 (13.9) 0.94 115 (10.7) 146 (12.6) 0.18 853 (13.8) 261 (11.7) 0.011
Average duration of low bivalirudin
regimen
421.9 " 228.5 425.5 " 241.3 0.82 429.2 " 298.8 474.8 " 314.5 0.24 423.7 " 234.8 454.7 " 307.9 0.094
Intra-aortic balloon pump 51 (1.6) 68 (2.2) 0.086 33 (3.1) 34 (2.9) 0.83 119 (1.9) 67 (3.0) 0.0037
PCI completed (n ¼ 2,634) (n ¼ 2,542) (n ¼ 733) (n ¼ 815) (n ¼ 5,176) (n ¼ 1,548)
TIMI flow grade 3 in all treated lesions 2,501 (95.0) 2,421 (95.2) 0.63 695 (94.8) 773 (94.8) 0.98 4,922 (95.1) 1,468 (94.8) 0.67
Coronary stenosis <30% in all treated lesions 2,524 (95.8) 2,423 (95.3) 0.38 695 (94.8) 780 (95.7) 0.41 4,947 (95.6) 1,475 (95.3) 0.64
Procedural success in all treated lesions 2,446 (92.9) 2,361 (92.9) 0.98 677 (92.4) 756 (92.8) 0.76 4,807 (92.9) 1,433 (92.6) 0.69
Duration of procedure, min 51.8 " 29.1 50.0 " 28.3 0.017 45.6 " 26.9 45.6 " 27.7 1.00 50.9 " 28.7 45.6 " 27.3 <0.0001
Continued on the next page
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comparisons but set the alpha error at 2.5% to cor-
rect for the 2 coprimary outcomes. We analyzed
secondary outcomes with a 2-sided alpha value set
at 5% to allow conventional interpretation of results.
Survival curves were constructed using Kaplan-
Meier estimates. We performed stratified analyses
according to the pre-specified subgroup of random-
ization to heparin or bivalirudin, and estimated
possible interaction terms across ordered groups
separately for the male and female study pop-
ulations. We also analyzed clinical outcomes in the
overall population irrespective of randomized access
to compare male and female patients, but due to the
significant differences in baseline and procedural
characteristics, multivariable adjustment was per-
formed including the following variables: age, type
TABLE 2 Continued
Male Patients Female Patients
Male
Patients
(n ¼ 6,172)
Female
Patients
(n ¼ 2,232) p Value
Radial
(n ¼ 3,126)
Femoral
(n ¼ 3,046) p Value
Radial
(n ¼ 1,071)
Femoral
(n ¼ 1,161) p Value
Fluoroscopic time, min 11.0 (6.7–17.1) 9.7 (5.5–15.2) 0.88 9.2 (5.0–15.0) 8.1 (4.2–14.4) 0.43 10.2 (6.0–16.2) 9.0 (4.5–14.6) 0.27
Treated vessel(s) per patient
Left main coronary artery 107 (4.1) 88 (3.5) 0.26 45 (6.1) 31 (3.8) 0.033 195 (3.8) 76 (4.9) 0.039
Left anterior descending artery 1,318 (50.1) 1,248 (49.2) 0.51 367 (50.1) 402 (49.3) 0.75 2,566 (49.6) 769 (49.7) 0.93
Left circumflex artery 707 (26.9) 709 (27.9) 0.39 197 (26.9) 200 (24.5) 0.29 1,416 (27.4) 397 (25.7) 0.18
Right coronary artery 872 (33.1) 833 (32.8) 0.81 244 (33.3) 289 (35.5) 0.38 1,705 (33.0) 533 (34.5) 0.28
Bypass graft 18 (0.7) 33 (1.3) 0.025 2 (0.3) 3 (0.4) 0.74 51 (1.0) 5 (0.3) 0.015
At least 2 vessels treated 344 (13.1) 339 (13.4) 0.76 107 (14.6) 101 (12.4) 0.20 683 (13.2) 208 (13.4) 0.80
Lesions treated per patient 1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.92 1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.71 1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.52
1 2,068 (78.5) 1,993 (78.5) 576 (78.7) 657 (80.6) 4,061 (78.5) 1,233 (79.7)
2 454 (17.2) 448 (17.6) 132 (18.0) 133 (16.3) 902 (17.4) 265 (17.1)
3 or more 111 (4.2) 98 (3.9) 24 (3.3) 25 (3.1) 209 (4.0) 49 (3.2)
At least 1 complex lesion 1,393 (52.9) 1,306 (51.4) 0.29 375 (51.2) 398 (48.8) 0.35 2,699 (52.2) 773 (49.9) 0.13
Median number of stents per patient 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.13 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.62 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.49
Overall stent length per patient, mm 71.3 " 44.9 70.5 " 44.5 0.54 66.6 " 39.7 66.9 " 42.7 0.88 70.9 " 44.7 66.8 " 41.3 0.0018
Lesions
Number of lesions with PCI (n ¼ 3,332) (n ¼ 3,205) (n ¼ 919) (n ¼ 1,000) (n ¼ 6,537) (n ¼ 1,919)
Lesions stented 3,052 (91.6) 2,892 (90.2) 0.070 826 (89.9) 909 (90.9) 0.57 5,944 (90.9) 1,735 (90.4) 0.51
At least 1 drug-eluting stent 2,251 (67.6) 2,150 (67.1) 0.51 565 (61.5) 647 (64.7) 0.068 4,401 (67.3) 1,212 (63.2) 0.0011
At least 1 bare-metal stent 801 (24.0) 742 (23.2) 0.77 261 (28.4) 262 (26.2) 0.093 1,543 (23.6) 523 (27.3) 0.0016
Lesions not stented 280 (8.4) 313 (9.8) 0.070 93 (10.1) 91 (9.1) 0.57 593 (9.1) 184 (9.6) 0.51
TIMI flow grade pre-procedure
0 or 1 1,289 (38.7) 1,254 (39.2) 0.80 342 (37.2) 371 (37.1) 0.79 2,543 (38.9) 713 (37.2) 0.070
2 428 (12.9) 417 (13.0) 0.86 103 (11.2) 113 (11.3) 0.95 845 (12.9) 216 (11.3) 0.070
3 1,613 (48.4) 1,532 (47.8) 0.90 474 (51.6) 516 (51.6) 0.81 3,145 (48.1) 990 (51.6) 0.0042
TIMI flow grade post-procedure
0 or 1 58 (1.7) 53 (1.7) 0.81 19 (2.1) 20 (2.0) 0.94 111 (1.7) 39 (2.0) 0.66
2 82 (2.5) 74 (2.3) 0.75 23 (2.5) 27 (2.7) 0.80 156 (2.4) 50 (2.6) 0.53
3 3,190 (95.8) 3,076 (96.0) 0.65 877 (95.4) 953 (95.3) 0.31 6,266 (95.9) 1,830 (95.4) 0.50
Coronary stenosis <30% 3,215 (96.5) 3,080 (96.2) 0.41 870 (94.7) 959 (95.9) 0.36 6,295 (96.4) 1,829 (95.3) 0.21
Procedural success 3,129 (93.9) 3,012 (94.0) 0.91 852 (92.7) 935 (93.5) 0.55 6,141 (93.9) 1,787 (93.1) 0.24
Number of lesions stented (n ¼ 3,052) (n ¼ 2,892) (n ¼ 826) (n ¼ 909) (n ¼ 5,944) (n ¼ 1,735)
Total stent length per lesion, mm 26.2 " 14.5 26.0 " 14.0 0.49 25.1 " 14.5 25.9 " 14.6 0.34 26.1 " 14.3 25.5 " 14.5 0.16
Average stent diameter per lesion, mm 3.1 " 0.5 3.1 " 0.5 0.74 3.0 " 0.4 2.9 " 0.4 0.33 3.1 " 0.5 3.0 " 0.4 <0.0001
At least 1 direct stenting 697 (22.8) 641 (22.2) 0.68 166 (20.1) 195 (21.5) 0.30 1,338 (22.5) 361 (20.8) 0.14
Post-dilatation 1,382 (45.3) 1,304 (45.1) 0.92 344 (41.6) 418 (46.0) 0.13 2,686 (45.2) 762 (43.9) 0.28
Values are mean " SD, n (%), or median (range).
GPI ¼ glycoprotein IIb/IIIa inhibitor; PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
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of ACS, body mass index, diabetes, smoking,
hypercholesterolemia, hypertension, previous MI,
previous CABG, previous stroke or transient
ischemic attack, Killip class, renal function,
crossover, glycoprotein IIb or IIIa, and intra-aortic
balloon pump. All analyses were performed using
the statistical package Stata 13.1 (StataCorp, College
Station, Texas).
TABLE 3 Clinical Outcomes at 30 Days in Male and Female Patients
Male
Patients
(n ¼ 6,172)
Female
Patients
(n ¼ 2,232)
Rate Ratio
(95% CI)
(Unadjusted)
Unadjusted
p Value
Rate Ratio
(95% CI)
(Adjusted)
Adjusted
p Value
Death, MI, stroke 560 (9.1) 238 (10.7) 0.84 (0.72–0.98) 0.030 1.04 (0.88–1.22) 0.67
Death, MI, stroke, BARC type 3 or 5 624 (10.2) 272 (12.2) 0.82 (0.70–0.95) 0.0071 1.02 (0.88–1.20) 0.76
Death, MI, stroke, BARC type 3 or 5, TVR, ST 636 (10.4) 274 (12.3) 0.83 (0.71–0.96) 0.011 1.03 (0.88–1.20) 0.74
Death 91 (1.5) 66 (3.0) 0.49 (0.36–0.68) <0.0001 0.80 (0.56–1.16) 0.24
Death cardiovascular 88 (1.4) 61 (2.7) 0.52 (0.37–0.72) 0.0001 0.82 (0.56–1.19) 0.30
MI 460 (7.5) 169 (7.6) 0.98 (0.81–1.17) 0.80 1.11 (0.92–1.34) 0.29
Stroke 20 (0.3) 12 (0.5) 0.60 (0.29–1.22) 0.15 0.75 (0.33–1.71) 0.49
TIA 6 (0.1) 12 (0.5) 0.18 (0.07–0.48) 0.0001 0.31 (0.10–0.91) 0.033
TVR 65 (1.1) 24 (1.1) 0.97 (0.61–1.55) 0.90 0.88 (0.53–1.47) 0.63
ST definite 45 (0.7) 12 (0.5) 1.35 (0.71–2.55) 0.36 1.32 (0.67–2.59) 0.43
Acute 26 (0.4) 7 (0.3) 1.34 (0.58–3.08) 0.50 1.15 (0.48–2.78) 0.75
Subacute 20 (0.3) 5 (0.2) 1.43 (0.54–3.81) 0.47 1.65 (0.58–4.71) 0.35
ST definite/probable 63 (1.0) 17 (0.8) 1.33 (0.78–2.27) 0.30 1.45 (0.81–2.57) 0.21
Acute 30 (0.5) 8 (0.4) 1.35 (0.62–2.95) 0.45 1.24 (0.54–2.85) 0.61
Subacute 35 (0.6) 9 (0.4) 1.39 (0.67–2.89) 0.38 1.82 (0.83–4.02) 0.14
Bleeding 654 (10.7) 302 (13.7) 0.76 (0.66–0.88) 0.0002 0.87 (0.75–1.01) 0.067
BARC type 1 327 (5.3) 147 (6.8) 0.79 (0.65–0.96) 0.020 0.84 (0.68–1.04) 0.11
BARC type 2 238 (3.9) 104 (4.7) 0.82 (0.65–1.03) 0.090 0.92 (0.71–1.18) 0.51
BARC type 3 93 (1.6) 45 (2.0) 0.74 (0.52–1.05) 0.094 1.06 (0.72–1.56) 0.77
BARC type 3a 47 (0.8) 26 (1.2) 0.65 (0.40–1.04) 0.072 1.03 (0.61–1.75) 0.91
BARC type 3b 42 (0.7) 18 (0.8) 0.84 (0.48–1.45) 0.52 1.11 (0.61–2.03) 0.73
BARC type 3c 5 (0.1) 1 (0.0) 1.79 (0.21–15.36) 0.59 1.55 (0.14–16.68) 0.72
BARC type 4 10 (0.2) 2 (0.1) 1.79 (0.39–8.17) 0.45 2.12 (0.43–10.48) 0.36
BARC type 5 6 (0.1) 15 (0.7) 0.14 (0.06–0.37) <0.0001 0.17 (0.06–0.50) 0.0012
BARC type 5a 3 (0.0) 12 (0.5) 0.09 (0.03–0.32) <0.0001 0.13 (0.03–0.51) 0.0036
BARC type 5b 3 (0.0) 3 (0.1) 0.36 (0.07–1.78) 0.19 0.25 (0.04–1.63) 0.15
BARC type 3 or 5 99 (1.6) 60 (2.7) 0.59 (0.43–0.81) 0.0011 0.84 (0.59–1.19) 0.32
BARC type 3 or 5 access site 33 (0.6) 26 (1.2) 0.45 (0.27–0.76) 0.0020 0.65 (0.37–1.16) 0.14
BARC type 3 or 5 non–access site 66 (1.1) 34 (1.5) 0.70 (0.46–1.05) 0.084 0.97 (0.62–1.53) 0.90
BARC type 2, 3, or 5 335 (5.5) 161 (7.3) 0.74 (0.61–0.90) 0.0019 0.90 (0.73–1.10) 0.29
BARC type 2, 3, or 5 access site 165 (2.7) 101 (4.6) 0.58 (0.45–0.74) <0.0001 0.64 (0.49–0.85) 0.0016
BARC type 2, 3, or 5 non–access site 176 (2.9) 60 (2.7) 1.06 (0.79–1.42) 0.71 1.39 (1.01–1.90) 0.042
TIMI major 38 (0.6) 25 (1.1) 0.54 (0.33–0.90) 0.017 0.68 (0.39–1.20) 0.18
TIMI minor 32 (0.6) 24 (1.1) 0.48 (0.28–0.81) 0.0050 0.75 (0.42–1.36) 0.35
TIMI major/minor 70 (1.2) 49 (2.2) 0.51 (0.35–0.74) 0.0002 0.71 (0.47–1.07) 0.10
GUSTO severe 32 (0.5) 18 (0.8) 0.64 (0.36–1.14) 0.12 0.91 (0.48–1.72) 0.77
GUSTO moderate 31 (0.5) 24 (1.1) 0.46 (0.27–0.79) 0.0036 0.65 (0.36–1.17) 0.15
GUSTO mild 591 (9.7) 264 (12.1) 0.79 (0.68–0.92) 0.0020 0.88 (0.75–1.03) 0.11
GUSTO moderate/severe 63 (1.0) 42 (1.9) 0.54 (0.36–0.79) 0.0015 0.74 (0.48–1.14) 0.18
Composite of surgical access site repair and
blood transfusion
61 (1.0) 53 (2.4) 0.41 (0.28–0.59) <0.0001 0.56 (0.37–0.84) 0.0056
Surgical access site repair 11 (0.2) 8 (0.4) 0.49 (0.20–1.22) 0.12 0.49 (0.18–1.32) 0.16
Blood transfusion 55 (0.9) 49 (2.2) 0.40 (0.27–0.59) <0.0001 0.56 (0.37–0.87) 0.0089
Values are n (%), unless otherwise indicated.
BARC ¼ Bleeding Academic Research Consortium; CI ¼ confidence interval; GUSTO ¼ Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded
Coronary Arteries; ST ¼ stent thrombosis; TVR ¼ other abbreviations as in Tables 1 and 2.
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RESULTS
PATIENTS. The MATRIX-Access trial enrolled 8,404
patients with ACS from 78 centers in Italy, the
Netherlands, Spain, and Sweden between October
2011 and November 2014. Of these patients, 6,172
(73.4%) were men, of whom 3,126 (37.2%) were allo-
cated to radial and 3,046 (36.2%) to femoral access;
and 2,232 (26.6%) were women, of whom 1,071 (12.8%)
were assigned to radial and 1,161 (13.8%) to femoral
access.
Baseline and procedural characteristics were
largely imbalanced between sexes (Tables 1 and 2).
Compared with men, women were older; had lower
body weight and body mass index; presented more
frequently with NSTE-ACS and advanced Killip class;
and had a higher prevalence of diabetes, hypercho-
lesterolemia, hypertension, renal dysfunction, and
prior cerebrovascular events. However, women less
frequently were smokers or had prior MI, PCI, or
CABG. Crossover rates, use of intra-aortic balloon
pump, left main treatment, and bare-metal stent im-
plantation occurred more often in women, while
attempted PCI, use of glycoprotein IIb/IIIa inhibitors,
and bypass graft treatment were less frequent in
women and stent diameter and length were lower
(Table 1). Before arrival in the catheterization labo-
ratory, female patients received aspirin and new
P2Y12 inhibitors less frequently as compared with
men (Table 1).
On the contrary, female and male subgroups allo-
cated to radial versus femoral access were generally
well matched in terms of demographics, medical
history, clinical presentation, and procedural aspects
(Tables 1 and 2). Medications at discharge are shown
in Online Table 1. Crossover rate from radial to
femoral was numerically higher in women as
compared with men (Table 2), however interaction
testing did not confirm heterogeneity across sexes
(interaction p ¼ 0.051).
CLINICAL OUTCOMES OF MALE VERSUS FEMALE
PATIENTS. MACCE and NACE were significantly
lower in men compared with women at unadjusted
analysis but they no longer differed after adjustment
for the multiple imbalances identified across patients’
characteristics (Table 3). Similarly, after adjustment,
neither of the single components of both coprimary
endpoints differed significantly in male compared
with female patients (Table 3). There was however a
trend toward higher risk of BARC type 3 or 5 access
site bleeding and a 36% increase of BARC type 2, 3, or
5 access site bleeding rates in women compared with
men after adjustment (Table 3). The need for trans-
fusion and the composite of surgical access site repair
and blood transfusion were also increased after
adjustment in female compared with male patients
(Table 3).
CLINICAL OUTCOMES OF RADIAL VERSUS FEMORAL
ACCESS ACCORDING TO SEX. Overall crossover
rates were higher in women as compared with men
(4.7% vs. 3.8%; p ¼ 0.037), however this difference
disappeared after adjustment (p ¼ 0.42).
No significant interaction was noted between ac-
cess site and sex with respect to both coprimary
endpoints of 30-day MACCE and NACE (interaction
p ¼ 0.15 and 0.18, respectively) (Figures 1 and 2,
Table 4). MACCE and NACE were significantly
reduced with radial as compared with femoral in fe-
male patients (MACCE: 9.1% vs. 12.2%; RR: 0.73; 95%
confidence interval [CI]: 0.56 to 0.95; p ¼ 0.019;
NACE: 10.4% vs. 13.9%; RR: 0.73; 95% CI: 0.56 to 0.93;
FIGURE 1 Main Outcomes of Radial Versus Femoral Access in Male and Female
Patients
Radial and femoral access were compared on the basis of sex subgroups, with rate ratios
and 95% confidence intervals (CIs), for the coprimary endpoints and their components
(death, myocardial infarction [MI], stroke, Bleeding Academic Research Consortium
[BARC] type 3 or 5).
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p ¼ 0.012) (Figure 1, Table 4) and trended in favor of
radial, albeit nonsignificantly in men (MACCE: 8.7%
vs. 9.5%; RR: 0.92; 95% CI: 0.77 to 1.09; p ¼ 0.31;
NACE: 9.6% vs. 10.8%; RR: 0.89; 95% CI: 0.76 to 1.05;
p ¼ 0.16) (Figure 1, Table 4). Radial access was
consistently (interaction p ¼ 0.79) associated to lower
all-cause fatalities in both sex groups (women: 2.4%
vs. 3.5%; RR: 0.70; 95% CI: 0.43 to 1.15; men: 1.3% vs.
1.7%; RR: 0.76; 95% CI: 0.50 to 1.15) (Figure 3, Table 4).
At further analysis, no signal of interaction was noted
between access site and sex for stroke (interaction
p ¼ 0.18), myocardial infarction (interaction p ¼ 0.25)
and for other secondary endpoints including
cardiovascular mortality (interaction p ¼ 0.92), stent
thrombosis (interaction p ¼ 0.18), target vessel
revascularization (interaction p ¼ 0.18), or the com-
posite of access site surgery or blood transfusion
(interaction p ¼ 0.18) (Figure 3, Table 4).
The key safety endpoint of BARC type 3 or 5
bleeding was similarly reduced (interaction
p ¼ 0.45) in the radial groups across sex, even if
formal statistical significance was achieved in fe-
male (2.0% vs. 3.4%; RR: 0.58; 95% CI: 0.34 to
0.98; p ¼ 0.040) but not in male patients (1.4% vs.
1.9%; RR: 0.74; 95% CI: 0.50 to 1.11; p ¼ 0.14)
(Table 4). Access site BARC type 3 or 5 bleeding
was consistently (interaction p ¼ 0.45) reduced in
both female and male patients whereas non–access
site BARC type 3 or 5 bleeding did not differ with
radial in both sexes (Table 4). Results remained
consistent across any BARC, TIMI, or GUSTO
bleeding scales.
ADDITIONAL ANALYSES. Figures 4 and 5 show the
consistency of randomized treatment effect (radial
vs. femoral) on MACCE, NACE, all-cause death and
BARC bleeds in female and male patients stratified by
randomly allocated antithrombin type (bivalirudin or
unfractionated heparin).
DISCUSSION
We assessed the role of sex disparities on clinical
outcomes in largely unselected ACS patients recruited
in the MATRIX-Access trial and undergoing invasive
management via either radial or femoral access. The
main findings are the following.
First, male and female patients differed consid-
erably for multiple baseline characteristics, proce-
dural features, and choice of medications. Although
unadjusted analyses apparently yielded greater risk
of main efficacy and safety endpoints in female
patients as compared with men, they no longer
differed after adjustment. Only access site
bleeding, but not overall bleeding, along with
transfusion rates alone or in combination with
surgical repair for the instrumented access site,
remained higher in female as compared with male
patients.
Second, there was no clear signal of heterogeneity
across sex with respect to any of the investigated
FIGURE 2 Coprimary Composite Outcomes at 30 Days in Male and Female Patients
(A, B) Cumulative incidence of the coprimary outcome of major adverse cardiac or ce-
rebrovascular events and net adverse clinical events, respectively. Blue indicates radial
access (transradial access [TRA]), red indicates femoral access (transfemoral access
[TFA]), continuous line indicates male patient, dashed line indicates female patient.
Abbreviations as in Figure 1.
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outcome measures, including the 2 coprimary com-
posite endpoints or each of the individual compo-
nents. Women but not men showed a significant
reduction of both coprimary endpoints (fulfilling the
pre-specified level of significance at an alpha error
of 2.5%) with radial access, indicating that the well-
known sex-specific procedural challenges of trans-
radial coronary catheterization and intervention do
not mitigate the expected benefits in female
patients.
TABLE 4 Clinical Outcomes at 30 Days in Radial Versus Femoral Access According to Sex
Male Patients Female Patients
p For
Interaction
Radial
(n ¼ 3,126)
Femoral
(n ¼ 3,046)
Rate Ratio
(95% CI) p Value
Radial
(n ¼ 1,071)
Femoral
(n ¼ 1,161)
Rate Ratio
(95%CI)
p
Value
Death, MI, stroke 272 (8.7) 288 (9.5) 0.92 (0.77–1.09) 0.31 97 (9.1) 141 (12.2) 0.73 (0.56–0.95) 0.019 0.15
Death, MI, stroke, BARC type 3 or 5 299 (9.6) 325 (10.8) 0.89 (0.76–1.05) 0.16 111 (10.4) 161 (13.9) 0.73 (0.56–0.93) 0.012 0.18
Death, MI, stroke, BARC type 3 or 5, TVR, ST 307 (9.9) 329 (10.9) 0.90 (0.77–1.06) 0.21 112 (10.5) 162 (14.0) 0.73 (0.57–0.93) 0.012 0.15
Death 40 (1.3) 51 (1.7) 0.76 (0.50–1.15) 0.20 26 (2.4) 40 (3.5) 0.70 (0.43–1.15) 0.15 0.79
Death cardiovascular 39 (1.2) 49 (1.6) 0.77 (0.51–1.18) 0.23 25 (2.3) 36 (3.1) 0.75 (0.45–1.25) 0.26 0.92
MI 228 (7.4) 232 (7.7) 0.95 (0.79–1.15) 0.62 71 (6.7) 98 (8.5) 0.77 (0.56–1.05) 0.10 0.25
Stroke 12 (0.4) 8 (0.3) 1.46 (0.60–3.57) 0.41 4 (0.4) 8 (0.7) 0.54 (0.16–1.78) 0.30 0.18
TIA 2 (0.1) 4 (0.1) 0.49 (0.09–2.65) 0.39 3 (0.3) 9 (0.8) 0.36 (0.10–1.32) 0.11 0.78
TVR 39 (1.3) 26 (0.9) 1.46 (0.89–2.40) 0.13 10 (0.9) 14 (1.2) 0.77 (0.34–1.73) 0.52 0.18
ST definite 26 (0.8) 19 (0.6) 1.33 (0.74–2.41) 0.34 4 (0.4) 8 (0.7) 0.54 (0.16–1.78) 0.30 0.18
Acute 18 (0.6) 8 (0.3) 2.19 (0.95–5.06) 0.058 3 (0.3) 4 (0.3) 0.81 (0.18–3.61) 0.78 0.24
Subacute 9 (0.3) 11 (0.4) 0.79 (0.33–1.92) 0.61 1 (0.1) 4 (0.4) 0.27 (0.03–2.40) 0.21 0.35
ST definite/probable 35 (1.1) 28 (1.0) 1.22 (0.74–2.00) 0.44 7 (0.7) 10 (0.9) 0.75 (0.29–1.98) 0.56 0.38
Acute 20 (0.6) 10 (0.3) 1.95 (0.91–4.17) 0.080 4 (0.4) 4 (0.3) 1.08 (0.27–4.31) 0.92 0.46
Subacute 17 (0.5) 18 (0.6) 0.92 (0.47–1.78) 0.80 3 (0.3) 6 (0.5) 0.54 (0.13–2.15) 0.37 0.49
Bleeding 236 (7.6) 418 (13.9) 0.53 (0.45–0.62) <0.0001 114 (10.7) 188 (16.5) 0.63 (0.50–0.80) 0.0001 0.23
BARC type 1 113 (3.6) 214 (7.1) 0.50 (0.40–0.63) <0.0001 55 (5.2) 92 (8.2) 0.63 (0.45–0.89) 0.0073 0.27
BARC type 2 85 (2.7) 153 (5.1) 0.53 (0.41–0.70) <0.0001 42 (4.0) 62 (5.4) 0.72 (0.49–1.08) 0.11 0.21
BARC type 3 37 (1.2) 56 (1.9) 0.64 (0.42–0.97) 0.034 17 (1.6) 28 (2.5) 0.65 (0.35–1.19) 0.16 0.97
BARC type 3a 18 (0.6) 29 (1.0) 0.60 (0.33–1.08) 0.087 11 (1.0) 15 (1.3) 0.79 (0.36–1.72) 0.55 0.59
BARC type 3b 17 (0.5) 25 (0.8) 0.66 (0.36–1.22) 0.18 6 (0.6) 12 (1.1) 0.54 (0.20–1.43) 0.21 0.72
BARC type 3c 2 (0.1) 3 (0.1) 0.65 (0.11–3.88) 0.63 0 (0.0) 1 (0.1) 0.36 (0.01–8.83) 1.00 0.46
BARC type 4 5 (0.2) 5 (0.2) 0.97 (0.28–3.36) 0.96 1 (0.1) 1 (0.1) 1.08 (0.07–17.16) 0.96 0.95
BARC type 5 6 (0.2) 0 (0.0) 12.67 (0.71–224.81) 0.031 4 (0.4) 11 (1.0) 0.39 (0.12–1.23) 0.095 0.0033
BARC type 5a 3 (0.1) 0 (0.0) 6.82 (0.35–131.98) 0.25 3 (0.3) 9 (0.8) 0.36 (0.10–1.32) 0.11 0.022
BARC type 5b 3 (0.1) 0 (0.0) 6.82 (0.35–131.98) 0.25 1 (0.1) 2 (0.2) 0.54 (0.05–5.95) 0.61 0.094
BARC type 3 or 5 43 (1.4) 56 (1.9) 0.74 (0.50–1.11) 0.14 21 (2.0) 39 (3.4) 0.58 (0.34–0.98) 0.040 0.45
BARC type 3 or 5 access site 8 (0.3) 25 (0.9) 0.31 (0.14–0.69) 0.0023 8 (0.8) 18 (1.6) 0.48 (0.21–1.10) 0.075 0.47
BARC type 3 or 5 non–access site 35 (1.2) 31 (1.0) 1.10 (0.68–1.78) 0.71 13 (1.2) 21 (1.8) 0.66 (0.33–1.33) 0.24 0.24
BARC type 2, 3, or 5 127 (4.1) 208 (6.9) 0.58 (0.47–0.73) <0.0001 62 (5.8) 99 (8.6) 0.66 (0.48–0.92) 0.012 0.51
BARC type 2, 3, or 5 access site 36 (1.2) 129 (4.3) 0.27 (0.18–0.39) <0.0001 33 (3.1) 68 (5.9) 0.51 (0.34–0.78) 0.0016 0.021
BARC type 2, 3, or 5 non–access site 92 (3.0) 84 (2.8) 1.06 (0.79–1.43) 0.68 29 (2.7) 31 (2.7) 1.01 (0.61–1.67) 0.98 0.85
TIMI major 19 (0.6) 19 (0.6) 0.97 (0.51–1.84) 0.93 7 (0.7) 18 (1.6) 0.42 (0.17–1.00) 0.043 0.12
TIMI minor 15 (0.5) 17 (0.6) 0.86 (0.43–1.72) 0.66 9 (0.8) 15 (1.3) 0.64 (0.28–1.48) 0.29 0.61
TIMI major/minor 34 (1.1) 36 (1.2) 0.92 (0.57–1.47) 0.72 16 (1.5) 33 (2.9) 0.52 (0.28–0.94) 0.029 0.14
GUSTO severe 17 (0.5) 15 (0.5) 1.10 (0.55–2.21) 0.79 6 (0.6) 12 (1.0) 0.54 (0.20–1.43) 0.21 0.24
GUSTO moderate 14 (0.5) 17 (0.6) 0.80 (0.39–1.62) 0.53 9 (0.9) 15 (1.3) 0.64 (0.28–1.47) 0.29 0.69
GUSTO mild 206 (6.6) 385 (12.8) 0.50 (0.42–0.60) <0.0001 100 (9.4) 164 (14.5) 0.64 (0.49–0.82) 0.0005 0.13
GUSTO moderate/severe 31 (1.0) 32 (1.1) 0.94 (0.57–1.54) 0.81 15 (1.4) 27 (2.4) 0.59 (0.32–1.12) 0.10 0.26
Composite of surgical access site repair and
blood transfusion
26 (0.9) 35 (1.2) 0.72 (0.43–1.20) 0.20 15 (1.4) 38 (3.3) 0.42 (0.23–0.77) 0.0035 0.18
Surgical access site repair 2 (0.1) 9 (0.3) 0.22 (0.05–1.00) 0.031 2 (0.2) 6 (0.5) 0.36 (0.07–1.78) 0.19 0.65
Blood transfusion 25 (0.9) 30 (1.0) 0.81 (0.48–1.38) 0.43 15 (1.4) 34 (3.0) 0.47 (0.26–0.87) 0.013 0.19
Values are n (%), unless otherwise indicated.
Abbreviations as in Tables 1 to 3.
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Advances in PCI procedures and optimization of
concomitant antithrombotic agents have improved
outcomes of patients with ACS by reducing ischemic
events, but at the cost of greater bleeding risk. The
latter remains a matter of concerns especially for
patients at increased procedural hemorrhagic risk
such as female patients. Although the spontaneous
(i.e., out of hospital) bleeding risk appears not to
differ among sexes (14–17), female patients have
been consistently shown to suffer the greatest from
access site hemorrhagic complications as compared
with male counterparts (1,5) Access site bleeds
represent a large part of periprocedural bleeding and
TRA has emerged as the most appealing and cost-
saving treatment strategy to mitigate those
complications. However, sex-specific procedural
challenges of transradial coronary catheterization
and intervention, possibly leading to a delayed or
less effective percutaneous treatment especially in
ACS female patients, remain a matter of concern.
Previous studies have reported that female sex is an
independent predictor of failure of transradial PCI
(18) and an independent predictor of radial spasm
(19), limiting the success of the transradial
procedure.
The MATRIX-Access trial is the largest (n ¼ 8,404)
randomized trial to compare radial and femoral ac-
cess, including unselected patients at high baseline
and procedural risk. Our current findings are in
agreement with those of previous observational
FIGURE 3 Components of Coprimary Composite Outcomes at 30 Days in Male and Female Patients
Panels show the cumulative incidence of the coprimary outcome of (A) all-cause death, (B) myocardial infarction, (C) stroke, and (D) BARC type 3 or 5 bleeding.
Blue indicates radial access (TRA), red indicates femoral access (TFA), continuous line indicates male patient, dashed line indicates female patient. Abbreviations as
in Figures 1 and 2.
Gargiulo et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 1 , N O . 1 , 2 0 1 8
MATRIX-Access Trial and Sex J A N U A R Y 8 , 2 0 1 8 : 3 6 – 5 0
46
FIGURE 4 Main Outcomes of Radial Versus Femoral Access Stratified by Antithrombin Type in Female Patients
Radial and femoral access were compared on the basis of the randomly assigned antithrombin type (bivalirudin or unfractionated heparin
[UFH]), with rate ratios and 95% CIs, for the coprimary endpoints, death, and BARC type 3 or 5. Abbreviations as in Figure 1.
FIGURE 5 Main Outcomes of Radial Versus Femoral Access Stratified by Antithrombin Type in Male Patients
Radial and femoral access were compared on the basis of the randomly assigned antithrombin type (bivalirudin or unfractionated heparin),
with rate ratios and 95% CIs, for the coprimary endpoints, death, and BARC type 3 or 5. Abbreviations as in Figure 1.
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studies (20,21), and those reported in the RIVAL
(Radial Vs femorAL access for coronary intervention)
trial. A pre-specified subgroup analysis of RIVAL
compared outcomes in women (n ¼ 1,861) and men
(n ¼ 5,160) who were randomized to radial versus
femoral access and showed that women undergoing
coronary angiography and PCI had a higher risk of
vascular access site complications compared with
men, but radial access was an effective method to
reduce these complications (7). In the RIVAL trial the
type of antithrombotic medications during coronary
intervention was not protocol-mandated. As a result,
the majority of patients were treated with heparin
rather than bivalirudin (approximately 2.6%).
Therefore, it was not possible to exclude that using
bivalirudin would have reduced the benefits of
radial access especially in female patients (22). In the
MATRIX-Access trial, heparin and bivalirudin were
randomly and evenly assigned to patients at the
time of coronary intervention. No signal of hetero-
geneity was noted for type of anticoagulant agent
and access site for both men and women across the
coprimary endpoints, mortality, or the key safety
bleeding endpoint. This novel and unique observa-
tion that the benefits of radial access remain
consistent in both sexes irrespective of the choice of
parenteral anticoagulation during PCI has notable
implications for current practice. Against the wide-
spread belief that radial access and use of bivalir-
udin represent competing treatment strategies to
minimize bleeding risks, our findings support their
complementary role to mitigate both access site and
non–access site bleeding risks, both in male and fe-
male patients.
The SAFE-PCI for Women (Study of Access Site for
Enhancement of PCI for Women) trial was unique for
selecting exquisitely women to undergo radial or
femoral access (6). The trial was stopped prematurely
due to lower than expected event rate and no signif-
icant difference was found in the primary efficacy
endpoint (BARC 2, 3, or 5 bleeding or vascular com-
plications requiring intervention) between TRA and
TFA in patients undergoing PCI (n ¼ 691; primary
endpoint cohort). However, in a secondary analysis
also including female patients who underwent car-
diac catheterization (n ¼ 1,787), radial access signifi-
cantly reduced bleeding and vascular complications
(6). Hence, the apparent lack of benefit of radial
over femoral access in this study likely reflects
limited study power more than lack of treatment ef-
fect in women.
We observed that women randomized to TRA
more frequently needed crossovers to TFA compared
with men (7.6% vs. 5.2%). This likely reflects greater
challenges in women to obtain vascular access when
attempting TRA, likely because of smaller and more
prone to spasm radial arteries. Yet, the duration of
the procedure was overall shorter in women as
compared with men, and in the former group TRA
did not require longer procedural or fluoroscopic
time as compared with TFA. This observation sug-
gests that female patients who are intervened upon
via the radial access do not pose specific further
technical challenges once vascular access has been
established.
Overall, present findings contribute to support the
concept that radial access should be preferred over
the femoral access, adding to the current knowledge
firm evidence that this approach is applicable to both
male and female patients, and that probably it is even
more beneficial in women who are characterized by
increased risk of bleeding and access site related
complications. Therefore, efforts should be done to
increase the adoption of radial access, but at the same
time improving the operators’ training, which is
fundamental to reach the most appropriate skills,
particularly in women where radial access might be
more challenging due to anatomical reasons.
STUDY LIMITATIONS. Although a sex subgroup
analysis was pre-specified, the MATRIX-Access trial
was not powered to explore differences between
sexes, and randomization was not stratified by sex. As
such, the current analyses may be subject to type II
error. As expected in an exploratory analysis of effect
modification, an ad hoc power analysis indicates a
30% power for the analysis of our primary outcome.
Female study population was smaller compared with
the male group, as observed in most trials investi-
gating patients with CAD. Yet, the benefits of TRA
over TFA were consistent across sexes and if anything
seemed to be slightly more pronounced among
women. We did not adjust for multiple comparisons,
increasing the risk of type I error. Radial artery oc-
clusion was not systematically looked for in the
context of the MATRIX study. Results apply to the
context of this trial in which most centers partici-
pating were highly experienced in the radial
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technique; therefore, similar outcomes may not
apply in centers performing lower volumes of radial
access.
CONCLUSIONS
This sex-specific analysis of the largest trial comparing
radial versus femoral access in ACS patients invasively
managed suggests that women experienced a higher
risk of severe bleeding and access site complications,
and radial access was an effective method to reduce
these complications, as well as composite ischemic
and ischemic or bleeding endpoints.
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WHAT IS NEW? The MATRIX-Access trial results showing su-
periority of TRA versus TFA were consistent across sexes. Women
experienced a higher risk of severe bleeding and access site
complications, and radial access was an effective method to
reduce these complications, as well as composite ischemic and
ischemic or bleeding endpoints.
WHAT IS NEXT? Radial access should become the default ac-
cess for patients with ACS undergoing invasive management,
irrespective of sex.
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ABSTRACT
BACKGROUND It remains unclear whether radial access (RA), compared with femoral access (FA), mitigates the risk of
acute kidney injury (AKI).
OBJECTIVES The authors assessed the incidence of AKI in patients with acute coronary syndrome (ACS) enrolled in the
MATRIX-Access (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of
Angiox) trial.
METHODS Among 8,404 patients, 194 (2.3%) were excluded due to missing creatinine values, no or an incomplete
coronary angiogram, or previous dialysis. The primary AKI-MATRIX endpoint was AKI, defined as an absolute
(>0.5 mg/dl) or a relative (>25%) increase in serum creatinine (sCr).
RESULTS AKI occurred in 634 patients (15.4%) with RA and 712 patients (17.4%) with FA (odds ratio [OR]: 0.87; 95%
confidence interval [CI]: 0.77 to 0.98; p ¼ 0.0181). A >25% sCr increase was noted in 633 patients (15.4%) with RA and
710 patients (17.3%) with FA (OR: 0.87; 95% CI: 0.77 to 0.98; p ¼ 0.0195), whereas a >0.5 mg/dl absolute sCr increase
occurred in 175 patients (4.3%) with RA versus 223 patients (5.4%) with FA (OR: 0.77; 95% CI: 0.63 to 0.95; p ¼ 0.0131).
By implementing the Kidney Disease Improving Global Outcomes criteria, AKI was 3-fold less prevalent and trended
lower with RA (OR: 0.85; 95% CI: 0.70 to 1.03; p ¼ 0.090), with stage 3 AKI occurring in 28 patients (0.68%) with RA
versus 46 patients (1.12%) with FA (p ¼ 0.0367). Post-intervention dialysis was needed in 6 patients (0.15%) with RA
and 14 patients (0.34%) with FA (p ¼ 0.0814). Stratified analyses suggested greater benefit with RA than FA in patients
at greater risk for AKI.
CONCLUSIONS In ACS patients who underwent invasive management, RA was associated with a reduced risk of AKI
compared with FA. (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of
angioX [MATRIX]; NCT01433627) (J Am Coll Cardiol 2017;69:2592–603) © 2017 by the American College of Cardiology
Foundation.
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A cute kidney injury (AKI) occurs in 10% to27% of patients with acute coronary syn-drome (ACS) who undergo percutaneous
coronary intervention (PCI) and is associated with
greater morbidity and mortality (1,2). Pathophysi-
ology of AKI in these patients is multifactorial,
involving contrast volume, impaired systemic and
renal hemodynamic conditions, imbalance of endog-
enous vasodilating and vasoconstrictive factors, and
direct cholesterol embolization (1). Although the risk
of AKI can be predicted (3), and contrast media vol-
ume plays a central role in its pathogenesis (4), the
possibility of implementing prophylactic interven-
tions is limited (5). This is especially relevant for pa-
tients who require urgent PCI, such as those
undergoing intervention for ACS. Observational
data with propensity matching (6,7) and a meta-
analysis (8) have suggested an association between
the use of radial access (RA) and a lower incidence
of AKI. Putative explanations for this effect are a
reduction of bleeding events (7) and/or a lower risk
of cholesterol embolization in the renal circulation
(9,10) offered by RA (11). However, no prospective
assessment of the incidence of AKI has been carried
out in randomized studies of patients receiving RA
compared with femoral access (FA). In the largest
randomized comparison between RA and FA to
date, the MATRIX (Minimizing Adverse Haemor-
rhagic Events by Transradial Access Site and
Systemic Implementation of Angiox) trial,
RA was associated with a reduced incidence
of net adverse clinical events because of a
reduction of bleeding and fatalities
compared with FA (12).
We pre-specified (11) a prospective assess-
ment of whether RA compared with FA
reduced the incidence of AKI in patients with
ACS, including analysis of patients with ST-
segment elevation myocardial infarction
(STEMI) or non"ST-segment elevation
myocardial infarction (NSTEMI) who under-
went invasive management.
METHODS
MATRIX-Access was designed as a random-
ized, multicenter, superiority trial
comparing RA with FA in patients with
myocardial infarction with or without ST-
segment elevation who underwent coronary
angiography, and, if clinically indicated, PCI
(12,13). This was the first of 3 randomized
comparisons of the MATRIX program and
was performed in all consenting patients.
The trial was approved by the institutional review
board at each center, and all patients gave written
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TABLE 1 Baseline Clinical and Procedural Characteristics
Radial Access
(n ¼ 4,109)
Femoral Access
(n ¼ 4,101) p Value
Clinical characteristics
Age, yrs 65.5 # 11.8 65.9 # 11.8 0.17
$75 yrs 1,040 (25.3) 1,076 (26.2) 0.34
Male 3,063 (74.5) 2,977 (72.6) 0.045
Hypotension* 26 (0.6) 33 (0.8) 0.36
Anemia† 796 (19.4) 810 (19.8) 0.66
Diabetes 936 (22.8) 917 (22.4) 0.65
Creatinine >1.5 mg/dl 4,003 (97.4) 4,003 (97.6) 0.58
Killip class III or IV 129 (3.1) 101 (2.5) 0.063
STEMI 1,977 (48.1) 1,975 (48.2) 0.97
NSTEMI 2,132 (51.9) 2,126 (51.8) 0.97
Troponin negative 233 (5.7) 255 (6.2) 0.29
Troponin positive 1,899 (46.2) 1,871 (45.6) 0.59
With ST-segment deviation 983 (23.9) 956 (23.3) 0.51
With T-wave inversion 637 (15.5) 656 (16.0) 0.54
Ejection fraction #35% 339 (8.6) 362 (9.2) 0.33
Systolic arterial pressure, mm Hg 138.6 # 25.5 139.0 # 25.7 0.50
Hemoglobin at baseline, g/dl 13.9 # 1.9 13.9 # 1.9 0.26
Glucose at baseline, mg/dl 138.3 # 66.8 138.9 # 63.9 0.67
Medications administered before catheterization laboratory
Statins 1,766 (43.0) 1,815 (44.3) 0.24
ACE inhibitors 1,227 (29.9) 1,266 (30.9) 0.32
Angiotensin II receptor antagonist 441 (10.7) 456 (11.1) 0.57
Loop diuretics 463 (11.3) 471 (11.5) 0.76
Potassium-sparing diuretics 85 (2.1) 95 (2.3) 0.44
Other diuretics 114 (2.8) 94 (2.3) 0.16
Procedural characteristics
Any crossover during index hospitalization 329 (8.0) 231 (5.6) 0.00012
Total amount of contrast used during index hospitalization 183.3 # 104.5 183.9 # 110.1 0.83
No PCI attempted after coronary angiography during index hospitalization 742 (18.1) 747 (18.2) 0.85
CABG 144 (3.5) 146 (3.6) 0.89
Patients with significant lesion and medical treatment 472 (11.5) 474 (11.6) 0.92
Patients without significant lesion 129 (3.1) 128 (3.1) 0.96
$1 PCI attempted 3,367 (81.9) 3,354 (81.8) 0.85
Died during PCI 1 (0.0) 0 (0.0) 1.00
$1 PCI completed during index hospitalization 3,366 (81.9) 3,354 (81.8) 0.88
Medications administered in and after the catheterization laboratory
Aspirin 228 (5.5) 274 (6.7) 0.032
Clopidogrel 270 (6.6) 257 (6.3) 0.57
Prasugrel 331 (8.1) 291 (7.1) 0.10
Ticagrelor 376 (9.2) 391 (9.5) 0.55
GPIs 582 (14.2) 522 (12.7) 0.057
Planned GPI 420 (10.2) 369 (9.0) 0.060
Bailout GPI 165 (4.0) 154 (3.8) 0.54
Unfractionated heparin 2,071 (50.4) 1,908 (46.5) 0.00044
Total unfractionated heparin, U/kg 41.0 # 51.3 37.9 # 48.8 0.0066
At least 1 subtherapeutic regimen, <50 U/kg 465 (11.3) 337 (8.2) <0.0001
At least 1 therapeutic regimen, $50 U/kg 1,643 (40.0) 1,597 (38.9) 0.33
Bivalirudin 1,697 (41.3) 1,719 (41.9) 0.57
Prolonged infusion post-PCI 863 (21.0) 868 (21.2) 0.86
Average of total duration of post-PCI bivalirudin infusion, min 82.2 # 201.8 87.5 # 223.8 0.26
Patients receiving full bivalirudin regimen post-PCI 320 (7.8) 301 (7.3) 0.44
Average of total duration of full bivalirudin regimen, min 21.7 # 86.9 21.1 # 104.6 0.78
Patients receiving low bivalirudin regimen post-PCI 552 (13.4) 580 (14.1) 0.35
Average of total duration of low bivalirudin regimen, min 60.4 # 187.8 66.4 # 203.8 0.17
$1 intra-aortic balloon pump 80 (1.9) 96 (2.3) 0.22
Continued on the next page
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informed consent. Patients were eligible if they had
ACS and planned coronary angiography, and the
interventional cardiologist was willing to proceed
with either RA or FA. That meant cardiologists were
required to have expertise in both, including at least
75 coronary interventions performed and at least
50% of interventions in ACS via the radial route
during the previous year. The main inclusion and
exclusion criteria of the MATRIX-Access trial were
previously reported (Online Appendix) (12,14). All
patients enrolled in MATRIX-Access were eligible for
the AKI-MATRIX substudy, except those with
incomplete creatinine data who did not receive a
complete angiogram or those who had end-stage
renal disease that required dialysis.
STUDY PROTOCOL AND RANDOMIZATION. Before
angiography, patients were centrally allocated 1:1 to
TABLE 1 Continued
Radial Access
(n ¼ 4,109)
Femoral Access
(n ¼ 4,101) p Value
$1 PCI completed 3,366 3,354
TIMI flow grade 3 in all treated lesions during whole index hospitalization 3,193 (94.9) 3,189 (95.1) 0.68
Coronary stenosis <30% in all treated lesions 3,206 (95.2) 3,185 (95.0) 0.59
Procedural success in all treated lesions 3,109 (92.4) 3,098 (92.4) 1.00
Duration of procedure 61.2 # 36.6 60.1 # 37.4 0.22
Amount of contrast used 202.8 # 103.1 204.2 # 109.6 0.61
Treated vessel(s) per patient
Left main coronary artery 175 (5.2) 156 (4.7) 0.30
Left anterior descending artery 1,846 (54.9) 1,813 (54.1) 0.51
Left circumflex artery 1,055 (31.4) 1,044 (31.1) 0.84
Right coronary artery 1,241 (36.9) 1,232 (36.7) 0.90
Bypass graft 21 (0.6) 37 (1.1) 0.034
At least 2 vessels treated 806 (24.0) 793 (23.7) 0.77
Lesions treated per patient, n 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.74
1 2,314 (68.8) 2,313 (69.0)
2 738 (21.9) 754 (22.5)
$3 312 (9.3) 286 (8.5)
$1 complex lesion 1,856 (55.2) 1,789 (53.4) 0.13
Stents per patient, n 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.26
Overall stent length per patient, mm 58.1 # 54.6 57.3 # 55.0 0.50
Lesions
Number of lesions with PCI 4,843 4,768
Lesions stented 4,437 (91.6) 4,324 (90.7) 0.13
$1 drug-eluting stent 3,281 (67.7) 3,240 (68.0) 0.79
$1 bare-metal stent 1,156 (23.9) 1,084 (22.7) 0.26
Lesions not stented 406 (8.4) 444 (9.3) 0.13
TIMI flow grade pre-procedure 0.88
0 or 1 1,657 (34.2) 1,645 (34.5) 0.87
2 565 (11.7) 562 (11.8) 0.87
3 2,619 (54.1) 2,559 (53.7) 0.99
TIMI flow grade post-procedure 0.76
0 or 1 79 (1.6) 73 (1.5) 0.73
2 106 (2.2) 103 (2.2) 0.98
3 4,656 (96.2) 4,590 (96.3) 0.78
Coronary stenosis <30% 4,661 (96.3) 4,582 (96.1) 0.67
Procedural success 4,554 (94.0) 4,489 (94.1) 0.82
Number of lesions stented 4,437 4,324
Total stent length per lesion, mm 26.2 # 14.7 26.5 # 14.9 0.61
Average stent diameter per lesion, mm 3.0 # 0.5 3.0 # 0.5 0.25
$1 direct stenting 978 (22.0) 922 (21.3) 0.77
Post-dilation 2,034 (45.8) 2,016 (46.6) 0.48
Values are mean # SD, n (%), n, or median (interquartile range). *Systolic blood pressure <80 mm Hg. †<12 g/dl for women, <13 g/dl for men.
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypass graft surgery; GPI ¼ glycoprotein IIb/IIIa inhibitor; NSTEMI ¼ non"ST-segment elevation myocardial
infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; TIMI ¼ Thrombolysis In Myocardial Infarction.
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RA or FA for diagnostic angiography and PCI, if indi-
cated, using a web-based system to ensure adequate
concealment of allocation. The randomization
sequence was computer-generated, blocked, and
stratified by site, intended new or ongoing use of
ticagrelor or prasugrel, type of ACS (STEMI or
NSTEMI, and in the latter case, whether troponin-
positive or not), and anticipated use of immediate
PCI. Patients proceeding to PCI were further ran-
domized to bivalirudin, administered according to
product labeling, or to unfractionated heparin, dosed
at 70 to 100 U/kg in patients who did not receive
glycoprotein IIb/IIIa inhibitors or at 50 to 70 U/kg in
patients who received planned glycoprotein IIb/IIIa
inhibitors. Use of other anticoagulants was not
allowed, whereas other antithrombotic medications,
including oral antiplatelet agents and non-
antithrombotic medications, were allowed as per
guidelines (15).
STUDY OUTCOMES. The endpoints of the MATRIX-
Access study have been previously reported (12,13).
The primary endpoint of the AKI-MATRIX substudy
was the incidence of AKI, defined as either an abso-
lute (>0.5 mg/dl) or a relative (>25%) increase from
baseline in serum creatinine (sCr) levels during hos-
pitalization in the intention-to-treat population (16).
The incidence of AKI was also assessed using either
defining criterion, as well as the Kidney Disease
Improving Global Outcomes (KDIGO) criteria and
staged for severity (17). Sensitivity analyses were also
performed in patients who had the randomly allo-
cated access site (i.e., excluding patients with access
site crossover) or in those proceeding to PCI after
diagnostic coronary angiography (i.e., excluding pa-
tients who received only an angiogram and no further
PCI). Bleeding complications were defined per the
Bleeding Academic Research Consortium (BARC)
scale (Online Appendix).
STATISTICAL ANALYSIS. Details related to the sam-
ple size calculation and the statistical analyses have
been described previously (12). No a priori sample
size considerations were performed to assess AKI-
MATRIX study power (11). However, for explorative
purposes, power analyses were previously computed
assuming a 5% absolute increase in sCr of >0.5 mg/dl
in the FA group and 50%, 35%, and 25% relative risk
reductions (RRRs) in the RA group. We conserva-
tively assumed a 5% incidence of AKI in the FA
group, although the incidence of AKI in contempo-
rary studies of PCI in ACS could be 3-fold higher.
Available data suggested a possible 25% RRR in AKI
incidence with the RA approach across unselected
populations who underwent PCI. Hypothesizing a
33% RRR of AKI with RA in the MATRIX study, with
3,400 patients per group who underwent PCI, we
would have >93% power of detecting a reduction in
the incidence of AKI to 3.3% in the RA group at the
5% alpha level.
All analyses were performed according to the
intention-to-treat principle. Differences across
groups were assessed using the Student t test in case
of continuous variables and the chi-square or Fisher
exact test in case of categorical data. The differences
at lesion level considered the nested structure of le-
sions within individuals, and then were analyzed
using multilevel general or generalized mixed
models, as appropriate. We applied both univariate
and multivariable logistic regression models to eval-
uate the association of AKI during index hospitaliza-
tion with Mehran’s score, bleeding, and measures of
bleeding severity. Furthermore, we performed strat-
ified logistic regressions by subgroups, including the
center’s proportion of radial PCI, diabetes at baseline,
estimated glomerular filtration rate (eGFR), age,
clinical presentation, Killip class, left ventricular
ejection fraction, and Mehran’s score. The analyses
were done using Stata release 14.1 (StataCorp LLC,
College Station, Texas) and R 3.3.0 (R Foundation,
Vienna, Austria).
RESULTS
Among 8,404 patients enrolled in the MATRIX-Access
trial from 78 centers in Italy, the Netherlands, Spain,
and Sweden between October 2011 and July 2014, 194
patients (2.3%) were excluded due to an incomplete
sCr dataset (96 FA and 82 RA patients), no or
an incomplete coronary angiogram (6 FA and 2
RA patients), or previous dialysis at randomization
(4 patients in each group) (Online Figure 1). Among
the 8,210 patients included in the analysis, one-half
(n ¼ 4,109) were allocated to RA and the other 4,101
participating patients were allocated to FA. Baseline
demographics and procedural characteristics were
similar for the 2 groups (Table 1).
AKI occurred in 1,345 patients (16.4%), per the
primary endpoint as defined by a relative (>25%) in-
crease in sCr and in 387 patients (4.7%) according to
an absolute increase in sCr of >0.5 mg/dl. Patients
with AKI were older and more frequently women, and
had a higher prevalence of diabetes and anemia
(Online Table 1). Study participants who developed
AKI were more likely to have presented with STEMI
and advanced Killip class; plus, their access site
crossover rate was twice as frequent. Patients with
AKI more commonly underwent PCI or received
treatment for complex or multiple lesions, including
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left main or left anterior coronary arteries (Online
Table 1). Patients who had AKI had lower rates of
statin therapy but higher rates of angiotensin II re-
ceptor blocker and diuretic use before presentation to
the catheterization laboratory. The amount of
contrast used and procedural failure rate were higher
in patients with AKI compared with those without
AKI (Online Table 1).
ENDPOINTS ACCORDING TO ACCESS SITE. Before
randomization, sCr and eGFR were similar between
the RA and FA groups (Table 2). Peak sCr after inter-
vention or at discharge did not differ in the RA group
versus the FA group, whereas nadir eGFR was
lower in the FA group during hospitalization (79.6 #
25.9 ml/min/1.73 m2 vs. 78.2 # 25.7 ml/min/1.73 m2;
p ¼ 0.0099) and at discharge (84.6 # 26.5 ml/min/
1.73 m2 vs. 83.4 # 26.1 ml/min/1.73 m2; p ¼ 0.030)
(Table 2).
The primary outcome of AKI occurred in signifi-
cantly fewer patients with RA than in those
with FA (15.4% vs. 17.4%; p ¼ 0.0181) (Central
Illustration, Table 3). Both components of the AKI
primary endpoint definition were significantly lower
in patients with RA. Specifically, a >25% increase in
sCr was observed in 633 patients (15.4%) with RA
and 710 patients (17.3%) with FA (odds ratio [OR]:
0.87; 95% confidence interval [CI]: 0.77 to 0.98;
p ¼ 0.0195), and a >0.5 mg/dl absolute increase in sCr
occurred in 175 patients (4.3%) with RA and 223
patients (5.4%) with FA (relative risk: 0.77; 95% CI:
0.63 to 0.95; p ¼ 0.0131). Post-intervention dialysis
occurred in fewer patients with RA than in those with
FA (0.15% vs. 0.34%; p ¼ 0.0814) (Table 3).
After excluding patients who did not receive the
randomly allocated access site (n ¼ 605), either
because it failed or it was not attempted, AKI
occurred in significantly fewer patients with RA
compared with FA (14.3% vs. 16.7%; p ¼ 0.0038)
because of significant reductions of both components
of the primary endpoint. The need for dialysis was
also lower with RA access compared with FA (OR:
0.16; 95% CI: 0.04 to 0.69; p ¼ 0.0146) (Table 3).
Among patients who received PCI after coronary
angiography during the index hospitalization (n ¼
6,616; 80.5% of the AKI-MATRIX population), RA was
associated with a 14% risk reduction of AKI compared
with FA (OR: 0.86; 95% CI: 0.76 to 0.98; p ¼ 0.0202).
Three (0.09%) patients in the RA group and 10 (0.3%)
patients in the FA group underwent dialysis therapy
(p ¼ 0.0659) (Table 3).
By implementing the KDIGO criteria, AKI occurred
in 213 patients (5.2%) with RA and 248 patients (6.1%)
with FA (p ¼ 0.090). Stage 1 or 2 AKI were not reduced
in the RA group (Table 2), but stage 3 was lower with
RA (0.7% vs. 1.1%; p ¼ 0.037) (Central Illustration,
Table 3).
SUBGROUP ANALYSIS AND MULTIVARIATE
MODELING. The effects of RA versus the effects of FA
in reducing the incidence of AKI was largely consis-
tent across subgroups, including the participating
center’s proportion of radial PCI, diabetes, age, and
clinical presentation (Figure 1). Positive quantitative
interaction testing was noted between the random-
ized access site and the pre-procedural renal function,
Killip class, and Mehran score, which suggested rela-
tively greater benefit with RA compared with FA in
patients at higher baseline risk for AKI. There was
significant interaction also between the access site
and antithrombotic therapy, with RA showing benefit
in patients who received unfractionated heparin, but
apparently no benefit was seen in those allocated to
bivalirudin. Online Figure 2 shows subgroup analysis
according to the components of the Mehran risk score.
At multivariable modeling, random allocation to
RA remained associated with a significantly lower risk
of AKI (OR: 0.87; 95% CI: 0.77 to 0.98; p ¼ 0.0217)
when the covariates included in the Mehran score
were entered (Table 4). When access site bleeding was
entered into the logistic model (model 2), random
allocation to RA was associated with a nonsignificant
11% RRR (p ¼ 0.0647), whereas an access-related
BARC score of $2 complications showed a 2-fold
significantly increased risk (OR: 2.19; 95% CI: 1.66 to
2.89; p < 0.0001) (Table 4). Hemoglobin drop after
randomization (model 3) and blood red transfusion
(model 4) were also associated with AKI (Table 4).
DISCUSSION
Among patients with ACS (with or without ST-
segment elevation) who were managed invasively,
TABLE 2 Renal Function
Randomized to
Radial Access
(n ¼ 4,109)
Randomized to
Femoral Access
(n ¼ 4,101) p Value
Creatinine, mg/dl
Pre-PCI 0.97 # 0.36 0.98 # 0.32 0.7434
Post-PCI 1.06 # 0.55 1.08 # 0.54 0.1271
At hospital discharge 0.99 # 0.44 1.00 # 0.43 0.2361
eGFR, ml/min/1.73 m2 (MDRD formula)
Pre-PCI 84.22 # 25.36 83.46 # 25.51 0.1786
Post-PCI 79.63 # 25.87 78.16 # 25.65 0.0099
At hospital discharge 84.62 # 26.50 83.35 # 26.10 0.0300
Values are mean # SD.
eGFR ¼ estimated glomerular filtration rate; MDRD ¼ Modification of Diet in Renal Disease;
PCI ¼ percutaneous coronary intervention.
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the use of RA was significantly associated with a
reduced occurrence of AKI compared with FA.
Both components of the primary endpoint (i.e., an
absolute >0.5 mg/dl or a relative >25% increase in
sCR) were reduced with RA, and fewer patients in the
RA group underwent dialysis, even if this difference
did not reach statistical significance. These findings
were consistent across pre-defined patient sub-
groups. However, there was quantitative positive
interaction testing in patients at the highest risk for
AKI, such as those with reduced eGFR, advanced
Killip class, or high Mehran score, in whom a greater
benefit of RA versus FA was observed. In the sub-
population of patients who entered the antithrombin
portion of the study, we also noted a significant
interaction with the type of allocated anticoagulant at
the time of PCI. A greater than average treatment
effect was observed in patients who received
unfractionated heparin, but no apparent effect was
seen in those allocated to bivalirudin.
Sensitivity analyses showed consistent results
among patients in whom access was made as
randomly allocated and in patients who underwent
PCI during their index hospitalization. The
CENTRAL ILLUSTRATION Radial Versus Femoral Approach in AKI Patients Undergoing
Invasive Management
16
18
20
14
12
10
8
Primary
Endpoint
17.36
6.05
3.73
1.10 1.19
0.68
1.12
3.41
5.18
15.43
KDIGO
classification
KDIGO stage 1 KDIGO stage 2 KDIGO stage 3
6
4
2
0
AK
I I
nc
id
en
ce
, %
OR: 0.87
(0.77-0.98)
P=0.018
OR: 0.85
(0.70-1.03)
P=0.090
OR: 0.91
(0.72-1.15)
P=0.430
OR: 0.92
(0.61-1.38)
P=0.671
OR: 0.60
(0.38-0.97)
P=0.037
Radial Femoral
Andò, G. et al. J Am Coll Cardiol. 2017;69(21):2592–603.
We assessed whether use of radial versus femoral access mitigated incidence of acute kidney injury (AKI) in patients with acute coronary syndrome who
underwent invasive management. Radial access significantly reduced AKI incidence in terms of the primary endpoint (defined as either a 25% relative
increase or a 0.5 mg/dl absolute increase of serum creatinine). Reductions also were seen by Kidney Disease Improving Global Outcomes (KDIGO)
classification, but only significantly so in stage 3. OR ¼ odds ratio.
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occurrence of AKI was further assessed according to
KDIGO criteria (17), which revealed a much lower
prevalence of AKI and a consistent 15% risk reduction
in favor of RA, even if the treatment effect did not
reach statistical significance. Notably, when analyzed
by AKI severity, rates of stage 1 or 2 AKI were similar
regardless of access site, but stage 3 AKI was reduced
by 40% with RA compared with FA.
No randomized controlled trial of RA versus FA has
assessed whether the access site might affect the risk
of AKI. Therefore, AKI-MATRIX was the first pre-
specified analysis of a large randomized controlled
trial that prospectively analyzed the occurrence of
AKI in relation to RA or FA.
The British Columbia Cardiac and Renal Registries
reported a reduced risk for chronic kidney disease
within 6 months after catheterization among patients
who underwent RA (18). However, the occurrence of
AKI during hospitalization was not collected. A
propensity-matched analysis of 17,714 patients who
received urgent or elective PCI from the Blue Cross
Blue Shield of Michigan Cardiovascular Consortium
database showed a 24% reduction in the risk of AKI,
defined as an absolute increase in sCr of >0.5 mg/dl in
patients who underwent RA (7). A single-center reg-
istry also showed a reduced risk of AKI (defined as sCr
>0.5 mg/dl or a 50% increase of sCr) with RA
compared with FA, but the access site was no longer
associated with increased risk of AKI after propensity
matching (OR: 1.48; 95% CI: 0.72 to 3.04; p ¼ 0.286)
(19). Finally, in a STEMI population that underwent
primary PCI at high-volume urban centers, FA
compared with RA was associated with a 56% greater
adjusted risk of AKI, which occurred in 12.7% of the
patients based on an increase in sCr >0.5 mg/dl or
>25% (6).
The prevalence of AKI varies largely across studies
based on the definition and the population investi-
gated (1,2). However, there is accumulating evidence
indicating that small increments in sCR are associ-
ated, in a variety of settings, with adverse outcomes
that manifest in short-term morbidity and mortality
as well as in longer term outcomes, including 1-year
mortality (1,2,20). Because no effective therapeutic
TABLE 3 Acute Kidney Injury
Randomized to
Radial Access
Randomized to
Femoral Access
Odds Ratio
(95% CI) p Value
All patients receiving an angiography and/or PCI 4,109 4,101
AKI according to primary endpoint definition 634 (15.43) 712 (17.36) 0.87 (0.77–0.98) 0.0181
AKI 25% relative increase 633 (15.41) 710 (17.31) 0.87 (0.77–0.98) 0.0195
AKI 0.5 absolute increase 175 (4.26) 223 (5.44) 0.77 (0.63–0.95) 0.0131
After index procedure only 605 (14.72) 670 (16.34) 0.88 (0.78–1.00) 0.0436
AKI 25% relative increase 603 (14.68) 668 (16.29) 0.88 (0.78–1.00) 0.0434
AKI 0.5 absolute increase 170 (4.14) 217 (5.29) 0.77 (0.63–0.95) 0.0138
After staged procedure only 75 (1.83) 95 (2.32) 0.78 (0.58–1.06) 0.1189
AKI 25% relative increase 72 (1.75) 95 (2.32) 0.75 (0.55–1.02) 0.0711
AKI 0.5 absolute increase 19 (0.46) 25 (0.61) 0.76 (0.42–1.38) 0.3625
AKI according to the KDIGO classification 213 (5.18) 248 (6.05) 0.85 (0.70–1.03) 0.0900
Stage 1 140 (3.41) 153 (3.73) 0.91 (0.72–1.15) 0.4295
Stage 2 45 (1.10) 49 (1.19) 0.92 (0.61–1.38) 0.6713
Stage 3 28 (0.68) 46 (1.12) 0.60 (0.38–0.97) 0.0367
Dialysis during hospitalization 6 (0.15) 14 (0.34) 0.43 (0.16–1.11) 0.0814
Patients without crossover during PCI 3,765 3,840
AKI according to primary endpoint definition 538 (14.29) 641 (16.69) 0.83 (0.73–0.94) 0.0038
AKI 25% relative increase 538 (14.29) 639 (16.64) 0.84 (0.74–0.95) 0.0046
AKI 0.5 absolute increase 140 (3.72) 198 (5.16) 0.71 (0.57–0.89) 0.0025
Dialysis during hospitalization 2 (0.05) 13 (0.34) 0.16 (0.04–0.69) 0.0146
Only patients who underwent index PCI* 3,317 3,299
AKI according to primary endpoint definition 530 (15.98) 598 (18.13) 0.86 (0.76–0.98) 0.0202
AKI 25% relative increase 529 (15.95) 596 (18.07) 0.86 (0.76–0.98) 0.0219
AKI 0.5 absolute increase 145 (4.37) 184 (5.58) 0.77 (0.62–0.97) 0.0244
Dialysis during hospitalization 3 (0.09) 10 (0.30) 0.30 (0.08–1.08) 0.0659
Values are n or n (%) unless otherwise indicated. *Excluding patients who underwent angiography only.
AKI ¼ acute kidney injury; CI ¼ confidence interval; KDIGO ¼ Kidney Disease Improving Global Outcomes; PCI ¼ percutaneous coronary intervention.
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measure, apart from renal replacement therapy, ex-
ists in patients with AKI, there is a growing awareness
in the medical community of the need to implement
preventive measures in patients at greater risk.
Hydration with isotonic saline remains the only
Class I recommended intervention in patients at
medium to high risk who are undergoing invasive
management (15). Yet, many patients with ACS,
especially those with ongoing myocardial ischemia,
are not eligible for this preventive treatment due
to the need to expedite catheterization. Therefore,
contrast minimization during intervention remains
the most important preventive intervention in
these patients. Importantly, we also confirmed
that some drug categories might help prevent
(statins) or increase the risk of AKI (renin-angio-
tensin inhibitors and diuretics) (Online Table 1), as
previously shown (21,22).
In a seminal paper, Nikolsky et al. (23) were the
first to investigate the association between baseline
hematocrit and AKI, which occurred in 13.9% of 6,773
consecutive patients treated with PCI, based on an
increase of $25% or $0.5 mg/dl in pre-procedure sCr.
By multivariate analysis, lower baseline hematocrit
was associated with contrast-induced nephropathy
(CIN); each 3% decrease in baseline hematocrit
resulted in a significant increase in the odds of CIN in
patients with and without chronic kidney disease
(11% and 23%, respectively) (23). When introduced
into the multivariate model, change in hematocrit
also showed a significant association with CIN
after coronary intervention. Interestingly, a
procedure-related drop in hematocrit was an inde-
pendent prognostic determinant of CIN, regardless
of baseline hematocrit (23). More recently, Ohno et al.
(24) confirmed that patients who experienced
FIGURE 1 Primary Endpoint: Subgroup Analysis
Center's proportion of radial PCI
AKI during index hospitalization Odds Ratio (95% CI) p Value p Value forinteraction
Numbers
needed to treat
to prevent 1
AKI
Randomized to
Radial Access
Randomized to
Femoral Access
Low (14.9-64.4%)
Intermediate (65.4-79.0%)
High (80.0-98.0%)
181/1391
230/1433
223/1285
225/1473
251/1400
236/1228
0.83 (0.67-1.02)
0.88 (0.72-1.07)
0.88 (0.72-1.08)
0.083
0.18
0.23
0.70*
0.68
0.027
0.31
0.98
0.65
0.026
0.013
0.018
45 (21 to ∞)
54 (22 to ∞)
54 (21 to ∞)
58 (19 to ∞)
50 (27 to 369)
15 (10 to 42)
108 (38 to ∞)
25 (13 to 265)
96 (37 to ∞)
46 (22 to ∞)
60 (27 to ∞)
85 (14 to ∞)
61 (31 to ∞)
9 (5 to 23)
111 (40 to ∞)
-2561 (42 to ∞)
24 (15 to 57)
6 (4 to 21)
62 (31 to 4767)
Yes
No
191/936
443/3173
203/917
509/3184
0.90 (0.72-1.13)
0.85 (0.74-0.98)
0.36
0.024
<60 ml/min/1.73 m2
≥60 ml/min/1.73 m2
126/688
508/3406
174/695
538/3396
0.67 (0.52-0.87)
0.93 (0.82-1.06)
0.0025
0.29
≥75 years
<75 years
239/1040
395/3069
291/1076
421/3025
0.80 (0.66-0.98)
0.91 (0.79-1.06)
0.031
0.23
<40%
≥40%
122/397
500/3566
135/423
552/3522
0.95 (0.70-1.27)
0.88 (0.77-1.00)
0.71
0.051
>10 points
≤10 points
79/274
550/3754
111/269
587/3774
0.58 (0.40-0.82)
0.93 (0.82-1.06)
0.0025
0.27
Bivalirudin
UFH
300/1770
271/1771
301/1780
345/1764
1.00 (0.84-1.20)
0.74 (0.62-0.89)
0.98
0.00087
Odds Ratio (95% CI)
0.5 1 2
Killip class III or IV
Killip class I or II
34/129
600/3980
44/101
668/4000
0.46 (0.27-0.81)
0.89 (0.79-1.00)
0.0066
0.047
STEMI
NSTEACS
354/1977
280/2132
397/1975
315/2126
0.87 (0.74-1.02)
0.87 (0.73-1.03)
0.079
0.11
Diabetes
Estimated glomerular filtration rate (eGFR)
Age
Clinical presentation
LVEF under 40%
Killip class
Mehran score
Randomization to bivalirudin
*P value for trend across ordered groups
Radial access reduced incidence of acute kidney injury (AKI) across analyzed subgroups. CI ¼ confidence interval; LVEF ¼ left ventricular ejection fraction; NSTEACS ¼
non"ST-segment elevation acute coronary syndrome; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; UFH ¼
unfractionated heparin.
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peri-procedural bleeding had a higher incidence of
AKI, the severity of which, in turn, correlated closely
with the severity of bleeding. The mechanism by
which the drop in hemoglobin causes AKI is likely the
impairment in renal perfusion due to significant
blood loss, regardless of changes in systemic blood
pressure (23,24). Blood transfusion was also identi-
fied as a risk factor for AKI in cardiac surgery (25) and
in transcatheter aortic valve replacement. Moreover,
in patients with ACS who underwent PCI within the
CathPCI Registry (n ¼ 1,756,864), blood transfusion
was strongly associated with AKI, which was
defined as an increase in sCr post-PCI of $0.5 mg/dl
or $25% during hospitalization compared with
baseline values (26).
Our present findings expanded on previous ob-
servations by showing that a bleeding minimization
strategy, such as RA as opposed to FA, reduced the
risk of AKI, with a greater effect observed in patients
at higher risk for AKI. The mechanisms by which RA
reduced the incidence of AKI might be due to a
reduction of bleeding events (7), by a reduction in
embolization in the renal circulation (9,10), or by a
combination of both (11). When access site bleeding,
hemoglobin drop, need for transfusion, and/or
randomly allocated access site were simultaneously
entered into the model, bleeding complications per
se and their possible consequences (i.e., hemoglobin
drop and blood transfusion) remained strongly
associated with AKI. However, only a trend
remained for the association between RA and AKI.
Hence, our results confirmed previous observations
that access site bleeding is associated with AKI, and
suggested that RA, by minimizing those, mitigated
the risk of AKI.
Unlike in the parent trial (12), the proportion of PCI
undertaken with RA among participating centers did
not emerge as an effect modifier for the study
endpoint. This finding suggested that kidney pro-
tection was conferred by RA at any stage of the
learning curve for transradial procedures. This
observation indirectly confirmed the importance of
bleeding prevention as a possible mechanism
through which RA reduces the risk of AKI; operator
proficiency significantly affected the occurrence of
major adverse cardiovascular events, but failed to
affect bleeding endpoints in our study (12).
Conversely, RA provided greater benefits for AKI
prevention in patients at higher risk of AKI and in
those randomly assigned to unfractionated heparin
compared with bivalirudin. This latter finding should
be interpreted with caution because it was based on
the subpopulation randomized to receive the 2 tested
parenteral anticoagulants, and no interaction was
observed between access site and type of anti-
thrombin in the MATRIX-Access or antithrombin type
programs with respect to both co-primary endpoints
or bleeding events.
It remains unclear as to whether RA, by avoiding
direct passage of catheters in proximity to renal ar-
teries, might also contribute to lower risk of AKI
through a reduction and/or avoidance of direct
embolization into the renal circulation. Coronary
angiography is the most common procedure to cause
embolisms (27). Estimates of the incidence of
cholesterol embolization syndrome (CES) after
vascular procedures ranged from 0.15% in clinical
studies to 25% to 30% in pathological series (27).
Clinical studies probably underestimated the inci-
dence because only a minority of patients could be
clinically recognized. Therefore, despite the impor-
tance of CES as a complication of percutaneous
diagnostic and interventional procedures, its relative
contribution remains uncertain to the overall occur-
rence of AKI in patients who have undergone vascular
cardiac catheterization and who received contrast
media.
In light of our findings, future studies should
evaluate whether the use of RA in patients with
TABLE 4 Associations of AKI During Index Hospitalization*
Odds Ratio (95% CI) p Value
Model 1
Randomized to radial access 0.87 (0.77–0.98) 0.0217
Components of the Mehran score†
Hypotension‡ 0.87 (0.44–1.72) 0.6957
Use of intra-aortic balloon pump 2.96 (2.13–4.11) <0.0001
Killip class III or IV 1.83 (1.35–2.50) 0.0001
Age >75 yrs 1.99 (1.75–2.27) <0.0001
Anemia§ 1.20 (1.04–1.39) 0.0135
Diabetes 1.33 (1.16–1.52) <0.0001
Contrast media volume, per 100 ml 1.34 (1.26–1.43) <0.0001
Creatinine >1.5 mg/dl 1.15 (0.76–1.72) 0.5108
Model 2
Randomized to radial access 0.89 (0.80–1.01) 0.0647
Bleeding BARC 2, 3, or 5 related to access site 2.19 (1.66–2.89) <0.0001
Model 3
Randomized to radial access 0.90 (0.80–1.01) 0.0758
Bleeding BARC 2, 3, or 5 related to access site 1.81 (1.36–2.40) <0.0001
Hemoglobin nadir <9 g/dl 3.35 (2.71–4.13) <0.0001
Model 4
Randomized to radial access 0.90 (0.80–1.02) 0.0868
Bleeding BARC 2, 3, or 5 related to access site 1.68 (1.25–2.25) 0.0005
Hemoglobin nadir <9 g/dl 2.81 (2.23–3.53) <0.0001
Blood transfusion 2.57 (1.63–4.03) <0.0001
Number of included patients ¼ 8,210. *With Mehran score, bleeding, and measures of bleeding severity. †Range
0 to 30. ‡Systolic blood pressure <80 mm Hg. §<12 g/dl for women and <13 g/dl for men.
BARC ¼ Bleeding Academic Research Consortium; CI ¼ confidence interval.
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advanced chronic kidney disease affects or prevents a
conduit for fistula for dialysis.
STUDY LIMITATIONS. Most centers participating in
the MATRIX program were highly experienced in RA;
similar outcomes might not be applicable in centers
that perform lower volumes of RA. Although reported
subgroups were pre-specified in the statistical anal-
ysis plan, we did not adjust for multiple comparisons,
increasing the risk of a type I error. We were not able
to adjust the results for the intensity of either peri-
procedural hydration or type of contrast media
used, because these 2 variables were not collected in
the data set. However, the unrestricted use of hy-
dration to expand intravascular fluid in clinical
practice is the simplest and cheapest intervention
aimed at preventing AKI and is unlikely to have
influenced the effect of RA (28). Patients with STEMI,
who are routinely referred to emergent intervention
without hydration, derived consistent benefit in
terms of lower AKI from RA. Time and date of sCr
peak during hospitalization and sCr values after
discharge were not collected. Although blood loss
minimization, also based on our multivariable model,
appeared to be the most likely explanation for our
findings, it remains possible that use of RA as
opposed to FA decreased the occurrence of CES.
Although with low sensitivity, presence of eosino-
philia could raise the level of suspicion for CES or
occurrence of extrarenal emboli, this was not sys-
tematically collected in the study case report form.
Hence, the mechanisms through which RA mitigated
the risk of AKI remain unclear.
CONCLUSIONS
Our results showed that in a broad population of pa-
tients with ACS who underwent invasive manage-
ment, the use of RA versus FA was associated with a
reduced incidence of post-procedural AKI. This
analysis lent further support to the concept that RA
should be prioritized over FA in ACS patients under-
going invasive management.
ADDRESS FOR CORRESPONDENCE: Prof. Marco
Valgimigli, Swiss Cardiovascular Center Bern, Bern
University Hospital, Freiburgstrasse 4, CH- 3010 Bern,
Switzerland. E-mail: marco.valgimigli@insel.ch.
RE F E RENCE S
1. Marenzi G, Cosentino N, Bartorelli AL. Acute
kidney injury in patients with acute coronary syn-
dromes. Heart 2015;101:1778–85.
2. McCullough PA, Choi JP, Feghali GA, et al.
Contrast-induced acute kidney injury. J Am Coll
Cardiol 2016;68:1465–73.
3. Mehran R, Aymong ED, Nikolsky E, et al.
A simple risk score for prediction of contrast-
induced nephropathy after percutaneous coro-
nary intervention: development and initial valida-
tion. J Am Coll Cardiol 2004;44:1393–9.
4. Gurm HS, Dixon SR, Smith DE, et al. Renal
function-based contrast dosing to define safe
limits of radiographic contrast media in patients
undergoing percutaneous coronary interventions.
J Am Coll Cardiol 2011;58:907–14.
5. Marenzi G, Ferrari C, Marana I, et al. Preven-
tion of contrast nephropathy by furosemide with
matched hydration: the MYTHOS (Induced
Diuresis With Matched Hydration Compared to
Standard Hydration for Contrast Induced Ne-
phropathy Prevention) trial. J Am Coll Cardiol
Intv 2012;5:90–7.
6. Cortese B, Sciahbasi A, Sebik R, et al. Compar-
ison of risk of acute kidney injury after primary
percutaneous coronary interventions with the
transradial approach versus the transfemoral
approach (from the PRIPITENA urban registry). Am
J Cardiol 2014;114:820–5.
7. Kooiman J, Seth M, Dixon S, et al. Risk
of acute kidney injury after percutaneous
coronary interventions using radial versus
femoral vascular access: insights from the
Blue Cross Blue Shield of Michigan Cardio-
vascular Consortium. Circ Cardiovasc Interv
2014;7:190–8.
8. Ando G, Costa F, Trio O, Oreto G, Valgimigli M.
Impact of vascular access on acute kidney injury
after percutaneous coronary intervention. Car-
diovasc Revasc Med 2016;17:333–8.
9. Fukumoto Y, Tsutsui H, Tsuchihashi M,
Masumoto A, Takeshita A. Cholesterol Embolism
Study I. The incidence and risk factors of choles-
terol embolization syndrome, a complication of
cardiac catheterization: a prospective study. J Am
Coll Cardiol 2003;42:211–6.
10. Scolari F, Ravani P, Gaggi R, et al. The chal-
lenge of diagnosing atheroembolic renal disease:
clinical features and prognostic factors. Circulation
2007;116:298–304.
11. Ando G, Cortese B, Frigoli E, et al. Acute kidney
injury after percutaneous coronary intervention:
rationale of the AKI-MATRIX (Acute Kidney Injury-
Minimizing Adverse Hemorrhagic Events by
Transradial Access Site and Systemic Imple-
mentation of AngioX) sub-study. Catheter Car-
diovasc Interv 2015;86:950–7.
12. Valgimigli M, Gagnor A, Calabro P, et al. Radial
versus femoral access in patients with acute cor-
onary syndromes undergoing invasive manage-
ment: a randomised multicentre trial. Lancet 2015;
385:2465–76.
13. Valgimigli M, Gagnor A, Calabrò P, et al.,
MATRIX investigators. Design and rationale for the
Minimizing Adverse haemorrhagic events by TRans-
radial access site and systemic Implementation of
angioX program. Am Heart J 2014;168:838–45.e6.
14. Valgimigli M, Calabro P, Cortese B, et al. Sci-
entific Foundation and Possible Implications for
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In patients with acute
coronary syndromes undergoing invasive manage-
ment, radial arterial access is associated with a lower
risk of acute kidney injury than femoral access.
TRANSLATIONAL OUTLOOK: Additional research
is needed to assess whether this advantage of radial
over femoral access applies across specific subsets of
patients, such as the elderly or those with cardiogenic
shock, coronary bypass grafts, or chronic kidney dis-
ease, and whether concurrent medication therapies
modify the difference in renal outcomes.
Andò et al. J A C C V O L . 6 9 , N O . 2 1 , 2 0 1 7
AKI After Radial or Femoral Access in ACS Patients M A Y 3 0 , 2 0 1 7 : 2 5 9 2 – 6 0 3
2602
Practice of the Minimizing Adverse Haemorrhagic
Events by Transradial Access Site and Systemic
Implementation of AngioX (MATRIX) Trial.
J Cardiovasc Transl Res 2014;7:101–11.
15. Task Force on the Management of ST-Segment
Elevation Acute Myocardial Infarction of the Eu-
ropean Society of Cardiology (ESC), Steg PG,
James SK, Atar D, et al. ESC guidelines for the
management of acute myocardial infarction in
patients presenting with ST-segment elevation.
Eur Heart J 2012;33:2569–619.
16. Slocum NK, Grossman PM, Moscucci M, et al.
The changing definition of contrast-induced ne-
phropathy and its clinical implications: insights
from the Blue Cross Blue Shield of Michigan Car-
diovascular Consortium (BMC2). Am Heart J 2012;
163:829–34.
17. Summary of recommendation statements.
Kidney Int Suppl 2012;2:8–12.
18. Vuurmans T, Byrne J, Fretz E, et al. Chronic
kidney injury in patients after cardiac catheter-
isation or percutaneous coronary intervention: a
comparison of radial and femoral approaches
(from the British Columbia Cardiac and Renal
Registries). Heart 2010;96:1538–42.
19. Damluji A, Cohen MG, Smairat R, Steckbeck R,
Moscucci M, Gilchrist IC. The incidence of acute
kidney injury after cardiac catheterization or PCI: a
comparison of radial vs. femoral approach. Int J
Cardiol 2014;173:595–7.
20. Mehta RL, Kellum JA, Shah SV, et al. Acute
Kidney Injury Network: report of an initiative to
improve outcomes in acute kidney injury. Crit Care
2007;11:R31.
21. Giacoppo D, Capodanno D, Capranzano P,
Aruta P, Tamburino C. Meta-analysis of randomized
controlled trials of preprocedural statin adminis-
tration for reducing contrast-induced acute kidney
injury in patients undergoing coronary catheteri-
zation. Am J Cardiol 2014;114:541–8.
22. Bainey KR, Rahim S, Etherington K, et al.
Effects of withdrawing vs continuing renin-
angiotensin blockers on incidence of acute
kidney injury in patients with renal insufficiency
undergoing cardiac catheterization: results from
the Angiotensin Converting Enzyme Inhibitor/
Angiotensin Receptor Blocker and Contrast
Induced Nephropathy in Patients Receiving Car-
diac Catheterization (CAPTAIN) trial. Am Heart J
2015;170:110–6.
23. Nikolsky E, Mehran R, Lasic Z, et al. Low he-
matocrit predicts contrast-induced nephropathy
after percutaneous coronary interventions. Kidney
Int 2005;67:706–13.
24. Ohno Y, Maekawa Y, Miyata H, et al.
Impact of periprocedural bleeding on incidence
of contrast-induced acute kidney injury in
patients treated with percutaneous coronary
intervention. J Am Coll Cardiol 2013;62:
1260–6.
25. Karkouti K, Grocott HP, Hall R, et al. Inter-
relationship of preoperative anemia, intra-
operative anemia, and red blood cell transfusion
as potentially modifiable risk factors for acute
kidney injury in cardiac surgery: a historical
multicentre cohort study. Can J Anaesth 2015;62:
377–84.
26. Karrowni W, Vora AN, Dai D, Wojdyla D,
Dakik H, Rao SV. Blood transfusion and the risk of
acute kidney injury among patients with acute
coronary syndrome undergoing percutaneous
coronary intervention. Circ Cardiovasc Interv 2016;
9:e003279.
27. Scolari F, Ravani P. Atheroembolic renal dis-
ease. Lancet 2010;375:1650–60.
28. Pannu N, Wiebe N, Tonelli M. Alberta Kidney
Disease Network. Prophylaxis strategies for
contrast-induced nephropathy. JAMA 2006;295:
2765–79.
KEY WORDS bleeding, coronary
intervention, creatinine, estimated
glomerular filtration rate, ST-segment
elevation
APPENDIX For supplemental information
regarding the MATRIX trial as well as
supplemental figures and table, please see
the online version of this article.
J A C C V O L . 6 9 , N O . 2 1 , 2 0 1 7 Andò et al.
M A Y 3 0 , 2 0 1 7 : 2 5 9 2 – 6 0 3 AKI After Radial or Femoral Access in ACS Patients
2603
Part 1
Trade-off for ischemia and 
bleeding during and immediately 
after percutaneous coronary 
interventions:
Stenting strategies to optimize 
clinical outcomes
the bmj | BMJ  2015;351:h5392 | doi: 10.1136/bmj.h5392
RESEARCH
1
OPEN ACCESS
1Department, Ferrarotto 
Hospital, Catania, Italy
2Department of General Surgery 
and Medical Surgical 
Specialties, Ferrarotto Hospital, 
University of Catania, 95124 
Catania, Italy
Correspondence to: 
D Capodanno  
dcapodanno@gmail.com
Additional material is published 
online only. To view please visit 
the journal online (http://dx.doi.
org/10.1136/bmj.h5392)
Cite this as: BMJ 2015;351:h5392
doi: 10.1136/bmj.h5392
Accepted: 22 September 2015
Treatment strategies for coronary in-stent restenosis: systematic 
review and hierarchical Bayesian network meta-analysis of 24 
randomised trials and 4880 patients
Daniele Giacoppo,1 Giuseppe Gargiulo,1 Patrizia Aruta,1 Piera Capranzano,1,2 Corrado Tamburino,1,2 
Davide Capodanno1,2 
ABSTRACT
STUDY QUESTION
What is the most safe and effective interventional 
treatment for coronary in-stent restenosis?
METHODS
In a hierarchical Bayesian network meta-analysis, 
PubMed, Embase, Scopus, Cochrane Library, Web of 
Science, ScienceDirect, and major scientific websites 
were screened up to 10 August 2015. Randomised 
controlled trials of patients with any type of coronary 
in-stent restenosis (either of bare metal stents or drug 
eluting stents; and either first or recurrent instances) 
were included. Trials including multiple treatments at 
the same time in the same group or comparing variants 
of the same intervention were excluded. Primary 
endpoints were target lesion revascularisation and late 
lumen loss, both at six to 12 months. The main analysis 
was complemented by network subanalyses, standard 
pairwise comparisons, and subgroup and sensitivity 
analyses.
STUDY ANSWER AND LIMITATIONS
Twenty four trials (4880 patients), including seven 
interventional treatments, were identified. Compared 
with plain balloons, bare metal stents, brachytherapy, 
rotational atherectomy, and cutting balloons, drug 
coated balloons and drug eluting stents were 
associated with a reduced risk of target lesion 
revascularisation and major adverse cardiac events, 
and with reduced late lumen loss. Treatment ranking 
indicated that drug eluting stents had the highest 
probability (61.4%) of being the most effective for 
target lesion vascularisation; drug coated balloons 
were similarly indicated as the most effective 
treatment for late lumen loss (probability 70.3%). The 
comparative efficacy of drug coated balloons and drug 
eluting stents was similar for target lesion 
revascularisation (summary odds ratio 1.10, 95% 
credible interval 0.59 to 2.01) and late lumen loss 
reduction (mean difference in minimum lumen 
diameter 0.04 mm, 95% credible interval −0.20 to 
0.10). Risks of death, myocardial infarction, and stent 
thrombosis were comparable across all treatments, 
but these analyses were limited by a low number of 
events. Trials had heterogeneity regarding 
investigation periods, baseline characteristics, and 
endpoint reporting, with a lack of information at long 
term follow-up. Direct and indirect evidence was also 
inconsistent for the comparison between drug eluting 
stents and drug coated balloons. 
WHAT THIS STUDY ADDS
Compared with other currently available interventional 
treatments for coronary in-stent restenosis, drug 
coated balloons and drug eluting stents are associated 
with superior clinical and angiographic outcomes, with 
a similar comparative efficacy. 
FUNDING, COMPETING INTERESTS, DATA SHARING
This study received no external funding. The authors 
declare no competing interests. No additional data 
available.
Introduction
Drug eluting stents have substantially reduced the risk 
of coronary in-stent restenosis and the need for target 
lesion revascularisation compared with bare metal 
stents by counteracting the exuberant neointimal pro-
liferation that follows stent implantation.1 However, 
current rates of in-stent restenosis in clinical practice 
remain higher than 10%.2 3
Management of patients with in-stent restenosis is 
challenging and the best therapeutic strategy remains 
unclear.4 Treatment with plain balloons is technically 
simple and generally associated with acceptable proce-
dural success, due to axial and longitudinal tissue 
extrusion and incremental stent expansion.5  However, 
observational studies and randomised trials have con-
sistently shown inferior clinical and angiographic 
results compared with implantation of a second drug 
eluting stent.6-8 Nevertheless, plain balloon angioplasty 
is still used for in-stent restenosis treatment in a consis-
tent proportion of patients.9 10 Furthermore, in-stent 
implantation of drug eluting stents tends to be 
WHAT IS ALREADY KNOWN ON THIS TOPIC
Management of patients with coronary in-stent restenosis is difficult, owing to 
many factors such as varying causes (aggressive neointimal proliferation, 
neoatherosclerosis) and the high tendency to recur
In the past 20 years, several strategies have been proposed to counteract in-stent 
restenosis, but randomised trials comparing different treatments have given mixed 
and inconclusive results
WHAT THIS STUDY ADDS
In a network meta-analysis, contemporary treatment strategies for coronary in-stent 
restenosis (drug coated balloons and drug eluting stents) were compared with 
other treatments investigated over the years
Pooled evidence suggested comparable clinical and angiographic antirestenotic 
efficacy for drug coated balloons and drug eluting stents; plain balloons, bare 
metal stents, brachytherapy, rotational atherectomy, and cutting balloons were 
associated with an increased risk of target lesion revascularisation and inferior 
angiographic results
No differences in death, myocardial infarction, and stent thrombosis were noted 
across all the treatments investigated
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restricted to a limited proportion of patients, owing to 
concerns related to positioning a permanent additional 
stent layer. Additional layers promote further endothe-
lial growth as well as potential mechanical complica-
tions, either acutely or later on (such as fracture, 
malapposition, thrombosis).4 11 
Recently, drug coated balloons have emerged as 
promising alternatives to drug eluting stents for in-stent 
restenosis, but large randomised trials comparing drug 
coated balloons with other therapeutic options are lim-
ited.12-14 Other treatment options for in-stent restenosis 
have been used over time with heterogeneous results, 
including implantation of bare metal stents, vascular 
brachytherapy, rotational atherectomy, and cutting bal-
loons.4 15
Network meta-analyses are an extension of tradi-
tional pairwise meta-analyses that enable the simulta-
neous pooling of data from clinical trials comparing at 
least two treatments and strengthen the inference on 
the relative efficacy of each treatment by including both 
direct and indirect information.16 17 The objective of this 
systematic review and hierarchical Bayesian network 
meta-analysis was to pool data from randomised trials 
comparing at least two interventional treatments for 
coronary in-stent restenosis and to identify which strat-
egy is eventually the most effective and safe.
Methods
Data sources and study strategy
This meta-analysis was performed in agreement with 
the PRISMA (preferred reporting items for systematic 
reviews and meta-analyses) statement, the PRISMA 
network meta-analysis extension statement, and the 
Cochrane Collaboration recommendations (web 
appendix, PRISMA checklist).18-20 Randomised trials 
comparing at least two different treatments were 
searched in PubMed, Embase, Scopus, Cochrane 
Library, Web of Science, and ScienceDirect electronic 
databases, as well as major scientific websites 
(www.tctmd.com, www.pcronline.com, www.clinical-
trials.gov, www.clinicaltrialresults.org, www.acc.org, 
www.heart.org, www.medscape.com). Abstracts and 
presentations from major cardiovascular meetings 
were considered. The electronic search process was 
integrated by tangential exploration of bibliography of 
relevant reviews on in-stent restenosis and major inter-
ventional cardiology books.
The web appendix reports the combination of subject 
headings used for studies identification. No language 
restriction or filters were imposed. The search was per-
formed from the date of databases’ inception to 10 
August 2015.
Selection criteria and study design
Inclusion criteria were the following: randomised con-
trolled trials of patients with coronary in-stent resteno-
sis; patients of any age, sex, ischaemic risk profile, and 
clinical presentation; either in-stent restenosis of a 
previously implanted bare metal stent (BMS-ISR) or 
in-stent restenosis of a previously implanted drug elut-
ing stent (DES-ISR); and either first or recurrent 
instances of in-stent restenosis. Exclusion criteria 
were: non-interventional treatment for in-stent reste-
nosis; comparison between variants of the same type of 
device (same treatment group); and investigations 
including combinations of multiple treatments in the 
same group at the same time, except for the use of 
plain balloons or cutting balloons for lesion prepara-
tion before other treatments (that is, brachytherapy or 
stent implantation).
Coronary in-stent restenosis is classically defined 
as the angiographic detection of a recurrent stenosis 
with diameter greater than 50% at the stent segment 
or its 5 mm adjacent segments (in-segment restenosis). 
However, some trials have considered only the seg-
ment of the implanted stent, without inclusion of 
proximal and distal edges (in-lesion restenosis).21 In 
this meta-analysis, we prioritised events related to 
in-segment restenosis; if they were not available, we 
included events related to in-lesion restenosis- 
related events.
The primary clinical endpoint was target lesion 
revascularisation at six to 12 months, defined as any 
repeated revascularisation involving the target lesion, 
both percutaneous and surgical; if target lesion revas-
cularisation was not available, target vessel revascular-
isation was pooled.22  The primary angiographic 
endpoint was late lumen loss at six to 12 months, 
defined as the difference between the minimum lumen 
diameter after the procedure and at follow-up, as evalu-
ated by quantitative coronary angiography.23  Late 
lumen loss was designated as a coprimary endpoint, 
because this angiographic measure is known to be con-
sistent and reliable in discriminating the propensity for 
restenosis.24
Secondary clinical endpoints were death, myocar-
dial infarction, stent thrombosis, and combined 
major adverse cardiac events including death, myo-
cardial infarction, target lesion revascularisation, 
and stent thrombosis.22  The definition of major 
adverse cardiac events was modified retrospectively 
because of the observed heterogeneity across the tri-
als, allowing for the inclusion of target vessel revas-
cularisation instead of target lesion revascularisation. 
Very dissimilar definitions, however, were not 
allowed, leading to the exclusion of the correspond-
ing trial from the meta-analysis for major adverse car-
diac events. Secondary angiographic endpoints were 
minimum lumen diameter and binary restenosis at 
six to 12 months.23
Search and screening of retrieved records at the title 
and abstract level were independently performed by 
three reviewers (DG, PA, GG). The same three reviewers 
assessed full text eligibility of the identified trials and 
discrepancies were resolved by consensus under the 
supervision of other two investigators (PC, DC). The 
validity of the meta-analysis was assessed by qualita-
tive appraisal of study designs and methods before sta-
tistical analyses were performed, with the use of the 
risk of bias tool recommended by the Cochrane Collab-
oration.20 Data from original reports were collected into 
specific electronic spreadsheets.
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Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
the design and implementation of the study. There are 
no plans to involve patients in dissemination.
Statistical analyses
Data used in this meta-analysis were intention to treat. 
Most of the included trials did not report as treated 
results. A hierarchical Bayesian network meta-analy-
sis was carried out for each endpoint using random 
effects consistency models.25-27 Briefly, in a network 
meta-analysis, each study provides an estimate of the 
study specific treatment effects, which are assumed to 
be similar and exchangeable (that is, transitivity), 
deriving from a normal common distribution.28 Each 
relative treatment effect estimate results from the com-
bination of the direct evidence between the two treat-
ments and the indirect evidence deriving from the 
network meta-analysis, which are assumed to be 
coherent.26 29  When a direct connection between two 
treatments is not available, the effect estimates derives 
only from indirect evidence.26 29 
We used random effects models because they are 
probably the most appropriate and conservative meth-
odology to account for between-trial heterogeneity 
within each comparison.29 30 Models were computed 
with Markov chain Monte Carlo simulations, using 
three chains with over-dispersed initial values, with 
Gibbs sampling based on 100 000 iterations after a 
burn-in phase of 50 000 iterations. Non-informative or 
vague priors for the overall mean effect (θ ~ N (0, 1002)) 
and the between-study standard deviation (τ ~ uniform 
(0, 2)) were given.27 29 31 We evaluated convergence 
according to Brooks-Gelman-Rubin.32 
The information was imputed according to the arm 
based approach, and modelled by use of binomial data 
(binomial likelihood, logit link) or sample means (nor-
mal likelihood, identity link) with normal distribution, 
according to the specific type of outcome explored.17 27 
We computed posterior mean effect, odds ratio or mean 
difference, where appropriate, and 95% credible inter-
vals for each comparison. The included treatments 
were ranked to define the probability associated 
to  each one being the best interventional strategy 
when significant variations in treatment effect were 
observed.30 33 
We assessed inconsistency by comparing statistics 
for the deviance information criterion in fitted consis-
tency and inconsistency models, and by contrasting 
direct evidence with indirect evidence from the entire 
network on each node (node-split).25-27 A Bayesian 
P value was calculated to estimate the measure of the 
conflict between direct and indirect evidence by count-
ing the proportion of times the direct treatment effect 
exceeded the indirect treatment effect.26 The estimates 
of Bayesian pairwise comparisons were also calculated 
with results complemented by standard frequentist 
DerSimonian-Laird meta-analyses with inverse vari-
ance weighting.34 In the frequentist framework, the 
pooled estimates were quantified as summary odds 
ratios or mean differences, where appropriate, and cor-
responding 95% confidence intervals.
The amount of the observed variance reflecting real 
differences in the effect size across the included trials 
was graded with the Q test and I2 statistic with values 
representing mild, moderate, and severe heterogene-
ity (<25%, 25-75%, and >75%, respectively).35 The vari-
ance of the true effect size across the included trials 
(τ²) was calculated.36 We assessed publication bias 
and small study effect by visual inspection of compar-
ison adjusted and contours enhanced funnel plots 
complemented by Peters’ and Egger’s tests, where 
appropriate.36-40 
We did subgroup analyses according to the type of 
restenotic stent (BMS-ISR or DES-ISR), and the genera-
tion of drug eluting stent implanted for in-stent resteno-
sis treatment (first or second generation). As another 
sensitivity analysis, we removed each trial from the oth-
ers when results suggested the mean effect to be poten-
tially driven by individual studies.36 All analyses were 
performed using R (version 3.1.1), Stata (version 12.1), 
and RevMan (version 5.3).
Results
Systematic review and qualitative assessment
A total of 24 trials (n=4880) and seven interventional 
treatments (plain balloon, drug coated balloon, drug 
eluting stent, bare metal stent, brachytherapy, rota-
tional atherectomy, and cutting balloon) were included. 
Fig 1  shows each phase of the screening process, and 
fig 2 shows the weighted network. The web appendix 
includes the list of acronyms and identification num-
bers (www.clinicaltrials.gov) of the trials included in 
the analysis. Potential sources of bias in trial design 
and investigational methods graded according to the 
Records screened after duplicates removed (n=7895)
Studies assessed for eligibility (n=42)
Studies included in quantitative and qualitative sythesis (n=24)*
Additional records identified
through other sources (n=7)
Records identified through
database searching (n=8772)
Studies not matching with
inclusion/exclusion criteria (n=18)
Records excluded (n=7853)
Fig 1 | Systematic search and screening process of trials. 
*The study by Ragosta and colleagues had two cohorts 
with independent randomisation processes that were 
separately included in the meta-analysis. Similarly, the 
study by Song and colleagues had two cohorts with 
independent randomisation processes, but only the first 
(cutting balloon v sirolimus eluting stent) was included in 
this meta-analysis because the second (sirolimus eluting 
stent v everolimus eluting stent) compared two variants of 
the same treatment. Finally, we considered the PACCOCATH 
ISR I and II trials together because the second study is the 
cohorts’ extension of the first one
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Cochrane’s Collaboration risk of bias tool (web fig 1) 
suggested most of the trials to be open label and there-
fore potentially affected by performance bias.20 
Table 1 describes key characteristics of the included 
studies (design, samples size, treatments, in-stent rest-
enosis definition, follow-up length, and original end-
points). Almost all trials were powered for angiographic 
endpoints, mainly late lumen loss, and scheduled for 
angiographic surveillance. Two trials did not plan mid-
term angiographic follow-up, and were excluded from 
all meta-analyses of angiographic endpoints. In about 
70% of trials, angiographic follow-up was performed 
starting from six months after procedure, while 62.5% 
of trials had planned clinical follow-up at 12 months. 
Almost 60% of trials included only patients with BMS-
ISR, nearly 30% included only patients with DES-ISR, 
while two trials included both stent types of in-stent 
restenosis.
Table 2 summarises the clinical and angiographic 
characteristics of patients enrolled in each trial. The 
included participants had a mean age of 64 years, were 
prevalently male (76%), and underwent repeated percu-
taneous coronary intervention mainly for silent isch-
aemia/stable angina or unstable angina. Prevalence of 
diabetes was highly variable across trials (14-62%). Web 
table 1 reports all the inclusion and exclusion criteria of 
each trial.
Bayesian network meta-analyses
With respect to the primary clinical endpoint (fig 3), use 
of drug coated balloons or drug eluting stents markedly 
reduced the risk of target lesion revascularisation 
 compared with all the other treatments. When com-
pared directly, drug coated balloons and drug eluting 
stents had similar antirestenotic efficacy (summary 
odds ratio 1.10, 95% credible interval 0.59 to 2.01). Treat-
ment ranking reflected the consistent reduction in the 
risk of target lesion revascularisation associated with 
drug coated balloons or drug eluting stents over the 
other strategies, but also indicated that drug eluting 
stents had a higher probability (61.4%) of being the best 
therapy. Rotational atherectomy was associated with 
the highest risk of target lesion revascularisation com-
pared with the other treatments. 
With respect to the primary angiographic endpoint 
(fig 4), use of a drug coated balloon or drug eluting stent 
were the most effective treatments, while use of a bare 
metal stent showed the highest mean difference in late 
lumen loss, followed by rotational atherectomy. Drug 
coated balloons emerged as the best therapy in treat-
ment ranking (probability of 70.3%), but the extent of 
the late lumen loss reduction compared with drug elut-
ing stents was marginal (mean difference −0.04 mm, 
95% credible interval −0.20 to 0.10).
Risk of major adverse cardiac events was consistently 
reduced with use of drug coated balloons or drug 
 eluting stents, compared with all the other treatments 
(fig  5 ). Rotational atherectomy therapy led to an 
increased risk also when compared with poorly effec-
tive treatments such as brachytherapy and bare metal 
stent. The endpoint of major adverse cardiac events was 
mainly driven by target lesion revascularisation, since 
no remarkable differences across treatment strategies 
were noted in terms of death and myocardial infarction 
(fig 6). However, the incidences of death and myocar-
dial infarction were overall extremely low and conclu-
sions about these endpoints remain limited, especially 
for treatment comparisons supported by single or few 
trials. The angiographic superiority of drug coated bal-
loons or drug eluting stents over the other treatments 
was also confirmed by evaluation of the angiographic 
secondary endpoints of minimum lumen diameter and 
binary restenosis (web fig 2). In particular, patients 
treated with a drug coated balloon or drug eluting stent 
achieved a higher minimum lumen diameter at fol-
low-up than did the other treatment strategies, and the 
risk of binary restenosis generally followed the distribu-
tion observed for target lesion revascularisation.
All models converged adequately. Heterogeneity 
(global I2) was moderate for target lesion revascularisa-
tion (43.5%), high for late lumen loss (95.3%), and low 
to moderate for secondary endpoints (major adverse 
cardiac events=8.5%, death=0%, myocardial infarc-
tion=11.8%, minimum lumen diameter=45.4%, binary 
restenosis=59.4%). Model fitting was compared by use 
of the deviance information criterion and shown to be 
similar. The node-split in the analyses for target lesion 
revascularisation and late lumen loss showed a signifi-
cant inconsistency in the comparison of drug coated 
balloons versus drug eluting stents. However, the node-
split for the secondary endpoint analyses showed sig-
nificant inconsistency between drug coated balloons 
and drug eluting stents only for myocardial infarction. 
1595
297
872
287
182
430
1217
C
B
A
G
F
4
4
5
6
3
1
1
1
2E
D
Fig 2 | Network of interventional treatments included 
in meta-analysis. A=plain balloon; B=drug coated 
balloon; C=drug eluting stent; D=bare metal stent; 
E=brachytherapy; F=rotational atherectomy; G=cutting 
balloon. Numbers on connecting lines between each 
intervention=head to head comparisons; numbers next to 
specific interventions=patients receiving a treatment
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We detected a significant inconsistency between com-
parisons involving cutting balloons for each endpoint.
Bayesian network subanalyses and frequentist head 
to head comparisons
The main network meta-analysis indicated that drug 
coated balloons and drug eluting stents were the most 
effective treatments; thus, we further investigated vari-
ations in mean effect, heterogeneity, and consistency in 
subanalyses. We did a network meta-analysis of closed 
loop plain balloons, drug coated balloons, and drug 
eluting stents (13 trials; 2417 patients) to reduce the 
inconsistency arising from indirect evidence. Web 
tables 2 and 3 show additional information on the trials 
included in this network meta-analysis. We also did 
standard, frequentist, pairwise meta-analyses to com-
plement the results of the network meta-analysis.
Compared with plain balloons, use of drug coated 
balloons and drug eluting stents continued to be asso-
ciated with a strong reduction in the risk of target lesion 
revascularisation (drug coated balloons v plain bal-
loons: summary odds ratio 0.21, 95% credible interval 
0.09 to 0.43; drug eluting stents v plain balloons: 0.19, 
0.08 to 0.42; fig 7 ). Similar results were observed for the 
mean difference in late lumen loss (−0.44 mm, −0.63 to 
−0.27; −0.39 mm, −0.60 to −0.18; fig 8). After comparison 
of drug coated balloons with and drug eluting stents, 
the risk estimates of target lesion revascularisation and 
late lumen loss did not show a significant benefit 
favouring one treatment over the other. The node-split 
analysis showed that the pooled risk of target lesion 
revascularisation and late lumen loss between the two 
treatments in the network meta-analysis was differen-
tially driven by indirect (plain balloon v drug coated 
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Fig 3 | Effect of interventional treatments on risk of target lesion revascularisation. Forest plots show relative effect of each treatment on target lesion 
revascularisation as compared with a common reference treatment. Histograms are shown for each treatment reflecting corresponding probabilities for 
each position in the ranking of the seven strategies (rankograms). I2 value=43.5%. PB=plain balloon; DCB=drug coated balloon; DES=drug eluting stent; 
BMS=bare metal stent; BT=brachytherapy; ROTA=rotational atherectomy; CUT=cutting balloon; OR=odds ratio; CrI=credible interval
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balloon; and plain balloon v drug eluting stent) and 
direct evidence (Bayesian values P=0.043 for target 
lesion revascularisation and P=0.036 for late lumen 
loss). Results of corresponding standard pairwise 
meta-analyses were concordant with those of the net-
work meta-analysis. 
At treatment ranking, use of plain balloons was asso-
ciated with a 99.9% probability of being the least effec-
tive treatment both in terms of target lesion 
revascularisation and late lumen loss. The risk of major 
adverse cardiac events was reduced in patients treated 
with drug coated balloons and drug eluting stents com-
pared with those treated with plain balloons, but simi-
lar effects were noted between the two strategies (web 
fig 3). The risk of death and myocardial infarction in 
both the network meta-analysis and standard pairwise 
meta-analyses tended to be lower with drug coated 
 balloons than with drug eluting stents (web figs 4 and 5). 
But owing to the low number of events, this distribution 
could reflect the effect of chance.
Subgroup and sensitivity analyses
To explore whether earlier devices are affected by a dif-
ferential response when treated for in-stent restenosis, 
we stratified patients by categories of BMS-ISR or DES-
ISR, and re-evaluated the antirestenotic efficacy of 
plain balloons, drug coated balloons, and drug eluting 
stents (figs 9  and 10). Drug coated balloons and drug 
eluting stents were consistently associated with a sig-
nificant reduction in the risk of target lesion revascular-
isation compared with plain balloons both in BMS-ISR 
and DES-ISR. Both the network and standard pairwise 
meta-analyses suggested that the magnitude of the 
 benefit of drug coated balloons compared with plain 
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Fig 4 | Effect of interventional treatments on late lumen loss. Forest plots show relative effect of each treatment on late lumen loss as compared with a 
common reference treatment. Histograms are shown for each treatment reflecting corresponding probabilities for each position in the ranking of the 
seven strategies (rankograms). I2 value=95.3%. PB=plain balloon; DCB=drug coated balloon; DES=drug eluting stent; BMS=bare metal stent; 
BT=brachytherapy; ROTA=rotational atherectomy; CUT=cutting balloon; MD=mean difference; CrI=credible interval
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balloons may be larger in BMS-ISR than in DES-ISR, 
whereas the effect of drug eluting stents compared with 
plain balloons was less influenced by restenotic stent 
type. After comparing drug coated balloons with drug 
eluting stents in BMS-ISR and DES-ISR, we saw no dif-
ferences in their respective network meta-analyses. 
However, the corresponding frequentist, pairwise 
meta-analysis showed a significant reduction in the risk 
of target lesion revascularisation associated with the 
reimplantation of drug eluting stents for DES-ISR.
Figure 11 shows the stratification of trials comparing 
drug coated balloons with drug eluting stents in stan-
dard pairwise meta-analyses according to the genera-
tion of drug eluting stent implanted for in-stent 
restenosis. Risk of target lesion revascularisation was 
similar between first generation drug eluting stents 
and drug coated balloons. However, the risk decreased 
consistently in the analysis of second generation drug 
eluting stents versus drug coated balloons, where 
repeated stenting with everolimus eluting stents was 
associated with a trend towards a 65% risk reduction 
(P=0.052).
In the study removal analysis, the PEPCAD II trial 
appeared to unduly influence the pooled estimate of 
target lesion revascularisation for the comparison of 
drug eluting stents versus drug coated balloons. After 
exclusion of PEPCAD II from the main analysis, use of 
drug eluting stents for in-stent restenosis was associ-
ated with a larger reduction in target lesion revascular-
isation compared with drug coated balloons. This 
finding was seen in both the network meta-analysis 
(summary odds ratio 0.49, 95% credible interval 0.22 to 
1.08) and corresponding standard pairwise meta-analysis 
(0.51, 95% confidence interval 0.31 to 0.84; fig 12).
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Fig 5  | Effect of interventional treatments on major adverse cardiac events. Forest plots show relative effect of each treatment on major adverse cardiac 
events as compared with a common reference treatment. Histograms are shown for each treatment reflecting corresponding probabilities for each 
position in the ranking of the seven strategies (rankograms). I2 value=8.5%. PB=plain balloon; DCB=drug coated balloon; DES=drug eluting stent; 
BMS=bare metal stent; BT=brachytherapy; ROTA=rotational atherectomy; CUT=cutting balloon; OR=odds ratio; CrI=credible interval
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A stent thrombosis network meta-analysis was not 
feasible due to the low number of events and trials 
reporting on such endpoint. However, we did standard 
pairwise meta-analyses for the loop plain balloons, 
drug coated balloons, and drug eluting stents. No sig-
nificant differences among treatments were observed 
(web fig 6).
We also excluded rotational atherectomy and 
brachytherapy from the main network and applied a 
study size filter of at least 50 patients per arm in the 
attempt to minimise possible influences of outdated 
treatments and smaller trials. The results of this net-
work subanalysis for target lesion revascularisation and 
late lumen loss did not show substantial variations 
compared with the conclusions of the main analysis 
(web fig 7).
Publication bias
Overall, visual estimation of comparison adjusted fun-
nel plots did not suggest significant asymmetry for all 
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Fig 6  | Effect of interventional treatments on secondary clinical endpoints. Forest plots show relative effect of each treatment on secondary clinical 
endpoints as compared with a common reference treatment. I2 values: death=0%; myocardial infarction=11.8%. PB=plain balloon; DCB=drug coated 
balloon; DES=drug eluting stent; BMS=bare metal stent; BT=brachytherapy; ROTA=rotational atherectomy; CUT=cutting balloon; OR=odds ratio; 
CrI=credible interval
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endpoints. However, a consistent number of trials 
(almost all involving drug coated balloons) fell outside 
the significance boundaries in the late lumen loss anal-
ysis (web figs 8 and 9). Contour enhanced funnel plots 
for the comparison of drug eluting stents versus drug 
coated balloon were implemented by Peters’ test (target 
lesion revascularisation) and Egger’s test (late lumen 
loss). These plots did not outline significant publication 
bias (web figs 10 and 11). However, for late lumen loss, 
this non-significance could be due to the limited number 
of trials, because visual inspection suggested an asym-
metric distribution and the Egger’s test P value of 0.127 
was close to the formal significance threshold of 0.10.
Discussion
This updated network meta-analysis comparing all 
available treatments for in-stent restenosis had four 
main findings. Firstly, drug coated balloons and drug 
eluting stents are the most effective interventional 
 treatments for in-stent restenosis compared with other 
currently available strategies, leading to superior and 
long term efficacy in terms of clinical, angiographic and 
antirestenotic outcomes. Secondly, use of a plain bal-
loon alone is significantly less effective than a drug 
coated balloon or a drug eluting stent. Thirdly, drug 
coated balloons might exert a larger efficacy in BMS-ISR 
than in DES-ISR. Finally, second generation everolimus 
eluting stents have shown a tendency to reduce the risk 
of target lesion revascularisation compared with drug 
coated balloons.
Recently, a meta-analysis by Lee and colleagues eval-
uated plain balloons, drug coated balloons, and drug 
eluting stents in the treatment of in-stent restenosis, 
suggesting drug coated balloons to be the best ther-
apy.41 Our meta-analysis differs from that earlier study 
in several ways. 
Firstly, the main objective of our study was the 
 evaluation of all existing interventional strategies for 
in-stent restenosis using data from randomised trials, 
whereas Lee and colleagues’ study included only three 
Ra
nk
 p
ro
ba
bi
lit
y
Rank probability
Ranking
PB DCB DES
PB
DCB
DES
0
20
40
60
80
100 1st rank
2nd rank
3rd rank
  Habara et al 2011
  PACCOCATH ISR I/II
  PEPCAD DES
  ISAR DESIRE 3
  Habara et al 2013
Total (95% CI)
Random effects model: τ2=0.606, P=0.012, I2=68.8%
0.06 (0.01 to 0.54)
0.07 (0.01 to 0.30)
0.31 (0.12 to 0.78)
0.39 (0.23 to 0.66)
0.07 (0.02 to 0.21)
0.16 (0.07 to 0.38)
P<0.001
10.8
16.2
23.5
28.5
21.0
100.0
0.01 0.1 1 10 100
Study
Network node-split Frequentist pair wise subanalyses
DCB v PB
  Direct
  Indirect
  Network
I2=61.7%
DES v PB
  Direct
  Indirect
  Network
I2=49.4%
DES v DCB
  Direct
  Indirect
  Network
I2=67.5%
Odds ratio
(95% CI)
Odds ratio
(95% CI)
0.15 (0.05 to 0.36)
0.47 (0.09 to 2.25)
0.21 (0.09 to 0.43)
P=0.174
0.28 (0.12 to 0.67)
0.07 (0.02 to 0.25)
0.19 (0.08 to 0.42)
P=0.066
0.64 (0.31 to 1.40)
3.00 (0.84 to 13.15)
0.95 (0.46 to 2.07)
P=0.043
Odds ratio
(95% Crl)
Weight
(%)
0.01
Global I2=57.2%
1 20
Odds ratio
(95% Crl)
1/25
2/54
11/72
30/137
4/136
48/424
DCB
10/25
20/54
14/38
56/134
22/71
122/322
PB
No of events/total
  ISAR DESIRE
  RIBS II
  CRISTAL
  ISAR DESIRE 3
Total (95% CI)
Random effects model: τ2=0, P=0.642, I2=0%
0.32 (0.18 to 0.57)
0.28 (0.11 to 0.67)
0.41 (0.15 to 1.16)
0.21 (0.11 to 0.38)
0.28 (0.19 to 0.40)
P<0.001
37.8
16.3
12.0
33.9
100.0
0.2 0.5 1 2 5
Study Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
27/200
8/76
8/136
17/131
60/543
DES
33/100
22/74
8/61
56/134
119/369
PB
No of events/total
  PEPCAD II
  ISAR DESIRE 3
  PEPCAD ISR China
  RIBS V
  SEDUCE
  RIBS IV
Total (95% CI)
Random effects model: τ2=0.344, P=0.051, I2=54.6%
2.82 (0.84 to 9.50)
0.53 (0.28 to 1.02)
0.76 (0.35 to 1.65)
0.16 (0.02 to 1.35)
2.00 (0.17 to 23.62)
0.32 (0.13 to 0.77)
0.67 (0.34 to 1.30)
P=0.234
16.0
25.9
23.4
7.5
6.0
21.2
100.0
0.1 0.5 1 2 10
Study Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
10/65
17/131
13/106
1/94
2/25
7/155
50/576
DES
4/66
30/137
17/109
6/95
1/24
20/154
78/585
DCB
No of events/total
1 2 3%
<0.01
43.7
56.3
<0.01
56.3
43.7
99.9
<0.01
<0.01
Fig 7 | Bayesian network subanalysis of closed loop plain balloons (PB), drug coated balloons (DCB), and drug eluting stents (DES), with additional 
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treatments. Secondly, the previous meta-analysis did not 
include two of the six available randomised trials com-
paring drug coated balloons with drug eluting stents 
(SEDUCE, RIBS IV), which could explain the disparity 
between our results and their conclusions. Thirdly, we 
also performed standard pairwise comparisons between 
treatment arms and multiple subanalyses to critically 
complement the results of the network meta-analysis. 
Finally, we also considered angiographic endpoints 
whereas the study by Lee and colleagues focused essen-
tially on clinical outcomes.
Use of drug coated balloons versus drug eluting 
stents for coronary in-stent restenosis
Intracoronary imaging indicates a leading role of exu-
berant neointimal proliferation among the potential 
mechanisms of in-stent restenosis.42  Use of drug coated 
balloons is an emerging treatment for in-stent resteno-
sis, with the putative advantage of delivering an 
 antiproliferative treatment without adding a second 
layer of metal.4  Our study showed that compared with 
plain balloons, drug coated balloons resulted in reduc-
tions of 79% relative risk of target lesion revascularisa-
tion and 0.44 mm mean difference in late lumen loss. 
However, in-stent restenosis has been also associated 
with stent underexpansion (that is, insufficient stent 
expansion at implantation or chronic recoil), uneven 
stent struts disposition in complex lesions, and neoath-
erosclerosis.43  44  These factors could theoretically disfa-
vour drug coated balloons, a treatment that cannot 
guarantee a constant radial strength.11  43 
In-stent implantation of drug eluting stents, providing 
additional permanent scaffolding inside the restenotic 
stent,45  could overcome the mechanical limitations of 
drug coated balloons. Although the trials in our system-
atic review showed no significant differences in peripro-
cedural complications and treatment crossover between 
drug coated balloons and drug eluting stents, repeated 
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Fig 8  | Bayesian network subanalysis of closed loop plain balloons (PB), drug coated balloons (DCB), and drug eluting stents (DES), with additional 
frequentist pairwise comparisons for the endpoint of late lumen loss. Network of trials investigating the effects of each treatment was considered. Left 
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evidence estimates represent results of the Bayesian pairwise meta-analyses, and I2 values for each comparison grade the heterogeneity between trials 
from a Bayesian estimate of τ2. Right section of figure shows standard, frequentist pairwise comparisons from the DerSimonian-Laird random effect 
model. MD=mean difference; CrI=credible interval; CI=confidence interval; SD=standard deviation
the bmj | BMJ  2015;351:h5392 | doi: 10.1136/bmj.h5392
RESEARCH
13
stenting with drug eluting stents might be a more reason-
able indication for relevant periprocedural tissue protru-
sion and in-stent or stent edge dissection. However, 
small vessel size and diabetes trigger further neointimal 
proliferation, and an additional metallic layer could crit-
ically amplify the risk of recurrent in-stent restenosis.46  47 
Selection of the best revascularisation strategy between 
drug coated balloons and drug eluting stents should be 
therefore tailored on a case by case basis according to 
lesion and patient characteristics.
The similar antirestenotic efficacy of drug coated bal-
loons and drug eluting stents observed in our 
meta-analysis could result from the trade-off between 
advantages and shortcoming of the two devices. Drug 
coated balloons are associated with worse acute angio-
graphic results, but are more respectful of the original 
coronary anatomy, induce lower vascular inflammatory 
response, and exert a lower stimulus to endothelial 
growth in the long term. Drug eluting stents guarantee 
a larger, immediate minimum lumen diameter and 
more predictable acute effects at the risk of reiterating 
the process of neointimal growth.45  48 The most relevant 
concern about drug coated balloons is the durability of 
the antirestenotic effect, because local drug use in the 
short term may not result in a longlasting inhibition of 
restenosis. However, the putative angiographic and 
clinical superiority of drug eluting stents in the long 
term for in-stent restenosis is presently not supported 
by a solid evidence basis.
Our meta-analysis suggests that second generation 
everolimus eluting stents might be the best strategy for 
in-stent restenosis. In agreement with large and unse-
lected observational studies,49  50 our stratified analysis 
showed that these second generation stents produced 
an almost significant 65% reduction in the risk of target 
lesion revascularisation compared with drug coated 
balloons. The efficacy of drug coated balloons and first 
generation stents was comparable. However, it is still 
unknown whether this possible benefit is generalisable 
to diffuse and neoatherosclerotic in-stent restenosis, 
especially if recurrent. 
The available data do not allow for comparison 
between drug coated balloons and drug eluting stents 
according to first or recurrent in-stent restenosis, and 
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Fig 9 | Subgroup analysis of antirestenotic efficacy of plain balloons, drug coated balloons, and drug eluting stents, according to BMS-ISR. Network 
node-split and treatment rank probabilities are displayed; direct evidence estimates represent the results of the Bayesian pairwise meta-analyses, and I2 
values for each comparison grade the heterogeneity between trials from a Bayesian estimate of τ2. Results of Bayesian analyses were implemented by 
frequentist, random effect, pairwise comparisons. OR=odds ratio; CrI=credible interval; CI=confidence interval 
doi: 10.1136/bmj.h5392 | BMJ  2015;351:h5392 | the bmj
RESEARCH
14
selection of the best strategy for patients with resistant 
in-stent restenosis (that is, at least three instances) 
remains uncertain. Owing to a lack of evidence, we 
could not establish whether implantation of drug elut-
ing stents for recurrent in-stent restenosis is better than 
repeat use of drug coated balloons after a failed drug 
coated balloon strategy. However, the first option seems 
to be a rational second line treatment.50  Overall, an ini-
tial approach to in-stent restenosis with drug coated 
balloons might be reasonable, especially in BMS-ISR 
and in patients with small vessels or diabetes. Second 
generation drug eluting stents should then be priori-
tised for DES-ISR and complex in-stent restenosis. 
Because patients with resistant in-stent restenosis tend 
to have multiple recurrent events, coronary artery 
bypass grafting should be also considered after multi-
ple failures of percutaneous coronary intervention.21
In view of the anatomical variables potentially influ-
encing early and late procedural antirestenotic efficacy 
depending on the selection of drug coated balloons or 
drug eluting stents, both treatments should be consid-
ered quick, safe, and effective for non-complex 
instances of coronary in-stent restenosis. However, in 
angiographic and unstable lesions and clinical pat-
terns, implantation of drug eluting stents could be pref-
erable owing to the superior mechanical guarantees of 
metallic scaffolding. In addition, the decision between 
these two treatments could be affected by varying post-
procedural pharmacological management.48 Second 
generation drug eluting stents have shown to be more 
biocompatible and less thrombogenic, hence allowing 
for only six months of dual antiplatelet therapy in de 
novo lesions.51  However, drug coated balloons deliver 
locally the antiproliferative medication and avoid per-
manent structures inside the vessel that need pro-
longed antithrombotic coverage. Although planned 
duration of dual antiplatelet therapy varies widely in 
randomised trials with drug coated balloons (including 
de novo lesions, in-stent restenosis, or peripheral artery 
disease), manufacturers advise three months of therapy 
following use of drug coated balloons. In some trials 
investigating the efficacy of drug coated balloons for 
in-stent restenosis or small vessel lesions, one month of 
dual antiplatelet therapy did not show any safety 
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Fig 10 | Subgroup analysis of antirestenotic efficacy of plain balloons, drug coated balloons, and drug eluting stents, according to DES-ISR. Network 
node-split and treatment rank probabilities are displayed; direct evidence estimates represent the results of the Bayesian pairwise meta-analyses, and I2 
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issue.48 Therefore, drug coated balloons might be indi-
cated in patients with urgent surgical indications or at 
high haemorrhagic risk.
Potential sources of inconsistency and 
heterogeneity
The need for a meta-analysis comparing drug eluting 
stents versus drug coated balloons is supported by the 
absence of robust antirestenotic differences between 
treatments across trials of in-stent restenosis. An objec-
tive of the meta-analysis is to combine non-conclusive 
evidence from individual trials to strengthen evidence 
from the comparison of two or more treatments. Impor-
tantly, characteristics of original trials (including 
design, eligibility criteria, clinical and procedural 
 features) can make the results of indirect comparisons 
quite different from those of direct comparison. The sig-
nificant incoherence between direct and indirect effects 
is known as inconsistency. 
We attempted to reduce potential sources of inconsis-
tency affecting the indirect evidence (that is, obsolete 
treatments, cutting balloon node) by restricting our 
analysis to the smallest network of plain balloons, drug 
coated balloons, and drug eluting stents. A network 
meta-analysis can identify external influences on the 
mean effect of a specific comparison that otherwise 
would have remained unreported with standard pair-
wise meta-analytical methods. However, even in the 
smallest network subanalysis, the inconsistency 
remained unchanged and significant Bayesian P values 
were observed. 
Therefore, the conflict between direct and indirect 
 evidence in the comparison of drug coated balloons ver-
sus drug eluting stents could have two explanations that 
are not mutually exclusive. Firstly, if we assume the direct 
evidence (which numerically favoured drug eluting 
stents) to be true, one possible explanation to the indirect 
evidence trending in the opposite direction is that trials 
comparing drug coated balloons with plain balloons 
overstate the efficacy of drug coated balloons, or trials 
comparing drug eluting stents with plain balloons under-
state the efficacy of drug eluting stents. In our analysis, 
we detected a high heterogeneity in the comparison of 
drug coated balloons versus plain balloons, with two 
smaller trials showing larger treatment effects. 
Secondly, if we assume the indirect evidence (which 
numerically disfavoured drug eluting stent) to be true, 
a possible explanation is a significant intrinsic incon-
sistency in the comparison of drug coated balloons with 
drug eluting stents. In the individual removal analysis, 
results were in line with this hypothesis, showing that 
the risk of target lesion revascularisation tended to be 
influenced by the oldest trial (PEPCAD II). Conversely, 
the inconsistency for late lumen loss could have been 
driven by very different, trial specific, mean estimates 
ranging from 0.04 to 0.55 mm for drug eluting stents 
and from 0.14 to 0.46 mm for drug coated balloons 
(same device).
Other treatments for coronary in-stent restenosis
Our results support the notion that bare metal stents 
and brachytherapy should be no longer considered in 
the contemporary management of in-stent restenosis. 
Indeed, although in-stent implantation of bare metal 
stents for in-stent restenosis provides higher acute 
lumen gain and better procedural results than plain 
balloons, it leads to a comparable minimum lumen 
diameter and percent diameter stenosis after only six 
months, largely due to significantly higher levels of late 
lumen loss.52  53 In addition, at six to 12 months, bare 
metal stents were associated with the highest mean dif-
ference in late lumen loss. Several trials in this network 
meta-analysis concluded that vascular brachytherapy 
is less effective in treating in-stent restenosis than drug 
eluting stents. We included brachytherapy in our 
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Fig 11 | Risk of target lesion revascularisation between use of first generation or second 
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results were implemented by frequentist analyses. DCB=drug coated balloon; DES=drug 
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 network meta-analysis to provide an additional refer-
ence for more effective strategies in the network, and to 
quantify a pooled estimate of the antirestenotic effect of 
this treatment compared with drug coated balloons and 
drug eluting stents.
This meta-analysis also underlines that rotational 
atherectomy cannot be considered a standalone treat-
ment for in-stent restenosis, because its outcomes are 
significantly inferior than those observed with the other 
treatments. Still, this strategy could be considered as 
complementary and preliminary to the implantation of 
drug eluting stents in old, hard, and calcified lesions 
caused by in-stent restenosis.54  55 Importantly, although 
rotational atherectomy for in-stent restenosis could be 
associated with a higher incidence of mechanical com-
plications (that is, stent fracture, coronary perforation, 
and plaque embolisation), we did not observe a signifi-
cant increase in death and myocardial infarction at 
 follow-up. 
Cutting balloon use was associated with a higher risk 
of target lesion revascularisation and higher mean dif-
ference in late lumen loss than use of a drug coated bal-
loon or drug eluting stent. We did not evaluate the 
effects of the newer scoring balloon in this meta-analy-
sis because data from randomised trials were not avail-
able. However, results from the ISAR-DESIRE 4 trial 
(NCT01632371) and other reports exploring the use of 
scoring balloons to prepare in-stent restenosis lesions 
for drug coated balloons are pending.
Future perspectives
Future direction of in-stent restenosis treatment will 
depend from the results of additional and larger 
 randomised trials currently comparing drug coated 
 balloons with second generation drug eluting stents. 
The ongoing DARE (NCT01127958) and TIS (NCT01735825) 
trials are investigating the superiority of second 
 generation everolimus eluting stents over drug coated 
 balloons. In the MAGIC-TOUCH trial (NCT02400632), 
researchers are investigating a new sirolimus coated 
balloon; these results will provide an additional refer-
ence for current types of drug coated balloons that elute 
paclitaxel. 
Isolated initial reports have suggested that bioresorb-
able scaffolds may offer sufficient mechanical support 
as well as reduced neointimal proliferative stimuli in 
in-stent restenosis.56  57  However, unfavourable proper-
ties of current bioresorbable scaffolds (that is, thick 
struts, lower radial force than drug eluting stents, and 
narrower margins for overexpansion after 
 deployment58) could frustrate this approach, which 
warrants validation in targeted investigations in a suffi-
cient number of patients.
Limitations
The results of our meta-analysis should be interpreted 
taking the following limitations into account. Firstly, a 
meta-analysis shares the limitations of the studies 
included. To minimise this unavoidable shortcoming, 
only randomised trials were included. The qualitative 
bias assessment did not suggest significant causes of 
concern, and differences in follow-up completeness 
were trivial as the consequence of the strict angio-
graphic surveillance scheduled in all studies. However, 
we noticed that studies had different proportions of dia-
betes mellitus, focal or diffuse angiographic patterns in 
in-stent restenosis, and different minimum lumen 
diameters at baseline, which cannot be fully appreci-
ated at the study level. 
Furthermore, the trials covered a period of about 15 
years, which could have introduced unmeasured differ-
ences among treatments. Almost all studies were of 
open label design; this was an unavoidable conse-
quence of the different constitutive characteristics of 
the devices under investigation, which do not consent 
complete masking to the operator, with few exceptions 
(plain balloons and drug coated balloons in PACCO-
CATH ISR I/II). 
The absence of long term follow-up and the varying 
periods of investigation across trials were also limita-
tions. There are insufficient data on clinical and angio-
graphic outcomes several years after in-stent restenosis 
treatment, and almost all the studies included in our 
meta-analysis did not provide information beyond 12 
months.
We were forced to select summary odds ratios as an 
outcome measure owing to the trials not providing 
enough information to indirectly calculate hazard 
ratios. However, we compared estimated summary 
odds ratios with hazard ratios from individual patient 
data from trials reporting those values, and found 
that the difference between the two outcome mea-
sures was trivial. This lack of difference could have 
been a result of the favourable follow-up length (≤12 
months) and the fact that very few patients were lost 
at follow-up.
Although this meta-analysis included nearly 5000 
patients, some trials were small, of which a large num-
ber were powered only for a specific angiographic end-
point, mainly late lumen loss. However, sensitivity 
analyses on target lesion revascularisation and late 
lumen loss that were restricted to newer and larger 
studies did not show relevant deviations from the main 
results. Additionally, although we observed a numerical 
distribution for myocardial infarction favouring some 
treatments over the others, the event rate was low and 
did not allow us to draw robust conclusions for this 
endpoint. For similar reasons, the network meta-analy-
sis for stent thrombosis was not feasible because most 
of the included trials did not report the number of stent 
thrombosis events, and the remaining reported a low 
incidence. 
Some trials were not included in all analyses because 
they did not have the specific endpoint of interest or 
report angiographic values as median and interquar-
tile range. In addition, although few older trials 
reported only target vessel revascularisation, we 
pooled these events with target lesion revascularisa-
tion, and events of the drug eluting stent group of the 
ISAR DESIRE trial were derived from collapsing the 
original groups using sirolimus eluting stents and pacl-
itaxel eluting stents.
the bmj | BMJ  2015;351:h5392 | doi: 10.1136/bmj.h5392
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Subgroup analyses according to the type of restenotic 
stent—either bare metal or drug eluting—could not ben-
efit from randomisation in all instances. The trial by 
Habara and colleagues (2013) included both devices, 
and in the PACCOCATH ISR I/II trial (which was 
included in the subgroup analysis for BMS-ISR), 4% of 
patients actually had DES-ISR. We did not stratify 
groups by first or recurrent in-stent restenosis because 
the original data did not allow a clear identification of 
such variants.
Unrelated mean effect models are not well suited to 
handle trials with more than two arms. Node-split, the 
most powerful tool to detect inconsistency, is limited to 
closed loops. However, our meta-analysis included only 
one three arm trial (ISAR DESIRE 3), and the most effec-
tive treatments were all part of closed loops. Finally, our 
meta-analysis investigated the efficacy of first genera-
tion and second generation everolimus eluting stents, 
but questions regarding the efficacy of newer stents 
(that is, second and third generations) remain.
Conclusions
In this network meta-analysis, drug coated balloons 
and drug eluting stents were shown to be the most effec-
tive treatments for in-stent restenosis. Plain balloons, 
bare metal stents, brachytherapy, rotational atherec-
tomy, and cutting balloons were associated with a 
higher risk of target lesion revascularisation and infe-
rior angiographic results. We saw no differences in 
death, myocardial infarction, and stent thrombosis 
among all included treatments, but such comparisons 
remain limited by the low number of events. The risk of 
major adverse cardiac events was consistently reduced 
with drug coated balloons and drug eluting stents, 
driven by target lesion revascularisation. Although the 
main analysis suggested a similar efficacy of drug 
coated balloons and drug eluting stents, an exploratory 
subgroup analysis indicated a trend towards a risk 
reduction in target lesion revascularisation with second 
generation everolimus eluting stents.
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Abstract
Aims: Our aim was to report one-year outcomes of Absorb bioresorbable scaffold implantation under real-
world conditions in an all-comers population of patients with high proportions of complex lesions.
Methods and results: Patients undergoing Absorb 1.1 implantation were included in a single-centre, 
prospective, all-comers registry. The primary outcome was target lesion failure (TLF), defined as the com-
bination of cardiac death, target vessel myocardial infarction (MI), or clinically driven target lesion revas-
cularisation (TLR). A total of 319 patients received 604 Absorb BVS in 406 lesions. Of note, 24.8% of 
patients had diabetes and 49.5% presented with an acute coronary syndrome. A total of 51% of lesions were 
type B2/C. The reference vessel diameter and lesion length were 2.9±0.5 and 21.2±16.8 mm, respectively. 
The one-year cumulative rate of TLF was 4.9%. Rates of cardiac death, target vessel MI and TLR were 
0.9%, 1.3% and 4.2%, respectively. The cumulative one-year rate of definite/probable scaffold thrombosis 
was 1.3%, with all events occurring within 30 days.
Conclusions: These data suggest that twelve-month clinical outcomes of Absorb use in “real-world” unse-
lected patients with high proportions of complex lesions are reasonably good.
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Introduction
Bioresorbable scaffolds (BRS) have recently been introduced for 
coronary interventions. These novel devices degrade completely 
over 12-36 months after implantation, enabling transient luminal 
support, while preventing long-term metallic “caging” of coronar-
ies, promising to overcome the limitations of permanent drug-elut-
ing stents (DES)1. Indeed, BRS implantation has been associated 
with vessel lumen enlargement, plaque/media reduction, vaso-
motion restoration, expansive remodelling (which may reduce 
angina), and new media formation, potentially reducing mecha-
nisms underlying late events, such as inflammation and neoath-
erosclerosis2. In addition to these biological effects, the complete 
bioresorption eliminates malapposed, fractured or non-endotheli-
alised struts, and late polymer/metal reactions, with the potential 
of reducing late thrombotic events triggered by these latter mecha-
nisms. Additional effects of BRS may be important in high-risk 
settings, in which mechanisms underlying late thrombotic events 
are more pronounced. However, BRS have specific features, 
including larger crossing profile, thicker struts and expansion 
capability limitations, which may impact on their clinical perfor-
mance, in complex lesions.
Among BRS, the everolimus-eluting scaffold (Absorb; Abbott 
Vascular, Santa Clara, CA, USA) has been the most extensively 
investigated in clinical studies. The use of the Absorb appears to 
provide a similar degree of safety and efficacy compared with 
metallic DES in the treatment of relatively simple lesions treated 
under trial conditions3,4. Clinical reports on the use of these novel 
devices in the more complex settings commonly encountered in 
routine practice have shown promising results overall5-9, although 
non-negligible rates of early scaffold thrombosis (ST) were 
observed in some registries5-8. Nevertheless, real-world data on 
BRS in unselected populations at more advanced stages of follow-
up and with the use of a standardised implantation technique are 
still limited10.
The aim of this single-centre study was to report one-year clini-
cal outcomes of Absorb implantation under real-world conditions 
in an unselected population with high proportions of complex cor-
onary lesions.
Methods
PATIENT POPULATION
The GHOST (Gauging coronary Healing with biOresorbable 
Scaffolding plaTforms) is an ongoing prospective non-randomised, 
single-centre registry conducted at Ferrarotto Hospital, University 
of Catania, Italy, from March 2013. The registry includes patients 
undergoing single-vessel or multivessel percutaneous coronary 
intervention (PCI) with the Absorb (revision 1.1). Concurrent 
implantation of DES or bare metal stents was allowed at the oper-
ator’s discretion.
Lesions suitable for stenting with a reference vessel diameter of 
≥2.0 mm and ≤3.8 mm were eligible for treatment with the Absorb. 
If these criteria were present and the correct scaffold size was in 
stock, all angiographic lesions were considered eligible, with the 
choice between Absorb and permanent metallic stents left to the 
discretion of the operator. Exclusion criteria for Absorb treatment 
included: contraindication to prolonged dual antiplatelet ther-
apy (DAPT); high likelihood of poor DAPT compliance; indica-
tion for oral anticoagulation; high bleeding risk; planned surgery 
within 12 months; cardiogenic shock; Killip class III or IV; unstable 
arrhythmias; cancer or comorbidities with limited expected survival.
The registry population also encompassed patients with clini-
cal and angiographic characteristics that were among the exclusion 
criteria of the ABSORB II trial11, reflecting a broader “real-world” 
use. Outcomes were compared between two subgroups stratified 
according to the entry and exit ABSORB II trial criteria.
Only patients with at least one-year follow-up eligibility were 
evaluated in the present analysis. The first 209 patients of our 
registry were part of the larger multicentre GHOST-EU registry, 
including patients from 10 European centres and reporting six-
month outcomes6.
The local ethics committee approved the use of aggregated 
clinical data for this analysis, and written informed consent was 
obtained from all patients.
INTERVENTIONAL PROCEDURE
All procedures were performed according to current PCI stand-
ards. Lesion preparation by predilatation with non-compliant bal-
loons 0.5 mm smaller than or equal to the scaffold device diameter 
was mandatory. The recommended pressure for scaffold implan-
tation was at least 10 atm. Post-dilatation at high pressure with 
non-compliant balloons 0.5 mm larger than or equal to the scaf-
fold device diameter was strongly recommended regardless of 
the angiographic results. The use of on-line quantitative coronary 
angiography (QCA) to assess appropriate device size and the use 
of intravascular imaging techniques were left to the discretion of 
the operator.
During the procedure, patients received appropriate anticoagu-
lation according to standard hospital practice. Glycoprotein IIb/
IIIa inhibitors were used at the physician’s discretion. A loading 
dose of aspirin 250-500 mg was given before PCI, followed by 
75-100 mg oral daily indefinitely thereafter. A loading dose of 
a P2Y12 inhibitor was administered before or immediately after 
PCI. Dual antiplatelet therapy (DAPT) was recommended for 
at least 12 months (with a strict minimum of six months) after 
Absorb implantation.
ANGIOGRAPHIC ANALYSIS
The QCA was performed with a dedicated software 
(Cardiovascular Angiographic Analysis System II; Pie Medical 
Imaging, Maastricht, The Netherlands) using an automated detec-
tion algorithm. The interpolated and proximal reference vessel 
diameters (RVD) in the treated segment were assessed. The acute 
gain was calculated as minimal lumen diameter (MLD) post scaf-
fold implantation minus MLD pre scaffold implantation.
Technical failure was defined as residual in-scaffold diameter 
stenosis >30% by QCA.
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Scaffold undersizing, correct sizing and oversizing were defined 
as the ratios between the nominal scaffold size and the proximal 
RVD ≤0.9, >0.9 and <1.1, and ≥1.1, respectively.
FOLLOW-UP DATA
Clinical follow-up information on medical therapy and the clini-
cal status of patients was prospectively collected through sched-
uled outpatient clinic evaluations and/or phone contact. Additional 
information, if necessary, was obtained from referring cardiolo-
gists and general practitioners. In case of inability to reach the 
patient and the referring doctor, the vital status was verified at the 
registry office. Clinical follow-up was scheduled at one, six and 
12 months. There was no independent or external monitoring of 
data entry.
OUTCOMES AND DEFINITIONS
The primary outcome of interest was a device-oriented composite 
endpoint (target lesion failure [TLF]), defined as the combination 
of cardiac death, target vessel myocardial infarction (MI), or clini-
cally driven target lesion revascularisation (TLR), either percuta-
neous or surgical12. Secondary outcomes of interest included the 
components of TLF, target vessel failure (TVF), defined as the 
composite of cardiac death, target vessel MI, or clinically driven 
target vessel revascularisation (TVR), and ST. Deaths that could 
not be attributed to another cause were regarded as cardiac deaths. 
Recurrent MI was defined according to the universal definition13. 
ST was classified according to the Academic Research Consortium 
criteria12.
STATISTICAL ANALYSIS
Continuous variables are presented as mean±standard deviations 
and were compared using a Student’s unpaired t-test for com-
parisons. Categorical variables are presented as counts and per-
centages, and were compared using chi-square or Fisher’s exact 
tests, as appropriate. Kaplan-Meier methods were used to derive 
the event rates at follow-up. Time-to-event curves were compared 
between groups using the log-rank test. All reported probability 
values are two-sided, and a probability value <0.05 was considered 
significant. All data were processed using the Statistical Package 
for Social Sciences, Version 20 (IBM Corp., Armonk, NY, USA).
Results
PATIENT POPULATION
Between March 2013 and June 2014, 319 patients underwent PCI 
with one or more Absorb in a total of 406 lesions. These Absorb-
treated patients represent 19.8% of the overall number of patients 
(n=1,610) undergoing PCI in the same period. Baseline clinical 
and angiographic characteristics of the overall population and in 
subgroups stratified by entry and exit criteria of ABSORB II are 
reported in Table 1 and Table 2. The mean age was 60.7±9.6 years 
and 85% were male. Of note, 24.8% of patients had diabetes 
and 49.5% presented with an acute coronary syndrome (ACS). 
Table 1. Baseline demographic and clinical characteristics of overall population and subgroups stratified according to ABSORB II trial 
inclusion and exclusion criteria.
Variable All patients N=319
ABSORB II inclusion 
N=89
ABSORB II exclusion
N=230 p-value
Age, years 60.7±9.6 61.1±8.7 60.6±9.9 0.70
Male 272 (85.3) 77 (86.5) 195 (84.8) 0.83
Hypertension 221 (69.3) 65 (73.0) 156 (67.8) 0.44
Diabetes 79 (24.8) 27 (30.3) 52 (22.6) 0.20
Current smoking 117 (36.7) 30 (33.7) 87 (37.8) 0.58
Family history of CAD 145 (45.5) 47 (52.8) 98 (42.6) 0.13
Hyperlipidaemia 187 (58.6) 58 (65.2) 129 (56.1) 0.18
Prior CABG 10 (3.1) 2 (2.2) 8 (3.5) 0.73
Prior PCI 102 (32.0) 24 (27.0) 78 (33.9) 0.29
Prior stroke/TIA 13 (4.1) 4 (4.5) 9 (3.9) 0.76
eGFR <60 ml/min 31 (9.7) na 31 (14.2)
Silent or stable angina 161 (50.5) 58 (65.2) 103 (44.8) 0.002
Unstable angina 54 (16.9) 31 (34.8) 23 (10.0) <0.001
NSTEMI 46 (14.4) na 46 (20.0)
STEMI 58 (18.2) na 58 (25.2)
LVEF (%) 51.1±8.7 51.6±8.9 50.8±8.7 0.48
LVEF <30% 6 (1.9) na 6 (2.8)
Multivessel disease 124 (38.9) 25 (28.1) 99 (43.0) 0.02
Data are presented as mean±SD or n (%). na: not applicable, because the variable was an exclusion criterion in the ABSORB II trial. CABG: coronary 
artery bypass graft; CAD: coronary artery disease; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; NSTEMI: non-ST-
elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction; TIA: transient ischaemic attack
e155
EuroIntervention 2
016
;12
:e
152-e
159
Bioresorbable scaffolds in a real-world setting
A total of 51% of lesions were type B2/C. The means of RVD 
and lesion length were 2.9±0.5 and 21.2±16.8 mm, respectively. 
The two subgroups did not differ for most demographic and clin-
ical characteristics, except for acute MI (ABSORB II exclusion 
criteria) and for multivessel disease, which were significantly 
more common among patients with ABSORB II exclusion crite-
ria. Compared with those fitting the trial entry criteria, these latter 
patients had higher proportions of type B2/C and longer lesions. 
Among patients with ABSORB exclusion criteria there were con-
siderable proportions of complex lesions (i.e., bifurcation 18.9%, 
chronic total occlusion [CTO] 11.5%).
PROCEDURAL DETAILS AND MEDICATIONS
A total of 604 Absorb of 3.1±0.4 mm mean scaffold diameter were 
implanted at a mean of 13.5±3.4 atm, with a mean number of scaf-
folds implanted per patient of 1.9±1.2 (Table 2). Predilation was 
performed in 96.3% of lesions. Mean scaffold length per lesion was 
32.8±21 mm and placement of overlapping scaffolds was required 
in 32.5% of lesions. Post-dilation, at a mean pressure of 16.6±4.3 
atm, was performed in 71.2% of lesions. Manual thrombectomy 
was performed in 59% of STEMI patients. Compared with those 
fitting the trial entry criteria, patients with ABSORB II exclu-
sion criteria had received higher means of number of scaffolds 
Table 2. Angiographic and procedural characteristics of overall population and subgroups stratified according to ABSORB II trial 
inclusion and exclusion criteria.
Variable Patients N=319 Lesions N=406
ABSORB II inclusion 
Patients n=89  
Lesions n=110
ABSORB II exclusion 
Patients n=230  
Lesions n=296
p-value
Scaffolds implanted, n 1.9±1.2* 1.5±0.7* 2.0±1.3* <0.001
Target vessel 0.07
LMCA 9 (2.2) na 9 (3.0)
LAD 202 (49.8) 59 (53.6) 143 (48.3)
CX 86 (21.2) 28 (25.5) 58 (19.6)
RCA 108 (26.6) 23 (20.9) 85 (28.7)
SVG 1 (0.2) na 1 (0.3)
Scaffolds and stents 69 (21.6)* 12 (13.5)* 57 (24.8)* 0.04
Lesion type 0.01
A 57 (14.0) 22 (20.0) 35 (11.8)
B1 141 (34.7) 46 (41.8) 95 (32.1)
B2 86 (21.2) 19 (17.3) 67 (22.6)
C 122 (30.0) 23 (20.9) 99 (33.4)
De novo lesions 381 (93.8) 110 (100) 271 (91.6) 0.004
In-stent restenosis 25 (6.2) na 25 (8.4)
Chronic total occlusion 34 (8.4) na 34 (11.5)
Ostial lesion 16 (3.9) na 16 (5.4)
Bifurcation 68 (16.7) 12 (10.9)# 56 (18.9) 0.07
Lesion length (mm) 21.2±16.8 16.4±7.9 22.9±18.7 <0.0001
Lesion length >34 mm 55 (13.5) 6 (5.5) 49 (16.6) 0.006
Interpolated RVD (mm) 2.9±0.5 2.9±0.5 2.9±0.5 0.32
Lesion %diameter stenosis 83.4±12.0 81.1±10.0 84.2±12.5 0.03
Total scaffold length (mm) 32.8±21.6 25.8±11.5 35.3±23.8 <0.0001
Mean scaffold diameter (mm) 3.1±0.4 3.1±0.4 3.2±0.4 0.11
Scaffold implantation pressure, atm 13.5±3.4 13.3±3.3 13.5±3.5 0.43
Predilatation 391 (96.3) 104 (94.5) 287 (97.0) 0.39
Post-dilatation 289 (71.2) 65 (59.1) 224 (75.7) 0.002
Post-dilation balloon pressure, atm 16.6±4.3 16.3±4.2 16.7±4.4 0.49
Overlapping 132 (32.5) 24 (21.5) 108 (36.5) 0.005
Intravascular ultrasound use 37 (11.6)* 10 (11.2)* 27 (11.7)* 1.00
Optical coherence tomography use 80 (25.1)* 8 (9.0)* 72 (31.3)* <0.0001
Data are presented as mean±SD or n (%). *Patient-based variable. # Side branch <2 mm. na: not applicable, because the variable was an ABSORB II 
exclusion criterion. LAD: left anterior descending; LCX: left circumflex; LMCA: left main coronary artery; RCA: right coronary artery; RVD: reference 
vessel diameter; SVG: saphenous vein graft
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per patient and of scaffold length per lesion, and underwent post-
dilatation, overlapping and intravascular imaging more frequently.
QCA data are shown in Table 3: the acute gain was 2.2±0.5 mm 
and 2.1±0.5 mm in the overall population and in patients with-
out baseline total occlusions, respectively. Technical failure was 
observed in seven patients (2.2%), six of whom had a CTO treated.
At discharge, DAPT was prescribed for 12 months in 97.2% of 
patients. Clopidogrel, prasugrel and ticagrelor were prescribed in 
50.8%, 23.2% and 26.0% of patients, respectively.
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Figure 1. One-year cumulative rates of target lesion failure in 
subgroups stratified according to ABSORB II trial inclusion and 
exclusion criteria.
Table 4. Kaplan-Meier estimates of cardiac events in the overall 
population.
Endpoint 6-month 1-year
Target lesion failure 2.6% 4.9%
Target vessel failure 2.6% 5.2%
All deaths 1.6% 1.9%
Non-cardiac death 0.6% 0.9%
Cardiac death 0.9% 0.9%
Any myocardial infarction* 1.3% 1.3%
TVR 2.2% 4.5%
TLR 2.2% 4.2%
Definite/probable ST 1.3% 1.3%
*All MIs were target vessel-related. TLR: target lesion revascularisation; 
TVR: target vessel revascularisation; ST: scaffold thrombosis
Table 5. One-year Kaplan-Meier estimates of cardiac events in 
subgroups stratified according to ABSORB II trial inclusion and 
exclusion criteria.
Endpoint
ABSORB II 
inclusion 
(N=89)
ABSORB II 
exclusion 
(N=230)
p-value
Target lesion failure 2.4% 5.8% 0.19
Target vessel failure 2.4% 6.3% 0.13
All deaths 2.2% 1.7% 0.40
Non-cardiac death 2.2% 0.4% 0.13
Cardiac death 0 1.3% 0.86
Any myocardial infarction* 0 1.8% 0.22
TVR 2.4% 5.3% 0.15
TLR 2.4% 4.9% 0.23
Definite/probable ST 0 1.7% 0.22
*All MIs were target vessel-related. TLR: target lesion revascularisation; 
TVR: target vessel revascularisation; ST: scaffold thrombosis
Table 3. Quantitative angiographic results. 
Angiographic data Lesion-based
Overall population
Baseline reference vessel diameter, mm 2.94±0.45
Final reference vessel diameter, mm 3.00±0.43
Baseline in-scaffold diameter stenosis, % 83.4±12.0
Final in-scaffold diameter stenosis, % 10.3±7.6
Baseline minimal lumen diameter, mm 0.49±0.39
Final minimal lumen diameter, mm 2.69±0.41
Acute gain, mm 2.19±0.53
Non-total occlusions
Baseline reference vessel diameter, mm 2.93±0.46
Final reference vessel diameter, mm 2.99±0.44
Baseline in-scaffold diameter stenosis, % 80.6±10.6
Final in-scaffold diameter stenosis, % 9.76±7.2
Baseline minimal lumen diameter, mm 0.58±0.36
Final minimal lumen diameter, mm 2.69±0.42
Acute gain, mm 2.10±0.51
CLINICAL OUTCOME
Complete clinical twelve-month follow-up information was avail-
able in 310 patients (97.2%). The vital status at one year was 
known in all patients, except one who had moved from Italy.
Over one year after Absorb implantation, TLF was recorded in 
15 patients, occurring between 0-30 days in four (26.7%) patients, 
30-180 days in four (26.7%) patients, and after 180 days in seven 
(46.6%) patients. The Kaplan-Meier cumulative incidences of 
TLF were 2.6% at six months and 4.9% at one year (Table 4). 
Cumulative one-year TLF rates were 2.4% and 5.8% (p=0.19) in 
the subgroups with ABSORB II trial inclusion and exclusion cri-
teria, respectively (Table 5, Figure 1). Patients with one-year TLF 
had significantly lower (1.91±0.38 mm) acute gain than patients 
without TLF (2.16±0.52 mm). In addition, one-year TLF occurred 
at rates of 9%, 5% and 3% among patients with scaffold under-
sizing (n=22), correct sizing (n=201) and oversizing (n=96), 
respectively.
At one year, in the overall population the rate of cardiac death 
was 0.9%, target vessel MI was 1.3%, TLR was 4.2%, TVR was 
4.5% and TVF was 5.2% (Table 4). All cases of cardiac death, MI 
and ST occurred among patients with ABSORB II trial exclusion 
criteria (Table 5).
Four ST were observed: two acute definite, and two sub acute, 
of which one was definite (at 25 days) and one was probable 
(at 26 days). No cases of ST were observed after 30 days. The 
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Kaplan-Meier cumulative ST incidence was 1.3% at one year. 
The first case of acute ST could probably be explained by resid-
ual distal edge dissection and on-treatment high platelet reactivity 
(HPR), as assessed by platelet function testing. The second case 
of acute ST occurred about one hour after PCI in a patient who 
had received the clopidogrel loading dose after the procedure, 
and who, at the time of ST, still had HPR. The subacute definite 
ST could be explained by DAPT cessation five days prior to ST. 
In the subacute probable ST, a scaffold underexpansion could be 
identified.
Discussion
One-year safety and efficacy data of BRS implantation in a real-
world setting for the treatment of unselected populations with 
high proportions of complex coronary lesions typically encoun-
tered in routine clinical practice are still limited10. Indeed, the 
few one-year reports on Absorb outcomes have mostly focused 
on ACS patients7,8 or have selective inclusion criteria14. We 
reported on the one-year clinical outcomes of patients enrolled 
in a prospective all-comers registry of Absorb from a single 
high-volume centre. Our data showed that Absorb were asso-
ciated with reasonably low rates of TLF at one year (4.9%), 
particularly when considering the complexity of patients and 
lesions included. Four cases of definite/probable early (within 
one month) ST were observed, but no cases of late (>1 month) 
thrombosis occurred, resulting in an overall cumulative inci-
dence of 1.3% at one year, quite similar to the incidence reported 
in contemporary all-comers trials and registries of second-gen-
eration DES15,16. For instance, in the ESTROFA-2 registry, the 
cumulative one-year incidences of definite/probable thrombosis 
were 1.3% and 1.4% for zotarolimus- and everolimus-eluting 
stents (EES), respectively16. Finally, the acute gain achieved in 
the present study was high and similar to that reported for DES, 
possibly explaining our favourable results.
Currently, the one-year outcomes of extended Absorb use in 
a real-world setting, including all-comers patients with a worse 
health status and higher proportion of complex lesions, while 
waiving the obligatory intravascular imaging guidance used in 
clinical trials, have been reported only by the ASSURE registry10. 
In this registry, very low rates (<3.0%) of device-related events 
were observed after Absorb implantation in 183 patients and 198 
lesions. One-year rates of TLR and TVR were 2.8% and 2.2%, 
respectively. Moreover, there were no ST cases. The authors stated 
that high scaffold expansion pressure and slight oversizing seem 
to be the key factors in achieving good results. Despite similar 
procedural features, twofold higher incidences of device-related 
events were reported in our registry, most likely due to the more 
complex population treated compared with the ASSURE registry 
(i.e., longer lesions, higher proportions of bifurcations and CTO 
and inclusion of acute MI in our registry). Of note, our one-year 
results were similar to those reported in the first 512 patients of 
the ABSORB EXTEND registry, which reported a 4.9% TVF rate 
in a relatively selected population14.
Recently, the results from the ABSORB II randomised trial 
comparing Absorb (n=335) versus XIENCE (Abbott Vascular) 
(n=166) have shown similar one-year rates of the device-oriented 
events (composite secondary endpoint) between the two devices 
(5% vs. 3%, respectively)5. Of note, patients of the present study 
had similar one-year outcomes to those included in the ABSORB 
II trial, who had relatively simpler lesions (4.9% vs. 5.0% of 
TLF, respectively). Interestingly, only 28% of patients included 
in the present registry had ABSORB II trial inclusion criteria. As 
expected, the one-year TLF rate was twofold higher within the 
group with ABSORB II exclusion criteria (5.8%) compared with 
the group with trial inclusion criteria, although this rate is similar 
to that reported for second-generation DES15.
Unexpectedly high six-month incidences of definite/probable 
ST, 2.1% and 3%, have been reported among all-comers com-
plex patients treated with Absorb in the multicentre GHOST-EU 
(1,189 patients) and in the single-centre Academic Medical Center 
(AMC, 135 patients) registries, respectively6,7. Importantly, in 
both registries, 70-75% of the ST cases occurred within 30 days 
after implantation, suggesting that procedural issues (i.e., resid-
ual dissection, stent malapposition or underexpansion) may be 
the underlying factors triggering most cases. In two out of four 
cases of the AMC registry, a residual distal edge dissection and 
an incomplete expansion of the distal scaffold edge were found. 
Similarly, in two of our four cases a residual distal edge dissec-
tion and underexpansion of the scaffold implanted on a severely 
calcified plaque were documented. Indeed, underexpansion has 
been identified as an important mechanism underlying ST17. 
These observations prompt the need for a more accurate lesion 
selection and for key implantation technique refinements, includ-
ing a more accurate sizing, the systematic use of high-pressure 
post-dilatation with non-compliant balloons, and the more lib-
eral use of intravascular imaging, especially in complex lesions. 
Of note, we observed a lower six-month ST rate (1.3%) com-
pared with the GHOST-EU and AMC registries. This difference 
may be in part attributed to several technical differences, includ-
ing greater post-dilatation rate, higher post-dilatation pressure, 
a more frequent use of intravascular imaging, especially among 
those with more complex lesions, and a slight scaffold oversizing 
in our registry. For instance, in the GHOST-EU registry, post-
dilatation was performed in 49% of overall lesions versus 71.2% 
in our registry, and its use decreased as more experience was 
accumulated. By contrast, our post-dilation rate increased from 
around 60% in the first enrolment period (the cohort included in 
the GHOST-EU) to >95% thereafter.
In the blood flow, the presence of thick struts creates flow-
dynamic alteration, resulting in high shear stress on top of the 
strut and low shear stress behind the strut, which may impact on 
vessel wall healing and trigger platelet aggregation18. In addition, 
in ex vivo studies thick-strut BRS showed higher acute thrombo-
genicity than thin-strut biodegradable polymer metallic EES19. 
Therefore, an adequate platelet inhibition is key to prevent ST. In 
the AMC registry, two out of four cases of ST occurred in patients 
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discontinuing DAPT. In our registry, DAPT-related issues were 
present in three out of four cases of ST. Whether the use of more 
potent antiplatelet agents (prasugrel or ticagrelor) after Absorb 
implantation might decrease ST is plausible but is not known and 
warrants dedicated investigations.
Study limitations
Our study suffers from the obvious limitations of an observational 
real-world registry, including patient selection bias and no inde-
pendent event adjudication. Patients who received metallic stents 
together with Absorb represented about 22% of the overall popu-
lation. To account for the potential influence of these patients on 
outcomes, the device-oriented composite endpoint was reported to 
represent the clinical performance of a new device12. Furthermore, 
the study lacks a control group. Finally, for the present general 
analysis we have not used a dedicated bifurcation QCA algorithm, 
which has recently been recommended20.
Conclusions
The GHOST registry has shown that one-year “real-world” safety 
and efficacy outcomes of Absorb use for the treatment of unse-
lected patients with high proportions of complex lesions are, over-
all, acceptable and comparable to those reported in the literature 
for second-generation DES. Several implantation technique fea-
tures are key to achieve good angiographic and clinical results 
with Absorb, especially in more complex settings. Nevertheless, 
longer follow-up and randomised comparisons versus best-in-class 
DES are needed to confirm the promising results.
Impact on daily practice
The present study provides favourable six-month and one-year 
safety and efficacy outcomes associated with the implantation 
of bioresorbable scaffolds (BRS) in an unselected population 
with a high proportion of complex lesions. These results pro-
vide additional supportive evidence for the use of BRS in daily 
practice under real-world conditions. In particular, the findings 
of the present study suggest a key positive association between 
good clinical results and an optimal implantation technique, 
which should be pursued in daily practice.
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ABSTRACT
OBJECTIVES The study sought to investigate the impact of different computing methods for composite endpoints
other than time-to-event (TTE) statistics in a large, multicenter registry of unprotected left main coronary artery
(ULMCA) disease.
BACKGROUND TTE statistics for composite outcome measures used in ULMCA studies consider only the first event,
and all the contributory outcomes are handled as if of equal importance.
METHODS The TTE, Andersen-Gill, win ratio (WR), competing risk, and weighted composite endpoint (WCE) computing
methods were applied to ULMCA patients revascularized by percutaneous coronary intervention (PCI) or coronary artery
bypass grafting (CABG) at 14 international centers.
RESULTS At a median follow-up of 1,295 days (interquartile range: 928 to 1,713 days), all analyses showed no differ-
ence in combinations of death, myocardial infarction, and cerebrovascular accident between PCI and CABG. When target
vessel revascularization was incorporated in the composite endpoint, the TTE (p ¼ 0.03), Andersen-Gill (p ¼ 0.04), WR
(p ¼ 0.025), and competing risk (p < 0.001) computing methods showed CABG to be significantly superior to PCI in the
analysis of 1,204 propensity-matched patients, whereas incorporating the clinical relevance of the component endpoints
using WCE resulted in marked attenuation of the treatment effect of CABG, with loss of significance for the difference
between revascularization strategies (p ¼ 0.10).
CONCLUSIONS In a large study of ULMCA revascularization, incorporating the clinical relevance of the individual
outcomes resulted in sensibly different findings as compared with the conventional TTE approach. In particular, using
the WCE computing method, PCI and CABG were no longer significantly different with respect to the composite
of death, myocardial infarction, cerebrovascular accident, or target vessel revascularization at a median of 3 years.
(J Am Coll Cardiol Intv 2016;9:2280–8) © 2016 by the American College of Cardiology Foundation.
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P ercutaneous coronary intervention (PCI) isbroadly accepted as an alternative to coronaryartery bypass grafting (CABG) when patients
with unprotected left main coronary artery (ULMCA)
disease present with low-to-intermediate angio-
graphic complexity, which reflects contemporary
guidelines (1) and the results of a plethora of meta-
analyses (2–4), trials (5–8), and registries (9–13).
Over the years, these studies have mostly investi-
gated the comparative efficacy of PCI and CABG
with respect to a primary composite endpoint mixing
disparate cerebrovascular outcomes (i.e., death,
myocardial infarction [MI], and cerebrovascular acci-
dent [CVA] with or without repeat revascularization).
In both randomized and nonrandomized studies,
the rationale behind merging events into a single
composite measure is that of increasing the power of
the comparison between study groups, which is
expected to reduce the chance of untruly negative
results. However, an inherent limitation of using a
composite endpoint in ULMCA studies is that all the
contributory outcomes are handled as if of equal
importance (14). This becomes problematic when the
implications of a relatively soft event (i.e., repeat
revascularization) are contrasted with those of other
disabling nonfatal events (i.e., MI or CVA). In addi-
tion, when composite endpoints are used, time-to-
event (TTE) statistics consider only the first event,
and the outcomes are typically counted in a non-
hierarchical order (i.e., if repeat revascularization
occurs in 1 group before death, only the first con-
tributes to the drop of the corresponding curve for
event-free survival). Finally, death may exert a
competing effect on the risk of nonfatal events (15).
To address these limitations, multiple statistical
approaches have been introduced that consider all
events occurring at follow-up, incorporate their clin-
ical relevance, or account for the competing risk of
death (16–19). The merit of these computing methods,
and their impact on the results of contemporary
studies comparing PCI and CABG for ULMCA disease,
have never been systematically investigated.
The aim of this study was to explore the
attributes of different analytical strategies for
composite endpoints using DELTA (Drug
Eluting stent for LefT main coronary Artery
disease), 1 of the largest contemporary regis-
tries of ULMCA disease, as an example.
METHODS
STUDY DESIGN AND POPULATION. The
methods and definitions of the DELTA regis-
try have been published previously (9).
Briefly, DELTA included all-comers patients
with ULMCA disease treated by PCI with
drug-eluting stents or CABG between April
2002 and April 2006 at 14 international sites
(9). The primary analysis was based on the
composite of death, MI, or CVA, and a sec-
ondary analysis was based on the composite
of death, MI, CVA, and target vessel revas-
cularization (TVR), herein cumulatively
referred as major adverse cardiac or cerebrovascular
events (MACCE). In the present study, the death/MI/
CVA and MACCE results of DELTA were used as a
reference to explore the effect of applying 4
computing strategies other than the conventional
TTE approach, namely: 1) Andersen-Gill; 2) win ratio
(WR); 3) competing risk; and 4) weighted composite
endpoint (WCE). Merits and limitations of these ap-
proaches are summarized in Table 1.
ANDERSEN-GILL. The Andersen-Gill counting pro-
cess is an extension of the traditional Cox model in
which a subject contributes to the risk set for an event
as long as being under observation at the time
the event occurs (20). At variance with the TTE
approach, repeated events are described among all
components of the primary endpoint for the overall
period, assuming equal probability. To avoid too
much weight for related events occurring at the same
time, a 1-day blanking period was applied. The results
were reported as hazard ratio (HR) and 95% confi-
dence interval (CI).
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AB BR E V I A T I O N S
AND ACRONYM S
CABG = coronary artery bypass
grafting
CI = confidence interval
CVA = cerebrovascular
accident
HR = hazard ratio
MACCE = major adverse
cardiac or cerebrovascular
event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
TTE = time-to-event
TVR = target vessel
revascularization
ULMCA = unprotected left
main coronary artery
WCE = weighted composite
endpoint
WR = win ratio
Cardiology, University of Turin, S. Giovanni Battista Molinette Hospital, Turin, Italy; mMount-Sinai Medical Center, New York,
New York; nKlinik für Kardiologie und Angiologie, Elisabeth-Krankenhaus, Essen, Germany; oColumbia University Medical
Center and Cardiovascular Research Foundation, New York, New York; pClinique Pasteur, Toulouse, France; and the qHopital
privé Jacques Cartier, Ramsay Générale de Santé, Massy, France. Dr. Gargiulo has received research grant support from the
European Association of Percutaneous Cardiovascular Intervention and from the CardioPaTh PhD program at Federico II
University of Naples. Dr. Makkar has served as a consultant for Abbott Vascular, Cordis, and Medtronic. Dr. Fajadet has received
educational grant support from Abbott Vascular, Boston Scientific, Medtronic, and Terumo. All other authors have reported that
they have no relationships relevant to the contents of this paper to disclose. Drs. Capodanno and Gargiulo contributed equally
to this work.
Manuscript received June 20, 2016; revised manuscript received July 25, 2016, accepted August 17, 2016.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 2 2 , 2 0 1 6 Capodanno et al.
N O V E M B E R 2 8 , 2 0 1 6 : 2 2 8 0 – 8 Composite Endpoints in Left Main Revascularization Studies
2281
WIN RATIO. The WR is a rank-based approach for
assessing treatment superiority by first ranking and
then pairing patients between treatment groups ac-
cording to different scores, as described by Pocock
et al. (17). To the purpose of the present study, 3
scores were used: 1) the propensity score built by lo-
gistic regression to match patients undergoing PCI or
CABG in the first report of the DELTA registry (9); 2)
the SYNTAX (Synergy between PCI with Taxus and
Cardiac Surgery) score; and 3) the SYNTAX score II
(PCI calculator). A multiple imputation strategy was
used for patients missing data required to compute
their SYNTAX and SYNTAX II-PCI scores, as previ-
ously described (21). In the 3 scenarios (propensity
score, SYNTAX score, and SYNTAX II score), each
patient pair was evaluated to establish whether one
had a death event before the other. If this was not
the case (i.e., both matched patients were alive at
the end of follow-up), the remaining pairs were then
evaluated for the occurrence of CVA, then subse-
quently MI, and finally TVR (the latter in the MACCE
analysis only). When pairing patients by the use of
the SYNTAX and SYNTAX II scores, the treatment
groups were unbalanced in number; therefore, after
ranking, patients in the larger group (i.e., PCI) were
randomly removed if a matching for the score was
not found with the CABG counterpart. When pa-
tients in the PCI group had the same score, a random
one was selected. Once the pairs were created, the
number of “wins” (i.e., pairs where the CABG group
had the event first) were divided by the number of
“losses” (i.e., pairs where the PCI group had the
event first) to provide the WR for PCI versus CABG
(i.e., with a WR >1 indicating PCI as the better
revascularization strategy, and values <1 indicating
PCI as worse). Corresponding 95% CIs and signifi-
cance tests for the WRs were calculated.
COMPETING RISK. A competing risk is an event that
either hinders the observation of the event of interest
or modifies the chance that this event occurs.
Competing risks methods take these issues into ac-
count and, for composite endpoints, allow disen-
tangling the contribution of an intervention on each
type of event (19). In this study, the competing risk of
death for combined nonfatal outcomes (MI/CVA or
MI/CVA/TVR) was accounted using the Fine-Gray
model, with results reported as HR and 95% CI (22).
WEIGHTED COMPOSITE ENDPOINT. The WCE
computing approach extends the traditional TTE
methodology by determining a weight for each of the
nonfatal events (16,23). Briefly, each patient was
attributed a weight of 1.0, which remained unaltered if
no events occurred at follow-up. Patients with
nonfatal events were considered to have their contri-
bution to the group size reduced in weight, such that
the additional weight was lost for subsequent events
and the full (or residual) weight was lost for a death
event. Consistent with a previous study (16), we
assigned weights of 0.47 and 0.38 for CVA and MI,
respectively. For TVR, a Markov decisional analytical
model was designed to identify the cut off value that
offsets the anticipated increase in TVR with PCI
compared with CABG (24). Data from available ULMCA
trials, registries, and meta-analyses were used to
inform the Markov model, which finally assigned a
weight of 0.25 to TVR (2–13). On the basis of the pre-
vious values, patients without events were attributed
a cumulative weighting of 1, patients with CVA had
0.53 (1.00 " 0.47), patients with MI had 0.62 (1.00 "
0.38), and patients with TVR had 0.75 (1.00 " 0.25).
Patient with $2 events during the follow-up period,
if any, were attributed a cumulative weight reduced by
all events.
STATISTICAL ANALYSIS. In the DELTA registry, the
propensity score was calculated by means of a non-
parsimonious multivariable logistic regression model
that included age, gender, diabetes, smoking, family
history of coronary artery disease, unstable angina,
acute MI, chronic kidney disease, left ventricular
ejection fraction, prior CABG, prior PCI, multivessel
disease, and concurrent right coronary artery disease
(9). Propensity score matching was performed 1:1 with
a #0.03 caliper and no replacement. A multivariable
Cox proportional hazards regression model was used
to obtain adjusted analyses, as previously described
(9). Traditional TTE curves for propensity-matched
patients were generated with the Kaplan-Meier
method and compared by the log-rank test. WCE
Kaplan-Meier curves were also plotted. The TTE
risks of death/MI/CVA and MACCE were reported
for PCI versus CABG as HRs and corresponding 95%
CIs. All the analyses were performed using SPSS
version 21.0 (SPSS Inc., Chicago, Illinois) and R
version 2.16 (R Foundation for Statistical Computing,
Vienna, Austria).
TABLE 1 Characteristics of Different Computing Methods for
Composite Clinical Outcomes
Time-to-
Event
Andersen-
Gill
Win
Ratio
Competing
Risk WCE
Uses first event Yes Yes No Yes Yes
Uses all events No Yes No No Yes
Death as most relevant No No Yes No Yes
Uses time-to-event Yes Yes No Yes Yes
Distribute weights No No No No Yes
WCE ¼ weighted composite event(s).
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RESULTS
The DELTA registry comprised a total of 2,775 patients
with ULMCA disease (1,874 treated with PCI and 901
treated with CABG) (9). Baseline clinical characteris-
tics of the study groups before and after propensity
score matching of 602 pairs are reported in Table 2.
The c-statistic of the propensity score model was
0.78, and the Hosmer-Lemeshow p value was 0.38,
indicating good discrimination and calibration,
respectively. At a median follow-up of 1,295 days
(interquartile range: 928 to 1,713 days), in the un-
matched cohort, there were 367 deaths, 108 MIs, 55
CVAs, and 334 TVRs (Table 3). In the matched cohort,
there were 141 deaths, 23 MIs, 18 CVAs, and 102 TVRs,
with only 4 patients experiencing a second event
within the follow-up period (2 patients had MI and
later had TVR, 1 patient had TVR and later had a CVA,
and 1 patient had TVR and later had MI).
TIME-TO-EVENT. Using the TTE approach, there were
no differences between PCI and CABG for death/MI/
CVA in either unadjusted (HR: 1.11; 95%CI: 0.89 to 1.36;
p ¼ 0.38), multivariable-adjusted (HR: 1.11; 95% CI:
0.85 to 1.42; p ¼ 0.47), or propensity score–matched
(HR: 0.91; 95% CI: 0.66 to 1.26; p ¼ 0.57) analyses. By
contrast, CABG was superior to PCI with respect to
MACCE in either unadjusted (HR: 1.58; 95% CI: 1.32 to
1.90; p < 0.0001), multivariable-adjusted (HR: 1.64;
95% CI: 1.33 to 2.03; p < 0.0001), or propensity score–
matched (HR: 1.35; 95% CI: 1.03 to 1.76; p ¼ 0.03) ana-
lyses, driven by a significant difference in TVR.
ANDERSEN-GILL. Applying the Andersen-Gill count-
ing process to the outcomes of the propensity-
matched cohort confirmed the results of the TTE
analysis. In fact, the HRs for death/MI/CVA and
MACCE were 1.01 (95% CI: 0.76 to 1.36; p ¼ 0.93) and
1.41 (95% CI: 1.12 to 1.79; p ¼ 0.04), respectively.
WIN RATIO. In the first scenario (propensity score,
602 pairs), the WRs for death/MI/CVA and MACCE
were 1.04 (95% CI: 0.77 to 1.39; p ¼ 0.82) and 0.75
(95% CI: 0.58 to 0.96; p ¼ 0.025). In the second
scenario (SYNTAX score, 901 pairs), the WRs for
death/MI/CVA and MACCE were 0.98 (95% CI:
0.77 to 1.26; p ¼ 0.90) and 0.79 (95% 0.64 to 0.97;
p ¼ 0.028). In the third scenario (SYNTAX II score,
901 pairs), the WRs for death/MI/CVA and MACCE
were 0.94 (95% CI: 0.73 to 1.20; p ¼ 0.611) and
0.71 (95% CI: 0.58 to 0.88; p ¼ 0.001). Overall, all 3
scenarios—regardless of the score used for pairing—
showed similar results that were consistent with the
TTE analysis, suggesting CABG to represent the best
strategy only when TVR was included in the com-
posite endpoint (Figure 1).
COMPETING RISK. After accounting for the com-
peting risk of death, the HRs for combined nonfatal
events were 0.85 (95% CI: 0.46 to 1.58; p ¼ 0.61)
with respect to MI/CVA and 1.89 (95% CI: 1.33 to
2.68; p < 0.001) with respect to MI/CVA/TVR.
WEIGHTED COMPOSITE ENDPOINTS. Kaplan-Meier
curves using the TTE approach and modified
TABLE 2 Baseline Characteristics of the Propensity-Matched Groups
All
(N ¼ 1,204)
PCI
(n ¼ 602)
CABG
(n ¼ 602)
p
Value
Male 797 (66.2) 406 (67.4) 391 (65.0) 0.36
Age, yrs 66.5 # 11.0 66.3 # 11.5 66.8 # 10.5 0.41
Family history of CAD 327 (27.2) 162 (26.9) 162 (27.4) 0.85
Hypertension 808 (67.1) 398 (66.1) 398 (68.1) 0.46
Dyslipidemia 757 (62.9) 363 (60.3) 363 (65.6) 0.07
Smoker 512 (42.5) 253 (42.0) 253 (43.0) 0.73
Diabetes 374 (31.1) 184 (30.6) 184 (31.6) 0.71
CKD 62 (5.1) 30 (5.0) 32 (5.3) 0.79
Clinical presentation
Unstable angina 532 (44.2) 532 (44.7) 532 (43.7) 0.73
Acute MI 178 (14.8) 178 (15.3) 178 (14.3) 0.63
Previous CABG 47 (3.9) 47 (4.3) 47 (3.5) 0.46
Previous PCI 198 (16.4) 198 (16.1) 198 (16.8) 0.76
LVEF, % 53.2 # 11.3 53.2 # 11.3 53.2 # 11.4 0.96
EuroSCORE, n 5.0 # 3.2 5.0 # 3.6 5.1 # 2.9 0.60
Multivessel disease 1,127 (93.6) 564 (93.7) 563 (93.5) 0.91
RCA disease 841 (69.9) 427 (70.9) 414 (68.8) 0.41
Distal lesion location 777 (64.5) 387 (64.5) 390 (64.8) 0.92
Values are n (%) or mean # SD.
CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease;
EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; LVEF ¼ left ventricular ejection fraction;
MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery.
TABLE 3 Clinical Events in the Unmatched Cohorts
PCI
(n ¼ 1,874)
CABG
(n ¼ 901)
In-hospital events
Cardiac death 33 (1.7) 20 (2.2)
Noncardiac death 8 (0.5) 9 (1.0)
MI 88 (4.7) 213 (23.6)
CVA 4 (0.2) 12 (1.3)
TVR 15 (0.8) 3 (0.3)
MACCE 148 (7.9) 257 (28.4)
Events at follow-up
Cardiac death 140 (7.5) 61 (6.8)
Noncardiac death 124 (6.6) 42 (4.6)
MI 75 (3.7) 33 (4.0)
CVA 30 (1.6) 25 (2.9)
TVR 290 (15.5) 44 (5.2)
MACCE 659 (34.9) 205 (23.5)
Values are n (%).
CVA ¼ cerebrovascular accident; MACCE ¼ major adverse cardiac or cerebro-
vascular event(s); TVR ¼ target vessel revascularization; other abbreviations as in
Table 2.
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Kaplan-Meier curves using WCEs are shown for PCI
and CABG groups of patients matched by propensity
score in Figure 2. Table 4 reports corresponding 1-,
2-, and 3-year Kaplan-Meier estimates of PCI and
CABG as reflected by the TTE and WCE analyses, as
well as the absolute risk differences between PCI
and CABG, and within PCI or CABG by using
different computing methods. The profile of the TTE
and WCE curves for death/MI/CVA was comparable
(Figure 2), with the outcomes of PCI and CABG
diverging during the first 100 days and the differ-
ence attenuating over time until the curves reached
substantial overlap at the end of the follow-up
period. Inclusion of TVR in the composite MACCE
endpoint resulted in CABG being superior to PCI in
the TTE analysis, with a progressive separation of
the curves starting at 9 months (p ¼ 0.003)
(Figure 2). By contrast, this difference was markedly
attenuated and no longer significantly different
(p ¼ 0.10) when the WCE computing method was
used (Table 4). This finding was consistent in a
sensitivity analysis where the weight given to TVR
was 0.30 rather than 0.25 (p ¼ 0.08).
EFFICIENCY OF EVENT USE. The distribution and
use of events according to the TTE, Andersen-Gill,
WR, competing risk, and WCE methods are reported
in Table 5. The Andersen-Gill and WCE methods
included all events, whereas the TTE, WR, and
competing risk methods used fewer than all collected
events.
DISCUSSION
TVR has been for years the driving force of the
observed superiority of CABG over PCI in ULMCA
studies (25). However, the true impact of repeat
revascularization on patient well-being and quality-
adjusted life-years has been questioned (26), and
some interventional cardiologists argue that the
reduction in revascularization with CABG does not
outweigh the increased recovery time of cardiac
surgery, and the higher risk of perioperative CVA
(14). In the DELTA registry, there was evidence of
substantial equipoise between PCI and CABG for
death/MI/CVA, but not for MACCE (9). This is in
line with the results of several meta-analyses
(2–4), randomized clinical trials (5–8), and observa-
tional studies (9–13). On this background, we sought
to explore whether applying alternative methods
for assessing clinical outcomes within composite
endpoints may depotentiate the confounding
effect of TVR, and provide insights on potentially
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FIGURE 1 Win Ratio Estimates Based on Different Matching Criteria
Graphical representation of win ratio (WR) estimates and corresponding 95% confidence intervals (CIs) in patients from the DELTA (Drug
Eluting stent for LefT main coronary Artery disease) registry for the comparison of percutaneous coronary intervention (PCI) and coronary
artery bypass grafting (CABG), based on different matching criteria. The results were confirmative of the corresponding traditional time-to-
event analyses and did not appear to rely on the method chosen for matching (i.e., propensity score, SYNTAX [Synergy between PCI with Taxus
and Cardiac Surgery] score, SYNTAX score II). CVA ¼ cerebrovascular accident; MACCE ¼ major adverse cardiac or cerebrovascular event(s);
MI ¼ myocardial infarction.
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different interpretations to the results of contem-
porary ULMCA studies.
In our analysis, the use of a computing method that
describes repeated events among all components of
the primary endpoint (i.e., Andersen-Gill), prioritizes
all follow-up events (i.e., WR), or accounts for the
potential of death to obscure subsequent nonfatal
outcomes (i.e., competing risk) determined no sig-
nificant deviation from what was obtained by
computing only the first event regardless of its fa-
tality rate (i.e., TTE). By contrast, incorporating the
clinical relevance of the individual outcomes (i.e.,
WCE) resulted in PCI and CABG being nonsignifi-
cantly different at a median of 3 years with respect to
the composite endpoint of MACCE, which comes at
variance with the propensity-matched TTE analysis of
PCI and CABG in DELTA. Overall, these findings imply
that the sizeable impact of TVR on MACCE in ULMCA
studies may be corrected or attenuated by using an
alternative computing approach that accounts for all
events occurring at follow-up and incorporates their
clinical relevance.
To the best of our knowledge, this is the first study
to apply additional methods other than TTE for
assessing clinical outcomes in the context of a study
of PCI or CABG for ULMCA disease. The Andersen-Gill
computing method was introduced in 1982, and is
regarded as a meaningful approach to account for
repeated events within the follow-up period (20).
Indeed, a patient undergoing ULMCA revasculariza-
tion may experience from repeated events during the
subsequent years (i.e., multiple TVRs), but this was
unlikely to happen in the propensity-matched cohort
of the DELTA registry, where the number of repeated
events was low, and the potential for events that
may be under-reported or insufficiently captured
by the extent of follow-up available cannot be
entirely ruled out (9). These considerations may
contribute to explain why in our study, the results of
the Anderson-Gill analysis substantially replicated
those of the TTE analysis, regardless of whether TVR
was incorporated or not in the composite endpoint.
In a population with multiple recurrent events, the
results of the Andersen-Gill method could have been
different. Also notably, the Andersen-Gill method
assumes equal probabilities for first and subsequent
events, which may be an unlikely assumption in a
general population, although this issue has been
likely minimal in this study due to the few number
of repeated events. Alternative models have been
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FIGURE 2 Event-Survival Curves in the Propensity-Matched Cohorts
Survival curves with 95% CIs in PCI and CABG patients from the DELTA (Drug Eluting stent for LefT main coronary Artery disease) registry,
matched by propensity score (602 pairs). Time-to-event freedom from (A) death/MI/CVA and (B) MACCE. WCE curves for (C) death/MI/CVA
and (D) MACCE. WCE ¼ weighted composite endpoint; other abbreviations as in Figure 1.
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described that take the varying nature of risk for
repeated events into account (27).
The WR analysis was introduced in 2012 and so far
investigated only in few clinical scenarios (16,17). This
approach allows prioritizing the hardest outcomes
within a composite endpoint. Interestingly, with the
WR, more of the component events are potentially
included and computed in the analysis, whereas TTE
retains only 1 event. However, because this method
prioritizes and retains events, a number of nonfatal
endpoints experienced by a subject are finally
excluded. This explains why the largest proportion of
events that went unused by the different computing
methods was observed with the WR. Being a rank-
based approach, calculation of the WR requires pair-
ing of patients between treatment groups according to
a risk score. The rationale for pairing patients by pro-
pensity score in our study was that of using one of the
most accepted methodologies to adjust for baseline
imbalances that could have influenced the patient
attribution to a treatment group rather than the other
in a large registry (28,29). For exploratory purposes,
the SYNTAX and SYNTAX II scores were also used to
reflect the underlying risk for the outcomes of interest
and investigate their individual ability and implica-
tion as a matching criterion (21,30). Interestingly, all
the 3 approaches provided similar results, which
highlights the ability of the SYNTAX score and SYN-
TAX score II to capture and possibly maximize the
control of major confounding factors affecting treat-
ment selection in ULMCA disease.
Because death was the most frequent first event in
the DELTA registry, we also explored whether a
competing risk of mortality exists over the composite
of nonfatal outcomes (i.e., MI/CVA and MI/CVA/TVR).
Obviously, if a patient dies, there is no chance to
experience subsequent nonfatal outcomes at later
follow-up. The results of the competing risk analysis
demonstrate that this bias was unlikely to affect the
results of the DELTA registry, and confirmed the
major role of TVR in driving the difference between
PCI and CABG.
Using WCE allows attributing a weight to each type
of event within a composite endpoint, differentiating
its components on the basis of their severity and
clinical impact. In addition, WCE allows including in
the analysis multiple events occurring over time.
Capturing the second event(s) is potentially relevant,
as recurrences have clear implications for both health
care costs and quality of life: this may be true espe-
cially when long-term follow-up is planned and the
majority of events are nonfatal. Even more impor-
tantly, the attribution of a differential weight to each
event addresses the problematic interpretation of
mixing hard and soft outcomes within a composite
endpoint, which frequently occurs in studies of
ULMCA revascularization. Notably, the WCE method
is different from the Andersen-Gill approach that also
considers second events, because in that case, the
weights of all recurrent events are considered equal.
Our hypothesis of the WCE analysis displaying
different results from the TTE computing method
proved to be true once tested in the DELTA registry.
In fact, PCI was no longer associated with worse
outcomes compared with CABG when the lower
prognostic weight of TVR over death, MI and CVA was
taken into account. It can be speculated that
weighting the lower risk of CVA compensates the
excess in TVR with PCI compared with CABG patients
(2). On this background, whether the use of second-
generation drug-eluting stents—poorly represented
in the DELTA registry—further modifies this equation,
moving the pendulum toward PCI, may warrant
future investigation.
The EXCEL (Evaluation of the Xience Everolimus-
Eluting Stent Versus Coronary Artery Bypass Surgery
for Effectiveness of Left Main Revascularization) trial
(NCT01205776) recently compared PCI with second-
generation drug-eluting stents and CABG with respect
to the composite of all-cause death, MI, or stroke at 3
years (31). By contrast, the NOBLE (Nordic-Baltic-
British Left Main Revascularization Study) trial
(NCT01496651) compared PCI with second-generation
drug-eluting stents and CABG with respect to the
5-year combined endpoint of death, stroke, MI, and
new revascularization (PCI or CABG) (32). Incorpora-
tion of repeat revascularization in the primary
endpoint of the NOBLE trial is one of the potential
explanations for the difference in the results and
conclusions of the two trials (31,32). In this context,
challenging the study findings of NOBLE by using
WCE is of interest.
TABLE 4 Kaplan-Meier Estimates of Survival Free From Death/MI/CVA and MACCE
Based on the TTE and WCE Computing Methods
TTE WCE
D
PCI
(A’-A)
D
CABG
(B’-B)
D
TTE
(B-A)
D
WCE
(B’-A’)
PCI
(A)
CABG
(B)
PCI
(A’)
CABG
(B’)
Death/MI/CVA
1 year 91.8% 88.9% 92.5% 89.9% þ0.7% þ1.0% –2.9% –2.6%
2 years 88.1% 86.4% 89.6% 87.9% þ1.5% þ1.5% –1.7% –1.7%
3 years 85.4% 84.9% 86.9% 86.7% þ1.5% þ1.8% –0.5% –0.2%
MACCE
1 year 84.1% 86.0% 89.5% 88.8% þ5.4% þ1.8% þ1.9% –0.7%
2 years 78.4% 82.4% 85.8% 86.4% þ7.4% þ4.0% þ4.0% þ0.6%
3 years 74.0% 80.3% 82.3% 84.9% þ8.3% þ4.5% þ6.3% þ2.6%
TTE ¼ time-to-event; WCE ¼ weighted composite event(s); other abbreviations as in Tables 2 and 3.
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STUDY LIMITATIONS. We acknowledge some impor-
tant limitations of our study. The impact of different
computing strategies for composite endpoints was
tested on a propensity-matched cohort from a large
registry, rather than a randomized clinical trial.
However, the propensity-matched results of the
DELTA registry are in line with existing literature,
including randomized trials, and the impact of con-
founding has been minimized—although not elimi-
nated—by a well-calibrated and discriminative model.
Indeed, using randomized data would have not
necessarily been a better method for investigating the
WR, which requires matching being performed by a
risk score rather than the play of chance. The attri-
bution of weights for the purposes of the WCE anal-
ysis might sound arbitrary. However, for MI and CVA,
we used weights attributed on the basis of a rigorous
consensus (16). Because such weights have not been
determined for TVR, we developed a Markov model,
and based on the available literature, we found a
clinically plausible value of 0.25. A sensitivity anal-
ysis in which the weight was increased at 0.30
showed consistent results. We finally acknowledge
that our results apply to the cohort of patients
included in the DELTA registry, but could have been
different in other settings with a higher rate of
recurrent events or a larger disproportion between
hard and soft endpoints.
CONCLUSIONS
Repeat revascularization is the major contributing
factor to explain the superiority of CABG over PCI for
MACCE in studies of ULMCA disease. In this post hoc
analysis of the DELTA registry, incorporating the
clinical relevance of individual outcomes within
MACCE resulted in a sensible deviation from the re-
sults otherwise obtained by the conventional TTE
analysis, with PCI and CABG being no longer different
at a median of 3 years.
REPRINT REQUESTS AND CORRESPONDENCE: Prof.
Davide Capodanno, Cardio-Thoracic-Vascular Depart-
ment, Division of Cardiology, Ferrarotto Hospital,
University of Catania, Via Citelli 6, Catania 95100, Italy.
E-mail: dcapodanno@gmail.com.
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Stent and Dual Antiplatelet Therapy Duration Comparisons in the
Setting of a Multicenter Randomized Controlled Trial: Can the
Operator Experience Affect the Study Results?
Giuseppe Gargiulo, MD; Dik Heg, PhD; Fabrizio Ferrari, MD; Gianfranco Percoco, MD; Gianluca Campo, MD; Carlo Tumscitz, MD;
Federico Colombo, MD; Andrea Zuffi, MD; Fausto Castriota, MD; Alberto Cremonesi, MD; Stephan Windecker, MD;
Marco Valgimigli, MD, PhD
Background-—Operator experience influences outcomes after percutaneous coronary intervention, but this association in the
controlled setting of a randomized, clinical trial is unclear.
Methods and Results-—We investigated operator-related outcomes (30-day and 2-year efficacy and safety end points) among
patients undergoing percutaneous coronary intervention and randomized to different dual antiplatelet therapy durations and stent
types. A total of 2003 patients were analyzed, and 7 operator groups were compared. The majority of preprocedural and
postprocedural characteristics were imbalanced. The primary end point of the study, the composite of death, myocardial infarction,
or cerebrovascular accidents, did not differ among operators at 30 days or 2 years. There were no significant differences also for
all other individual and composite end points analyzed at 30 days and 2 years, except for 2-year stent thrombosis (P=0.048) and
bleeding events (P=0.022 for Bleeding Academic Research Consortium type 2, 3, or 5). Adjusted comparisons for the main end
points showed slight differences among operators at 30 days, but not at 2 years. There was no interaction of operator with dual
antiplatelet therapy duration (P=0.112) or stent type (P=0.300). Results remained entirely consistent when operators were
stratified by their experience.
Conclusions-—There was a weak signal of heterogeneity across study operators for the 30-day, but not the 2-year, main study
outcomes. No clear effect of operator or operator experience was observed for the comparative efficacy and safety profile of the
randomized stent types or dual antiplatelet therapy duration regimens.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00611286. ( J Am Heart Assoc. 2017;6:
e007150. DOI: 10.1161/JAHA.117.007150.)
Key Words: clinical outcomes • operator • percutaneous coronary intervention • randomized trial
O wing to innovations in device technology and improvedoperator techniques, percutaneous coronary interven-
tion (PCI) has become a widely used and reproducible
therapeutic procedure for the entire spectrum of coronary
artery disease.1,2
Complications during and after PCI have dramatically
declined during the past decades. Yet, periprocedural and
postprocedural ischemic and bleeding adverse events still
occur in a sizable proportion of patients. Although patient-
related factors are known to play a key role for those
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occurrences, it is currently unknown to which degree these
adverse events may be also operator dependent. Overall
number of procedures performed and the operator experience
may affect outcomes of patients undergoing PCI, but this
evidence is mainly based on observational studies.1–11
Randomized, controlled trials have played a major role in
informing the community on the incidence, predictors, and
implications of PCI-related adverse events. However, although
the role of the center is often investigated or at least
accounted for as a source of heterogeneity for the primary
end point results, little is known on the potential impact of
different operators on results of PCI studies. Operator
expertise and the potential impact on outcomes has recently
become a contentious topic for studies assessing access
site.12–16 Whether operators may also affect outcomes of
studies assessing the performance of various stent platforms
or durations of dual antiplatelet therapy (DAPT) after coronary
stenting remains unclear. This analysis is frequently hampered
by lack of proper data collection or inclusion of few cases by
each single operator.
The aim of this study is to investigate whether an
interoperator performance variation may exist in terms of
efficacy and safety in the setting of the all-comer PRODIGY
(Prolonging Dual Antiplatelet Treatment After Grading Stent-
Induced Intimal Hyperplasia Study; NCT00611286) where
patient recruitment was carried out by few interventional
cardiologists, each recruiting a high number of patients.
Methods
The design and main findings of the PRODIGY trial have been
previously reported.17–19 PRODIGY is a 4-by-2 randomized,
multicenter, open-label clinical trial designed to evaluate the
efficacy and safety of prolonging the duration of clopidogrel
therapy for up to 24 months in all-comer patients receiving a
balanced mixture of stents with various anti-intimal hyper-
plasia potency and belonging to both first- and second-
generation drug-eluting stent. Briefly, all-comer PCI patients
(n=2013) were randomly allocated in a 1:1:1:1 fashion to 1 of
4 stent types, including everolimus-eluting stent, paclitaxel-
eluting stent, zotarolimus-eluting Endeavor Sprint stent, or
thin-strut bare metal stent. Patients alive at 30 days (n=1970)
were then randomly allocated to either 6 or 24 months of
DAPT. Selection criteria were broad, reflecting routine clinical
practice. Randomization to 6- or 24-month DAPT was
stratified by center, ongoing ST-segment-elevation myocardial
infarction, presence of diabetes mellitus, and need for
intervening for at least 1 in-stent restenotic lesion. The study
was conducted in accord with the principles of the Declara-
tion of Helsinki. The Ethics Committees of the 3 participating
centers independently approved the protocol, and all partic-
ipants gave written informed consent.
Operators
Interventional cardiologists of the 3 participating centers were
trained operators, each with >500 cumulative PCI volume as
first operator and all involved in the 24-hour on-call duty
schedule at their referral institutions. During the trial, 6
operators performed PCI in the majority of patients enrolled,
with each treating more than 50 patients. For the present
study, each of them will represent an independent group. In
order to explore the effect of PCI experience, operators were
also further stratified in “More Experienced” and “Experi-
enced” based on: (1) number of active years as first operator,
(2) overall PCI volume, and (3) PCI volume/year in the 2 years
before the trial initiation. “More experienced” operators were
Clinical Perspective
What Is New?
• Observational studies suggest that operator volume/expe-
rience influences outcomes after percutaneous coronary
intervention, but this is poorly explored in randomized,
clinical trials, and there is ongoing debate on whether
operator experience may influence reliability of trials
findings.
• We compared operators in PRODIGY (Prolonging Dual
Antiplatelet Treatment After Grading Stent-Induced Intimal
Hyperplasia Study), a 4-by-2 randomized multicenter all-
comer percutaneous coronary intervention trial comparing 4
stent types and 2 dual antiplatelet therapy duration
regimens.
• We observed imbalances in the patient’s and procedural
characteristics and found weak differences in rates of
clinical outcomes.
• After adjustment, there was a weak signal of heterogeneity
across operators for 30-day, but not 2-year, main outcomes.
• When operators were stratified by their experience, no
effect on clinical outcomes was observed.
What Are the Clinical Implications?
• No significant interactions were found between operators or
operator experience and randomized dual antiplatelet
therapy duration or stent type; thus, overall findings of the
trial remained consistent.
• A prolonged dual antiplatelet therapy regimen failed to
improve outcomes, irrespective of the operators.
• The routine collection of high-quality data sets should be
encouraged to evaluate and improve operator competence
and to allow investigation of operator as effect modifier of
findings, especially for short-term outcomes after percuta-
neous coronary intervention, even in the controlled setting
of a randomized, clinical trial.
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those with >5 years, >1000 overall PCI, and >75 PCI/year,
whereas “Experienced” were those with <5 years, 500 to
1000 overall PCI, and <75/year. Few other operators
performed less than 50 procedures each, thus they were
pooled in the seventh group named “other operators” overall
including 142 patients/procedures (Figure 1).
Treatment Protocol and Follow-up
All patients received aspirin (80–160 mg orally indefinitely)
and clopidogrel (75 mg/day) according to the randomization
scheme as follows: for either 6 months in the short DAPT arm
or 24 months in the prolonged DAPT arm irrespective of the
previously implanted stent type or indication for PCI.
The randomized patients returned for study visits at
30 days and then every 6 months up to 2 years. During
follow-up visits, patients were examined and assessed for
adverse events, asked for the antiplatelet therapy compliance,
and 12-lead ECG recordings were obtained.
Study End Points
The primary efficacy end point of the PRODIGY trial was the
composite of death, MI, or cerebrovascular accident, whereas
the key safety end point included Bleeding Academic
Research Consortium (BARC) type 2, 3, or 5 bleeding. The
net effect on the combined ischemic and bleeding complica-
tions was obtained by 2 net adverse clinical event (NACE) end
points that were generated by combining the primary efficacy
end point of death, MI, or cerebrovascular accident with either
the primary safety end point of BARC type 2, 3, or 5 bleeding
or with BARC type 3 or 5 events. Other end points included
each component of the primary efficacy end point, cardio-
vascular death, stent thrombosis (ST) defined on the basis of
the Academic Research Consortium criteria, and BARC type 3
or 5 bleeding. Other safety end points included bleeding
events adjudicated according to the thrombolysis in myocar-
dial infarction and global use of strategies to open occluded
coronary arteries scales. All study end point definitions were
previously reported.
All end points were confirmed on the basis of documen-
tation collected at each hospital and were centrally adjudi-
cated by the clinical events committee, whose members were
unaware of the patients’ treatment-group assignments. The
time frame of interest for the primary end point was from
30 days (ie, after the primary end point randomization) to
24 months.
Statistical Analysis
The PRODIGY trial was designed to enroll at least 1700
patients to detect a 40% reduction in the relative risk of the
primary end point in the 24-month clopidogrel group
compared with 6-month duration of clopidogrel therapy, with
statistical power of >80% at a 2-sided significance level of
0.05. The planned sample size was finally increased up to
2000 to allow for fatalities occurring within the first 30 days,
noncompliance, and loss to follow-up as previously
described.17–19
Categorical variables were expressed as frequency (per-
centage), whereas continuous variables were expressed as
mean and SD. Baseline and procedural characteristics among
503
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Figure 1. Operator procedure distribution.
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the 7 groups were compared using chi-square test for
categorical variables and ANOVA F test for continuous
variables. Crude events among groups were compared with
likelihood ratio P values testing the shared frailty effect across
operators using an inverse gamma distribution in Weibull
time-to-event regression. Estimation of the cumulative major
adverse cardiovascular event (MACE) rate, as well as of BARC
bleeding and NACE, was performed by the Kaplan–Meier
method.
In order to compare clinical outcomes among groups,
hazard ratios with 95% confidence intervals were calculated
from adjusted Weibull time-to-event regression comparing
each operator (operator 2 to operator 6) versus operator 1
who was elected as reference because of the highest number
of patients/procedures performed. The adjustment was
performed including the following variables: age, sex, body
mass index, hypertension, dyslipidemia, current smoking,
family history of coronary artery disease, previous PCI,
previous coronary artery bypass graft, peripheral arterial
disease, creatinine clearance, left ventricular ejection fraction,
acute coronary syndrome, femoral access, multivessel PCI,
PCI performed by 2 or more operators (versus 1 operator
only), 1 or more complex lesions, 1 or more restenotic lesions,
randomized stent (4 categories), total stent length, and
CRUSADE (Can Rapid risk stratification of Unstable angina
patients Suppress ADverse outcomes with Early implementa-
tion of the ACC/AHA Guidelines) score.
Proportional-hazards assumption was tested on the basis
of Schoenfeld residuals after fitting a Cox regression model
for each of the 4 end points (P≥0.7 in each case).
Univariate analysis was conducted to explore whether
operator category may predict 2-year MACE, BARC type 2, 3,
or 5, or NACE.
Interaction testing was performed to determine whether
the effect of randomization to DAPT duration or to stent type
on the primary end point was consistent irrespective of
operator category or volume of PCI performed by each
operator.
To explore the effect of operator experience, all the
analyses were also computed contrasting “more experienced”
versus “experienced” operators on study end points.
A 2-sided probability value of <0.05 was considered
significant. All analyses were performed with Stata Statistical
Software (release 14; StataCorp LP, College Station, TX).
Results
A total of 2013 patients were recruited into the study and
randomly assigned to 1 of the 4 stent types. Ten patients
withdrew consent. Thirty-three (1.6%) patients died within
30 days, thus 1970 patients were randomly allocated at
1 month to undergo 24-month versus 6-month duration of
clopidogrel therapy. Seven operator groups were created by
matching cases to first treating operator as follows: operator
1 (n=503), operator 2 (n=425), operator 3 (n=373), operator 4
(n=306), operator 5 (n=157), operator 6 (n=97), and other
operators including 10 operators performing each less than
50 procedures and cumulatively recruiting 142 patients into
the study (Figure 1).
Baseline and Procedural Characteristics
Table 1 reports baseline and procedural characteristics
according to the operator groups. There were notable
imbalances across operators that were mainly driven by the
other operators group, which recruited patients who were
slightly younger, more frequently affected by stable coronary
artery disease (one fourth of patients in this group presented
acute coronary syndrome as compared with three fourths of
patients in all other operator groups), with preserved renal
and left ventricular function, and lower bleeding risk. Operator
1 treated the highest rate of past MI or ST-segment-elevation
myocardial infarction patients or those requiring more
frequently left main coronary artery intervention, or present-
ing with the mean lowest mean left ventricular ejection
fraction (Table 1). On the other hand, operator 6 treated the
highest number of lesions per procedure, with at least 1
complex lesion per procedure as well as more patients with
past coronary artery bypass graft. Multivessel or saphenous
vein graft intervention was more frequently accomplished by
operator 2, whereas operator 5 performed the lowest number
of multivessel/multilesion interventions (Table 1). Radial
access was the default access site across all operators.
Clinical Outcomes
At 30 days, there were no significant differences among
operator groups for any analyzed individual or composite end
points (Table 2). The highest rate of the primary end point was
observed for operator 6, who experienced, however, the
lowest number of any or access-site bleeding events.
Operator 2 had the highest rate of cerebrovascular accident,
BARC bleeding, as well as NACE. Operator 1 was the one
experiencing the lowest rate of death and cerebrovascular
accident, whereas operator 5 was associated with the lowest
rate of MACE and NACE. Operator 1 and 2 were associated
with the highest rate of access-site–related bleeding
(Table 2). In the group of other operators, none of the
patients died or had stroke or ST or target vessel revascu-
larization or bleeding, and all events within 30 days were MI.
At 2-year follow-up, there were no significant differences
among operators for the primary end point as well as the
majority of secondary end points, except for ST, mainly driven
by no event in the other operator group and for BARC type 2,
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3, or 5, mainly driven by difference for BARC 2 across
operator groups (Table 3). ST was more frequently observed
with operator 2, whereas operator 5 was associated with the
highest rate of overall and most severe bleeding events. On
the other hand, operator 5 was associated with the lowest
rate of MI, ST, and target vessel revascularization. Operator 6
was the one with highest rate of the primary end point, as well
as NACE, predominantly driven by the highest rates of death
and MI (Table 3), whereas the primary end point was lowest
for operator 3. Overall, the group of other operators who
treated more stable patients was associated with lowest rates
of death, bleeding, and composite end points (Table 3).
Adjusted comparisons for the main efficacy and safety end
points at 30 days and 2 years are shown in Table 4. At
30 days, MACE and NACE were significantly increased with
operator 2 compared with operator 1. Trends toward higher
risk of MACE (49–56%) and NACE (45–52%) were also noted
for Operator 4 and 6 as compared with operator 1, mainly
attributable to increased risk of ischemic events. At 2 years,
there was, however, no notable difference in operators’
Table 2. Clinical Outcomes at 30 Days
Event
Operator
1 (N=503)
Operator
2 (N=425)
Operator
3 (N=373)
Operator
4 (N=306)
Operator
5 (N=157)
Operator
6 (N=97)
Other
Operators
(N=142) P Value
P Value
Without
Other
Operators
Primary efficacy end point
All-cause death, MI, or CVA 46 (9.1) 54 (12.7) 35 (9.4) 38 (12.4) 13 (8.3) 13 (13.4) 18 (12.7) 0.420 0.401
Secondary efficacy end points
All-cause death or MI 45 (8.9) 47 (11.1) 34 (9.1) 37 (12.1) 12 (7.6) 12 (12.4) 18 (12.7) 1.000 1.000
All-cause death 4 (0.8) 6 (1.4) 11 (2.9) 6 (2.0) 4 (2.5) 2 (2.1) 0 (0.0) 0.211 0.279
Cardiovascular death 4 (0.8) 6 (1.4) 11 (2.9) 6 (2.0) 4 (2.5) 2 (2.1) 0 (0.0) 0.211 0.279
Stroke or TIA 1 (0.2) 8 (1.9) 2 (0.5) 1 (0.3) 3 (1.9) 1 (1.0) 0 (0.0) 0.057 0.074
Myocardial infarction 43 (8.5) 43 (10.1) 27 (7.3) 32 (10.5) 8 (5.1) 10 (10.3) 18 (12.7) 1.000 1.000
Definite ST 5 (1.0) 4 (0.9) 1 (0.3) 4 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 1.000 1.000
Definite or probable ST 7 (1.4) 6 (1.4) 4 (1.1) 7 (2.3) 1 (0.6) 1 (1.0) 0 (0.0) 1.000 1.000
Definite probable or possible ST 7 (1.4) 6 (1.4) 5 (1.4) 7 (2.3) 1 (0.6) 1 (1.0) 0 (0.0) 1.000 1.000
TVR 6 (1.2) 5 (1.2) 3 (0.8) 4 (1.3) 1 (0.7) 0 (0.0) 0 (0.0) 1.000 1.000
Safety end points
Access-site related bleeding* 8 (1.6) 7 (1.6) 2 (0.5) 2 (0.7) 1 (0.6) 0 (0.0) 1 (0.7) 0.065 0.047
BARC classification
Key safety end point—type 2, 3, or 5 12 (2.4) 10 (2.4) 5 (1.4) 5 (1.6) 3 (2.0) 0 (0.0) 0 (0.0) 1.000 1.000
Type 3 or 5 4 (0.8) 4 (0.9) 2 (0.5) 2 (0.7) 1 (0.7) 0 (0.0) 0 (0.0) 1.000 1.000
TIMI classification
Minor 3 (0.6) 1 (0.2) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1.000 1.000
Major 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0.145 0.153
Minor or major 3 (0.6) 1 (0.2) 2 (0.5) 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1.000 1.000
GUSTO classification
Moderate 2 (0.4) 3 (0.7) 1 (0.3) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0) 1.000 1.000
Severe 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0.145 0.153
Moderate or severe 2 (0.4) 3 (0.7) 1 (0.3) 2 (0.7) 1 (0.7) 0 (0.0) 0 (0.0) 1.000 1.000
Net clinical adverse events (NACE)
All-cause death, MI, CVA, or BARC 2, 3, or 5 58 (11.5) 63 (14.8) 40 (10.7) 41 (13.4) 16 (10.2) 13 (13.4) 18 (12.7) 1.000 1.000
All-cause death, MI, CVA, or BARC 3 or 5 50 (9.9) 58 (13.6) 37 (9.9) 39 (12.7) 14 (8.9) 13 (13.4) 18 (12.7) 0.453 0.419
Likelihood ratio P value testing the shared frailty effect across operators using an inverse gamma distribution in Weibull time-to-event regression. BARC indicates Bleeding Academic
Research Consortium; CVA, cerebrovascular accident; GUSTO, global use of strategies to open occluded coronary arteries; MI, myocardial infarction; ST, stent thrombosis; TIA, transient
ischemic attack; TIMI, thrombolysis in myocardial infarction; TVR, target vessel revascularization.
*Access-site related bleeding analyzed with mixed effects logistic regression.
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performances. Operator category did not predict 2-year MACE
(P=0.74), BARC type 2, 3, or 5 (P=0.31), or NACE (P=0.66 and
0.85 for NACE with BARC 2, 3, or 5, and BARC 3 or 5,
respectively).
Operator Interaction With DAPT and Stent
Randomized Groups for the Primary Outcome
When the primary end point of all-cause death, MI, or
cerebrovascular accident was stratified according to the
operators, no significant interaction emerged between oper-
ator and DAPT randomization (P=0.112; Figure 2), and this
was confirmed at 6-month landmark analysis (from 6 months
to 2 years: P=0.425; Figure S1).
Similarly, interaction testing between operator and stent
type (P=0.300; Figure 2) was negative. Also, no interaction
was observed between operator and DAPT or randomized
stent at stratified analysis by operator volume (Figures S2 and
S3). Three-way interaction among operator-randomized DAPT
duration-randomized stent was similarly negative (P=0.210).
Table 3. Clinical Outcomes at 2 Years
Event
Operator
1 (N=503)
Operator
2 (N=425)
Operator
3 (N=373)
Operator
4 (N=306)
Operator
5 (N=157)
Operator
6 (N=97)
Other
Operators
(N=142) P Value
P Value
Without
Other
Operators
Primary efficacy end point
All-cause death, MI, or CVA 108 (21.5) 93 (21.9) 64 (17.2) 61 (20.0) 28 (17.8) 25 (25.8) 24 (17.0) 1.000 1.000
Secondary efficacy end points
All-cause death or MI 100 (19.9) 83 (19.5) 62 (16.6) 58 (19.0) 28 (17.8) 24 (24.8) 23 (16.2) 1.000 1.000
All-cause death 40 (8.0) 36 (8.5) 33 (8.8) 21 (6.9) 16 (10.2) 11 (11.4) 6 (4.3) 1.000 1.000
Cardiovascular death 29 (5.8) 23 (5.5) 23 (6.2) 10 (3.3) 10 (6.4) 8 (8.4) 3 (2.2) 1.000 1.000
Stroke or TIA 14 (2.9) 15 (3.6) 6 (1.7) 4 (1.4) 5 (3.2) 3 (3.2) 1 (0.7) 0.386 0.486
Myocardial infarction MI 75 (15.1) 61 (14.5) 38 (10.3) 41 (13.5) 13 (8.4) 15 (15.9) 18 (12.7) 0.349 0.300
Definite ST 11 (2.2) 10 (2.4) 2 (0.5) 6 (2.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.042 0.126
Definite or probable ST 18 (3.7) 17 (4.1) 5 (1.4) 9 (3.0) 1 (0.6) 3 (3.3) 0 (0.0) 0.048 0.195
Definite probable or possible ST 35 (7.1) 31 (7.4) 15 (4.1) 14 (4.7) 6 (3.9) 6 (6.5) 3 (2.2) 0.158 0.310
TVR 70 (14.4) 47 (11.5) 50 (14.1) 26 (8.7) 11 (7.4) 9 (10.0) 10 (7.1) 0.054 0.115
Safety end points
BARC classification
Key safety end
point—type 2, 3, or 5
39 (8.0) 40 (9.7) 25 (7.0) 16 (5.4) 16 (10.6) 5 (5.7) 1 (0.7) 0.022 0.421
Type 3 or 5 13 (2.7) 20 (4.9) 15 (4.2) 8 (2.7) 7 (4.6) 2 (2.3) 1 (0.7) 0.340 0.494
TIMI classification
Minor 9 (1.9) 7 (1.7) 6 (1.7) 1 (0.3) 1 (0.7) 2 (2.3) 0 (0.0) 1.000 1.000
Major 3 (0.6) 8 (2.0) 5 (1.4) 3 (1.0) 4 (2.6) 0 (0.0) 1 (0.7) 0.467 0.449
Minor or major 12 (2.5) 15 (3.7) 11 (3.1) 4 (1.3) 5 (3.3) 2 (2.3) 1 (0.7) 1.000 1.000
GUSTO classification
Moderate 8 (1.6) 9 (2.2) 8 (2.2) 5 (1.7) 2 (1.4) 2 (2.3) 0 (0.0) 1.000 1.000
Severe 5 (1.0) 9 (2.2) 5 (1.4) 3 (1.0) 4 (2.6) 0 (0.0) 1 (0.7) 1.000 1.000
Moderate or severe 13 (2.7) 18 (4.4) 13 (3.7) 8 (2.7) 6 (4.0) 2 (2.3) 1 (0.7) 1.000 1.000
Net clinical adverse events (NACE)
All-cause death, MI, CVA,
or BARC 2, 3, or 5
136 (27.1) 120 (28.3) 77 (20.6) 72 (23.6) 40 (25.5) 28 (29.0) 24 (17.0) 0.120 0.227
All-cause death, MI, CVA,
or BARC 3 or 5
116 (23.1) 101 (23.8) 69 (18.5) 66 (21.6) 32 (20.4) 26 (26.9) 24 (17.0) 1.000 1.000
Likelihood ratio P value testing the shared frailty effect across operators using an inverse gamma distribution in Weibull time-to-event regression. BARC indicates Bleeding Academic
Research Consortium; CVA, cerebrovascular accident; GUSTO, global use of strategies to open occluded coronary arteries; MI, myocardial infarction; ST, stent thrombosis; TIA, transient
ischemic attack; TIMI, thrombolysis in myocardial infarction; TVR, target vessel revascularization.
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Operator Experience
When analyses were conducted comparing “More experi-
enced” with “Experienced” operators, no significant effect
emerged on clinical outcomes at 30-day or 2-year and no
interaction was noted with respect to randomized DAPT
duration or stent type (Tables S1 through S4; Figures S4 and
S5).
Discussion
The present study explored the interoperator impact on
clinical outcomes of patients undergoing PCI in the setting of
a randomized, clinical trial. Across each operator stratum,
there were several differences for patient and procedural
characteristics, making interpretation of unadjusted clinical
outcomes problematic. After adjustment, there were some
differences for 30-day outcomes, mainly owing to different
risks of ischemic events across operators. However, adjusted
analyses failed to show heterogeneous outcomes across
operator groups at 2 years, and operators did not impact on
the comparative efficacy or safety profile of different DAPT
durations or stent types. Therefore, the present analysis
provides reassurance that operator per se or operator
experience/operator volume was not a significant effect
modifier of our study findings.
The optimal duration of DAPT after PCI is a matter of
ongoing discussion, attributed to a clear trade-off between
benefits and risks. A prolonged DAPT regimen prevents
recurrent or new MI related or not to stent thrombosis.
Furthermore, procedural complexity has emerged as an
important driver of DAPT duration, with prolonged DAPT
being beneficial in more-complex procedures.20 Accordingly,
it is plausible that different operators with different technical
skills, expertise, and case volume, as well as different
procedural tactics (predilatation and postdilatation, duration
and pressure of dilatation, stent implantation sizing and
technique, use of intravascular imaging modalities, etc) may
be associated with different clinical outcomes. In this respect,
however, we did not find significant interaction between
operator, type of stent, and DAPT regimen, suggesting that
our overall study results were consistent across operators,
which has notable implications for the external validity of our
findings. There was, however, signal that operator may impact
events/nr of 
patients 
events/nr of 
patients 
Hazard Ratio 
(95% CI) p-value
interaction  
p-value 
Randomized DAPT*: Short DAPT Long DAPT Long vs Short 
All-cause Death, MI or CVA from 30 to 720 days 0.112 
Operator 1 36/254 28/245 0.79 (0.48-1.29) 0.340 
Operator 2 16/206 27/213 1.68 (0.91-3.12) 0.099 
Operator 3 17/186 14/176 0.87 (0.43-1.76) 0.692 
Operator 4 16/150 7/150 0.41 (0.17-1.01) 0.052 
Operator 5 7/ 75 10/ 78 1.42 (0.54-3.73) 0.476 
Operator 6 5/ 45 8/ 50 1.51 (0.49-4.63) 0.468 
Other Operators*** 3/ 71 4/ 71 1.36 (0.31-6.10) 0.684 
Randomized to any DES** or BMS: DES** BMS DES vs BMS 
All-cause Death, MI or CVA from 0 to 720 days 0.300 
Operator 1 75/383 33/120 0.69 (0.46-1.04) 0.079 
Operator 2 65/316 28/109 0.80 (0.51-1.24) 0.314 
Operator 3 45/264 19/109 0.98 (0.57-1.67) 0.937 
Operator 4 49/222 12/ 84 1.59 (0.85-2.99) 0.150 
Operator 5 20/118 8/ 39 0.79 (0.35-1.80) 0.575 
Operator 6 19/ 81 6/ 16 0.61 (0.24-1.52) 0.287 
Other Operators*** 20/117 4/ 25 1.05 (0.36-3.06) 0.936 
Figure 2. Stratified effect of operators on the primary comparisons of the primary outcome in the PRODIGY trial. Hazard ratios from Weibull
time-to-event regression on the composite of all-cause death, MI, or CVA comparing the randomized DAPT durations or randomized stents and
testing for effect modification by the Operators n (1–6). *Short DAPT randomized to 6 months of DAPT, Long DAPT randomized to 24 months of
DAPT. **ZES-S (zotarolimus-eluting Endeavor Sprint stent), PES (paclitaxel-eluting stent), and EES (everolimus-eluting stent) combined. ***The
Other Operators are shown for completeness, but not used for interaction testing. BMS indicates bare metal stent; CVA, cerebrovascular
accidents; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; MI, myocardial infarction.
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on outcomes in the early period after PCI when indeed
operator and procedural factors are more likely to play a role.
On the contrary, at 2 years, we did not observe significant
differences across operator groups, likely as a reflection that
procedural technicalities adopted by each operator have
limited impact on long-term outcomes.
Physician competence is a critical component in the
provision of optimal health care. All physicians must have the
appropriate training, fund of knowledge, clinical decision
making, and technical skills. In the setting of PCI, operators
must perform these procedures at a requisite level of
proficiency and competency.
Patients treated by high-volume operators and at high-
volume centers have been shown to experience a higher rate
of procedural success and lower rates of mortality and
postprocedural complications.1–11 As a consequence, stan-
dards of assistance have been recommended for PCI oper-
ators.1,2,6 Recently, in an observational study, operator
experience has emerged as an important prognostic factor
in a complex intervention, such as left main PCI, where
patients treated by high-volume and experienced operators
had better outcomes.9 Operators were shown to impact on
outcomes in the setting of different complex procedures, such
as chronic total occlusions,21 the implantation of specific
devices as bioresorbable vascular scaffolds,22 and structural
interventions.23
During the past decades, the cardiology community has
been largely informed in terms of clinical practice by the
results of many randomized trials. In order to achieve enough
of a number of observations, and to reduce the bias related to
single-center studies, multicenter studies are frequently
performed and currently regarded as the study design allowing
for the greatest external validity. Multicenter PCI studies can,
however, also critically depend on expertise and proficiency of
the multiple operators involved. Although subgroup analyses
are frequently performed to explore the consistency of study
results across different geographical locations, and sometimes
randomization is stratified by center, the role of each operator
within each center is almost never appropriately investigated.
Operators are very rarely matched with the corresponding
treated patients within each multicenter study, and even when
this information is available, each study operator generally
contributes with a limited number of patients within each
study. There are, however, relevant exceptions. Interoperator
variation was previously investigated in 1071 patients enrolled
in the TAPAS (Thrombus Aspiration During Percutaneous
Coronary Intervention in Acute Myocardial Infarction Study)
trial.16 The primary end point of the study, which was
myocardial blush grade 3, was analyzed across 6 operator
groups, and it was shown to significantly differ across
operators after adjustment for baseline and procedural
imbalances. This post-hoc analysis suggested that, even in a
controlled setting, significant interoperator variation might
exist in the efficacy of primary PCI.16 Interestingly, however,
no data on patient outcomes were available across operators
at long-term follow-up.
More recently, the operator experience, and its potential
impact on outcomes, has become a matter of debate in the
comparison of radial versus femoral access site for PCI. In the
MATRIX-Access (Minimizing Adverse Haemorrhagic Events by
TRansradial Access Site and Systemic Implementation of
angioX),12 the benefit of radial versus femoral access
appeared consistent across major patient subgroups including
tertiles of the centers’ annual volume of PCI. However,
positive tests for trend were found across tertiles of the
centers’ percentage of radial PCI for both co-primary end
points and all-cause mortality at 30 days, suggesting a more-
pronounced benefit of radial access in centers that did 80% or
more-radial PCI,12 and this generated great interest.13–15,24,25
Whether these differences will remain detectable also at
longer-term follow-up remains currently unclear.
All together, our results are consistent with previous
observations that operators may impact on procedural or PCI
short-term (ie, 30-day) clinical outcomes whereas such an
effect seems to vanish at time frames more remote from the
index intervention. This may reflect the existence in
contemporary practice of well-standardized percutaneous
techniques and improved biomedical technologies for the
treatment of patients with coronary artery disease. In this
context, factors, which are largely unrelated to the revascu-
larization procedure per se, such as adherence to and
optimal titration of secondary prevention medication as well
as comorbidities and disease progression, may affect long-
term outcomes more than procedural technical features. On
the other hand, the effect of operator on PCI outcomes
seemed to be, at best, minimal, and when operators were
stratified for their volume/experience before the trial initi-
ation, this effect disappeared. The absence of a definite
experience-outcome relationship for individual operators
should not be regarded as surprising in such a context
where centers and operators were at high volume of PCI.
However, volume per se might not be an appropriate marker
of quality (high volume may not correspond to high quality
because practice/volume by itself is of little value if the
procedure is not properly executed).2,26
Therefore, our current findings extends previous results of
the PRODIGY trial by suggesting that the impact of stent
selection or DAPT durations on ischemic and bleeding
outcomes remained consistent across study operators.
Limitations
This is a post hoc analysis sharing limitations of other not
prespecified and not powered analyses. PRODIGY is a
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3-center trial, and it cannot be excluded that, in larger trials
with many different centers and operators involved, a certain
degree of interoperator variation may exist and may have a
significant interaction with safety and efficacy end points.
Although the comparisons between operators were
adjusted for main variables, it cannot be excluded that other
confounders may affect these findings.
The number of events in some cases (ie, stroke or ST) was
too low to allow an appropriate adjusted comparison among 6
or 7 groups.
Conclusions
After adjustment for multiple patient- and procedure-related
imbalances, there was a weak signal of heterogeneity across
individual study operators for the 30-day, but not the 2-year,
main study outcomes, and no differences were observed across
operators’ past PCI volumes. Accordingly, no clear effect of the
operator was observed for the comparative efficacy and safety
profile of the randomized stent types or DAPT duration
regimens in our study, which has notable implications for the
external validity of the PRODIGY study results.
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Background: The impact of coronary artery disease (CAD) extension/complexity on outcomes and on the compar-
ative benefits/risks of zotarolimus-eluting stent (ZES) versus bare-metal stents (BMS) remains unclear in pa-
tients at high risk of bleeding or thrombosis or at low restenosis risk.
Methods:We performed a post-hoc analysis of the ZEUS trial. The impact of coronary anatomic complexity mea-
sured by the SYNTAX score on the differences in outcomes following ZES and BMS was assessed at 1 year.
Results: The mean SYNTAX score was 16.3 ± 13.1 with a median of 12 (IQR: 7 to 22). We stratified patients ac-
cording to SYNTAX tertiles (0–8: n = 563; N8–19 n = 532; N19: n = 511), and observed that the higher the
score, the correspondingly higher was the rate of the primary endpoint of major adverse cardiovascular events
(MACE) and other ischemic events, but not bleeding after adjustment. The superior efficacy of ZES versus BMS
for MACE was consistent across SYNTAX tertiles (tertile 1: HR 0.71, 95% CI 0.44–1.13; tertile 2: HR 0.71, 95% CI
0.46–1.09; tertile 3: HR 0.83, 95% CI 0.61–1.10) without significant heterogeneity (p for trend = 0.55). This
between-groups difference mainly reflected a reduction in MI and TVR without effect on mortality. There was
no significant interaction between the SYNTAX score and allocated stent typewith respect to ischemic and bleed-
ing endpoints.
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1. Introduction
The Synergy Between Percutaneous Coronary Intervention with
Taxus and Cardiac Surgery (SYNTAX) score is an angiographic scoring
system that was developed to quantify the complexity and extension
of coronary artery disease (CAD) in patients undergoing coronary revas-
cularization. It has become an important tool to assist in deciding the
optimal revascularization strategy in patients with complex CAD
[1–4]. The score has been found to predict ischemic event recurrences
and mortality during long-term follow-up percutaneous coronary
intervention (PCI) in various patient populations, including all-comers,
those with multivessel/complex disease, for whom the score was origi-
nally developed, or with ST-segment elevation myocardial infarction
(STEMI) [2,5–8].
The ZEUS trial included patients at high bleeding risk, high throm-
botic risk or low restenosis risk to assess the efficacy and safety of
drug-eluting stent (DES) implantation using a stent with a biocompati-
ble polymer and fast drug-eluting characteristics, instead of a bare-
metal stent (BMS), followed, in all patients, by an abbreviated, tailored
dual antiplatelet therapy (DAPT) [9]. In this context of selected patients,
it remains unclear if CAD extension and/or complexity impacts on out-
comes in terms of ischemic and bleeding risks and how it may affect
the comparative safety and effectiveness of the two allocated stent
types.
2. Methods
2.1. Study population
The design andmain study findings of the ZEUS trial (NCT01385319)were previously
reported [9–11]. Briefly, itwas amultinational, randomized single-blinded trial whichwas
conducted at 20 sites in 4 European countries (Italy, Switzerland, Portugal, and Hungary)
and included patients with at least 1 qualifying criterion among the pre-specified uncer-
tain DES recipients (high bleeding risk, high thrombosis risk or low restenosis risk) under-
going elective, urgent, or emergent PCI with intended stent implantation. Patients were
randomly allocated 1:1 to receive Endeavor Sprint zotarolimus-eluting stent (E-ZES) or
a thin-strut (thickness b 100 mm) BMS followed by a DAPT regimen independent of
stent type, but clinical-profile–driven.
The study was conducted in accordance with the principles of the Declaration of Hel-
sinki. The ethics committees of all participating centers independently approved the pro-
tocol, and all participants gave written informed consent.
2.2. Devices and therapy
The E-ZES (Medtronic Vascular, Minneapolis, Minnesota) is a cobalt-based alloy stent
(91-μm strut thickness) with a phosphorylcholine polymer (4.8 μm) loaded with
zotarolimus at a dose concentration of 10-μg/mm stent length. Approximately 95% of
the zotarolimus is eluted from the stent within 15 days of implantation, although drug
concentrations within surrounding vascular tissue may be detected as late as 30 days
after stent deployment. All commercially available thin-strut BMS were allowed by the
protocol.
All patients received aspirin (160 to 325mg orally or 500mg intravenously as a load-
ing dose and then 80 to 160 mg orally per day) and clopidogrel (300 to 600 mg orally as
loading dose followed by 75 mg/day), or prasugrel (60 mg as loading dose followed by
10 or 5 mg/day) or ticagrelor (180 mg as loading dose followed by 90 mg twice a day).
Duration of antiplatelet therapywaspre-specifiedon the basis of the inclusion criteria.
Patients at high bleeding risk had a pre-specified 30-day DAPT regimen. Patients at high
thrombosis risk had a pre-specified tailored duration of therapy on the basis of the specific
condition conferring the high risk of thrombosis. This included a single antiplatelet regi-
men for patients intolerant of aspirin or available P2Y12 inhibitors, and a 30-day regimen
in stable patients, or 6 to 12 months in unstable patients, in low restenosis risk patients.
As anticoagulation during PCI, unfractionated heparin or bivalirudin were used ac-
cording to guidelines.
Staged procedures were allowed by protocol; in patients allocated to a 30-day course
of DAPTwho underwent staged intervention(s), therapy had to be prolonged or restarted
for 30 additional days.
2.3. Study endpoints and follow-up
The aim of the ZEUS trial was to assess whether ZES implantation followed by
a shorter than the currently recommended course of DAPT, tailored to the patient's clinical
profile (tailored DAPT) and independent of stent type, would decrease the incidence of
12-month major adverse cardiovascular events (MACE), including all-cause death, non-
fatal myocardial infarction (MI), or any target vessel revascularization (TVR), compared
with BMS [9].
Secondary efficacy endpoints included each component of the primary endpoint, car-
diovascular death, the composite of death and MI, the composite of cardiovascular death
and MI; target lesion revascularization (TLR), ischemic stroke, and Academic Research
Consortium–defined stent thrombosis (ST). Type of MI was also adjudicated according
to the third universal definition of MI. Secondary safety endpoints comprised bleeding
events according to both Bleeding Academic Research Consortium (BARC) and Thrombol-
ysis InMyocardial Infarction (TIMI) classifications. Study endpoint definitionswere previ-
ously reported [9]. All endpoints were confirmed on the basis of the documentation
collected at each site and were centrally adjudicated by the clinical events committee,
whose members were unaware of treatment assignment.
Thirty-day and 6- and 12-month follow-up visits were performed according to study
protocol to evaluate potential adverse events and compliance with medications and to re-
cord a 12‑lead electrocardiogram.
2.4. SYNTAX score
A single senior interventional cardiologist (AP), blinded to clinical data, clinical pre-
sentation, and outcomes calculated the SYNTAX score at baseline for each patient by scor-
ing all coronary lesions with a diameter stenosis ≥50%, in vessels ≥1.5 mm, using the
SYNTAX score algorithm available online (http://www.syntaxscore.com).
2.5. Statistical analysis
Categorical variables were expressed as frequency and percentage, and compared
using the Fisher exact test, whereas continuous variables were expressed as median and
interquartile range, and compared with the Wilcoxon rank sum test.
The population was stratified according to SYNTAX score tertiles and sensitivity anal-
yses were performed using different cutoff values. Estimation of the cumulative incidence
of events was performed by the Kaplan-Meier method, and hazard ratios (HRs) with 95%
confidence intervals (CIs) and p values were calculated using the Cox regression model.
The proportionality assumptions were checked by visual estimation after plotting the
log cumulative hazard versus (log) time at follow-up after index procedure and by apply-
ing a test for nonproportional hazards using the Schoenfeld residuals. Cox-regression anal-
ysis with interaction testing was performed to determine whether the effect of stent type
on the primary efficacy endpoint was consistent across SYNTAX subgroups. The interac-
tion between treatment effect and SYNTAX score was also explored modelling the score
as a continuous variable and was analyzed with a fractional polynomial interaction [12].
We also evaluated the effect of SYNTAX score on clinical outcomes in the overall pop-
ulation irrespective of stent randomization.We analyzed rates of clinical events according
to SYNTAX tertiles, and we also modulated the score as a continuous variable testing the
risk of ischemic and bleeding events in the overall population by means of both unad-
justed andmultivariable-adjusted, restricted cubic splineswith three knots of the distribu-
tion (10th, 50th, and 90th percentiles). Multivariable adjustment of MACE and BARC type
2 to 5 bleedingwas performedby including in themodel all variableswith a p value b0.1 at
univariable analysis.
Sensitivity analyses were also performed testing the consistency of study results
according to pre-defined 3 major criteria qualifying patients for inclusion (i.e. HBR,
HTR, LRR).
A 2-sided p value b0.05 was considered significant. All analyses were performed on
thebasis of the intention-to-treat principle using SPSS version 23.0 (SPSS, Chicago, Illinois)
and Stata 13.
3. Results
From June 2011 to September 2012, a total of 5288 patients were
screened and 1606 were finally randomized. Approximately one-half
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of the patients (n= 828) entered the study due to HBR criteria, mainly
due to age 80 years or older in 425 (26.5%) patients and/or need for oral
anticoagulation in 311 (19.4%) patients. A high thrombotic risk and a
low-restenosis risk were detected in 285 (17.7%) and in 941 (58.6%) pa-
tients, respectively. The median age was 74, nearly two-thirds of pa-
tients presented with acute coronary syndromes (acute STEMI in
20%). In total, the SYNTAX score ranged from 0 to 81, with a mean ±
SD of 16.3 ± 13.1 and a median of 12 (interquartile range: 7 to 22)
(Supplementary Fig. 1). In the main analysis, the overall population
was stratified according to SYNTAX tertiles (0 to 8: n= 563; N8 to 19
n = 532; N19: n = 511), and the ZES and BMS groups remained well
balanced with regard to baseline clinical and angiographic characteris-
tics (Supplementary Tables 1 and 2). Patients in the highest SYNTAX
tertilewere older,more frequentlywith diabetes, renal dysfunction, his-
tory of MI or CABG, multivessel disease and more frequently received
multivessel intervention, had complex lesions, and received multiple
stents, reflecting the higher CAD complexity.
3.1. SYNTAX score and clinical outcomes
During follow-up, 71 patients (12.6%) in the first SYNTAX tertile, 87
patients (16.4%) in the second SYNTAX tertile, and 160 patients (31.3%)
in the third SYNTAX tertile reached the primary endpoint (p b 0.0001;
Fig. 1, Table 1). Similarly, all-cause death (p b 0.0001), cardiovascular
death (p b 0.0001), MI (p b 0.0001), TVR (p b 0.0001), TLR (p b
0.0001), and definite ST (p = 0.001), as well as BARC bleeding (p =
0.011) were significantly higher according to SYNTAX score tertiles
(Fig. 1, Table 1).When analyzing SYNTAX score as a continuous variable,
or after multivariable adjustment for possible confounders, the SYNTAX
score remained an independent predictor of the primary outcome,
as well as of all additional secondary ischemic endpoints but stroke,
whereas it did not remain associated to bleeding events (Fig. 2,
Supplementary Tables 3 and 4).
3.2. SYNTAX score and the comparative effectiveness of ZES vs. BMS
The superior efficacy of ZES versus BMS for the primary endpoint
was consistent across SYNTAX teriles (tertile 1: HR 0.71, 95% CI 0.44–
1.13; tertile 2: HR 0.71, 95% CI 0.46–1.09; tertile 3: HR 0.83, 95% CI
0.61–1.10)with no signal of heterogeneity (p for trend=0.55). The dif-
ference between ZES andBMS groupsmainly reflected a reduction inMI
(tertile 1:HR0.23, 95% CI 0.07–0.83; tertile 2: HR0.20, 95% CI 0.06–0.70;
tertile 3: HR 0.45, 95% CI 0.25–0.79; p for trend=0.21), and TVR (tertile
1: HR 0.29, 95% CI 0.12–0.68; tertile 2: HR 0.66, 95% CI 0.35–1.27; tertile
3: HR 0.60, 95% CI 0.36–0.98; p for trend = 0.21), but not mortality
(tertile 1: HR 1.15, 95% CI 0.62–2.15; tertile 2: HR 0.81, 95% CI 0.47–
1.42; tertile 3: HR 1.01, 95% CI 0.67–1.52; p for trend = 0.84)
(Supplementary Table 5). When MI types were further considered,
both type 1 and type 4b were significantly higher according to
SYNTAX tertiles (p b 0.0001 for both) and were reduced in the ZES as
compared to BMS arm, consistently across SYNTAX score tertiles
(Supplementary Table 6). The rate of definite, definite/probable and
definite/probable/possible stent thrombosis trended lower in the ZES
group in all the SYNTAX tertiles without heterogeneity. No heterogene-
ity was observed across SYNTAX tertiles for all ischemic and bleeding
outcomes (Supplementary Table 5), nor for MACE and BARC type 2–5
when SYNTAX score was modelled as a continuous variable (Fig. 3).
3.3. Additional analyses
The consistency of ZES benefits over BMS, irrespective of angio-
graphic CAD complexity, was confirmed when the study population
was stratified based on the median SYNTAX score value (i.e. 12),
when the first two tertiles were combined and contrasted to the third
one or based on the SYNTAX score boundaries which were generated
in the context of the SYNTAX trial of 0–22, 23–32, ≥33) (data not
shown). Similarly, when population was stratified according to single
or multivessel disease (Supplementary Table 7).
Finally, there was no signal of heterogeneity for ZES benefits over
BMS across SYNTAX tertiles when main outcomes (the primary end-
point of death from any cause, MI, or TVR, as well the secondary end-
point of death from any cause or MI or the individual endpoints of MI
and TVR) were separately appraised across patients at high risk of
bleeding or thrombosis or at low risk of restenosis (Supplementary
Table 8).
4. Discussion
The ZEUS study focused on a unique patient population composed of
patients with high bleeding risk, high thrombotic risk, or low restenosis
risk who were largely excluded from the pivotal DES trials that led to
regulatory approval. The main findings of the present analysis can be
summarized as follows:
1. Anatomic complexity as assessed by the SYNTAX score indepen-
dently predicted major adverse cardiovascular events, and death,
MI, TVR or ST in the overall population as well as in each of the
three patient categories which were included.
Fig. 1. Ischemic events according to SYNTAX score tertiles.
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2. The SYNTAX score appeared at univariable analysis to be marginally
but significantly associated to bleeding events. However, after ad-
justment, the SYNTAX score did not remain associated to the bleed-
ing risk across different bleeding scales in the overall population as
well as in high bleeding risk, high thrombotic risk, or low restenosis
risk patients when separately appraised.
3. The SYNTAX score did not show significant interaction with the ran-
domly allocated treatment suggesting that ZES remains superior to
BMS across the whole spectrum of CAD complexity.
Optimal DAPT regimen and stent selection remain topics of great de-
bate [13,14]. The E-ZES is a hydrophilic polymer-based second-
generation device with a unique drug fast-release profile which results
in less powerful inhibition of intimal hyperplasia, but also in a rapid
and/or complete stent strut coverage. This property allows shortening
DAPT duration while maintaining superior efficacy compared with
BMS. The ZEUS study, which mandated a tailored DAPT duration
based on patients' characteristics, showed a lower incidence of
MACE after E-ZES as compared with BMS in uncertain DES recipients
[9]. E-ZES implantation provided superior efficacy and safety as com-
pared with conventional BMS also among high bleeding risk patients
(N50% of the patients fulfilled at least 1 criterion) who were to be
treated with a 30-day course of DAPT only [11].
The present study is the first to assess the impact of SYNTAX score in
uncertain DES candidates undergoing PCI. It confirms the ability of the
SYNTAX score to identify patients who are at highest risk of adverse
events also in the specific subsets of high bleeding risk, high thrombotic
risk and low restenosis risk patients. This provides further evidence
supporting the potential utility of the SYNTAX score in the assessment
of ischemic risk in patients undergoing PCI.
When comparing DES and BMS performance, angiographic charac-
teristics and complexity of CAD might have an important role,
Table 1
Clinical Outcomes at 12 months according to SYNTAX score tertiles.
SYNTAX Low
Tertile 1 (0–8)
(N= 563)
SYNTAX Intermediate
Tertile 2 (N8–19)
(N= 532)
SYNTAX High
Tertile 3 (N19)
(N = 511)
P value
Primary efficacy endpoint
Death from any cause, MI or TVR 71 (12.6) 87 (16.4) 160 (31.3) b0.0001
Secondary efficacy endpoints
Death from any cause or MI 53 (9.4) 63 (11.8) 129 (25.2) b0.0001
Death from cardiovascular cause or MI 36 (6.4) 46 (8.6) 113 (22.1) b0.0001
Death from any cause 40 (7.1) 50 (9.4) 91 (17.8) b0.0001
Death from cardiovascular cause 23 (4.1) 32 (6.0) 73 (14.3) b0.0001
MI 15 (2.7) 18 (3.4) 55 (10.8) b0.0001
TVR 29 (5.2) 38 (7.1) 66 (12.9) b0.0001
TLR 27 (4.8) 36 (6.8) 63 (12.3) b0.0001
Ischemic stroke 6 (1.1) 6 (1.1) 9 (1.8) 0.55
Definite ST 5 (0.9) 4 (0.8) 17 (3.3) 0.001
Probable ST 4 (0.7) 5 (0.9) 14 (2.7) 0.01
Possible ST 8 (1.4) 12 (2.3) 27 (5.3) b0.0001
Definite or probable ST 9 (1.6) 9 (1.7) 31 (6.1) b0.0001
Definite, probable, or possible ST 17 (3.0) 21 (3.9) 58 (11.4) b0.0001
Safety endpoints
TIMI classification
Major or minor 6 (1.1) 11 (2.1) 14 (2.7) 0.13
Major 5 (0.9) 6 (1.1) 9 (1.8) 0.42
Minor 1 (0.2) 5 (0.9) 5 (1.0) 0.19
Requiring medical attention 14 (2.5) 22 (4.1) 27 (5.3) 0.06
BARC classification
Type 5 or 3 10 (1.8) 14 (2.6) 23 (4.5) 0.027
Type 5, 3 or 2 22 (3.9) 30 (5.6) 42 (8.2) 0.011
Type 5 3 (0.5) 5 (0.9) 3 (0.6) 0.68
Type 5A 1 (0.2) 4 (0.8) 2 (0.4) 0.35
Type 5B 2 (0.4) 1 (0.2) 1 (0.2) 0.82
Type 4 0 0 0 –
Type 3 7 (1.2) 9 (1.7) 20 (3.9) 0.007
Type 3A 3 (0.5) 3 (0.6) 5 (1.0) 0.62
Type 3B 3 (0.5) 5 (0.9) 14 (2.7) 0.005
Type 3C 1 (0.2) 1 (0.2) 1 (0.2) 0.99
Type 2 12 (2.1) 16 (3.0) 19 (3.7) 0.30
Abbreviations: BARC=Bleeding Academic Research Consortium; MI=Myocardial infarction; ST= Stent thrombosis; TIMI= Thrombolysis inmyocardial infarction; TLR= Target lesion
revascularization; TVR = Target vessel revascularization.
Fig. 2. Spline curves for the HR of theMACE and BARC type 2–5 bleeding vs. SYNTAX score
modelled as a continuous variable. Patients with SYNTAX score in the first decile
(corresponding to score value ≤4; n = 211) represent the referent group with the HR
set to 1. The variables used for the adjustments are listed in the Table 4. BARC: Bleeding
Academic Research Consortium; HR: hazard ratio; MACE: major adverse cardiovascular
events.
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particularly when a very short (30-day) course of DAPT is required,
therefore we explored whether the benefits of ZES over BMS were con-
sistent across SYNTAX score strata. Although SYNTAX score properly
identifies patients at higher risk of events and could be hypothesized
to help deciding the stent selection in uncertain DES candidates, we
found that ZES was superior to BMS irrespective of CAD extension and
complexity. Thus, a very short (30-day) course of DAPT in the ZES
group did not pose a significant risk, whereas it achieved superior clin-
ical efficacy even in patients with intermediate-to-high angiographic
complexity of CAD as compared to BMS. Interestingly, we noted that
higher SYNTAX score seemed also to be associated with increased risk
of bleeding. This predictive feature of the score, however,wasnot attrib-
utable to the score per se but was rather influenced by concomitant pa-
tients' characteristics; indeed, this effect was not significant after
adjustment. This analysis carries new important implications as it con-
firms the specific ability of this score to predict ischemic but not bleed-
ing recurrences after PCI and provides strong rational for combining in
future analyses this score with dedicated algorithms modelled to pre-
dict the bleeding risk [15,16].
An additional intriguing observation in our current analysis merits
further discussion. A trend towards lower bleeding risk was previously
noted in the ZES vs BMS groups with respect to BARC 2, 3, or 5 bleeding
in the overall population or in HBR patients [9,11], despite the random-
ized nature of the comparison and the fact that both patient groups
received a similarly short/tailored course of DAPT after index interven-
tion. This was justified by higher TVR rate in the BMS group over the
course of follow-up, owing to the need to re-institute a DAPT regimen
thereafter. When the SYNTAX score was modelled as a continuous var-
iable, the benefits towards lower BARC 2, 3 or 5 bleeding occurrences
were apparently more evident in patients with low SYNTAX score
value. However, interaction testing with respect to the bleeding risk
and the SYNTAX score, modelled as continuous variable, was negative
and when BARC 3 or 5 events were considered across SYNTAX score
tertiles, the greatest relative risk reduction for bleeding in favour of
the ZES armwas noted in the highest tertile. Hence, there is clear signal
that the use of a ZES instead of a BMS in our patient population has po-
tential to mitigate the bleeding risk consistently across angiographic
CAD complexity strata.
There is evidence suggesting that the use of DES, instead of BMS,
leads not only to TVR but also MI, ST and cardiac mortality benefits
[9,11,17,18]. Indeed, an intriguing finding of the ZEUS trial is that ZES
compared with BMS significantly reduced TVR as expected, but also
provided a significant reduction of MI, owing to a significant reduction
of both type I (spontaneous) and type 4b (ST-related) MI, and here we
confirmed that this effect was consistent in all SYNTAX score tertiles.
The reduction of ST antagonizes previous concerns about DES-related
ST and further confirms large evidence accumulated in last years that
new-generation DES are associated with lower ST than BMS. Lower
rates of spontaneous MI might be interpreted in light of the fact that
DES reduces restenosis, which has historically been considered a benign
process presenting in most cases with recurrent stable angina, while
today is well known to be also related to MI occurrence. Conversely, in
the Norwegian coronary stent trial (NORSTENT), which recruited 9013
patients with stable or unstable CAD and assigned them to PCI with
the implantation of either contemporary DES (96% received either
everolimus- or zotarolimus-eluting stents) or BMS [19], the composite
outcome of death from any cause and nonfatal spontaneousMI, or qual-
ity of life, did not differ in-between groups. It was therefore suggested
that, based on the excellent results achieved with BMS in NORSTENT,
contemporary BMS still should be considered a viable alternative for
some setting of patients, such as those who need anticoagulation,
those who cannot complete the longer DAPT period because of a need
for noncardiac surgery or other medical conditions with increased
bleeding risk, those who have cancer and those with low restenosis
rates [14]. On this scenario, our study adds to the current knowledge
and could contribute to this debate by showing that DES is superior
to BMS in specific clinical settings (still considered from someone
“uncertain” candidates to DES) and irrespective of the angiographic
complexity of the coronary disease. This finding further supports the
most recent European guidelines recommending the use of new-
generation DES over BMS in all patients undergoing PCI [4].
4.1. Study limitations
The present study has some limitations. First, the ZEUS study was
not powered to explore SYNTAX subgroups, thus, it should be consid-
ered hypothesis-generating only. Yet, our results may not apply to pa-
tients with very high SYNTAX score who were only marginally
represented in our study population; however, the absence of heteroge-
neity across SYNTAX subgroups was consistently observed even when
different cutoffs were used orwhen the scorewasmodelled as continu-
ous. Second, it had a single-blind design, and no specific safeguards
were adopted to ensure that patients and treating physicians remained
unaware of treatment allocation beyond formal recommendations in
the protocol, therefore it should be considered as an open-label study
with evident limitations. Third, the findings apply to the studied ZES
(Endeavor Sprint, which is no longer on the market) and cannot be
expended to other new-generation DES. Fourth, longer follow-up is re-
quired to confirm durability of these findings. However, given the
proven superior efficacy of other DES to inhibit intimal hyperplasia as
Fig. 3. Fractional polynomial interaction between randomized stent and SYNTAX score for
theMACE and BARC type 2–5 bleeding. The treatment-by-SYNTAX interaction is analyzed
by considering SYNTAX score as a continuous variable. The red line represents the
treatment effect of ZES vs. BMS and the area represents the 95% CI of treatment effect.
(For interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)
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compared to the Endeavor-ZES, it remains likely that other DES would
have resulted in even greater efficacy as compared to BMS in preventing
the need for re-intervention in the previously instrumented vessel(s).
Fifth, the present findings should be interpreted considering that the
majority of patients received a clopidogrel-based DAPT (prasugrel or
ticagrelor at discharge were in b1%). Finally, we did not test intra/
inter-observer variability in the SYNTAX score calculation, however,
the single observer performing the blinded angiographic analysis was
an experienced interventionalist and was well trained for SYNTAX
score calculation.
5. Conclusion
Among patients with high bleeding risk, high thrombotic risk, or low
restenosis risk undergoing PCI, anatomic complexity as assessed by the
SYNTAX score predicted major adverse cardiovascular but no bleeding
events. The SYNTAX score did not show significant interaction with
treatment effect suggesting that in these patient categories ZES remains
superior to BMS, both with similar short courses of DAPT, across the
whole spectrum of CAD complexity.
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Part 1
Trade-off for ischemia and 
bleeding during and immediately 
after percutaneous coronary 
interventions:
Pharmacological strategies to 
prevent the risk of AKI
1Over the past 25 years, the number of percutaneous pro-cedures requiring contrast media administration has 
increased exponentially.1 Contrast-induced acute kidney 
injury (CIAKI) is not an infrequent complication of coronary 
angiography and percutaneous coronary intervention and has 
been associated with increased mortality and cardiovascular 
events.2,3
See Editorial by Bangalore and Briguori
The optimal CIAKI prevention strategy for patients with 
suspected or confirmed coronary artery disease undergoing 
percutaneous coronary procedures is unknown. A wide array 
of medications and hydration regimens have been investi-
gated in recent years.4–6 Indeed, the large variety of available 
Background—The effectiveness of currently available effective preventive strategies for contrast-induced acute kidney 
injury (CIAKI) is a matter of debate.
Methods and Results—We performed a Bayesian random-effects network meta-analysis of 124 trials (28 240 patients) 
comparing a total of 10 strategies: saline, statin, N-acetylcysteine (NAC), sodium bicarbonate (NaHCO3), NAC+NaHCO3, 
ascorbic acid, xanthine, dopaminergic agent, peripheral ischemic preconditioning, and natriuretic peptide. Compared 
with saline, the risk of CIAKI was reduced by using statin (odds ratio [OR], 0.42; 95% credible interval [CrI], 0.26–0.67), 
xanthine (OR, 0.32; 95% CrI, 0.17–0.57), ischemic preconditioning (OR, 0.48; 95% CrI, 0.26–0.87), NAC+NaHCO3 
(OR, 0.50; 95% CrI, 0.33–0.76), NAC (OR, 0.68; 95% CrI, 0.55–0.84), and NaHCO3 (OR, 0.66; 95% CrI, 0.47–0.90). 
The benefit of statin therapy was consistent across multiple sensitivity analyses, whereas the efficacy of all the other 
strategies was questioned by restricting the analysis to high-quality trials. Overall, high heterogeneity was observed for 
comparisons involving xanthine and ischemic preconditioning, although the impact of NAC and xanthine was probably 
influenced by publication bias/small-study effect. Hydration alone was the least effective preventive strategy for CIAKI. 
Meta-regressions did not reveal significant associations with baseline creatinine and contrast volume. In patients with 
diabetes mellitus, no strategy was found to reduce the incidence of CIAKI.
Conclusions—In patients undergoing percutaneous coronary procedures, statin administration is associated with a 
marked and consistent reduction in the risk of CIAKI compared with saline. Although xanthine, NAC, NaHCO3, 
NAC+NaHCO3, ischemic preconditioning, and natriuretic peptide may have nephroprotective effects, these results 
were not consistent across multiple sensitivity analyses.  (Circ Cardiovasc Interv. 2017;10:e004383. DOI: 10.1161/
CIRCINTERVENTIONS.116.004383.)
Key Words: acetylcysteine ◼ acute kidney injury ◼ chronic kidney disease ◼ contrast media  
◼ creatinine ◼ meta-analysis ◼ percutaneous coronary intervention
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comparative trials provided extremely contradictory conclu-
sions that has made it difficult to ascertain the best strategy for 
CIAKI prevention in clinical practice. Moreover, differences 
in the baseline clinical and procedural characteristics that are 
responsible for the interindividual susceptibility to CIAKI (ie, 
chronic kidney disease, diabetes mellitus, and contrast media 
volume) have significantly confounded the results of these 
studies.7,8
Network meta-analyses are extensions of standard pair-
wise meta-analyses that allow for simultaneous pooling of data 
related to multiple interventions, combination of direct and indi-
rect components of the evidence in a single estimate, and com-
parison of treatments without a direct connection on the basis of 
indirect information.9,10 We performed a comprehensive network 
meta-analysis of randomized clinical trials comparing preventa-
tive strategies for CIAKI in patients with suspected or confirmed 
coronary artery disease undergoing contrast media administra-
tion in the setting of a percutaneous coronary procedure.
Methods
This study was conducted in keeping with the PRISMA consen-
sus (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses for Protocols)11 (PRISMA checklist, Appendix in the Data 
Supplement), the PRISMA extension statement for network meta-
analyses,12 and the Cochrane Collaboration recommendations.13
Search Strategy and Selection Criteria
PubMed, Embase, Scopus, Cochrane Library, and Web of Knowledge 
databases were searched for randomized clinical trials investigating 
the effects of preventive strategies for CIAKI, from the date of data-
base inception to November 15, 2016. Additional specifications are 
reported in the Methods in the Data Supplement.
Inclusion and Exclusion Criteria
Studies were considered for inclusion only if they were randomized 
controlled trials of patients undergoing percutaneous coronary proce-
dures (ie, coronary angiography with or without intervention) com-
paring ≥2 preventive strategies for CIAKI. Conference proceedings, 
unpublished reports, and trials with unclear treatments posology and 
CIAKI definition were excluded. Screening and data extraction are 
reported in the Methods in the Data Supplement.
End Points
The end point of interest was CIAKI, defined according to the most 
common definition as a relative ≥25% or an absolute ≥0.5 mg/dL 
serum creatinine increase within 48 to 72 hours from the procedure.3,7 
In some studies, CIAKI was defined as either a relative ≥25% or an 
absolute ≥0.5 mg/dL serum creatinine increase from baseline to 48 to 
72 hours from the procedure. Some studies used definitions with time 
≤1 week from the procedure. The rare studies (n=6) using only an 
AKIN (Acute Kidney Injury Network)/RIFLE-derived (Risk, Injury, 
Failure, Loss of Function, End Stage Renal Disease) definition of 
CIAKI were retained only in the main analysis. Trials using CIAKI 
definitions other than those listed above, mostly including definitions 
based on alternative biomarkers (ie, cystatin C, neutrophil gelatinase–
associated lipocalin, urine creatinine, etc), were excluded.
Statistical Analyses
We performed a hierarchical Bayesian network meta-analysis using 
random-effects consistency models and noninformative priors.14–16 
After arm-level data imputation, the models were computed by 
Markov chain Monte Carlo simulations using 3 chains with over-
dispersed initial values, and Gibbs sampling was based on 100 000 
iterations following discard of 50 000 (burn-in). Convergence was 
appraised according to Brooks and Gelman.17 Posterior inference 
was summarized as odds ratio (OR) and 95% credible interval (CrI). 
Treatments were ranked to define the probability associated to each 
one to be the best strategy.18 Inconsistency was assessed by compar-
ing the deviance information criterion of consistency and inconsis-
tency models and by contrasting direct and indirect evidence from 
the network (node-split).15 Direct estimations represent the summary 
effects of Bayesian meta-analyses of trials comparing 2 strategies. 
Heterogeneity was graded based on I2 statistics with values <25%, 
25% to 50%, and >50%, representing mild, moderate, and severe 
heterogeneity, respectively.19 All analyses were performed using R 
(version 3.1.1), WinBUGS (version 1.4), and STATA (version 12.1).
Sensitivity Analyses
Several sensitivity analyses according to different CIAKI definitions, 
moderate-to-advanced chronic kidney disease, diabetes mellitus, 
methodological characteristics of included trials (sample size, global 
qualitative assessment, blinding, and independent event adjudication), 
imputation of patients lost at follow-up, trial design, and treatment po-
sology were run to investigate the robustness of the results and explore 
potential sources of inconsistency. Two network sensitivity analyses 
were also performed: (1) detachment of complex nodes of the primary 
network to the individual components and (2) selection of a network 
including only consistent comparisons and nodes with acceptable bal-
ance. The full methodology relevant to all these sensitivity analyses is 
more extensively described in the Methods in the Data Supplement.
WHAT IS KNOWN
• CIAKI is a relatively common complication of per-
cutaneous coronary procedures, which has been as-
sociated with increased mortality and cardiovascular 
events.
• True effectiveness of several preventive strategies 
for CIAKI continues to be matter of debate as con-
sequence of the extreme heterogeneity of available 
evidence.
WHAT THE STUDY ADDS
• This Bayesian network meta-analysis of 124 ran-
domized clinical trials and 28 240 patients simulta-
neously compares the 10 most representative CIAKI 
preventive strategies tested in the past 25 years.
• When compared with saline hydration alone, peri-
procedural administration of a statin was associ-
ated with a significant CIAKI risk reduction with 
consistent results across multiple analyses, whereas 
the notable benefit of xanthine seemed to be sig-
nificantly influenced by between-trial heterogeneity 
and disappeared after pooling only of patients with 
moderate-to-severe chronic kidney disease and trials 
with highest quality.
• NAC, NaHCO3, NAC+NaHCO3, and ischemic pre-
conditioning reduced the risk of CIAKI when com-
pared with saline hydration alone, but results were 
highly inconsistent across sensitivity analyses; hy-
dration with saline was found to be the least effec-
tive strategy without significant variations after pool-
ing only of trials ensuring an intense and prolonged 
infusion. by guest on M
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Meta-Regression
The results of the main analysis were adjusted for baseline creatinine 
and contrast volume (see the Methods in the Data Supplement for 
further details).
Qualitative Assessment
Qualitative trial assessment was performed according to the 7-domain 
tool of the Cochrane Collaboration, whereas publication bias/small-
study effect was inspected by comparison-adjusted funnel plot.13 A 
description of qualitative assessment and comparison-adjusted funnel 
plot is provided in the Methods in the Data Supplement.
Results
Figure 1 illustrates the selection process and the geometry of 
the network. A total of 124 trials (n=28 240 patients) inves-
tigating 10 different preventive strategies (saline, statin, 
N-acetylcysteine [NAC], sodium bicarbonate [NaHCO3], 
NAC+NaHCO3, ascorbic acid, xanthine, dopaminergic agent, 
peripheral ischemic preconditioning, and natriuretic peptide) 
were finally selected (Figure I in the Data Supplement; Meth-
ods in the Data Supplement). References of the included trials 
and key trial–level methodological and clinical characteristics 
are reported in the Appendix in the Data Supplement (Trials 
List, Tables I and II in the Data Supplement). In about 95% 
of trials, CIAKI was reported according to the main defini-
tion or its 2 variants, although a 48 to 72 hours adjudication 
time was available in about 80%. Trial-level baseline creati-
nine and contrast volume values were significantly variable 
across trials.
Network Meta-Analysis
The incidence of CIAKI ranged from about 4% to 24% across 
strategies. Forest plots and rankograms of the network meta-
analysis are illustrated in Figure 2. Compared with saline, 
the risk of CIAKI was reduced by statin (OR, 0.42; 95% CrI, 
0.26–0.67), xanthine (OR, 0.32; 95% CrI, 0.17–0.57), isch-
emic preconditioning (OR, 0.48; 95% CrI, 0.26–0.87), NAC 
(OR, 0.68; 95% CrI, 0.55–0.84), NaHCO3 (OR, 0.66; 95% 
CrI, 0.47–0.90), and NAC+NaHCO3 (OR, 0.50; 95% CrI, 
0.33–0.76). When comparing these strategies head to head, 
statin reduced the risk of CIAKI by 49% compared with NAC, 
whereas xanthine reduced the risk of CIAKI by 53%, 52%, 
56%, and 59% compared with NAC, NaHCO3, ascorbic acid, 
and dopaminergic agent, respectively (Figure 2). At treat-
ments ranking, xanthine and statin emerged as the best strate-
gies, whereas dopaminergic agent and saline were the worst.
Inconsistency Analysis, Node-Split, 
and Heterogeneity
The deviance information criterion was lower in the con-
sistency model but to a small extent. Sources of inconsis-
tency in specific segments of the network were inspected 
by node-split (Figure II in the Data Supplement). A signifi-
cant inconsistency was detected only for the comparisons of 
NAC+NaHCO3 versus saline (P=0.017) and xanthine versus 
NAC (P=0.039). Heterogeneity was extremely variable across 
comparisons, ranging from mild-to-extreme degree (Figure 
II in the Data Supplement). The comparison of statin versus 
saline presented a mild degree of heterogeneity (I2=23.4%), 
whereas the comparison of xanthine versus saline showed a 
high degree of heterogeneity (I2=66.0%). The comparisons 
of preconditioning versus saline and preconditioning versus 
NAC showed extreme heterogeneity.
Sensitivity Analyses
Figure 3 and Tables III through VI in the Data Supplement 
show the risk distribution of different strategies using saline 
Figure 1. Flow diagram and network geometry. Left, The flow diagram describes the trials screening process. Right, Network of contrast-
induced acute kidney injury preventive strategies. The node size is proportional to the number of patients included, and solid black lines 
define direct comparisons among strategies with thickness proportional to the number of trials involved. NAC indicates N-acetylcysteine; 
and NaHCO3, sodium bicarbonate.
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Figure 2. Continued
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as the common reference after stratification by type of CIAKI 
definition. In trials reporting CIAKI events using both relative 
(≥25%) and absolute (≥0.5 mg/dL) serum creatinine criteria 
and trials using only relative criteria, the benefit of xanthine 
was no longer observable. Many strategies, including statin, 
xanthine, NAC, NaHCO3, and NAC+NaHCO3, were not sensi-
tive to the different definitions.
Figure 4 and Tables VII and VIII in the Data Supplement 
show the risk distribution of different strategies using saline 
as common reference in analyses restricted to patients with 
moderate-to-severe chronic kidney disease or diabetes melli-
tus. In patients with estimated glomerular filtration rate ≤60 
mL/min per 1.73 m2 (or, when not available, estimated cre-
atinine clearance ≤60 mL/min) or serum creatinine ≥1.5 mg/
dL, statin, NAC, and ischemic preconditioning were associ-
ated with a risk reduction. In patients with diabetes mellitus, 
none of the strategies were found to reduce the risk of CIAKI 
compared with saline.
Figure 5 and Tables IX through XII in the Data Supplement 
show the risk distribution according to study quality assess-
ment. After exclusion of smaller trials, the benefit of NAC, 
NaHCO3, and NAC+NaHCO3 over saline was reduced but per-
sisting, whereas the superiority of statin and xanthine remained 
unchanged. By contrast, in analysis restricted to higher-qual-
ity trials, the effect associated with xanthine compared with 
saline was comparable, whereas statin and NAC continued to 
reduce the risk of CIAKI. Although in this analysis ischemic 
preconditioning and natriuretic peptide were associated with a 
notable risk reduction, they were supported by few trials, and 
high heterogeneity was noticed for ischemic precondition-
ing. Xanthine was no longer beneficial in trials with patient 
blinding or independent event adjudication. Only the risk 
reduction associated with statin and ischemic preconditioning 
compared with saline resulted unchanged or enhanced after 
pooling of trials with independent event adjudication, and 
NAC, NaHCO3, and NAC+NaHCO3 showed similar efficacy 
compared with saline. No trials investigating natriuretic pep-
tide effectiveness were available for this analysis. The results 
remained consistent after imputation of the number of patients 
lost to follow-up and exclusion of the 3- or 4-arm trials which 
theoretically could have lost the benefit of randomization after 
removal of 1 arm testing a treatment that was not of interest 
(6.5%) or combination of 2 arms investigating the same treat-
ment with different posology (4.0%; Figure III in the Data 
Supplement; Table XIII in the Data Supplement). Pooling 
only trials with a more generous and prolonged periprocedural 
0.9% saline hydration regime and a intermediate-to-intense 
posology for each strategy (Figure 6; Table XIV in the Data 
Supplement) showed that statin and xanthine were the only 
2 strategies associated with a marked CIAKI risk reduction 
compared with saline. However, whereas no heterogeneity 
was detected for statin versus saline, the comparison of xan-
thine versus saline showed high heterogeneity (I2=76.3%).
Overall, the heterogeneity across these analyses showed 
a distribution generally similar to that of the main analysis 
(Table III in the Data Supplement). Although comparisons 
involving preconditioning showed extreme I2 values and the 
xanthine versus saline comparison showed moderate-to-high 
heterogeneity, only a mild-to-moderate degree of heterogene-
ity was detected for statin versus saline.
After detaching complex nodes of the primary network 
(Figure IV in the Data Supplement), statin—both alone and 
combined with NAC and NaHCO3—consistently reduced the 
risk of CIAKI compared with saline. Among xanthines, only 
theophylline—alone and in combination with NAC—was asso-
ciated with a risk reduction. However, comparisons involving 
theophylline+NAC were inconsistent (Figure IV in the Data 
Supplement). Excluding nodes affected by significant P values 
at node-split and applying a minimum number of studies per 
node/sample size filter, the risk of CIAKI was reduced only in 
patients receiving statin, NAC, and NaHCO3 (Figure V in the 
Data Supplement; Table XV in the Data Supplement).
Meta-Regressions
Bayesian network meta-regressions using weighted trial–level 
mean values of baseline creatinine (mg/dL) and contrast vol-
ume (mL) did not reveal significant changes for all the strate-
gies other than ischemic preconditioning which resulted more 
effective than saline (Figure VI in the Data Supplement).
Qualitative Assessment
Bias assessment is schematically illustrated in Figures VII and 
VIII in the Data Supplement. Approximately 50% of trials did 
not ensure any blinding, and approximately 55% did not prop-
erly describe the process of random sequence generation. In 
addition, significant concerns arose from the high proportion 
of trials with unclear performance of allocation concealment 
(about 60%–65%) and blinded events adjudication (about 
80%). Although the comparison-adjusted funnel plot did not 
display an asymmetrical distribution of the estimates for most 
strategies (Figure IX in the Data Supplement), a moderate 
asymmetry favoring treatment efficacy compared with control 
and a possible small-study effect was observed for NAC and 
xanthine.
Discussion
The main findings of this network meta-analysis can be sum-
marized as follows. First, treatment with statin, xanthine, 
and—to a lesser extent—NAC, NaHCO3, and NAC+NaHCO3 
is associated with a significant reduction in the risk of CIAKI 
compared with saline. Second, in contrast to xanthine, the 
benefit of statin was robust and consistent in multiple sensitiv-
ity analyses. Third, diabetes mellitus may offset the benefit 
of preventive strategies for CIAKI. Fourth, although often 
promoted as the best strategy against CIAKI, periprocedural 
hydration alone resulted to be the least effective preventive 
treatment without significant variation after inclusion of only 
trials ensuring an intense and prolonged infusion. In aggre-
gate, these findings underscore the prominent role of statin 
and the possible role of xanthine as the best treatment options 
Figure 2 Continued. Main analysis. Left, The forest plots illustrate the risk distribution across the included strategy referred to a different 
common reference at a time. Right, Treatments are ranked according to the relative probability to be the first, the second, the third, etc., 
most effective. CrI indicates credible interval; NAC, N-acetylcysteine; NaHCO3, sodium bicarbonate; and OR, odds ratio.
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for preventing CIAKI in patients undergoing percutaneous 
coronary procedures with contrast media administration.
Inflammation, oxidative stress, direct tubular injury, 
osmotic loading, and medullary hypoxia play a significant 
role in the pathogenesis of CIAKI.20,21 Preventive strate-
gies have been tested on the assumption of a significant 
effect on one or more of these mechanisms.5,6 Statins have 
known pleiotropic effects that act by decreasing local and 
systemic inflammation, improving endothelial function, 
and modulating regulatory mechanisms of cell survival.22–24 
Statins may be particularly effective in CIAKI prevention if 
patients present with a high expression of inflammation bio-
markers25 but can also play a beneficial role downstream by 
counteracting one of the possible common final pathways of 
the CIAKI process, namely contrast-induced tubular cells 
apoptosis.24,26 In a recent in vitro study, statins reduced the 
activation of apoptosis in human kidney cells, with a lower 
phosphorylation of JNK and p53 and a lower expression of 
caspase 3.26 Results on rats were comparable.27 Although 
these findings are preliminary, they are consistent with a 
biologically plausible mechanism. In our study, the renopro-
tective effects observed in patients receiving preprocedural 
statin administration were marked and consistent regard-
less of the different CIAKI definitions used across trials, 
the presence of baseline moderate-to-severe chronic kidney 
disease, and the quality of the studies analyzed. Because 
the methodological quality of trials included in a meta-
analysis can significantly influence pooled estimate,13 we 
inspected the consistency of results associated with statin 
after pooling only trials with larger sample size, blinding, 
independent adjudication of the events, and higher cumu-
lative methodological quality as defined by the Cochrane 
Collaboration13 without detecting any significant change. In 
addition, heterogeneity across analyses was overall accept-
able, and no asymmetry in trial-level estimates distribution 
was observed. Finally, meta-regression analyses did not 
suggest significant associations with basal creatinine and 
contrast volume variations across trials.
Theophylline or aminophylline (theophylline–ethylenedi-
amine) and pentoxifylline are nonselective A1 and A2 adenos-
ine receptors antagonists that produce renal vasodilation by 
blocking A1 adenosine receptor–mediated vasoconstriction 
and induce diuresis by reducing sodium reabsorption in the 
proximal tubules.28,29 We found a marked risk reduction in 
CIAKI with xanthine when compared with saline. However, 
although not sensitive to the definition of CIAKI and varia-
tions in posology, this effect was significantly mitigated in 
critical subsets, such as advanced chronic kidney disease and 
diabetes mellitus, and in trials with higher quality, blinding, 
and independent event adjudication. In addition, results asso-
ciated with xanthine were supported only by 11 small trials 
(nearly 600 patients), and inspection of local inconsistency 
of the network showed that direct evidence significantly con-
trasted with indirect evidence for the comparison of xanthine 
Figure 3. Subgroup analyses according to different contrast-
induced acute kidney injury definitions. Trials and contrast-
induced acute kidney injury events were pooled according to 
3 different criteria: (1) main definition+contrast-induced acute 
kidney injury as serum creatinine increase ≥25%; (2) main 
definition+contrast-induced acute kidney injury as serum creati-
nine increase ≥0.5 mg/dL; and (3) events occurring between 48 
and 72 h. CrI indicates credible interval; NAC, N-acetylcysteine; 
NaHCO3, sodium bicarbonate; and OR, odds ratio.
Figure 4. Subgroup analyses according to moderate-to-
advanced chronic kidney disease and diabetes mellitus. In 2 
different subgroup analyses, patients with advanced chronic 
kidney disease, defined as estimated glomerular filtration rate 
≤60 mL/min per 1.73 m2 (or, when not available, estimated cre-
atinine clearance ≤60 mL/min) or serum creatinine ≥1.5 mg/mL 
and diabetes mellitus were pooled. CKD indicates chronic kidney 
disease; Crl, credible interval; NAC, N-acetylcysteine; NaHCO3, 
sodium bicarbonate; and OR, odds ratio.
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versus NAC. After detachment of the network to individual 
strategies, we found that the benefit of xanthine is mostly 
attributable to theophylline and not pentoxifylline. Finally, 
concerns about the xanthine strategy arose from the high 
degree of heterogeneity detected across analyses, and funnel 
plot inspection showed a moderate asymmetry in the distri-
bution of trial-level estimates likely with the presence of a 
small-study effect.
When compared with saline, we also observed a reduced 
risk of CIAKI with NAC, NaHCO3, and NAC+NaHCO3. 
The trials investigating these therapies included about 40% 
of patients included in the meta-analysis. The available data 
on the efficacy of NAC for CIAKI prevention, including sev-
eral meta-analyses, provided contradictory conclusions.5,30,31 
Indeed, although NAC reduced CIAKI without significant 
variations across definitions, we found that these results 
could be influenced by trials with lower global quality and 
absence of independent event adjudication. These findings 
are in agreement with a systematic review appended to the 
ACT trial (Acetylcysteine for Contrast-Induced Nephropathy 
Trial),31 in which deficiencies in allocation concealment and 
blinding provided partial explanation for the extreme vari-
ability in results across trials. In addition to these findings, 
low doses of NAC with or without inadequate hydration regi-
mens may have introduced heterogeneity, and a publication 
bias/small-study effect amplifying NAC efficacy cannot be 
excluded. Interestingly, the removal of all trials with at least 1 
arm, including <50 patients, produced a pooled effect compa-
rable with saline.
Infusion of NaHCO3 is another traditional strategy tested 
over time with mixed results.32,33 NaHCO3 was more effec-
tive than saline in the main analysis and was associated with 
efficacy similar to NAC. However, NaHCO3 exhibited marked 
variations across subanalyses and was no longer effective in 
patients with moderate-to-severe chronic kidney disease or 
diabetes mellitus and trials of higher methodological qual-
ity. The exclusion of trials without systematic and adequate 
hydration regimens and medium-to-intense NaHCO3 posol-
ogy confuted the main analysis conclusions.
The combination of NAC+NaHCO3 in a single strategy 
was explored in several trials in the attempt to amplify the 
effects of individual treatment components, but the results 
were not univocal.34,35 In the main analysis, we observed a 
notable risk reduction associated with NAC+NaHCO3 com-
pared with saline, which had higher extent than the individ-
ual components of NAC+NaHCO3 potentially indicating a 
cumulative effect. However, we revealed by network node-
split a significant inconsistency for NAC+NaHCO3 versus 
saline, with direct estimation reporting a similar effect of the 
2 strategies. Finally, although the combination of statin with 
Figure 5. Subgroup analyses according to trials quality. Trials 
and contrast-induced acute kidney injury events were pooled 
according to 4 different methodological aspects: (1) trials with 
≥50 patients per arm; (2) trials with high methodological quality, 
defined as a cumulative score ≥5.5 by combining components 
of the Cochrane Collaboration tool13; (3) trials planning at least 
patients blinding; and (4) trials having a blinded committee for 
contrast-induced acute kidney injury events adjudication. CrI 
indicates credible interval; NA, not available; NAC, N-acetylcyste-
ine; NaHCO3, sodium bicarbonate; and OR, odds ratio.
Figure 6. Sensitivity analysis of trials with intense posology. 
In this sensitivity analysis, only trials with systematic intense 
0.9% (≥1 mL kg−1 h−1) saline hydration regimens, from at least 
6 h before to at least 6 h after the procedure, medium-to-high 
dose of medications, and reasonable periprocedural application 
(cycles for peripheral ischemic preconditioning) were considered. 
This sensitivity analysis sought to minimize the influence of trials 
including patients not hydrated or receiving saline solution with 
limited amount or duration. Secondary objective was to remove 
the influence of trials using low dose of medications, by includ-
ing only trials using medium-to-high doses (ie, atorvastatin ≥40 
mg, rosuvastatin ≥20 mg, simvastatin ≥20 mg, etc). CrI indicates 
credible interval; NAC, N-acetylcysteine; NaHCO3, sodium bicar-
bonate; and OR, odds ratio.
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NAC+NaHCO3 was associated with the highest effect among 
statin-based strategies, this result was supported only by 1 
trial,26 which demands additional confirmation.
Ischemic preconditioning and natriuretic peptide showed 
a notable risk reduction when compared with saline in several 
analyses. Although these results are promising and deserve 
further attention in future, they should be considered with cau-
tion because, when compared with other strategies, the isch-
emic preconditioning and natriuretic peptide nodes included 
fewer patients and fewer trials. The limited data can explain 
the variable findings across analyses, where the selection of 
some trial having strong influence on pooled estimate could 
have driven the results. Moreover, some of the included trials 
investigating ischemic preconditioning were primarily con-
ducted for other purpose. This consideration may explain the 
extreme heterogeneity constantly observed.
By node-split, we provided updated direct evidence esti-
mates of different CIAKI prevention strategies (Figure II in 
the Data Supplement). Indeed, we are able to supplement con-
siderably the latest frequentist meta-analyses of CIAKI5,33,36–38 
because in our study the direct component of evidence deriv-
ing from each available pair of preventive strategies is similar 
to a standard meta-analysis.
In aggregate, the results of our meta-analysis generate 2 
additional considerations. First, although few studies have 
directly addressed volume expansion against CIAKI, intense 
hydration is commonly advocated as the cornerstone preven-
tive strategy.3,5–7 However, in our meta-analysis, hydration 
with saline solution alone was the least effective strategy, 
and the inclusion only of trials ensuring a more generous and 
prolonged periprocedural infusion did not modify this conclu-
sion. On the one hand, our results do not contradict the central 
role of saline infusion, taking into consideration that all arms 
of included trials received a similar regimen, but on the other 
hand highlight the limitations of a preventive strategy based 
only on hydration. Second, comparisons between strategies 
other than saline tended to produce limited differences that 
can be only partially explained by the number of direct com-
parison in the network. The differential relative effectiveness 
across nonsaline-based strategies reflects the real magnitude 
of required advances against CIAKI.
Finally, in our study, we observed a significant negative 
impact of diabetes mellitus on the effectiveness of CIAKI 
preventive strategies, including statin and xanthine. Diabetes 
mellitus is an important cause of nephropathy and, although 
these conditions can be observed in the same patient, both can 
independently predispose to CIAKI.2,3,7 However, on the one 
hand, according to our findings more information is needed to 
identify effective preventive strategies against CIAKI in dia-
betic patients, and on the other hand, the absence of individual 
patient data and event reporting in a significant proportion of 
trials limited our sample size.
Limitations
As with any meta-analysis, this study shares the limitations 
of the original trials included, and despite the multiple sensi-
tivity analyses conducted, some remaining questions would 
only be addressed by individual patient data. More specifi-
cally, the results of our meta-analysis should be interpreted 
taking the following limitations into account. First, some of 
the included trials were heterogeneous, with differences in 
definitions, methods, and posology. Although our sensitiv-
ity analyses detected a modest influence of these variables, 
the influence of other unmeasured confounding factors can-
not be ruled out. Moreover, as with any meta-analysis, the 
results of some restrictive analyses might be influenced by 
the reduction of included trials. Second, the estimation of a 
cutoff value to exclude underemployed strategies (ie, add-
ing heterogeneity without producing any relevant additional 
finding) may imply a possible selection bias. However, as 
observable in the Figure I in the Data Supplement, this was 
necessary because about 50% of treatments identified before 
applying our ad hoc filter included <100 patients and as such 
would have been compared with strategies including several 
thousands of patients (ie, saline, statin, NAC, and NaHCO3). 
Similarly, the exclusion of treatments investigated in <5 tri-
als was empirical but preserved from the risk of considering 
strategies in which the evidence was supported only by a sin-
gle large trial or unequally shared across few trials. As a mat-
ter of fact, the impact of this filter was not marked because it 
led to removal of only 1 strategy (ie, furosemide), and about 
85% of patients treated with furosemide came only from 
a single medium-quality trial. A threshold for a minimum 
population size assigned to each identified treatment was 
also established using nonconservative parameters, which 
allowed for the inclusion of a large number of strategies, 
while excluding at the same time poorly represented and 
noninformative treatments. Third, analysis of treatment com-
binations implies per se a risk of bias (lumping). However, 
by detaching the network into the most elementary variants 
of strategies, the results remained unchanged and supported 
a similar effect within nodes, including similar treatments, 
with the exception of xanthine, as described earlier. Fourth, 
although our results apply to patients with suspected or 
confirmed coronary artery disease undergoing coronary 
diagnostics or procedures, about 10% of the trials enrolled 
a minor (<35%) proportion of patients who also underwent 
contrast administration for peripheral angiography or inter-
vention sometimes performed in the same setting of the 
coronary procedures. Conversely, we deliberately excluded 
patients undergoing contrast media administration in the 
setting of computed tomographic diagnostics, transcatheter 
aortic valve replacement, and fully endovascular procedures 
because these procedures potentially entail different patient 
profiles and mechanisms of acute kidney injury. Fifth, the 
lack of specific trial-level outcomes did not enable exploring 
the influence of clinical presentation (ie, acute coronary syn-
drome, stable angina, silent angina, etc.) on the results of the 
meta-analysis. However, the posology subanalysis, includ-
ing only trials requiring an intense hydration regimen for an 
adequate interval of time before the procedure, led to the 
exclusion of patients presenting with ST-segment–elevation 
myocardial infarction or undergoing emergency coronary 
procedure. Finally, detaching the statin node according to 
statin type (ie, atorvastatin, rosuvastatin, simvastatin, etc.) 
was not feasible. However, in 2 recent frequentist pairwise 
meta-analyses, no difference between statin types in terms of 
CIAKI risk reduction was observed.36,38
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Conclusions
A preventive approach with statin was found to reduce the 
risk of CIAKI in patients undergoing coronary catheteriza-
tion compared with saline. A xanthine-based strategy also 
proved effective compared with saline, but these results could 
be influenced by the presence of moderate-to-severe chronic 
kidney disease and the inclusion of lower-quality and small 
trials exaggerating the benefit of this strategy. NAC, NaHCO3, 
and NAC+NaHCO3 administration may be associated with a 
mild CIAKI risk reduction compared with saline, although the 
benefit of these strategies was attenuated in some sensitivity 
analyses. Ischemic preconditioning and natriuretic peptide 
may present a nephroprotective effect but larger and high-
quality trials are required to draw conclusions. In patients with 
diabetes mellitus, none of the investigated strategies reduced 
the incidence of CIAKI.
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Introduction
Primary percutaneous coronary intervention (PPCI) is the 
recommended method of coronary reperfusion in patients 
with ST-segment elevation myocardial infarction 
(STEMI).1,2 Given the pivotal pathophysiologic role of 
activated platelets in thrombotic coronary artery occlusion, 
dual-antiplatelet therapy (DAPT), consisting of aspirin plus 
an oral adenosine diphosphate (ADP) receptor (P2Y12) 
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antagonist (clopidogrel, prasugrel or ticagrelor), has been 
established as an important adjunct to PPCI.1,2 Despite the 
lack of clear supporting evidence, current guidelines rec-
ommend that a P2Y12 inhibitor should be given as early as 
possible to patients with STEMI and planned PPCI in order 
to favor and sustained reperfusion of the infarct-related 
artery (IRA), preventing peri-procedural thrombotic 
complications.1,2
Recently, the ATLANTIC (Administration of Ticagrelor 
in the Cath-Lab or in the Ambulance for New ST-Elevation 
Myocardial Infarction to Open the Coronary Artery) study 
showed that prehospital (in the ambulance) versus in-hospi-
tal (in the catheterization laboratory) treatment with tica-
grelor does not improve pre-PCI coronary reperfusion.3,4 In 
the era of fast-transfer protocols and short-time access to 
PPCI, this may be attributed to the lack of effective platelet 
inhibition at the time of angiography, given the known 
delay to the onset of action of oral antiplatelet agents in 
STEMI.5–7 However, the link between coronary reperfusion 
and the varying degrees of P2Y12 inhibition reached at the 
time of angiography is unknown in STEMI patients under-
going PPCI. Indeed, while there is convincing evidence 
showing that the risk of ischemic events after PCI increases 
in patients with high platelet reactivity (HPR) on treatment, 
there is limited evidence assessing the association between 
the level of residual P2Y12-mediated platelet reactivity and 
angiographic outcomes of PPCI for STEMI.8–10 Given the 
association between pre-PCI IRA patency, thrombotic bur-
den and post-PCI coronary perfusion with improved sur-
vival,11–13 understanding the effect of HPR on these 
surrogate endpoints would provide important insights into 
the clinical impact of achieving adequate P2Y12 inhibition 
as early as possible in the setting of PPCI. Therefore, the 
objective of this pharmacodynamic study conducted in 
STEMI patients undergoing PPCI who were pretreated 
with a P2Y12 receptor inhibitor was to investigate the 
impact of pre-PCI HPR on: 1) pre-PCI IRA patency; 2) 
thrombus burden; and 3) angiographic indices of coronary 
reperfusion.
Methods
Patient population
STEMI patients undergoing PPCI and platelet function test-
ing from October 2012 to August 2014 at the Ferrarotto 
Hospital-University of Catania, Catania, Italy, were collected 
as part of the prospective, observational PROMETHEUS 
(Platelet Reactivity of STEMI Patients on Antithrombotic 
Therapy Undergoing Primary Angioplasty) registry. Patients 
were enrolled if they were older than 18 years of age, admit-
ted with symptoms of ischemia lasting at least 30 minutes 
with an electrocardiographic ST-segment elevation >1 mm 
in two or more contiguous electrocardiogram leads or pre-
senting with a new left bundle branch block and if they were 
undergoing PCI at <12 hours of symptoms onset and were 
pretreated with a P2Y12 antagonist. Any of the oral P2Y12 
antagonists (clopidogrel, prasugrel or ticagrelor) was permit-
ted because the present study aimed to evaluate the associa-
tion between the absolute degree of P2Y12 inhibition reached 
at the time of angiography and the coronary reperfusion, 
regardless of which agent was used to reach this inhibition. 
Patients were excluded in case of the following: administra-
tion of fibrinolytics and/or glycoprotein IIb/IIIa inhibitors 
(GPIs) upstream for <30 days; presentation with stent throm-
bosis; culprit lesion located in a coronary bypass graft or in a 
vessel segment <2.0 mm; spontaneous dissection; cardio-
genic shock; chronic DAPT; concomitant use of other 
antithrombotic drugs (i.e., oral anticoagulant, dipyridamole, 
cilostazol or non-steroid anti-inflammatory drugs); aspirin 
allergy or intolerance; platelet count <100 × 106/mL; hema-
tocrit <25%; liver disease (bilirubin level >2 mg/dL); active 
bleeding; recent or chronic infective or inflammatory dis-
eases; any malignancy; recent stroke; surgery or trauma in 
the previous 30 days.
All patients underwent platelet function testing with the 
VerifyNow™ assay (Accumetrics, Inc., San Diego, CA, 
USA). From the beginning of the study in October 2012 to 
August 2013, only STEMI patients presenting during 
weekdays during regular working hours (8:00 a.m. to 8:00 
p.m.) were included in the registry due to logistics related 
to performing platelet function testing, also including light 
transmission aggregometry (LTA), at nights and weekends. 
After August 2013, only the VerifyNow™ assay was used, 
and all STEMI patients, including those presenting off-
hours, were also screened.
For the purpose of the present study, in order to define 
pre-PPCI HPR and to assess the associations between the 
latter and both pre- and post-PPCI angiographic outcomes, 
we used pharmacodynamic data derived from the 
VerifyNow™ assay measured before PPCI, immediately 
after diagnostic coronary angiography. Multiple angio-
graphic endpoints, as described below, were compared 
between patients with and without HPR measured at this 
time point. The local hospital Ethics Committee approved 
the study and informed consent was obtained from all 
patients. The study complied with the Declaration of 
Helsinki. The authors had full access to the data and take 
responsibility for its integrity.
Study medications and interventions
Upon presentation, all patients received aspirin 150 mg 
intravenously and an anticoagulant including unfraction-
ated heparin and weight-adjusted, low-molecular-weight 
heparin. All patients were pretreated in the emergency 
department or at the referring center with a loading dose of 
clopidogrel (600 mg), prasugrel (60 mg) or ticagrelor (180 
mg). The choice of the P2Y12 antagonist was left to the dis-
cretion of the referring physician. The antithrombotic 
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regimen during procedure, the use of thrombus aspiration 
and the type of stent were left to the discretion of the inter-
ventional cardiologist. PPCI was performed according to 
standard techniques.
Blood sampling and platelet function 
analysis
Blood samples for platelet function testing were collected 
from an antecubital vein immediately after coronary angi-
ography, before intra-procedural administration of any 
antithrombotic drug. The first 2–4 mL of blood were dis-
carded in order to avoid spontaneous platelet activation, 
and samples were processed for functional assessments 
within 1 hour after blood drawing.
The VerifyNow™ P2Y12 assay was performed in order 
to assess platelet function, as previously described,14 and 
was used to define HPR.8 This assay reports the results as 
P2Y12 reaction units (PRU), with higher values represent-
ing higher platelet reactivity. HPR was defined as PRU 
>208, in keeping with current standards.9
LTA was performed by the turbidimetric method in a 
two-channel aggregometer (Chrono-Log 490 Model, 
Chrono-Log Corp., Havertown, PA, USA) according to 
standard protocols.14 Platelet-rich plasma was obtained as a 
supernatant after centrifugation of citrated blood at 195 g 
for 10 minutes, and platelet-poor plasma was obtained by a 
second centrifugation of the blood fraction at 1528 g for 10 
minutes. Aggregation curves were recorded for 6 minutes. 
Maximum platelet aggregation (MPA) was measured at 
peak, following challenge with ADP (5 and 20 µM).14 
Based on the LTA findings, HPR was defined as MPA-ADP 
(20 µM) >59% and MPA-ADP (5 µM) >46%.8
Angiographic analysis
The angiographic images were acquired with a General 
Electric Innova 2100 single-plane system. For the angio-
graphic assessment after the procedure, a long final run at 
30 frames/second was acquired in specific projections in 
order to minimize the superimposition of the perfusion ter-
ritories of different arteries. Two experienced interven-
tional cardiologists (BF and YO), who were blinded to 
platelet function testing, adjudicated the angiographic out-
comes. All angiograms were assessed with respect to 
Thrombolysis in Myocardial Infarction (TIMI) flow scale 
of the IRA prior to and after PCI.15 The corrected TIMI 
frame count (cTFC) and the myocardial blush grade (MBG) 
were determined on the post-PCI final angiogram, as previ-
ously described.16,17
The thrombus score (TS) was used as an angiographic 
index of thrombotic burden at the site of stenosis and calcu-
lated on the pre-PCI angiogram. Intracoronary thrombus 
was scored in five grades as previously described.12 In 
brief, in TS grade 0, no cine-angiographic characteristics of 
thrombus are present; in TS grade 1, possible thrombus is 
present (i.e., reduced contrast density, haziness, irregular 
lesion contour or a smooth, convex “meniscus” at the site 
of total occlusion suggestive, but not diagnostic of throm-
bus); in TS grade 2, definite thrombus is present, with the 
greatest dimension at less than or equal to half of the vessel 
diameter; in TS grade 3, definite thrombus is present, but 
with the greatest linear dimension at greater than half but 
less than two vessel diameters; in TS grade 4, definite 
thrombus is present, with the largest dimension at greater 
than or equal to two vessel diameters; finally, in TS grade 5, 
there is a total occlusion (i.e., inability to assess thrombus 
burden due to total vessel occlusion).12 Since TS grade 5 is 
essentially a classification of flow and not of thrombus, 
patients initially presenting in this group were reclassified 
into one of the other four categories after vessel recanaliza-
tion by either wire crossing or passage/dilatation of a small 
(1.5-mm diameter) balloon.12
Study endpoints and sample size calculation
The primary endpoint was the rate of coronary artery 
patency prior to PCI, defined as TIMI flow grade 2 or 3. 
Assuming an incidence of 66% of TIMI flow grade 2 or 3 
in patients without HPR,10 we calculated that at least 46 
patients in each group (HPR and no-HPR) were needed to 
detect a relative difference of 50% in the rate of TIMI flow 
grade 2 or 3 between groups, assuming 90% power and a 
two-sided significance level of 0.05. This assumption was 
based on the results of the only available study assessing 
the impact of HPR on pre-procedural IRA patency.10
Secondary endpoints included: i) the rates of pre-PCI 
TIMI flow grade 3; ii) the rates of pre-PCI TS grade 3/4 or 
4 (high thrombus burden); iii) the rates of post-PCI TIMI 
flow grade <3 or MBG 0/1 (indices of impaired coronary 
perfusion); and iv) post-PCI cTFC (an angiographic index 
of myocardial perfusion used as a continuous variable).
Other secondary non-angiographic endpoints included 
⩾70% resolution of ST-segment elevation at 60 minutes 
after PCI and levels of cardiac enzymes (creatine kinase-
MB and troponin T) at peak.
Cardiac magnetic resonance
A cardiac magnetic resonance (CMR) assessment of infarct 
size and microvascular obstruction (MVO) was proposed 
for only the first 50 consecutive patients due to hospital 
resources and logistics. All CMR studies were performed 
from 7 to 10 days after the index event with a 1.5-Tesla 
MRI scanner (Achieva, Philips Medical Systems, The 
Netherlands). Long- and short-axis images were acquired 
using a standard cine steady-state free precession 
(SSFP), T2-weighted and inversion recovery fast gradient 
echo (IR-GRE) late gadolinium enhancement sequences. 
Anonymized images were independently assessed by an 
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external CMR core laboratory (CMR Unit, Bristol Heart 
Institute, Bristol, UK). The images were analyzed with a 
commercially available software program (CMR42, Circle 
Cardiovascular Imaging, Canada). Semi-automated com-
puter-aided threshold detection was used to identify regions 
of myocardium at risk, MVO, myocardial hemorrhage and 
infarcted myocardium, as previously described.18 The myo-
cardial edema and infarct size were expressed as a mass in 
grams (g).
Statistical analysis
Categorical variables are expressed as frequencies and per-
centages and were compared with the use of the chi-square 
test or Fisher’s exact test, as appropriate. Continuous varia-
bles were expressed as means ± standard deviations or as 
medians and inter-quartile ranges (IQRs), and were com-
pared by non-paired t-tests or Mann–Whitney’s U tests, as 
appropriate. To assess independent predictors of the primary 
endpoint, a multivariate binary logistic regression model 
was used for estimating the odds ratio (OR) and the corre-
sponding 95% confidence interval (95% CI). First, a uni-
variate exploratory analysis was performed to test for the 
association of the primary endpoint with HPR and several 
potentially impacting variables. Next, only those variables 
with a p-value of ⩽0.10 were entered en-bloc into the mul-
tivariate models. Tested variables included: age, male gen-
der, hypertension, hyperlipidemia, diabetes mellitus, prior 
myocardial infarction Killip’s class, left anterior descending 
as culprit vessel, culprit vessel reference diameter, time 
from symptom onset to P2Y12 loading dose, time from the 
P2Y12 inhibitor administration to coronary angiography, 
total ischemic time and the use of clopidogrel and morphine. 
Furthermore, univariate linear regression analysis was 
performed with cTFC as the dependent variable. The tested 
variables were the same entered into the binary logistic 
regression model as covariates, plus culprit vessel stent 
length, thrombus aspiration and high thrombotic burden as 
previously defined. Next, a multivariate linear regression 
analysis included those variables with a p-value of ⩽0.10 at 
the univariate analysis plus thrombectomy.
A p-value of <0.05 was considered statistically signifi-
cant. Statistical analysis was performed using SPSS version 
15.0 software (SPSS Inc., Chicago, IL, USA).
Results
A total of 164 patients who fulfilled the eligibility criteria 
were included in the study (Figure 1). At a median time 
of 55 (IQR 40–75) minutes from the loading dose 
administration to angiography, the mean PRU value was 
227.9 ± 82.0, and a PRU value >208 was observed in 117 
(71.3%) patients.
Clinical and procedural characteristics of patients with 
and without HPR are listed in Tables 1 and 2, respectively. 
There were no significant differences in patient demo-
graphics and clinical characteristics according to HPR, 
except for the type of PY12 inhibitor, with clopidogrel and 
ticagrelor being more often administered to patients with 
and without HPR, respectively (Table 1). Clopidogrel was 
only used in 14 patients overall. No significant differences 
between groups were noted with respect to all procedural 
variables, with the exception of manual thrombus aspira-
tion, which was more frequently performed in the HPR 
group, and the mean culprit vessel reference diameter, 
which was slightly higher in patients with HPR.
Key time intervals according to HPR status are listed 
in Table 3, with no evidence of significant differences 
Figure 1. Study flow chart.
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between the two groups, except for the time interval from 
P2Y12 inhibitor loading dose administration to angiography 
(65 [IQR 50–90] minutes vs. 50 [IQR 40–70] minutes, 
p = 0.0002), and for the total ischemic time (220 [IQR 
160–365] minutes vs. 190 [IQR 145–242] minutes, p = 0.02), 
which were slightly longer in patients without HPR. After 
excluding the seven patients receiving the P2Y12 inhibitor 
more than 2 hours before angiography, there were no more 
Table 1. Baseline clinical characteristics of study patients according to pre-procedural HPR status.
Variable Overall population 
(n = 164)
No-HPR PRU ⩽208 
(n = 47)
HPR PRU >208 
(n = 117)
p-value
Age, years 61.2 ± 11.8 61.8 ± 11.2 61.0 ± 12.0 0.68
Male gender, n (%) 120 (73.2) 35 (74.5) 85 (72.6) 0.97
Body mass index, kg/m2 27.4 ± 4.1 27.1 ± 4.1 27.5 ± 4.2 0.61
Hypertension, n (%) 95 (57.9) 22 (46.8) 73 (62.4) 0.10
Hyperlipidemia, n (%) 57 (34.8) 17 (36.2) 40 (34.2) 0.95
Diabetes, n (%) 31 (18.9) 7 (14.9) 24 (20.5) 0.54
Smoking, n (%) 107 (65.2) 35 (74.5) 72 (61.5) 0.16
Killip’s class, n (%) 0.33
 I 135 (82.3) 36 (76.6) 99 (84.6)  
 II 28 (17.1) 11 (23.4) 17 (14.5)  
 III 1 (0.6)  0 1 (0.9)  
P2Y12 inhibitor LD, n (%) 0.03
 Clopidogrel 14 (8.5) 1 (2.1) 13 (11.1)  
 Prasugrel 63 (38.4) 14 (29.8) 49 (41.9)  
 Ticagrelor 87 (53.0) 32 (68.1) 55 (47.0)  
Anticogulation at ED, n (%) 0.91
 UFH bolus 137 (83.5) 40 (85.1) 97 (82.9)  
 LMWH 27 (16.5) 7 (14.9) 20 (17.1)  
Morphine use 42 (25.6) 11 (23.4) 31 (26.5) 0.83
Time of blood sampling, n (%) 0.38
 6 a.m.–12 p.m. 46 (28.0) 13 (27.7) 33 (28.2)  
 12 p.m.–18 p.m. 65 (39.6) 23 (48.9) 42 (35.9)  
 18 p.m.–24 a.m. 33 (20.1) 7 (14.9) 26 (22.2)  
 24 a.m.–6 a.m. 20 (12.2) 4 (8.5) 16 (13.7)  
HPR: high platelet reactivity; ED: emergency department; LD: loading dose; LMWH: low molecular weight heparin; UFH: unfractionated heparin.
Table 2. Procedural characteristics of study patients according to pre-procedural HPR status.
Variable Overall population 
(n = 164)
No-HPR PRU ⩽208 
(n = 47)
HPR PRU >208 
(n = 117)
p-value
Culprit vessel, n (%) 0.26
  LAD 84 (51.2) 21 (44.7) 63 (53.8)  
  LCx 19 (11.6) 4 (8.5) 15 (12.8)  
  RCA 61 (37.2) 22 (46.8) 39 (33.3)  
Intervention, n (%) 0.84
  Bare metal stent 27 (16.5) 8 (17.0) 19 (16.2)  
  Drug-eluting stent 129 (78.7) 36 (76.6) 93 (79.5)  
  Balloon angioplasty 8 (4.9) 3 (6.4) 5 (4.3)  
Manual thrombus aspiration, n (%) 93 (56.7) 18 (38.3) 75 (64.1) 0.004
Mean vessel diameter 3.3 ± 0.48 3.2 ± 0.46 3.4 ± 0.48 0.04
Mean stent length 27.4 ± 12.2 27.1 ± 12.4 27.5 ± 12.1 0.86
GPI use, n (%) 64 (39.0) 14 (29.8) 50 (42.7) 0.17
GPI bailout, n (%) 19 (11.6) 4 (8.5) 15 (12.8) 0.61
Bivalirudin use, n (%) 16 (9.8) 6 (12.8) 10 (8.5) 0.59
HPR: high platelet reactivity; LAD: left anterior descending; LCx: left circumflex artery; RCA: right coronary artery; GPI: glycoprotein IIb/IIIa inhibitor.
Data are presented as mean ± standard deviation when appropriate.
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the significant differences in the time from P2Y12 inhibitor 
loading dose administration to angiography and in total 
ischemic time between the HPR and no-HPR groups.
There were no significant differences in demographic 
and clinical characteristics according to HRP defined using 
LTA. No significant differences between HPR and no-HPR 
groups as defined with LTA were found for all procedural 
variables, except for manual thrombus aspiration and for 
bare metal stent implantation, which were both more fre-
quently performed in the HPR group. Finally, with regards 
to the key time intervals according to HPR status defined 
with LTA, no evidence of significant differences between 
the two groups was found, except for the time intervals 
from P2Y12 inhibitor loading dose administration to angi-
ography and from symptom onset to PPCI, which were 
slightly longer in patients without HPR.
HPR and pre-PCI angiographic parameters
Pre-PCI TIMI flow grades 2/3 or 3 at the baseline angio-
gram were found in 65 (39.6%) and 41 (25.0%) patients, 
respectively. A significantly lower rate of the primary end-
point of pre-PCI TIMI flow grades 2 or 3 was observed in 
the HPR group compared with the no-HPR group (32.5% 
vs. 51.1%, p = 0.04) (Figure 2). Similar findings were repli-
cated in the subgroup in which HPR was defined using 
LTA (Table 4). The rate of pre-PCI TIMI flow grade 3 was 
numerically, albeit not significantly, lower in the HPR 
group compared with the no-HPR group (22.2% vs. 31.9%, 
p = 0.27) (Figure 2).
In the binary logistic multivariate analysis, HPR was 
negatively associated with the primary endpoint (OR 0.43, 
95% CI 0.20–0.94, p = 0.03) (Table 5). Other independent 
predictors of lower rates of the primary endpoint included 
Killip’s class on admission and morphine use (Table 5).
Half of the population (n = 83, 50.6%) presented with an 
occluded vessel (TS grade 5) and reclassification into a 
thrombus grade 0–4 was feasible in all of these patients 
after recanalization. TS grades 3/4 or 4 at baseline angio-
gram were found in 75 (45.7%) and 45 (27.4%) patients, 
respectively. Higher rates of patients with a TS grade 3/4 
(52.1% vs. 29.8%, p = 0.015) and TS grade 4 (32.5% vs. 
14.9%, p = 0.037) were observed in the HPR group compared 
with the no-HPR group, respectively (Figure 3). Among 
patients with TS grade 4 (n = 45), 85.7% vs. 18.4% of those 
without and with HPR, respectively, had received a P2Y12 
inhibitor loading dose at >3 hours from symptom onset.
Similar findings were found after excluding the 14 
patients receiving clopidogrel. Moreover, the results were 
consistent after excluding seven patients receiving the 
P2Y12 inhibitor at more than two hours before angiography.
HPR and post-PCI outcomes
Post-PCI TIMI flow grades 0/1, 2 and 3 were observed in 6 
(3.7%), 31 (18.9%) and 127 (77.4%) patients, respectively. 
The rates of final TIMI flow grade <3 or MBG 0/1 
Table 3. Timing intervals of study patients according to pre-procedural HPR status.
Variable Median (interquartile range), min
Overall population 
(n = 164)
No-HPR PRU ⩽208 
(n = 47)
HPR PRU >208 (n = 117) p-value
Symptom onset to P2Y12 inhibitor 120 (70–190) 120 (80–240) 110 (70–180) 0.21
Symptom onset to PPCI 193 (145–264) 220 (160–335) 190 (145–242) 0.02*
ED to PPCI 100 (85–138) 100 (85–160) 100 (85–121) 0.33
Heparin to angiography 73 (60–108) 70 (60–125) 75 (60–100) 0.73
P2Y12 inhibitor loading to angiography 55 (40–75) 65 (50–90) 50 (40–70) 0.002*
HPR: high platelet reactivity; PPCI: primary percutaneous coronary intervention; ED: emergency department;
*These differences were no more significant after excluding the seven patients receiving the P2Y12 inhibitor at >2 hours before angiography.
Figure 2. Rates of pre-procedure TIMI flow grades 2/3 or 3 
according to the HPR status defined using PRU.
Bars represent the percentages of patients with pre-PCI TIMI flow 
grades 2/3 or 3 among the subgroups without HPR (red bars) and with 
HPR (blue bars).
TIMI: Thrombolysis in Myocardial Infarction; HPR: high platelet reactiv-
ity; PRU: P2Y12 reaction units.
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(no-reflow) were 22.6% and 21.3%, respectively. No sig-
nificant differences in the rates of post-PCI TIMI flow 
grade <3 (23.9% vs. 19.1%, p = 0.65) and MBG grade 0/1 
(23.1% vs. 17.0%, p = 0.52) were observed between the 
HPR and no-HPR groups, respectively.
In the overall population, the median of cTFC was 25.9 
(IQR 20.0–34.6), with significantly lower values in the no-
HPR group compared with the HPR group, 23.2 (IQR 
15.8–32.5) vs. 26.0 (IQR 21.0–35.0), p = 0.02, respectively) 
(Figure 4). Consistent results with regards to the rates of 
post-PCI TIMI flow grade <3 or MBG 0/1 and cTFC were 
found when HPR was defined using LTA (Table 4).
After adjusting for potential confounders, age (β 0.19, 
p = 0.01), diabetes (β 0.16, p = 0.03), TS grade 4 (β 0.31, 
p < 0.001) and HPR (β 0.15, p = 0.05) were independently 
associated with higher cTFC (Table 6).
In addition, similar findings were observed after excluding 
the 14 patients receiving clopidogrel and among patients only 
receiving the P2Y12 inhibitor at 2 hours before angiography.
The proportion of patients with ⩾70% resolution of 
ST-segment elevation at 60 minutes was numerically higher 
in the no-HPR group compared with the HPR group (72.3% 
vs. 58.1%, respectively, p = 0.12), although this difference 
did not reach statistical significance.
Table 4. Angiographic outcomes according to the pre-procedural HPR status defined using light transmission aggregometry.
Variable No-HPR HPR p-value No-HPR HPR p-value
 MPA-ADP (5 μM) 
⩽46% (n = 36)
MPA-ADP (5 μM) 
>46% (n = 50)
MPA-ADP (20 μM) 
⩽59% (n = 22)
MPA-ADP (20 μM) 
>59% (n = 64)
 
Pre-PCI TIMI flow grades 
2 or 3, n (%)
19 (52.8) 14 (28.0) 0.04 12 (54.5) 21 (32.8) 0.12
Thrombus score grade 
3/4, n (%)
13 (36.1) 28 (56.0) 0.11 8 (36.4) 33 (51.6) 0.33
Thrombus score grade 
4, n (%)
5 (13.9) 15 (30.0) 0.14 2 (9.1) 18 (28.1) 0.13
Post-PCI TIMI flow grade 
<3, n (%)
9 (25.0) 15 (30.0) 0.79 6 (27.3) 18 (28.1) 1.00
Post-PCI MBG 0/1, n (%) 6 (16.7) 18 (36.0) 0.08 4 (18.2) 20 (31.2) 0.37
Corrected TIMI frame 
count*
25 (18.5–34.8) 30 (22–48.2) 0.01 25 (7.5–33.5) 30 (22.0–44.6) 0.04
HPR: high platelet reactivity; MPA: maximum platelet aggregation; ADP: adenosine diphosphate; PCI: percutaneous coronary intervention; TIMI: 
Thrombolysis in Myocardial Infarction; MBG: myocardial blush grade.
*Expressed as median (interquartile range).
Table 5. Univariate and multivariate models for predicting pre-PCI TIMI flow grade 2 or 3 (primary endpoint).
Variable Univariate OR (95% CI) p-value Multivariate OR (95% CI) p-value
Age 0.98 (0.95–1.01) 0.11 – –
Male gender 1.38 (0.67–2.84) 0.38 – –
Hypertension 0.36 (0.19–0.69) 0.002 0.56 (0.27–1.16) 0.12
Hyperlipidemia 0.52 (0.26–1.04) 0.06 0.73 (0.33–1.61) 0.43
Diabetes 0.56 (0.24–1.31) 0.18 – –
Prior myocardial infarction 0.33 (0.11–1.04) 0.06 0.87 (0.23–3.30) 0.84
Killip’s class on admission 0.26 (0.10–0.72) 0.01 0.23 (0.07–0.75) 0.01
LAD culprit 1.24 (0.66–2.32) 0.50 –  
Vessel diameter 0.48 (0.24–0.96) 0.04 0.58 (0.27–1.26) 0.17
Symptom onset to P2Y12 inhibitor 0.99 (0.99–1.02) 0.43 – –
P2Y12 to angiography 1.00 (0.99–1.01) 0.84 – –
Symptom onset to PPCI 0.99 (0.94–1.00) 0.37 – –
Heparin to angiography 1.00 (0.99–1.01) 0.99 – –
Clopidogrel 0.91 (0.30–2.84) 0.87 – –
Morphine 0.49 (0.23–1.07) 0.08 0.42 (0.18–0.99) 0.05
HPR >208 0.52 (0.26–1.03) 0.06 0.43 (0.19–0.94) 0.03
PCI: percutaneous coronary intervention; TIMI: Thrombolysis in Myocardial Infarction; OR: odds ratio; CI: confidence interval; LAD: left anterior 
descending; PPCI: primary percutaneous coronary intervention; HPR: high platelet reactivity.
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The peak levels of creatine kinase-MB (133 ± 110 vs. 166 
± 90 ng/mL, p = 0.045) and troponin T (3217 ± 2657 vs. 4272 
± 3130 ng/L, p = 0.044) were significantly lower in the no-
HPR group compared with the HPR group, respectively.
Seven (4.3%) clinical adverse events occurred in-hospi-
tal. These included four cardiovascular death (2.4%) and 
three (1.8%) non-fatal acute stent thromboses. Six of these 
events occurred in patients with HPR; only one event 
(death) occurred in a patient without HPR.
CMR findings
Among the 50 first patients enrolled in the registry, CMR 
was performed in 41 (82%), and quantified imaging analy-
sis was possible in 36 (72%) patients. Among these 36 
patients included in the analysis, 20 (55.5%) had HPR and 
16 (44.4%) had no-HPR. No relevant significant differ-
ences between these HPR and no-HPR subgroups were found 
for clinical characteristics, procedural variables and time 
intervals. Compared with no-HPR patients, those with HPR 
had a significantly higher area at risk (30 g [IQR 18.3–41] 
vs. 13 g [IQR 1–36.3], p = 0.04) and a trend towards higher 
infarct mass (23 g [IQR 11.8–38.5] vs. 13.5 [IQR 5–27.5], 
p = 0.07), respectively. MVO was observed in five cases 
(13.9%): four (20%) with HPR and one (6.3%) with no 
HPR. Intra-myocardial hemorrhage was found in two 
patients: one with HPR (but receiving GPI in bailout) and 
one with no HPR.
Discussion
The impact on coronary reperfusion of different degrees of 
residual P2Y12-mediated platelet reactivity, regardless of the 
type of oral antagonist given in order to achieve this inhibi-
tion, has been poorly investigated in the setting of PPCI for 
STEMI.19 In an attempt to fill this gap, the present observa-
tional study prospectively assessed ADP-induced platelet 
reactivity prior to PPCI in patients with STEMI who were 
pretreated with a loading dose of an oral P2Y12 receptor 
antagonist and reported on their angiographic outcomes 
according to the achieved level of residual P2Y12-mediated 
platelet reactivity. The main findings of our study can be 
summarized as follows: 1) at the time of initial angiography, 
after pretreatment with a loading dose of any P2Y12 inhibi-
tor, approximately two-thirds of patients were found to have 
HPR; 2) pre-PCI IRA patency, defined as TIMI flow grade 
2 or 3, was more commonly observed in patients without 
HPR; 3) HPR, as well as Killip’s class on admission and 
morphine use, were independently associated with lower 
pre-PCI TIMI grade 2 or 3, even after adjustment for clopi-
dogrel use and time from P2Y12 administration to angiogra-
phy; 4) high thrombus burden prior to PCI, which emerged 
as a predictor of lower cTFC, was significantly lower in the 
no-HPR group; 5) HPR was independently associated with 
higher cTFC, an index of impaired myocardial perfusion; 6) 
no significant differences in the rates of no-reflow were 
found between the two groups; 7) stent thrombosis resolu-
tion was numerically lower in the HPR group without reach-
ing statistical significance; and 8) HPR patients tended to 
Figure 3. Rates of thrombus score grades 3/4 or 4 according 
to the HPR status defined using PRU.
Bars represent the percentages of patients with thrombus score grades 
3/4 or 4 among the subgroups without HPR (red bars) and with HPR 
(blue bars).
HPR: high platelet reactivity; PRU: P2Y12 reaction units.
Figure 4. cTFC according to the HPR status defined using 
PRU.
Values of cTFC are reported among the subgroups without HPR (“0”) 
and with HPR (“1”). The central box represents the values from the 
lower to upper quartile (25th–75th percentile). The middle horizontal 
line represents the median (50th percentile). The vertical line extends 
from the minimum to the maximum value within 1.5 box heights from 
the top or bottom of the box. Outliers are displayed as separate points.
cTFC: corrected TIMI frame count; TIMI: Thrombolysis in Myocardial 
Infarction; HPR: high platelet reactivity; PRU: P2Y12 reaction units.
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have higher infarct sizes and areas at risk, as assessed by 
CMR. Overall, these observations support the hypothesis 
that in patients with STEMI undergoing PPCI, achieving an 
adequate level of P2Y12-mediated platelet inhibition at the 
time of initial angiography may be beneficial in terms of 
better pre- and post-PCI angiographic outcomes.
The optimal timing of P2Y12 inhibitor initiation in the 
setting of PPCI for STEMI has not been established yet. 
Current guidelines on STEMI management recommend 
that a loading dose of a P2Y12 receptor antagonist should be 
given as early as possible.1,2 However, this recommenda-
tion is not supported by strong clinical evidence.3,20–26 
Observational investigations evaluating pre-hospital versus 
peri-interventional clopidogrel administration in PPCI for 
STEMI20–26 suggested that clopidogrel pretreatment was 
associated with improved pre-PCI patency and post-PCI 
myocardial perfusion21 and some degree of clinical bene-
fit.21–23 Conversely, in two small randomized studies, clopi-
dogrel pretreatment in the ambulance was not shown to 
improve pre- and post-PCI reperfusion, most likely because 
of too short (about 1 hour) clopidogrel loading-to-angiogra-
phy time.24,25 The recently published ATLANTIC trial has 
found no benefit in terms of pre-PCI coronary reperfusion 
of prehospital treatment with ticagrelor in STEMI patients 
undergoing PPCI.3 In light of our observations suggesting a 
negative association between HPR and pre-PCI patency 
and myocardial perfusion, the lack of benefit in reperfusion 
with pretreatment in these latter randomized studies might 
be explained by the failure to achieve a difference between 
the compared groups (pretreatment vs. no pretreatment) in 
the proportions of patients with adequate platelet inhibition 
over a too-short time difference in P2Y12 antagonist loading 
dose-to-angiography (the median loading dose-to-angiog-
raphy time difference between the two treatment strategies 
was 31 minutes in the ATLANTIC study). Indeed, in the 37 
patients undergoing platelet function testing in the 
ATLANTIC study, platelet reactivity at the time of angiog-
raphy was similarly high between prehospital and in-hospi-
tal administration of ticagrelor, being above the threshold 
defining HPR.3 Therefore, based on our results, we specu-
late that pretreatment with agents with faster onsets of 
action could be associated with better reperfusion outcomes 
compared with no pretreatment or very short pretreatment 
times with currently approved oral P2Y12 inhibitors.
Recently published data have shown that prasugrel com-
pared with clopidogrel provided better coronary reperfu-
sion after PPCI for STEMI, implying a beneficial effect of 
achieving more potent P2Y12 inhibition.26,27 In addition to 
this, our observation that pre-PCI IRA patency and post-
PCI myocardial perfusion are better in patients without 
HPR prior to PPCI suggests that there is a need to achieve 
effective inhibition of ADP-mediated pathways as soon as 
possible. Although the novel P2Y12 antagonists prasugrel 
and ticagrelor are faster and more potent inhibitors than 
clopidogrel, recent studies have shown that both drugs 
exhibit an initial delay in the onset of their antiplatelet 
action in patients with STEMI undergoing PPCI,5–7 with a 
consistent proportion of patients, ranging from 35% to 
50%, persisting with a PRU of >208 at 2 hours after tica-
grelor or prasugrel loading doses.5–7 These latter observa-
tions provide a basis for investigating alternative antiplatelet 
agents with faster onsets of action.
Table 6. Univariate and multivariate predictors of corrected TIMI frame count.
Variables Univariate β coefficient p-value Multivariate β coefficient p-value
Age 0.22 0.005 0.19 0.02
Male gender 0.02 0.78 – –
Hypertension 0.05 0.54 – –
Hyperlipidemia 0.01 0.91 – –
Diabetes 0.23 0.004 0.18 0.02
Prior myocardial infarction 0.04 0.63 – –
Killip’s class on admission 0.03 0.67 – –
LAD culprit 0.04 0.62 – –
Thrombus aspiration 0.11 0.18 0.10 0.21
Vessel diameter 0.12 0.15 – –
Stent length 0.05 0.53 – –
Symptom onset to P2Y12 inhibitor 0.03 0.74 – –
P2Y12 to angiography 0.10 0.22 – –
Symptom onset to PPCI 0.08 0.31 – –
Clopidogrel 0.09 0.27 – –
Morphine 0.08 0.31 – –
HPR >208 0.18 0.02 0.16 0.04
Thrombus burden grade 4 0.33 <0.001 0.29 <0.001
TIMI: Thrombolysis in Myocardial Infarction; LAD: left anterior descending; PPCI: primary percutaneous coronary intervention; HPR: high platelet 
reactivity.
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An option for achieving rapid and effective P2Y12 inhibi-
tion is represented by cangrelor, which is a direct-acting, 
intravenously administered, highly selective P2Y12 antago-
nist with a short half-life (≈2.6 minutes) and a rapid onset and 
offset (30–60 minutes) of action.28 The pharmacologic profile 
of cangrelor makes it an attractive strategy when fast P2Y12 
inhibition is needed. A recent trial (CHAMPION-PHOENIX) 
showed that cangrelor compared with clopidogrel signifi-
cantly reduced ischemic events at 48 hours in about 11,000 
subjects undergoing PCI for stable angina or acute coronary 
syndrome, including STEMI.29 However, in this latter study, 
cangrelor was not given upstream and patients did not receive 
pretreatment with other P2Y12 inhibitors. Cangrelor was 
recently approved in Europe and the USA in patients under-
going PCI. The effects of cangrelor on reperfusion indices 
remain to be determined, and further dedicated studies with 
cangrelor in the setting of STEMI will be conducted.
An intriguing finding of our study is represented by the 
evidence of a significant independent association between 
HPR and a well-validated angiographic index of microvas-
cular dysfunction, namely cTFC.30 Several mechanisms 
can explain this association. Distal embolization of athero-
thrombotic debris during PCI leading to mechanical occlu-
sion of microvessels and to activation of coagulation and 
inflammation pathways is one of the key mechanisms 
underlying microvascular dysfunction.31 Higher thrombus 
burden has been correlated to distal embolization leading to 
microvascular dysfunction.32 Consistently, in our study, a 
TS of grade 4 emerged as an independent predictor of lower 
cTFC, regardless of thrombectomy, which was higher in 
the HPR group. The observed association between HPR 
and increased rates of high TS may explain the impact of 
HPR on microvascular dysfunction. Furthermore, it has 
been suggested that intracoronary platelet-derived micro-
particles (PMPs) have a direct role in the pathogenesis of 
microvascular impairment, perhaps favoring thrombus 
generation in the coronary microcirculation.33 As PMPs are 
released upon platelet activation, P2Y12-mediated platelet 
inhibition might decrease levels of intracoronary PMPs and 
thus, in turn, improve microvascular perfusion indepen-
dently of the thrombotic burden.34
Study limitations
Owing to the sample size, a single-center prospective 
investigation such as this should be regarded as exploratory 
and hypothesis generating, especially with regards to post-
PCI outcomes. While the single-center design may limit the 
generalizability of the present results, it allows for a reduc-
tion of procedure heterogeneity, potentially introducing 
fewer confounding variables. Nevertheless, our results 
need to be confirmed in larger multicenter studies. Although 
we have performed a multivariate analysis, due to the 
observational design of our investigation, the direct effects 
of several confounders, such as the use of morphine, cannot 
be completely excluded. The association between HPR and 
clinical outcomes was not evaluated in the present analysis, 
which focused on angiographic endpoints. Ultimately, for 
the sake of the feasibility of conducting platelet function 
testing using multiple assays, in the first study period, when 
LTA was also performed, only patients who presented on 
weekdays during regular working hours were recruited. 
However, the clinical characteristics and time intervals of 
off-hours and on-hours patients were not significantly dif-
ferent (data not shown). In addition, it appears unlikely that 
the time of enrollment will have impacted on the associa-
tion between the absolute levels of platelet inhibition and 
reperfusion, which was the primary focus of the present 
study. In any case, no significant differences were observed 
between the no-HPR and HPR groups in the 6-hour time 
intervals of the day in which blood was collected. Finally, 
although angiography is limited in terms of accurately 
assessing thrombus, the angiographic estimation of throm-
bus burden according to the applied classification is practi-
cal in an urgent setting such as STEMI and has been related 
to survival.
Conclusions
In patients undergoing PPCI for STEMI who were pre-
treated with a P2Y12 receptor inhibitor, an adequate level of 
ADP-induced platelet reactivity inhibition assessed at the 
time of initial coronary angiography was found to be asso-
ciated with higher pre-PCI IRA patency and significantly 
lower thrombotic burden. Regarding post-PCI coronary 
reperfusion, only one index (cTFC) of angiographic reper-
fusion was improved in the no-HPR group, while there 
were no significant differences in categorical variables 
such as no-reflow and stent thrombosis resolution. 
Moreover, the CMR assessment (performed only in a sub-
group of patients) showed trends towards reduced area at 
risk and infarct size in the no-HPR group. Overall, our find-
ings suggest that achieving effective P2Y12 inhibition as 
early as possible in STEMI might be useful for pre-PCI 
patency and probably for post-PCI outcomes. In addition, 
these observations may have relevant therapeutic implica-
tions for patients presenting with STEMI and planned 
PPCI. Indeed, given current fast-transfer protocols and 
rapid access to PPCI, along with the known delay to the 
onset of action of oral P2Y12 antagonists in STEMI, faster-
acting intravenous agents such as cangrelor might be useful 
in the STEMI setting in order to potentially improve reper-
fusion and achieve better clinical outcomes, but data are 
needed in order to assess this latter claim. Nevertheless, our 
results need confirmation in adequately powered studies, 
especially for post-PCI reperfusion outcomes.
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Impact of proton pump inhibitors on clinical
outcomes in patients treated with a 6- or
24-month dual-antiplatelet therapy duration:
Insights from the PROlongingDual-antiplatelet
treatment after Grading stent-induced Intimal
hyperplasia studY trial
GiuseppeGargiulo, MD, a,b Francesco Costa, MD, c,d Sara Ariotti, MD, a SimoneBiscaglia, MD, e Gianluca Campo,MD, e
Giovanni Esposito, MD, PhD, b Sergio Leonardi, MD, f Pascal Vranckx, MD, PhD, g Stephan Windecker, MD, a and
Marco Valgimigli, MD, PhDa,c Bern, Switzerland; Naples, Messina, Ferrara, Pavia, Italy; Ferrara, Italy; Rotterdam,
The Netherlands; and Hasselt, Belgium
Background Proton pump inhibitors (PPIs) are frequently prescribed in combination with clopidogrel, but conflicting data
exist as to whether PPIs diminish the efficacy of clopidogrel.We assessed the association between PPI use and clinical outcomes for
patients treated with percutaneous coronary intervention (PCI) and dual-antiplatelet therapy (DAPT) with clopidogrel plus aspirin.
Methods and results In the PRODIGY trial, 1,970 patients were randomized to 6- or 24-month DAPT at 30 days
from index procedure. Among them, 738 patients (37.5%) received PPI (mainly lansoprazole; 90.1%) at the time of
randomization. Proton pump inhibitor users were older, were most likely to be woman, had a lower creatinine clearance,
presented more frequently with acute coronary syndrome, and had a higher CRUSADE bleeding score. After adjustment, the
primary efficacy end point (composite of all-cause death, myocardial infarction, and cerebrovascular accident) was similar
between no PPI and PPI users (9.2% vs 11.5%, adjusted hazard ratio [HR] 1.051, 95% CI 0.788-1.400, P = .736). Bleeding
rates did not differ between the 2 groups (Bleeding Academic Research Consortium type 2, 3, or 5: adjusted HR 0.996, 95%
CI 0.672-1.474, P = .980). Net clinical adverse events were also similar in no PPI and PPI patients (12.9% vs 14.9%, adjusted
HR 0.99, 95% CI 0.772-1.268, P = .93). Results remained consistent at sensitivity analysis when focusing on the 548 patients
who remained on PPI for the whole study duration.
Conclusions The current findings suggest that the concomitant use of PPIs, when clinically indicated, in patients
receiving clopidogrel is not associated with adverse clinical outcome. (Am Heart J 2016;174:95-102.)
Dual-antiplatelet therapy (DAPT) is the cornerstone of
antithrombotic treatment in patients undergoing percu-
taneous coronary intervention (PCI), although its optimal
duration still remains debated.1-3 Notably, these patients
are frequently treated with a proton pump inhibitor (PPI)
to prevent gastrointestinal (GI) complications such as
ulceration and bleeding or due to preexisting gastric
disease.4-7 However, clopidogrel is a prodrug that requires
metabolic transformation in the liver by cytochrome P-450
isoenzyme (mainly CYP2C19) to elicit its antiplatelet effect.
Proton pump inhibitors are also metabolized by CYP
enzymes, leading to a potential inhibition of CYP2C19
(mainly omeprazole and esomeprazole) translating into
reduced metabolic activation of clopidogrel when taken
together. Indeed, some pharmacodynamic studies dem-
onstrated a reduction of clopidogrel-induced antiplatelet
effect when a PPI, mainly omeprazole, was concomi-
tantly administered.8-11 The Food and Drug Administra-
tion and the European Medicine Agency discourage the
From the aDepartment of Cardiology, Bern University Hospital, Bern, Switzerland,
bDepartment of Advanced Biomedical Sciences, Federico II University of Naples, Naples,
Italy, cThoraxcenter, ErasmusMedical Center, Rotterdam, TheNetherlands, dDepartment of
Clinical and Experimental Medicine, Policlinico “G. Martino,” University of Messina,
Messina, Italy, eCardiovascular Institute, Azienda Ospedaliero-Universitaria Sant’Anna,
Ferrara, Italy, fFondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy, and gDepartment
of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Hasselt, Belgium.
Clinical trial registration: RCT no. NCT00611286.
Submitted October 12, 2015; accepted January 20, 2016.
Reprint requests: Marco Valgimigli, MD, PhD, Department of Cardiology, Bern University
Hospital, CH-3010 Bern, Switzerland.
E-mail: marco.valgimigli@insel.ch
0002-8703
© 2016 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ahj.2016.01.015
Clinical Investigation
concomitant use of omeprazole and clopidogrel.12,13
The clinical impact of the combined administration has
been studied, but results have been discordant, with some
studies reporting an increased risk of cardiovascular
adverse events, whereas others did not confirm this
concern.5-7,11,14-23 Pooled analyses also provided inconclu-
sive results, owing to the risk ofmisinterpretation related to
poor-quality observational studies, thus supporting the
need for high-quality studies.14,15
Therefore, the purpose of the present subanalysis of
the PRODIGY randomized trial is to assess whether
medical therapy with PPI compared to that without PPI
may impact clinical outcomes in the setting of an all-comer
population undergoing PCI and with a randomly allocated
short (6months) or prolonged (24months) DAPT regimen,
consisting of clopidogrel and aspirin.
Methods
The design andmain findings of the PRODIGYhave been
previously reported.1,24 Briefly, all-comer PCI patients
receiving a balanced mixture of stents with varying
anti-intimal hyperplasia potency and belonging to both
first- and second-generation drug-eluting stent (DES) at
3 Italian sites were randomly allocated at 30 days to either
6 or 24 months of DAPT. Selection criteria were broad,
reflecting routine clinical practice. Randomization to
6- or 24-month DAPT was stratified by center, ongoing
ST-segment elevation myocardial infarction (MI), the
presence of diabetes mellitus, and need for intervening of
at least 1 in-stent restenotic lesion. The studywas conducted
in accordance with the principles of the Declaration of
Helsinki. The Ethics Committees of the 3 participating
centers independently approved the protocol, and all
participants gave written informed consent.
Treatment protocol
All patients received aspirin (75-100mg orally indefinitely)
and clopidogrel (75 mg/d) according to the randomization
scheme as follows: for either 6 months in the short DAPT
armor 24months in theprolongedDAPTarm irrespective of
the previously implanted stent type or indication for PCI.
Follow-up
The randomized patients returned for study visits at
30 days and then every 6 months up to 2 years. During
follow-up visits, patients were examined and assessed for
adverse events and asked for the antiplatelet therapy
compliance, and 12-lead electrocardiogram recordings
were obtained.
Proton pump inhibitor use
The decision to start the treatment with a PPI as well as
the type of PPI to be used was left at the physician's
discretion and was not randomly assigned or mandated
by protocol. Proton pump inhibitor use was identified
both at study baseline and at each study follow-up visit,
along with other concomitant medication use. For the
present analysis, patients were defined as PPI users if on
treatment at 30-day follow-up visit, at the time point
when the randomization to short- versus long-term DAPT
was performed. We performed sensitivity analyses to
investigate the effect of PPI versus no PPI on clinical
outcomes after excluding patients who had changed their
initial status (no PPI or PPI) during the follow-up.
Study end points
The primary efficacy end point of the PRODIGY trial was
the composite of death, MI, or cerebrovascular accident
(CVA), whereas the key safety end point included Bleeding
Academic Research Consortium (BARC) type 2, 3, or 5
bleeding. The net effect on the combined ischemic and
bleeding complications was obtained by 2 net adverse
clinical event (NACE) end points that were generated by
Table I. Baseline characteristics in PPI-treated versus
non–PPI-treated patients
No PPI
(n = 1232)
PPI
(n = 738) P
Age (y) 68.1 (59.0-75.4) 71.2 (63.2-77.3) b.0001
Male sex 79.2% (976) 72.5% (535) .001
Bodymass index (kg/m2) 26.9 (24.7-29.4) 26.2 (24.2-29.3) .923
Diabetes 24.8% (305) 23.3% (172) .461
Insulin dependent 5.7% (70) 6.0% (44)
Hypertension 71.3% (879) 72.5% (535) .486
Hyperlipidemia 55.3% (681) 53.8% (397) .596
Current cigarette use 24.4% (301) 22.6% (167) .380
Creatinine clearance
(mL/min)
77.7 (58.3-99.2) 69.5 (53.3-91.0) b.0001
Prior MI 26.1% (321) 27.0% (199) .520
Prior PCI 18.6% (229) 16.1% (119) .180
LVEF 55.0 (45-60) 50.0 (43-60) .080
Clinical presentation
Stable angina pectoris 30.5% (376) 17.5% (129) b.0001
ACS 69.5% (856) 82.5% (609)
STEMI 30.2% (372) 37.4% (276) .001
NSTEMI 21.3% (262) 25.5% (188) .031
Unstable angina 18.0% (222) 19.6% (145) .369
Multivessel disease 70.5% (868) 69.2% (511) .569
No. of treated lesions 1 (1-2) 1 (1-2) .370
≥2 treated lesions 37.3% (459) 37.5% (277) .900
≥3 treated lesions 11.8% (145) 10.6% (78)
Multivessel intervention 26.5% (327) 27.0% (199) .837
At least 1 complex lesion
(type B2 or C)⁎
67.0% (825) 65.2% (481) .416
Total ACC/AHA score† 3 (2-5) 3 (2-4) .600
CRUSADE score 24 (16-34) 27 (18-38) b.0001
Aspirin 100% (1232) 100% (738) N.999
Clopidogrel 98.8% (1230) 99.9% (737) .882
Statin 90.3% (1093) 90.9% (671) .627
Abbreviations: LVEF, Left ventricular ejection fraction; STEMI, ST-segment elevation
myocardial infarction; NSTEMI, non–ST-segment elevation myocardial infarction;
ACC, American College of Cardiology; AHA, American Heart Association.
⁎According to the American College of Cardiology/American Heart Association
coronary lesion classification.
† Type A stenoses were coded 1 point; type B1 stenoses, 2 points; type B2 stenoses,
3 points; and type C stenoses, 4 points.
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combining the primary efficacy end point of death, MI, or
CVAwith either the primary safety endpoint of BARC type2,
3, or 5 bleeding or with BARC type 3 or 5 events. Other end
points included each component of the primary efficacy end
point, cardiovascular death, stent thrombosis (ST) defined
based on the Academic Research Consortium criteria, and
BARC type 3 or 5 bleeding. Other safety end points included
bleeding events adjudicated according to the Thrombolysis
in Myocardial Infarction (TIMI) and Global Use of Strategies
to Open Occluded Coronary Arteries scales. All study end
point definitions were previously reported.
All end points were confirmed based on documentation
collected at each hospital and were centrally adjudicated
by the clinical events committee, whose members were
unaware of the patients' treatment-group assignments. The
time frame of interest for the primary end point was from
30 days (ie, after the primary endpoint randomization)
to 24 months.
Statistical analysis
Categorical variables were expressed as frequency
(percentage),whereas continuous variableswere expressed
as median (interquartile range). Continuous variables were
compared between randomized groups using theWilcoxon
rank sum test, whereas for binary variables the χ2 test
was used.
Hazard ratios (HRs) with 95% CIs were calculated for no
PPI versus PPI treated patients (ie, values N1 indicated
increased hazard in the PPI group) with a proportional
hazards model. Cox regression was used for multivariate
analysis. Clinical and angiographic characteristics that were
imbalanced at a nominal 5% significance level between the
2 groups treated or not treated with PPI were identified and
included the final adjusted model; these included sex, age,
creatinine clearance, clinical presentation, and CRUSADE
score. As sensitivity analyses, adjusted outcomes were also
evaluated after excluding patients who had modified their
PPI status (assumption of PPI in thosewith no PPI therapy at
30 days or interruption of PPI in those with PPI therapy at
30 days) during follow-up. Further sensitivity analyses
included the assessment of adjusted outcomes with
landmark analysis at 6 to 24 months and the analysis
restricted to those patients treated with lansoprazole as PPI
type (exclusion of other PPI types).
Table II. Baseline characteristics in PPI versus no PPI treated patients stratified for the randomly allocated DAPT duration
24-m clopidogrel 6-m clopidogrel
No PPI (n = 612) PPI (n = 375) P No PPI (n = 620) PPI (n = 363) P
Age (y) 67.9 (58.9-74.5) 71.8 (63.8-77.7) b.0001 68.1 (59.2-76.6) 70.1 (61.7-76.9) .04
Male sex 80.6% (493) 72.3% (271) .003 77.9% (483) 72.7% (264) .070
Body mass index (kg/m2) 27.0 (24.9-29.4) 26.0 (23.9-29.3) .450 26.8 (24.2-29.2) 26.4 (24.2-29.3) .200
Diabetes 24.7% (151) 24.8% (93) .900 24.9% (154) 21.8% (79) .290
Insulin dependent 6.2% (38) 5.6% (21) 5.2% (32) 6.3% (23)
Hypertension 71.4% (437) 75.7% (284) .140 71.3% (442) 69.1% (251) .410
Hyperlipidemia 56.5% (346) 55.2% (207) .680 54.0% (335) 52.3% (190) .640
Current cigarette use 23.9% (146) 20.3% (176) .200 25.3% (156) 25.1% (91) .450
Creatinine clearance (mL/min) 77.7 (58.1-102.7) 68.9 (53.0-91.9) .001 77.8 (58.4-96.5) 70.7 (53.8-90.6) .002
Prior MI 28.3% (173) 25.9% (97) .410 24.8% (154) 28.1% (102) .300
Prior PCI 20.9% (128) 16.3% (61) .070 17.7% (110) 16.5% (60) .490
LVEF 54.0 (43-60) 55.0 (45-60) .520 55.0 (45-60) 50.0 (40-60) .002
Clinical presentation
Stable angina pectoris 31.2% (191) 17.1% (64) b.0001 29.8% (185) 17.9% (65) b.0001
ACS 68.8% (421) 82.9% (311) 70.2% (435) 82.1% (298)
STEMI 31.0% (190) 34.9% (131) .210 29.4% (182) 39.9% (145) .001
NSTEMI 21.1% (129) 25.9% (97) .080 21.5% (133) 25.1% (91) .190
Unstable Angina 16.7% (102) 22.1% (83) .03 19.4% (120) 17.1% (62) .370
Multivessel disease 70.4% (431) 70.4% (264) .990 70.5% (437) 68.0% (247) .420
No. of treated lesions 1 (1-2) 1 (1-2) .320 1 (1-2) 1 (1-2) .780
≥2 treated lesions 37.4% (229) 36.3% (136) .720 37.1% (230) 38.8% (141) .590
≥3 treated lesions 11.4% (70) 10.1% (38) .520 12.1% (75) 11.0% (40) .610
Multivessel intervention 25.8% (158) 25.3% (95) .870 27.3% (169) 28.7% (104) .640
At least 1 complex lesion (type B2 or C)⁎ 67.3% (412) 61.3% (230) .060 66.6% (413) 69.1% (251) .410
Total ACC/AHA score† 3 (2-4) 3 (2-4) .600 3 (2-5) 3 (2-5) .840
CRUSADE score 24 (15-35) 28 (19-38) b.0001 24 (18-33) 27 (18-38) .004
Aspirin 100% (612) 100% (375) N.999 100% (620) 100% (365) N.999
Clopidogrel 99.8% (611) 99.7% (374) .726 99.8% (619) 100% (363) .444
Statin 89.2% (539) 90.4% (339) .560 91.3% (554) 91.5% (332) .920
⁎According to the ACC/AHA coronary lesion classification.
† Type A stenoses were coded 1 point; type B1 stenoses, 2 points; type B2 stenoses, 3 points; and type C stenoses, 4 points.
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Interaction testing was performed to determine whether
the effect of DAPT duration was consistent irrespective of
PPI treatment on the primary and secondary end points of
the study. This was performedwith likelihood ratio tests of
the null hypothesis that the interaction coefficient was
zero. A 2-sided P value of b.05 was considered significant.
All analyses were based on the intention-to-treat principle
and were performed with SPSS, version 21.0 (SPSS, Inc,
Chicago, IL).
For the present analysis, no extramural fundingwas used
to support this work. The authors are solely responsible for
the design and conduct of this study, all study analyses, and
drafting and editing of the manuscript.
Results
Among 1,970 patients randomized to 6- versus 24-month
DAPT at 30 days from the PCI, 738 patients (37.5%) were
receiving a PPI. Most of them were treated with
lansoprazole (671 patients, 90.9%), whereas the others
received pantoprazole (56 patients, 7.6%) and few patients
received other PPI types (omeprazole, esomeprazole, and
rabeprazole, 1.5%).
Baseline characteristics of population with PPI and
without PPI are summarized in Table I, whereas Table II
describes their characteristics in the setting of the 2
randomized arms of DAPT regimens (24 vs 6 months).
Compared with patients who did not receive PPI, those
receiving PPI were older, were more likely female, had a
lower creatinine clearance, presented more frequently
with acute coronary syndrome (ACS), and had a higher
CRUSADE bleeding score (Tables I and II). The primary
efficacy end point (composite of all-cause death, MI, and
CVA) was similar between patients with PPI and without
PPI use (9.2% vs 11.5%, adjusted HR 1.051, 95% CI
0.788-1.400, P = .736) (Figure 1). Results were consistent
across other secondary end points as reported in Table III.
Safety end points of bleeding did not differ between the
2 groups (BARC type 2, 3, or 5: adjusted HR 0.996, 95% CI
0.672-1.474,P = .980; BARC type 3 or 5: adjustedHR 1.478,
95% CI 0.856-2.553, P = .160) (Figure 1 and Table III).
Overall, major bleeding evaluatedwith different definitions
was more frequent in PPI users compared with those
without PPI (BARC 3 or 5: 3.7% vs 2.1%, TIMImajor 1.5% vs
0.9%, GUSTO moderate or severe 3.7% vs 1.9%); however,
after adjustment for confounding factors, none of them
remained significant (Table III). The composite of efficacy
and safety end points in the NACEwas also similar in no PPI
and PPI patients (12.9% vs 14.9%, adjusted HR 0.99, 95% CI
0.772-1.268, P = .93) (Figure 1 and Table III).
Finally, there was no signal for heterogeneity between
PPI use and explored clinical end points with respect to
randomized DAPT duration (Figure 2, Supplementary
Figure 1, Table IV, and Supplementary Tables I-III).
At sensitivity analyses, PPI therapy during follow-up
was taken into account (1 month: 738 PPI patients 37%,
6 months: 685 PPI patients 35%, 12 months: 690 PPI
patients 35%, 18months: 709 PPI patients 36%, 24months:
734 PPI patients 37%). A specific analysis of clinical
outcomes was also performed in patients who remained
consistently on a PPI throughout the follow-up period
and excluding those who had started or interrupted PPI
Figure 1
C 
P = .042 
P = .566 
P = .043 
P = .161 
A 
P = .094 
P = .736 
B 
Survival free from ischemic and bleeding events according to PPI
treatment. Cox proportional model plot for the primary end point of
death for all causes, MI, and CVA (A), bleeding defined as BARC
class 3 or 5 (B), and NACEs (C) in patients treated or not treated with
PPI. Dashed lines represent the unadjusted risk model. Solid lines
represent the adjusted risk model.
98 Gargiulo et al
American Heart Journal
Month 2016
therapy. Results remained robust showing the absence
of significant differences for ischemic and bleeding
events (Supplementary Table IV). This was further
confirmed by landmark analyses (Supplementary Table V)
and by restriction of analysis to lansoprazole as PPI
(Supplementary Table VI).
Discussion
The present post hoc analysis from the PRODIGY
randomized trial investigated the impact of concomitant
PPI use on clinical outcomes in all-comer patients
undergoing PCI and receiving DAPT with clopidogrel as
thienopyridine component.
Although, at univariate analysis, PPI use was associated
with an increased risk of ischemic and bleeding events, after
multivariate adjustment, PPI therapy was no longer related
to different rates of ischemic events, bleeding, or NACE at
2 years irrespective of the short or prolonged regimen of
DAPT. The findings of our study are consistent with the
results of the COGENT trial, showing thus no association of
PPI use with increased risk of ischemic events.
Several studies assessing the inhibition of platelet
aggregation suggested that PPIs may significantly reduce
the antiplatelet effect of clopidogrel when the 2 drugs are
coadministered.8-11 In particular, some PPIs (omeprazole
and esomeprazole) highly inhibit CYP2C19 isoenzyme,
whereas other PPIs are weak inhibitors (lansoprazole) or
do not inhibit this isoenzyme (pantoprazole). However,
the findings from pharmacodynamic studies may not
necessarily translate into differences in clinical outcomes,
and the design and quality of studies might be the major
determinant of such contrasting evidence.14,15 Indeed,
most studies supporting an increased risk of cardiovas-
cular ischemic events when using any type of PPI in
patients on clopidogrel are observational studies. Con-
versely, randomized trials and propensity score–matched
studies did not support such concerns. Nonetheless, new
evidence from a recent US analysis of N60,000 patients
with gastroesophageal reflux disease exposed to PPIs
raised new questions by reporting a 1.2-fold increased
risk of MI and a 2-fold increased risk of cardiovascular
mortality, irrespective of clopidogrel use.20
Protonpump inhibitorusewas associatedwith an increased
risk of Major Adverse Cardiovascular Events and MI but not
death and target vessel revascularization in the subgroup
analysis of the BASKET trial.22 Similarly, the CAPRIE trial
showed a higher rate of ischemic events among patients
treated with PPIs and clopidogrel, whereas the most recent
subanalysis from the ADAPT-DES trial showed increased rate
of Major Adverse Cardiovascular Events due to death and
target vessel revascularization rather than MI or ST.17,23
In contrast, the dedicated COGENT trial did not support
these findings.16 This trial randomly assigned patients with
an indication for DAPT to receive clopidogrel in combina-
tion with either omeprazole or placebo, in addition to
Table III. Clinical outcomes in PPI-treated versus non–PPI-treated patients
No PPI (n = 1232) PPI (n = 738) UnadjustedHR (95%CI) P Adjusted HR (95% CI) P
Primary efficacy end point
Death for any cause, MI, or CVA 113 (9.2) 85 (11.5) 1.272 (0.960-1.685) .094 1.051 (0.788-1.400) .736
Secondary efficacy end points
Death for any cause or MI 107 (8.7) 75 (10.2) 1.178 (0.877-1.582) .278 0.957 (0.708-1.293) .773
Death for any cause 77 (6.2) 53 (7.2) 1.150 (0.811-1.632) .433 0.918 (0.642-1.311) .636
Death for cardiovascular cause 44 (3.6) 29 (3.9) 1.101 (0.689-1.759) .688 0.865 (0.534-1.400) .554
MI 48 (3.9) 32 (4.3) 1.115 (0.713-1.744) .633 0.941 (0.597-1.485) .790
Definite or probable ST 19 (1.5) 9 (1.2) 0.780 (0.353-1.723) .539 0.682 (0.306-1.523) .350
Definite, probable, or possible ST 47 (3.8) 37 (5.0) 1.320 (0.858-2.030) .207 1.028 (0.662-1.597) .900
Safety end points
BARC classification
Key safety end point (type 2, 3, or 5) 64 (5.2) 43 (5.8) 1.127 (0.766-1.659) .545 0.996 (0.672-1.474) .980
Type 3 or 5 26 (2.1) 27 (3.7) 1.746 (1.019-2.992) .043 1.478 (0.856-2.553) .161
TIMI classification
Minor 10 (0.8) 10 (1.4) 1.680 (0.699-4.036) .246 1.434 (0.589-3.492) .428
Major 11 (0.9) 11 (1.5) 1.679 (0.728-3.873) .224 1.465 (0.627-3.421) .378
Minor or major 21 (1.7) 21 (2.8) 1.684 (0.920-3.084) .091 1.453 (0.786-2.687) .234
GUSTO classification
Moderate 13 (1.1) 14 (1.9) 1.803 (0.848-3.836) .126 1.449 (0.676-3.110) .341
Severe 12 (1.0) 13 (1.8) 1.820 (0.830-3.988) .135 1.626 (0.732-3.613) .232
Moderate or severe 24 (1.9) 27 (3.7) 1.893 (1.092-3.281) .023 1.582 (0.905-2.763) .107
NACE
Death for any cause;MI; CVA; or BARC 2, 3, or 5 bleeding 159 (12.9) 110 (14.9) 1.172 (0.919-1.494) .202 0.989 (0.772-1.268) .933
Death for any cause, MI, CVA, or BARC 3 or 5 bleeding 125 (10.1) 97 (13.1) 1.317 (1.010-1.717) .042 1.083 (0.826-1.419) .566
Abbreviations: GUSTO, Global Use of Strategies to Open Occluded Coronary Arteries.
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aspirin. The composite of cardiovascular death, MI,
revascularization, or stroke did not differ, but GI events
were less frequent in the omeprazole group.16
In the subgroup analyses of the PRINCIPLE and
TRITON-TIMI 38 trials, a significant impact of PPI
therapy on reducing the effect of clopidogrel on platelet
aggregation was further substantiated. However, the
pharmacodynamic changes did not translate into adverse
clinical outcomes.11
Our study is in linewith and importantly adds to previous
evidence indicating that the use of PPIs, largely consisting
of lansoprazole, in conjunction with clopidogrel is safe. In
addition, this observation held true in the 2 randomized
groups of short- versus long-term DAPT, indicating that PPI
therapy does not increase ischemic events irrespective
of whether clopidogrel is administered for short periods
(ie, 6 months) or prolonged times (ie, 24 months). The
incidence of ST was low and did not differ in patients with
or without concomitant PPI use.
In the subgroup analysis of the PLATO trial on PPI use,
the association between PPI use and clinical adverse events
in patients treated with clopidogrel was likely due to
confounding (observed also in those receiving ticagrelor
and in those receiving non-PPI GI drugs), with PPI use
emerging as amarker for, rather than a cause of higher rates
of cardiovascular adverse events.18 Interestingly, the role
of confounding factors appeared to also be relevant in the
present study as the PPI population showed an increased
risk of both ischemic and bleeding events. However, after
multivariate adjustment, differences in outcomes were no
longer present.
Proton pump inhibitors are often prescribed in patients
with DAPT to reduce bleeding complications or due to
specific clinical indication (ie, gastric disease). Generally,
the PPI use is left to the discretion of clinicians, and often, a
selection of patients is performed with those receiving PPI
being at increased risk for ischemic and bleeding events.
This explains at least in part the results of observational
Figure 2
No PPI 
PPI 
Adj. Log HR (95% CI) Adj. HR (95% CI)   p value P int. 
No PPI 
PPI 
No PPI 
PPI 
No PPI 
PPI 
No PPI 
PPI 
No PPI 
PPI 
No PPI 
PPI 
Death, MI or CVA
Death for any cause 
Death for cardiovascular cause 
MI 
Definite or probable ST
BARC type 3 or 5 
NACE 
0.868 (0.593-1.271)         0.470 
1.218 (0.790-1.878)         0.370 0.19 
0.962 (0.608-1.523)         0.870 
1.051 (0.609-1.814)         0.860 0.74 
1.033 (0.561-1.902)         0.920 
0.890 (0.424-1.870)         0.760 0.80 
0.945 (0.523-1.708)         0.850 
0.890 (0.444-1.782)         0.740 0.99 
0.63 0.784 (0.314-1.958)         0.600 1.141 (0.304-4.277)         0.840 
1.465 (0.667-3.221)         0.340 
2.266 (0.988-5.194)         0.053 0.44 
0.34 0.993 (0.692-1.425)         0.970 1.247 (0.831-1.871)         0.290 
0,1 1 10
24-month better better6-month
Forest plots for clinical outcomes in short versus prolonged DAPT duration according to PPI treatment. Proton pump inhibitor and no-PPI subgroups are
shown, with HRs and 95% CIs, for the primary end point of death for any cause, MI, or CVA; death for any cause; cardiovascular death; MI; definite or
probable stent thrombosis; BARC type 3 or 5 bleeding; and NACEs among patients randomly assigned to either the 6- or 24-month DAPT.
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studies on PPI use and increased ischemic risk. In the
present study, PPIs were prescribed to patients with a
greater bleeding risk, as indicated by a more advanced age,
more female patients, and ACS, a worse renal function and
a higher CRUSADE score. However, after adjustment for
these confounding factors, the differences between PPI
and no-PPI populations were not clinically relevant for
most clinical outcomes. Although the COGENT trial
excluded patients with prior indication for PPI use or
H2-receptor antagonists and patients at higher risk for GI
bleeding, the results of the present study can be extended
to an all-comer population of patients undergoing PCI and
DAPT therapy.
Limitations
This is a post hoc not randomized and not prespecified
analysis of the PRODIGY trial, and the prescription of a
PPI was left to the physician's discretion.
Rates of overall but not specifically GI bleeding were
evaluated and available for this analysis, so potential benefits
of PPI on reducingGI bleeding events could not be analyzed.
Although multivariate adjustment was performed, it
cannot be excluded that unknown/unmeasured factors
may have impacted findings.
Data on PPI dosage were not prospectively collected,
so it was not possible to make specific analysis on
dose-dependent effects.
“In the PRODIGY, lansoprazole was by far the most
frequently used PPI. Hence, it remains unclear whether
our findings may be extrapolated to other PPIs such as
omeprazole or esmoprazole.”
Genetic analysis to test the predisposition for reduced
clopidogrel responsiveness was not available. Therefore,
it cannot be excluded that PPIs may have a different
impact on outcomes in this subgroup of patients.
Conclusion
Overall, PPI use was not associated with an increased
risk of cardiovascular events in all-comer patients
undergoing PCI and receiving DAPT. Our findings do
not support the need to avoid concomitant use of PPIs
and DAPT with aspirin plus clopidogrel, when
clinically indicated.
Appendix. Supplementary data
Supplementary data to this article can be found online
at http://dx.doi.org/10.1016/j.ahj.2016.01.015.
Table IV. Adjusted clinical outcomes in PPI-treated versus non–PPI-treated patients stratified for the randomly allocated DAPT duration
24-m clopidogrel 6-m clopidogrel
No PPI
(n = 612)
PPI
(n = 375)
Adjusted HR
(95% CI) P
No PPI
(n = 620)
PPI
(n = 363)
Adjusted HR
(95% CI) P Pint
Primary efficacy end point
Death for any cause, MI, or CVA 52 (8.5) 48 (12.8) 1.375 (0.916-2.064) .125 61 (9.8) 38 (10.2) 0.852 (0.562-1.291) .449 .19
Secondary efficacy end points
Death for any cause or MI 48 (7.8) 40 (10.7) 1.218 (0.789-1.881) .372 59 (9.5) 35 (9.6) 0.824 (0.538 -1.261) .372 .33
Death for any cause 37 (6.0) 28 (7.5) 1.070 (0.645-1.777) .792 40 (6.5) 25 (6.9) 0.865 (0.519-1.441) .578 .74
Death for cardiovascular cause 22 (3.6) 14 (3.7) 0.877 (0.437-1.757) .711 22 (3.5) 15 (4.1) 0.974 (0.494-1.923) .941 .80
MI 23 (3.8) 16 (4.3) 0.980 (0.505-1.904) .953 25 (4.0) 16 (4.4) 0.923 (0.490-1.739) .803 .99
Definite or probable ST 8 (1.3) 5 (1.3) 0.718 (0.231-2.225) .566 11 (1.8) 4 (1.1) 0.652 (0.204-2.085) .471 .63
Definite, probable, or possible ST 19 (3.1) 19 (5.1) 1.431 (0.743-2.755) .283 28 (4.5) 18 (5.0) 0.868 (0.473-1.593) .647 .34
Safety end points
BARC classification
Key safety end point (type 2, 3, or 5) 41 (6.7) 32 (8.5) 1.227 (0.762-1.977) .400 23 (3.7) 11 (3.0) 0.661 (0.321-1.362) .261 .34
Type 3 or 5 15 (2.5) 19 (5.1) 1.881 (0.937-3.777) .076 11 (1.8) 8 (2.2) 1.048 (0.418-2.627) .920 .44
TIMI classification
Minor 7 (1.1) 4 (1.1) 0.741 (0.212-2.592) .639 3 (0.5) 6 (1.7) 3.572 (0.861-14.827) .080 .15
Major 6 (1.0) 10 (2.7) 2.569 (0.905-7.290) .076 5 (0.8) 1 (0.3) 0.264 (0.031-2.265) .225 .11
Minor or major 13 (2.1) 14 (3.7) 1.559 (0.717-3.391) .262 8 (1.3) 7 (1.9) 1.388 (0.479-3.739) .579 .91
GUSTO classification
Moderate 8 (1.3) 9 (2.4) 1.487 (0.562-3.934) .424 5 (0.8) 5 (1.4) 1.488 (0.424-5.222) .535 .96
Severe 6 (1.0) 10 (2.7) 2.569 (0.905-7.288) .076 6 (1.0) 3 (0.8) 0.705 (0.175-2.843) .623 .26
Moderate or severe 13 (2.1) 19 (5.1) 2.079 (1.007-4.292) .048 11 (1.8) 8 (2.2) 1.050 (0.419-2.633) .917 .31
NACE
Death for any cause; MI; CVA;
or BARC 2, 3, or 5 bleeding
87 (14.2) 65 (17.3) 1.140 (0.818-1.589) .440 72 (11.6) 45 (12.4) 0.875 (0.599-1.277) .489 .60
Death for any cause, MI, CVA,
or BARC 3 or 5 bleeding
61 (10.0) 55 (14.7) 1.329 (0.911-1.939) .141 64 (10.3) 42 (11.6) 0.928 (0.625-1.379) .712 .34
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The dual antiplatelet therapy (DAPT) consisting of aspirin 
and a P2Y12 inhibitor exerts protection against ischemic 
myocardial recurrences. During last two decades, DAPT 
has become the mainstay for treating patients with coronary 
artery disease (CAD) undergoing percutaneous coronary 
intervention (PCI), following the initial demonstration 
that DAPT was superior to anticoagulant therapy in these 
patients. Initially, and for many years, DAPT was prescribed 
for 2 to 6 months after PCI in important trials of stent 
implantation leading to the approval of early-generation 
drug-eluting stents (DES) by the US Food and Drug 
Administration. However, the subsequent increasing safety 
concerns related to the potential occurrence of late and 
very late stent thrombosis (ST) after implantation of early-
generation DES lead to the recommendation of prolonging 
DAPT to 12 months by the American guidelines (1). 
On this background, different studies have specifically 
investigated the comparison of different DAPT regimens 
after PCI and the optimal duration of DAPT still remains 
matter of discussion (2-9). 
From one hand, some trials explored the effects of a 
short DAPT regimen (3 to 6 months) compared with 
12 months DAPT supporting that such approach is as 
effective and safer being associated with similar ischemic 
events but reduced risk of bleeding. In patients with clinical 
characteristics such as to be considered at high bleeding 
risk, a 1-month DAPT was also found to be safe and 
effective after new-generation DES (10,11). On the other 
hand, other trials, consisting mainly of patients treated with 
elective DES implantation, compared prolonged DAPT (total 
therapy duration: 18 to 48 months) with 6 to 12 months of 
DAPT to determine whether extended therapy reduces late 
and very late stent thrombosis and prevents ischemic events 
associated with disease progression and plaque rupture 
at other nonstented sites. The majority of these trials 
(PRODIGY, ITALIC, DES-LATE, OPTIDUAL, ARCTIC 
Interruption) did not support the hypothesized benefits of 
DAPT prolongation, rather underlying concerns in terms 
of bleeding events (8,9,12). In contrast, the largest of these 
trials, the DAPT study, found that prolonging DAPT was 
associated with reduction of ischemic events, although this 
was mainly proven for the larger population of patients 
receiving DES implantation (n=9,961) rather than in those 
receiving a bare metal stent (n=1,687) (13,14). In the DAPT 
study, patients treated with DES or BMS implantation who 
received DAPT for 12 months and were without ischemic 
or bleeding events during this period were randomized to an 
additional 18 months of DAPT or to aspirin monotherapy. 
In the overall cohort and in the DES subgroup, extended 
DAPT resulted in a significant reduction in very late ST, 
myocardial infarction (MI), major adverse cardiac and 
cerebrovascular events (MACCE defined as death or MI or 
stroke), and increased risk of moderate or severe bleeding. 
In the patients receiving BMS, the DAPT prolongation did 
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not reduce significantly ischemic outcomes but increased 
bleeding events, however, it should be noted that there was 
no significant interaction between subgroups (DES and 
BMS) and the BMS subset may have been underpowered to 
identify such differences (14). 
Some have hypothesized that “the longer, the better”, 
however, this remains a matter of ongoing debate with 
many concerns on this approach. Indeed, a major issue that 
emerged from the DAPT study was the increase of non-
cardiovascular mortality observed in patients prolonging 
DAPT and subsequently this was further confirmed in 
meta-analyses (5,8,9,13).
The large body of contrasting evidence accumulated 
during last years on the optimal duration of DAPT after 
stent implantation has led to growing discussion. Currently, 
the common consensus among opinion leaders is that 
there is no “one size fits all” approach and no common rule 
for the duration of DAPT after implantation of coronary 
stents (4,5,15). Consequently, a tailored approach may be 
advisable, wherein the personalized risks of ischemic versus 
bleeding events are carefully considered for each patient. A 
realistic estimation of the long-term ischemic and bleeding 
risk in each patient undergoing PCI is of paramount 
importance to tailor the optimal DAPT duration. 
Accordingly, DAPT prolongation after the mandatory 
period seems to be more appropriate in patients at high 
risk for ischemic events but with relatively low risk of 
bleeding. In opposite, a 3- to 6-month DAPT regimen 
may be the ideal approach for patients with increased 
risk of bleeding based on the relatively high incidence of 
late bleeding events during DAPT therapy with harmful 
effect on survival. A shorter DAPT (i.e., 1-month) has 
been found to be safe and effective in patients with high 
risk of bleeding (i.e., elderly, need for oral anticoagulation, 
need for major noncardiac surgery, severe anemia, history 
of bleeding or transfusion, non-skin cancer, renal failure, 
severe liver disease, thrombocytopenia, planned long-
term use of steroids or nonsteroidal anti-inflammatory 
drugs). Thus, there is a great interest in exploring specific 
clinical conditions that can identify patients in whom the 
benefit-risk ratio could be in favor or disfavor of DAPT 
continuation. Some subgroups have shown to benefit from 
extending DAPT due to their increased ischemic risk, such 
as patients with ACS at presentation (16), prior myocardial 
infarction (17), peripheral arterial disease (18) or those 
with multivessel disease or complex lesions (19,20). On the 
contrary, other conditions, such as diabetes (21), gender 
(22,23), chronic kidney disease (24), and elderly patients (25) 
did not emerge to be per se relevant drivers of the DAPT 
prolongation. 
In line with the strategy to search for factors helping 
to individualize the optimal DAPT regimen patient-by-
patient, Resor and colleagues recently investigated the 
impact of optimal medical therapy (OMT) on the treatment 
effect of DAPT (26). This analysis was conducted in the 
setting of all patients enrolled in the randomized DAPT 
study, including those treated with DES or BMS. 
OMT was defined at the time of randomization as 
a combination of any dose statin, β-blocker, and ACE 
inhibitor/ARB use in patients with class I indication for 
each medication in agreement with American guidelines: 
(I) statin: all patients were considered to have an indication; 
(II) β-blocker: reduced ejection fraction, congestive heart 
failure, previous MI or ACS; (III) ACE inhibitor/ARB: 
hypertension, diabetes mellitus, reduced ejection fraction, 
or chronic kidney disease (26). 
The overall finding of the study that DAPT prolongation 
provided ischemic benefits at the cost of increased bleeding 
was confirmed irrespective of OMT status, therefore, this 
analysis suggested that the decision to continue or interrupt 
DAPT beyond 12 months should not be based on the 
OMT.
OMT is recommended in patients with CAD due to 
the evidence of being associated with decrease of ischemic 
events and death. However, it is unknown whether the 
reduced risk in OMT patients may be also associated with 
a reduced or ischemic benefit related to prolongation of 
DAPT exposing thus the patient only to the increased 
bleeding risk related to such a strategy. The present 
subanalysis of the DAPT study seems to support the 
concept that there is no interaction between OMT and 
DAPT, rather suggesting that they may act synergistically 
through different mechanisms in order to reduce ischemic 
events (26). The authors also explored predictors of 
being or not on OMT and found that younger patients 
or those presenting with ACS or receiving clopidogrel 
instead of prasugrel were associated with higher rates of 
OMT. It is, however, an important concern that delicate 
categories such as patients with previous MI, previous 
PCI, renal insufficiency or hypertension more frequently 
were associated with lower rates of OMT. Although 
potentially interesting, these observations may have been 
related, at least in part, to different regional patterns of 
drug management, indeed, suboptimal OMT was mainly 
observed in North America compared with other sites.
The study is interesting, original, well conducted, 
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includes a large number of patients, and almost complete 
data on concomitant medication.
The findings, however, require some important 
considerations to allow an appropriate interpretation: 
 First, the study was not prespecified and should be 
considered hypothesis-generating only;
 Second, OMT was a binary definition and the two 
groups (on OMT and off OMT) were attributed on 
the basis of therapy at enrollment, but OMT status 
is actually dynamic and in individual patients may 
have been modified throughout the study; 
 Third, the definition of OMT status was performed 
without considering real reasons for not assuming 
a specific drug (contraindication, allergy, etc.) or 
taking into account lipid and blood pressure levels 
(did patients defined to be on OMT really reach the 
recommended targets for OMT?) or the dosage of 
drugs (i.e., this is particularly relevant for patients 
with reduced ejection fraction and indication to 
b-blockers);
 Fourth, the impact of OMT was only tested for 
the period of randomized treatment to DAPT 
versus aspirin alone between 18−30 months. In the 
DAPT analysis restricted to DES implantation, an 
important rebound effect was observed after DAPT 
interruption from 30 to 33 months and it would be 
interesting to know if OMT did not play a relevant 
role also in this phenomenon; 
 Finally, there was a selective reporting of outcomes. 
Although mortality, stent thrombosis and stroke 
outcomes were included in the MACCE, they 
were not individually reported, thus a potential 
interaction of OMT status with these endpoints 
cannot be excluded. Especially in the DAPT study, 
all-cause mortality has emerged as an important 
and debated issue in the group of patients receiving 
DAPT prolongation and it would be interesting if 
this outcome had been reported. Indeed, we do not 
know whether OMT would have mitigated or not 
the increased risk of mortality described in those 
patients. 
OMT represents a crucial but often underestimated 
aspect of post-procedural PCI care (26,27). The control 
of multiple cardiovascular risk factors decreases the 
incidence of cardiovascular events (27,28). OMT is a 
broad term that includes specific pharmacotherapy to 
control arterial hypertension, hyperlipidemia, and chronic 
hyperglycemia as well as the control of lifestyle risk factors 
(weight loss, smoking cessation, dietary regimen, exercise, 
and life rhythms). Importantly, the European Society of 
Cardiology guidelines highlighted that OMT should not 
be considered an alternative but a synergistic approach to 
revascularization (28).
In our opinion, from a practical point of view, the most 
relevant and also worrisome aspect emerged from this 
study, irrespective of DAPT regimen, and confirming 
other previous evidence, is the suboptimal frequency 
of OMT, indeed, approximately 37% of patients were 
not on OMT. Importantly, this appears to be even more 
alarming when we consider that the patients enrolled in the 
DAPT study represented a selected population of patients 
that were assumed to be at low risk of altered adherence 
to medical therapy; indeed, 12 months after PCI, only 
patients event-free and with appropriate compliance to 
thienopyridine therapy (defined as having taken 80% to 
120% of the drug without stopping it for >14 days) were 
eligible for randomization. Although adherence to therapy 
was not assessed individually in each group, the overall 
good adherence of the enrolled patients to the medical 
treatment was confirmed by consistency of the rates of 
patients assuming statin, β-blocker, ACEi/ARB and OMT 
at randomization (12 months after PCI) and at end of the 
study (30 months after PCI). We may therefore assume 
that the rates of those without OMT in real practice 
might be much higher, which should raise a red flag for all 
practitioners. Notably, patients without OMT had higher 
rates of MI, MACCE and moderate or severe bleeding 
compared with patients on OMT. Therefore, given that the 
proportion of patients not on OMT still remains large, this 
study underlines a major unmet need in current practice: 
more and more organized efforts are needed to increase 
adherence and adherence awareness in our community and 
within our patients. 
The real challenge in the 21-century seems to be finding 
ways to let the community apply established evidence even 
more than identifying new treatment venues. 
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Effects of Carvedilol Versus Metoprolol on Platelet
Aggregation in Patients With Acute Coronary
Syndrome: The PLATE-BLOCK Study
Federica Ilardi, MDa,1, Giuseppe Gargiulo, MDa,b,1, Gabriele Giacomo Schiattarella, MD, PhDa,c,1,
Giuseppe Giugliano, MD, PhDa, Roberta Paolillo, MDa, Giovanni Menafra, MDa,
Elena De Angelis, MDa, Laura Scudiero, MDa, Anna Franzone, MD, PhDa,b, Eugenio Stabile, MD, PhDa,
Cinzia Perrino, MD, PhDa, Plinio Cirillo, MD, PhDa, Carmine Morisco, MDa, Raffaele Izzo, MDa,
Valentina Trimarco, MDd, and Giovanni Esposito, MD, PhDa,*
Platelet aggregation plays a pivotal role in acute coronary syndrome (ACS). In this setting,
β-blockers (BBs) are used to counteract the effects of catecholamines on heart. Circulating
catecholamines can also potentiate platelet reactivity, mainly through α2- and β2-adrenoceptors
on human platelets’ surface, thus BB may affect platelet aggregation; however, the effects
of different BBs on platelet aggregation in contemporary-treated patients with ACS have
been poorly investigated. One hundred patients with ACS on dual antiplatelet therapy with
aspirin and ticagrelor were randomized to receive treatment with carvedilol, a nonselec-
tive BB (n = 50), or metoprolol, a selective β1-blocker (n = 50), at maximum tolerated dose.
Light transmission aggregometry was performed at randomization (T0) and at 30-day follow-
up (T30), and the results were expressed as a percentage of maximum platelet aggregation
(MPA). The primary end point was epinephrine-induced MPA at 30 days. Patients were
predominantly men (80%), and mean age was 57.3 ± 9.7 years. The 2 randomized groups
were well balanced for baseline characteristics. At T0, mean MPA was similar between the
groups (18.96 ± 9.05 vs 18.32 ± 9.21 with 10 µM epinephrine, 14.42 ± 9.43 vs 15.98 ± 10.08
with 20 µM adenosine diphophate (ADP), and 13.26 ± 9.83 vs 14.30 ± 9.40 with 10 µM ADP
for carvedilol and metoprolol, respectively, all p = NS). At 30 days, platelet aggregation induced
by epinephrine was significantly lower in the carvedilol group than in the metoprolol group
(23.52 ± 10.25 vs 28.72 ± 14.37, p = 0.04), with a trend toward the lower values of ADP-
induced MPA (20 µM ADP 19.42 ± 13.84 vs 24.16 ± 13.62, p = 0.09; 10 µM ADP 19.12 ± 12.40
vs 22.57 ± 13.59, p = 0.19). In conclusion, carvedilol, a nonselective BB, reduces residual plate-
let reactivity in patients with ACS compared with the selective BB, metoprolol. © 2018
Elsevier Inc. All rights reserved. (Am J Cardiol 2018;122:6–11)
Platelet aggregation plays a pivotal role in the pathogen-
esis of ischemic events during and after acute coronary
syndrome (ACS).1–3 Myocardial ischemia is associated with
a high activity of the sympathetic nervous system, which is
reflected by increased plasma levels of epinephrine and nor-
epinephrine. In patients with ACS, β-blocker (BB) drugs are
important to counteract the effects of catecholamines on heart,
and many compounds are available (some with selective
β1-adrenoceptor blockade and some with nonselective α- and
β-inhibition properties4), but there is no molecule recom-
mended over the other.5–7 Besides their effects on heart,
circulating catecholamines have also demonstrated to affect
platelet reactivity in different manners, such as potentiating
the proaggregant effect of other substances, influencing the
response to antiplatelet agents, directly interacting with
platelets’ surface adrenergic receptors (α2A subtype is the most
abundant, but β2 type is also present).8–12 Additionally, non-
selective BB seem also able to decrease plasma catecholamine
levels more than selective ones,13 and their lipophilicity can
increase the ability to indirectly affect platelet aggregation
by a chemical interaction with platelet’s cell membrane.14
A recent meta-analysis suggested that nonselective lipo-
philic BB reduced platelet aggregation more effectively
than selective nonlipophilic BB, but included studies were
well outdated (mainly conducted in 1970s to 1980s), and
none of them included patients with ACS treated with con-
temporary dual antiplatelet therapy (DAPT).8 The aim of our
study was to compare the effects of the nonselective BB,
carvedilol, with the selective metoprolol on platelet aggre-
gation induced by epinephrine and adenosine diphosphate
(ADP) in the contemporary setting of patients with ACS re-
ceiving DAPT with aspirin and ticagrelor.
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Methods
The PLATE-BLOCK study is an investigator-initiated,
single-center, open-label, prospective randomized trial. Con-
secutive patients hospitalized for an ACS (ST-segment elevation
myocardial infarction [STEMI], non–ST-segment elevation
myocardial infarction [NSTEMI], unstable angina) pre-
sented at the coronary care unit of University Federico II of
Naples, undergoing acid acetylsalicylic and ticagrelor treat-
ment and percutaneous coronary intervention, were screened.
Exclusion criteria were as follows: age <18 years; contrain-
dication to BB therapy; ongoing prasugrel, ticlopidine, or
clopidogrel therapy; creatinine clearance <30 ml/min; mod-
erate to severe anemia (hemoglobin <10 mg/dl); platelet count
>600,000/mm3 or <130,000/mm3; hematocrit >50% or <25%;
known blood dyscrasia or bleeding diathesis; concomitant neo-
plastic or immune-mediated pathologies; ongoing oral
anticoagulation therapy. Patients were treated with aspirin
(loading dose of 150 to 300 mg orally or 75 to 150 mg in-
travenously, and 100 mg once a day as maintenance dose) and
ticagrelor (180 mg loading dose, 90 mg twice daily as main-
tenance dose). All patients eligible for enrollment who accepted
to participate provided written informed consent and were ran-
domly assigned to carvedilol or metoprolol treatment at
maximum tolerated dosage. Randomization occurred using
concealed table that was previously generated using Re-
search Randomizer (https://www.randomizer.org). The study
complied with the Declaration of Helsinki. The local insti-
tutional ethics committee approved the study protocol, and
all patients gave written informed consent to participate. The
trial protocol is registered within ClinicalTrials.gov, number
NCT02809820.
Clinical events occurring within 30 days were recorded.
Any death, unless an unequivocal noncardiovascular cause
could be established, was defined as death from cardiovas-
cular causes. Myocardial infarction was defined in accordance
with the third universal definition proposed in 2012.15 Stent
thrombosis was defined according to the Academic Re-
search Consortium criteria.16 Stroke was defined as focal loss
of neurologic function caused by an ischemic or hemor-
rhagic event, with residual symptoms lasting at least 24 hours
or leading to death. Bleeding was defined according to Throm-
bolysis In Myocardial Infarction (TIMI) and Bleeding
Academic Research Consortium criteria.17
Samples for platelet function testing were taken at base-
line (within 48 hours after coronary angiography after diagnosis
of ACS) and at 30 days. The measurements were performed
in the morning just before the administration of the morning
ticagrelor dose. When GPIIb/IIIa inhibitors were pre-
scribed, an interval of 18 to 24 hours after completion of the
infusion was required before platelet function testing was per-
formed, to avoid interference with aggregation assay. Platelet
aggregation was measured by light transmission aggregometry
(LTA) using a dual channel lumi-aggregometer (model 700;
Chrono-Log, Havertown, Pennsylvania). Platelet-rich plasma
was prepared from blood that was drawn from the antecubital
vein by venipuncture into 3.8% trisodium citrate (w/v)
Vacutainer blood collection tubes. Platelet-rich plasma was
obtained by centrifugation of blood at 180 g at 25°C for 10
minutes. Platelet-poor plasma was obtained by centrifuga-
tion of the rest of the blood at 1,500 g at 25°C for 10 minutes.3
Platelet aggregation was monitored at 37°C with constant stir-
ring (1,200 rpm) and measured as the increase in light
transmission for 6 minutes, with the addition of epineph-
rine (10 µM) and ADP (10 and 20 µM) as a proaggregatory
stimulus. All measurements were obtained within 2 hours of
sample collection, and the results are reported as percent-
age of maximum platelet aggregation (MPA).
The primary end point of the study was to evaluate the
effects of metoprolol versus carvedilol after 30 days of treat-
ment on platelet aggregation induced by 10 μM epinephrine,
in patients with ACS on DAPT. Epinephrine test was elected
to be the primary end point given the anticipated effects of BB
on reducing catecholamine-induced platelet aggregation. Sec-
ondary end points were the evaluation ofADP-induced platelet
aggregation (10 and 20 µM) and adverse clinical events, in-
cluding ischemic and bleeding complications at 30 days.
The primary hypothesis of the study is that the % MPA
with epinephrine at 30 days will be reduced in the carvedilol
group compared with the metoprolol group. Based on pre-
vious studies, standard deviation (SD) of MPA is quite variable,
and probably different timing, different drugs, and different
methodologies contribute to this.18,19 Assuming an SD of at
least 8% and that an absolute 5% would be a clinically rel-
evant difference in the % MPA induced by epinephrine, a
sample size of at least 100 subjects (50 for each group) would
detect a true difference between groups with statistical power
≥80% at an alpha significance level of 0.05. The planned
sample size was then increased up to 120 to allow occur-
rence of new contraindications or adverse events or incomplete
aggregometry data. Variables were expressed as absolute
numbers and percentage or mean ± SD. Comparisons were
made by chi-square test or Student t test, as appropriate. Sta-
tistical analyses were performed using IBM-SPSS, version
23 (SPSS Inc, Chicago, Illinois).
Results
Between June 2016 and December 2016, 204 patients with
ACS (STEMI, NSTEMI, and unstable angina) were as-
sessed for eligibility. Of these, 84 did not meet the study entry
criteria or refused to consent, whereas 120 provided their
written informed consent to participate in the study; of these,
111 were randomized (metoprolol, n = 55; carvedilol, n = 56),
representing the enrolled population. A total of 100 patients
(metoprolol, n = 50; carvedilol, n = 50) were the primary popu-
lation and finally analyzed (Figure 1). Baseline clinical
characteristics are shown in Table 1. The mean age was
57.3 ± 9.7, and the majority of patients were males and
smokers, 18% had diabetes, and 16% had history of myo-
cardial infarction. At clinical presentation, 62% had STEMI,
with an average left ventricle ejection fraction at transtho-
racic echocardiogram of about 45% and a relatively stable
hemodynamic profile. The 2 randomized groups were ho-
mogenous in terms of cardiovascular risk factors, routine
laboratory variables, or medications (Table 1). Angiographic
and procedural characteristics of the 2 study groups are shown
in Table 1. The culprit lesion was the left anterior descend-
ing artery in half of patients, and 1/3 of patients had multivessel
disease. The majority of patients received percutaneous coro-
nary intervention with stent implantation and had a final TIMI
3 flow.
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Table 2 lists the mean value and SD of MPA induced by
epinephrine and ADP in the 2 groups, at baseline (T0) and
at 30 days (T30). At baseline, results of the platelet assess-
ment were comparable between the 2 groups, with the expected
platelet inhibition as a result of the DAPT. At T30, the results
of MPA were significantly higher than baseline in the 2 groups
for all proaggregative stimuli. Interestingly, patients in the
carvedilol group showed an epinephrine-induced MPA at T30
significantly lower than that observed in the metoprolol popu-
lation (23.5 ± 10.2 vs 28.7 ± 14.3, p = 0.040) (Figure 2). In
secondary analyses, when ADP was used as proaggregative
stimulus, a trend toward reduction in the carvedilol group com-
pared with metoprolol group was observed and was more
pronounced with higher ADP concentration (10 µM ADP
19.12 ± 12.40 vs 22.57 ± 13.59, p = 0.19; 20 µM ADP
19.42 ± 13.84 vs 24.16 ± 13.62, p = 0.088). Overall, no patient,
but one in the metoprolol group, showed a high on-treatment
residual platelet reactivity (MPA>59% with ADP stimulation).
Clinical outcomes at 30 days, in terms of ischemic and
bleeding end points, are shown in Table 2. No death,
myocardial infarction, or urgent revascularization occurred.
Two patients in the carvedilol group underwent a new
hospitalization within 30-day follow-up, both of them for heart
failure. Notably, 1 minor bleeding was observed in the
metoprolol group (blood loss from pre-existing hemor-
rhoids) without need for modification of DAPT and no major
bleeding events were reported.
Discussion
There is evidence that BB can inhibit the catecholamine-
induced platelet aggregability, but there is limited evidence
regarding the role of specific BB agents to affect platelet ac-
tivity and there are no data on ACS patients treated with
contemporary DAPT including aspirin and a new more potent
P2Y12 inhibitor. To our knowledge, this is the first random-
ized, open-label study on patients with ACS receiving aspirin
and ticagrelor to compare carvedilol, a nonselective BB, with
metoprolol, a selective β1-blocker. We found that carvedilol
significantly reduced residual platelet aggregation 30 days after
the index event compared with metoprolol. Notably, this benefit
was additional to DAPT and was observed despite the therapy
with a new potent P2Y12 inhibitor (i.e., ticagrelor). This
finding might have important clinical implications in the daily
practice when choosing the type of BB agent to be used in
this setting of patients.
BBs competitively inhibit the myocardial effects of cir-
culating catecholamines and reduce myocardial oxygen
consumption by lowering heart rate, blood pressure, and myo-
cardial contractility. They are recommended for secondary
Figure 1. Flowchart of the study. ACS, acute coronary syndrome; STEMI = ST-segment elevation myocardial infarction; NSTEMI = non–ST-segment eleva-
tion myocardial infarction; UA = unstable angina.
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prevention in patients with ACS, regardless of reperfusion
therapy, given their beneficial effects on prognosis.5–7 Nowa-
days, many BB compounds are available, with different
pharmacologic profiles. Generally, BBs without intrinsic sym-
pathomimetic activity are suggested, especially β-1 blockers
such as sustained release metoprolol succinate, bisoprolol, or
the β-1 and α-1 blocker carvedilol, which are also the ones
demonstrating mortality benefits in patients with heart failure
and systolic dysfunction.5 Among them, often β-1 blockers
Table 1
Baseline, angiographic, and procedural characteristics according to beta-
blockage therapy
Variable Carvedilol
(n = 50)
Metoprolol
(n = 50)
P value
Age (years) 57.8 ± 9.5 56.8 ± 9.8 0.600
Men 41 (82%) 39 (78%) 0.617
Smoker 36 (72%) 36 (72%) 1.000
Hypertension 29 (58%) 25 (50%) 0.422
Hypercholesterolemia* 23 (46%) 17 (34%) 0.221
Diabetes Mellitus 10 (20%) 8 (16%) 0.603
BMI (kg/m2) 27.9 ± 4.9 28.5 ± 4.5 0.596
Previous MI 10 (20%) 6 (12%) 0.275
Previous PCI 9 (18%) 6 (12%) 0.401
Previous TIA/Stroke 1 (2%) 1 (2%) 0.977
Previous coronary bypass 2 (4%) 1 (2%) 0.558
Creatinine (mg/dl) 0.92 ± 0.23 0.87 ± 0.16 0.199
Creatinine clearance (ml/min)† 100.8 ± 32.4 109.8 ± 31.7 0.165
COPD 8 (16%) 7 (14%) 0.779
Clinical presentation
Killip class >1 7 (14%) 7 (14%) 1.000
LVEF (%) 45.0 ± 6.3 44.9 ± 5.7 0.921
RWMS 1.6 ± 0.3 1.7 ± 0.3 0.559
Heart rate (bpm) 71.8 ± 9.1 74.4 ± 10.6 0.196
Systolic BP (mm Hg) 122.6 ± 17.2 123.0 ± 17.4 0.921
Diastolic BP (mm Hg) 79.1 ± 9.3 76.7 ± 11.3 0.256
STEMI 31 (62%) 31 (62%) 1.000
NSTEMI 18 (36%) 19 (38%) 0.836
Unstable angina pectoris 1 (2%) 0 (0%) 0.315
Laboratory parameters
Hemoglobin (g/dl) 13.8 ± 1.5 14.0 ± 1.5 0.520
Hematocrit (%) 41.7 ± 4.6 41.8 ± 4.1 0.984
Platelet count (×103/ml) 210.2 ± 56.1 230.2 ± 62.9 0.097
Cardiovascular medications
Proton Pump Inhibitors 49 (98%) 50 (100%) 0.315
ACEi/ARBs 25 (50%) 32 (64%) 0.157
Statins 49 (98%) 48 (96%) 0.558
Diuretics 3 (6%) 2 (4%) 0.630
Insulin 4 (8%) 2 (4%) 0.371
Oral antidiabetics 8 (16%) 6 (12%) 0.509
Thrombolysis 5 (10%) 2 (4%) 0.240
Randomized beta-blocker dosage
Mean (standard deviation) 13.5 ± 6.5 98.0 ± 26.6 -
Median (range) 12.5 (6.25–25) 100 (50–200) -
Periprocedural antithrombotics
UFH 49 (98%) 47 (94%) 0.307
Bivalirudin 0 (0%) 1 (2%) 0.315
Glycoprotein IIb/IIIa inhibitors 15 (30%) 20 (40%) 0.366
Culprit coronary artery
Left main 0 (0%) 1 (2%) 0.315
Left anterior descending artery 23 (46%) 29 (58%) 0.230
Left circumflex 12 (24%) 7 (14%) 0.202
Right coronary artery 13 (26%) 13 (26%) >0.999
Multi-vessel coronary disease 13 (26%) 17 (34%) 0.383
TIMI flow pre-PCI
0 20 (40%) 16 (32%) 0.405
1 5 (10%) 7 (14%) 0.538
2 12 (24%) 9 (18%) 0.461
3 13 (26%) 18 (36%) 0.280
TIMI flow post-PCI
0 0 (0%) 0 (0%) -
1 0 (0%) 0 (0%) -
2 1 (2%) 0 (0%) 0.315
3 49 (98%) 50 (100%) 0.315
(continued)
Table 1
(continued)
Variable Carvedilol
(n = 50)
Metoprolol
(n = 50)
P value
Procedural details
Stent 47 (94%) 49 (98%) 0.307
Diameter of stent (mm) 3.11 ± 0.47 3.12 ± 0.35 0.828
Length of stent (mm) 21.93 ± 7.37 20.31 ± 7.01 0.270
Values are n (%) or mean ± SD.
ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin re-
ceptor blocker; BMI = body mass index; BP = blood pressure; COPD = chronic
obstructive pulmonary disease; HR = heart rate; LVEF = left ventricle ejec-
tion fraction; MI = myocardial infarction; NSTEMI = non–ST-segment
elevation myocardial infarction; PCI = percutaneous coronary interven-
tion; RWMS = regional wall motion score; STEMI = ST-segment elevation
myocardial infarction; TIA = transient ischemic attack; TIMI = Thromboly-
sis In Myocardial Infarction; UFH = unfractionated heparin.
* Hypercholesterolemia refers to patients receiving lipid-lowering therapy
at baseline (before index event).
† Estimated creatinine clearance was calculated according to Cockcroft-
Gault formula.
Table 2
Results of platelet aggregation induced by epinephrine and ADP with LTA and
30-day clinical outcomes
Carvedilol
(n = 50)
Metoprolol
(n = 50)
p
Epinephrine 10 µmol/L
T0 18.96 ± 9.05 18.32 ± 9.21 0.727
T30 23.52 ± 10.25* 28.72 ± 14.37* 0.040
ADP 10 µmol/L
T0 13.26 ± 9.83 14.30 ± 9.40 0.590
T30 19.12 ± 12.40* 22.57 ± 13.59* 0.190
ADP 20 µmol/L
T0 14.42 ± 9.43 15.98 ± 10.08 0.426
T30 19.42 ± 13.84* 24.16 ± 13.62* 0.088
Clinical outcomes
Death 0 0 -
Myocardial Infarction 0 0 -
Stent Thrombosis 0 0 -
Stroke 0 0 -
Urgent TVR 0 0 -
Intracranial bleeding 0 0 -
TIMI major bleed 0 0 -
TIMI minor bleed 0 1 (2%) 0.315
BARC type 3 or 5 0 0 -
BARC type 2 0 1 (2%) 0.315
Hospitalization 2 (4%) 0 0.153
Values are expressed as % of maximum platelet aggregation (MPA) ± SD.
* p <0.05 versus T0.
BARC = Bleeding Academic Research Consortium; TIMI = Thromboly-
sis In Myocardial Infarction; TVR = target vessel revascularization.
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are chosen to reduce pulmonary complications related to bron-
chospasm; however, there is no preferential guideline
recommendation of 1 molecule over the other;5–7 thus, our
study could be relevant to provide useful insights on this topic
and to help guide the selection of the optimal BB type. The
early administration of BB agents in myocardial infarction
is supported by several studies that demonstrated favorable
effect in reducing blood pressure, heart rate, arrhythmias, and
improving left ventricle systolic function. Different studies
and a recent meta-analysis have suggested that, besides these
well-known beneficial clinical effects, BBs could exert their
protective action by also inhibiting platelet aggregation.8–10
The effects of circulating catecholamines on platelet re-
activity have been extensively investigated, reporting an
increased ADP- and collagen-induced platelet aggregation in
conditions of elevated adrenergic system activity, such as myo-
cardial infarction and angina. Catecholamines are supposed
to exhibit their proaggregating effects, interacting mainly with
α2A adrenoceptors, whose stimulation determines the inhi-
bition of adenylate cyclase through Gi protein.11,20 Platelet
surface also exhibits a small amount of β2-receptor, whose
activation results in AMP cyclic (cAMP) formation, which
is known to inhibit platelet aggregation through mecha-
nisms involving Ca++.12 β2-receptor could be targeted by
nonselective BB, with a consequent inhibition of platelets
cAMP formation, decrease of calcium availability, and in turn
platelet activation. Conversely, the use of selective β1-blockers
would protect from this mechanism, as suggested by Winther
et al21 that showed higher levels of plasma and platelet cAMP
and lower platelet aggregation in patients treated with
metoprolol compared with propranolol. However, com-
pared with placebo, metoprolol did not show any reduction
of ADP-induced platelet aggregation in patients with myo-
cardial infarction.22 Therefore, the antiplatelet effect of BB
is only partially explained by the direct interaction with the
platelet adrenoceptors, but there are also other indirect mecha-
nisms. Indeed, it is known that BBs are able to decrease plasma
levels of catecholamines, with a more pronounced effect of
nonselective compounds.23,24 In particular, in patients with heart
failure, the long-term therapy with carvedilol but not
metoprolol reduced coronary sinus norepinephrine levels.13
In addition, some nonselective BBs, such as carvedilol and
propranolol, have shown a membrane-stabilizing effect that
affects Ca++ availability in the platelets and inhibits platelet
aggregation.14,25 Petrikova et al26,27 investigated the antiplatelet
activity of carvedilol and showed that, besides the antagonistic
effects onα-adrenoceptors, carvedilol, thanks to its lipophilicity,
inhibits platelet aggregation and thromboxane B2 formation
through the interaction with membrane macromolecules, such
as phospholipids, ion channels, enzymes, and other molecules.
In accordance with the available data, our study demon-
strates that patients receiving carvedilol showed lower
epinephrine-induced platelet aggregation than those treated
with metoprolol after ACS. Based on the results of LTA,
carvedilol was not able to significantly reduce ADP-induced
platelet aggregation. Also, this finding is in accordance with
previous studies27,28 that demonstrated an in vitro dose-
dependent reduction of aggregation when epinephrine was used
as stimulus, whereas carvedilol was least effective in plate-
lets stimulated with ADP even at high concentrations.
Notably, the baseline level of platelet aggregation is lower
than T30 values. This finding seems to be consistent with phar-
macodynamic studies of patients treated with ticagrelor, which
showed that, after 6 weeks of treatment, the inhibitor effect
on platelet aggregation measured with LTA was slightly lower
than 24 hours after the loading dose.19 In our study, base-
line aggregation was performed within 24 to 48 hours since
the coronary angiography, so platelet aggregation could be
still influenced by different kinds of medications.
This study explored platelet aggregation and was not
powered to assess clinical events. However, the 2 BBs in-
vestigated are routinely used in the daily practice and none
of them is expected to significantly impact on ischemic and
bleeding events compared with the other. Additionally, it is
well known that DAPT with more potent P2Y12 inhibitors
is the standard of care after ACS and percutaneous coro-
nary intervention,29,30 and platelet reactivity is associated with
thrombotic events; thus, its reduction could be beneficial in
reducing thrombotic complications.2 Our data were focused
on ticagrelor-based DAPT and cannot be extended to pa-
tients receiving different DAPT regimens (i.e., prasugrel or
clopidogrel) or single antiplatelet therapy associated with an-
ticoagulation therapy (i.e., patients with atrial fibrillation or
mechanic valves).
In conclusion, our study showed that in patients with ACS
receiving contemporary DAPT with aspirin and ticagrelor, the
use of carvedilol, a nonselective BB, is associated with a
reduced residual platelet aggregation compared with
metoprolol, a selective β1-blocker. This finding might have
important clinical implications, given the enhanced adrener-
gic signaling in the setting of ACS and its known association
with platelet reactivity, thrombotic events, and long-term out-
comes. However, further studies are needed to evaluate the
translational effect of this benefit on clinical outcomes.
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Figure 2. Maximum platelet aggregation 30 days after acute coronary syn-
drome according to the randomized treatment with carvedilol or metoprolol.
MPA = maximum platelet aggregation.
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Part 2
Trade-off for ischemia and bleeding 
after percutaneous coronary 
interventions: which is the optimal 
regimen of antiplatelet therapy?
Personalizing type and 
duration of DAPT
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Abstract
Evidence from studies published more than 10 years ago suggested that patients receiving first-generation 
drug-eluting stents (DES) needed dual antiplatelet therapy (DAPT) for at least 12 months. Current evidence 
from randomised controlled trials (RCT) reported within the past five years suggests that patients with 
stable ischaemic heart disease who receive newer-generation DES need DAPT for a minimum of three to 
six months. Patients who undergo stenting for an acute coronary syndrome benefit from DAPT for at least 
12 months, but a Bayesian network meta-analysis confirms that extending DAPT beyond 12 months con-
fers a trade-off between reduced ischaemic events and increased bleeding. However, the network meta-ana-
lysis finds no credible increase in all-cause mortality if DAPT is lengthened from three to six months to 
12 months (posterior median odds ratio [OR] 0.98; 95% Bayesian credible interval [BCI]: 0.73-1.43), from 
12 months to 18-48 months (OR 0.87; 95% BCI: 0.64-1.17), or from three to six months to 18-48 months 
(OR 0.86; 95% BCI: 0.63-1.21). Future investigation should focus on identifying scoring systems that have 
excellent discrimination and calibration. Although predictive models should be incorporated into systems 
of care, most decisions about DAPT duration will be based on clinical judgement and patient preference.
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Abbreviations
ACS acute coronary syndrome
ARCTIC-  Assessment by a double Randomisation of 
a Conventional antiplatelet strategy versus 
a monitoring-guided strategy for drug-eluting 
stent implantation and, of Treatment Interruption 
versus Continuation 1 year after stenting
BES biolimus-eluting stent
BMS bare metal stent(s)
CAD coronary artery disease
CAPRIE a randomised, blinded, trial of Clopidogrel versus 
Aspirin in Patients at Risk of Ischaemic Events
CHARISMA Clopidogrel for High Atherothrombotic Risk 
and Ischemic Stabilization, Management, and 
Avoidance
CLASSICS Clopidogrel Aspirin Stent International 
Cooperative Study
CREDO Clopidogrel for the Reduction of Events During 
Observation
CURE Clopidogrel in Unstable angina to prevent 
Recurrent Events
DAPT dual antiplatelet therapy
DES drug-eluting stent(s)
DES-LATE Optimal Duration of Clopidogrel Therapy 
with DES to Reduce Late Coronary Arterial 
Thrombotic Events
EXCELLENT Efficacy of Xience/Promus Versus Cypher in 
rEducing Late Loss After stENTing
FANTASTIC Full Anticoagulation Versus Aspirin and 
Ticlopidine
I-LOVE-IT 2 Evaluate Safety and Effectiveness of the Tivoli® 
DES and the Firebird DES for Treatment of 
Coronary Revascularization
ISAR Intracoronary Stenting and Antithrombotic 
Regimen study
ISAR-SAFE Intracoronary Stenting and Antithrombotic 
Regimen: Safety And EFficacy of 6 Months Dual 
Antiplatelet Therapy After Drug-Eluting Stenting
ITALIC Is There A LIfe for DES after discontinuation of 
Clopidogrel
IVUS-XPL Impact of Intravascular Ultrasound Guidance 
on Outcomes of Xience Prime Stents in Long 
Lesions
LEADERS-FREE Prospective Randomised Comparison of the 
BioFreedom Biolimus A9 Drug-Coated Stent 
Versus the Gazelle Bare-Metal Stent in Patients at 
High Bleeding Risk
MACCE major adverse cardiac and cerebrovascular events
MATTIS Multicentre Aspirin and Ticlopidine Trial after 
Intracoronary Stenting
MI myocardial infarction
NIPPON Nobori Dual Antiplatelet Therapy as Appropriate 
Duration
OPTIDUAL OPTImal DUAL antiplatelet therapy after drug-
eluting stent implantation
OPTIMIZE Optimised Duration of Clopidogrel Therapy 
Following Treatment with the Endeavor 
Zotarolimus-Eluting Stent in Real-World Clinical 
Practice
PCI percutaneous coronary intervention
PRODIGY PROlonging Dual-antiplatelet treatment after 
Grading stent-induced Intimal hyperplasia studY
RCT randomised controlled trial(s)
RESET REal Safety and Efficacy of 3-month dual anti-
platelet Therapy following Endeavor zotarolimus-
eluting stent implantation
SECURITY Second-generation Drug-eluting Stent 
Implantation Followed by 6- versus 12-month 
dual antiplatelet therapy
ST stent thrombosis
STARS Stent Anticoagulation Restenosis Study
ZEUS Zotarolimus-eluting Endeavor sprint stent in 
Uncertain DES candidates
Introduction
In its 40th anniversary, percutaneous coronary intervention (PCI) 
has achieved excellent early and late outcomes thanks to advances 
in technologies, operator expertise, and antithrombotic therapy. 
Although the advent of drug-eluting stents (DES) has been crucial 
for the overall success of PCI, stent thrombosis (ST) and myocar-
dial infarction may occur unless patients adhere to a strict regimen 
of dual antiplatelet therapy (DAPT), which consists of concurrent 
use of aspirin and a P2Y12 platelet receptor blocker. The use of 
DAPT, however, confers an increased risk of major bleeding that 
in some instances is fatal.
The purpose of the current report is to review the early develop-
ments that have led to replacement of anticoagulation therapy with 
DAPT after stent implantation, current recognition of the prognos-
tic significance of major bleeding, and ultimate awareness that the 
duration of DAPT after DES implantation must be prescribed on 
an individual basis.
The past
On 16 September 1977, Andreas Grüntzig performed the first 
coronary balloon angioplasty in a 37-year-old man with a proxi-
mal stenosis in the left anterior descending artery. The result was 
successful and durable1,2. However, in the series of 624 patients 
undergoing coronary angioplasty between 1977 and 1981 in Zurich 
and Atlanta, emergency operations due to sudden closure or spasm 
of the artery occurred in 5% and Q-wave myocardial infarction 
(MI) in 3%, but no in-hospital deaths occurred1. At that time, the 
optimal pharmacotherapy to prevent failure and complications 
remained uncertain3. Early investigators recommended the use 
of warfarin as long-term adjunctive therapy after femoropopliteal 
transluminal angioplasty and its use was also adopted for the treat-
ment of acute MI, whereas other studies demonstrated benefit 
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from the administration of aspirin after MI4. In a randomised com-
parison of aspirin and coumadin in 248 PCI patients, aspirin did 
not reduce recurrent stenoses as compared with coumadin at nine 
months of follow-up (27% vs. 36%; p=not significant)4.
In subsequent studies, evidence supported benefits of aspirin 
therapy after MI or PCI5, but at the same time balloon angioplasty 
seemed to be limited by a high incidence of abrupt vessel clo-
sure after dilatation and requirement for reintervention for reste-
nosis. The implantation of an expandable metal stent to maintain 
vessel patency after balloon dilatation emerged as the solution to 
these problems6,7. Nevertheless, the inherent thrombogenicity of 
metal stents that were in contact with circulating blood resulted in 
thrombotic stent occlusion despite aggressive anticoagulant ther-
apy. In a pivotal trial, angiographic follow-up after placement of 
a self-expanding coronary artery stent showed that early occlusion 
occurred in approximately 20% of cases8. Additionally, haemor-
rhagic and peripheral vascular complications due to the intensive 
anticoagulation adopted for the first few weeks after the procedure 
seriously limited the benefits of PCI.
Two studies in 1995 were the first to suggest that the combi-
nation of aspirin and ticlopidine was a safe replacement for anti-
coagulant therapy after coronary stent implantation9,10. In 1996, 
ISAR suggested advantages of DAPT over anticoagulation by 
showing that combined antiplatelet therapy (aspirin plus ticlopi-
dine) after the placement of coronary stents reduced the incidence 
of both cardiac events and haemorrhagic and vascular compli-
cations compared with conventional anticoagulation-based ther-
apy (intravenous heparin, phenprocoumon, and aspirin)11. Later, 
STARS demonstrated that DAPT was superior to anticoagulant 
therapy after implantation of bare metal stents (BMS) and reduced 
ST by 85% as compared with aspirin alone12. In the FANTASTIC 
study, which studied both elective and unplanned coronary stent-
ing, DAPT with aspirin and ticlopidine significantly reduced rates 
of bleeding and subacute stent occlusion compared with conven-
tional anticoagulation13. In the MATTIS study, high-risk patients 
receiving aspirin and ticlopidine after coronary stenting had 
significantly reduced bleeding and vascular complications and 
there was a marked trend towards decreased cardiac events com-
pared with aspirin and anticoagulation14. At the same time, clopi-
dogrel appeared, which was a new thienopyridine derivative that 
had fewer side effects than ticlopidine. The CAPRIE trial sug-
gested that clopidogrel could be used in place of aspirin to pre-
vent ischaemic stroke, MI or vascular death in patients at risk of 
ischaemic events15. Then the CLASSICS study supported replace-
ment of ticlopidine by clopidogrel after coronary stenting due its 
safer profile16. The CURE study confirmed the efficacy and safety 
of clopidogrel added to aspirin in patients with ACS and in those 
undergoing PCI17,18.
Evidence from early studies thus suggested that a strategy based 
on aspirin and a thienopyridine was substantially more effective 
and better tolerated than anticoagulation, thus facilitating a wide-
spread adoption of stenting in clinical practice. Indeed, the last two 
decades have established the pivotal role of DAPT in preventing 
both stent- and non-stent-related ischaemic events after PCI com-
pared with single antiplatelet therapy or anticoagulation. Recently, 
new hypotheses have been studied or are still under evaluation 
(i.e., very short DAPT regimens and aspirin interruption during 
follow-up)5. However, the optimal duration of DAPT after stent 
implantation has been a matter of contention for years. Indeed, in 
parallel with the evolution of the DAPT regimens, stent techno-
logy has evolved from BMS to first-generation DES, a change 
that has implications for DAPT regimens. When clopidogrel was 
approved in 1997 by the U.S. Food and Drug Administration 
(FDA), it was recommended for two weeks after BMS implan-
tation19 and then later for four weeks16. When sirolimus-eluting 
stents were approved in 2003, the labelling recommended three 
months of clopidogrel because that is how the agent had been used 
in clinical trials20. When paclitaxel-eluting stents were approved in 
2004, the labelling recommended six months of clopidogrel, again 
based on how it had been used in trials21. Later, this DAPT dura-
tion was seriously questioned due to increasing safety concerns 
that were initially related to late and very late ST in first-genera-
tion DES, but also to an increase in death and MI. Indeed, 2006 
was a critical year for evidence on first-generation DES, but an 
expert FDA panel concluded that DES appeared to increase the 
risk of late stent thrombosis, but not the risk of death or MI22. At 
that time, the concerns about DES led to the empirical recommen-
dation of 12 months of DAPT. The panel also agreed on the urgent 
need for studies on ST and the duration of DAPT22.
The recommendation of 12 months of DAPT was maintained 
in the following few years with the sole exception of patients in 
whom the risk of bleeding outweighed the anticipated benefit. 
Based on previous findings from the PCI-CURE (stenting com-
prised 80% of the PCI cases, but all stents were BMS and the 
mean duration of DAPT was nine months) and CREDO studies 
(all BMS; only 63% of patients assigned to clopidogrel finished 
one year of therapy)18,23, and observational studies reporting a per-
sistent risk of ST beyond six months after stenting, particularly in 
the context of DAPT cessation24-26, the 2011 American guideline 
recommended a minimum DAPT duration of at least 12 months 
after DES implantation27. The European guidelines in 2010 recom-
mended one month of DAPT after BMS in stable patients, but six 
to 12 months after DES, and 12 months in the case of ACS28. An 
additional relevant milestone of DAPT history was the introduc-
tion of the new P2Y12 inhibitors, prasugrel in 2007
29 and ticagre-
lor in 200930, which further improved outcomes of ACS patients 
undergoing PCI and receiving DAPT.
Figure 1 shows the main steps in the advent and evolution of 
DAPT, and Figure 2 shows the mechanism of action of DAPT.
The present
GUIDELINES, TRIALS AND META-ANALYSES OF DAPT 
DURATION
The guidelines from the European Society of Cardiology recom-
mend at least one month of DAPT for stable ischaemic heart 
disease (SIHD) treated with BMS and at least six months if 
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treated with DES, while in ACS patients a 12-month DAPT was 
recommended, suggesting that shorter courses in patients with 
SIHD or longer courses in patients with a history of ACS may 
be considered31,32. A 2016 focused update on DAPT from the 
American College of Cardiology/American Heart Association33 
recommended a minimal mandatory duration of DAPT of six 
months after implantation of newer-generation DES in patients 
with SIHD and replaced the 2011 guideline recommendation 
of at least 12 months27. The abbreviated course of therapy for 
patients with SIHD seemed reasonable, because the risk of ST 
with newer-generation DES was lower than it was with first-gen-
eration DES34.
Figure 1. History of DAPT in PCI.
Figure 2. Sites of action of DAPT. DAPT includes aspirin, a cyclooxygenase-1 (COX-1) inhibitor, and a P2Y12 receptor inhibitor (ticlopidine, 
clopidogrel, prasugrel, or ticagrelor). ADP: adenosine diphosphate; PAR-1: protease-activated receptor-1
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Since publication of the DAPT update, new evidence regard-
ing DAPT duration has emerged. Data from 14 RCT (Figure 3) 
of patients undergoing implantation of DES, with more than two 
thirds of subjects receiving newer-generation stents (Table 1), and 
randomised to either prolonged or short-course DAPT, have been 
published35-50. The largest RCT of DAPT duration, the DAPT trial43, 
randomly assigned 9,961 patients to prolonged DAPT of 2.5 years 
or to short-course DAPT of 12 months after DES implantation. 
Prolonged DAPT was associated with a reduced rate of ST (0.4% 
vs. 1.4%; HR 0.29, 95% CI: 0.17-0.48, p<0.001), MACCE (4.3% 
vs. 5.9%; HR 0.71, 95% CI: 0.59-0.85, p<0.001) and reduced MI 
(2.1% vs. 4.1%, HR 0.47, p<0.001) but was associated with a bor-
derline increased risk of death from any cause (2.0% vs. 1.5%, 
HR 1.36, 95% CI: 1.00-1.85, p=0.05) and increased moderate or 
severe bleeding (2.5% vs. 1.6%, p=0.001).
When aggregate data from the 14 RCT including the DAPT 
trial are pooled (Appendix), short compared with prolonged DAPT 
is associated with no significant difference in mortality (odds 
ratio [OR] 0.85; 95% CI: 0.72-1.01) and reduced major bleeding 
(OR 0.68, 95% CI: 0.55-0.82). On the other hand, as shown in 
Figure 4, shorter courses of DAPT are associated with more cases 
of MI (OR 1.37, 95% CI: 1.12-1.67) and ST (OR 1.69, 95% CI: 
1.13-2.54).
The absence of a mortality benefit from prolonged DAPT may 
seem counterintuitive given the reductions in MI and ST, but these 
findings may reflect a temporal attenuation in mortality risk attrib-
utable to ST. While acute and subacute ST are associated with 
mortality rates approaching 50%, late and very late ST are associ-
ated with mortality rates of about 10%51. As a result, it is possible 
that extension of DAPT beyond 12 months may simultaneously 
reduce both MI and ST without influencing mortality. On the 
other hand, major bleeding may be more dangerous than non-fatal 
MI52-57. Taken together, the reductions in mortality from lowering 
thrombosis with prolonging DAPT may be counterbalanced by an 
increase in mortality from bleeding complications58.
Although a large number of meta-analyses of the DAPT RCT 
have been published37,59-63, they have produced mixed results. 
Apparent discrepancies may have arisen because traditional 
meta-analyses comparing outcomes use a binary short-versus-
long definition of DAPT duration. This poses a problem, even for 
Figure 3. Trials of DAPT after PCI. Trial result is reported according to whether the hypothesis was demonstrated ( , green colour) or not 
( , red colour). Five trials are reported with yellow colour due to premature interruption of planned enrolment.
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the traditional meta-analysis presented here (Figure 4), because 
12 months of DAPT was defined as “short” in four trials35,41,43,47 
and as “long” in seven trials38-40,42,46,48,49. Comparing outcomes at 
12 months with outcomes at 12 months in a meta-analysis may 
unintentionally introduce noise in the statistical models. An alterna-
tive approach is to avoid 12-month versus 12-month comparisons, 
as was done by Navarese and colleagues in a stratified meta-ana-
lysis62, but a Bayesian network meta-analysis may take advantage 
of the complete evidence base and provide an optimal approach to 
compare outcomes after short (three to six months), intermediate 
(12 months), and prolonged (18-48 months) durations of DAPT.
The use of network meta-analysis clarifies the differences 
in outcomes after short durations of three to six months, the 
standard comparator of 12 months, and prolonged durations of 
18-48 months of DAPT (Figure 5) and reveals no credible reduc-
tions in mortality when DAPT was used for three to six months 
as compared with 12 months (posterior OR 0.98; 95% Bayesian 
credible interval [BCI]: 0.73-1.43), when DAPT was used for 
12 months as compared with 18-48 months (OR 0.87; 95% BCI: 
0.64-1.17), or when DAPT was used for three to six months as 
compared with 18-48 months (OR 0.86, 95% BCI: 0.63-1.21). 
Moreover, no difference in any major outcome was seen between 
three to six months and 12 months of DAPT, but bleeding was 
lower when DAPT was used for three to six months as compared 
with 18-48 months (OR 0.53, 95% BCI: 0.33-0.81), a finding that 
is counterbalanced by increased MI (OR 1.72, 95% BCI: 1.18-
2.42) and ST (OR 2.56, 95% BCI: 1.23-5.03).
ISCHAEMIC AND BLEEDING RISKS OF DAPT AND DECISION 
MAKING ON DAPT DURATION
DAPT with aspirin and a P2Y12 inhibitor reduces ischaemic recur-
rences but increases bleeding risk, which is related to the treatment 
Table 1. RCT summaries.
Study 
duration 
(comparison)
Year Age Diabetes (%)
Follow-up 
(mo)
Newer-
genera-
tion stents 
(%)
Trial 
completion Primary endpoint
Proportion 
with prior 
MI (%)
Proportion 
with current 
MI (%)
Expected 
event rate in 
control group 
(%)
Observed 
event rate in 
control group 
(%)
DES-LATE (36 
vs. 12 mo)35
2010 62 28 24 30.0 Enrolment 
completed
Cardiac death, MI or 
stroke <24 hrs
3.9 23.3 2.7 2.6
PRODIGY (24 
vs. 6 mo) 36,37
2012 68 24 24 50.0 Enrolment 
completed
Death, MI or stroke 27.3 55.7 8.0 10.1
EXCELLENT (12 
vs. 6 mo)38
2012 63 38 12 75.0 Enrolment 
completed
Cardiac death, MI, or 
ischaemia-driven TVR
5.1 27.4 10.0 4.5
RESET (12 vs. 3 
mo) 39
2012 62 29 12 85.0 Enrolment 
completed
Cardiac death, MI, ST, 
revasc, or bleeding
1.7 14.3 10.5 4.7
OPTIMIZE (12 
vs. 3 mo)40
2013 62 35 12 100.0 Enrolment 
completed
NACCE - death, MI, 
stroke, or bleed
23.8 11.0 9.0 6.0
ARCTIC (17 vs. 
12 mo)41
2014 64 33 12 63.0 Enrolment 
completed
Death, MI, ST, stroke, 
or urgent TVR
30.4 0.0 6.0 4.0
SECURITY (12 
vs. 6 mo)42
2014 65 31 12 100.0 Stopped after 
1,399 of 2,740 
planned
Cardiac death, MI, ST, 
or stroke
20.7 0.0 6.0 4.5
DAPT (30 vs. 12 
mo)43
2014 62 31 18 59.0 Enrolment 
completed
Coprimary: ST and 
MACCE
21.3 26.0 0.5/2.9 0.5/2.4
ITALIC (24 vs. 6 
mo)44,45
2015 62 37 12 100.0 Stopped after 
2,031 of 2,475 
planned
Death, MI, urgent TVR, 
stroke, or major 
bleeding
15.1 7.5 3.0 1.5
ISAR-SAFE (12 
vs. 6 mo)46
2015 67 25 12 72.0 Stopped after 
4,005 of 6,000 
planned
Death, MI, ST, stroke, 
or TIMI major bleed
25.2 18.4 10.0 1.5
OPTIDUAL (48 
vs. 12 mo)47
2016 64 31 36 65.0 Stopped after 
1,385 of 1,966 
planned
Death, MI, stroke, or 
major bleeding
17.4 26.9 7.0 7.5
I-LOVE-IT 2 (12 
vs. 6 mo)48
2016 60 23 18 100.0 Enrolment 
completed
Cardiac death, TVMI or 
TVR
16.9 24.5 8.3 5.9
IVUS-XPL (12 
vs. 6 mo)49
2016 64 37 12 100.0 Enrolment 
completed
Cardiac death, MI, 
stroke, or TIMI major 
bleeding
5.0 15.6 7.0 2.2
NIPPON (18 vs. 
6 mo)50
2017 67 38 12 100.0 Stopped after 
3,307 of 4,598 
planned
All-cause mortality, 
MI, stroke, and major 
bleeding
12 13.7 4.5 2.1
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duration. It is now clear that both ischaemic and bleeding risks can 
negatively impact on prognosis52-58. Therefore, the decision as to 
whether DAPT should be continued beyond one year after PCI 
requires preliminary clarification of the relative weight of ischae-
mic and bleeding events on mortality. Choosing between these two 
negative outcomes with similar frequencies and prognostic impli-
cations remains a great challenge. Tailored treatment algorithms 
maximising benefits over risks represent the only sensible way 
forward.
Some subgroups of patients undergoing DES implantation may 
benefit from extending DAPT, such as patients with prior MI64,65, 
ACS at presentation66,67, complex PCI68 or peripheral arterial dis-
ease69,70. On the other hand, other patient characteristics may not 
benefit from extending DAPT, such as diabetes71, chronic kidney 
disease72, or advanced age73. In patients with high bleeding risk, 
a course of DAPT as short as one month has been found to be 
feasible74,75.
Against this background, recently proposed tools derived from 
randomised studies, namely the DAPT and PRECISE-DAPT 
scores76,77, may help to guide the decision making. The DAPT 
score was proposed for patients who tolerated 12 months of DAPT 
to select those eligible for treatment prolongation78. It was derived 
from 11,648 patients randomised in the entire DAPT database 
and is based on ischaemic and bleeding risk factors to help iden-
tify patients with greater expected benefit versus greater expected 
harm from prolonging DAPT over one year after stenting. It 
assigns 1 point each for MI at presentation, prior MI or PCI, dia-
betes, stent diameter less than 3 mm, smoking, and paclitaxel-elut-
ing stent; 2 points each for history of congestive heart failure/low 
HMHFWLRQIUDFWLRQDQGYHLQJUDIWLQWHUYHQWLRQíSRLQWIRUDJHWR
\HDUVDQGíSRLQWVIRUDJH\HDUV,QSDWLHQWVZLWKFOLQLFDO
predictive scores of 2 or higher, continued thienopyridine therapy 
was associated with an absolute risk reduction in MI or ST that 
was 8.2 times greater than the absolute risk increase in moderate 
or severe bleeding. On the other hand, among patients with scores 
lower than 2, DAPT prolongation was associated with an absolute 
increase in bleeding that was 2.4 times the absolute reduction in 
MI or ST79. Of note, the DAPT score is only applicable to patients 
who have completed one year of DAPT after coronary stent treat-
ment without a major ischaemic or bleeding event and cannot be 
applied earlier, at the time of PCI, to select less than 12 months of 
treatment in patients at high bleeding risk.
More recently, a novel risk score (PRECISE-DAPT) has been 
proposed for the prediction of out-of-hospital bleeding in patients 
treated with DAPT using age, creatinine clearance, white blood cell 
count, haemoglobin, and history of bleeding77. High bleeding risk 
Figure 4. Forest plot of event rates after prolonged or short course of DAPT after drug-eluting stent implantation. Original figures created 
with the open-source statistical program [R] 3.0.3 85 and library package “meta” 3.8-0 86. Note: OPTIMA-C trial (6 vs. 12-month DAPT) was 
completed in 2015, presented orally in 2015 but not yet published, recently registered on clinicaltrials.gov (NCT03056118), and therefore not 
included here. Adapted with permission from the American Heart Association87. CI: confidence interval; OR: odds ratio
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a shortened (i.e., <12 months) DAPT duration. Conversely, patients 
not at high bleeding risk (score <25) might receive a standard (i.e., 
12 months) or prolonged (i.e., >12 months) treatment without being 
exposed to significant bleeding liability. The PRECISE-DAPT score 
is a simple bedside risk assessment tool, which can be easily imple-
mented in everyday clinical practice and might be useful at the time 
of treatment initiation. A suggested algorithm for decision making 
based on these two scores is shown in Figure 6.
Authors’ perspectives
We believe that, in low-risk patients who have undergone newer-
generation DES implantation, a minimum DAPT duration of 
three to six months is sufficient to prevent stent-related throm-
botic events. On the other hand, patients at high risk of throm-
botic events79 and low risk of bleeding77 may derive a benefit from 
extension of DAPT beyond six to 12 months. Several scoring sys-
tems have appeared, but additional prospective investigation will 
be required to define their utility in everyday practice80. Future 
studies will need to identify optimal DAPT duration in patients 
who receive bioresorbable scaffolds81.
In accordance with a personalised approach, patients at high 
bleeding risk on DAPT need special attention. The multicentre 
randomised open-label MASTER-DAPT trial (NCT03023020) is 
currently enrolling 4,300 high bleeding risk patients in >100 inter-
national centres to compare one-month DAPT with a more pro-
longed regimen consisting of at least three or six months of DAPT 
depending on whether the patient has or has not a concomitant 
indication to oral anticoagulation.
The future role of aspirin is also a matter of ongoing inves-
tigation5. Historical evidence comparing aspirin with placebo 
showed a great reduction in thrombotic risk and supports current 
Figure 5. Caterpillar plot of event rates and duration of DAPT. In a network meta-analysis, the number of events after each duration of DAPT 
was modelled using a binomial distribution, and the logit of each rate had a non-informative prior distribution to ensure that the posterior 
inference would be dominated by the likelihood of the data. Data presented as posterior mean odds ratio and 95% Bayesian credible intervals. 
Original figures were created with OpenBUGS (Bayesian inference using Gibbs sampling) and Markov chain Monte Carlo modelling, starting 
with non-informative priors centred at 0.000 with precision of 0.0001 and using 10,000 draws of the Gibbs chain, to ensure that the posterior 
distribution would be dominated by the likelihood, using described methods (Figure 7) 85,87-89. Adapted with permission from the American 
Heart Association87
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recommendations. However, P2Y12 inhibitors have mostly been 
studied as adjuncts to aspirin; the comparison of single antiplate-
let therapy with new P2Y12 inhibitors alone versus DAPT after 
ACS or PCI for secondary prevention of atherothrombotic events 
is a new field of research. While up-to-date research has focused 
on DAPT and its duration, an alternative and original approach 
is the “less is more” paradigm exploring the role of monotherapy 
with new P2Y12 inhibitors for efficacy and also for the reduction in 
risk of bleeding. The GLOBAL LEADERS (NCT01813435) trial 
is designed to assess the role of ticagrelor as a single antiplatelet 
agent after a short course of DAPT for the long-term prevention 
of adverse cardiac events, across a wide spectrum of patients, fol-
lowing BES implantation82.
The subject of several ongoing trials is the comparison of treat-
ment regimens combining an oral anticoagulant (warfarin or novel 
oral anticoagulants) with single or dual antiplatelet therapy for 
patients with atrial fibrillation and ACS or coronary stents5,83,84. 
The role of long-term secondary prevention with novel oral anti-
coagulant (NOAC)-based regimens (i.e., NOAC alone or in com-
bination with aspirin) will be re-assessed and will probably impact 
on our future practice. The routine use of platelet function testing 
or genotyping to guide clinical decisions is not currently recom-
mended, but future evidence may eventually provide new insights 
on this topic.
Finally, only selected DES have received CE mark approval for 
one-month DAPT for patients in need; however, this was based on 
limited data. Whether DAPT should be stent-specific or whether 
the newer-generation DES have different DAPT requirements 
remains a matter of ongoing investigation.
Conclusions
No single DAPT recommendation applies to every patient. In low-
risk patients who receive a newer-generation DES, a minimum 
DAPT duration of three to six months may be sufficient to pre-
vent early and largely stent-related thrombotic events. Patients who 
undergo stenting for acute coronary syndrome may benefit from 
DAPT for at least 12 months. Extension of DAPT beyond 12 months 
entails a trade-off between increased bleeding and reduced ischae-
mic events. Because RCT can only elucidate broad principles and 
scoring systems only consider a small number of risk factors for 
bleeding or ischaemic risk, the fine details of DAPT duration must 
be defined by clinicians for each patient on an individual basis.
Figure 6. Decision making on DAPT duration based on PRECISE-DAPT and DAPT scores. Variables included in the scores are associated 
with increased bleeding risk (red dot), increased ischaemic risk (blue dot) or neutral effect (black dot). *In the validation study, short-term 
DAPT consisted of three to six months of therapy and standard DAPT consisted of at least 12 months of DAPT.
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Appendix. Methods
Aggregate data from 14 randomised controlled trials (RCT) of 
patients undergoing implantation of predominantly newer-gener-
ation drug-eluting stents (DES) and randomised to either shorter 
or longer courses of dual antiplatelet therapy (DAPT)35-50 com-
prise the evidence base for the analysis of DAPT duration after 
DES implantation. As described previously63,89, data from each 
trial had been abstracted in duplicate by two reviewers (J.A. Bittl 
and U. Baber). The present review uses the previously abstracted 
data to create the original forest plots and caterpillar plots using 
procedures and data shown here (Table 2 and Figure 7).
BAYESIAN NETWORK META-ANALYSIS
Because each RCT performed two-way DAPT comparisons of 
DAPT durations that varied widely, an indirect three-way com-
parison of outcomes after short, medium or long durations of 
DAPT was carried out using Bayesian network meta-analysis. 
As described in detail, we modelled the number of deaths after 
short courses of DAPT in the seven studies that had both three- 
to six-month and 12-month arms38-40,42,46,48,49 by using a binomial 
distribution. We assumed that the difference of log odds between 
a short (S) duration of DAPT and a 12-month duration (M) of 
DAPT from each study δi,SM followed a normal random effects dis-
Table 2. Data on mortality.
s[] t[] r[] nn[] b[]
DES-LATE (36 vs. 12 mo) 1 2 32 2,514 1
DES-LATE (36 vs. 12 mo) 1 3 46 2,531 1
PRODIGY (24 vs. 6 mo) 2 1 45 751 1
PRODIGY (24 vs. 6 mo) 2 3 49 750 1
EXCELLENT (12 vs. 6 mo) 3 1 4 722 1
EXCELLENT (12 vs. 6 mo) 3 2 7 721 1
RESET (12 vs. 3 mo) 4 1 5 1,059 1
RESET (12 vs. 3 mo) 4 2 8 1,058 1
OPTIMIZE (12 vs. 3 mo) 5 1 43 1,563 1
OPTIMIZE (12 vs. 3 mo) 5 2 45 1,556 1
ARCTIC (18 vs. 12 mo) 6 2 9 624 1
ARCTIC (18 vs. 12 mo) 6 3 7 635 1
SECURITY (12 vs. 6 mo) 7 1 8 682 1
SECURITY (12 vs. 6 mo) 7 2 8 717 1
DAPT (30 vs. 12 mo) 8 2 74 4,941 1
DAPT (30 vs. 12 mo) 8 3 98 5,020 1
ITALIC (24 vs. 6 mo) 9 1 8 912 1
ITALIC (24 vs. 6 mo) 9 3 7 910 1
ISAR-SAFE (12 vs. 6 mo) 10 1 8 1,997 1
ISAR-SAFE (12 vs. 6 mo) 10 2 12 2,003 1
OPTIDUAL (48 vs. 12 mo) 11 2 24 690 1
OPTIDUAL (48 vs. 12 mo) 11 3 16 695 1
I-LOVE-IT 2 (12 vs. 6 mo) 12 1 11 909 1
I-LOVE-IT 2 (12 vs. 6 mo) 12 2 14 920 1
IVUS-XPL (12 vs. 6 mo) 13 1 5 699 1
IVUS-XPL (12 vs. 6 mo) 13 2 10 701 1
NIPPON (18 vs. 6 mo) 14 1 16 1,654 1
NIPPON (18 vs. 6 mo) 14 3 7 1,653 1
ARCTIC41: assessment by a double randomisation of a conventional antiplatelet strategy versus a monitoring-guided strategy for drug-eluting stent 
implantation and of treatment interruption versus continuation 1 year after stenting; CI: confidence interval; DAPT43: dual antiplatelet therapy; 
DES-LATE35: Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Events; EXCELLENT38: Efficacy of Xience/
Promus Versus Cypher in rEducing Late Loss After stENTing; I-LOVE-IT 248: Evaluate Safety and Effectiveness of the Tivoli® DES and the Firebird DES 
for Treatment of Coronary Revascularization; ISAR-SAFE46: Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual 
Antiplatelet Therapy After Drug-Eluting Stenting; ITALIC44,45: Is There A LIfe for DES after discontinuation of Clopidogrel; IVUS-XPL: Impact of 
Intravascular Ultrasound Guidance on Outcomes of Xience Prime Stents in Long Lesions; NIPPON50: Nobori Dual Antiplatelet Therapy as Appropriate 
Duration; OPTIDUAL47: OPTImal DUAL antiplatelet therapy after drug-eluting stent implantation; OPTIMIZE: Optimized Duration of Clopidogrel Therapy 
Following Treatment with the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice; OR: odds ratio; PRODIGY36,37; PROlonging Dual-
antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY; RESET39: REal Safety and Efficacy of 3-month dual antiplatelet Therapy 
following Endeavor zotarolimus-eluting stent implantation; SECURITY38-40,42,46,48,49: Second-generation Drug-eluting Stent Implantation Followed by 
6- versus 12-month dual antiplatelet therapy
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DDdat<-read.csv("Z:/Users/johnbittl/Dropbox/EuroInterventionDAPT/NetworkDAPTDeath.csv",as.is=TRUE,
header=T)
str(DDdat)
s<-c(DDdat$s)
t<-c(DDdat$t)
r<-c(DDdat$r)
nn<-c(DDdat$nn)
b<-c(DDdat$b)
#Specify the model in BUGS language, but save it as a string in [R]
modelString="
model
{ # i counts the two arms of all 14 studies
for (i in 1:28)
{
r[i] ~ dbin(p[i], nn[i]);
logit(p[i]) <- mu[s[i]]+delta[i]*(1-equals(t[i],b[i]));
delta[i] ~ dnorm(md[i], prec);
md[i] <- d[t[i]]-d[b[i]];
}
# j represents the CABG arm
for (j in 1:14)
{
mu[j] ~ dnorm(0, .001);
}
prec ~ dgamma(0.001, 0.001);
d[1] <- 0;
# K represents the relative treatment comparator: k1 = Short, k=2 is 12 mo, k=3 is Long
for (k in 2:3)
{
d[k] ~ dnorm(0, .001)
}
for (c in 1:2)
{
for (k in (c+1):3)
{
lor[c,k] <- d[k]-d[c];
log(or[c,k]) <- lor[c,k];
}
}
}
"
# Write the modelString to a file
writeLines (modelString,con="model.txt")
# Use BRugs to check model
modelCheck ("model.txt")
#load data
dataList = list(s=c(s),
t=c(t),
r=c(r),
nn=c(nn),
b=c(b)
)
#Use BRugs commands to put the data into a file and ship the file to BUGS
modelData(bugsData(dataList))
#Initialize the chains
nChain=1
modelCompile(numChains = nChain) #Compile the model
initsList = list(d=c(NA,0,0), prec=1, mu=c(0,0,0,0,0,0,0,0,0,0,0,0,0,0))
modelInits(bugsData(initsList))
modelGenInits()
#R defines a new variable to specify an arbitrary chain length
chainLength1 = 5000
#BRugs tells BUGS to generate a MCMC chain
modelUpdate (chainLength1)
#BRugs keeps a record of parameters
samplesSet(c("lor"))
#BRugs asks BUGS for summary statistics
chainLength2 = 10000
thinStep = 2
modelUpdate (chainLength2)
thetaSummaryObs = samplesStats (c("lor")); thetaSummaryObs
thetaSummaryObs<-thetaSummaryObs[order(thetaSummaryObs$mean),]
expTheta<-exp(thetaSummaryObs)
print(thetaSummaryObs)
print(expTheta)
###############################################################################################
#caterpillar plot
x<-seq(from=-0.8,to=0.6,by=0.01)
#Short vs. 12 mo
x<--thetaSummaryObs$mean
y<-c(3,2,1)
plot(x,y,xlim=c(-0.6,1.0),ylim=c(3.5,0),pch=23,cex=4,ylab="",yaxt="n",col="black",bg="purple",
cex.axis=1.0, xlab="log(e)OR", cex.lab=1.6)
axis (4, pos=0.0, tck = 0, labels=FALSE, col="black")
text (0.73,3,"3-6 mos vs. 12 mos", cex= 1.4)
text (0.75,1,"3-6 mos vs. 18-48 mos",cex = 1.4)
text (0.75,2, "12 mos vs. 18-48 mos", cex = 1.4)
text (0, 0,"All-Cause Mortality",cex = 1.6,font =2)
text (0.4, 0.6, "Long DAPT Better",cex=1.6,font=3)
text (-0.4, 0.6, "Short DAPT Better",cex=1.6,font=3)
text (-thetaSummaryObs$mean[3], 1.2, font=2, round(1/expTheta$mean[3],2))
text (-thetaSummaryObs$val2.5pc[3], 1.2, font=2,round(1/expTheta$val2.5pc[3],2))
text (-thetaSummaryObs$val97.5pc[3], 1.2, font=2,round(1/expTheta$val97.5pc[3],2))
text (-thetaSummaryObs$mean[1],3.2,font=2,round(1/expTheta$mean[1],2))
text (-thetaSummaryObs$val2.5pc[1], 3.2, font=2,round(1/expTheta$val2.5pc[1],2))
text (-thetaSummaryObs$val97.5pc[1], 3.2, font=2,round(1/expTheta$val97.5[1],2))
text (-thetaSummaryObs$mean[2], 2.2, font=2,round(1/expTheta$mean[2],2))
text (-thetaSummaryObs$val2.5pc[2], 2.2, font=2,round(1/expTheta$val2.5pc[2],2))
text (-thetaSummaryObs$val97.5pc[2], 2.2, font=2,round(1/expTheta$val97.5pc[2],2))
segments(-thetaSummaryObs$val2.5pc[3], 1, -thetaSummaryObs$mean[3]+0.027, 1, lty=1, col="black", lwd=3)
segments(-thetaSummaryObs$val97.5pc[3], 1, -thetaSummaryObs$mean[3]-0.029, 1, lty=1, col="black", lwd=3)
segments(-thetaSummaryObs$val2.5pc[1], 3, -thetaSummaryObs$mean[1]+0.027, 3, lty=1, lwd=3)
segments(-thetaSummaryObs$val97.5pc[1], 3, -thetaSummaryObs$mean[1]-0.029, 3, lty=1, lwd=3)
segments(-thetaSummaryObs$val2.5pc[2], 2, -thetaSummaryObs$mean[2]+0.027, 2, lty=1, lwd=3)
segments(-thetaSummaryObs$val97.5pc[2], 2, -thetaSummaryObs$mean[2]-0.029, 2, lty=1, lwd=3)
mtext ("Posterior Odds Ratio (OR)",3, line =2, cex = 1.6)
axis (3, at=c(-0.91,-0.69, -0.51,-0.35, -0.22, -0.105,0.0, 0.095,0.182, 0.262,0.336,
0.405,0.47,0.531,0.588,0.693, 0.833, 0.956, 1.10,1.19, 1.281,1.386,1.46,1.53,1.61,1.67,1.72,1.79),
labels=c(0.4,0.5,0.6, 0.7, 0.8,0.9, "1.0", 1.1,1.2, 1.3,1.4,1.5, 1.6,1.7, 1.8, "2.0", 2.3, 2.6, "3.0",
3.3,3.6,"4.0",4.3,4.6,"5.0",5.3,5.6,"6.0"))
#To create good margins
mar.default <- c(5,4,4,2) + 0.0
par(mar = mar.default + c(0, 2, 0, 0))
#To copy in eps and pdf formats to your original folder. (Change the date each time or you will 
overwrite.)
dev.copy2eps(file="NetworkDAPTDeathMay20Caterpillar.eps")
dev.copy2pdf(file="NetworkDAPTDeathMay20Caterpillar.pdf")
#Export data from Excel in comma-separated format containing a csv suffix, which is the best way to 
input data into [R}. Remember that "Z:" is a common designation of the hard disk on a Mac running 
Windows, but "C:" is used on a PC. Remember also to replace "johnbittl" with your user name on your 
computer, "Dropbox" and "EuroInterventionDAPT" with your folder names, and "NetworkDAPTDeath.csv" with 
your file name (see Bittl JA, He Y: Bayesian analysis: practical approach to interpret clinical trials 
and create clinical practice guidelines. Circulation Cardiovasc Qual Outcomes 2017;10:1-11)87.  
Figure 7. R Code for Figure 5: network meta-analysis for DAPT mortality and caterpillar plot.
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tribution with mean dSM and variance τ 2SM, where dSM characterised 
the comparative effectiveness between a short duration of DAPT 
and 12 months of therapy. Similarly, we modelled the number of 
deaths after prolonged DAPT in the four studies that had treatment 
arms comparing 12 months (M) of DAPT with long (L) durations 
of DAPT of 18-48 months35,41,43,47,49 as a binomial distribution. We 
assumed that the difference of log odds from each study δi ,ML fol-
lowed a normal random effects distribution with mean dML and 
variance τ 2ML, where dML characterised the comparative effective-
ness between prolonged DAPT and 12 months of therapy.
The difference between dSM and dML can be denoted by dSL=dSM–dML 
to describe the comparative effectiveness between short and long 
durations of DAPT under the model. Finally, we completed the 
PRGHOVSHFL¿FDWLRQE\ LPSRVLQJ WKHIROORZLQJSULRUGLVWULEXWLRQV
to the parameters:
 dSM ~ N [0,10
3]
 dML ~ N [0,10
3],
 τ 2SM ~ IG [10 –3,10 –3],
 τ 2ML ~ IG [10 –3,10 –3],
where d is the mean difference in the log odds of an outcome after 
S, M or L DAPT and τ 2  is the associated variance modelled using 
a normal (N) or inverse gamma (IG) distribution, based on the 
complete model described in other reports87.
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Siddiqi et al. performed a retrospective analysis of the 
large Veterans database to explore the effect of clopidogrel 
prolongation beyond 12 months compared with 12 months 
or less after coronary stenting (1). Patients treated between 
2002 and 2006 were divided in two groups: normal renal 
function (n=18,162) or chronic kidney disease (CKD, 
n=4,880) based on an estimated glomerular filtration rate 
(eGFR) cut-off of ≥ or <60 mL/min, respectively. A further 
stratification was made to compare patients treated with 
bare metal stents (BMS) and those treated with drug-eluting 
stents (DES). Outcomes were evaluated in patients free from 
ischemic or bleeding events within the first 12 months after 
percutaneous coronary intervention (PCI), at a follow-up 
ranging from 1 to 4 years after PCI. The primary endpoint 
was the combined outcome of death or acute myocardial 
infarction (MI), which was significantly increased in 
patients with CKD in both DES and BMS subgroups. 
However, CKD was also associated with an increased risk of 
disabling or life-threatening bleeding after DES and BMS 
implantation.
The authors reported that clopidogrel use of more than 
12 months after PCI in patients with CKD receiving DES 
was associated with lower risk of death or MI (18% vs. 
24%, HR=0.74; 95% CI, 0.58 to 0.95), and death (15% 
vs. 23%, HR=0.61; 95% CI, 0.47 to 0.80). At multivariate 
and propensity-score adjusted analyses, however, results 
were confirmed for death but not for the composite 
of death or MI. Furthermore, the potential benefits 
of prolonged dual antiplatelet therapy (DAPT) on the 
primary endpoint did not apply to patients treated with 
BMS. No significant increase of life-threatening bleeding 
was observed by prolonging DAPT administration after 
both DES or BMS implantation in patients with CKD at 
multivariate or propensity analyses, however: (I) a trend 
of increased risk was present (significant at univariate 
analysis in DES subgroup); (II) the rates of major bleeding 
were not reported and (III) the number of life-threatening 
bleeding events was probably too low to detect a significant 
difference between subgroups. 
Finally, in patients with normal renal function, the 
authors observed consistent findings but the magnitude of 
ischemic risk reduction was lower than that observed in 
CKD patients treated with DES.
Although affected by some inherent critical limitations, 
this large retrospective study is well conducted and of 
interest to the community because it deals with a specific 
patient population (i.e., patients affected by CKD) in whom 
few data from randomized trials are available.
DAPT administration aims to reduce the risk of stent 
thrombosis (ST) after coronary stent implantation and 
prevent coronary atherothrombotic events at sites outside 
of the stented segment. However, the optimal duration of 
DAPT after stent implantation in general, and following 
DES implantation in particular, is matter of ongoing 
debate (2,3). 
Does this study help in identifying the target population 
in which DAPT should be prolonged well beyond 
12 months? We believe the reader should apply caution 
while interpreting study results. Beyond the obvious 
limitations carried by a retrospective and non-randomized 
analysis, these findings should be critically contrasted with 
the results of randomized controlled studies, which showed 
a clear effect of DAPT prolongation on non-fatal ischemic 
endpoints, i.e., MI and very late ST, in the absence of a 
mortality benefit. How can we reconcile those with the 
observed reduction in mortality but not mortality or MI 
risk in the current analysis? A plausible interpretation is that 
in clinical practice clinicians are able to identify patients 
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who benefit from prolonged DAPT duration and using 
sophisticated statistical tools, no adjustment can be made 
for baseline or updated covariates that are not routinely 
captured, and perhaps not even capturable, in registries.
Drug eluting stents have consistently reduced in-stent 
restenosis as compared with BMS but at the expense of 
safety concerns duo to an increase in late and very late 
ST. In particular, first-generation DES were associated 
with a four- to five-fold higher risk of very late ST as 
compared with BMS, which fueled  “the longer the better” 
recommendation for DAPT duration in patients treated 
with DES (4). Conversely, second-generation devices were 
shown to be safer in terms of ST as compared with both 
first-generation DES and BMS ().
Recent trials, reviews and meta-analyses (2,6-12) 
compared efficacy and safety of short (<12 months) and 
long term (≥12 months) DAPT after first- and second-
generation DES implantation with respect to the currently 
recommended 12-month therapy (13,14). A short course 
of DAPT was associated with a significant reduction in 
major bleeding without significant differences in ischemic 
or thrombotic outcomes. Moreover, patients associated with 
high risk of bleeding events were recently evaluated in two 
different trials (15,16) in which DAPT was stopped very 
early (1 month) after second-generation DES implantation 
without safety concerns in terms of ischemic events. In 
particular, the ZEUS trial (15) compared Zotarolimus-
eluting Endeavor sprint stent followed by 30-day DAPT 
with BMS followed by the same DAPT regimen, while 
the LEADERS FREE trial (16) compared a polymer-free 
Biolimus-eluting stent with a very similar BMS platform 
followed by 1-month DAPT. Both studies demonstrated 
that a treatment strategy consisting of second-generation 
DES implantation followed by a shorter than currently 
recommended DAPT regimen (30 days) resulted in a lower 
risk of MACE as compared with BMS in high-bleeding risk 
patients. 
Conversely, prolonging DAPT over 12 months yielded 
a significant reduction in terms of MI and ST, in particular 
in trials including first-generation DES use (10,17), but 
at the price of a substantial increasing in major bleeding. 
Moreover, all-cause mortality was also significantly 
increased in the long-term DAPT population (10,11,18). 
Actually, bleeding and ST may have a different impact on 
mortality as highlighted in a recent meta-analysis reporting 
a significant association between bleeding and non-
cardiovascular death but not between ST and cardiovascular 
death (19).
As a result, a personalized DAPT duration based on 
patient’s bleeding and ischemic risk seems to be a more 
logical strategy in order to reach maximum benefits with 
limited side effects. 
Patients with CKD represent a sizable proportion of 
patients (between 33% and 50%) with myocardial ischemia 
undergoing percutaneous coronary stent implantation (20), 
although frequently excluded or marginally represented in 
major randomized trials evaluating clopidogrel duration 
after coronary stenting. Siddiqi et al. included a high 
number of patients with eGFR <60 mL/min in whom 
primary and secondary outcomes were evaluated with 
multivariate and propensity analyses (1). The sensitivity 
analyses using the CKD-Epi equation, which seems to 
be more precise in estimating renal function, supported 
the consistency of their results. Unfortunately, due to the 
small number of subjects with eGFR < 30 mL/min, the 
differences across different degrees of CKD have not been 
evaluated in this study (1).
In early-stage CKD population the risk for premature 
cardiovascular disease is increased by 25% to 30% while in 
end-stage CKD patients it is more than 30- to 50-fold higher. 
On the other hand, also the bleeding risk is increased 
in patients with renal dysfunction (1,20). Indeed, renal 
disease was identified to be commonly used in the clinical 
practice to weigh the bleeding risk after DES implantation 
in a recent survey (3), and it is also included in the most 
relevant available bleeding risk scores (i.e., CRUSADE 
and HAS-BLEED). 
Siddiqui et al. concluded that: “in patients with CKD, 
prolonging clopidogrel beyond 12 months after PCI 
may decrease the risk of death or MI only in patients 
receiving first-generation DES as compared with BMS”. 
Key questions remains with respect to whether and how 
much these results may be applicable to patients with more 
severely reduced renal function (i.e., eGFR <30 mL/min) 
or to patients treated with contemporary devices, such as 
newer generation DES. 
The observation that prolonged DAPT did not increase 
bleeding risk, a finding which has been remarkably 
consistent across all randomized controlled studies and 
meta-analyses, further raising concerns on the adequacy of 
adjustment for biases in the current analysis. 
Conclusions
Prolongation of DAPT still remains highly debated, 
irrespective of specific subgroups of patients, because it 
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is associated with ischemic benefits, but also with a time-
dependent risk of major and clinically relevant bleeding 
complications, which in turn significantly affect morbidity 
and mortality.
The present study offers data for additional debate as 
it focuses on a large sub-population of patients with high 
ischemic and bleeding risks, who are frequently under-
represented in randomized trials on DAPT duration and/
or stent types. The key lesson here is that perhaps clinicians 
seem to be able to select the ideal CKD population in 
whom DAPT may and should be prolonged, better than 
conventional inclusion or exclusion criteria so far employed 
in clinical trials. Hence, once more trialists and device or 
drug manufacturing companies need to learn from clinicians 
more than vice versa.  
Randomized trials of new generation DES and reliable 
P2Y12 inhibitors (ticagrelor or prasugrel) are needed to help 
clinicians to perform even better. 
Acknowledgements
None.
 
Footnote
Provenance: This is a Guest Editorial commissioned by 
the Section Editor Yue Liu (Department of Cardiology, 
the  Firs t  Af f i l i a ted  Hospi ta l  of  Harbin  Medica l 
University, Harbin, China).
Conflicts of Interest: The authors have no conflicts of interest 
to declare. 
References
1. Siddiqi OK, Smoot KJ, Dufour AB, et al. Outcomes 
with prolonged clopidogrel therapy after coronary 
stenting in patients with chronic kidney disease. Heart 
2015;101:1569-76.
2. Valgimigli M, Ariotti S, Costa F. Duration of 
dual antiplatelet therapy after drug-eluting stent 
implantation: will we ever reach a consensus? Eur Heart J 
2015;36:1219-22.
3. Valgimigli M, Costa F, Byrne R, et al. Dual antiplatelet 
therapy duration after coronary stenting in clinical 
practice: results of an EAPCI survey. EuroIntervention 
2015;11:68-74.
4. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-
term outcomes with drug-eluting and bare-metal coronary 
stents: a mixed-treatment comparison analysis of 117 
762 patient-years of follow-up from randomized trials. 
Circulation 2012;125:2873-91.
5. Valgimigli M, Tebaldi M, Borghesi M, et al. Two-year 
outcomes after first- or second-generation drug-eluting 
or bare-metal stent implantation in all-comer patients 
undergoing percutaneous coronary intervention: a pre-
specified analysis from the PRODIGY study (PROlonging 
Dual Antiplatelet Treatment After Grading stent-induced 
Intimal hyperplasia studY). JACC Cardiovasc Interv 
2014;7:20-8.
6. Valgimigli M, Campo G, Percoco G, et al. Randomized 
comparison of 6- versus 24-month clopidogrel therapy 
after balancing anti-intimal hyperplasia stent potency in 
all-comer patients undergoing percutaneous coronary 
intervention Design and rationale for the PROlonging 
Dual-antiplatelet treatment after Grading stent-induced 
Intimal hyperplasia study (PRODIGY). Am Heart J 
2010;160:804-11.
7. Valgimigli M, Campo G, Monti M, et al. Short- versus 
long-term duration of dual-antiplatelet therapy after 
coronary stenting: a randomized multicenter trial. 
Circulation 2012;125:2015-26.
8. Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. ISAR-
SAFE: a randomized, double-blind, placebo-controlled 
trial of 6 vs. 12 months of clopidogrel therapy after drug-
eluting stenting. Eur Heart J 2015;36:1252-63.
9. Gilard M, Barragan P, Noryani AA, et al. 6- versus 
24-month dual antiplatelet therapy after implantation of 
drug-eluting stents in patients nonresistant to aspirin: the 
randomized, multicenter ITALIC trial. J Am Coll Cardiol 
2015;65:777-86.
10. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 
months of dual antiplatelet therapy after drug-eluting 
stents. N Engl J Med 2014;371:2155-66.
11. Navarese EP, Andreotti F, Schulze V, et al. Optimal 
duration of dual antiplatelet therapy after percutaneous 
coronary intervention with drug eluting stents: 
meta-analysis of randomised controlled trials. BMJ 
2015;350:h1618.
12. Montalescot G, Brieger D, Dalby AJ, et al. Duration 
of Dual Antiplatelet Therapy After Coronary Stenting: 
A Review of the Evidence. J Am Coll Cardiol 
2015;66:832-47.
13. Levine GN, Bates ER, Blankenship JC, et al. 2011 
ACCF/AHA/SCAI Guideline for Percutaneous Coronary 
Intervention. A report of the American College of 
Cardiology Foundation/American Heart Association 
4 Ariotti et al. Prolonged DAPT in CKD patients
© Journal of Thoracic Disease. All rights reserved.   J Thorac Dis 2015www.jthoracdis.com
Task Force on Practice Guidelines and the Society for 
Cardiovascular Angiography and Interventions. J Am Coll 
Cardiol 2011;58:e44-122.
14. Authors/Task Force members, Windecker S, Kolh P, 
et al. 2014 ESC/EACTS Guidelines on myocardial 
revascularization: The Task Force on Myocardial 
Revascularization of the European Society of Cardiology 
(ESC) and the European Association for Cardio-
Thoracic Surgery (EACTS)Developed with the special 
contribution of the European Association of Percutaneous 
Cardiovascular Interventions (EAPCI). Eur Heart J 
2014;35:2541-619.
15. Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-
eluting versus bare-metal stents in uncertain drug-eluting 
stent candidates. J Am Coll Cardiol 2015;65:805-15.
16. Urban P, Meredith IT, Abizaid A, et al. Polymer-free 
Drug-Coated Coronary Stents in Patients at High 
Bleeding Risk. N Engl J Med 2015;373:2038-47.
17. Valgimigli M, Borghesi M, Tebaldi M, et al. Should 
duration of dual antiplatelet therapy depend on the 
type andor potency of implanted stent? A pre-specified 
analysis from the PROlonging Dual antiplatelet treatment 
after Grading stent-induced Intimal hyperplasia studY 
(PRODIGY). Eur Heart J 2013;34:909-19.
18. Giustino G, Baber U, Sartori S, et al. Duration of dual 
antiplatelet therapy after drug-eluting stent implantation: 
a systematic review and meta-analysis of randomized 
controlled trials. J Am Coll Cardiol 2015;65:1298-310.
19. Capodanno D, Gargiulo G, Buccheri S, et al. Meta-
Analyses of Dual Antiplatelet Therapy Following Drug-
Eluting Stent Implantation: Do Bleeding and Stent 
Thrombosis Weigh Similar on Mortality? J Am Coll 
Cardiol 2015;66:1639-40.
20. Palmer SC, Di Micco L, Razavian M, et al. Effects of 
antiplatelet therapy on mortality and cardiovascular and 
bleeding outcomes in persons with chronic kidney disease: 
a systematic review and meta-analysis. Ann Intern Med 
2012;156:445-59.
Cite this article as: Ariotti S, Gargiulo G, Windecker S, 
Valgimigli M. Time for science to catch up with clinical practice? 
J Thorac Dis 2015. doi: 10.3978/j.issn.2072-1439.2015.12.26
Impact of Sex on 2-Year Clinical
Outcomes in Patients Treated
With 6-Month or 24-Month
Dual-Antiplatelet Therapy Duration
A Pre-Specified Analysis From the PRODIGY Trial
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ABSTRACT
OBJECTIVES The aim of this study was to assess the impact of sex on 2-year outcomes after percutaneous coronary
intervention (PCI) in patients randomly allocated to 24-month versus 6-month dual-antiplatelet therapy (DAPT).
BACKGROUND The optimal duration of DAPT after PCI is highly debated. Whether sex per se should drive decision
making on DAPT duration remains unclear.
METHODS The primary efficacy endpoint of PRODIGY (Prolonging Dual Antiplatelet Treatment After Grading
Stent-Induced Intimal Hyperplasia Study) was the composite of death, myocardial infarction, or cerebrovascular accident
at 24-month follow-up. The key safety endpoint was type 2, 3, or 5 bleeding according to the Bleeding Academic
Research Consortium criteria.
RESULTS Women (n ¼ 459 [23.3%]) were older and more likely to have hypertension, lower creatinine clearance, and
acute coronary syndrome but had a lower severity of coronary artery disease. After adjustment, prolonged DAPT,
compared with 6-month treatment, did not reduce the primary endpoint in both men (adjusted hazard ratio: 1.080;
95% confidence interval: 0.766 to 1.522; p ¼ 0.661) and women (adjusted hazard ratio: 1.013; 95% confidence interval:
0.588 to 1.748; p ¼ 0.962) (interaction p ¼ 0.785). No sex disparity was identified across multiple secondary ischemic
endpoints, including overall or cardiovascular mortality, myocardial infarction, and stent thrombosis. There was also
no clear sex-related effect on clinically relevant bleeding, including Bleeding Academic Research Consortium type 3 or 5,
TIMI (Thrombolysis in Myocardial Infarction), and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries)
scales.
CONCLUSIONS The present findings suggest that men and women undergoing PCI have similar adjusted 2-year
ischemic and bleeding outcomes, despite being characterized by different clinical presentation. Sex failed to emerge as a
treatment modifier with respect to DAPT duration, suggesting that decision making on DAPT duration in female patients
should weigh ischemic versus bleeding risks. (J Am Coll Cardiol Intv 2016;9:1780–9) © 2016 by the American College of
Cardiology Foundation.
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P ercutaneous coronary intervention (PCI) is themost frequently performed revascularizationprocedure for coronary artery disease (CAD)
in both male and female patients. Sex influences age,
cardiovascular risk factors, clinical presentation, and
angiographic features, including extension of disease
and vessel size. However, the impact of sex on clinical
outcomes after PCI remains debated. Although female
sex has been identified as an independent predictor of
adverse outcomes after PCI in some studies (1–4), it
had no or minimal impact on outcomes in others
(5–10).
Dual-antiplatelet therapy (DAPT) is the corner-
stone of antithrombotic treatment in patients under-
going PCI, although its optimal duration remains
controversial (11–17). Whether sex should be taken
into account when selecting the DAPT regimen is still
unknown. Female sex per se was recently proposed as
a single covariate to identify patients in whom short
DAPT duration would be advisable (18). Yet the evi-
dence appraising the role of sex in the choice of the
optimal DAPT duration is limited.
The aim of this subanalysis of the PRODIGY
(Prolonging Dual Antiplatelet Treatment After
Grading Stent-Induced Intimal Hyperplasia Study)
randomized trial was to compare 2-year clinical
outcomes in male and female patients and to
assess the impact of sex in the setting of an all-
comer population undergoing PCI and with a
randomly allocated short (6-month) or prolonged
(24-month) DAPT regimen, consisting of clopidogrel
and aspirin.
METHODS
The present study is a pre-specified analysis of
PRODIGY (NCT00611286). The design and main find-
ings have been previously reported (11,19). Briefly,
all-comer PCI patients (n ¼ 2,013) were randomized
to 4 types of stent (bare-metal, zotarolimus-eluting,
paclitaxel-eluting, or everolimus-eluting stents)
with varying anti-intimal hyperplasia potency and
belonging to both the first and second generations
of drug-eluting stent at 3 Italian sites. At 30 days,
patients (n ¼ 1,970) were randomly allocated to either
6 or 24 months of DAPT. Selection criteria were broad,
reflecting routine clinical practice. Randomization
to 6- or 24-month DAPT was stratified by center,
ongoing ST-segment elevation myocardial infarction
(MI), the presence of diabetes mellitus, and need for
intervening on at least 1 in-stent restenotic lesion.
The study was conducted in accordance with
the principles of the Declaration of Helsinki. The
ethics committees of the 3 participating centers
independently approved the protocol, and all
participants gave written informed consent.
TREATMENT PROTOCOL. All patients received
aspirin (80 to 160 mg orally indefinitely) and
clopidogrel (75 mg/day) according to the
randomization scheme as follows: for either
6 months in the short-DAPT arm or 24 months
in the prolonged-DAPT arm, irrespective of
the previously implanted stent type or indi-
cation for PCI.
FOLLOW-UP. The randomized patients re-
turned for study visits at 30 days and then
every 6months up to 2 years. During follow-up
visits, patients were examined and assessed
for adverse events and asked about anti-
platelet therapy compliance, and 12-lead
electrocardiographic recordings were obtained.
TABLE 1 Baseline Characteristics in Male and Female Patients
Male
(n ¼ 1,511)
Female
(n ¼ 459) p Value
Age (yrs) 67.8 (58.8–75.1) 73.6 (66.2–79.3) <0.0001
Body mass index (kg/m2) 26.8 (24.6–29.4) 26.2 (23.5–28.9) 0.950
Diabetes 24.0% (362) 25.1% (115) 0.631
Insulin dependent 5.8% (87) 5.9% (27)
Hypertension 69.2% (1,045) 80.4% (369) <0.0001
Hyperlipidemia 54.6% (825) 55.1% (253) 0.845
Current cigarette use 25.5% (385) 18.3% (84) 0.002
Creatinine level (mg/dl) 1.0 (0.9–1.2) 0.9 (0.7–1.1) 0.002
Creatinine clearance (ml/min) 80.6 (59.8–99.8) 60.5 (46.5–79.8) <0.0001
Prior myocardial infarction 28.4% (429) 21.1% (97) 0.006
Prior PCI 19.5% (295) 13.9% (64) 0.013
LVEF 50.0 (45–60) 52.4 (45–60) 0.521
Clinical presentation
Stable angina pectoris 26.9% (406) 21.6% (99) 0.023
Acute coronary syndrome 73.1% (1,105) 78.4% (360)
STEMI 32.9% (497) 32.9% (151) 0.998
NSTEMI 22.7% (343) 23.3% (107) 0.785
Unstable angina 17.5% (265) 22.2% (102) 0.024
Multivessel disease 72.1% (1,089) 63.2% (290) <0.0001
Number of treated lesions 1 (1–2) 1 (1–2) 0.005
$2 treated lesions 39.1% (591) 31.6% (145) 0.004
$3 treated lesions 12.0% (181) 9.2% (42) 0.094
Multivessel intervention 28.1% (424) 22.2% (102) 0.013
At least 1 complex lesion (type B2 or C)* 67.3% (1,017) 63.0% (289) 0.085
Total ACC/AHA score† 3 (2–5) 3 (2–4) 0.027
Aspirin 100% (1,511) 100% (459) >0.999
Clopidogrel 99.9% (1,510) 99.6% (457) 0.075
Warfarin 1.8% (27) 1.5% (7) 0.716
Statin 90.8% (1,360) 89.4% (404) 0.351
Values are median (interquartile range) or % (n). *According to the ACC/AHA coronary lesion classification. †Type
A stenoses were coded 1 point, type B1 stenoses 2 points, type B2 stenoses 3 points, and type C stenoses 4
points.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; LVEF ¼ left ventricular ejection
fraction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention;
STEMI ¼ ST-segment elevation myocardial infarction.
AB BR E V I A T I O N S
AND ACRONYM S
BARC = Bleeding Academic
Research Consortium
CAD = coronary artery disease
CI = confidence interval
CVA = cerebrovascular
accident
DAPT = dual-antiplatelet
therapy
HR = hazard ratio
MI = myocardial infarction
PCI = percutaneous coronary
intervention
ST = stent thrombosis
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STUDY ENDPOINTS. The primary efficacy endpoint of
the PRODIGY trial was the composite of death, MI, or
cerebrovascular accident (CVA), while the key safety
endpoint included Bleeding Academic Research
Consortium (BARC) type 2, 3, or 5 bleeding. The net
effect on the combined ischemic and bleeding com-
plications was obtained by 2 net adverse clinical
event endpoints that were generated by combining
the primary efficacy endpoint of death, MI, or CVA
with either the primary safety endpoint of BARC type
2, 3, or 5 bleeding or BARC type 3 or 5 events. Other
endpoints included each component of the primary
efficacy endpoint, cardiovascular death, stent
thrombosis (ST) defined on the basis of the Academic
Research Consortium criteria, and BARC type 3 or 5
bleeding. Other safety endpoints included bleeding
events adjudicated according to the TIMI (Throm-
bolysis in Myocardial Infarction) and GUSTO (Global
Use of Strategies to Open Occluded Coronary Arteries)
scales. All study endpoint definitions were previously
reported.
All endpoints were confirmed on the basis of
documentation collected at each hospital and were
centrally adjudicated by the clinical events commit-
tee, whose members were unaware of the patients’
treatment group assignments. The time frame of in-
terest for the primary endpoint was from 30 days
(i.e., after the primary endpoint randomization) to 24
months.
STATISTICAL ANALYSIS. Categorical variables are
expressed as frequency (percentage), whereas
continuous variables are expressed as median (inter-
quartile range). Continuous variables were compared
between randomized groups using the Wilcoxon rank
sum test, whereas for binary variables, the chi-square
test was used. Multiple imputation (the iterative
Markov-chain Monte Carlo algorithm [fully condi-
tional specification or chained equations imputation]
TABLE 2 Baseline Characteristics According to Randomization for Dual-Antiplatelet Therapy Duration
Male (n ¼ 1,511) Female (n ¼ 459)
24-Month Clopidogrel
(n ¼ 764)
6-Month Clopidogrel
(n ¼ 747) p Value
24-Month Clopidogrel
(n ¼ 223)
6-Month Clopidogrel
(n ¼ 236) p Value
Age (yrs) 68.2 (58.8–74.8) 67.5 (58.7–75.6) 0.627 74.0 (66.7–79.1) 73.0 (64.2–79.4) 0.365
Body mass index (kg/m2) 26.7 (24.8–29.4) 26.9 (24.5–29.4) 0.599 26.2 (23.9–29.1) 26.2 (23.4–28.5) 0.277
Diabetes 24.7% (189) 23.2% (173) 0.472 24.7% (55) 25.4% (60) 0.851
Insulin dependent 5.9% (45) 5.6% (42) 6.3% (14) 5.5% (13)
Hypertension 70.5% (539) 67.9% (506) 0.237 81.6% (182) 79.2% (187) 0.851
Hyperlipidemia 56.8% (434) 52.3% (391) 0.081 53.4% (119) 56.8% (134) 0.521
Current cigarette use 24.6% (188) 26.4% (197) 0.431 15.2% (34) 21.2% (50) 0.100
Creatinine level (mg/dl) 1.0 (0.9–1.2) 1.0 (0.9–1.2) 0.674 0.9 (0.8–1.1) 0.9 (0.7–1.0) 0.028
Creatinine clearance (ml/min) 80.1 (59.1–103.3) 81.1 (60.8–96.6) 0.157 60.3 (45.0–79.6) 61.4 (47.2–80.1) 0.280
Prior myocardial infarction 29.7% (227) 27.1% (202) 0.250 19.3% (43) 22.9% (54) 0.345
Prior PCI 21.1% (161) 18.0% (134) 0.124 12.6% (28) 15.3% (36) 0.404
LVEF 50.0 (45–60) 50.0 (44–60) 0.780 55.0 (45–60) 50.0 (45–60) 0.080
Clinical presentation
Stable angina pectoris 27.4% (209) 26.4% (197) 0.666 20.6% (46) 22.5% (53) 0.634
Acute coronary syndrome 72.6% (555) 73.6% (550) 0.666 79.4% (177) 77.5% (183) 0.634
STEMI 32.6% (249) 33.2% (248) 0.801 32.3% (72) 33.5% (79) 0.787
NSTEMI 22.5% (172) 22.9% (171) 0.861 24.2% (54) 22.5% (53) 0.656
Unstable angina 17.5% (134) 17.5% (131) 0.999 22.9% (51) 21.6% (51) 0.746
Multivessel disease 72.9% (557) 71.2% (532) 0.465 61.9% (138) 64.4% (152) 0.575
Number of treated lesions 1 (1–2) 1 (1–2) 0.024 1 (1–2) 1 (1–2) 0.393
$2 treated lesions 37.8% (289) 40.4% (302) 0.300 34.1% (76) 29.2% (69) 0.265
$3 treated lesions 11.3% (86) 12.7% (95) 0.382 9.9% (22) 8.5% (20) 0.605
Multivessel intervention 25.9% (198) 30.3% (226) 0.061 24.7% (55) 19.9% (47) 0.221
At least 1 complex lesion (type B2 or C)* 65.7% (502) 68.9% (515) 0.180 62.8% (140) 63.1% (149) 0.937
Total ACC/AHA score† 3 (2–4) 3 (3–5) 0.036 3 (2–4) 3 (2–4) 0.627
Aspirin 100% (764) 100% (747) >0.999 100% (223) 100% (236) >0.999
Clopidogrel 99.9% (763) 100% (747) 0.323 99.6% (222) 99.6% (235) 0.968
Warfarin 1.3% (10) 2.3% (17) 0.153 1.4% (3) 1.7% (4) 0.756
Statin 90.0% (683) 91.7% (677) 0.241 88.6% (195) 90.1% (209) 0.617
Values are median (interquartile range) or % (n). *According to the ACC/AHA coronary lesion classification. †Type A stenoses were coded 1 point, type B1 stenoses 2 points, type
B2 stenoses 3 points, and type C stenoses 4 points.
Abbreviations as in Table 1.
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implemented in SPSS [IBM, Armonk, New York] was
used to create 5 datasets with imputation of missing
values on the basis of their potential predictors) was
used for missing values of creatinine levels at base-
line (n ¼ 21) and ejection fraction (n ¼ 136).
Hazard ratios (HRs) with 95% confidence intervals
(CIs) were calculated for male versus female (values
>1 indicated increased hazard in the male group) and
24-month versus 6-month DAPT (values >1 indi-
cated increased hazard with 24-month DAPT) with a
proportional hazards model. Cox regression was
used for multivariate analysis. Clinical and angio-
graphic characteristics that were imbalanced at a
nominal 5% significance level between the 2
groups were identified and included the final
adjusted model; these included age, hypertension,
smoking, baseline creatinine level, prior MI, clinical
presentation, multivessel intervention and total
American College of Cardiology/American Heart As-
sociation score.
Interaction testing was performed to determine
whether the effect of DAPT duration was consistent
irrespective of sex on the primary and secondary end-
points of the study. This was performed with likelihood
ratio tests of the null hypothesis that the interaction
coefficient was zero. A 2-sided p value <0.05 was
considered to indicate statistical significance. All ana-
lyses were based on the intention-to-treat principle and
were performed with SPSS version 23.0.
RESULTS
Among 1,970 patients randomized to 6- versus
24-month DAPT at 30 days from PCI, 1,511 (76.7%)
were men, and 459 (23.3%) were women. Baseline
characteristics are summarized in Table 1, while
Table 2 describes baseline characteristics of the 2
randomized arms of DAPT regimens (24 vs. 6 months)
in male and female patients. Compared with men,
women were older, had a higher prevalence of
TABLE 3 Clinical Outcomes in Female and Male Patients
Male
(n ¼ 1,511)
Female
(n ¼ 459)
Unadjusted Hazard Ratio
(95% CI) p Value
Adjusted Hazard Ratio
(95% CI) p Value
Primary efficacy endpoint
Death from any cause, MI, or CVA 140 (9.3) 58 (12.6) 0.716 (0.527–0.972) 0.032 0.912 (0.658–1.262) 0.577
Secondary efficacy endpoints
Death from any cause or MI 124 (8.2) 58 (12.6) 0.631 (0.462–0.863) 0.004 0.792 (0.568–1.103) 0.168
Death from any cause 89 (5.9) 41 (8.9) 0.650 (0.449–0.941) 0.023 0.834 (0.564–1.234) 0.365
Death from cardiovascular cause 48 (3.2) 25 (5.4) 0.576 (0.355–0.933) 0.025 0.775 (0.467–1.286) 0.324
Stroke or TIA 25 (1.7) 7 (1.5) 1.083 (0.468–2.504) 0.852 1.363 (0.569–3.268) 0.487
MI 53 (3.5) 27 (5.9) 0.588 (0.370–0.934) 0.025 0.698 (0.424–1.150) 0.158
Definite ST 11 (0.7) 4 (0.9) 0.822 (0.262–2.581) 0.737 1.161 (0.244–5.520) 0.851
Definite or probable ST 21 (1.4) 7 (1.5) 0.914 (0.389–2.150) 0.837 1.224 (0.491–3.055) 0.664
Definite, probable, or possible ST 59 (3.9) 25 (5.4) 0.705 (0.442–1.126) 0.144 0.963 (0.583–1.588) 0.881
Safety endpoints
BARC classification
Key safety endpoint (type 2, 3, or 5) 77 (5.1) 30 (6.5) 0.763 (0.500–1.163) 0.209 0.927 (0.588–1.462) 0.745
Type 3 or 5 38 (2.5) 15 (3.3) 0.756 (0.416–1.374) 0.358 1.005 (0.531–1.899) 0.989
Type 2 39 (2.6) 15 (3.3) 0.775 (0.427–1.406) 0.402 0.883 (0.456–1.710) 0.711
TIMI classification
Minor 14 (0.9) 6 (1.3) 0.695 (0.267–1.808) 0.456 0.858 (0.298–2.467) 0.776
Major 17 (1.1) 5 (1.1) 1.017 (0.375–2.758) 0.973 1.384 (0.488–3.919) 0.541
Minor or major 31 (2.1) 11 (2.4) 0.840 (0.422–1.671) 0.619 1.103 (0.526–2.313) 0.795
GUSTO classification
Moderate 18 (1.2) 9 (2.0) 0.596 (0.268–1.327) 0.205 0.820 (0.346–1.941) 0.651
Severe 20 (1.3) 5 (1.1) 1.199 (0.450–3.194) 0.717 1.641 (0.594–4.532) 0.339
Moderate or severe 37 (2.4) 14 (3.1) 0.789 (0.427–1.460) 0.450 1.104 (0.573–2.126) 0.767
Net adverse clinical events
Death from any cause, MI, CVA, or
BARC type 2, 3 or 5 bleeding
189 (12.5) 80 (17.4) 0.696 (0.536–0.904) 0.007 0.835 (0.633–1.102) 0.203
Death from any cause, MI, CVA, or
BARC type 3 or 5 bleeding
153 (10.1) 69 (15.0) 0.654 (0.493–0.870) 0.003 0.833 (0.615–1.128) 0.238
Values are n (%) unless otherwise indicated. Multivariate adjustment for age, hypertension, smoking, creatinine level, prior MI, ACS, multivessel intervention, and total ACC/
AHA score.
BARC ¼ Bleeding Academic Research Consortium; CI ¼ confidence interval; CVA ¼ cerebrovascular accident; GUSTO ¼ Global Use of Strategies to Open Occluded Coronary
Arteries; MI ¼ myocardial infarction; ST ¼ stent thrombosis; TIA ¼ transient ischemic attack; TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
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hypertension, had lower creatinine clearance, pre-
sented more frequently with acute coronary syn-
drome, were less likely smokers, and had a lower
prevalence or extension of CAD with less need for
multivessel intervention (Table 1). Overall, baseline
characteristics were well balanced in patients ran-
domized to 24-month or 6-month DAPT in both male
and female subgroups (Table 2).
At 2 years, crude events and unadjusted HRs
showed that women had higher rates of death, MI,
and the composite of ischemic events or ischemic and
bleeding events (Table 3). The primary efficacy
endpoint (death, MI, or CVA) occurred in 58 women
(12.6%) and 140 men (9.3%) (HR: 0.716; 95% CI:
0.527 to 0.972; p ¼ 0.032) (Table 3). After multivar-
iate adjustment for baseline imbalances, no signifi-
cant difference was noted between men and
women in the primary efficacy endpoint (adjusted
HR: 0.912; 95% CI: 0.658 to 1.262; p ¼ 0.577) (Table 3).
Consistent results were observed across all other
ischemic or bleeding endpoints between sexes
(Table 3). In an age-matched sensitivity analysis,
major adverse cardiovascular events and net adverse
clinical events were not affected by sex (all interac-
tion p values > 0.05) (Figure 1) or by stent type
(Online Table 1).
In both randomized DAPT groups, the primary
endpoint was similar in female and male patients
after adjustment (24-month DAPT: adjusted HR:
0.923; 95% CI: 0.586 to 1.453; p ¼ 0.729; 6-month
DAPT: adjusted HR: 0.828; 95% CI: 0.515 to 1.331;
p ¼ 0.436; p for interaction ¼ 0.785) (Figure 2, Online
Table 2). Accordingly, event rates did not differ with
respect to DAPT duration in male (adjusted HR: 1.080;
95% CI: 0.766 to 1.522; p ¼ 0.661 (Figure 3, Table 4)
and female (adjusted HR: 1.013; 95% CI: 0.588 to
1.748; p ¼ 0.962) (Figure 3, Table 4) patients.
The key safety endpoint of BARC type 2, 3, or 5
bleeding occurred in 30 women (6.5%) and 77 men
(5.1%). Men treated with longer DAPT experienced
higher rates of bleeding events (adjusted HR: 3.506;
95% CI: 2.013 to 6.104; p < 0.0001) (Table 4), whereas
women did not (adjusted HR: 0.827; 95% CI: 0.382 to
1.794; p ¼ 0.631) (Table 4), with positive interaction
testing (p for interaction ¼ 0.002). This difference
appeared to be driven mainly by BARC 2 bleeding
FIGURE 1 Interaction Between Age and Sex on 2-Year Composite Endpoints
Male and female patients were compared on the basis of age subgroups, with hazard ratios (HRs) and 95% confidence intervals (CIs), for
the primary endpoint of death from any cause, myocardial infarction, or cerebrovascular accident and net adverse clinical events (NACEs).
MACE ¼ major adverse cardiovascular event.
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events (men: adjusted. HR: 6.651; 95% CI: 2.592 to
17.065; p < 0.0001; women: adjusted HR: 0.764; 95%
CI: 0.240 to 2.431; p ¼ 0.649; p for interaction ¼
0.003) (Table 4). Accordingly, when bleeding was
assessed in terms of BARC type 3 or 5, prolonged
versus short DAPT did not differ with respect to
clinical outcomes in men (adjusted HR: 1.969; 95% CI:
0.965 to 4.019; p ¼ 0.063) (Figure 3, Table 4) or
women (adjusted HR: 0.971; 95% CI: 0.331 to 2.851;
p ¼ 0.957) (Figure 3, Table 4) separately appraised,
with negative interaction testing (p for interaction ¼
0.237). Assessing the impact of sex across TIMI and
GUSTO bleeding scales provided consistent results
(Table 4).
According to major adverse cardiovascular event
and BARC results, the rates of net adverse clinical
events did not show a significant interaction be-
tween DAPT duration and sex (BARC type 2, 3, or 5:
p for interaction ¼ 0.091; BARC type 3 or 5: p for
interaction ¼ 0.753) (Figure 4, Table 4). No relevant
interaction was found between age or stent type and
sex in DAPT arms (Online Tables 3 and 4).
DISCUSSION
In the present analysis from the PRODIGY trial, we
assessed the impact of sex on clinical outcomes in all-
comer patients undergoing PCI and receiving
different durations of DAPT. The main findings can
be summarized as follows. 1) Twenty-four-month
DAPT duration was not associated with ischemic
benefits in male and female patients, consistent with
the overall PRODIGY results. 2) Male but not female
patients had a significantly increased risk for
bleeding events with prolonged DAPT according to
the key safety endpoint of BARC type 2, 3 or 5
bleeding. However, the rate of bleeding did not differ
between male and female patients when treated with
6- or 24-month DAPT duration after exclusion of
BARC type 2 events.
This is the first dedicated sex-based analysis of a
randomized trial comparing a short with a prolonged
DAPT regimen. Our analysis suggests that the overall
results of the PRODIGY trial can be extended with
confidence to both sexes.
FIGURE 2 Survival Free From Death, Myocardial Infarction, or Cerebrovascular Accident According to Sex and
Dual-Antiplatelet Therapy Duration
Cox proportional model plot for the primary endpoint of death from all causes, myocardial infarction (MI), or cerebrovascular accident.
DAPT ¼ dual-antiplatelet therapy.
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PRODIGY was designed to detect a 40% reduction in
the composite endpoint of death, MI, or CVA in the
prolonged-DAPT armbut failed to support such a benefit
in largely unselected patients (25.6% with stable CAD
and 74.4% with acute coronary syndrome) undergoing
PCI with a balanced mixture of stent types, including
both first- and second-generation drug-eluting stents.
Overall, these results are consistent with those of other
trials exploring the impact of DAPT prolongation (12,14–
17), which either showed no benefit of prolonged DAPT
or benefit on recurrent MI and very late ST but no sig-
nificant impact on death or cardiovascular death. The
PEGASUS–TIMI 54 (Prevention of Cardiovascular Events
in Patients With Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin–
Thrombolysis In Myocardial Infarction 54) study was
the only trial to observe a significant reduction of
stroke in patients treated with 60 mg but not in those
taking a 90-mg twice-daily ticagrelor regimen compared
with aspirin only (20). All studies consistently observed
increases in bleeding events, depending on study power
and bleeding endpoint definitions.
When taken together, currently available studies
suggest that decision making regarding DAPT dura-
tion toward either shorter or longer than the con-
ventional 12-month time frame should involve a
“patient-by-patient” approach, aiming at balancing
ischemic versus bleeding risks. With that respect,
whether sex per se should be taken into account in
tailoring patient’s therapy is still unclear.
Although many studies support sex differences in
cardiovascular outcomes (1–4), an equally large body
of evidence suggests that women treated for CAD are
older and have a higher prevalence of comorbidities,
and as a result significant differences in outcomes
between male and female patients are no longer
demonstrated following adjustment for these base-
line differences (5–10). Consistent with the latter
studies, the results of the current analysis show that
in an all-comer population of patients treated with
stent implantation, men and women feature similar
ischemic as well as clinically relevant bleeding risks
when baseline confounders are accounted for in the
multivariate model.
FIGURE 3 Interaction Between Sex and Randomization to 24-Month or 6-Month Dual-Antiplatelet Therapy on 2-Year Clinical Outcomes
Male and female subgroups are shown, with hazard ratios (HRs) and 95% confidence intervals (CIs), for the primary endpoint of death from any
cause, myocardial infarction (MI), or cerebrovascular accident (CVA), death from any cause, cardiovascular death, MI, definite or probable stent
thrombosis (ST), Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding, and net adverse clinical events (NACEs) among patients
randomly assigned to either 6-month or 24-month dual-antiplatelet therapy.
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Age is a major confounder when analyzing out-
comes stratified for sex (21,22). Hence, in our analysis,
we also compared women and men on the basis of age
subcategories, which confirmed the results of the
adjusted analysis.
Some evidence suggests that women undergoing
PCI are at increased risk for bleeding. Hence, it could
be speculated that DAPT prolongation should be
avoided in women, who are on average older (18).
However, the increased bleeding risk in women
compared with men appears to be restricted largely to
the periprocedural period, with sex failing to predict
long-term bleeding risk (7,10,23,24). This is consistent
with our study findings, which suggest that clinically
relevant bleeding occurring from 30 days onward
after intervention is not affected by sex.
The DAPT trial showed that DAPT prolongation
significantly reduced both MI and definite or probable
ST in men but not in women (sex interaction 0.03 and
0.04 for MI and ST, respectively). However, the sex
interaction for bleeding (GUSTO moderate or severe)
or major adverse cardiovascular and cerebrovascular
events was not significant (25). Sex subgroup analysis
in the ARCTIC Interruption trial did not show differ-
ences between sexes in the primary (composite of all-
cause death, MI, stroke or transient ischemic attack,
urgent coronary revascularization, and ST) and sec-
ondary (composite of ST or urgent revascularization)
endpoints (26). Similarly, the DES-LATE trial
confirmed consistency between men and women for
the primary endpoint (composite of cardiac death, MI,
or stroke 24 months after randomization) (27), as did
the PEGASUS–TIMI 54 trial (20).
Hence, the results of our dedicated analysis are
consistent with the results of subgroup analysis of
other major DAPT studies and support the concept
that sex is not a treatment modifier with respect to
DAPT duration.
TABLE 4 Adjusted Clinical Outcomes in Patients Randomized to 24-Month Versus 6-Month Dual-Antiplatelet Therapy Stratified by Sex
Male (n ¼ 1,511) Female (n ¼ 459)
p Value for
Interaction
24-Month
Clopidogrel
(n ¼ 764)
6-Month
Clopidogrel
(n ¼ 747)
Adjusted
Hazard Ratio
(95% CI)
p
Value
24-Month
Clopidogrel
(n ¼ 223)
6-Month
Clopidogrel
(n ¼ 236)
Adjusted
Hazard Ratio
(95% CI)
p
Value
Primary efficacy endpoint
Death from any cause, MI, or CVA 72 (9.4) 68 (9.1) 1.080 (0.766–1.522) 0.661 28 (12.6) 30 (12.7) 1.013 (0.588–1.748) 0.962 0.785
Secondary efficacy endpoints
Death from any cause or MI 60 (7.9) 64 (8.6) 0.962 (0.668–1.386) 0.835 28 (12.6) 30 (12.7) 1.013 (0.588–1.748) 0.962 0.972
Death from any cause 46 (6.0) 43 (5.8) 1.121 (0.724–1.737) 0.608 19 (8.5) 22 (9.3) 0.919 (0.479–1.765) 0.800 0.505
Death from cardiovascular cause 23 (3.0) 25 (3.3) 0.851 (0.473–1.530) 0.590 13 (5.8) 12 (5.1) 1.042 (0.459–2.368) 0.921 0.674
MI 23 (3.0) 30 (4.0) 0.739 (0.423–1.290) 0.287 16 (7.2) 11 (4.7) 1.754 (0.763–4.030) 0.186 0.098
Stroke or TIA 19 (2.5) 6 (0.8) 3.609 (1.344–9.765) 0.011 1 (0.4) 6 (2.5) 0.170 (0.020–1.448) 0.105 0.010
Definite ST 6 (0.8) 5 (0.7) 1.182 (0.355–3.939) 0.785 2 (0.9) 2 (0.8) >10 (0–>1,000) 0.968 0.935
Definite or probable ST 11 (1.4) 10 (1.3) 1.149 (0.486–2.716) 0.752 2 (0.9) 5 (2.1) 0.433 (0.084–2.248) 0.319 0.293
Definite, probable, or possible ST 26 (3.4) 33 (4.4) 0.735 (0.433–1.246) 0.253 12 (5.4) 13 (5.5) 0.969 (0.412–2.278) 0.943 0.471
Safety endpoints
BARC classification
Key safety endpoint (type 2, 3, or 5) 60 (7.9) 17 (2.3) 3.506 (2.013–6.104) <0.0001 13 (5.8) 17 (7.2) 0.827 (0.382–1.794) 0.631 0.002
Type 3 or 5 26 (3.4) 12 (1.6) 1.969 (0.965–4.019) 0.063 8 (3.6) 7 (3.0) 0.971 (0.331–2.851) 0.957 0.237
Type 2 34 (4.5) 5 (0.7) 6.651 (2.592–17.065) <0.0001 5 (2.2) 10 (4.2) 0.764 (0.240–2.431) 0.649 0.003
TIMI classification
Minor 7 (0.9) 7 (0.9) 0.822 (0.285–2.374) 0.718 4 (1.8) 2 (0.8) 1.407 (0.219–9.051) 0.719 0.674
Major 14 (1.8) 3 (0.4) 6.054 (1.355–27.043) 0.018 2 (0.9) 3 (1.3) 0.712 (0.144–4.410) 0.716 0.071
Minor or major 21 (2.7) 10 (1.3) 1.946 (0.882–4.294) 0.099 6 (2.7) 5 (2.1) 1.060 (0.298–3.762) 0.929 0.328
GUSTO classification
Moderate 11 (1.4) 7 (0.9) 1.348 (0.519–3.501) 0.540 6 (2.7) 3 (1.3) 1.550 (0.353–6.794) 0.561 0.953
Severe 14 (1.8) 6 (0.8) 2.293 (0.813–6.466) 0.117 2 (0.9) 3 (1.3) 0.712 (0.114–4.440) 0.716 0.242
Moderate or severe 24 (3.1) 13 (1.3) 1.687 (0.837–3.399) 0.143 8 (3.6) 6 (2.5) 1.162 (0.379–3.562) 0.792 0.484
Net adverse clinical events
Death from any cause, MI, CVA, or
BARC type 2, 3, or 5 bleeding
113 (14.8) 76 (10.2) 1.548 (1.147–2.091) 0.004 39 (17.5) 41 (17.4) 0.994 (0.626–1.578) 0.979 0.091
Death from any cause, MI, CVA, or
BARC type 3 or 5 bleeding
81 (10.6) 72 (9.6) 1.137 (0.819–1.579) 0.443 35 (15.7) 34 (14.4) 1.058 (0.641–1.747) 0.825 0.753
Multivariate adjustment for age, hypertension, smoking, creatinine level, prior MI, ACS, multivessel intervention, and total ACC/AHA score.
Abbreviations as in Tables 1 and 3.
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STUDY LIMITATIONS. Although this was a pre-
specified analysis of the PRODIGY trial, sex was not
used for stratification at the time of randomization.
The female study population was smaller compared
with the male group, as observed in most trials
investigating patients with CAD. Yet this analysis
suffered from both type I and type II errors. This
study should be regarded as exploratory and hy-
pothesis generating.
CONCLUSIONS
Women undergoing PCI differed from their male
counterparts in that they were typically older, more
often had hypertension and reduced renal function,
but less frequently were smokers and had a lower
degree of CAD complexity. However, after adjust-
ment, 2-year ischemic and clinically relevant bleeding
outcomes did not differ. DAPT prolongation did not
mitigate the high risk at baseline; indeed, compared
with short-term DAPT, a prolonged DAPT regimen did
not benefit both male and female patients, suggesting
that sex should not be a primary covariate to be
considered in decision making on DAPT duration
after coronary stenting.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Marco Valgimigli, Bern University Hospital, Depart-
ment of Cardiology, CH-3010 Bern, Switzerland.
E-mail: marco.valgimigli@insel.ch.
FIGURE 4 Survival Free From Net Adverse Clinical Events According to Sex and Dual-Antiplatelet Therapy Duration
Cox proportional model plot for net adverse clinical events (NACEs). DAPT ¼ dual-antiplatelet therapy.
PERSPECTIVES
WHAT IS KNOWN? Contrasting evidence exists on
the optimal DAPT duration and on the impact of sex
on long-term clinical outcomes after PCI.
WHAT IS NEW? Women and men have similar rates
of long-term ischemic and bleeding events. Pro-
longed DAPT did not reduce ischemic events in both
sexes.
WHAT IS NEXT? Sex should not be a primary co-
variate to be considered in decision making on DAPT
duration after coronary stenting.
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Prolonged vs Short Duration of Dual Antiplatelet Therapy
After Percutaneous Coronary Intervention in Patients
With orWithout Peripheral Arterial Disease
A Subgroup Analysis of the PRODIGY Randomized Clinical Trial
Anna Franzone, MD; Raffaele Piccolo, MD; Giuseppe Gargiulo, MD; Sara Ariotti, MD; Marcello Marino, MD; Andrea Santucci, MD; Andrea Baldo, MD;
Giulia Magnani, MD, PhD; Aris Moschovitis, MD; StephanWindecker, MD; Marco Valgimigli, MD, PhD
IMPORTANCE Patients with concomitant peripheral arterial disease (PAD) experience worse
cardiovascular outcomes after percutaneous coronary intervention (PCI).
OBJECTIVE To assess the efficacy and safety of prolonged (24months) vs short (!6months)
dual antiplatelet therapy (DAPT) in patients with PAD undergoing PCI.
DESIGN, SETTING, AND PARTICIPANTS This subanalysis of the randomized Prolonging Dual
Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY)
trial assessed unselected patients from tertiary care hospitals with stable coronary artery
disease or acute coronary syndromes with or without concomitant PAD fromDecember
2006 to December 2008. Data analysis was performed from January 7 to April 4, 2016.
INTERVENTIONS Percutaneous coronary intervention.
MAIN OUTCOMES ANDMEASURES Rates of the primary efficacy end point, composite of
death, myocardial infarction, or cerebrovascular accidents, and occurrence of the key safety
end point, a composite of Bleeding Academic Research Consortium type 2, 3, or 5.
RESULTS This analysis comprised 246 and 1724 patients with and without PAD, respectively.
In the patients with PAD, mean (SD) age was 73.2 (9.2) in the prolonged group and 75.7 (8.7)
years in the short DAPT group, and 97 (82.2%) weremale in the prolonged group and 92
(71.9%) weremale in the short DAPT group. In the patients without PAD, mean (SD) age was
67.1 (11.2) years in the prolonged group and 66.8 (11.3) years in the short DAPT group, and 667
(76.8%) weremale in the prolonged group and 655 (76.6%) weremale in the short DAPT
group. Status of PADwas associated with a higher risk of death and ischemic events (hazard
ratio [HR], 2.80; 95% CI, 2.05-3.83; P < .001). Prolonged vs short DAPT conveyed a lower risk
of the primary efficacy end point in patients with PAD (19 [16.1%] vs 35 [27.3%]; HR, 0.54;
95% CI, 0.31-0.95; P = .03) but not in patients without PAD (81 [9.3%] vs 63 [7.4%]; HR, 1.28;
95% CI, 0.92-1.77; P = .15), with positive interaction (P = .01). The risk of definite or probable
stent thrombosis was significantly lower in patients with PAD treated with prolonged
compared with short DAPT (HR, 0.07; 95% CI, 0-1.21; P = .01). Bleeding Academic Research
Consortium type 2, 3, or 5 bleeding occurred in 6 patients with PAD (5.2%) receiving
prolonged DAPT relative to 8 (6.9%) of those receiving short DAPT (HR, 0.77; 95% CI,
0.27-2.21; P = .62), with a significant interaction (P = .04) compared with patients without
PAD.
CONCLUSIONS AND RELEVANCE Peripheral artery disease confers a poor prognosis in patients
undergoing PCI in the setting of stable coronary artery disease or acute coronary syndromes.
Prolonged DAPT lowers the risk of ischemic events with no apparent bleeding liability in this
high-risk group.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00611286.
JAMA Cardiol. doi:10.1001/jamacardio.2016.2811
Published online August 30, 2016.
Invited Commentary
Supplemental content at
jamacardiology.com
Author Affiliations:Department of
Cardiology, Bern University Hospital,
Bern, Switzerland (Franzone, Piccolo,
Gargiulo, Ariotti, Marino, Santucci,
Baldo, Magnani, Moschovitis,
Windecker, Valgimigli); Department
of Advanced Biomedical Sciences,
Federico II University, Naples, Italy
(Gargiulo); Thoraxcenter, Erasmus
Medical Center, Rotterdam, the
Netherlands (Ariotti, Valgimigli).
Corresponding Author:Marco
Valgimigli, MD, PhD, Department of
Cardiology, Bern University Hospital,
3010 Bern, Switzerland (marco
.valgimigli@insel.ch).
Research
JAMACardiology | Original Investigation
(Reprinted) E1
Downloaded From: https://cardiology.jamanetwork.com/ by Giuseppe Gargiulo on 08/30/2016
Copyright 2016 American Medical Association. All rights reserved.
C oncomitantperipheral arterial disease (PAD) is increas-ingly recognized as an important risk factor amongpa-tients with coronary artery disease (CAD).1,2 Clinically
relevantatherosclerosis thataffects theperipheralvascular cir-
culation is detected inup to40%ofpatientswithCAD,3-5with
anadverseeffectonclinical outcomes.6-8Amongpatientswith
CAD who require percutaneous coronary intervention (PCI),
thosewith concomitantPADhavea2-fold increase in theearly
and long-term risk of death.2
Antiplatelet therapy is pivotal to prevent cardiovascular
events in patients with isolated PAD.9,10 Evidence suggests
that extended duration of dual antiplatelet therapy (DAPT)
after PCI provides more effective protection against athero-
thrombotic events compared with short-term regimens, at
the risk of more frequent bleeding.11Whether the duration of
DAPT in patients undergoing PCI should be tailored based on
concomitant PAD is currently unknown, to our knowledge.
In a survey initiated by the European Association of Percuta-
neous Cardiovascular Interventions that assessed DAPT pre-
scription patterns after coronary stenting, concomitant PAD
was not identified as a clinically important factor affecting
the decision regarding treatment duration in 1134 responders
from 92 countries.12 Against this background, we performed
a subgroup analysis of the Prolonging Dual Antiplatelet
Treatment After Grading Stent-Induced Intimal Hyperplasia
Study (PRODIGY) trial13 to evaluate the effect of PAD on
ischemic and bleeding events and to assess the efficacy and
safety of a prolonged (24-month) vs a short (≤6-month)
DAPT duration according to the presence of concomitant
PAD.
Methods
The randomized,multicenter, open-label PRODIGY trial com-
pared the safety and efficacy profile of prolongedvs short du-
ration of DAPT in aminimally selected population of patients
undergoingcoronary stenting fromDecember2006 toDecem-
ber2008.13DataanalysiswasperformedfromJanuary7 toApril
4, 2016. All participants gave written informed consent, and
their data were deidentified. The Cardiology Department at
University of Ferrara (Ferrara, Italy) led the study, and thepro-
tocol was independently approved by the ethics committees
of the participating centers. The studydesign andprimary re-
sults of the PRODIGY trial have been previously described14
and are summarized in the eMethods in the Supplement.
Study Population
For the purpose of this intention-to-treat analysis, the study
population was stratified according to PAD status. At base-
line, patientswith intermittent claudication or prior amputa-
tion or percutaneous or surgical peripheral revascularization
were identified as having PAD. All patients were followed up
through clinic visits at 30 days and up to 2 years after PCI.
Study End Points
Definitionsof studyoutcomeshavebeenpreviously reported.13
Theprimaryefficacyendpointwasacompositeofdeath,myo-
cardial infarction (MI), or cerebrovascular accident (CVA) up
to 2 years. The primary key safety end point included a com-
posite of type2,3, or5bleeding according to theBleedingAca-
demicResearchConsortium(BARC)criteria.15Otherendpoints
were death, cardiovascular death, MI, and stent thrombosis,
defined according to the Academic Research Consortium
criteria.16Anet adverse clinical events (NACE) endpoint com-
bining theprimaryefficacyendpointofdeath,MI, orCVAwith
BARC type3or5bleedingwas additionally analyzed.All study
endpointswereadjudicatedbyaclinical events committeeun-
aware of treatment allocation.
Statistical Analysis
Categorical baseline variables were presented as frequencies
andpercentageswithPvalues calculatedwithunpaired t tests,
χ2 tests, or Fisher exact tests. Continuous variables were ex-
pressed as mean (SD) and compared with the independent-
samples t test. The effect of PAD on clinical outcomes was
evaluatedbyCoxproportional hazards regression analyses by
adjusting forbaselinevariables associatedwith theprimaryef-
ficacy andkey safety endpoint at theunivariate analysiswith
a significance level of P < .20. The efficacy and safety of pro-
longed DAPT vs short DAPT for patients with vs without PAD
was evaluated at 24months and from 6 to 24months. Clini-
cal events were expressed as counts with rates computed ac-
cording to the Kaplan-Meier method. Cox proportional haz-
ards regression analysis was used to calculate hazard ratios
(HRs) with 95% CIs, and an interaction test was provided to
evaluate the effect of treatment in patients with vs without
PAD. As sensitivity analysis, the efficacy and safety of differ-
ent durations ofDAPT inpatientswithPADwere evaluatedby
adjusting for baseline variables that significantly differ be-
tweenpatients randomized toprolongedvsshortDAPT.Analy-
ses were performed with STATA statistical software, release
13 (StataCorp).
Results
Of 1970 patients enrolled in the PRODIGY trial, a history of
PAD was present in 246 participants (12.5%). Among the
Key Points
Question What is the ideal duration of dual antiplatelet therapy
(DAPT) after coronary stenting in patients with concomitant
coronary and peripheral arterial disease?
Findings In this subanalysis of a randomized clinical trial,
peripheral arterial disease emerged as a treatment modifier in
terms of DAPT duration in patients undergoing percutaneous
coronary intervention, with a prolonged regimen (up to 24
months) associated with a significantly lower risk of death and
atherothrombotic events and unaffected risk of bleeding.
Meaning The significant prognostic effect of concomitant
peripheral arterial disease should be taken into account when
managing the duration of DAPT after percutaneous coronary
intervention.
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PAD group, 118 and 128 patients were randomized to the
prolonged and short DAPT groups, respectively. A total of
869 and 855 patients without PAD were randomized to the
prolonged and short DAPT groups, respectively (Table).
Baseline Clinical and Angiographic Characteristics
Patients with PAD were older and more often had hyperten-
sion, type 1or type2diabetes, previousMI, andprevious coro-
nary artery bypass grafting than patients without PAD. In
addition, they were more likely to present with non–
ST-segment elevation MI, had more complex CAD, and more
frequentlyunderwentmultivessel intervention.At30days,pa-
tientswithPADweremoreoften takingdiuretics,whereas the
use ofβ-blockers and statinswashigher amongpatientswith-
out PAD (eTable 1 and eTable 2 in the Supplement).
Patients with PAD randomized to prolonged DAPT were
younger, had a higher body mass index, and less frequently
underwent PCI of the leftmain coronary artery than those al-
located to short DAPT. Otherwise, the baseline and peripro-
cedural characteristicswerewellmatched between the study
groups (Table and eTable 3 in the Supplement).
Clinical Outcomes According to PAD Status
Patients with PAD experienced higher rates of ischemic
events at 2-year follow-up compared with patients without
PAD: the composite of death, MI, or CVA occurred in 54
patients with PAD (21.9%) vs 144 patients without PAD
(8.4%) (adjusted HR, 1.75; 95% CI, 1.26-2.44; P = .001). Mor-
tality was higher among patients with PAD (39 [15.8%] vs 91
patients without PAD [5.3%]; adjusted HR, 1.87; 95% CI,
Table. Baseline Characteristics According to PAD and DAPTDurationa
Characteristic
Patients With PAD Patients Without PAD
P Value for
Interaction
Prolonged DAPT
(n = 118)b
Short DAPT
(n = 128)c P Value
Prolonged DAPT
(n = 869)b
Short DAPT
(n = 855)c P Value
Age, mean (SD), y 73.2 (9.2) 75.7 (8.7) .03 67.1 (11.2) 66.8 (11.3) .53 .06
Male 97 (82.2) 92 (71.9) .07 667 (76.8) 655 (76.6) .95 .08
BMI, mean (SD) 27.5 (5.0) 26.3 (3.5) .04 27.8 (13.0) 27.7 (10.3) .91 .47
Hypertension 103 (87.3) 112 (87.5) .96 618 (71.1) 581 (68.0) .16 .67
Dyslipidemia 60 (50.8) 80 (62.5) .07 493 (56.7) 445 (52.0) .05 .02
Smoking 18 (15.3) 20 (15.6) .94 204 (23.5) 227 (26.5) .15 .71
Diabetes, type 1 or 2 36 (30.5) 47 (36.7) .34 208 (23.9) 186 (21.8) .30 .17
Insulin-treated diabetes 14 (11.9) 13 (10.2) .69 45 (5.2) 42 (4.9) .83 .80
Family history of CAD 33 (28.0) 22 (17.2) .05 256 (29.5) 242 (28.3) .63 .08
Previous MI 47 (39.8) 53 (41.4) .90 223 (25.7) 203 (23.7) .37 .55
Previous PCI 24 (20.3) 35 (27.3) .23 165 (19.0) 135 (15.8) .09 .06
Previous CABG 16 (13.6) 28 (21.9) .10 94 (10.8) 75 (8.8) .17 .03
Creatinine clearance, mean (SD),
mL/min/1.73 m2
62.4 (29.0) 60.7 (24.9) .61 81.6 (43.6) 80.2 (29.2) .41 .95
Previous stroke 2 (1.7) 2 (1.6) .99 4 (0.5) 6 (0.7) .54 .67
Congestive HF or LV dysfunction 9 (7.6) 7 (5.5) .61 31 (3.6) 33 (3.9) .80 .45
Indication of PCI .64 .82 .58
Stable CAD 29 (24.6) 38 (29.7) 226 (26.0) 212 (24.8)
NSTE-ACS 65 (55.1) 64 (50.0) 346 (39.8) 342 (40.0)
STEMI 24 (20.3) 26 (20.3) 297 (34.2) 301 (35.2)
Acute MI at presentation 62 (52.5) 62 (48.4) .53 485 (55.8) 489 (57.2) .59 .42
Drug therapy at 30 d
ACE inhibitors or receptor
blockers
100 (84.7) 104 (81.2) .50 767 (88.3) 721 (84.3) .02 .81
β-Blockers 94 (79.7) 96 (77.4) .75 734 (85.2) 715 (84.5) .68 .82
Statins 105 (89.0) 107 (83.6) .26 781 (89.9) 792 (92.6) .05 .05
Diuretics 48 (40.7) 57 (46.0) .43 203 (23.6) 234 (27.7) .05 .99
Proton pump inhibitors 50 (42.4) 45 (35.2) .29 325 (37.4) 318 (37.2) .96 .29
Abbreviations, ACE, angiotensin-converting enzyme inhibitor; BMI, bodymass index (calculated as the weight in kilograms divided by the square of height in
meters); CABG, coronary artery bypass grafting; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; HF, heart failure; LV, left ventricular; MI, myocardial
infarction; NSTE-ACS, non–ST-segment elevation acute coronary syndrome; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention;
STEMI, ST-segment elevationmyocardial infarction.
SI conversion factors: To convert creatinine clearance tomilliliters per second per square meters, multiply by 0.0167.
a Data are presented as number (percentage) of patients unless otherwise indicated.
b 24months.
c 6months or less.
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1.25-2.79; P = .002); cardiac death was specifically reported
in 24 patients with PAD (10.0%) compared with 49 patients
without PAD (2.9%) (adjusted HR, 2.21; 95% CI, 1.30-3.76;
P = .003) (Figure 1 and eFigure 1A in the Supplement).
BARC type2, 3, or5bleedingwasnot increasedamongpa-
tientswith PAD comparedwith thosewithout PAD (14 [6.0%]
vs 93 [5.5%]; adjusted HR, 0.75; 95% CI, 0.42-1.33; P = .32)
(Figure 1 and eFigure 1B in the Supplement). Similar results
wereobtainedbyapplyingotherbleedingdefinitions. The risk
ofNACEwas significantly increased inpatientswithPADcom-
pared with those without PAD (54 [21.9%] vs 168 [9.8%]; ad-
justed HR, 1.50; 95%CI, 1.08-2.08; P = .02).
Figure 2. Kaplan-Meier Curves at 24Months
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Kaplan-Meier curves are shown for the composite of death, myocardial
infarction (MI), or cerebrovascular accident (CVA) and for Bleeding Academic
Research Consortium (BARC) type 2, 3, or 5 bleeding. DAPT indicates dual
antiplatelet therapy; PAD, peripheral arterial disease; PCI, percutaneous
coronary intervention. Prolonged DAPT refers to 24months and short DAPT,
6months or less.
Figure 1. Effect of Peripheral Artery Disease (PAD) on Clinical Outcomes at 24-Month Follow-up
P Value PAD Better PAD Worse
101.00.1
HR (95% CI)
Patients
With PAD,
No. (%)
(n = 246)
Crude Analysis
HR (95% CI)Bleeding Event
Ischemic events
P Value
Adjusted Analysis
HR (95% CI)
54 (21.9) 2.80 (2.05-3.83) <.001Death, MI, or CVA 1.75 (1.26-2.44) .001
42 (17.4) 2.72 (1.91-3.88) <.001Cardiac death, MI, or CVA 1.70 (1.17-2.48) .005
51 (20.7) 2.89 (2.09-4.00) <.001Death or MI 1.82 (1.29-2.56) .001
39 (15.8) 3.15 (2.16-4.58) <.001Death 1.87 (1.25-2.79) .002
24 (10.0) 3.58 (2.19-5.83) <.001 2.21 (1.30-3.76) .003Cardiac death
18 (7.5) 2.09 (1.24-3.54) .006MI 1.28 (0.74-2.22) .38
3 (1.3) 1.82 (0.51-6.46) .35Definite ST 1.39 (0.35-5.50) .64
7 (3.0) 2.43 (1.03-5.72) .04Definite or probable ST 1.69 (0.67-4.23) .26
27 (11.4) 3.48 (2.20-5.50) <.001Definite, probable, or possible ST 2.14 (1.30-3.50) .003
Bleeding events
6 (2.6) 1.22 (0.51-2.89) .66TIMI minor or major 0.69 (0.28-1.67) .41
14 (6.0) 1.11 (0.63-1.94) .73BARC type 2, 3, 5 0.75 (0.42-1.33) .32
7 (3.0) 1.11 (0.50-2.46) .79BARC type 3 or 5 0.62 (0.27-1.40) .25
12 (5.2) 1.09 (0.59-2.00) .78BARC type 2 or 3 0.76 (0.40-1.41) .38
6 (2.6) 0.97 (0.41-2.28) .95 0.56 (0.23-1.35) .20GUSTO moderate or severe
Net adverse clinical events
54 (21.9)
Patients
Without PAD,
No. (%)
(n = 1724)
144 (8.4)
115 (6.7)
131 (7.6)
91 (5.3)
49 (2.9)
62 (3.6)
12 (0.7)
21 (1.2)
57 (3.3)
36 (2.1)
93 (5.5)
46 (2.7)
81 (4.8)
45 (2.7)
168 (9.8) 1.64 (1.20-2.25) .002
Death, MI, or CVA or BARC
type 3 or 5 bleeding 1.50 (1.08-2.08) .02
Ischemic end points were adjusted for age, sex, hypertension, smoking, type 1
or 2 diabetes, family history of coronary artery disease (CAD), previous
myocardial infarction (MI), previous percutaneous coronary intervention (PCI),
previous coronary artery bypass graft, creatinine level, left ventricular ejection
fraction, and indication to PCI. Bleeding end points were adjusted for age,
previous MI, previous PCI, creatinine level, and left ventricular ejection fraction.
BARC indicates Bleeding Academic Research Consortium; CVA, cerebrovascular
accident; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Arteries; HR, hazard ratio; ST, stent thrombosis;
TIMI, Thrombolysis in Myocardial Infarction.
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Efficacy of Prolonged DAPT According to PAD
As shown in Figure 2 and Figure 3, among patients with PAD,
prolonged DAPT was associated with a lower risk of the pri-
maryefficacyendpoint comparedwith shortDAPT (19 [16.1%]
vs 35 [27.3%]; HR, 0.54; 95% CI, 0.31-0.95; P = .03). In con-
trast, no significant differencewas found in the risk of thepri-
mary end point between the 2 DAPT regimens among pa-
tients without PAD (81 [9.3%] in the prolonged-duration
regimenvs63 [7.4%] in the short-duration regimen;HR, 1.28;
95% CI, 0.92-1.77; P = .15), resulting in a significant qualita-
tive interaction (P = .01). This differencewasmainlydrivenby
a significant interaction for death (P = .006),whichwas lower
in thegroupofpatientswithPADtreatedwithprolongedDAPT
(12 [10.2%] in the prolonged-duration regimen vs 27 [21.1%]
in the short-duration regimen; HR, 0.45; 95% CI, 0.23-0.88;
P = .02) comparedwithpatientswithout PAD (53 [6.1%] in the
prolonged-duration regimen vs 38 [4.5%] in the short-
duration regimen; HR, 1.39; 95%CI, 0.91-2.10; P = .12). In the
landmark analysis, the interaction test for the occurrence of
the primary efficacy endpoint remained significant (P = .02),
with a lower risk of events in patients with PAD allocated to
prolonged DAPT compared with patients in the short DAPT
group (15 [13.2%] vs 25 [21.2%]; HR, 0.59; 95% CI, 0.31-1.12;
P = .10) (eTable 4 in the Supplement).
Definite orprobable stent thrombosiswas significantly re-
duced in patients with PAD randomized to prolonged DAPT
comparedwith shortDAPT (0 [0%]vs 7 [6.0%];HR,0.07;95%
CI, 0-1.21; P = .01), with significant interaction (P = .03) com-
pared with patients without PAD, in whom prolonged DAPT
had no effect (13 [1.5%] vs 8 [1.0%]; HR, 1.62; 95% CI, 0.67-
3.90; P = .28) (Figure 3).
Baseline clinical characteristics of patients experiencing
stent thrombosis with PAD or without PAD were comparable
(eTable5 in theSupplement), althoughmultivesseldiseaseand
multiple treated lesionsweremore frequently observed inpa-
tients with PAD (eTable 6 in the Supplement).
Safety of Prolonged DAPT According to PAD
The cumulative time-to-event curves for the key safety end
point are shown in Figure 2. BARC type 2, 3, or 5 bleedingwas
not significantly affected byDAPTduration in the PADcohort
(6 [5.2%] in theprolonged-duration regimenvs8 [6.9%] in the
short-duration regimen;HR,0.77;95%CI,0.27-2.21,P = .62),
whereas patients without PAD receiving prolonged DAPT
Figure 3. Ischemic Events at 24Months According to Randomized Dual Antiplatelet Therapy (DAPT) and Peripheral Arterial Disease (PAD) Status
P Value
Prolonged
DAPT Better
Short DAPT
Better
1.0 100.10.01
HR (95% CI)
Patients Receiving
Prolonged DAPT, 
No. (%) HR (95% CI)Bleeding Event
Death, MI, or CVA
P Value for
interaction
19 (16.1) 0.54 (0.31-0.95) .03PAD
.01
81 (9.3) 1.28 (0.92-1.77) .15No PAD
Cardiac death, MI, or CVA
14 (12.1) 0.50 (0.26-0.96) .04PAD
64 (7.4) 1.25 (0.86-1.80) .24
.02
No PAD
Death or MI 
16 (13.6) 0.45 (0.25-0.82) .008PAD
.005
72 (8.3) 1.21 (0.86-1.71) .28No PAD
12 (10.2) 0.45 (0.23-0.88) .02
Death
PAD
53 (6.1) 1.39 (0.91-2.10) .12No PAD
.006
Cardiac death
7 (6.1) 0.42 (0.17-1.00) .051PAD
29 (3.4) 1.44 (0.81-2.55) .21No PAD
.02
7 (6.0) 0.68 (0.26-1.74) .42
MI
PAD
32 (3.7)
Patients Receiving
Short DAPT, 
No. (%)
35 (27.3)
63 (7.4)
28 (22.3)
51 (6.0)
35 (27.3)
59 (6.9)
27 (21.1)
38 (4.5)
17 (13.7)
20 (2.4)
11 (8.9)
30 (3.5) 1.05 (0.64-1.73) .84No PAD
.42
0 (0.0) 0.15 (0.01-2.87)a .25
Definite ST
PAD
8 (0.9) 1.99 (0.60-6.61) .26No PAD
.11
Definite or probable ST
0 (0.0) 0.07 (0.00-1.21)a .01PAD
13 (1.5) 1.62 (0.67-3.90) .28No PAD
.03
6 (5.2) 0.28 (0.11-0.70) .006
Definite, probable, or possible ST
PAD
32 (3.7)
3 (2.7)
4 (0.5)
7 (6.0)
8 (1.0)
21 (17.2)
25 (3.0) 1.27 (0.76-2.15) .36No PAD
.005
CVA indicates cerebrovascular accident; HR, hazard ratio; MI, myocardial
infarction; ST, stent thrombosis. Prolonged DAPT refers to 24months and short
DAPT, 6months or less.
a Continuity corrected relative risk with Fisher exact test for zero events.
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experiencedhigher ratesofbleedingevents according toBARC
and other prespecified criteria comparedwith patients in the
short DAPT group (Figure 4). These findings were confirmed
in the landmark analysiswith focus between6 and24months
(eTable 4 in the Supplement).
Net Adverse Clinical Events
Cumulative incidencecurvesofNACEaccording toDAPTdura-
tion among patients with andwithout PAD are shown in eFig-
ure2 in theSupplement.The riskofNACEwas significantlyde-
creased in theprolongedDAPTgroupcomparedwith the short
DAPTgroup in thePADpopulation (19 [16.1%] in theprolonged-
duration regimen vs 35 [27.3%] in the short-duration regimen;
HR,0.54; 95%CI,0.31-0.95; P = .03). Among patientswithout
PAD,NACEoccurredin97patients(11.2%)intheprolongedDAPT
groupand71patients (8.3%) in the shortDAPTgroup (HR, 1.36;
95%CI, 1.00-1.85; P for interaction = .047).
Safety and Efficacy of Prolonged DAPT According
to Clinical Presentation
Asreported ineTable7 in theSupplement, amongpatientswith
PAD presenting with stable CAD, no significant difference in
the rate of theprimary efficacy endpoint at 2yearswas found
between those receivingprolongedand shortDAPT (4 [13.8%]
vs6 [15.8%],P = .82).AmongpatientswithPADandacutecoro-
nary syndromes at presentation, the primary end point arose
in 15 patients (16.9%) randomized to prolonged DAPT com-
paredwith29 (32.2%)of those randomized to shortDAPT (HR,
0.46;95%CI,0.25-0.87;P = .02;P for interaction = .36). BARC
type 2, 3, or 5 bleeding were not significantly different be-
tween the prolonged and short DAPT groups in patients with
PAD with stable CAD (2 [6.9%] vs 2 [5.4%], P = .77) or acute
coronary syndromes (4 [4.6%] vs 6 [7.7%], P = .44).
Sensitivity Analysis
After adjustment for age, bodymass index, and leftmain PCI,
the adjusted HR for the primary efficacy end point was 0.66
(95% CI, 0.37-1.16; P = .15), with positive interaction testing
(P = .05). Furthermore, prolongedDAPT in patientswith PAD
was still associatedwith a reduction in the composite of death
or MI (16 [13.6%] in the prolonged-duration regimen vs 35
[27.3%] in the short-duration regimen; adjustedHR,0.51;95%
CI,0.28-0.94; P = .02) and overall stent thrombosis (6 [5.2%]
in the prolonged-duration regimen vs 21 [17.2%] in the short-
duration regimen; adjusted HR, 0.33; 95% CI, 0.13-0.82;
P = .01).
Discussion
The salient findings of the present analysis are as follows.
First, in patients undergoing PCI, concomitant PAD was
associated with a 2-fold increased risk of ischemic events,
whereas the risk of bleeding was unaffected. Second, pro-
longed DAPT duration of 24 months after PCI reduced the
risk of the primary efficacy end point of death, MI, or CVA
compared with short DAPT of 6 months or less in patients
with PAD. The improved efficacy of prolonged DAPT in
patients with PAD was not offset by an increased risk of
actionable bleeding episodes.
Atherosclerosis of peripheral vessels portends a higher
burden of CAD, accounting for impaired survival and worse
cardiovascular outcomes. In a pooled analysis of 19 867
patients from 8 randomized clinical trials, PAD was a signifi-
cant predictor of the composite of death, MI, and target-
vessel revascularization 6 months after PCI (HR, 1.17; 95%
CI, 1.05-1.31; P = .005) and was independently associated
Figure 4. Bleeding Events at 24Months According to Randomized Dual Antiplatelet Therapy (DAPT) and Peripheral Arterial Disease (PAD) Status
P Value
Prolonged
DAPT Better
Short DAPT
Better
101.00.1
HR (95% CI)
Patients Receiving
Prolonged DAPT, 
No. (%) HR (95% CI)Bleeding Event
TIMI major or minor
P Value for
interaction
2 (1.8) 0.50 (0.09-2.74) .43PAD
.11
25 (3.0) 2.27 (1.12-4.61) .02No PAD
BARC type 2, 3, or 5
6 (5.2) 0.77 (0.27-2.21) .62PAD
67 (8.0) 2.61 (1.66-4.11) <.001
.04
No PAD
BARC type 3 or 5 
3 (2.6) 0.76 (0.17-3.40) .72PAD
.22
31 (3.7) 2.07 (1.12-3.83) .02No PAD
5 (4.4) 0.73 (0.23-2.31) .60
BARC type 2 or 3
PAD
59 (7.1) 2.72 (1.67-4.44) <.001No PAD
.04
GUSTO moderate or severe
3 (2.6) 1.02 (0.21-5.04) .98PAD
29 (3.4) 1.81 (0.98-3.33) .06No PAD
.51
Patients Receiving
Short DAPT, 
No. (%)
4 (3.5)
11 (1.3)
8 (6.9)
26 (3.1)
4 (3.4)
15 (1.8)
7 (6.0)
22 (2.6)
3 (2.6)
16 (1.9)
BARC indicates Bleeding Academic Research Consortium; GUSTO, Global
Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded
Arteries; HR, hazard ratio; TIMI, Thrombolysis in Myocardial Infarction.
Prolonged DAPT refers to 24months and short DAPT, 6months or less.
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with an increased risk of mortality throughout follow-up.2
Among outpatients with stable CAD included in the REACH
(Reduction of Atherothrombosis for Continued Health) regis-
try, the 1-year rate of cardiovascular death, MI, stroke, or
hospitalization for atherothrombotic events was 23.1% in
patients with concomitant PAD compared with 13% among
patients with isolated PAD and 17% among patients with iso-
lated CAD.17 Consistently, the GRACE (Global Registry of
Acute Coronary Events) registry reported higher in-hospital
mortality among patients with acute coronary syndromes
and concomitant PAD, with a 6-month rate of major cardio-
vascular events of 14.6% compared with 7.2% in patients
without PAD.8
Several pathophysiologic and clinical observations sup-
port the detrimental association of CAD and PAD. Amultives-
sel coronary involvement, alongwith a proinflammatory sta-
tus, is more common among patients with concomitant CAD
andPAD.18,19Moreover, theonsetof clinical symptomsand the
identification of CAD are frequently camouflaged by PADow-
ing to the impaired functional status of patients.6,20 Finally,
theunderestimationof thishigh-risk condition inclinicalprac-
tice accounts for awell-described tendency towithholdphar-
macologic therapies for secondary prevention in these
patients.21Our study lends further support to thenotionof an
increased riskof ischemicevents inpatientswithCADandcon-
comitant PAD. More specifically, the risks of NACE and car-
diovascular mortality were more than doubled among pa-
tients with concomitant PAD.
Although patients with PAD experienced higher rates of
ischemic events, they did not have a parallel increase in the
risk of bleeding. These results are difficult to interpret
because they conflict with other studies,6,22,23 hence, poten-
tially reflecting a power issue. Nonetheless, because we
assessed bleeding events starting from 30 days after PCI, it
may be possible that the exclusion of periprocedural events,
which are more common in patients with PAD,24 may
explain the lack of association noted in our study between
PAD status and bleeding risk. In addition, the high burden of
mortality observed in patients with PAD may have camou-
flaged the occurrence of bleeding events. In the PEGASUS-
TIMI 54 (Prevention of Cardiovascular Events in Patients
With Prior Heart Attack Using Ticagrelor Compared to Pla-
cebo on a Background of Aspirin–Thrombolysis In Myocar-
dial Infarction 54) study, PAD status was not associated with
bleeding, and ticagrelor compared with placebo did not
result in a higher risk of major or minor bleeding at both the
60-mg and 90-mg doses.25 Furthermore, there is evidence
demonstrating an increased platelet reactivity in patients
with multisite atherosclerosis as a consequence of the larger
amount of diseased endothelium and diffuse high shear
stress.26 An inverse association between platelet reactivity
and bleeding exists.27,28
Antiplatelet therapy has the potential to mitigate the
risk of atherothrombotic events in patients with PAD. In the
CAPRIE (Clopidogrel vs Aspirin in Patients at Risk of Ische-
mic Events) trial,29 clopidogrel monotherapy conveyed
higher cardiovascular ischemic protection and low major
bleeding in patients with stable PAD vs aspirin. The
CHARISMA (Clopidogrel for High Atherothrombotic Risk
and Ischemic Stabilization, Management, and Avoidance)
trial10 tested the benefit of DAPT with aspirin and clopido-
grel in patients with established stable atherosclerotic vas-
cular disease or multiple atherothrombotic risk factors.
Overall, DAPT was not superior to aspirin monotherapy for
the primary end point of death, MI, or stroke (534 of 7802
[6.8%] vs 773 of 7801 [7.3%], P = .22). However, DAPT was
associated with lower rates of MI and hospitalization for
ischemic events without increasing the risk of major bleed-
ing among patients with PAD. The addition of vorapaxar, an
antagonist of protease-activated receptor 1 of thrombin, to
aspirin and clopidogrel significantly reduced acute limb
ischemia and peripheral revascularization but increased the
risk of serious (intracranial) bleeding among patients with
PAD included in the TRA2°P-TIMI 50 trial (Trial to Assess
the Effects of SCH 530348 in Preventing Heart Attack and
Stroke in Patients With Atherosclerosis).30
To our knowledge, this is the first study to evaluate the
safety and efficacy of different DAPT durations in patients
with concomitant CAD and PAD after PCI. Although in the
overall population of the PRODIGY trial prolonged DAPT
was not more effective, the relative risk of the primary effi-
cacy end point was approximately halved by prolonged
DAPT in patients with PAD with an interaction testing sug-
gesting heterogeneity of treatment effect according to PAD
status. Despite a high residual burden of risk in this patient
population (the composite end point still occurred in
roughly 16% of patients allocated to prolonged DAPT), a
positive interaction was found for all-cause mortality, car-
diovascular mortality, and definite or probable stent throm-
bosis. These results should be interpreted in the context of
the DAPT study11 that demonstrated a significantly reduced
risk of stent thrombosis and major adverse cardiovascular
and cerebrovascular events among 9961 patients randomly
assigned to continue thienopyridine treatment or to receive
placebo beyond 1 year after PCI.
Nevertheless, the implementation of prolonged DAPT in
clinical practice remains controversial because of the higher
risk of bleeding invariably reported in studies11,14 comparing
different DAPT durations. Although prolonged DAPT
increased the bleeding risk compared with short DAPT
among patients without PAD, we did not observe a signifi-
cant effect of prolonged DAPT on bleeding risk among
patients with PAD. The disconnect between PAD status and
bleeding risk remains difficult to explain and could have
been in part related to the exceedingly high incidence of
ischemic events and the modest sample size. However, it is
consistent with previous reports.10,25 Overall, our results
should be considered hypothesis generating for future dedi-
cated randomized clinical trials.
We acknowledge the following limitations. First, this
was not a prespecified analysis and therefore has all the
potential shortcomings of such studies, including limited
number of patients and events. Furthermore, because the
randomization was not stratified by PAD status, our results
may be attributable to differences in baseline variables. Sec-
ond, PAD status was ascertained solely on the basis of clini-
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cal history; therefore, underreporting cannot be excluded.
Third, we were unable to indicate the peripheral vascular
district primarily diseased and the rates of subsequent limb-
related outcomes. Furthermore, we did not ascertain the
safety and efficacy of different DAPT durations according to
the clinical presentation (claudication, previous peripheral
revascularization) of PAD. Fourth, DAPT in the PRODIGY
trial was based on the use of aspirin and clopidogrel admin-
istration. Therefore, whether new P2Y12 receptor inhibitors
may further improve clinical outcomes in this high-risk sub-
set remains unanswered. This issue will be ascertained in
part by the ongoing EUCLID (Examining Use of Ticagrelor in
PAD) trial, testing the superiority of ticagrelor compared
with clopidogrel monotherapy in reducing the risk of car-
diovascular events among 13 500 patients with PAD (clini-
caltrials.gov, NCT01732822).31
Conclusions
The coexistence of PAD and CAD conveyed higher risks of
cardiovascular morbidity and mortality among patients
undergoing PCI. A prolonged DAPT duration (up to 24
months) resulted in a lower risk of atherothrombotic events,
including a mortality benefit, than short DAPT. The appar-
ent neutral effect of longer DAPT on bleeding risk of
patients with PAD requires further evaluation in adequately
powered studies.
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Abstract
Purpose of Review This review aims to summarize and dis-
cuss safety and effectiveness of the long-term use of ticagrelor
in patients with coronary artery disease (CAD).
Recent Findings Ticagrelor is an orally administered, direct,
and reversible inhibitor of the P2Y12-platelet receptor. Long-
term use of ticagrelor in patients with previous myocardial
infarction (MI) has been investigated in the PEGASUS-
TIMI-54 trial. Overall, 21,162 patients with a spontaneous
MI 1 to 3 years before randomization were randomly assigned
to ticagrelor 90 mg bid, ticagrelor 60 mg bid, or placebo.
Compared with placebo, both doses of ticagrelor showed that
they were capable of significantly reducing the primary effi-
cacy endpoint, although with a significant increase in TIMI
major bleeding. Intracranial hemorrhage or fatal bleeding did
not differ across groups.
Summary These findings establish clear benefit of DAPT ex-
tension with ticagrelor beyond 1 year of treatment, which
comes with a tradeoff of clinically meaningful bleeding.
Altogether, current evidence suggests that the duration of
DAPT remains a patient-by-patient decision based on throm-
botic and bleeding risk profiles.
Keywords Antiplatelet therapy .P2Y12inhibitor .Ticagrelor .
Coronary artery disease . Ischemic events . Bleeding events
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Practice
PAD Peripheral arterial disease
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Prevention of Cardiovascular Events in
Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a
Background of Aspirin—Thrombolysis In
Myocardial Infarction 54
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TRA2P-TIMI
50
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Introduction
The synergistic effect of aspirin and a P2Y12-receptor inhibitor
has been investigated in several trials, showing a greater re-
duction in platelet reactivity as compared to that achieved by
each drug separately [1–4]. For more than 10 years, dual an-
tiplatelet therapy (DAPT) with aspirin and clopidogrel has
remained the cornerstone of treatment for patients with stable
coronary artery disease (CAD) as well as acute coronary
syndrome (ACS), including unstable angina (UA), non-ST-
elevation myocardial infarction (NSTEMI), and ST-elevation
myocardial infarction (STEMI). Two new and more potent
oral P2Y12-receptor inhibitors, prasugrel and ticagrelor, were
approved in 2009 and 2011, respectively, by the FDA for
clinical use in the setting of ACS, and more recently also, an
intravenous agent named cangrelor was added to this scenario
(Table 1) [5, 6].
Ticagrelor is a cyclopentyl-triazolopyrimidine that directly
and reversibly inhibits the platelet P2Y12-receptor through
allosteric modulation. Ticagrelor is orally administrated twice
daily; it is not a prodrug and does not require metabolic acti-
vation. Furthermore, 30–40% of its antiplatelet activity is me-
diated by an active metabolite (AR-C124910XX) coming
from hepatic CYP3A4 and CYP3A5 processing. When relat-
ed with clopidogrel, ticagrelor exhibits a more potent and
more predictable antiplatelet effect with a faster onset and
offset of action. In the PLATO trial [7], ticagrelor was com-
pared with clopidogrel in terms of safety and efficacy in ACS
patients who were intended for either invasive or non-invasive
treatment. Ticagrelor reduced the primary endpoint, a com-
posite of death from vascular causes, myocardial infarction
(MI), and stroke at 12 months, mainly through a decrease in
cardiovascular death and MI. The number needed to treat for
benefit was in the range of 54. Ticagrelor did not increase
overall or fatal bleeding. However, there was a higher risk of
bleeding unrelated to coronary artery bypass grafting
(CABG), with a number needed to treat for harm in the range
of 167. Ticagrelor therapy showed a superior efficacy also in
specific patient subsets such as those with recurrences of car-
diovascular events [8], STEMI [9], diabetes mellitus [10],
chronic kidney disease (CKD) [11], age >75 years, a body
weight <60 kg [7], and a history of stroke or transient ischemic
attack (TIA) [12].
Unlike other P2Y12 inhibitors, ticagrelor exerts off-target
cardiovascular effects, mainly related to its capability in in-
creasing adenosine plasma levels [13, 14]. Adenosine is re-
leased in the plasma after ischemia, hypoxia, or oxidative
stress and quickly taken up by red blood cells through
sodium-dependent and sodium-independent equilibrative nu-
cleoside transporters or converted into inosine by adenosine
deaminase. Ticagrelor therapy was associated with increased
adenosine plasma levels by inhibition of sodium-independent
equilibrative nucleoside transporter-1 (ENT-1). Moreover,
ticagrelor induces adenosine triphosphate (ATP) release from
human red blood cells in a dose-dependent manner [15]. The
combined effects of ticagrelor on both ATP release and aden-
osine reuptake may result in circulating plasma levels of aden-
osine which may determine (1) vasodilation, (2) reduction in
ischemia/reperfusion injury and electrical conduction, (3) in-
crease in platelet inhibition, (4) decrease of glomerular filtra-
tion rate, (5) dyspnea, and (6) improvement in microcircula-
tion. In a recent non-randomized trial, ticagrelor therapy was
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associated with improved endothelial function in patients who
experienced an ACS as compared with prasugrel, clopidogrel,
or no P2Y12 inhibitors [16]. A prospective crossover random-
ized trial is currently ongoing to confirm or dispute these
findings (clinicaltrials.gov, NCT02587260).
The aim of this review is to summarize and discuss the
safety and effectiveness of the long-term use of ticagrelor in
patients with CAD.
Long-Term DAPTApproach: a Contemporary
Update
The optimal duration of DAPT in patients with CAD or after
percutaneous coronary intervention (PCI) remains a matter of
ongoing debate [17–23, 24•, 25•, 26, 27••, 28, 29]. During the
last two decades, several trials have explored this issue in
patients undergoing PCI, with some investigating the
benefit/risk profile of a shortened DAPT duration regimen of
3–6 months (RESET, OPTIMIZE, EXCELLENT,
SECURITY, ISAR-SAFE, I-LOVE-IT 2, IVUS-XPL,
NIPPON, PRODIGY, ITALIC) [30–38], while others are
comparing 12-month DAPT versus a prolonged regimen
(DAPT, ARCTIC Interruption, OPTIDUAL, DES-LATE)
[39–41, 42••, 43]. The rationale of investigating a longer than
12-month treatment duration is strong, as the evidence that
patients with CAD, especially after ACS, remain at long-
term risk of new ischemic events is mounting [44].
Nevertheless, the results of long-term DAPT trials have
shown contrasting findings. Both PRODIGYand ITALIC tri-
als have demonstrated that 24-month DAPT did not provide
benefits compared with 6-month DAPT. The PRODIGY
failed indeed to demonstrate the superiority of 24-month
DAPT in terms of death, MI, or cerebrovascular events, but
rather showed that this prolonged regimen did not decrease
ischemic events while increasing bleeding, the need for trans-
fusion as well as the composite of ischemic and bleeding
events (net clinical adverse events, NACE) [31]. The
ITALIC trial showed the non-inferiority of 6-month DAPT
compared with 24-month DAPT with no significant differ-
ences in each safety, ischemic, or composite endpoint [30].
The ARCTIC Interruption, DES-LATE, and OPTIDUAL
trials supported the concept that there is no apparent benefit
but instead potential harm with extension of DAPT beyond
1 year after coronary stenting. In the ARCTIC Interruption
trial, at 1 year after DES implantation, 1259 patients were
randomized to interruption of DAPTwhere the thienopyridine
was interrupted and a single aspirin antiplatelet treatment was
Table 1 Principal characteristics of P2Y12 inhibitors
Clopidogrel Prasugrel Ticagrelor Cangrelor
Chemical class Thienopyridine Thienopyridine Cyclopentyl-triazolopyrimidine Stabilized ATP analogue
Administration Oral Oral Oral Intravenous
P2Y12 blocking Irreversible Irreversible Reversible Reversible
Regimen 300–600 mg then
75 mg a day
60 mg then 10
mg a day
180 mg then 90 mg
twice a day
30 μg/kg bolus then
4 μg/kg/min infusion
Dose in CKD
eGFR 15–60 ml/min/1.73 m2 No adjustment No adjustment No adjustment No adjustment
eGFR < 15 ml/min/1.73m2 Use only for selected indications
(e.g., ST prevention)
Not recommended Not recommended No adjustment
Activation Prodrug, with variable liver
metabolism
Prodrug, with
predictable
liver metabolism
Active drug, with additional
active metabolite
Active drug
Onset of loading dose actiona 2–6 hb 30 minb 30 minb 2 minb
Offset of action 3–10 days 7–10 days 3–5 days 30–60 min
Withdrawal before surgery 5 days 7 days 5 days 1 h
Plasma half-life of active drug 30–60 min 30–60 minc 6–12 h 5–10 min
Adenosine reuptake inhibition No No Yes Yes (the inactive
metabolite only)
Interaction with CYP-targeted
drugs
CYP2C19 No CYP3A4/5 No
ATP adenosine triphosphate, CKD chronic kidney disease, eGFR estimated glomerular filtration rate
a 50% inhibition of ADP-induced platelet aggregation
bOnset of action may be delayed if intestinal absorption is delayed (e.g., by opiate)
c The distribution phase half-life is reported since it most likely reflects duration of clinically relevant plasma levels, while the corresponding elimination
phase half-life is approximately 7 h
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maintained (interruption group) or a strategy of DAPTcontin-
uation for 6–18 months (continuation group) [39]. The major-
ity of patients in DAPT received clopidogrel, while less than
10% received prasugrel. After a median follow-up of
17 months, the primary endpoint (composite of death, myo-
cardial infarction, stent thrombosis, stroke, or urgent revascu-
larization) did not differ between groups (hazard ratio [HR]
1.17 [95% CI 0.68–2.03]; p = 0.58), while bleeding events
occurred more often in the continuation group compared with
the interruption group (major bleeding: HR 0.15 [0.02–1.20];
p = 0.073; major or minor bleeding: HR 0.26 [0.07–0.91];
p = 0.04) [39]. In the DES-LATE, 5045 patients who received
DES and were free of major adverse cardiovascular events
(MACE) and major bleeding for at least 12 months after stent
placement were randomly allocated to additional 24months of
DAPT (clopidogrel plus aspirin, overall 36 months) versus
aspirin alone but DAPT prolongation did not reduce the risk
of the composite endpoint of death from cardiac causes, myo-
cardial infarction, or stroke [41]. In the OPTIDUAL trial,
1385 patients free of major cardiovascular/cerebrovascular
events (MACCE) or major bleeding and on aspirin and
clopidogrel 12 months after stenting were randomized to con-
tinuing clopidogrel 75 mg daily (extended DAPT group) or
discontinuing clopidogrel (aspirin group) [40]. Median
follow-up after stenting was 33.4 months, and the primary
outcome (NACE: composite of death, MI, stroke, or major
bleeding) as well as single endpoints were similar between
the two groups. Although DAPT prolongation failed to dem-
onstrate superiority, this trial was underpowered due to pre-
mature interruption [40]. On the other hand, the DAPT trial
clearly demonstrated that prolonging DAPT beyond 1 year
offers ischemic benefits [42••]. Continued treatment (30-
month DAPT) with thienopyridine, as compared with place-
bo, reduced the rates of stent thrombosis (HR 0.29 [0.17–
0.48]; p < 0.001), MACCE (HR 0.71 [0.59–0.85];
p < 0.001), and MI (HR 0.47 [0.37–0.61]; p < 0.001). The
rate of death from any cause was 2.0% in the group that con-
tinued thienopyridine therapy and 1.5% in the placebo group
(HR 1.36 [1.00–1.85]; p = 0.05), and the rate of moderate or
severe bleeding was increased with continued thienopyridine
treatment (2.5% vs. 1.6%, p = 0.001) [42••]. Although the trial
supported ischemic advantages of 30-month DAPT compared
with 12-month DAPT, some concerns were raised in terms of
safety. While the increase of bleeding was expected in the
prolonged DAPT group, the increase of all-cause death was
unexpected and has become a matter of great discussion
[42••]. The higher mortality in the DAPT trial was putatively
attributed to increased non-cardiovascular death due to cancer,
bleeding, and trauma-related deaths; however, an imbalance in
the baseline number of patients with a history of cancer might
have partly contributed to this risk.
In order to address this issue, a recent meta-analysis of ten
randomized trials including 31,666 patients found a reduction
ofMI and stent thrombosis with treatment with DAPT beyond
1 year after DES implantation, but also an increase of major
bleeding and all-cause mortality, owing to higher non-
cardiovascular mortality, not offset by a decrease in cardiac
mortality [21]. In this meta-analysis, the large patient cohort
provided sufficient statistical power and 351 (67%) of the 523
total deaths were recorded in trials other than DAPT [21]. This
meta-analysis was different from a prior one by Elmariah et al.
that included 14 trials and 69,644 randomly assigned patients
concluding that DAPT prolongations were not associated
with increased mortality [20]. The latter indeed included a
heterogeneous population of patients with atherosclerotic
disease (patients treated with PCI but also patients with
peripheral artery disease, atrial fibrillation, and CAD man-
aged medically) and did not include the ISAR-SAFE and
ITALIC trials that were included in the meta-analysis by
Palmerini et al. and these differences may contribute to
explain opposite results.
Altogether, studies of long-term DAPT for an additional 18
to 36 months after DES found an absolute decrease in late
stent thrombosis and ischemic complications of 1–2% and
an absolute increase in bleeding complications of ≈1%
[45••]. A weighted risk-benefit analysis of studies with pa-
tients treated with DES found 6 fewer MIs and 3 fewer stent
thrombosis but 5 additional major bleeds per 1000 patients
treated with prolonged DAPT per year [45••].
Based on this evidence described, a general approach may
be suggested considering a short-term (3 or 6 months) DAPT
strategy in patients at low risk of recurrent coronary events
(i.e., stable CAD), in those at low risk of stent thrombosis
(especially after treatment with contemporary DES), and in
those at high risk of bleeding. Conversely, an extended
DAPT strategy (>1 year) might still be considered in some
patients in whom prevention of stent and non-stent-related
coronary events is likely to counterbalance its potential ad-
verse events, thus resulting in reduced or a neutral effect on
mortality.
Long-Term Ticagrelor-Based DAPT in Patients
with Prior Myocardial Infarction
The use of long-term DAPT with ticagrelor in patients with
previous MI has been investigated only in the PEGASUS-
TIMI-54 trial [46••]. A total of 21,162 patients who experi-
enced a spontaneous myocardial infarction 1 to 3 years earlier
were randomly assigned, in a double-blind 1:1:1 fashion, to
ticagrelor 90 mg twice a day, ticagrelor 60 mg twice a day, or
placebo. All patients were also treated with low-dose aspirin.
The primary efficacy endpoint, at a median follow-up of
33 months, was a composite of cardiovascular death, myocar-
dial infarction, or stroke, while the primary safety endpoint
was the rate of major bleedings using the TIMI classification.
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At 3 years, the primary efficacy endpoint was significantly
reduced using each of the two doses of ticagrelor as compared
with placebo: 9.04% in the placebo group, 7.85% in the 90-
mg ticagrelor group (HR 0.85 [0.75–0.96], p = 0.008), and
7.77% in the 60-mg ticagrelor group (HR 0.84 [0.74–0.95],
p = 0.004) (Fig. 1). On the contrary, the primary safety end-
point was significantly increased in ticagrelor-treated patients
as comparedwith placebo: 1.06% in the placebo group, 2.60%
in the 90-mg ticagrelor group (p < 0.001), and 2.30% in the
60-mg ticagrelor group (p < 0.001) (Fig. 1). Nevertheless,
intracranial hemorrhage or fatal bleeding did not differ across
groups. Moreover, there was a trend towards a reduction of
cardiovascular death alone using both doses of ticagrelor as
compared with placebo, even if a statistical significance was
not achieved. An exploratory analysis showed a significant
decrease in the rate of MI with both doses of ticagrelor as
compared to placebo as well as a significant reduction in the
stroke rate using ticagrelor 60 mg twice daily. In the intention-
to-treat analysis, both doses of ticagrelor showed that they
have the same magnitude of efficacy, while the 60-mg dose
twice daily was associated with a lower rate of bleedings and
dyspnea, showing a more attractive benefit-risk profile. The
results of the PEGASUS-TIMI-54 trial suggested that patients
with a previous ACS, mainly those in whom the risk of ische-
mic events and cardiovascular death outweighs the risk of
major or life-threatening bleedings, might benefit from
prolonged ticagrelor-based DAPT. In fact, the new update of
the European Society of Cardiology (ESC)NSTE-ACS guide-
lines [47], published on 2016, now include a recommendation
that DAPT beyond 1 year may be considered depending on
the ischemic and bleeding patient risk (tailored prolonged
DAPT).
In order to explore the pharmacokinetics and pharmacody-
namics of the two doses of ticagrelor, an analysis of the
PEGASUS-TIMI-54 has found that ticagrelor 60 mg bid
achieved similar levels of peak and trough platelet inhibition
in nearly all patients as compared with the 90-mg bid dosage
[43]. Yet, the 60-mg ticagrelor regimen was associated with a
better safety profile in the trial, and regulatory agencies both in
the USA and EU have granted approval to the ticagrelor 60-
mg regimen only for DAPT extension in the form of aspirin
and ticagrelor beyond 1 year.
In the PEGASUS-TIMI-54, the adherence to the study drug
in patients treated with ticagrelor was significantly lower as
compared to placebo [48]. Non-adherence is a common issue
in clinical trials as well as in routine clinical practice, which
significantly affects clinical outcomes and health costs. In the
90-mg ticagrelor group, the rate of drug discontinuation was
32%, in the 60-mg ticagrelor group 29%, and in the placebo
group 21% (p < 0.001). The treatment discontinuation was
mainly driven by non-serious adverse events, such as non-
major bleeding and mild to moderate dyspnea, with a high
rate early after initiation of the study drug and a low rate for
patients completing 1 year of treatment. These data showed
how defined “non-serious” adverse events in a clinical trial
may influence the quality of life, reducing the patient’s adher-
ence to the medical treatment and requiring heedful counsel-
ing after the start of ticagrelor administration, in order to max-
imize drug effectiveness. Importantly, from a practical point of
view, another substudy has recently shown that when consid-
ering the prolongation of P2Y12 inhibitor therapy in high-risk
patients, there is a greater benefit in the continuation of such
therapy without interruption after MI, rather than re-initiating
such therapy in patients who have remained stable for an
extended period [49], highlighting the importance of avoiding
temporary or permanent DAPT discontinuation.
The results of the PEGASUS-TIMI-54 trial were con-
sistent in the subgroups of patients deemed to be at very
Fig. 1 Three-year safety and efficacy outcomes of the PEGASUS-TIMI-
54 trial. a Reports 3-year safety and efficacy outcomes related to the
comparison between ticagrelor 90 mg twice daily vs. placebo within the
PEGASUS-TIMI-54 trial. b Reports 3-year safety and efficacy outcomes
related to the comparison between ticagrelor 60 mg twice daily vs.
placebo within the PEGASUS-TIMI-54 trial. CV cardiovascular, MI
myocardial infarction, TIMI thrombolysis in myocardial infarction
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high ischemic risk. The addition of ticagrelor to aspirin in
patients with diabetes mellitus and prior MI significantly
reduced the risk of recurrent ischemic events, including
cardiovascular death and coronary heart disease [50], as
well as in patients with chronic kidney disease [51]. PAD
is known to be more frequent in CAD patients. The pres-
ence of PAD in CAD patients worsens prognosis [52–54].
A recent subanalysis of the PEGASUS-TIMI-54 has dem-
onstrated that among stable patients with prior MI, those
with concomitant PAD have heightened ischemic risk and
ticagrelor in these patients reduced MACE, with a large
absolute risk reduction, as well as major adverse limb
events [55]. In the PRODIGY trial, PAD patients (approx-
imately 12.5%) were confirmed to be at increased risk of
ischemic events and interestingly they benefited by DAPT
prolongation up to 24 months with no apparent greater
bleeding risk compared with patients without PAD [56].
The effects of ticagrelor in patients with PAD will be
definitively assessed by the ongoing EUCLID trial
(clinicaltrials.gov, NCT01732822), including 13,500
patients with PAD and testing the superiority of
ticagrelor over clopidogrel monotherapy in the reduction
of the risk of cardiovascular events.
Finally, a recent analysis of the PEGASUS-TIMI-54
showed that high-risk patients with prior MI are at concomi-
tant high risk for stroke, approximately one third of which are
fatal or lead to moderate-to-severe disability [57]. Patients
treated with ticagrelor 60 mg twice daily had a significant
decrease of stroke risk without an increase of hemorrhagic
stroke but with more major bleeding [57].
After PEGASUS-TIMI-54 publication, the topic of
cancer-related increased mortality risk after long-term an-
tithrombotic therapy has emerged once more as matter of
discussion within the community [58]. Bonaca et al. re-
ported higher rates of cancer-related death among patients
receiving either 90 or 60 mg of ticagrelor than among
those receiving placebo (1.10% and 0.92% vs. 0.76%),
and when these findings were pooled with those of the
DAPT trial, a significant relative increase of 41% in the
number of cancer-related deaths among patients who were
treated with extended DAPT [58] was shown. Also, in the
case of PEGASUS-TIMI-54, however, it seems that an
imbalance of cancer patients in the randomized groups
may contribute to partly explain this issue. Future studies
are needed to shed light on this matter [58]. However,
unlike the null effect of long-term thienopyridine admin-
istration, which tended to increase non-CV mortality and
exerted a null effect on CV mortality, the long-term treat-
ment of ticagrelor in the PEGASUS-TIMI-54 trial was
associated with a numerical (even if not statistically sig-
nificant) decrease of CV deaths, which overcompensated
a small yet consistent increase of non-CV deaths (Costa F.
et al. IJC 2015).
Long-Term DAPT in Patients with Prior Myocardial
Infarction
The search for a tailored approach to the decision-making for
the DAPT duration has moved the interest towards subgroups
that may benefit by long-term DAPT with no or acceptable
bleeding risk. An initial trial on clopidogrel, the CHARISMA,
enrolled patients with established atherosclerosis or at high
risk of clinical atherosclerotic disease and randomized them
to either DAPT or aspirin monotherapy [59]. At a median
follow-up of 28 months, the DAPT arm had no significant
reduction in ischemic events but a 0.4% absolute increase in
severe bleeding was observed [59]. Notably, a post hoc anal-
ysis of patients enrolled in the study with previousMI showed
a 1.7% absolute reduction of the composite endpoint (cardio-
vascular death, MI, or stroke) with DAPT, with no benefit in
those with CADwithout prior MI [60]. In accordance with the
interesting findings of the PEGASUS-TIMI-54 trial in this
specific setting of patients, a recent meta-analysis has ex-
plored the role of long-term DAPT for secondary prevention
in patients with previous MI [27••]. In particular, 6 trials were
pooled together (PEGASUS-TIMI-54, PRODIGY,
CHARISMA, DAPT, ARCTIC Interruption, and DES-
LATE) including 33,435 patients followed over a mean of
31 months [27••]. Of these patients, only those from the
PEGASUS-TIMI-54 received ticagrelor as P2Y12 inhibitor.
Long-term DAPT reduced the risk of MACE compared with
aspirin alone (risk ratio, RR, 0.78 [0.67–0.90]; p = 0.001) and
cardiovascular death (RR 0.85 [0.74–0.98]; p = 0.03), without
differences in non-cardiovascular death (RR 1.03 [0.86–1.23];
p = 0.76) or all-cause mortality (RR 0.92 [0.83–1.03];
p = 0.13). Long-term DAPT also reduced MI (RR 0.70
[0.55–0.88]; p = 0.003), stroke (RR 0.81 [0.68–0.97];
p = 0.02), and stent thrombosis (RR 0.50 [0.28–0.89];
p = 0.02), but at the cost of an increased risk of major bleeding
(RR 1.73 [1.19–2.50]; p = 0.004), although not fatal bleeding
was similar in the two regimens (RR 0.91 [0.53–1.58];
p = 0.75). Therefore, this study supported the concept that
despite increased major bleeding, long-term DAPT, irrespec-
tive of type of P2Y12 inhibitor used, may offer benefits in
terms of ischemic events without increasing mortality in pa-
tients with prior MI [27••]. Interestingly, this study did not
show a significant reduction in all-cause mortality; thus,
Bonaca and Sabatine recently expanded this meta-analysis
also including the cohort of patients with prior MI in the
TRA2P-TIMI-50 trial (excluding patients with stroke/TIA be-
cause vorapaxar is not approved for them) and focused only
on the ticagrelor 60-mg group of the PEGASUS-TIMI-54
which is the dose currently approved [61]. They obtained a
significant 11.5% decrease of all-cause mortality, which was
attributable to reduction of cardiovascular mortality without
reduction or increase of non-cardiovascular death. They con-
cluded that long-term intensive DAPT was beneficial in
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patients with prior MI and no high risk of bleeding [61].
However, this study did not include the OPTIDUAL trial,
another long-term negative trial, and was also criticized based
on the concept that post hoc mixing of different trials with
different antiplatelet drugs, different overall findings, and dif-
ferent follow-ups introduces clinical heterogeneity in the anal-
ysis [62]. It was argued, indeed, that it is not reliable to esti-
mate all-cause mortality from pooling subgroups with nega-
tive or inconclusive findings from underpowered studies due
to the high risk of false-positive conclusions, which alter the
possibility to translate these findings into health care and daily
practice [62]. Therefore, although patients with prior MI seem
to benefit from DAPT prolongation, current evidence is not
sufficient to support survival advantages with this approach,
which on the contrary can be obtained with other recommend-
ed strategies including drugs (aspirin, statins, beta-blockers,
and ACE inhibitors) or lifestyle changes (i.e., stop smoking,
regular exercise) [62].
How to Select the Optimal Candidates
for a Long-Term DAPT in Contemporary Clinical
Practice
The translation of trial findings into clinical practice is a com-
plex process that needs to take always into account the single
patient features. A tailored approach is the most often recom-
mended strategy in order to select the DAPT duration in each
patient based on the patient’s risk of ischemic and bleeding
events. In line with this concept, a dedicated algorithm would
be helpful to properly select the best candidates for a long-
term use of DAPT. A pre-specified analysis of the DAPT trial
population has recently proposed a 9-item score [63••], named
DAPT score (Table 2), which comprised age (≥75 years or 65
to 74 years), prior MI or PCI, stent diameter <3 mm, conges-
tive heart failure or left ventricular ejection fraction (LVEF)
<30%, MI at presentation, paclitaxel-eluting stent, smoking,
and diabetes. In this exploratory analysis, the composite end-
point of stent thrombosis or MI in patients with DAPT score
<2 was not significantly different in the long-term DAPT arm
as compared with aspirin alone (1.7% vs. 2.3%, respectively;
p = 0.07), while GUSTO moderate or severe bleeding oc-
curred more frequently in the long-term DAPT group (3.0%
vs. 1.4%; p < 0.001). Contrarily, patients with a DAPT score
≥2 treated with prolonged thienopyridines had a significantly
lower rate of ST or MI compared with aspirin alone (2.7% vs.
5.7%; p < 0.001) and no significant difference in terms of
GUSTO moderate to severe bleedings (1.8% vs. 1.4%;
p = 0.26). Similar results were confirmed also in the subpop-
ulation of patients with previous MI of the DAPT trial [64].
Main limitations of this score are the following: (a) It comes
from a post hoc analysis; (b) it is not powered to examine
differences in outcomes between subgroups; (c) unmeasured
confounders cannot be excluded.
Moreover, the score is applicable to patients with clinical
characteristics similar to those enrolled in the trial, but the
translation and the generalizability to all patients with CAD
treated with PCI or with prior MI are limited and not a plau-
sible scenario for daily practice. For example, the DAPTscore
is not applicable to the PEGASUS-TIMI-54 patient popula-
tion due to the different design of the two trials, the inclusion
of PCI procedural items in the score (approximately 20% of
patients in the PEGASUS-TIMI-54 did not receive PCI), and
the P2Y12 inhibitor used (mainly clopidogrel in the DAPT
study with approximately 30% of patients receiving prasugrel,
while ticagrelor only in the PEGASUS-TIMI-54; patients re-
ceiving ticagrelor or other antiplatelet combinations could
have a different risk/benefit ratio). Additionally, the use of
the DAPT score has not yet demonstrated to improve patient
outcomes. The future validation of the DAPTscore in contem-
porary datasets is mandatory to assess the prediction rule of
this score in other cohorts and its potential usefulness on pa-
tient treatment in daily clinical practice. Thus, it should be
used with caution until further validation is performed, and
optimal clinical and procedural care to reduce overall bleeding
and ischemic risks should be performed irrespective of the
patient’s score.
Conclusion
Results of recent trials, in particular the PEGASUS-TIMI-54
trial, seem to encourage the long-term use of ticagrelor in
patients with CAD who are deemed at high thrombotic and/
or low bleeding risks. Whether long-term use of ticagrelor is
able to reducemortality remains to be clarified. Doubtless, it is
associated with lower thrombotic risks but also with an
Table 2 DAPT score
Items Points
Age
<65 years 0
65–75 years −1
>75 years −2
Vein graft stent 2
Cigarette smoking within last 2 years 1
Diabetes mellitus 1
Myocardial Infarction at presentation 1
Stent diameter <3 mm 1
History of CHD or LVEF <30% 2
Prior MI or prior PCI 1
Paclitaxel-eluting stent 1
CHD chronic heart disease, LVEF left ventricle ejection fraction, MI
myocardial infarction, PCI percutaneous coronary intervention
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increased risk of bleeding, although not fatal or intracranial
ones. Therefore, tailoring therapy remains the optimal ap-
proach to be recommended and selecting patients at high risk
of ischemic events but low risk of bleeding may be a potential
strategy to identify patients who may benefit by a more ag-
gressive long-term DAPT regimen.
Compliance with Ethical Standards
Conflict of Interest Sara Ariotti declares that she has no conflict of
interest. Giuseppe Gargiulo receives research grant support from
Cardiopath PhD program (Federico II University). Marco Valgimigli re-
ceives speakers’ bureau and institutional research grant from
AstraZeneca.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
References
Papers of Particular Interest, Published Recently, Have Been
Highlighted as:
• of Importance
•• of Major Importance
1. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K,
Boneu B. Early potent antithrombotic effect with combined aspirin
and a loading dose of clopidogrel on experimental arterial
thrombogenesis in humans. Circulation. 2000;101:2823–8.
2. Schomig A, Neumann FJ, Kastrati A, et al. A randomized compar-
ison of antiplatelet and anticoagulant therapy after the placement of
coronary-artery stents. N Engl J Med. 1996;334:1084–9.
3. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing
three antithrombotic-drug regimens after coronary-artery stenting.
Stent Anticoagulation Restenosis Study Investigators N Engl J
Med. 1998;339:1665–71.
4. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of
anticoagulation versus antiplatelet therapy after coronary stent im-
plantation in high-risk patients: the multicenter aspirin and
ticlopidine trial after intracoronary stenting (MATTIS).
Circulation. 1998;98:2126–32.
5. Gargiulo G, Moschovitis A, Windecker S, Valgimigli M.
Developing drugs for use before, during and soon after percutane-
ous coronary intervention. Expert Opin Pharmacother. 2016;17:
803–18.
6. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coro-
nary syndrome. Nat Rev Cardiol. 2015;12:30–47.
7. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus
clopidogrel in patients with acute coronary syndromes. N Engl J
Med. 2009;361:1045–57.
8. Kohli P, Wallentin L, Reyes E, et al. Reduction in first and recurrent
cardiovascular events with ticagrelor compared with clopidogrel in
the PLATO Study. Circulation. 2013;127:673–80.
9. Steg PG, James S, Harrington RA, et al. Ticagrelor versus
clopidogrel in patients with ST-elevation acute coronary syndromes
intended for reperfusion with primary percutaneous coronary
intervention: A Platelet Inhibition and Patient Outcomes
(PLATO) trial subgroup analysis. Circulation. 2010;122:2131–41.
10. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel
in patients with acute coronary syndromes and diabetes: a substudy
from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Eur Heart J. 2010;31:3006–16.
11. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in
acute coronary syndromes in relation to renal function: results from
the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Circulation. 2010;122:1056–67.
12. James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus
clopidogrel in patients with acute coronary syndromes and a history
of stroke or transient ischemic attack. Circulation. 2012;125:2914–
21.
13.•• Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of
ticagrelor: evidence and potential clinical relevance. J Am Coll
Cardiol. 2014;63:2503–9. This study evaluated possible clinical
implications derived from ticagrelor capability to increase adeno-
sine plasma concentration (off-target properties of ticagrelor).
14. Bonello L, LaineM, KipsonN, et al. Ticagrelor increases adenosine
plasma concentration in patients with an acute coronary syndrome.
J Am Coll Cardiol. 2014;63:872–7.
15. Ohman J, Kudira R, Albinsson S, Olde B, Erlinge D. Ticagrelor
induces adenosine triphosphate release from human red blood cells.
Biochem Biophys Res Commun. 2012;418:754–8.
16. Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D. Ticagrelor
improves peripheral arterial function in patients with a previous
acute coronary syndrome. Cardiology. 2013;124:252–8.
17.•• Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual
antiplatelet therapy after percutaneous coronary intervention with
drug eluting stents: meta-analysis of randomised controlled trials.
BMJ. 2015;350:h1618. Relevant meta-analysis of 10 DAPT trials
in patients treated with DES implantation.
18.•• Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet ther-
apy after drug-eluting stent implantation: will we ever reach a con-
sensus? Eur Heart J. 2015;36:1219–22. Critical analysis of the ev-
idence regarding the optimal duration of DAPT after DES
placement.
19.•• Capodanno D, Gargiulo G, Buccheri S, GiacoppoD, Capranzano P,
Tamburino C. Meta-analyses of dual antiplatelet therapy following
drug-eluting stent implantation: do bleeding and stent thrombosis
weigh similar on mortality? J Am Coll Cardiol. 2015;66:1639–40.
First meta-analysis showing a possible differential impact of bleed-
ing and stent thrombosis on mortality.
20. Elmariah S, Mauri L, Doros G, et al. Extended duration dual anti-
platelet therapy and mortality: a systematic review and meta-anal-
ysis. Lancet. 2015;385:792–8.
21.•• Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in
patients treated with extended duration dual antiplatelet therapy
after drug-eluting stent implantation: a pairwise and Bayesian net-
work meta-analysis of randomised trials. Lancet. 2015;385:2371–
82. Essential meta-analysis, including network analysis, exploring
and underlying concerns about the effects of long-term DAPT on
mortality.
22. Ariotti S, Gargiulo G,Windecker S, Valgimigli M. Time for science
to catch up with clinical practice? J Thorac Dis. 2015;7:E603–6.
23. Costa F, Adamo M, Ariotti S, Navarese EP, Biondi-Zoccai G,
Valgimigli M. Impact of greater than 12-month dual antiplatelet
therapy duration on mortality: drug-specific or a class-effect? A
meta-analysis. Int J Cardiol. 2015;201:179–81.
24.• Montalescot G, Brieger D, Dalby AJ, Park SJ, Mehran R. Duration
of dual antiplatelet therapy after coronary stenting: a review of the
evidence. J Am Coll Cardiol. 2015;66:832–47. Clinical review by
opinion leaders in the field of antiplatelet therapy.
25.• Palmerini T, Stone GW. Optimal duration of dual antiplatelet ther-
apy after drug-eluting stent implantation: conceptual evolution
 2 Page 8 of 10 Curr Cardiol Rep  (2017) 19:2 
based on emerging evidence. Eur Heart J. 2016;37:353–64. Clinical
review by opinion leaders in the field of antiplatelet therapy.
26. Gargiulo G, Costa F, Ariotti S, et al. Impact of proton pump inhib-
itors on clinical outcomes in patients treated with a 6- or 24-month
dual-antiplatelet therapy duration: insights from the PROlonging
Dual-antiplatelet treatment after Grading stent-induced Intimal hy-
perplasia studY trial. Am Heart J. 2016;174:95–102.
27.•• Udell JA, Bonaca MP, Collet JP, et al. Long-term dual anti-
platelet therapy for secondary prevention of cardiovascular
events in the subgroup of patients with previous myocardial
infarction: a collaborative meta-analysis of randomized trials.
Eur Heart J. 2016;37:390–9. Relevant meta-analysis focused
on the long-term DAPT administration in patients with previ-
ous myocardial infarction.
28. Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting
versus bare-metal stents in uncertain drug-eluting stent candidates.
J Am Coll Cardiol. 2015;65:805–15.
29. Ariotti S, Adamo M, Costa F, et al. Is bare-metal stent implantation
still justifiable in high bleeding risk patients undergoing percutane-
ous coronary intervention?: a pre-specified analysis from the ZEUS
trial. JACC Cardiovasc Interv. 2016;9:426–36.
30. Gilard M, Barragan P, Noryani AA, et al. 6- versus 24-month dual
antiplatelet therapy after implantation of drug-eluting stents in pa-
tients nonresistant to aspirin: the randomized, multicenter ITALIC
trial. J Am Coll Cardiol. 2015;65:777–86.
31. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term
duration of dual-antiplatelet therapy after coronary stenting: a ran-
domized multicenter trial. Circulation. 2012;125:2015–26.
32. Han Y, Xu B, Xu K, et al. Six versus 12 months of dual antiplatelet
therapy after implantation of biodegradable polymer sirolimus-
eluting stent: randomized substudy of the I-LOVE-IT 2 Trial. Circ
Cardiovasc Interv. 2016;9:e003145.
33. Hong SJ, Shin DH, Kim JS, et al. 6-month versus 12-month dual-
antiplatelet therapy following long everolimus-eluting stent implan-
tation: the IVUS-XPL randomized clinical trial. JACC Cardiovasc
Interv. 2016;9:1438–46.
34. Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-
eluting stent implantation followed by 6- versus 12-month dual
antiplatelet therapy: the SECURITY randomized clinical trial. J
Am Coll Cardiol. 2014;64:2086–97.
35. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual
antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE
randomized trial. JAMA. 2013;310:2510–22.
36. Schulz-Schupke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a
randomized, double-blind, placebo-controlled trial of 6 vs.
12 months of clopidogrel therapy after drug-eluting stenting. Eur
Heart J. 2015;36:1252–63.
37. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month
dual antiplatelet therapy after implantation of drug-eluting stents:
the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss
After Stenting (EXCELLENT) randomized, multicenter study.
Circulation. 2012;125:505–13.
38. Kim BK, Hong MK, Shin DH, et al. A new strategy for discontin-
uation of dual antiplatelet therapy: the RESET Trial (REal Safety
and Efficacy of 3-month dual antiplatelet Therapy following
Endeavor zotarolimus-eluting stent implantation). J Am Coll
Cardiol. 2012;60:1340–8.
39. Collet JP, Silvain J, Barthelemy O, et al. Dual-antiplatelet treatment
beyond 1 year after drug-eluting stent implantation (ARCTIC-
Interruption): a randomised trial. Lancet. 2014;384:1577–85.
40. Helft G, Steg PG, Le Feuvre C, et al. Stopping or continuing
clopidogrel 12 months after drug-eluting stent placement: the
OPTIDUAL randomized trial. Eur Heart J. 2016;37:365–74.
41. Lee CW, Ahn JM, Park DW, et al. Optimal duration of dual anti-
platelet therapy after drug-eluting stent implantation: a randomized,
controlled trial. Circulation. 2014;129:304–12.
42.•• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30months of dual
antiplatelet therapy after drug-eluting stents. N Engl J Med.
2014;371:2155–66. Largest trial on long-term DAPT in patients
treated with DES implantation.
43. Storey RF, Angiolillo DJ, Bonaca MP, et al. Platelet inhibition with
ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI
54 trial. J Am Coll Cardiol. 2016;67:1145–54.
44. Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and
under-recognized: the late consequences of acute coronary syn-
drome (GRACE UK-Belgian Study). Eur Heart J. 2010;31:2755–
64.
45.•• Bittl JA, Baber U, Bradley SM,Wijeysundera DN. Duration of dual
antiplatelet therapy: a systematic review for the 2016 ACC/AHA
guideline focused update on duration of dual antiplatelet therapy in
patients with coronary artery disease: a report of the American
College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines. Circulation 2016. Most recent meta-
analysis on DAPT therapy accompanying and guiding American
recommendations.
46.•• Bonaca MP, Braunwald E, Sabatine MS. Long-term use of
ticagrelor in patients with prior myocardial infarction. N Engl J
Med. 2015;373:1274–5.
47. Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the
management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation: Task Force for the
Management of Acute Coronary Syndromes in patients presenting
without persistent ST-segment elevation of the European Society of
Cardiology (ESC). Eur Heart J. 2016;37:267–315.
48. BonacaMP, Bhatt DL, Oude Ophuis T, et al. Long-term tolerability
of ticagrelor for the secondary prevention of major adverse cardio-
vascular events: a secondary analysis of the PEGASUS-TIMI 54
trial. JAMA Cardiol. 2016;1:425–32.
49. BonacaMP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of
ticagrelor in relation to time from P2Y12 inhibitor withdrawal in
patients with prior myocardial infarction: insights from PEGASUS-
TIMI 54. Eur Heart J. 2016;37:1133–42.
50. Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in ischemic
events with ticagrelor in diabetic patients with prior myocardial
infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67:
2732–40.
51. Magnani G, Storey RF, Steg G, et al. Efficacy and safety of
ticagrelor for long-term secondary prevention of atherothrombotic
events in relation to renal function: insights from the PEGASUS-
TIMI 54 trial. Eur Heart J. 2016;37:400–8.
52. Saw J, Bhatt DL, Moliterno DJ, et al. The influence of peripheral
arterial disease on outcomes: a pooled analysis of mortality in eight
large randomized percutaneous coronary intervention trials. J Am
Coll Cardiol. 2006;48:1567–72.
53. Esposito G, Schiattarella GG, Perrino C, et al. Dermcidin: a skeletal
muscle myokine modulating cardiomyocyte survival and infarct
size after coronary artery ligation. Cardiovasc Res. 2015;107:431–
41.
54. Giugliano G, Di Serafino L, Perrino C, et al. Effects of successful
percutaneous lower extremity revascularization on cardiovascular
outcome in patients with peripheral arterial disease. Int J Cardiol.
2013;167:2566–71.
55. BonacaMP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of
ischemic events after myocardial infarction in patients with periph-
eral artery disease. J Am Coll Cardiol. 2016;67:2719–28.
56. Franzone A, Piccolo R, Gargiulo G, et al. Prolonged vs short
duration of dual antiplatelet therapy after percutaneous coro-
nary intervention in patients with or without peripheral arterial
disease: a subgroup analysis of the PRODIGY randomized
c l i n i c a l t r i a l . JAMA Card io l . 2 016 ; do i : 10 . 1001
/jamacardio.2016.2811.
Curr Cardiol Rep  (2017) 19:2 Page 9 of 10  2 
57. Bonaca MP, Goto S, Bhatt DL et al. Prevention of stroke with
ticagrelor in patients with prior myocardial infarction: insights from
PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in
Patients With Prior Heart Attack Using Ticagrelor Compared to
Placebo on a Background of Aspirin-Thrombolysis in Myocardial
Infarction 54). Circulation 2016.
58. Costa F, Valgimigli M. Long-term use of ticagrelor in patients
with prior myocardial infarction. N Engl J Med. 2015;373:
1271–2.
59. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus
aspirin alone for the prevention of atherothrombotic events. N Engl
J Med. 2006;354:1706–17.
60. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior
myocardial infarction, stroke, or symptomatic peripheral ar-
terial disease in the CHARISMA trial. J Am Coll Cardiol.
2007;49:1982–8.
61. Bonaca MP, Sabatine MS. Antiplatelet therapy for long-term sec-
ondary prevention after myocardial infarction. JAMA Cardiol.
2016; doi:10.1001/jamacardio.2016.2110.
62. Bittl JA, Bates ER, Kaul S. Extended dual antiplatelet therapy in
patients with prior myocardial infarction. JAMA Cardiol. 2016;
doi:10.1001/jamacardio.2016.2252.
63.•• Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and
validation of a prediction rule for benefit and harm of dual anti-
platelet therapy beyond 1 year after percutaneous coronary inter-
vention. JAMA. 2016;315:1735–49. First score created to balance
both ischemic and bleeding risk to be considered in the decision-
making of the DAPT prolongation or interruption over 12 months
after PCI.
64. Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT score utility for
risk prediction in patients with or without previous myocardial in-
farction. J Am Coll Cardiol. 2016;67:2492–502.
 2 Page 10 of 10 Curr Cardiol Rep  (2017) 19:2 
the bmj | BMJ 2016;355:i5483 | doi: 10.1136/bmj.i5483
RESEARCH
1
OPEN ACCESS
For numbered affiliations see 
end of article.
Correspondence to: M Valgimigli 
marco.valgimigli@insel.ch
Additional material is published 
online only. To view please visit 
the journal online.
Cite this as: BMJ 2016;355:i5483
 http://dx.doi.org/10.1136/bmj.i5483
Short term versus long term dual antiplatelet therapy after 
implantation of drug eluting stent in patients with or without 
diabetes: systematic review and meta-analysis of individual 
participant data from randomised trials
Giuseppe Gargiulo,1,2 Stephan Windecker,1 Bruno R da Costa,1,3 Fausto Feres,4 Myeong-Ki Hong,5 
Martine Gilard,6 Hyo-Soo Kim,7 Antonio Colombo,8 Deepak L Bhatt,9 Byeong-Keuk Kim,5  
Marie-Claude Morice,6 Kyung Woo Park,7 Alaide Chieffo,8 Tullio Palmerini,10 Gregg W Stone,11 
Marco Valgimigli1 
ABSTRACT
OBJECTIVE
To compare clinical outcomes between short term 
(up to 6 months) and long term (12 months) dual 
antiplatelet therapy (DAPT) after placement of a drug 
eluting stent in patients with and without diabetes.
DESIGN
Individual participant data meta-analysis. Cox 
proportional regression models stratified by trial 
were used to assess the impact of diabetes on 
outcomes.
DATA SOURCE
Medline, Embase, and Cochrane databases and 
proceedings of international meetings searched for 
randomised controlled trials comparing durations of 
DAPT after placement of a drug eluting stent. Individual 
patient data pooled from six DAPT trials.
PRIMARY OUTCOME
Primary study outcome was one year risk of major 
adverse cardiac events (MACE), defined as cardiac 
death, myocardial infarction, or definite/probable 
stent thrombosis. All analyses were conducted by 
intention to treat.
RESULTS
Six trials including 11 473 randomised patients were 
pooled. Of these patients, 3681 (32.1%) had diabetes 
and 7708 (67.2%) did not (mean age 63.7 (SD 9.9) and 
62.8 (SD 10.1), respectively), and in 84 (0.7%) the 
information was missing. Diabetes was an 
independent predictor of MACE (hazard ratio 2.30, 
95% confidence interval 1.01 to 5.27; P=0.048 At one 
year follow-up, long term DAPT was not associated with 
a decreased risk of MACE compared with short term 
DAPT in patients with (1.05, 0.62 to 1.76; P=0.86) or 
without (0.97, 0.67 to 1.39; P=0.85) diabetes (P=0.33 
for interaction). The risk of myocardial infarction did 
not differ between the two DAPT regimens (0.95, 0.58 
to 1.54; P=0.82; for those with diabetes and 1.15, 0.68 
to 1.94; P=0.60; for those without diabetes (P=0.84 
for interaction). There was a lower risk of definite/
probable stent thrombosis with long term DAPT among 
patients with (0.26, 0.09 to 0.80; P=0.02) than 
without (1.42, 0.68 to 2.98; P=0.35) diabetes, with 
positive interaction testing (P=0.04 for interaction), 
although the landmark analysis showed a trend 
towards benefit in both groups. Long term DAPT was 
associated with higher rates of major or minor 
bleeding, irrespective of diabetes (P=0.37 for 
interaction).
CONCLUSIONS
Although the presence of diabetes emerged as an 
independent predictor of MACE after implantation of 
a drug eluting stent, compared with short term DAPT, 
long term DAPT did not reduce the risk of MACE but 
increased the risk of bleeding among patients with 
stents with and without diabetes.
Introduction
Dual antiplatelet therapy (DAPT) represents the evi-
dence based standard of care among patients undergo-
ing percutaneous coronary intervention. Treatment 
aims to reduce the risk of stent thrombosis after 
implantation of a coronary stent and prevent coronary 
atherothrombotic events at sites outside the stented 
segment. The optimal duration of DAPT after stent 
implantation in general, and particularly after implan-
tation of a drug eluting stent, however, remains a mat-
ter of  controversy.1-7  Currently, a minimum duration of 
six months has been advocated in professional 
 guideline documents and adopted worldwide for 
WHAT IS ALREADY KNOWN ON THIS TOPIC
Dual antiplatelet therapy (DAPT) is the standard of care among patients undergoing 
percutaneous coronary intervention, but its optimal duration is debated, 
particularly after implantation of a drug eluting stent
Some trials have shown that short term (up to 6 months) DAPT is not inferior to 12 
months of treatment
As diabetes is a well known risk factor for cardiovascular disease as well as for 
disease progression and ischaemic complications after percutaneous coronary 
intervention, patients might benefit from prolonged DAPT
WHAT THIS STUDY ADDS
After percutaneous coronary intervention with implantation of a drug eluting stent, 
patients with diabetes, including those receiving treatment with insulin, were 
confirmed to be at higher risk of ischaemic events compared with patients without 
diabetes, though long term compared with short term DAPT did not reduce 
ischaemic or composite endpoints and slightly increased the risk of bleeding in 
patients with and without diabetes
Short term DAPT after implantation of a drug eluting stent is as effective as long 
term DAPT in patients with or without diabetes and might reduce risks and costs of 
prolonged treatment
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 management of patients receiving drug eluting stents, 
irrespective of type.8-10
Diabetes mellitus is a widely recognised risk factor 
for atherosclerosis, disease progression, and restenosis 
after percutaneous coronary intervention.11-14  Although 
new generation drug eluting stents have also been 
shown to provide improved safety and efficacy com-
pared with balloon angioplasty, bare metal stents, and 
early generation drug eluting stents among patients 
with diabetes, such patients, particularly when they 
need treatment with insulin, have a high ischaemic 
risk.15-18  Increased platelet and thrombin reactivity and 
decreased response to therapeutic agents including 
aspirin and clopidogrel have been described in patients 
with diabetes.19 20
Whether diabetes should be taken into consideration 
in the selection of the most appropriate duration of 
DAPT remains unclear. Recently, it was proposed that 
the presence of diabetes can identify patients who ben-
efit from prolonged DAPT because of the increased 
related ischaemic risk.4 6 21  Yet the evidence appraising 
the role of diabetes in the choice of the optimal duration 
is limited.22
We assessed the impact of diabetes status on out-
comes after implantation of drug eluting stents in 
patients treated with short term (≤6 months) or long 
term (12 months) DAPT. We conducted a patient level 
pooled analysis of randomised trials comparing clinical 
outcomes between short term and long term treatment 
after implantation of a drug eluting stent and stratified 
outcomes according to diabetes status.
Methods
Study design
The present study was an individual participant data 
(IPD) meta-analysis of randomised controlled trials 
designed to investigate the efficacy and safety of long 
versus short term DAPT in patients with or without 
medically treated diabetes. The present meta-analysis 
was performed according to the PRISMA-IPD state-
ments.23
In November 2015, we searched Medline, Embase, 
Cochrane controlled trials register databases, and main 
international websites and meetings for randomised 
controlled trials directly comparing short term (3-6 
months) and long term (≥12 months) DAPT among 
patients undergoing percutaneous coronary 
 intervention with drug eluting stents. We excluded tri-
als that looked at DAPT for 12 months compared with 
more than 12 months. The following keywords were 
used: “randomized clinical trial”, “drug-eluting stent”, 
“dual  antiplatelet therapy”, “clopidogrel”, “aspirin”, 
“thienopyridines” (see appendix for supplementary 
methods). No language or publication date restrictions 
were imposed. The most recent data for a given study 
were abstracted. The internal validity of randomised 
controlled trials was assessed by evaluating conceal-
ment of allocation, blind adjudication of events, and 
inclusion of all randomised patients in the analysis. The 
quality of trials included in the meta-analysis was 
appraised with Cochrane methods (selection bias, per-
formance bias, detection bias, attrition bias, reporting 
bias, and other bias).
Three investigators (GG, MV, and TP) independently 
did the systematic search and critically identified stud-
ies to ensure satisfaction of the collected studies.
Among qualifying trials, those for which we obtained 
patient level data from the principal investigators were 
finally included in the present meta-analysis and com-
bined in a single pooled database. In addition to the 
four previously included randomised controlled tri-
als,24-28  we included the SECURITY29  and the ITALIC30 
trials (fig 1 ; tables A-D in appendix). The intention to 
treat population was used for these analyses, including 
all patients according to randomised treatment arm 
regardless of actual treatment. Data beyond one year 
were censored to preserve analysis homogeneity. Fur-
thermore, we excluded a quarter of patients randomised 
to bare metal stents from the PRODIGY population to 
restrict the analysis to patients receiving a drug eluting 
stent.25 31 Characteristics of the included studies are 
described in tables A-D in the appendix.
Definitions end endpoints
Our primary endpoint was the one year rate of major 
adverse cardiac events (MACE), including the compos-
ite of cardiac death, myocardial infarction, or definite/
probable stent thrombosis, as previously described.24 
Secondary endpoints included the one year rate of 
major and minor bleeding, all cause death, cardiac 
death, stroke, myocardial infarction, stent thrombosis 
(definite, probable, and definite/probable), and target 
vessel revascularisation, and combinations of these 
endpoints.
Individual patient data (n=11 473)
Diabetes (n=3681; 32.1%)
(677 (5.9%) treated with insulin)
No diabetes (n=7708; 67.2%) Missing data (n=84; 0.7%)
RESET
3 v 12 month DAPT
(n=2117)
Randomised controlled trials comparing ≤6 v ≥12 month DAPT regimens after PCI with DES implantation and available for individual patient analysis
OPTIMIZE
3 v 12 month DAPT
(n=3119)
EXCELLENT
6 v 12 month DAPT
(n=1443)
SECURITY
6 v 12 month DAPT
(n=1399)
PRODIGY
6 v 24 month DAPT
(n=1501)
ITALIC
6 v 24 month DAPT
(n=1894)
Fig 1 | Studies and patients included in analysis of individual patient data. PCI=percutaneous coronary intervention; 
DES=drug eluting stent 
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We incorporated the endpoint definitions as applied 
in each trial. Stent thrombosis was defined according to 
criteria from the academic research consortium.32  Four 
of the included trials defined bleeding according to 
TIMI (thrombolysis in myocardial infarction) criteria.33 
One trials used the modified REPLACE-2/GUSTO 
 criteria,26  while another trial used the BARC (bleeding 
academic research consortium) criteria.34 In each trial a 
blinded clinical event committee adjudicated events 
(table B in appendix). Table C in the appendix reports 
endpoint definitions in each included trial.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
the design and implementation of the study. There are 
no plans to involve patients in dissemination.
Statistical analysis
We report categorical variables as count and percent-
ages and compared them with a conditional regression 
analysis stratified by trial. Continuous variables are 
reported as means and standard deviation and were 
compared with a two way analysis of variance stratified 
by trial. We carried out an individual patient data 
meta-analysis with a one stage approach.
Results are reported as hazard ratios with 95% confi-
dence intervals. We used a mixed effects Cox regression 
model that took into account the variation between tri-
als in baseline hazard and hazard ratios to derive an 
overall hazard ratio across trials (see supplementary 
methods in appendix).35 36 We used Cox regression for 
formal interaction testing to evaluate consistency of 
treatment effect between the groups with and without 
diabetes. Cumulative survival curves were constructed 
with the Kaplan-Meier model.
From the pooled patient level database, we also 
investigated all endpoints in the subgroup of patients 
with diabetes who were receiving treatment with insu-
lin. We also examined the risk of MACE with long term 
versus short term DAPT in prespecified subgroups: by 
clinical presentation (acute coronary syndrome or sta-
ble), age (<65 or ≥65), sex, and presence of multivessel 
disease.
As a sensitivity analysis, we compared long term ver-
sus short term DAPT for MACE, myocardial infarction, 
definite/probable stent thrombosis, and major or minor 
bleeding after censoring clinical events occurring 
before the landmark time point (landmark analyses at 
time of DAPT discontinuation) and excluding patients 
who prematurely discontinued DAPT (defined by stop-
ping at least one month before the period scheduled by 
randomisation, unless caused by an adverse event such 
as bleeding).
We performed a further sensitivity analysis including 
the two randomised controlled trials for which we did 
not have patient level data.37 38  In this case, we com-
pared ≤6 month versus 12 month DAPT in patients with 
and without diabetes for net clinical adverse events 
(NACE; defined as the composite of all cause death, 
myocardial infarction, stroke, or major bleeding) 
because the published data ffom these two randomised 
controlled trials only reported hazard ratios for this 
endpoint in patients with or without diabetes. We used 
a two stage approach for this analysis. We calculated 
hazard ratios and 95% confidence intervals from the 
individual patient data available from the six ran-
domised controlled trials and used the hazard ratios 
and risk ratios published in the subgroup analyses for 
the ISAR-SAFE and I-LOVE-IT 2 trials, respectively (see 
table E in appendix).37 38 We then combined all the esti-
mates of effectiveness using standard meta-analysis 
methods.
We assessed heterogeneity with τ2 statistic, with val-
ues <0.04, 0.04-0.36, and >0.36 representing mild, mod-
erate, and severe heterogeneity, respectively.39
Values of P<0.05 were considered significant for all 
analyses. We used Stata version 14 (StataCorp, College 
Station, TX), R (R Foundation for Statistical Computing, 
Vienna, Austria), and Reviewer Manager version 5.2 
(RevMan; Nordic Cochrane Centre, Copenhagen).
Results
Figure 1  shows the study population (the study flow 
diagram is shown in fig A in the appendix). Six trials 
were included in the final analysis, comprising PROD-
IGY,25  OPTIMIZE,26  EXCELLENT,27  RESET,28  SECU-
RITY,29  and ITALIC30  (tables A-C in appendix). Among 
these randomised controlled trials, two studies com-
pared 3 month with 12 month DAPT (RESET and OPTI-
MIZE), two studies compared 6 month with 12 month 
DAPT (EXCELLENT and SECURITY), and two studies 
compared 6 month with 24 month DAPT (PRODIGY and 
ITALIC) (fig 1). The risk of bias was generally low, 
although the treatment was open label in all trials, and 
SECURITY and ITALIC were stopped early because of 
recruitment problems (table D in appendix). When we 
checked the individual patient data, we did not identify 
any relevant issues undermining the data integrity.
Patient population
Among the 11 473 randomised patients identified, 3681 
(32.1%) had diabetes (mean age 63.7, SD 9.9), 7708 
(67.2%) did not have diabetes (mean age 62.8, SD 11.0), 
and the information was missing in 84 (0.7%) (fig 1). 
Among patients with diabetes, 677 patients (mean age 
62.8, SD 10.1) were treated with insulin (18.4% of those 
with diabetes; 5.9% of the overall population). The 
numbers randomised to long term versus short term 
DAPT were, respectively, 1853 and 1828 in the group 
with diabetes, 340 and 337 in the group with diabetes 
treated with insulin, and 3848 and 3860 in the group 
without diabetes.
Baseline characteristics
Baseline characteristics were well balanced between 
long term and short term DAPT arms within the groups 
with and without diabetes (table 1). There were, how-
ever, distinct differences in almost every variable 
between patients with and without diabetes (table F in 
appendix). Patients with diabetes were older, 
more  likely to be women, and had higher rates of 
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 cardiovascular disease (hypertension, hypercholestero-
laemia, previous myocardial infarction, previous percu-
taneous coronary intervention, previous coronary 
artery bypass grafting, previous stroke, and renal dys-
function) than those without diabetes (table F in appen-
dix). Stable angina was more often the clinical 
presentation in both those with and without diabetes. 
Patients with diabetes had more extensive coronary 
artery disease, as evidenced by the higher number of 
diseased vessels, treated vessels and lesions, bifurca-
tion treatment, stents implanted, and longer total stent 
length but smaller stent diameter implanted (table F in 
appendix).
Impact of diabetes on the primary endpoint
Diabetes (P=0.046), number of diseased vessels 
(P=0.004), and total stent length per patient (P=0.002) 
were independent predictors of MACE. Compared with 
patients without diabetes, those with diabetes had sig-
nificantly higher rates of MACE (adjusted hazard ratio 
2.30, 95% confidence interval 1.01 to 5.27; P=0.048) (fig 2).
Long term v short term DAPT for primary endpoint 
according to diabetes status
The rates of MACE at one year were similar among 
patients treated with long term versus short term DAPT 
in each subgroup (hazard ratio 1.05, 95% confidence 
Table 1 | Baseline characteristics according to randomisation for duration of dual antiplatelet therapy (DAPT) after implantation of drug eluting stent in 
randomised controlled trials according to diabetes status. Figures are percentages (numbers) of patients unless specified otherwise
Characteristic
Diabetes (n=3681) No diabetes (n=7708)
Long DAPT (n=1853) Short DAPT (n=1828) P value Long DAPT (n=3848) Short DAPT (n=3860) P value
Mean (SD) age (years) 63.7 (10.0) 63.6 (9.9) 0.60 62.8 (11.1) 62.8 (10.8) 0.73
Men 64.0 (1186/1853) 65.8 (1202/1828) 0.27 72.0 (2770/3848) 72.2 (2787/3860) 0.83
Hypertension 87.4 (1618/1852) 87.0 (1591/1828) 0.76 75.1 (2889/3846) 74.5 (2873/3856) 0.54
Hypercholesterolaemia 72.3 (1326/1834) 71.9 (1302/1810) 0.81 60.7 (2308/3803) 60.1 (2296/3821) 0.59
Smoking 17.6 (274/1558) 19.5 (301/1543) 0.17 23.6 (799/3381) 24.0 (816/3403) 0.74
Previous myocardial infarction 22.6 (371/1638) 25.2 (416/1652) 0.09 21.2 (742/3505) 20.2 (706/3501) 0.30
Previous PCI 19.5 (321/1646) 21.4 (354/1658) 0.19 15.7 (550/3511) 16.6 (585/3516) 0.27
Previous CABG 7.7 (126/1645) 7.3 (121/1657) 0.70 5.6 (196/3507) 5.4 (190/3518) 0.73
Previous stroke 4.4 (54/1230) 6.2 (78/1257) 0.05 3.3 (81/2457) 3.1 (78/2482) 0.76
Creatinine >106.08 μmol/L 10.9 (79/725) 8.2 (59/720) 0.08 7.4 (133/1804) 6.9 (125/1812) 0.58
Clinical presentation:
     Stable angina pectoris 62.5 (1159/1853) 59.8 (1094/1828)
0.09
56.6 (2178/3847) 57.7 (2227/3860)
0.34
     Acute coronary syndrome 37.5 (694/1853) 40.2 (734/1828) 43.4 (1669/3847) 42.3 (1633/3860)
STEMI 3.3 (61/1853) 3.0 (55/1828) — 6.4 (247/3847) 6.9 (265/3860) —
NSTEMI 7.4 (137/1853) 7.2 (131/1828) — 9.0 (348/3847) 8.5 (328/3860) —
Unstable angina 26.8 (496/1853) 30.0 (548/1828) — 27.9 (1074/3847) 26.9 (1040/3860) —
Discharge drugs:
     Aspirin 99.9 (1292/1293) 99.9 (1277/1278) 0.99 99.5 (2693/2706) 99.8 (2694/2699) 0.06
     Clopidogrel 99.8 (1290/1293) 99.6 (1273/1278) 0.47 99.7 (2699/2706) 99.6 (2688/2699) 0.49
     β blockers 71.5 (765/1070) 70.8 (759/1072) 0.72 70.0 (1555/2222) 68.4 (1527/2232) 0.26
     ACEI/ARB 60.3 (645/1070) 62.6 (671/1072) 0.27 56.9 (1265/2222) 57.1 (1275/2232) 0.90
     Statins 86.5 (926/1070) 87.7 (940/1072) 0.43 86.8 (1928/2222) 88.1 (1966/2232) 0.19
Mean (SD) diseased vessels/patient 1.53 (0.9) 1.54 (0.9) 0.79 1.48 (0.8) 1.49 (0.8) 0.81
Mean (SD) No of treated vessels/patient 1.22 (0.5) 1.25 (0.5) 0.15 1.21 (0.4) 1.20 (0.4) 0.41
Mean (SD) No of stents/patient 1.58 (0.9) 1.60 (0.9) 0.64 1.51 (0.8) 1.48 (0.8) 0.31
Mean (SD) No of lesions stented/patient 1.33 (0.6) 1.34 (0.6) 0.83 1.26 (0.5) 1.26 (0.5) 0.53
Mean (SD) total stent length/patient (mm) 39.0 (26.1) 39.3 (26.7) 0.85 34.6 (22.9) 33.9 (23.1) 0.35
Mean (SD) smallest stent implanted (mm) 3.0 (0.5) 3.0 (0.4) 0.35 3.1 (0.8) 3.1 (0.5) 0.78
Type of drug eluting stent:
     PES 4.1 (75/1844) 4.2 (76/1820)
<0.001
4.8 (182/3831) 4.8 (183/3840)
<0.001
     SES 4.3 (80/1844) 3.7 (68/1820) 11.1 (425/3831) 2.5 (96/3840)
     EES 39.4 (727/1844) 34.7 (631/1820) 35.4 (1357/3831) 30.9 (1185/3840)
     ZES 47.5 (875/1844) 52.9 (962/1820) 44.1 (1689/3831) 57.0 (2190/3840)
     BES 4.0 (74/1844) 3.8 (70/1820) 4.0 (154/3831) 4.2 (160/3840)
     Mixed 0.5 (9/1844) 0.4 (8/1820) 0.5 (19/3831) 0.3 (13/3840)
     Other 0.2 (4/1844) 0.3 (5/1820) 0.1 (5/3831) 0.3 (13/3840)
Stented coronary artery:
     Left main 2.3 (23/998) 2.7 (27/1002) 0.58 2.3 (54/2369) 2.2 (52/2372) 0.84
     LAD 62.5 (726/1161) 65.5 (763/1165) 0.14 62.8 (1657/2639) 62.3 (1656/2659) 0.70
     LCx 35.1 (381/1087) 33.0 (358/1085) 0.31 31.2 (778/2497) 30.7 (758/2472) 0.71
     RCA 39.7 (428/1078) 39.8 (434/1091) 0.97 34.5 (862/2497) 30.6 (868/2508) 0.95
Bifurcation 18.4 (115/624) 18.8 (115/612) 0.87 16.0 (225/1410) 14.3 (203/1424) 0.21
Chronic total occlusion 2.0 (22/1084) 2.7 (29/1083) 0.32 2.3 (51/2240) 2.4 (55/2247) 0.71
BES=biolimus eluting stent; CABG=coronary artery bypass graft; EES=everolimus eluting stent; GFR=glomerular filtration rate; LAD=left anterior descending artery; NSTEMI=non-ST elevation 
myocardial infarction; PCI=percutaneous coronary intervention; PES=paclitaxel eluting stent; SES=sirolimus eluting stent; STEMI= ST elevation myocardial infarction; SVG=saphenous vein 
graft; ZES=zotarolimus eluting stent.
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interval 0.62 to 1.76, P=0.86, τ2=0.16, for those with dia-
betes; 0.97, 0.67 to 1.39, P=0.85, τ2=0.06, for those with-
out diabetes; interaction P=0.33) (fig 3 , table 2).
Within the group of patients with diabetes, there 
were no significant differences in MACE between long 
term and short term DAPT at one year among prespeci-
fied subgroups (sex, age ≥65, acute coronary syndrome, 
multivessel disease) as well as in patients without dia-
betes (table 3 ). Even in subgroups there was no signifi-
cant interaction between diabetes and DAPT regimen 
(table 3).
Bleeding events
There were no significant differences in terms of bleed-
ing in patients with or without diabetes (adjusted haz-
ard ratio 0.62, 95% confidence interval 0.19 to 2.02; 
P=0.43) (fig 2; table G in appendix). Conversely, 12 
month DAPT was associated with a significantly higher 
rate of major or minor bleeding compared with short 
term DAPT in patients with diabetes (1.89, 1.10 to 3.27; 
P=0.02; τ2=0.02) and a non-significant increase in those 
without diabetes (1.43, 0.96 to 2.11; P=0.08; τ2=0.01; 
interaction P=0.37) (fig 3 , table 2). Major bleeding 
events were consistently increased with long term DAPT 
in both populations, though significantly only in 
patients without diabetes (1.72, 0.72 to 4.10, P=0.22, 
τ2=0.00, for those with diabetes; 2.56, 1.08 to 6.07, 
P=0.03, τ2=0.43, in those without diabetes; interaction 
P=0.69; table 2).
Other clinical outcomes
The risk of myocardial infarction was significantly 
increased among patients with diabetes compared with 
those without diabetes (adjusted hazard ratio 3.66, 95% 
confidence interval 1.25 to 10.69; P=0.018), and it was 
the major determinant of the overall increase of MACE 
(table G in appendix). There were, however, no signifi-
cant differences in the risk of myocardial infarction 
between long term versus short term DAPT (0.95, 0.58 to 
1.54, P=0.82, τ2=0.03, for those diabetes; 1.15, 0.68 to 
1.94, P=0.60, τ2=0.19, for those without diabetes; inter-
action P=0.84; table 2).
The risk of definite or probable stent thrombosis was 
numerically but not significantly increased among 
patients with diabetes compared with those without 
(adjusted hazard ratio 1.89, 95% confidence interval 
0.31 to 11.38; P=0.49; table G in appendix). There was a 
reduction in the risk of definite/probable stent throm-
bosis with long term compared with short term DAPT 
among patients with diabetes but with severe heteroge-
neity (0.26, 0.09 to 0.80; P=0.02; τ2=0.47), whereas no 
such effect was observed in patients without diabetes 
(1.42, 0.68 to 2.98; P=0.35; τ2=0.00), with positive inter-
action testing (interaction P=0.04; table 2).
Table 2 (and table G in appendix) reports all other 
endpoints. No significant differences emerged between 
patients treated with long term versus short term DAPT 
in patients with and without diabetes.
Sensitivity analyses
Consistent with the main analysis, rates of MACE were 
similar with long term or short term DAPT in both 
patients with and without diabetes in a landmark anal-
ysis in which we censored events encountered before 
DAPT discontinuation and excluding patients who 
stopped DAPT early (table H in appendix). This analysis 
confirmed the absence of differences observed in terms 
of myocardial infarction and the trend towards an 
increased risk of bleeding with DAPT for 12 months. In 
contrast with the main analysis, the rates of definite/
probable stent thrombosis showed a trend towards 
reduced event rates in both patients with and without 
diabetes treated with DAPT for 12 months compared 
with short term treatment.
The overall results suggesting similar outcomes with 
short term and long term DAPT, irrespective of diabetes 
status, were further confirmed when we carried out the 
meta-analysis including published results from the 
ISAR-SAFE38  and I-LOVE-IT 237 trials. The composite of 
all cause death, myocardial infarction, stroke, or major 
bleeding was similar between short term and long term 
DAPT in both patients with diabetes (5074 patients; 
hazard ratio 0.92, 95% confidence interval 0.69 to 1.23; 
P=0.56; I2=12%; fig 4) and without diabetes (12 141 
patients; 0.99, 0.78 to 1.25; P=0.69; I2=15%; fig 4), with-
out significant heterogeneity between these subgroups 
(P=0.69; I2=0%; fig 4).
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Fig 2 | Ischaemic and bleeding events in patients with and 
without diabetes. PCI=percutaneous coronary intervention
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Discussion
This patient level analysis of six randomised trials 
assessed clinical outcomes of long term versus short 
term DAPT in patients with or without diabetes. It 
showed that patients with diabetes, including those 
treated with insulin, had a higher baseline risk profile 
and showed an increased risk of MACE but not of 
 bleeding, even after adjustment. Compared with short 
term DAPT, long term DAPT was associated with similar 
rates of MACE in patients with and without diabetes, 
although stent thrombosis was reduced. The risk of 
MACE did not differ across the prespecified subgroups 
of patients (by acute coronary syndrome, sex, multives-
sel disease, and age ≥65). Short term DAPT was associ-
ated with reduced risks of bleeding, irrespective of 
diabetes status.
To date, nine randomised controlled trials have 
looked at 3 or 6 months compared with 12 or more 
months of DAPT after implantation of a drug eluting 
stent.25-30 37 38 40 To our knowledge, this is the first com-
prehensive study to explore the comparison of clinical 
outcomes of short term (≤6 months) with long term (12 
months) DAPT after drug eluting stent implantation 
according to diabetes status. The strength of our analy-
sis is represented by the inclusion of individual patient 
level data from a large patient population from six mul-
ticentre multinational randomised trials. Individual 
patient level meta-analysis overcomes important limita-
tions of study level meta-analysis and improves internal 
validity and allows for time to event, subgroup, and 
covariable adjusted analyses.
Drug eluting stents and DAPT
Compared with bare metal stents, drug eluting stents 
have consistently reduced the risk of restenosis and 
repeat revascularisation at the expense of safety con-
cerns because of an increase in late and very late stent 
thrombosis.41 42  In particular, first generation drug elut-
ing stents were associated with a four to fivefold higher 
risk of late and very late stent thrombosis compared 
with bare metal stents, leading to the concept of “the 
longer the better” regarding duration of DAPT in 
patients with drug eluting stents. Of note, new genera-
tion stents have been shown to be safer in terms of stent 
thrombosis than both early generation stents and bare 
metal stents.43-45  Prolonged DAPT, however, is associ-
ated with increased risks of bleeding and death, as well 
as healthcare costs.3 46 Therefore, the optimal duration 
is of paramount clinical relevance, although still a mat-
ter of debate.
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Diabetes mellitus and DAPT
Diabetes mellitus is a key risk factor for atherosclerosis, 
disease progression, and restenosis during follow-up, 
particularly if patients are insulin dependent, even 
after coronary revascularisation.11 12 15-18  Notably, the 
detrimental metabolic state that accompanies diabetes 
is responsible for abnormalities in endothelial and 
platelet function that can contribute to accelerated ath-
erosclerosis and increase the risk of adverse cardiovas-
cular events.19 20  A large body of evidence has described 
the role of increased platelet activity and adhesion in 
the progression of vascular complications observed in 
patients with diabetes, characterised by a high inci-
dence of cardiovascular events and lower antithrom-
botic efficacy of treatment with aspirin and 
clopidogrel.19 20 Indeed, patients with diabetes mellitus 
might have a smaller than expected response to aspirin 
(because of accelerated renewal of platelets and alter-
ation of thromboxane pathway) and clopidogrel (the 
lower response to the drug in those with diabetes is 
mainly caused by abnormalities in the active metabolite 
pharmacokinetic profile, with only a minor contribu-
tion of platelet dysfunction related to the P2Y12 signal-
ling pathway). Therefore, the clinical translation of 
these findings could lead to the concept that prolonged 
DAPT in patients with diabetes might be the rational 
approach, although it has not been clearly demon-
strated.
A recent large observational study has suggested that 
extending the duration of clopidogrel treatment beyond 
12 months could decrease rates of very late death or 
myocardial infarction only in patients with diabetes 
who had been treated with a first generation drug elut-
ing stent compared with either patients without diabe-
tes or those who had other stent types, although the 
latter group had an overall event rate higher than 
patients with a drug eluting stent.21  This study, how-
ever, like other retrospective studies, has relevant lim-
itations, and appropriate adjustment is unlikely to 
eliminate selection bias.22 Randomised studies compar-
ing different DAPT regimens have provided results of 
subgroup analyses. Interestingly, some contrasting evi-
dence emerged from these analyses on the role of diabe-
tes, although dedicated studies on the impact of 
diabetes, including in patients treated with insulin, 
have not been published to date.
In the EXCELLENT trial, there was a significant inter-
action between diabetes status and duration of DAPT 
(interaction P<0.001) for the primary endpoint (com-
posite of cardiac death, myocardial infarction, or isch-
aemia driven target vessel revascularisation at 12 
months), with patients with diabetes having a signifi-
cant benefit with DAPT for 12 months compared with 6 
months, whereas patients without diabetes had a sig-
nificantly lower event rate with short term DAPT.27  Also 
the DAPT trial showed a significant interaction between 
diabetes and treatment arm (interaction P=0.01), 
although patients with diabetes did not benefit from 
prolonged DAPT (30 months) compared with patients 
without diabetes who experienced a lower risk of 
MACCE (major adverse cardiovascular and cerebrovas-T
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cular events) (mainly because of a decreased risk of 
myocardial infarction and stent thrombosis).46  The 
recent dedicated subanalysis of the DAPT trial showed 
that prolonged DAPT reduced the risk of myocardial 
infarction, but this benefit was attenuated in patients 
with diabetes compared with those without diabetes.47 
Similarly, in the DES-LATE, patients with diabetes 
showed a trend towards benefit from interrupting DAPT 
at 12 months, although the P value for interaction was 
borderline (P=0.07).48  Conversely, other trials, includ-
ing OPTIMIZE,26  RESET,28  I-LOVE-IT 2,37  ISAR-SAFE,38 
ARCTIC Interruption,49  and the recently published 
IVUS-XPL40  did not show significant heterogeneity 
between subgroups with and without diabetes. Even if 
characterised by a different design not matching with 
eligibility criteria of our meta-analysis (inclusion of 
patients with a history of myocardial infarction one to 
three years before, irrespective of percutaneous 
 coronary intervention performed or drug eluting stent 
implanted), the recent substudy by the PEGASUS-TIMI 
Table 3 | Major adverse cardiac events (MACE) for long term versus short term dual antiplatelet therapy (DAPT) after implantation of drug eluting stent 
in subgroups of patients with or without diabetes
Diabetes (n=3681) No diabetes (n=7708)
P for interaction 
for diabetes/DAPTHR (95% CI) P value τ2
P for 
interaction HR (95% CI) P value τ2
P for 
interaction
Age (years):
 <65 1.26 (0.33 to 4.77) 0.74 1.87
0.84
0.84 (0.52 to 1.34) 0.46 0.04
0.50
0.58
 ≥65 1.09 (0.68 to 1.76) 0.71 0.00 1.05 (0.68 to 1.63) 0.82 0.05 0.91
Sex:
 Women 1.32 (0.78 to 2.21) 0.30 0.03
0.09
1.25 (0.65 to 2.37) 0.50 0.14
0.20
0.90
 Men 0.67 (0.38 to 1.21) 0.90 0.08 0.77 (0.55 to 1.10) 0.15 0.00 0.69
Clinical presentation:
 Stable CAD 1.10 (0.63 to 1.92) 0.74 0.09
0.84
1.21 (0.79 to 1.85) 0.38 0.03
0.20
0.79
 ACS 0.98 (0.37 to 2.58) 0.97 0.83 0.76 (0.43 to 1.33) 0.34 0.16 0.66
Multivessel disease:
 No 1.74 (0.91 to 3.32) 0.09 0.17
0.09
1.27 (0.82 to 1.96) 0.28 0.06
0.12
0.43
 Yes 0.75 (0.36 to 1.57) 0.44 0.38 0.69 (0.37 to 1.28) 0.24 0.20 0.87
ACS=acute coronary syndrome; CAD=coronary artery disease. 
Diabetes
  EXCELLENT
  I-LOVE-IT 2
  ISAR-SAFE
  ITALIC
  OPTIMIZE
  PRODIGY
  RESET
  SECURITY
Subtotal
Test for heterogeneity: τ2=0.02, χ2=7.97, df=7, P=0.34, I2=12%
Test for overall effect: z=0.58, P=0.56
No diabetes
  EXCELLENT
  I-LOVE-IT 2
  ISAR-SAFE
  ITALIC
  OPTIMIZE
  PRODIGY
  RESET
  SECURITY
Subtotal
Test for heterogeneity: τ2=0.02, χ2=8.20, df=7, P=0.32, I2=15%
Test for overall effect: z=0.09, P=0.93
Total (95% CI)
Test for heterogeneity: τ2=0.01, χ2=16.36, df=15, P=0.36, I2=8%
Test for overall effect: z=0.41, P=0.69
Subgroup difference: χ2=0.16, df=1, P=0.69, I2=0%
1.82 (0.76 to 4.35)
1.27 (0.72 to 2.23)
0.73 (0.31 to 1.73)
0.42 (0.15 to 1.18)
1.04 (0.58 to 1.87)
0.61 (0.29 to 1.29)
0.99 (0.35 to 2.83)
0.68 (0.30 to 1.56)
0.92 (0.69 to 1.23)
0.46 (0.17 to 1.22)
1.01 (0.69 to 1.49)
1.01 (0.54 to 1.88)
0.72 (0.30 to 1.72)
1.07 (0.64 to 1.79)
1.11 (0.65 to 1.89)
0.50 (0.20 to 1.24)
1.70 (0.91 to 3.18)
0.99 (0.78 to 1.25)
0.96 (0.81 to 1.15)
4
9
4
3
8
5
3
4
39
3
16
7
4
10
10
4
7
61
100
0.01 0.1 1 10 100
Study
Favours short
term DAPT
Favours long
term DAPT
Random hazard
ratio (95% CI)
Random hazard
ratio (95% CI)
Weight
(%)
0.599 (0.444)
0.239 (0.288)
-0.315 (0.439)
-0.868 (0.526)
0.039 (0.299)
-0.494 (0.381)
-0.01 (0.535)
-0.386 (0.424)
-0.777 (0.499)
0.01 (0.198)
0.01 (0.318)
-0.329 (0.444)
0.068 (0.262)
0.104 (0.271)
-0.693 (0.463)
0.531 (0.319)
Log HR (SE)
272
211
495
348
554
188
260
206
2534
450
698
1501
568
1009
563
799
471
6059
8593
Short
term total
278
203
484
356
549
189
258
223
2540
443
717
1517
551
1007
561
800
486
6082
8622
Long
term total
Fig 4 | Net adverse clinical events in patients with and without diabetes according to long term and short term DAPT in 
eight randomised trials
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54 trial also confirmed the absence of potential signifi-
cant heterogeneity related to diabetes status.50  Indeed, 
consistent with the findings in patients without diabe-
tes, those with diabetes had long term benefits in terms 
of ischaemia and cardiovascular death but increased 
risk of bleeding with ticagrelor compared with placebo 
in addition to a background treatment with aspirin.50
Perspectives for clinical practice
Our study shows that compared with short term DAPT, 
long term DAPT does not provide benefits in terms of 
ischaemic protection but rather increases the risk of 
bleeding, irrespective of diabetes status. Although 
patients with diabetes are at increased risk for isch-
aemic events, and prolonged DAPT is often advised in 
these patients, our analysis indicates that prolonged 
treatment is not associated with improved outcomes 
among patients with stents with and without diabetes, 
even when we restricted the analysis to the subgroup of 
patients with diabetes treated with insulin (see supple-
mentary results in appendix). Although we observed a 
lower risk of definite/probable stent thrombosis with 
DAPT for 12 months in patients with diabetes, this find-
ing should be interpreted in the context of high 
 heterogeneity between trials, hampering definitive con-
clusions; moreover the absence of consistent benefit in 
terms of composite endpoints of ischaemic events (add-
ing stent thrombosis to myocardial infarction or death 
(cardiac or all cause)) as well as at the landmark analy-
ses (in which we excluded events occurring in the first 
three to six months when both randomised treatments 
were, by study design, identical) was reassuring on the 
clinical implications of this small excess of stent throm-
bosis in such patients. On the contrary, the relevance of 
our overall findings should be interpreted in light of the 
baseline characteristics of the included patients, partic-
ularly concerning the risk of bleeding. Indeed, com-
pared with studies dedicated to patients with high risk 
(such as LEADERS-FREE with 18.6% of all bleeding and 
7.3% of major bleeding (BARC type 3 or 5) at one year51), 
our study population can be considered at low risk 
given that the overall rate of major or minor bleeding 
events was about 1.5% at one year, of which major 
bleeding was 0.6% compared with 0.4%, 0.4%, 2.6%, 
0.7%, 0.9%, and 0.3% in RESET, EXCELLENT, PRODIGY, 
OPTIMIZE, SECURITY, and ITALIC trials, respectively. 
Furthermore, a recent meta-regression analysis of DAPT 
trials underlined the concept that in the contemporary 
era of drug eluting stents, bleeding has a stronger 
impact on mortality than stent thrombosis.5 In line with 
this, the absence of benefit at the expense of an 
increased risk of bleeding in patients with diabetes 
treated with long term compared with short term DAPT 
is relevant and underlines the opportunity to shorten 
DAPT in this subset of patients.
Limitations
Our study shares limitations of other meta-analyses, 
although the analysis of patient level data mitigates 
some of them. As the six randomised controlled trials 
we included were not specifically designed to investi-
gate outcomes in the subgroup of patients with diabe-
tes, our study has intrinsic limitations of subgroup 
analyses and should be considered as hypothesis gen-
erating. The pooling of data, however, allowed us to 
obtain a large number of patients with diabetes 
(n=3681) as well as insulin treated diabetes (n=677) to 
be compared with patients without diabetes. Even 
though we collected individual data from randomised 
controlled trials, the post hoc nature of this analysis 
introduces biases. Furthermore, it remains unclear if 
our findings could be applicable to all patients with dia-
betes irrespective of its type (type 1 or 2) as this informa-
tion was not available.
The results described cannot be extended to all types 
of drug eluting stent because zotarolimus and everoli-
mus eluting stents were more commonly implanted. 
Similarly, as all patients received clopidogrel, our find-
ings could have differed if novel anti-platelet agents 
such as prasugrel or ticagrelor had been used. Defini-
tions of some clinical endpoints differed slightly across 
trials, potentially introducing effect modifiers. 
Although the meta-analysis of eight randomised con-
trolled trials confirmed the findings of short versus 
long term DAPT, this was conducted without patient 
level data from two randomised controlled trials, and 
net clinical adverse events was the only endpoint that 
we were able to analyse from the published data in the 
subgroups for diabetes status. Finally, most of the trials 
randomised patients at the time of the percutaneous 
coronary intervention or a month later, before the three 
to six months planned discontinuation of DAPT. Differ-
ences in events occurring within three to six months of 
DAPT are chance effects, but the sensitivity analysis 
that excluded those events confirmed the findings of 
the main analysis.
Conclusions
Although the presence of diabetes emerged as an inde-
pendent predictor of MACE, long term compared with 
short term DAPT did not reduce the risk of MACE but 
increased the risk of bleeding among patients with and 
without diabetes. This study might have relevant impli-
cations for clinicians and patients and could modify 
current daily clinical practice. A shorter DAPT regimen 
was found to be effective and safe in patients with and 
without diabetes. Diabetes per se should not be a driver 
for prolonging DAPT over the mandatory period after 
implantation of a drug eluting stent because of 
increased risks compared with potential benefits of this 
strategy. Future studies should be specifically designed 
and powered to deal with patients with diabetes and 
should explore the optimal duration of DAPT according 
to the type of diabetes and its medical management.
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“The unexamined life is not worth living.”  
—Socrates1
ABSTRACT: Aspirin represents the sine qua non for antiplatelet 
pharmacotherapy in patients with cardiovascular diseases because of its 
well-established role in secondary prevention and its widespread availability 
and affordability. Historical studies, conducted in an era that bears little 
resemblance to contemporary clinical practice, demonstrated large 
reductions in thrombotic risk when aspirin was compared with placebo, 
thus forming the evidence base promulgated in practice guidelines and 
recommendations. P2Y12 inhibitors have mostly been studied in addition 
to aspirin; dual-antiplatelet therapy proved superiority compared with aspirin 
monotherapy for the prevention of ischemic events, despite increased 
bleeding risks. An alternative approach currently under investigation includes 
evaluation of single-antiplatelet therapy with P2Y12 inhibitors alone versus 
dual-antiplatelet therapy after acute coronary syndromes or coronary stent 
implantation. As the availability of more effective antiplatelet agents increases, 
it is time to revisit the existing and long-standing paradigm supporting aspirin 
use for secondary prevention of atherothrombotic events. Ongoing trials 
will provide new evidence whether the less-is-more strategy is justified.
Every year millions of patients worldwide undergo percutaneous coronary inter-vention (PCI) for treatment of coronary artery disease (CAD). To date, dual-antiplatelet therapy (DAPT), consisting of low-dose acetylsalicylic acid (ASA or 
aspirin) and an inhibitor of the adenosine diphosphate (ADP) P2Y12 platelet receptor, 
is mandatory to prevent thrombosis among patients with stable CAD after stent 
implantation and following acute coronary syndromes (ACS), irrespective of final 
management (invasive or noninvasive).2–6 An alternative approach currently under 
investigation includes evaluation of single-antiplatelet therapy with P2Y12 inhibitors 
alone after ACS or coronary stent implantation.
The aim of this article is to critically review the available evidence for aspirin use 
after ACS and PCI and to discuss the scientific rational for ongoing studies testing 
the risks and benefits of omission or early discontinuation of aspirin in favor of P2Y12 
inhibitor monotherapy.
PLATELET PATHOPHYSIOLOGY AND ROLE OF ANTIPLATELET AGENTS
Platelets are critical modulators of hemostasis following tissue trauma and vascular 
injury. Thus, inhibition of platelet adhesion and aggregation consistently resulted in an 
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increased risk of bleeding.7 Platelet activation plays a cru-
cial role in the development of atherosclerosis and ACS; 
thus, its inhibition is pivotal to prevent ischemic compli-
cations after stent implantation, including stent thrombo-
sis (ST). Platelets adhere to the injured endothelium of 
blood vessels at sites of endothelial cell activation and 
contribute to the development of chronic atherosclerotic 
plaques. Moreover, platelets trigger the acute onset of 
arterial thrombosis in response to atherosclerotic plaque 
rupture.7 Although platelet adhesion and activation is 
a physiological response to the fissuring or rupture of 
atherosclerotic plaques, eventually contributing to re-
pair, uncontrolled progression of this process, through 
a series of self-sustaining amplification loops, may lead 
to intraluminal thrombus formation and vascular occlu-
sion.8 Platelet activation determines several responses, 
including shape change; dense granule secretion of ATP, 
5-hydroxytryptamine, and ADP (it binds to P2Y12 recep-
tors that have a potent effect on amplification of platelet 
activation); α-granule secretion of chemokines (leading to 
activation of leukocytes and endothelial cells) and coagu-
lation factors; and procoagulant changes in the platelet 
surface membrane supporting thrombin generation and 
activation of GPIIb/IIIa leading to platelet aggregation and 
outside-in signaling further amplifying platelet activation.8 
Consequently, platelet inhibition is the mainstay in the 
prevention of recurrent ischemic events (Figure 1), and 
current guidelines recommend a period of DAPT ranging 
from a minimum of 1 month to well beyond 1 year among 
patients undergoing PCI.2–6,9 The pharmacopeia of P2Y12 
antagonists has rapidly expanded in recent years. 10,11 
In comparison with clopidogrel, which has been shown 
to improve outcomes vis-à-vis placebo on a background 
therapy of aspirin12 as well as aspirin monotherapy,13 the 
new P2Y12 inhibitors, prasugrel and ticagrelor, are char-
acterized by faster onset of action and more consistent 
and potent inhibition of platelet function. Unlike aspirin, 
P2Y12 inhibitors block the amplification process of plate-
let activation.7,11 Both prasugrel and ticagrelor have been 
tested thus far in clinical trials involving ACS patients with 
ASA serving as background therapy. Accordingly, the 
safety and efficacy of monotherapy with these potent 
agents remains unknown. Prasugrel, an irreversible inhibi-
tor of P2Y12 receptor, was associated with a lower risk 
of major adverse cardiovascular events (MACE), largely 
driven by reduction in myocardial infarction (MI), but a 
higher risk of spontaneous and coronary artery bypass 
grafting (CABG)–related major bleeding compared with 
clopidogrel among ACS patients14 already on background 
ASA therapy. Notably, fatal bleeding was slightly but sig-
nificantly increased in prasugrel in comparison with clop-
idogrel-treated patients.
The direct and reversible P2Y12 antagonist ticagrelor 
offers at least similar inhibition of the P2Y12 receptor as 
prasugrel,15 but yields faster offset of platelet inhibition 
in comparison with prasugrel and clopidogrel. Ticagre-
lor significantly reduced the risk of MACE, but also all-
cause and cardiovascular mortality in comparison with 
clopidogrel in ACS patients, irrespective of the final man-
agement strategy (invasive or noninvasive).16 Ticagrelor 
increases nonprocedural but not CABG-related or fatal 
bleeding in comparison with clopidogrel. Prasugrel or 
ticagrelor, when used with background aspirin therapy, 
are therefore preferred over clopidogrel in ACS patients, 
based on superior prevention of ischemic events despite 
both carrying higher risk of spontaneous (ie, nonproc-
edural) bleeding hazard.2,3,5 
Given the delicate balance between ischemic and 
bleeding risks in patients receiving DAPT and notwith-
standing the recent evidence that long-term DAPT further 
decreases the risk of MACE, 17,18 there remains uncer-
tainty on the optimal DAPT duration after ACS or stent 
implantation.19 As a result, a personalized approach to 
administration and duration of DAPT therapy is advocat-
ed, integrating anticipated ischemic over bleeding risks. 
Remarkably, such a treatment strategy has never been 
tested prospectively. At the time of DAPT discontinua-
tion, current guidelines recommend indefinite aspirin 
monotherapy as a secondary prevention measure.2–6
Recently, exploration of novel strategies for patients 
with ACS has yielded mixed results. The use of low-dose 
rivaroxaban at 2.5 mg twice daily in the ATLAS-ACS 2 trial 
(Anti-Xa Therapy to Lower Cardiovascular Events in Addi-
tion to Standard Therapy in Subjects With Acute Coronary 
Syndrome ACS 2),20 and vorapaxar in the TR A2°P-TIMI50 
(Thrombin Receptor Antagonist in Secondary Prevention 
of Atherothrombotic Ischemic Events-Thrombolysis in Myo-
cardial Infarction 50)21 and TRACER (Thrombin Receptor 
Antagonist for Clinical Event Reduction in Acute Coronary 
Syndrome)22 trials have been shown to reduce the risk of 
ischemic adverse events at the cost of greater bleeding 
in comparison with DAPT consisting of aspirin and clopi-
dogrel. Conversely, less favorable results were observed 
for rivaroxaban at a dose of 5 mg twice daily (ATLAS-ACS), 
for dabigatran (twice daily administration of 50, 75, 110, 
or 150 mg) in the RE-DEEM study (Dabigatran Versus 
Placebo in Patients With ACS on DAPT: A Randomized, 
Double-Blind, Phase II Trial),23 apixaban (5 mg twice daily) 
in the APPRAISE-2 study (Apixaban for Prevention of Acute 
Ischemic and Safety Events),24 and darexaban (all doses) 
in the RUBY-1 trial (Study Evaluating Safety, Tolerability and 
Efficacy of YM150 in Subjects With Acute Coronary Syn-
dromes).25 More specifically, these trials generally showed 
a magnitude of incremental bleeding risk that was not 
counterbalanced by a concordant reduction in thrombotic 
events thereby rendering a neutral or negative net ben-
efit. Because these strategies were examined by adding 
the novel agent to a background of DAPT, inferences 
surrounding the omission of ASA in the experimental arm 
are not possible based on these studies.
Given the well-recognized trade-off between ischemic 
prevention and bleeding risk in patients receiving DAPT 
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or triple therapy, alternative strategies that optimize net 
clinical benefit by preserving ischemic reduction without 
increasing bleeding harm are needed. An intriguing and 
emerging area of research is to avoid aspirin therapy 
altogether in favor of long-term P2Y12 inhibitor mono-
therapy. Ongoing studies aim to discern whether mono-
therapy with a P2Y12 inhibitor can safely and effectively 
replace conventional DAPT regimens after ACS or PCI, 
or even replace ASA for long-term secondary prevention.
ASPIRIN
Mechanism of Action
ASA was synthesized in 1897 and then commercialized 
as aspirin in 1899. It was used worldwide because of its 
anti-inflammatory/analgesic effects until the 1970s when 
its antiplatelet effects became apparent. For this latter 
mechanism of action, aspirin has become the cornerstone 
in the antithrombotic therapy for the prevention and treat-
ment of wide range of cardiovascular diseases worldwide.
Arachidonic acid is released from membrane phos-
pholipids by several isoforms of phospholipase A2 
(Figure 2). Free arachidonic acid is converted to the un-
stable intermediates prostaglandin G2 and prostaglan-
din H2 by cytosolic prostaglandin H synthases through 
its cyclooxygenase (COX) and hydroperoxidase activi-
ties, respectively.26–29 Prostaglandin H2 is converted by 
tissue-specific isomerases to multiple prostanoids that 
activate specific cell membrane receptors. Although 
high-dose aspirin inhibits both COX-1 and COX-2, low-
dose aspirin selectively and irreversibly inhibits COX-1 
in the arachidonic acid pathway (Figure 2), subsequently 
blocking the production of thromboxane A2 (TXA2), a 
platelet agonist (rapidly transformed in TXB2), thereby 
reducing thrombus formation.26,29 More specifically, as-
pirin first binds to an arginine 120 residue, as do other 
nonsteroidal anti-inflammatory drugs, but unlike these, 
aspirin then acetylates the serine 529 residue of human 
COX-1 (serine 516 in human COX-2 for higher doses of 
aspirin) located in the narrowest section of the channel, 
irreversibly inhibiting access to the COX catalytic site by 
Figure 1. Antithrombotic agents. 
Illustration of the process of platelet aggregation and the mechanism of actions of the main antithrombotic agents. AA indicates 
arachidonic acid; ADP, adenosine diphosphate; Ca, calcium; COX, cyclooxygenase; GP, glycoprotein; LMWH, low-molecular-weight 
heparin; PAR, protease-activated receptor; TXA2, thromboxane A2; UFH, unfractionated heparin; and vWF, von Willebrand factor.
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arachidonic acid.26,29 This antiplatelet effect persists for 
the lifespan of platelets because the permanent inactiva-
tion of the platelet COX-1 can be reversed only through 
the generation of new platelets.28 Although aspirin is 
characterized by a very short half-life (≈15 minutes in 
plasma), it needs to be administered only once daily for 
the purpose of platelet inhibition.
Importantly, there is a nonlinear relationship between 
low-dose aspirin-induced inactivation of platelet COX-
1 and inhibition of TXA2-dependent platelet function.8 
This translates into crucial implications: (1) a less than 
maximal inactivation of COX-1 determines a significant 
reduction in platelet inhibition; (2) after aspirin discon-
tinuation, the recovery of platelet function is dispropor-
tionately rapid, occurring within 3 to 4 days; (3) most 
traditional nonsteroidal anti-inflammatory drugs  are 
not able to completely and persistently inhibit platelet 
COX-1. Additionally, the selective inhibition by ASA of 
TXA2-dependent platelet function alone, without any ef-
fect on other pathways of platelet activation (ADP-P2Y12, 
thrombin-protease–activated receptor-1) forms the phys-
iological rationale for dual- or triple-antiplatelet therapy 
in high-risk settings where further platelet inhibition is 
necessary (Figure 1).8
The gastrointestinal adverse effects of aspirin and 
nonsteroidal anti-inflammatory drugs (erosive gastritis 
and bleeding) are mainly a result of COX-1 inhibition.29 
Indeed, COX-1 is ubiquitous, constitutively expressed 
in the human body and able to produce prostaglandins 
involved in platelet aggregation (mainly TXA2), but also 
in the maintenance of gastrointestinal mucosal integrity 
(mainly prostaglandin E2 and prostaglandin I2).
29
Clinical Outcomes
Numerous studies have clearly demonstrated that low-
dose aspirin reduces cardiovascular morbidity and mor-
tality in patients with ACS or previous MI and confers 
Figure 2. Aspirin mechanism of antiplatelet action. 
Illustration of the process of formation and action of prostanoids and the mechanism of action of aspirin. COX indicates cyclo-
oxygenase; cPGE, cytosolic prostaglandin E; cPLA2, cytosolic phospholipase A2; HOX, hydroperoxidase; mPGE, microsomal 
prostaglandin E; PG, prostaglandin; sPLA2, secretory phospholipase A2; and TX, thromboxane.
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a durable long-term benefit. 30,31 Most randomized trials 
have been summarized by the Antithrombotic Trialists’ 
Collaboration, which included 16 secondary preven-
tion randomized trials (17 000 individuals at high-risk, 
43 000 person-years, 3306 serious vascular events) 
and compared long-term aspirin versus control.30 As-
pirin significantly reduced the risk of serious vascular 
events (6.7% versus 8.2% per year, P<0.0001), with a 
nonsignificant increase in intracranial hemorrhage but 
reductions in total stroke (2.08% versus 2.54% per year, 
P=0.002) and coronary events (4.3% versus 5.3% per 
year, P<0.0001). Among the 16 secondary prevention 
trials, only 6 included post-MI patients (overall 10 859 
patients), whereas the other 10 trials enrolled post–tran-
sient ischemic attack (TIA)/stroke patients. Convincing 
results notwithstanding, these findings must be inter-
preted within the context of several important limitations 
that might limit generalizability to contemporary clinical 
practice. First and perhaps most relevant, most studies 
were conducted several decades ago and do not reflect 
the modern-day clinical settings, therapeutics, and event 
rates (Tables 1 and 2).31 Second, most included young 
and predominantly male patients. Third, the ASA regi-
mens used in most of these studies differ significantly 
from current clinical norms in terms of dosing frequency 
and amount. As a result, it is unclear whether the ben-
efits associated with ASA use in these studies would be 
replicated in the contemporary era.
Further evidence supporting the preventive role of 
aspirin was yielded by a meta-analysis exploring the haz-
ards inherent to aspirin withdrawal or noncompliance in 
subjects at risk for, or with established, CAD.32 Overall, 
the nonadherence or withdrawal of aspirin was associ-
ated with a 3-fold increased risk of MACE. However, 
reasons for aspirin discontinuation were not accounted 
for in this aggregate data analysis, which may explain 
the higher ischemic hazards at least as much as aspirin 
withdrawal.
Resistance and Hypersensitivity
Treatment with aspirin confers a long-lasting functional 
defect in platelets, which is detectable with laboratory 
tests for platelet reactivity26,33 and also prolongs the 
bleeding time. The effect of ASA on platelet COX-1 has 
also been characterized through measurements of se-
rum TXB2 and urinary metabolites of TXB2.33–35 Given 
that the maximal biosynthetic capacity of human plate-
lets is several thousand times as high as the basal rate 
of TXA2 biosynthesis in healthy subjects, the relationship 
between the inhibition of platelet COX-1 activity and TXA2 
biosynthesis in vivo is nonlinear. The inhibition of plate-
let COX-1 has functional relevance when a reduction by 
at least 95% in the maximal capacity to generate TXA2 
is reached. However, it should be noted that, recently, 
the nonlinear relationship between COX-1 inhibition and 
platelet function has been questioned.36 In this study, a 
linear relationship was observed between aggregation 
and TXA2 production for all combinations of arachidonic 
acid or collagen and aspirin, and similar relationships 
were found in combinations of aspirin-treated and naïve 
platelets, and in blood from individuals taking an anti-
thrombotic dose of aspirin.36
The term aspirin resistance has been used to de-
scribe the inability of aspirin to produce a measurable 
response on ex vivo tests of platelet function, to inhibit 
TXA2 biosynthesis in vivo, or to protect individual pa-
tients from thrombotic complications. A large body of 
data has reported lower-than-expected inhibition of plate-
let function in a variable proportion of patients treated 
with aspirin.35,37 Some data showed that patients defined 
to have aspirin resistance were found to be at increased 
risk for recurrent cardiovascular events with greater 
clinically relevant long-term morbidity and mortality.38,39
The interpatient variability in aspirin response (aspi-
rin resistance) has been mainly attributed to the variable 
turnover rate of its target receptor (platelet COX-1). Re-
markably, the dosage of TXB2 serum levels at different 
time points was used to identify patients with a faster 
recovery of COX-1 activity and consequently character-
ized by aspirin resistance.40 In this study, some factors 
were associated with resistance: younger age, higher 
mean platelet volume and body mass index in diabetic 
patients, whereas only higher body mass index was a 
predictor in patients without diabetes mellitus. A twice-
daily regimen of low-dose aspirin was originally proposed 
for patients with high platelet turnover rates,41 this has 
also been shown to rescue the limited duration of the 
antiplatelet effect in patients with aspirin resistance.40,42
Although several studies have been published on 
the topic of aspirin resistance, its definition, diagnosis, 
causes, and clinical consequences remain controver-
sial.43 The term resistance should be used when the 
drug is unable to bind to its pharmacological target, 
either because of the inability to reach it (as a conse-
quence of reduced bioavailability, in vivo inactivation, 
or negative interaction with other substances) or altera-
tions of the target.43 Accordingly, it is inappropriate to 
consider all patients experiencing atherothrombotic 
events while on aspirin treatment to be resistant. This 
phenomenon has been called clinical resistance, but 
it should be more properly named treatment failure.43 
Given that arterial thrombosis is multifactorial, an arte-
rial thrombotic event in a patient may reflect treatment 
failure rather than resistance.44 Additionally, the finding 
of high residual platelet reactivity in vitro in patients on 
aspirin treatment has often been confused with aspirin 
resistance, but may not necessarily imply that these pa-
tients are resistant to treatment, particularly if platelet 
function is measured through laboratory tests that are 
not specific for the effect of aspirin on its pharmaco-
logical target. Doubtless, unspecific tests are useful to 
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Table 1. Secondary Prevention Trials of Aspirin Versus Control in Patients With Previous Myocardial Infarction
Trial Name
Starting 
Year
Publication 
Year
Aspirin Daily 
Dose, mg
No. of 
Patients
Study 
Duration Age
Male, 
%
Htn, 
%
Diabetes 
Mellitus, %
β-Blocker, 
%
Time From MI 
to Enrollment
Revascularization  
(PCI/CABG), %
Prior MI
 Cardiff I 1971 1974 300 1239 13 mo 55 100 NA NA NA 10 wk 0
 Cardiff II NA 1979 900 1725 12 mo 56 85 NA 0.5 NA 95% <7days 0
 PARIS I* 1975 1980 972 1216 41 mo 56 87 NA 10 15.4 8 wk to 60 mo 0
 AMIS 1975 1980 1000 4524 38 mo 55 89 NA 11 12 8 wk to 60 mo 0
 CDP-A† 1972 1976 972 1529 22 mo 56 100 NA 14 NA 75% >60 mo 0
 GAMIS‡ 1970 1980 1500 626* 24 mo 59 78 19 20 NA 30–42 days 0
 Micristin NA 1979 1500 1340 24 mo NA NA NA NA NA NA NA
Acute MI
 ISIS-pilot§ 1983 1987 162.5 619 1 mo 60 80 22 5 40 <24 h 0
 ISIS-2‖ 1985 1988 162.5 17187 35 days NA NA NA NA NA <24 h 0
 Dutch-aspirin NA 1990 100 100 3 62.5 74 NA NA 32 <12 h Rare, none within 1 wk
 Huddinge
NA 1988
167 (500 every 
3 days)
20
1 mo  
(12 mo)
63 80 NA NA 20 <24 h 10
 Frankfurt NA 1976 1320 39 14 days NA NA NA NA NA NA NA
 APRICOT¶ NA 1993 325 192 3 mo 57 81 NA NA 43 48 h 10.4
Unstable angina
 VA-pilot 1974 1986 324 50 3 mo NA 100 NA NA NA NA NA
 VA-main 1974 1983 324 1266 3 mo 56 100 41 17 74 48 h 3.5
 RISC 1985 1990 75 796 12 mo 58 100 30 8 88 72 h 3.9
 ALDUSA-pilot# NA 1987 324–340 84 12 mo NA NA NA NA NA NA NA
 Thèroux** 1986 1988 650 479
6 days (3 
mo)
58 71 38 13 96 <24 h 48
 ATACS-pilot†† 1987 1990 325–380 93 3 mo 62 60 49 37 39 <48 h 50
Coronary angioplasty
 Perth‡‡ 1986 1991 100 212 6 mo 55 84 34 4 58 – 100% PCI for stable CAD
 M-HEART II‖‖ NA 1995 325 503 6 mo 58 83 50 18 NA – 100% PCI for stable CAD
Stable CAD
 SAPAT¶¶ 1985 1992 75 2035 50 67 52 41 7 100 – 3.9
  VA bypass  
IV-B##
1983 1989 325 502 24 58 100 46 NA NA –
100% enrolled after 
CABG
ALDUSA-pilot indicates Aspirin at Low Dose in Unstable Angina; AMIS, Aspirin Myocardial Infarction Study; APRICOT, Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis; 
ASA, aspirin; ATACS-pilot, Antithrombotic Therapy in Acute Coronary Syndromes; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CDP-A, Coronary Drug Project-Aspirin; GAMIS, 
German-Austrian Myocardial InfarctionStudy; Htn, hypertension; ISIS, International Studies of Infarct Survival; M-HEART II, Multi-Hospital Eastern Atlantic Restenosis Trialists II; MI, myocardial infarction; 
NA, not available; PARIS I, Persantine-Aspirin Reinfarction Study I; PCI, percutaneous coronary intervention; RISC, Research Group on Instability in Coronary Artery Disease; SAPAT, Swedish Angina 
Pectoris Aspirin Trial; and VA, Veterans Administration.
*PARIS I included 3 groups (ASA+dipyridamole=810; ASA=810; placebo=406).
†Patients enrolled were all those previously enrolled in the CDP study that included 3 groups (dextrothyroxine, estrogen 5 mg/d and estrogen 2.5 mg/d)
‡GAMIS included 3 groups (ASA=317, placebo=309, phenprocoumon=320).
§ISIS-pilot: patients with suspected acute MI were randomly assigned to receive either a high-dose short-term intravenous infusion of streptokinase or placebo. Using a 2×2×2 factorial design, 
patients were also randomly assigned to receive either oral ASA (325 mg on alternate days for 28 days) or placebo, and separately randomly assigned to receive either intravenous heparin (1000 IU h–1 
for 48 h) or no heparin.
‖Patients up to 24 h after the onset of suspected acute MI were randomly assigned to 4 groups: 1-hour intravenous infusion of streptokinase; 1 month of 162.5 mg/d enteric-coated ASA; both 
active treatments or neither.
¶Patients treated with intravenous thrombolytic therapy followed by intravenous heparin were eligible when a patent infarct-related artery was demonstrated at angiography <48 h. Patients were 
randomly assigned to either 325 mg ASA daily (n=102) or placebo (n=90) with discontinuation of heparin or to Coumadin (n=92).
#ALDUSA-pilot: In the 40-mg arm, patients were to receive ASA 120 mg on day 1 and 40 mg daily thereafter.
**Patients were randomly assigned to 4 groups: ASA (n=121), heparin (n=118), ASA+heparin (n=122) or placebo (n=118).
††Patients were randomly assigned to receive ASA (325 mg daily; n=32), or full-dose heparin followed by warfarin (n=24), or the combination of ASA (80 mg/d) plus heparin and then warfarin (n=37).
‡‡After angioplasty of a previously untreated native coronary artery and after 2 wk of ASA therapy, 216 subjects (aged <70 y without acute MI) were randomly assigned to treatment with soluble 
ASA (n=108), 100 mg/d, or placebo (n=104) to study the effect on restenosis.
‖‖Patients were randomly assigned to ASA (325 mg daily; n=248), sulotroban (800 mg 4 times a day; n=249), or placebo (n=255), started within 6 h before PTCA and continued for 6 mo.
¶¶Patients with symptoms of chronic stable angina pectoris treated with increasing doses of sotalol were randomly assigned to ASA 75 mg daily (n=1009) or placebo (1026).
##The study determined how to improve saphenous vein graft patency after coronary artery bypass grafting by comparing ASA (325 mg once daily; n=104), ASA (325 mg 3 times daily; n=96), 
ASA+dipyridamole (325 mg and 75 mg, respectively, 3 times daily; n=99), sulfinpyrazone (267 mg 3 times daily; n=96), and placebo (3 times daily; n=107).
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Table 2. Individual Results of Trials of Aspirin Versus Control
Trial Name 
Treatment 
Regimen 
Patients
Nonfatal 
MI 
Nonfatal 
Stroke
Vasc 
Deaths Vasc Events
Nonvasc 
Deaths Major Bleeds
APT Ctrl APT Ctrl APT Ctrl APT Ctrl APT Ctrl APT Ctrl APT Ctrl
Prior MI
 Cardiff-I A300 615 624 10 15 – – 47 61 57 76 2 4 – (0) – (0)
 Cardiff-II A900 847 878 31 65 0 0 98 122 129 187 5 5 – (0) – (0)
 PARIS-I A972 + D225 1620 406 105 34 15 3 147 45 265 82 26 7 – (0) – (0)
 AMIS A1000 2267 2257 140 173 29 49 214 199 379 411 32 20 – (0) – (0)
 CDP-A A972 758 771 27 32 7 9 43 61 76 102 2 4 – (0) – (0)
 GAMIS A1500 317 309 11 15 0 0 22 30 33 45 5 2 – (0) – (0)
 Micristin A1500 672 668 22 35 9 15 34 56 65 106 15 15 2 (1) 2 (1)
Acute MI
 ISIS-pilot A325 (SK), A325, 
A325 (H), A325 
(H + SK)
313 306 7 9 1 2 25 35 33 46 0 0 1 (0) 1 (0)
 ISIS-2 A162.5 (SK), 
A162.5
8587 8600 74 161 29 52 815 1026 915 1236 2 7 24 (2) 18 (3)
 Dutch-aspirin A100 (H) 50 50 2 6 1 0 9 12 12 18 0 0 0 (0) 0 (0)
 Huddinge A167 10 10 0 0 0 0 0 0 0 0 0 1 0 (0) 0 (0)
 Frankfurt A1320 + D300, 
A1320
25 14 0 0 0 0 1 1 1 1 0 0 0 (0) 0 (0)
 APRICOT A325 (H + FIB) 107 95 3 10 0 0 1 2 4 12 0 0 – (–) – (–)
Unstable angina
 VA-pilot A324 26 24 0 1 0 0 1 3 1 4 0 0 0 (0) 0 (0)
 VA-main A324 661 677 27 49 3 2 15 24 45 75 0 0 0 (0) 0 (0)
 RISC A75 474 471 36 69 0 0 9 16 45 85 2 2 0 (0) 0 (0)
 ALDUSA-pilot A325, A40 56 28 5 0 1 0 1 1 7 1 0 0 – (0) – (0)
 Théroux A650, A650 (H) 243 236 6 12 0 0 0 2 6 14 0 0 4 (0) 2 (0)
 ATACS-pilot A80 (H + W) 37 24 0 3 – – 0 1 0 4 0 0 1 (0) 0 (0)
Coronary angioplasty
 Perth A100 124 128 0 2 – – – – 0 2 – – – (–) – (–)
 M-HEART II A325, ST 497 255 5 10 – – 1 1 6 11 – – – (–) – (–)
Stable CAD
 SAPAT A75 1009 1026 40 61 21 27 53 71 111 159 29 35 18 (9) 11 (5)
  VA bypass 
IV-B
A325 161 173 3 3 – – 3 4 6 7 0 0 – (–) – (–)
The number of patients per group or the total number of patients could not correspond to Table 1 because ATT had access to individual patient 
data for many of the trials. Numbers of nonfatal major (extracranial) bleeds are shown first, with fatal bleeds in parentheses. Nonfatal stroke includes 
ischemic and hemorrhagic strokes, together with strokes of unknown etiology. Vascular deaths includes deaths that were known to have a vascular 
cause, and deaths of unknown cause. A indicates aspirin; ALDUSA-pilot, Aspirin at Low Dose in Unstable Angina; AMIS, Aspirin Myocardial Infarction 
Study; APRICOT, Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis; APT, antiplatelet; ATACS-pilot, Antithrombotic Therapy in 
Acute Coronary Syndromes; CAD, coronary artery disease; CDP-A, Coronary Drug Project-Aspirin; Ctrl, control; D, dipyridamole; FIB, fibrinolytic therapy; 
GAMIS, German-Austrian Myocardial Infarction Study; H, heparin; ISIS, International Studies of Infarct Survival; M-HEART II, Multi-Hospital Eastern Atlantic 
Restenosis Trialists II; MI, myocardial infarction; Nonvasc, nonvascular; PARIS-I, Persantine-Aspirin Reinfarction Study I; RISC, Research Group on Instability 
in Coronary Artery Disease; SAPAT, Swedish Angina Pectoris Aspirin Trial; SK, streptokinase; ST, sulotroban; W, warfarin; VA, Veterans Administration; Vasc, 
vascular; and –, data unavailable. 
Adapted from Antithrombotic Trialists’ Collaboration30 with permission of the publisher. Copyright © 2002, BMJ Publishing Group Limited.
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identify patients with high residual platelet reactivity, but 
only specific tests measuring the pharmacological ef-
fect of aspirin can clarify whether platelet hyperreactiv-
ity is attributable to insufficient pharmacological effect 
of aspirin or to other causes. Consequently, resistance 
to aspirin should be limited to situations in which aspirin 
is unable to inhibit COX-1–dependent TXA2 production 
(and thus, TXA2-dependent platelet functions). Mea-
suring the capacity of platelets to directly synthesize 
TXA2 has been recommended to monitor the effect of 
aspirin.45 The measurement of serum TXB2 to assess 
aspirin response showed that the prevalence of poor 
responders is extremely low.45 Confounding problems 
may contribute to inappropriate use of the term resis-
tance. The most frequent and plausible cause of insuf-
ficient inhibition of COX-1 by aspirin is probably poor 
patient compliance to therapy. Furthermore, genetic 
considerations, increased platelet turnover in some dis-
eases (with a more rapid recovery of COX-1–dependent 
platelet function) and interference with the aspirin mech-
anism (ie, competition of aspirin with other nonsteroidal 
anti-inflammatory drugs, such as ibuprofen, can prevent 
aspirin irreversible acetylation and inactivation of the 
COX-1) could also account for interindividual variability 
of response to aspirin.45
Currently, aspirin resistance is not evaluated in rou-
tine clinical practice and efforts to enhance susceptibility 
to ASA, for instance, by increasing the aspirin daily regi-
men, should not be pursued given the lack of outcome 
data in this specific population.30,31
Aspirin may also be associated with hypersensitivity 
or intolerance, challenging secondary prevention.46–49 
Hypersensitivity refers to a history of respiratory, cuta-
neous, or systemic reactions, whereas the term intoler-
ance refers to a history of severe indigestion incurred by 
low-dose aspirin.47 Aspirin intolerance may be frequent, 
varying from 6% to 20%, whereas true hypersensitivity is 
rare at 0.6% to 2.4% of the general population.47 These 
patients may be managed via desensitization protocols, 
which have been shown to be effective, but remain unde-
rused.47–49 However, potentially fatal systemic reactions 
are rare and the number of patients with a true contra-
indication to low-dose aspirin is rather low.47 In a study 
of patients with CAD undergoing cardiac catheterization 
and coronary stent implantation, Rossini et al50 found 
that 2.6% reported histories of aspirin sensitivity charac-
terized by respiratory or cutaneous manifestations (no 
anaphylactic reactions). The authors tested a novel rapid 
desensitization procedure (6 sequential doses of aspirin 
[1, 5, 10, 20, 40, and 100 mg] over 5.5 hours without 
corticosteroids or antihistamines) before cardiac cath-
eterization (ST-segment–elevation MI patients underwent 
desensitization before hospital discharge) and found 
that this was safe and effective (success in 89%, during 
1-year follow-up aspirin was tolerated well, without devel-
oping allergic reactions).50
Dosage
It is known that aspirin inhibition of platelet TXA2 is cu-
mulative on repeated daily dosing and saturable at low 
doses (daily administration of ASA 30 mg determines a 
virtually complete suppression of platelet TXA2 after 1 
week) in healthy individuals because of its irreversible 
nature, but some clinical conditions (diabetes mellitus, 
metabolic syndrome, CABG, etc) are associated with 
suboptimal antiplatelet inhibition by aspirin.26 Thus, typi-
cal regimens of 75 to 100 mg daily clearly exceed the 
minimal effective dose required for a full pharmacody-
namic effect, but accommodate some degree of interin-
dividual variability.26
It has been suggested that aspirin doses <75 mg 
daily may be more effective than higher doses because 
they spare prostacyclin (an antiplatelet and vasodilator) 
and cause less gastrointestinal toxicity. In the Antithrom-
botic Trialists’ meta-analysis, no significant differences in 
outcomes were observed when ASA ≥75 mg was com-
pared with ASA <75 mg among 3570 patients in 3 tri-
als.31 However, aspirin doses of <75 mg have been less 
widely assessed than doses of 75 to 150 mg daily, and 
uncertainty remains as to whether such low doses are as 
effective as daily doses of ≥75 mg. Among trials evaluat-
ing higher daily doses of ASA versus no-ASA, the relative 
reduction in vascular events was 19% with doses of 500 
to 1500 mg daily, 26% with doses of 160 to 325 mg 
daily, and 32% with doses of 75 to 150 mg daily, where-
as daily doses <75 mg seemed to have a somewhat 
smaller effect (proportional reduction 13%).31 In trials 
comparing ASA with control, the proportional increase in 
the risk of a major extracranial bleed was similar with all 
daily aspirin doses <325 mg (odds ratios 1.7 [95% con-
fidence interval [CI] 0.8–3.3] for <75 mg; 1.5 [1.0–2.3] 
for 75–150 mg; and 1.4 [1.0–2.0] for 160–325 mg). 
Two trials that compared 75 with 325 mg aspirin daily 
with <75 mg daily also found no significant difference in 
major extracranial bleeds (2.5% with 75–325 mg versus 
1.8% with <75 mg; P=nonsignificant).
A systematic review of clinical trials in 2007 suggest-
ed that available clinical data did not support the routine, 
long-term use of aspirin dosages >75 to 81 mg daily 
in the setting of cardiovascular disease prevention and 
that higher dosages, which were commonly prescribed, 
were not more effective at preventing events, but rather 
were associated with increased risks of gastrointestinal 
bleeding.51 A subanalysis of the CURE trial (Clopidogrel 
in Unstable Angina to Prevent Recurrent Events) strati-
fied patients based on ASA dosage (≤100, 101–199, 
and ≥200) demonstrating that the higher ASA doses did 
not reduce ischemic events but significantly increased 
the risk of major or life-threatening bleeding.52 The CUR-
RENT-OASIS 7 trial (Double-Dose Versus Standard-Dose 
Clopidogrel And High-Dose Versus Low-Dose Aspirin in 
Individuals Undergoing PCI for ACS) confirmed no sig-
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nificant differences in MACE between patients with ACS 
randomly assigned to high-dose (300–325 mg) versus 
low-dose (75–100 mg) ASA.53 Although overall bleed-
ing complications were nonsignificantly different, there 
was a higher incidence of gastrointestinal bleeding with 
high-dose ASA.53 Interestingly, in the PLATO trial (Plate-
let Inhibition and Patient Outcomes), variation in ASA 
dose emerged as a possible explanation for observed 
regional differences (lower effect of ticagrelor in North 
America than in the rest of the world) and the lowest risk 
of cardiovascular death, MI, or stroke with ticagrelor in 
comparison with clopidogrel was associated with a low 
maintenance dose of concomitant aspirin.54 Importantly, 
high-dose ASA also reduced the benefits of ticagrelor 
outside the United States.54 On the contrary, an analysis 
from the TRITON–TIMI 38 (Trial to Assess Improvement 
in Therapeutic Outcomes by Optimizing Platelet Inhibi-
tion With Prasugrel–Thrombolysis in Myocardial Infarc-
tion 38) showed that, although North American patients 
received high-dose ASA more frequently than in other 
countries, the bleeding and ischemic events of prasugrel 
in comparison with those of clopidogrel were direction-
ally consistent regardless of ASA dose.55
More recent data from US clinical practice still re-
flects uncertainty regarding the optimal aspirin dose for 
secondary prevention.56 Indeed, despite previous data 
supporting lower doses of ASA, an analysis from 2014 
showed that ≈60% of US patients with heart disease 
were discharged with 325-mg aspirin doses, whereas 
most of the remainder received lower doses (81 mg dai-
ly in 36%). Even among patients who experienced major 
in-hospital bleeding, 57% received the 325-mg dose. Fur-
thermore, high-dose ASA was also commonly adopted in 
patients treated without revascularization (45%), in those 
treated with CABG (48%), or in those prescribed triple 
therapy (44%).56 Similarly, the recent analysis from the 
Treatment with ADP Receptor Inhibitors: Longitudinal As-
sessment of Treatment Patterns and Events after Acute 
Coronary Syndrome study (TRANSLATE-ACS) showed 
that among 10 213 patients with MI who underwent PCI, 
63% were discharged on ASA 325 mg and 37% with ASA 
81 mg daily.57 The adjusted risk of MACE was nonsignifi-
cantly different between the 2 regimens, but high-dose 
ASA was associated with greater risk of any Bleeding Ac-
ademic Research Consortium–defined bleeding, driven 
mostly by minor Bleeding Academic Research Consor-
tium type 1 or 2 events not requiring hospitalization.57
Recently, American guidelines have incorporated the 
low-dose ASA recommendation stating that a daily aspi-
rin dose of 81 mg (range 75–100 mg) is recommended 
in patients treated with DAPT.6 However, the ADAPTABLE 
trial (Aspirin Dosing: A Patient-Centric Trial Assessing 
Benefits and Long-term Effectiveness; NCT02697916) 
is expected to offer additional information on optimal 
ASA dosages. This study is funded by a Patient-Centered 
Outcomes Research Institute Award and will be conduct-
ed through PCORnet (National Patient-Centered Clinical 
Research Network).58 The primary composite outcome 
(death, hospitalization for nonfatal MI, or stroke) and a 
primary safety end point of major bleeding complica-
tions were chosen with input from patients. The trial 
will compare a daily dose of ASA 81 versus 325 mg in 
20 000 high-risk patients with atherosclerotic heart dis-
ease (defined as MI, or catheter ≥75% stenosis of ≥1 
epicardial vessel, or PCI/CABG) and at least one of the 
following: age >65 years, creatinine 1.5 mg/dL, diabe-
tes mellitus, 3-vessel disease, cerebrovascular disease 
or peripheral arterial disease, ejection fraction <50% (by 
echocardiogram, catheter or nuclear imaging), or cur-
rent smoking. Patients will be excluded if they are <18 
years of age, have a documented ASA allergy or contra-
indication (including pregnancy or nursing), a significant 
gastrointestinal bleed within the past 12 months, a sig-
nificant bleeding disorder, need warfarin or non-Vitamin 
K oral anticoagulants or ticagrelor. Enrollment is planned 
to occur over 24 months, and the maximum follow-up 
will be 30 months.
Dual-Antiplatelet Therapy
The activation of platelets by a primary agonist, such as 
exposed collagen or thrombin at a site of vessel injury or 
plaque rupture, triggers platelet production of TXA2 and 
the release of ADP from platelet-dense granules, as well. 
TXA2 and ADP then act as autocrine and paracrine ago-
nists via activation of platelet thromboxane-prostanoid 
and ADP (P2Y1 and P2Y12) receptors, respectively. By 
targeting both COX-1 and P2Y12 pathways of platelet ac-
tivation, aspirin and P2Y12 inhibitors yield an additive or 
even synergistic effect when used in concert.59
Twenty years ago, the ISAR study (Intracoronary 
Stenting and Antithrombotic Regimen) first demonstrat-
ed that DAPT was superior to anticoagulant therapy in 
patients undergoing to PCI.60,61 Subsequently, the CURE 
trial showed the benefits of adding clopidogrel to ASA 
monotherapy in ACS patients and also in those undergo-
ing PCI, although at the cost of increased bleeding.12,62 
Over the past 2 decades, the coadministration of P2Y12 
inhibitors with aspirin has been shown to further reduce 
the risk of acute thrombotic events in several clinical 
settings, albeit always at the price of greater bleed-
ing.2,8,12 As a result, equipoise and controversy persist 
surrounding the optimal duration of DAPT after PCI.63 
Multiple studies have consistently shown the feasibility 
of reducing DAPT duration to 6 (PRODIGY, EXCELLENT, 
SECURITY, ITALIC, ISAR-SAFE, I-LOVE-IT 2, IVUS-XPL, 
NIPPON) or even 3 months (OPTIMIZE, RESET), result-
ing in lower bleeding hazards without any incremental 
increase in ischemic events.64 Nevertheless, other trials 
investigated the value of prolonging DAPT beyond 12 
months (ARCTIC Interruption, DAPT, DES-LATE, OPTIDU-
AL), providing partially conflicting results as it relates to 
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the benefit to reduce nonfatal ischemic events including 
MI and very late ST at the expense of greater bleeding 
and potentially fatal outcomes. A meta-analysis of 10 thi-
enopyridine trials including 31 666 patients showed that 
shorter DAPT was associated with a lower risk of major 
bleeding, but a higher risk of MI and ST.63 Notably, this 
analysis also demonstrated that longer DAPT was as-
sociated with a significantly increased risk of all-cause 
mortality that was attributable to noncardiac mortality.63 
The caveat of this analysis, however, is that by pooling 
all available thienopyridine studies, a 12-month DAPT 
duration was included in both control and experimental 
groups, thereby failing to provide information on optimal 
DAPT duration. As an alternative approach, these 10 
thienopyridine trials have been stratified more recently 
based on DAPT duration in the control group, by keeping 
12 months as the control therapy and contrasting it to 
either a shortened (ie, 6 or 3 months) or a prolonged (ie, 
≥18 months) DAPT regimen.19 This analysis showed that 
DAPT discontinuation before 12 months after PCI with 
drug-eluting stent (DES) yielded fewer bleeding events 
without an apparent increase of ischemic complications. 
DAPT continuation beyond 12 months reduced ischemic 
and thrombotic events at the expense of more frequent 
major bleeding and all-cause mortality. Hence, it has been 
suggested that the currently recommended 12-month 
DAPT duration after DES implantation is a compromise 
between ischemic and bleeding risk of uncertain value, 
and it highlights the challenge of identifying a uniformly 
ideal DAPT duration across patient ischemic and bleed-
ing risk profiles in practice.
Although it has been suggested that early-generation 
DES, in comparison with new-generation DES, may am-
plify the need for prolonged DAPT,65 an emerging new 
paradigm is that the benefit of prolonged DAPT may 
largely be stent independent. DAPT consisting of aspirin 
and clopidogrel beyond 12 months has been shown to 
reduce the risk of MI not related to stented segments.18 
The benefits and risks of aspirin and ticagrelor at dos-
es of 60 mg twice daily and 90 mg twice daily beyond 
1-year treatment was investigated in patients with estab-
lished CAD, revealing a reduced risk of ischemic events, 
including myocardial infarction and stroke, again at the 
expense of increased bleeding risk. The paradigm shift 
(from stent to patient protection) supports the notion of 
extending DAPT beyond the vulnerability window intrinsic 
to and related to stents (subacute or late ST). Yet this 
benefit must be interpreted in the context of the continu-
ous increase in bleeding risk observed during the course 
of DAPT duration. Previous evidence that, in patients on 
DAPT bleeding, may decrease over time (ie, CHARISMA) 
has been challenged by recent studies (DAPT, PRODI-
GY, PEGASUS [Prevention of Cardiovascular Events in 
Patients With Prior Heart Attack Using Ticagrelor Com-
pared to Placebo on a Background of Aspirin]) suggest-
ing a linear relationship between DAPT duration and 
bleeding risk. Although a high risk of bleeding is some-
what expected soon after the initiation of DAPT, multiple 
long-term DAPT studies have clearly shown that this risk 
never abates over time, even after several years of treat-
ment. A recent subanalysis from PEGASUS explored the 
reasons for and timing of discontinuation of ticagrelor 
among stable patients with prior MI and found that bleed-
ing was the main cause of discontinuation. The rate of 
treatment discontinuation because of bleeding was 3.5% 
in the ticagrelor 60 mg arm and 5% in the ticagrelor 90 
mg arm (in comparison with <1% in the placebo group) 
and it increased to ≈5% and 6.5%, respectively, at an 
average 3-year follow-up (in comparison with ≈1.2% in 
the placebo group).66
In a pooled analysis of trials comparing short versus 
prolonged DAPT durations, bleeding was potentially 
more causally associated with all-cause mortality than 
ST, which highlights the need to minimize the risks of 
bleeding to optimize the fatality rate.67 This appears 
consistent with the results of a large survey capturing 
DAPT prescription practices, where attempts to individu-
alize DAPT duration based on conventional ischemic and 
bleeding risk factors emerged as the most common pre-
scription pattern.68
It remains unclear whether the type of DAPT (ie, the 
type of P2Y12 inhibitor paired with aspirin) affects the 
comparative effectiveness/safety profile of a shortened 
versus a prolonged DAPT duration.
The PEGASUS study randomly assigned 21 162 pa-
tients with an MI 1 to 3 years earlier to ticagrelor 90 mg 
twice daily, ticagrelor 60 mg twice daily, or placebo.17 
All patients received low-dose aspirin and were followed 
for a median of 33 months. In comparison with placebo, 
both ticagrelor doses reduced the rate of the primary ef-
ficacy end point, with cumulative event rates at 3 years 
of 7.85% in the 90 mg twice daily group, 7.77% in the 60 
mg twice daily group, and 9.04% in the placebo group 
(hazard ratio [HR] for 90 mg of ticagrelor versus placebo, 
0.85; 95% CI, 0.75–0.96; P=0.008; HR for 60 mg of 
ticagrelor versus placebo, 0.84; 95% CI, 0.74–0.95; 
P=0.004). Both ticagrelor doses significantly reduced 
rates of MI, whereas the 60 mg twice daily ticagrelor regi-
men also reduced the risk of stroke and trended toward a 
reduction in cardiovascular mortality. When pooling both 
doses, there was no signal of harm related to all-cause 
mortality, which is at variance with the previously dis-
cussed results of the pooled analysis using clopidogrel 
for DAPT.69 Whether the observed heterogeneity with re-
spect to overall mortality after prolonged DAPT reflects 
the characteristics of the P2Y12 inhibitor used in the DAPT 
regimen (ie, a thienopyridine versus a nonthienopyridine 
agent) or rather different patient selections across stud-
ies (ie, a uniform post-MI population in PEGASUS versus a 
mix of stable and unstable CAD patients undergoing stent 
implantation in other thienopyridine trials) is unclear and 
warrants subsequent investigation.69–72
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SINGLE-ANTIPLATELET P2Y12 INHIBITOR 
THERAPY AFTER PCI
Rationale 
Under the assumption that aspirin is the default antiplate-
let therapy, all the studies in the past decades investi-
gating, among others, P2Y12 antagonists or oral antico-
agulants, both in patients with or without an established 
indication to systemic anticoagulation, have been con-
ducted as add-on therapy in the context of background 
aspirin treatment. A prolonged DAPT, despite being ef-
ficacious in mitigating the risks of MI and ST, may dis-
proportionally increase bleeding liability, leading to unfa-
vorable effects on noncardiovascular and total mortality. 
Although the addition of rivaroxaban to a DAPT regimen 
consisting of aspirin and clopidogrel was effective in 
reducing a composite ischemic end point, including a 
significant reduction in cardiovascular mortality, relevant 
increases in overall, life-threatening, and intracranial 
bleeding were also observed.
These findings may reflect the ceiling effect associ-
ated with further intensification of antithrombotic drugs 
wherein additional exposure increases bleeding toxicity 
without any reduction in thrombosis. Consequently, the 
less-is-more concept has been proposed in an effort to 
mitigate bleeding potential while preserving antithrom-
botic efficacy achieved through the concomitant inhi-
bition of multiple platelet activation pathways, thereby 
optimizing net clinical benefit. Recently, a stand-alone 
P2Y12 inhibition strategy has been proposed to replace 
long-term DAPT regimens for long-term secondary pre-
vention. Interestingly, Rollini et al73 compared the anti-
platelet effect of aspirin monotherapy and clopidogrel 
monotherapy in patients with atherosclerotic disease 
in a prospective pharmacodynamics study and showed 
that clopidogrel was associated with increased platelet 
inhibition in heavy smokers.
Although the results of large randomized studies are 
awaited to validate this potentially new treatment mo-
dality, 3 large-scale studies testing different anticoagu-
lants in ACS patients have shown that bleeding preven-
tion may be causally linked to mortality benefit, despite 
slightly higher risks of ST or catheter thrombosis.74–76 
The net clinical effect of adding aspirin in patients re-
ceiving newer more potent P2Y12 antagonists is unknown 
and aspirin may increase bleeding while not further miti-
gating the ischemic risk. This may be particularly true in 
patients treated with newer P2Y12 antagonists,11 which 
unlike ticlopidine77 or clopidogrel,78,79 exert a predictable 
inhibition of the target receptor.
Biochemical Considerations
Several lines of evidence suggest that P2Y12 antago-
nists might also affect TXA2 platelet production, thereby 
minimizing any additional antiplatelet effect realized with 
aspirin use.80–85 Experiments with platelet-rich plasma 
from healthy volunteers have shown that prasugrel ac-
tive metabolites inhibit platelet release of both TXA2 
and ATP+ADP, and the addition of aspirin to prasugrel 
failed to provide any additional inhibition of platelet ag-
gregation.82 However, the study had some limitations, 
particularly in how the effect of aspirin was assessed. 
These findings are related to the strong P2Y12 inhi-
bition, so they also can be extended to ticagrelor. In-
deed, in a recent pharmacodynamics study in diabetic 
patients, both prasugrel and ticagrelor were associ-
ated with inhibitory effects on measures of non–ADP-
induced platelet reactivity (ie, thromboxane-, collagen-, 
and thrombin-induced).86 Nevertheless, it remains to be 
proven whether these in vitro and ex vivo observations 
will translate into clinical implications. However, the over-
all effect of adding aspirin (particularly at daily doses 
>100 mg) to new P2Y12 antagonists could be deleteri-
ous because of its inhibition of protective prostanoids in 
other cells and tissues, including vascular endothelium, 
stomach, and kidney.80 High-dose aspirin does not pro-
vide greater treatment efficacy but increases bleeding 
risks in comparison with a low-dose aspirin regimen.54,87 
In the PLATO trial, geographical differences in clinical 
outcomes were observed, namely, an apparent lack of 
superior treatment effect of ticagrelor over clopidogrel 
in the study cohort recruited in the United States.15,54 
Of the 37 baseline and postrandomization factors ex-
plored, aspirin maintenance dose was found to be the 
most important covariate explaining at least in part 
these regional differences.54 In particular, the lowest risk 
of cardiovascular death, MI, or stroke with ticagrelor in 
comparison with clopidogrel, was associated with a low 
maintenance dose of concomitant aspirin, whereas the 
higher maintenance dose of aspirin used in the United 
States in comparison with other regions (≥300 mg/d in 
53.6% versus 1.7% of patients, respectively) seemed to 
be responsible for these geographic differences. This 
study suggested that high-dose aspirin added to ticagre-
lor could be deleterious and could blunt ticagrelor bene-
fits, in the United States, and in the as non-United States, 
as well.54  Notably, 2 small studies showed that aspirin 
had no direct effect on ticagrelor pharmacokinetics or 
its platelet inhibition.88
Evidence contradicting the possible biochemical in-
teraction between P2Y12 and COX-1 inhibition has also 
been provided. Cattaneo et al89 assessed whether P2Y12 
antagonists have off-target/indirect inhibitory effects on 
platelet TXA2 production. They studied 3 patients with 
inherited deficiency of P2Y12 receptors and 33 healthy 
subjects, demonstrating that P2Y12 inhibition did not af-
fect the platelet capacity to synthesize TXA2: (1) serum 
TXB2 (TXA2 metabolite) levels were similar in P2Y12R-
deficient patients and healthy subjects and were not de-
creased by P2Y12 antagonists in vitro; (2) serum TXB2 
levels did not decrease in patients treated with prasugrel 
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(10 mg) or placebo for 14 days; (3) ASA inhibited TXB2 
production more effectively than a P2Y12 antagonist, and 
only the combination of ASA plus P2Y12 antagonist inhib-
ited platelet aggregation induced by high concentrations 
of collagen.
Clinical guidelines supporting the prophylactic use of 
aspirin for purposes of secondary prevention acknowl-
edge the cardiovascular benefits, weighed against the 
potential risks of bleeding.
However, it should be mentioned that new aspirin 
formulations have a better pharmacokinetic/pharmaco-
dynamic profile and gastrointestinal tolerability that may 
open new avenues for aspirin in the future.
Furthermore, there is also relevant evidence sup-
porting other benefits related to low-dose aspirin use, 
including chemoprevention and reduced risk of demen-
tia, and these effects would be lost in case of long-
term treatment with new P2Y12 antagonists instead 
of aspirin.90–93 It has been suggested that low-dose 
aspirin is associated with decreased incidence and 
mortality for colorectal cancer, potentially because 
of its interference with neoplastic transformation of a 
normal intestinal epithelium (mainly in the colorectal re-
gion) toward a sporadic adenoma and its progression 
to cancer.90–92 It has also been speculated that even a 
10% reduction in overall cancer incidence starting in 
the first 10 years of treatment may favorably tip the 
balance of benefits and risks in average-risk popula-
tions.91 Preliminary evidence also suggests that low-
dose aspirin reduces cognitive decline in the elderly, 
possibly by reducing brain inflammation (inhibition of 
platelet-related inflammation and release of lipoxins).93 
Long-term studies comparing aspirin versus P2Y12 in-
hibitors alone would be required to confirm or disprove 
these potential aspirin-specific effects.
Clinical Evidence 
Initial experience supporting the use of P2Y12 inhibitors 
over aspirin was provided by the TASS (Ticlopidine As-
pirin Stroke Study) and the CAPRIE (Clopidogrel Versus 
Aspirin in Patients at Risk of Ischemic Events) trials.13,94 
Ticlopidine was more effective than aspirin in prevent-
ing strokes in a high-risk population with similar bleed-
ing risk.94 In the CAPRIE trial, long-term administration 
of clopidogrel among patients with atherosclerotic 
vascular disease was as safe as, but more effective 
than aspirin in reducing the combined risk of ischemic 
stroke, MI, or vascular death.13 The recent SOCRATES 
(Acute Stroke or TIA Treated with Aspirin or Ticagrelor 
and Patient Outcomes) was an international double-
blind controlled trial in 674 centers in 33 countries, 
in which 13 199 patients with a nonsevere ischemic 
stroke or high-risk TIA were randomly assigned within 
24 hours after symptom onset, in a 1:1 ratio, to re-
ceive either ticagrelor (180 mg loading dose on day 1 
followed by 90 mg twice daily for days 2–90) or aspirin 
(300 mg on day 1 followed by 100 mg daily for days 
2–90).95 The primary end point (stroke, MI, or death 
within 90 days) occurred in 442 of the 6589 patients 
(6.7%) treated with ticagrelor, versus 497 of the 6610 
patients (7.5%) treated with aspirin (HR, 0.89; 95% CI, 
0.78–1.01; P=0.07).95 Approximately 32% of patients 
were taking aspirin before randomization, and the pre-
specified subgroup analysis of the primary end point 
showed that these patients tended to derive greater 
benefit from ticagrelor (previous aspirin patients: HR, 
0.76; 95% CI, 0.61–0.95; no previous aspirin patients: 
HR, 0.96; 95% CI, 0.82–1.12), although the interaction 
P value was nonsignificant (interaction P=0.10). Inter-
estingly, major bleeding occurred in 0.5% of patients 
treated with ticagrelor and in 0.6% of patients treated 
with aspirin, intracranial hemorrhage in 0.2% and 0.3%, 
respectively, and fatal bleeding in 0.1% and 0.1%.95 
This study failed to conclusively show superiority of 
ticagrelor versus aspirin in poststroke/TIA patients; 
however, it adds to the growing evidence that a P2Y12 
inhibitor monotherapy strategy may result in greater 
protection from ischemic recurrences than aspirin, with 
a similar bleeding profile.
Further evidence supporting the use of P2Y12 inhibi-
tors without aspirin in patients with established athero-
sclerotic disease was provided in the context of the 
MATCH trial (Molecular Analysis for Therapy Choice).96 
In MATCH, 7599 high-risk patients with recent ischemic 
stroke or TIA and at least 1 additional vascular risk factor, 
who were already receiving clopidogrel 75 mg/d, were 
randomly assigned to aspirin 75 mg/d or placebo.96 This 
study showed that adding aspirin to clopidogrel did not 
decrease major vascular events but increased the risk of 
major and life-threatening, including intracranial, bleed-
ing complications.96 This supported the concept that 
adding ASA to clopidogrel was more dangerous than 
adding clopidogrel to ASA as was previously observed 
in the CURE trial.
Finally, evidence suggesting an improved safety 
profile of aspirin omission after PCI comes from the 
proof-of-concept WOEST study (What Is the Optimal Anti-
platelet and Anticoagulant Therapy in Patients With Oral 
Anticoagulation and Coronary Stenting) that compared 
the use of clopidogrel alone in patients on vitamin K an-
tagonist and showed fewer bleeding complications with-
out an apparent increase of thrombotic events, including 
a lower mortality risk in comparison with triple therapy.97 
It should be emphasized, however, that concomitant oral 
anticoagulant therapy largely increases bleeding risk, 
but it also mitigates thrombotic risks, including the re-
duction of ST incidence. Therefore, caution should be 
used in extrapolating the effect of aspirin removal in pa-
tients taking oral anticoagulants to those not in need of 
such therapy (ie, who have indication to DAPT only) after 
ACS or PCI.
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Table 3. Characteristics of Trials Assessing Anticoagulation Therapy in Patients With AF Undergoing PCI
 REDUAL-PCI PIONEER AF-PCI AUGUSTUS ENTRUST-AF-PCI
Title A Prospective 
Randomised, Open Label, 
Blinded End point (PROBE) 
Study to Evaluate DUAL 
Antithrombotic Therapy 
With Dabigatran Etexilate 
(110 mg and 150 mg 
BID) Plus Clopidogrel 
or Ticagrelor vs Triple 
Therapy Strategy With 
Warfarin (INR 2.0–3.0) 
Plus Clopidogrel or 
Ticagrelor and Aspirin in 
Patients With Non Valvular 
Atrial Fibrillation (NVAF) 
That Have Undergone a 
Percutaneous Coronary 
Intervention (PCI) With 
Stenting
An Open-label, Randomized, 
Controlled, Multicenter Study 
Exploring Two Treatment 
Strategies of Rivaroxaban and 
a Dose-Adjusted Oral Vitamin 
K Antagonist Treatment 
Strategy in Subjects With 
Atrial Fibrillation Who 
Undergo Percutaneous 
Coronary Intervention
An Open-label, 2×2 
Factorial, Randomized 
Controlled, Clinical Trial 
to Evaluate the Safety of 
Apixaban vs Vitamin K 
Antagonist and Aspirin vs 
Aspirin Placebo in Patients 
With Atrial Fibrillation and 
Acute Coronary Syndrome 
or Percutaneous Coronary 
Intervention
Evaluation of the Safety and Efficacy 
of an Edoxaban-based Compared 
to a Vitamin K Antagonist-based 
Antithrombotic Regimen in Subjects 
With Atrial Fibrillation Following 
Successful Percutaneous Coronary 
Intervention (PCI) With Stent 
Placement
ClinicalTrials.
gov identifier
NCT02164864 NCT01830543 NCT02415400 NCT02866175
Sponsor Boehringer Ingelheim Janssen Scientific Affairs, 
LLC
Bristol-Myers Squibb Daiichi Sankyo Inc.
Estimated 
enrollment
2502 2127 4600 1500
Study start 
date
July 2014 May 2013 June 2015 February 2017
Estimated 
completion 
date
March 2017 July 2016 September 2017 February 2019
Allocation Randomized Randomized Randomized Randomized
End point 
classification
Safety/efficacy study Safety study Safety study Safety/efficacy study
Intervention 
model
Parallel assignment Single-group assignment Factorial assignment Parallel assignment
Masking Open label Open label Open label Open label
Active 
comparator
Warfarin 5 or 3 or 1 
mg plus aspirin plus 
clopidogrel or ticagrelor
Dose-adjusted VKA once daily 
(target INR 2.0–3.0) plus 
low-dose aspirin, 75 to 100 
mg/d, and clopidogrel 75 mg 
once daily (or prasugrel 10 
mg once daily or ticagrelor 
90 mg twice daily) followed 
by dose-adjusted VKA once 
daily (target INR 2.0–3.0 or 
2.0–2.5 at the investigator 
discretion) plus low-dose 
aspirin for 12 mo
VKA orally once daily plus 
aspirin film-coated tablet 
orally once daily (81 mg or 
placebo)
VKA plus clopidogrel 75 mg  
once daily (or in the presence of a 
documented clinical need prasugrel [5 
mg or 10 mg once daily] or ticagrelor 
[90 mg twice daily] may be used).
(Continued )
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Experimental 
comparator
Dabigatran etexilate 110 
mg plus clopidogrel or 
ticagrelor
Dabigatran etexilate 150 
mg plus clopidogrel or 
ticagrelor
Rivaroxaban 2.5 mg twice 
daily plus low-dose aspirin 
75–100 mg once daily and 
clopidogrel 75 mg once daily 
(or prasugrel 10 mg once 
daily or ticagrelor 90 mg twice 
daily) followed by rivaroxaban 
15 mg (10 mg if moderate 
CKD) once daily plus low-dose 
aspirin for 12 mo
Rivaroxaban 15 mg (10 mg 
if moderate CKD) once daily 
plus clopidogrel 75 mg once 
daily (or prasugrel 10 mg 
once daily or ticagrelor 90 mg 
twice daily) for 12 mo
Apixaban 2.5 or 5 mg orally 
twice per day plus aspirin 
film coated tablet orally once 
daily (81 mg or placebo)
Edoxaban 60 mg once daily or 30 mg 
once daily in selected subjects
Primary 
outcome
First ISTH major or CRNM 
bleeding (up to 30 mo)
Clinically significant bleeding 
at 12 mo (composite of 
TIMI major bleeding, minor 
bleeding, and bleeding 
requiring medical attention)
Occurrence of ISTH major or 
CRNM bleeding during the 
time the patient is taking 
the medicine which is 6 
mo (between apixaban and 
VKA; between aspirin and 
no-aspirin)
Number of ISTH major or CRNM 
bleeding (≤12 mo)
Secondary 
outcome
At 30 mo: Undetermined 
cause of death; 
noncardiovascular death; 
cardiovascular death; 
all death; MI; stroke; ST; 
SE; death+MI+stroke; 
unplanned revascularization 
(PCI or CABG); death or 
first thrombotic event (all 
death, MI, stroke/SE); death 
or first thrombotic event or 
unplanned revascularization
Clinically significant bleeding 
and adverse cardiovascular 
events, and adverse events at 
10 d, 30 d, 3 mo, 6 mo, 9 mo, 
12 mo.
Composite of clinically 
significant bleeding and 
adverse cardiovascular 
events at the end of DAPT 
period (1 mo or 6 mo or 12 
mo) and at 12 mo
Superiority on major+CRNM 
bleeding between apixaban 
versus VKA at 6 mo
Composite of death and 
ischemic events (stroke, MI, 
ST, urgent revascularization) 
between apixaban versus 
VKA and between aspirin 
and no-aspirin at 6 mo
First rehospitalization for 
any cause between apixaban 
versus VKA and between 
aspirin and no-aspirin at 6 mo
At 12 mo: composite number of 
cardiovascular death, stroke, SE, MI, 
and ST events; composite number of 
cardiovascular death, stroke, SE, MI, 
ST events, and ISTH-defined bleeding 
events; Number of ISTH major 
bleeding
Inclusion 
criteria
1.  Male or female patients 
aged ≥18 y
2.  Patients with 
nonvalvular AF
3.  Patient presenting 
with: an ACS (STEMI, 
NSTEMI, or UA) that was 
successfully treated by 
PCI and stenting (either 
BMS or DES) or stable 
coronary artery disease 
with at least 1 lesion 
eligible for PCI that was 
successfully treated  
by elective PCI and 
stenting (either BMS or 
DES)
4.  The patient must be able 
to give informed consent
1.  History of paroxysmal, 
persistent, or permanent 
nonvalvular AF
2.  Have undergone PCI with 
stent placement for primary 
atherosclerotic disease
3.  INR of ≤2.5 to be 
randomized
4.  Women must be 
postmenopausal before 
entry or practicing a highly 
effective method of birth 
control when heterosexually 
active
5.  Be willing and able to 
adhere to the prohibitions 
and restrictions specified in 
the study protocol
1.  Adults with either active or 
a history of nonvalvular AF 
or flutter with the planned 
or existing use of an oral 
anticoagulant for prophylaxis 
of thromboembolism. In 
addition, subjects must 
have had an ACS or PCI 
with a stent within the 
previous 14 days
2.  Planned use of antiplatelet 
agents for at least 1 to 6 mo
3.  Men and women ≥18 y
4.  Women of childbearing 
potential must have a 
negative serum or urine 
pregnancy test within 24 
h before the start of study 
drug
Oral anticoagulant therapy indication 
for AF for a period of at least 12 mo 
following successful PCI with stenting. 
Eligibility is assessed 4 h after sheath 
removal and within 5 days after 
successful PCI with stent placement. 
If a staged PCI is planned, eligibility is 
assessed after completion of the last 
stage.
Table 3. Continued
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Exclusion 
criteria
1.  Mechanical or 
biological heart valve 
prosthesis
2.  Cardiogenic shock 
during current 
hospitalization
3.  Stroke within 1 mo 
before screening visit
4.  Major surgery within 
the month before 
screening
5.  Gastrointestinal 
hemorrhage within 1 
mo before screening, 
unless, in the opinion 
of the Investigator, 
the cause has been 
permanently eliminated
6.  Major bleeding 
episode including life-
threatening bleeding 
episode in 1 mo before 
screening visit
7.  Anemia (Hb <10g/dL) 
or thrombocytopenia 
including 
heparin-induced 
thrombocytopenia 
(platelet count 
<100×109/L) at 
screening
8.  Severe CKD (estimated 
CrCl by Cockcroft-
Gault <30 mL/min at 
screening
9. Active liver disease
1.  Any condition that 
contraindicates 
anticoagulant or 
antiplatelet therapy 
or would have an 
unacceptable risk of 
bleeding, such as, but not 
limited to: platelet count 
<90 000/μL at screening, 
history of intracranial 
hemorrhage, 12 mo history 
of clinically significant 
gastrointestinal bleeding, 
non-VKA-induced elevated 
prothrombin time (PT) at 
screening
2.  Anemia of unknown cause 
with a Hb level <10 g/dL
3. History of stroke or TIA
4.  Calculated CrCl <30 mL/
min at screening
5.  Known significant liver 
disease or liver function 
test abnormalities
6.  Any severe condition that 
would limit life expectancy 
to <12 mo
1.  Conditions other than 
AF that require chronic 
anticoagulation (eg, 
prosthetic mechanical 
heart valve)
2.  Severe CKD (serum 
creatinine >2.5 mg/dL or 
a calculated CrCl < 30 
mL/min
3.  History of intracranial 
hemorrhage
4.  Patients have had or will 
undergo CABG for their 
index ACS event
5.  Known ongoing bleeding 
or coagulopathies
6.  Any contraindications 
or allergies to VKA, 
apixaban, or to intended 
P2Y12 antagonists or to 
aspirin
1.  Bleeding risks or systemic conditions
2.  Known bleeding diathesis, including  
but not limited to:
a.  Uncontrolled active bleeding,  
encompassing both ISTH major and 
clinically relevant nonmajor  
bleeding, preceding randomization.  
Lesion or condition, if considered to 
be a significant risk for major 
bleeding. This may include but 
is not limited to: unresolved 
gastrointestinal ulceration, presence 
of malignant neoplasms at high 
risk of bleeding (eg, malignancies 
with metastasis), recent unresolved 
brain or spinal injury, recent brain, 
spinal, or ophthalmic surgery, any 
intracranial hemorrhage, known 
or suspected esophageal varices, 
arteriovenous malformations, 
vascular aneurysms (of >3.5 cm) 
or major intraspinal or intracerebral 
vascular abnormalities.
b. Medication-related
3.  INR > 2.5 (the subject can be  
reconsidered at a later time, but  
within 5 days of sheath removal).
4.  Contraindication to edoxaban,  
VKA, ASA. and P2Y12 antagonists;
5.  Concomitant treatment with other 
antithrombotic agents, fibrinolytic  
therapy. and chronic nonsteroidal  
anti-inflammatory drugs (NSAIDs).
6.  Critically ill or hemodynamically  
unstable subjects (at the time of 
randomization) including:
a.  Cardiogenic shock or acute 
decompensated heart failure, 
with the requirement for 
vasopressor agents or inotropic 
support or mechanical support to 
support circulation
b.  Respiratory failure requiring 
endotracheal intubation and 
mechanical ventilation.
7.  Any prior mechanical valvular 
prosthesis;
8.  Planned coronary or vascular 
intervention or major surgery within 
12 mo; Randomization must be 
deferred to the last stage in a 
multistep, multivessel PCI procedure; 
9.  Moderate or severe mitral stenosis;
10.  Ischemic stroke within 2 wk before 
randomization;
Table 3. Continued
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Exclusion 
criteria 
(Continued)
11.  Uncontrolled severe hypertension 
with a systolic blood pressure 
(BP) ≥180 mm Hg and diastolic 
BP≥120 mm Hg;
12.  Severe renal impairment with 
estimated CrCl <15 mL/min or on 
dialysis;
13.  Known abnormal liver function before 
randomization (including hepatic 
disease or biochemical evidence of 
significant liver derangement known 
before randomization).
14.  Any of the following abnormal 
local laboratory results prior to 
randomization:
a.  Platelet count < 50×109/L
b.  Hemoglobin <8 mg/dL
15.  Unable to provide written IC; 
Female subjects of childbearing 
potential without using adequate 
contraception (female of childbearing 
potential is defined as one who 
has not been postmenopausal 
for at least 1 y, or has not been 
surgically sterilized, or has not had 
a hysterectomy at least 3 mo before 
the start of this study [Visit 1]). 
Females taking oral contraceptives 
should have been on therapy for at 
least 3 mo. Adequate contraceptives 
include hormonal intrauterine 
devices, hormonal contraceptives 
(oral, depot, patch, or injectable), 
and double-barrier methods such 
as condoms or diaphragms with 
spermicidal gel or foam.
16.  Pregnant or breastfeeding 
subjects;
17.  Assessment that the subject is 
not likely to comply with the study 
procedures or have complete 
follow-up;
18.  Participating in another clinical 
trial that potentially interferes with 
the current study;
19.  Previous randomization in this study;
20.  Known drug or alcohol 
dependence within the past 12 mo 
as judged by the Investigator;
21.  Life expectancy <12 mo.
ACS indicates acute coronary syndrome; AF, atrial fibrillation; BID, twice daily; BMS, bare metal stent; CABG, coronary artery bypass graft; CKD, chronic 
kidney disease; CrCl, creatinine clearance; CRNM, clinically relevant nonmajor; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; Hb, hemoglobin; 
IC, informed consent; INR, international normalized ratio; ISTH, international society on thrombosis and hemostasis; MI, myocardial infarction; NSTEMI, 
non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; SE, systemic embolism; ST, stent thrombosis; STEMI, ST-
segment–elevation myocardial infarction; TIA, transient ischemic attack; UA, unstable angina; and VKA, vitamin-K antagonist.
Table 3. Continued
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Table 4. Characteristics of GLOBAL LEADERS, TWILIGHT, and TICO Trials
 GLOBAL LEADERS TWILIGHT TICO
Title Comparative Effectiveness of 1 mo 
of Ticagrelor Plus Aspirin Followed 
by Ticagrelor Monotherapy Versus 
a Current-day Intensive Dual 
Antiplatelet Therapy in All-comers 
Patients Undergoing Percutaneous 
Coronary Intervention With Bivalirudin 
and BioMatrix Family Drug-eluting 
Stent Use
Ticagrelor With Aspirin or Alone in High-
Risk Patients After Coronary Intervention
Ticagrelor Monotherapy After 3 mo in the 
Patients Treated With New Generation 
Sirolimus Stent for Acute Coronary 
Syndrome
ClinicalTrials.
gov identifier
NCT01813435 NCT02270242 NCT02494895
Sponsor European Cardiovascular Research  
Institute (ECRI)
Mount Sinai School of Medicine Yonsei University
Estimated 
enrollment
16 000 9000 3056
Study start 
date
May 2013 July 2015 July 2015
Estimated 
completion 
date
June 2016 October 2018 July 2020
Allocation Randomized Randomized Randomized
End point 
classification
Safety/efficacy study Safety/efficacy study Safety/efficacy study
Intervention 
model
Parallel assignment Parallel assignment Parallel assignment
Masking Open label Double blind Open label
Active 
comparator
Aspirin (≤100 mg qd) + Ticagrelor 
(90 mg bid) for 12 mo followed by 
aspirin monotherapy for 12 mo in 
case of ACS;
Aspirin (≤100 mg qd) + clopidogrel (75 
mg qd) for 12 mo followed by aspirin 
monotherapy for 12 mo in case of 
stable CAD
Aspirin (81 mg daily for 12 mo) + 
ticagrelor (90 mg bid for 15 mo)
Aspirin + ticagrelor
Experimental 
comparator
Aspirin (≤100 mg qd) + ticagrelor (90 
mg bid) for 1 mo followed by 23 mo of 
ticagrelor monotherapy.
Placebo (daily for 12 mo)+ ticagrelor (90 
mg bid for 15 mo)
Ticagrelor monotherapy at 3 mo after PCI
Primary 
outcome
Composite of all-cause mortality or 
nonfatal new Q-wave MI up to 2 y
Bleeding: the time to first occurrence of 
clinically relevant bleeding, defined as 
BARC types 2, 3, or 5 bleeding at 1 y (15 
mo after PCI)
Major adverse cardiovascular  
clinical events (MACCE) 1 y after the 
procedure
Major bleeding (TIMI) 1 y after the 
procedure
Secondary 
outcome
Bleeding: The composite of investigator-
reported BARC3 or BARC5 bleeding up 
to 2 y
Ischemic episode: the time to first 
occurrence of confirmed cardiovascular 
death, nonfatal MI, ischemic stroke, or IDR 
at 1 y (15 mo after PCI)
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Inclusion 
criteria
All-comer patients:
1.  Age ≥18 y;
2.  Presence of ≥1coronary artery 
stenoses of ≥50% in a native 
coronary artery or in a saphenous 
venous or arterial bypass conduit 
suitable for coronary stent 
implantation. The vessel should have 
a reference vessel diameter of at 
least 2.25 mm (no limitation on the 
number of treated lesions, vessels, or 
lesion length);
3.  Able to provide informed consent and 
willing to participate in 2-y follow-up 
period.
High-risk patients who have undergone 
successful elective or urgent PCI with at 
least one locally approved drug-eluting 
stent discharged on DAPT with aspirin 
and ticagrelor of at least 3 mo intended 
duration will be eligible.
Enrollment into the study will require 
meeting at least one clinical inclusion, one 
angiographic inclusion, and none of the 
exclusion criteria.
Clinical Inclusion Criteria:
1.  Adult patients ≥ 65 y of age
2.  Recent (≥3 days) presentation with 
acute coronary syndrome with clinical 
stabilization and decreasing cardiac 
enzymes
3.  Established vascular disease defined as 
previous MI, documented PAD or CAD/
PAD revascularization
4.  Diabetes mellitus treated with 
medications (oral hypoglycemic, 
subcutaneous injection of insulin)
5.  CKD defined as an eGFR <60 mL·min–
1·1.73m–2 or creatinine clearance (CrCl) 
<60 mL/min
Angiographic Inclusion Criteria:
1.  Multivessel CAD
2.  Target lesion requiring total stent length 
>30 mm
3.  SYNTAX score ≥23
4.  Bifurcation lesions with Medina X:X:1 
classification requiring at least 2 stents
5.  Left main (≥50%) or proximal LAD 
(≥70%) lesion
6.  Calcified target lesion requiring 
atherectomy
1. Patients ≥19 y old
2. Patients who received new-generation 
sirolimus-eluting (Osiro) stent implantation 
for treating ACS
3. Patients without significant clinical 
events such as MI, stent thrombosis, or 
revascularization until 3 mo after PCI
4.  Provision of informed consent
Exclusion 
criteria
1.  Known intolerance to aspirin, P2Y12 
inhibitors, bivalirudin, stainless steel, 
or biolimus;
2.  Known intake of a strong CYP3A4  
inhibitor (eg, ketoconazole, 
clarithromycin, nefazodone, ritonavir, and 
atazanavir), because coadministration 
may lead to a substantial increase in 
exposure to ticagrelor;
3.  Known moderate to severe 
hepatic impairment (alanine-
aminotransferase ≥3×ULN);
4.  Planned surgery, including CABG as 
a staged procedure (hybrid) within 12 
mo of the index procedure, unless 
dual-antiplatelet therapy is maintained 
throughout the perisurgical period;
1. Under 18 y of age
2. Contraindication to aspirin
3. Contraindication to ticagrelor
4. Planned surgery within 90 days
5.  Planned coronary revascularization 
(surgical or percutaneous) within 90 
days
6.  Need for chronic oral anticoagulation
7. Prior stroke
8. Dialysis-dependent renal failure
9.  Active bleeding or extreme risk for major 
bleeding (eg, active peptic ulcer disease, 
gastrointestinal pathology with a raised risk 
for bleeding, malignancies with a raised 
risk for bleeding)
1. Age > 80 y
2.  Increased risk of bleeding, anemia, 
thrombocytopenia
3.  A need for oral anticoagulation therapy
4.  Pregnant women or women with 
potential childbearing
5. Life expectancy <1 y
6.  Patients treated with strong CYP3A4 
inhibitors (eg, ketoconazole, 
clarithromycin, nefazodone, ritonavir, or 
atazanavir)
7.  Patients who had history of intracranial 
hemorrhage
Table 4. Continued
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Ongoing Studies 
Based on the considerations outlined above and to fur-
ther evaluate the contemporary value of aspirin as a 
secondary prevention medication, numerous random-
ized trials are currently being conducted in patients with 
(Table 3) or without (Table 4) an established indication for 
concomitant oral anticoagulation.
Table 3 shows the trials testing the less-is-more approach 
(ie, clopidogrel monotherapy in the absence of concomitant 
aspirin therapy) after PCI in patients with atrial fibrillation.
Table 4 shows ongoing trials in patients without atrial 
fibrillation. The GLOBAL LEADERS (GLOBAL LEADERS: 
A Clinical Study Comparing Two Forms of Anti-platelet 
Therapy After Stent Implantation; NCT01813435) is a 
superiority all-comers (with the exception of patients 
with an indication for oral anticoagulant) study among 
patients undergoing PCI. It is designed to assess wheth-
er a 24-month antithrombotic regimen with ticagrelor 
and 1-month aspirin, in comparison with 12-month 
conventional DAPT followed by aspirin monotherapy, 
improves outcome.98 This is an investigator-initiated, 
randomized, open-label, outcome trial, which recruited 
16 001 patients admitted for stable CAD or ACS under-
going PCI under standardized treatment consisting of bi-
valirudin-supported biolimus-eluting stent implantation. 
Patients were enrolled in >100 interventional cardiology 
sites in Europe, Asia, Brazil, Australia, and Canada from 
July 2013 to November 2015. Patients were randomly 
assigned (1:1 ratio) to ticagrelor 90 mg twice daily for 
24 months plus ASA ≤100 mg for 1-month versus con-
ventional DAPT with either ticagrelor in ACS patients or 
clopidogrel for 12 months plus ASA ≤100 mg for 24 
months in stable CAD patients (Figure 3). Under the as-
sumption that less may be more, this study is powered 
to show the superiority of ticagrelor monotherapy in 
terms of all-cause mortality or Q-wave MI. Results are 
to be released in the first or second quarter of 2018.
The TWILIGHT (Ticagrelor With Aspirin or Alone 
in High-Risk Patients After Coronary Intervention; 
NCT02270242) is a double-blind, multicenter trial en-
rolling ≈9000 high-risk patients undergoing elective or 
urgent PCI (emergent or salvage PCI or ST-segment–ele-
vation MI presentation is an exclusion criterion) with DES 
(Table 4). Subjects meeting eligibility criteria at 3 months 
after enrollment are randomly assigned to ticagrelor (90 
mg twice daily) and aspirin (81–100 mg/d) or ticagrelor 
and placebo for an additional 12 months. It is powered 
to show a reduction of bleeding with ticagrelor mono-
therapy (Figure 4). The first patient was enrolled in July 
2015, and results are expected in 2019.
In the TICO study (Ticagrelor Monotherapy After 
3 Months in the Patients Treated With New Genera-
tion Sirolimus Stent for Acute Coronary Syndrome; 
NCT02494895), 3056 patients with ACS treated with 
new-generation sirolimus-eluting stent implantations 
are randomly assigned to ticagrelor monotherapy or ti-
cagrelor plus aspirin at 3 months after PCI. The primary 
end point is the rate of major adverse cardiovascular 
Exclusion 
criteria 
(Continued)
5.  Need for chronic oral anticoagulation 
therapy;
6.  Active major bleeding or major 
surgery within the past 30 days;
7.  Known history of intracranial 
hemorrhagic stroke or intracranial 
aneurysm;
8.  Known stroke (any type) within the 
past 30 days;
9.  Known pregnancy at time of 
randomization;
10.  Female who is breastfeeding at time 
of randomization;
11.  Currently participating in another 
trial and not yet at its primary end 
point
10.  Emergent or salvage PCI or STEMI 
presentation.
11.  Liver cirrhosis
12. Life expectancy <1 y
13.  Unable or unwilling to provide 
informed consent
14.  Women of childbearing potential (as 
determined by hospital standard of 
care)
15.  Fibrinolytic therapy within 24 h of 
index PCI
16.  Concomitant therapy with a strong 
cytochrome P-450 3A inhibitor or 
inducer
17. Platelet count <100 000 mm3
18.  Requiring ongoing treatment with 
aspirin >325 mg daily
8.  Moderate to severe hepatic dysfunction
9.  Increased risk of bradycardia-related 
symptom (guidance and reference)
ACS indicates acute coronary syndrome; BARC, bleeding academic research consortium; bid, twice daily; CABG, coronary artery bypass graft; CAD, 
coronary artery disease; CKD, chronic kidney disease; DAPT, dual-antiplatelet therapy; eGFR, estimated glomerular filtration rate; IDR, ischemia-driven 
revascularization; LAD, left anterior descending artery; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; 
qd, every day; STEMI, ST-segment–elevation myocardial infarction; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and 
Cardiac Surgery; and ULN, upper limit normal.
Table 4. Continued
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clinical events and major bleeding at 1 year after the 
procedure (Table 4).
Following the encouraging results of a 2.5 mg twice 
daily rivaroxaban regimen added to aspirin and clopi-
dogrel,20 the COMPASS (Rivaroxaban for the Preven-
tion of MACE in Coronary or Peripheral Artery Disease; 
NCT01776424) is recruiting (from February 2013 to 
March 2018) 27 400 patients with coronary or peripher-
al artery disease randomly allocated to rivaroxaban and 
aspirin or rivaroxaban alone in comparison with aspirin 
monotherapy for the prevention of recurrent ischemic 
events, stroke, or cardiovascular death. The primary 
Figure 4. Design of the TWILIGHT 
trial. 
Illustration of the study diagram of the 
TWILIGHT trial. ASA indicates aspirin; 
BARC, Bleeding Academic Research 
Consortium; DAPT, dual-antiplatelet 
therapy; and PCI, percutaneous coro-
nary intervention.
Figure 3. Design of the GLOBAL LEADERS trial.  
Illustration of the study diagram of the GLOBAL LEADERS trial. Adapted from Figure 1 of Vranckx et al97 with permission of the 
publisher. Copyright © 2016, Europa Digital & Publishing. ACS indicates acute coronary syndromes; ASA, aspirin; CAD, coronary 
artery disease; MI, myocardial infarction; and PCI, percutaneous coronary intervention.
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efficacy end point is the occurrence of MI, stroke, or 
cardiovascular death at 5 years, and the occurrence of 
major bleeding is the primary safety end point. On the 
other hand, the GEMINI-ACS1 trial (A Study to Compare 
the Safety of Rivaroxaban Versus Acetylsalicylic Acid in 
Addition to Either Clopidogrel or Ticagrelor in Partici-
pants With Acute Coronary Syncrome; NCT02293395) 
is a phase II prospective, randomized, double-dummy, 
double-blind, active-controlled trial testing the safety of 
dual-antithrombotic therapy (rivaroxaban 2.5 mg twice 
daily plus P2Y12 inhibitor) in comparison with DAPT (as-
pirin 100 mg plus P2Y12 inhibitor) within 10 days of an 
ACS event in 3000 patients.99 Patients will be randomly 
assigned in a 1:1 ratio stratified by intended P2Y12 in-
hibitor use (clopidogrel 75 mg daily or ticagrelor 90 mg 
twice daily), with 1500 patients expected in each P2Y12 
inhibitor strata. The primary end point is TIMI clinically 
significant bleeding (major, minor, or requiring medical 
attention). The exploratory efficacy determination will 
be a composite of cardiovascular death, MI, ischemic 
stroke, and ST.
Similar to PCI setting, ASA alternatives are also be-
ing explored in patients undergoing transcatheter aortic 
valve implantation (ie, GALILEO, ATLANTIS, and POPU-
LAR-TAVI trials), in whom the balance between ischemic 
and bleeding risks may be more challenging because of 
advanced age and comorbidities.100
CONCLUSION
Single-antiplatelet therapy with P2Y12 inhibitors is being 
explored as a potential alternative to a DAPT regimen 
after ACS or coronary stent implantation, and a poten-
tially more effective long-term treatment than aspirin 
monotherapy, as well. Given the well-established role 
of aspirin as a secondary prevention medication, its 
widespread availability and affordability, aspirin should 
remain a critical antithrombotic compound in patients 
with established coronary or cardiovascular disorders. 
However, as the availability of newer, potentially saf-
er and more effective antiplatelet or antithrombotic 
agents increases, the quest for the ideal long-term 
secondary prevention medication mandates reapprais-
ing the value of aspirin, an historical antiplatelet agent 
whose efficacy was proven largely versus placebo in 
the setting of studies that appear largely outdated in 
comparison with contemporary cardiovascular prac-
tice.
The optimal duration of a DAPT regimen post-ACS or 
stent implantation remains unresolved and is most likely 
variable from patient to patient. The results of ongoing 
trials appraising the value of dropping aspirin in favor 
of P2Y12 inhibitor monotherapy will soon shed new light 
on the less-is-more approach for long-term secondary 
prevention.
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Ischaemic and bleeding outcomes in elderly patients 
undergoing a prolonged versus shortened duration of dual 
antiplatelet therapy after percutaneous coronary intervention: 
insights from the PRODIGY randomised trial
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Abstract
Aims: The aim of this study was to evaluate the efficacy and safety of 24-month vs. six-month dual anti-
SODWHOHWWKHUDS\'$37DPRQJHOGHUO\\HDUVDQGQRQHOGHUO\SDWLHQWV\HDUVXQGHUJRLQJSHUFX-
taneous coronary intervention.
Methods and results: The primary efficacy endpoint of the PRODIGY trial was the composite of death, 
myocardial infarction, or cerebrovascular accident at 24-month follow-up. The key safety endpoint was 
W\SHRUEOHHGLQJDFFRUGLQJWRWKH%$5&FULWHULD2ISDUWLFLSDQWVZHUHHOGHUO\DQG
had a higher risk of adverse events compared with younger patients. The risk of the primary endpoint was 
QRWVLJQLILFDQWO\UHGXFHGZLWKPRQWKFRPSDUHGWRVL[PRQWK'$37DPRQJERWKHOGHUO\+5
&,S  DQGQRQHOGHUO\SDWLHQWV +5&,S  DOWKRXJK LQWHUDF-
WLRQWHVWLQJZDVVLJQLILFDQWS $PRQWKYHUVXVVL[PRQWK'$37VLJQLILFDQWO\LQFUHDVHGWKHULVN
RI%$5&W\SHRUEOHHGLQJLQERWKROGHU+5&,S DQG\RXQJHUSDWLHQWV
+5&,S SLQWHUDFWLRQ +RZHYHUPHDVXUHVRIDEVROXWHULVNGLIIHUHQFH
indicated a less favourable safety profile of prolonged DAPT for older rather than younger patients.
Conclusions: In the PRODIGY trial, prolonging clopidogrel-based DAPT beyond six months in elderly 
patients increased the risk of bleeding, without affording a significant prevention of ischaemic events.
KEYWORDS
• bleeding
• clinical trials
• elderly
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Abbreviations
BARC Bleeding Academic Research Consortium
CVA cerebrovascular accident
DAPT dual antiplatelet therapy
GUSTO Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Arteries
MI myocardial infarction
PCI percutaneous coronary intervention
TIMI Thrombolysis In Myocardial Infarction
Introduction
Elderly individuals account for an increasing proportion of patients 
with coronary artery disease undergoing percutaneous coro-
nary intervention (PCI), due to the ageing of the population with 
increased life expectancy1-3. Dual antiplatelet therapy (DAPT) with 
aspirin and oral P2Y12 adenosine diphosphate receptor inhibitors 
represents the standard of treatment to prevent new atherothrom-
botic events after PCI, yet its optimal duration remains controver-
sial4-6. Results from randomised trials and meta-analyses indicate 
that extended (i.e., >12 months) duration of DAPT is associated 
with a lower risk of ischaemic events, even though this benefit 
is partly offset by a higher risk of clinically relevant bleeding. 
However, extrapolating such findings to elderly patients is chal-
lenging in view of the increased risk of bleeding and ischaemic 
events occurring in this subgroup. In addition, elderly individuals 
have been underrepresented among randomised trials that evalu-
ated different durations of DAPT following PCI. The Prolonging 
Dual Antiplatelet Treatment After Grading Stent-Induced Intimal 
Hyperplasia Study (PRODIGY) compared a strategy of DAPT 
extended to 24 months with a shorter course of DAPT up to six 
months in a broadly inclusive population of PCI patients, with the 
inclusion of a relatively high proportion of elderly participants.
Therefore, we sought to evaluate the impact of age in modu-
lating the hazard of ischaemic and bleeding events and to inves-
tigate the outcomes of 24-month vs. six-month DAPT in elderly 
 \HDUV YV \RXQJHU SDWLHQWV  \HDUV HQUROOHG LQ WKH
PRODIGY trial.
Methods
Details on study design and primary results of the PRODIGY trial 
have been reported elsewhere. Briefly, all-comer patients under-
going treatment with a balanced mixture of stents were randomly 
DOORFDWHGDWGD\VWRHLWKHUXSWRVL[PRQWKVRUWRPRQWKVRI
DAPT. The ethics committees of the participating centres inde-
pendently approved the protocol and all participants gave written 
informed consent.
TREATMENT PROTOCOL
$OO SDWLHQWV UHFHLYHG DVSLULQ PJ RUDOO\ LQGHILQLWHO\ DQG
FORSLGRJUHOPJGD\DFFRUGLQJWRWKHUDQGRPLVDWLRQVFKHPHDV
follows: for either up to six months in the short DAPT group or to 
24 months in the prolonged DAPT arm, irrespective of the previ-
ously implanted stent type or indication for PCI.
STUDY ENDPOINTS
The primary efficacy endpoint of the PRODIGY trial was the 
composite of death, myocardial infarction (MI), or cerebrovas-
cular accident (CVA), whereas the key safety endpoint included 
Bleeding Academic Research Consortium (BARC) type 2, 3, or 
5 bleeding. Other endpoints included each component of the pri-
mary efficacy endpoint, cardiovascular death, stent thrombosis 
defined on the basis of the Academic Research Consortium crite-
ria, and BARC type 3 or 5 bleeding. Additional safety endpoints 
were bleeding events adjudicated according to the Thrombolysis 
In Myocardial Infarction (TIMI) and the Global Utilization of 
Streptokinase and Tissue Plasminogen Activator for Occluded 
Arteries (GUSTO) criteria. More detailed definitions of the end-
points have been provided previously11. A clinical events commit-
tee blinded to treatment allocation adjudicated all efficacy and 
bleeding events.
STATISTICAL ANALYSIS
Continuous variables are presented as mean±standard deviation 
and were compared with the Wilcoxon rank-sum test. Categorical 
variables are expressed as counts and percentages and were com-
pared with chi-square or Fisher’s exact tests as appropriate. We 
evaluated the effect of age, modulated as a continuous vari-
able, on the risk of ischaemic and bleeding events in the overall 
population by means of multivariable-adjusted, restricted cubic 
VSOLQHV ZLWK WKUHH NQRWV RI WKH GLVWULEXWLRQ th th DQG th 
percentiles)12. The effect of age on clinical events was analysed 
LQ WKH FDWHJRULHV RI SDWLHQWV  YV  \HDUV E\ XVLQJ &R[
regression analyses. Both analyses were adjusted for baseline 
clinical variables associated with the primary efficacy and key 
safety endpoints at the univariate analysis with a significance 
OHYHO RI S 7KH HIILFDF\ DQG VDIHW\ RI PRQWK '$37
YV VL[PRQWK '$37 IRU HOGHUO\  \HDUV YV QRQHOGHUO\
\HDUVSDWLHQWVZDVHYDOXDWHGDWPRQWKV&OLQLFDOHYHQWV
were expressed as counts with rates computed according to the 
Kaplan-Meier method. Cox regression analysis was used to cal-
FXODWH KD]DUG UDWLRV +5VZLWK FRQILGHQFH LQWHUYDOV &,V
and an interaction test was provided to evaluate the effect of 
treatment in the elderly vs. non-elderly. Sensitivity analyses were 
conducted to evaluate the efficacy and safety of DAPT from six 
to 24 months by using a landmark analysis and to assess whether 
results were consistent by applying the cut-off of 65 years to 
define the elderly status. In addition, we evaluated the risk of 
deaths associated or not with MI if they occurred within a seven-
day window from MI onset. Risk difference and the number 
needed to treat for benefit or harm (NNTB or NNTH) with rela-
WLYH  &, ZHUH DOVR SURYLGHG LQ RUGHU WR DFFRXQW IRU DEVR-
lute risk estimates. Finally, the interaction between treatment 
effect and ageing, modelled as a continuous variable, was ana-
lysed with a fractional polynomial interaction13. All p-values are 
WZRVLGHG DQG VWDWLVWLFDO VLJQLILFDQFH ZDV DVVXPHG IRU S
All analyses were carried out with Stata Statistical Software, 
Release 13 (StataCorp LP, College Station, TX, USA).
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Results
2ISDUWLFLSDQWVHQUROOHGLQWKH352',*<WULDO
SDWLHQWV ZHUH  \HDUV RI DJH DQG   SDWLHQWV ZHUH
\HDUVRIDJH$VVKRZQ LQTable 1 and Table 2, baseline and 
periprocedural features were largely comparable within the elderly 
vs. non-elderly groups between patients assigned to 24-month or 
six-month DAPT.
EFFECT OF AGEING ON CLINICAL OUTCOMES
There was a direct graded relationship between age and the risks 
of the primary efficacy or the key safety endpoint, with a steeper 
LQFUHDVHLQWKHKD]DUGWUDMHFWRULHVEH\RQG\HDUVRIDJH(Figure 1). 
A similar direct association between age and bleeding events was 
observed for BARC type 3 or 5, TIMI minor or major, or GUSTO 
moderate or severe bleeding (data not shown). When dichotomised, 
SDWLHQWVZLWKDJH\HDUVFRPSDUHGZLWK\RXQJHUSDUWLFLSDQWVKDG
a higher risk of death, MI or CVA and BARC type 2, 3 or 5 bleeding.
EFFICACY OF PROLONGED DAPT AMONG ELDERLY VS. 
NON-ELDERLY PATIENTS
Figure 2A shows the analysis of efficacy endpoints at two-year 
IROORZXS7KHUHZDVDVLJQLILFDQW LQWHUDFWLRQS EHWZHHQ
Table 1. Baseline characteristics.
Age ≥75 years Age <75 years
p-interaction24-month 
DAPT
N=283
≤6-month 
DAPT
N=304
p-value
24-month 
DAPT
N=704
≤6-month 
DAPT
N=679
p-value
Age, years 80.2±3.7 80.6±4.3 0.47 62.9±9.1 62.3±8.7 0.07 0.19
Male 186 (65.7) 200 (65.8) 1.00 578 (82.1) 547 (80.6) 0.49 0.64
BMI, kg/m2 26.8±9.5 26.4±3.6 0.58 28.1±13.3 28.1±11.4 0.22 0.78
Hypertension 232 (82.0) 237 (78.0) 0.26 489 (69.5) 456 (67.2) 0.39 0.54
Dyslipidaemia 142 (50.2) 149 (49.0) 0.81 411 (58.4) 376 (55.4) 0.28 0.70
Smoking 18 (6.4) 29 (9.5) 0.17 204 (29.0) 218 (32.1) 0.22 0.38
Diabetes 83 (29.3) 82 (27.0) 0.58 161 (22.9) 151 (22.2) 0.80 0.72
Insulin-treated diabetes 17 (6.0) 22 (7.2) 0.62 42 (6.0) 33 (4.9) 0.41 0.31
Family history of CAD 70 (24.7) 39 (12.8) <0.001 219 (31.1) 225 (33.1) 0.42 <0.001
Previous MI 93 (32.9) 93 (30.6) 0.60 177 (25.1) 163 (24.0) 0.66 0.84
Previous PCI 47 (16.6) 64 (21.1) 0.17 142 (20.2) 106 (15.6) 0.03 0.018
Previous CABG 44 (15.5) 40 (13.2) 0.41 66 (9.4) 63 (9.3) 1.00 0.54
Creatinine clearance, mL/min 53.6±19.7 54.9±18.7 0.28 89.7±44.8 87.8±27.5 0.82 0.32
Peripheral artery disease 55 (19.4) 74 (24.3) 0.16 63 (8.9) 54 (8.0) 0.56 0.14
LVEF, % 49.8±10.6 48.5±11.0 0.12 51.5±10.0 51.4±10.1 0.92 0.20
Congestive HF or LV dysfunction 24 (8.5) 21 (6.9) 0.54 16 (2.3) 19 (2.8) 0.61 0.35
Indication to PCI 0.62 0.99 0.66
Stable CAD 56 (19.8) 58 (19.1) 0.84 199 (28.3) 192 (28.3) 1.00
NSTE-ACS 149 (52.7) 151 (49.7) 0.51 262 (37.2) 255 (37.6) 0.91
STEMI 78 (27.6) 95 (31.2) 0.37 243 (34.5) 232 (34.2) 0.91
Acute MI at presentation 162 (57.2) 188 (61.8) 0.27 385 (54.7) 363 (53.5) 0.67 0.23
Values are n (%) or mean±SD. BMI: body mass index; CABG: coronary artery bypass graft; CAD: coronary artery disease; DAPT: dual antiplatelet therapy; 
HF: heart failure; LV: left ventricular; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NSTE-ACS: non-ST-segment elevation acute 
coronary syndrome; STEMI: ST-segment elevation myocardial infarction.
Figure 1. Multivariable-adjusted spline curves for the HR of the 
primary ischaemic and bleeding endpoint vs. age modelled as 
DFRQWLQXRXVYDULDEOH3DWLHQWVZLWKDJH\HDUVUHSUHVHQWWKH
referent group with the HR set to 1. The dotted lines represent the 95% 
CI of the hazard function. The variables used for the adjustments are 
listed in the Methods section. BARC: Bleeding Academic Research 
Consortium; CI: confidence intervals; CVA: cerebrovascular 
accident; HR: hazard ratio; MI: myocardial infarction
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DJHGLFKRWRPLVHGDW DJH\HDUV FXWRIISRLQW DQG WKHSULPDU\
efficacy endpoint. Although the primary efficacy endpoint did not 
differ based on the randomly allocated DAPT duration among 
elderly patients, event rates were numerically lower for prolonged 
'$37+5&,S &RQYHUVHO\DWUHQG
towards an increased risk of the primary endpoint was observed 
among younger patients randomised to 24-month vs. six-month 
'$37 +5   &,  S  7KLV GLIIHUHQFH
was mainly driven by cardiac mortality, which occurred more fre-
quently among younger patients randomised to 24-month DAPT 
+5   &,  S  +RZHYHU WKH DJHE\
treatment interaction was significant for deaths not related to MI 
S  EXW QRW IRU WKRVH UHODWHG WR0, S 7KH WHVW IRU
LQWHUDFWLRQ IRU WKHSULPDU\HQGSRLQWZDVQRW VLJQLILFDQW S 
from six to 24 months (Figure 2B). By using a cut-off of 65 years, 
WKHUH ZDV QR VLJQLILFDQW LQWHUDFWLRQ S  ZLWK PRQWK YV
six-month DAPT with respect to the primary ischaemic endpoint 
DPRQJSDWLHQWV\HDUV +5&,S 
YVWKRVH\HDUV+5&,S 
SAFETY OF PROLONGED DAPT AMONG ELDERLY VS. 
NON-ELDERLY PATIENTS
Figure 3A shows the analysis of safety endpoints at two-year follow-
up. BARC type 2, 3 or 5 bleeding was significantly increased in both 
HOGHUO\+5&,S DQGQRQHOGHUO\SDWLHQWV
+5&,S S IRU LQWHUDFWLRQ  UDQ-
domised to 24-month versus six-month DAPT. The NNTH was 
ORZHUIRUHOGHUO\117+&,117+WR117+WKDQ
IRU QRQHOGHUO\ SDWLHQWV 117+  &, 117+  WR 117+
 $OWKRXJK QRW VLJQLILFDQWO\ LQFUHDVHG EOHHGLQJ HYHQWV DFFRUG-
ing to TIMI and GUSTO definitions were numerically higher in 
patients randomised to 24-month DAPT vs. six-month DAPT. In the 
analysis between six and 24 months (Figure 3B), the relative risks 
of BARC type 2, 3 or 5 bleeding were consistently higher in both 
SDWLHQWV DJHG\HDUV +5&,S  DQG
SDWLHQWV  \HDUV +5   &,  S  S IRU
LQWHUDFWLRQ 7KHFRUUHVSRQGLQJ117+IRUWKHWZRJURXSVZDV
 &, 117+  WR 117+  DQG  &, 117+ 
to NNTH 21), respectively. After six months, moderate or severe 
Table 2. Angiographic and procedural characteristics.
Age ≥75 years Age <75 years
p-interaction24-month 
DAPT
N=283
≤6-month 
DAPT
N=304
p-value
24-month 
DAPT
N=704
≤6-month 
DAPT
N=679
p-value
Angiographic features 0.09 0.73 0.08
Single-vessel disease 58 (20.5) 79 (26.0) 234 (33.2) 220 (32.4)
Two-vessel disease 84 (29.7) 100 (32.9) 267 (37.9) 250 (36.8)
Three-vessel disease 141 (49.8) 125 (41.1) 203 (28.8) 209 (30.8)
Multivessel disease 225 (79.5) 225 (74.0) 0.12 470 (66.8) 459 (67.6) 0.78 0.13
Multivessel PCI 88 (31.1) 98 (32.2) 0.79 165 (23.4) 175 (25.8) 0.32 0.74
≥2 treated lesions 116 (41.0) 127 (41.8) 0.87 249 (35.4) 244 (35.9) 0.87 0.97
≥3 treated lesions 33 (11.7) 32 (10.5) 0.69 75 (10.7) 83 (12.2) 0.40 0.39
≥4 treated lesions 10 (3.5) 14 (4.6) 0.54 28 (4.0) 30 (4.4) 0.69 0.74
Treated vessel
Left anterior descending artery 151 (53.4) 161 (53.0) 0.93 367 (52.1) 357 (52.6) 0.87 0.86
Left circumflex artery 113 (39.9) 93 (30.6) 0.02 208 (29.5) 225 (33.1) 0.16 0.006
Right coronary artery 86 (30.4) 113 (37.2) 0.10 260 (36.9) 250 (36.8) 1.00 0.14
Left main artery 24 (8.5) 24 (7.9) 0.88 31 (4.4) 32 (4.7) 0.80 0.71
Saphenous vein graft 7 (2.5) 7 (2.3) 1.00 16 (2.3) 10 (1.5) 0.32 0.59
At least one type B2/C lesion 185 (65.4) 221 (72.7) 0.06 457 (64.9) 443 (65.2) 0.91 0.12
At least one restenotic lesion 7 (2.5) 15 (4.9) 0.13 38 (5.4) 33 (4.9) 0.72 0.12
Randomised stent 0.58 0.88 0.45
Bare metal stent 82 (29.0) 80 (26.3) 164 (23.3) 166 (24.4)
Paclitaxel-eluting stent 66 (23.3) 68 (22.4) 182 (25.9) 177 (26.1)
Zotarolimus-eluting stent 59 (20.8) 78 (25.7) 186 (26.4) 167 (24.6)
Everolimus-eluting stent 76 (26.9) 78 (25.7) 172 (24.4) 169 (24.9)
Number of implanted stents 1.9±1.3 1.9±1.0 0.22 1.8±1.2 1.9±1.3 0.52 0.59
Overall stent length, mm* 38.6±28.8 39.3±24.3 0.26 39.3±30.8 40.5±30.5 0.53 0.87
Mean stent diameter, mm* 2.9±0.4 3.0±0.4 0.04 3.0±0.5 3.0±0.5 0.008 0.004
All data are shown per patient. *Information available in 1,964 patients. DAPT: dual antiplatelet therapy; PCI: percutaneous coronary intervention
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bleeding according to GUSTO criteria was significantly increased in 
elderly but not in younger patients treated with 24-month DAPT. The 
FRUUHVSRQGLQJ117+ZDV117+&,117+ WR117+
IRUROGHUYV117+&,117%WR117+IRU
\RXQJHUSDWLHQWV$VLJQLILFDQWLQWHUDFWLRQS IRUWKHDEVROXWH
risk difference of moderate or severe GUSTO bleeding was present 
EHWZHHQROGHU&,DQG\RXQJHUJURXSV
&, ± DIWHU VL[PRQWK IROORZXS%\ XVLQJ D FXW
RII RI  \HDUV WKHUH ZDV QR VLJQLILFDQW LQWHUDFWLRQ S  ZLWK
24-month vs. six-month DAPT with respect to the primary bleed-
LQJHQGSRLQWDPRQJSDWLHQWV\HDUV+5&,
S YVWKRVH\HDUV+5&,S 
INTERACTION BETWEEN AGEING AND TREATMENT EFFECT 
OF DAPT
The age-by-treatment interaction evaluated by fractional polyno-
PLDODQDO\VHVZDVQRWVLJQLILFDQWIRUWKHSULPDU\HIILFDF\S 
DQGNH\VDIHW\HQGSRLQWVS )RUWKHFRPSRVLWHRIGHDWK0,
RU&9$WKHDUHDUHSUHVHQWLQJWKH&,WUHDWPHQWHIIHFWFURVVHG
the no effect line throughout all ages (Figure 4A). In contrast, the 
area of treatment effect for the key safety endpoint was above the 
line of no effect for a wide range of ages, indicating a harmful 
effect of 24-month over six-month DAPT in terms of bleeding 
complications for most age values (Figure 4B).
Discussion
The main findings of the present analysis of the PRODIGY trial 
can be summarised as follows.
1) Elderly patients undergoing PCI have a higher risk of ischae-
mic and bleeding events compared with younger patients, with 
a similar effect of ageing on the hazards of such events.
2) In both elderly and non-elderly patients, prolonging DAPT for 
24 months did not reduce the risk of the primary efficacy end-
point of death, MI or CVA compared with a six-month DAPT.
Figure 2. Analysis of efficacy outcomes stratified by age. A) Ischaemic events at 24 months. B) Ischaemic events from six to 24 months. CI: confidence 
intervals; CVA: cerebrovascular accident; DAPT: dual antiplatelet therapy; HR: hazard ratio; MI: myocardial infarction; ST: stent thrombosis
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Figure 3. Analysis of safety outcomes stratified by age. A) Bleeding events at 24 months. B) Bleeding events from six to 24 months. BARC: 
Bleeding Academic Research Consortium; GUSTO: Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded 
Arteries; TIMI: Thrombolysis In Myocardial Infarction
Figure 4. Fractional polynomial interaction for the primary efficacy and key safety endpoints. A) Death, MI or CVA. B) BARC type 2, 3 or 5 
bleeding. The treatment-by-age interaction is analysed by considering age as a continuous variable. The green line represents the treatment 
effect of 24-month vs. six-month DAPT and the area represents the 95% CI of treatment effect. The dotted red line represents the no treatment 
effect. The comparison of 24-month vs. six-month DAPT is significant for the age values where the green area does not cross the line of no 
treatment effect. In this case, the effect of prolonged DAPT in increasing the risk of the key safety endpoint was significant for the range of 50 
to 80 years.
3) A strategy of 24-month DAPT compared with six-month DAPT 
was associated with a greater risk of the key safety endpoint 
of BARC type 2, 3 or 5 bleeding in both elderly and non-
elderly patients. Although the relative magnitude of treatment 
effect on bleeding was similar, the absolute risk difference with 
prolonged DAPT was greater in elderly compared with younger 
participants.
DAPT is an evidence-based, guideline-recommended, standard 
of care treatment after PCI14. Recently, two large randomised tri-
als, DAPT and PEGASUS-TIMI 54 (Prevention of cardiovascular 
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events in patients with prior heart attack using ticagrelor compared 
WRSODFHERRQDEDFNJURXQGRIDVSLULQ±WKURPERO\VLV LQP\RFDUGLDO
infarction 54), showed a significant reduction in ischaemic events 
with long-term DAPT among patients undergoing PCI as well as 
among high-risk patients with prior myocardial infarction. 
Nevertheless, the optimal treatment duration of DAPT remains con-
troversial as the protection afforded by extended DAPT in terms 
of ischaemic events is counterbalanced by an increase in bleeding 
complications. Although the PEGASUS-TIMI 54 trial reported 
consistent results in terms of the primary ischaemic endpoint accord-
LQJWRDJHHOGHUO\SDWLHQWVUHSUHVHQWHGOHVVWKDQRIWKHRYHUDOO
population15. However, despite being formally not significant (p for 
LQWHUDFWLRQ  HOGHUO\ YHUVXV QRQHOGHUO\ SDWLHQWV GHULYHG OHVV
LVFKDHPLFEHQHILWIURPPJRIWLFDJUHORUYVSODFHER$WYDULDQFH
DPRQJ SDUWLFLSDQWV DOORFDWHG WR WLFDJUHORU PJ HOGHUO\ SDWLHQWV
derived a similar magnitude of benefit to non-elderly patients with 
regard to the primary efficacy endpoint. A treatment-by-age hetero-
geneity for the primary endpoint according to age has been observed 
LQ WKH ,6$56$)( S IRU LQWHUDFWLRQ  DQG ,986;3/ WULDOV
SIRULQWHUDFWLRQ IDYRXULQJWKHXVHRIVKRUWWHUP'$37LQ
elderly rather than younger patients. However, the primary end-
point in both trials included a composite of ischaemic and bleeding 
events, which did not allow complete assessment of the benefit-risk 
ratio associated with DAPT in elderly patients.
We found that elderly patients experienced a greater risk of both 
ischaemic and bleeding events, with risk trajectories proceeding 
similarly with ageing. Such a pattern is similar to that described 
by Roe and colleagues in a cohort of patients with acute coronary 
syndrome managed without revascularisation19. Prolonged DAPT 
did not reduce the risk of ischaemic events among both elderly 
and non-elderly patients, which is in keeping with the results in the 
overall finding of the PRODIGY trial. However, interaction test-
ing showed heterogeneity in treatment effect for the primary effi-
cacy endpoint, with a possible harmful effect with 24-month DAPT 
in non-elderly subjects. In this regard, the higher risk of cardiac 
instead of non-cardiac death among younger patients randomised 
to 24-month DAPT, although not related to MI, remains biologi-
cally counterintuitive and difficult to explain. Such a finding could 
also be the result of variable categorisation rather than a direct 
effect, because the age-by-treatment interaction on a continuous 
basis was not significant at the fractional polynomial analysis.
Our study provides a nuanced interpretation for the alleged dif-
ference in the risk of bleeding associated with DAPT use among 
elderly patients. We found that prolonged DAPT had a similar 
effect on the key bleeding endpoint of BARC type 2, 3 or 5 among 
elderly and non-elderly patients at 24-month follow-up. However, 
owing to the higher rate of bleeding events, elderly patients had 
a greater increase in the absolute risk of BARC 2, 3 or 5 bleed-
LQJ ZLWK PRQWK '$37 UHVXOWLQJ LQ D ORZHU 117+  YV
29). During the period between six and 24 months, the absolute 
risk difference in BARC 2, 3 or 5 bleeding tended to increase, as 
ZHOO DV WKH GLIIHUHQFH LQ WKH117+  YV 7DNHQ WRJHWKHU
these findings suggest that relative and absolute risks of bleeding 
should be disentangled in the decision process for DAPT duration 
in elderly people, by factoring the similar relative risk of bleeding 
associated with prolonged DAPT with the higher absolute risk dif-
ference due to the increased event rate.
Limitations
The results of this study have to be interpreted in the light of several 
limitations. First, our observations are based on subgroup popula-
tions within an overall trial, which failed to show the superiority of 
prolonged DAPT in the main population. Second, although there is 
JHQHUDODJUHHPHQWWKDWSHRSOH\HDUVFDQEHGHILQHGDV³HOGHUO\´
DJHLQJLVDFRQWLQXRXVSURFHVVDQGWKHFXWRIIRI\HDUVUHPDLQV
arbitrary. Nevertheless, we tried to accommodate this limitation 
by evaluating the age-by-treatment interaction also on a continu-
ous basis. Furthermore, a cut-off of 65 years yielded similar results. 
Third, the group of elderly patients was relatively modest in size, 
and all the analyses should be considered as hypothesis-generating 
and exploratory in nature. However, it is noteworthy that the mean 
age in the PRODIGY trial was the highest across available trials 
with comparable design. This might explain the differential effect of 
elderly status on the risk of ischaemic events observed in this study 
compared with other trials enrolling relatively younger patients. 
Fourth, randomisation in the PRODIGY trial was not stratified by age.
Conclusions
In an all-comers population of PCI patients, elderly participants 
experienced a higher risk of ischaemic and bleeding events com-
pared with their non-elderly counterparts with a comparable effect 
of ageing on the hazards of such events. Prolonging DAPT for 
24 months was not associated with a significantly different risk 
of the primary efficacy endpoint among elderly and non-elderly 
patients. However, elderly patients seemed to derive a greater 
absolute risk of clinically relevant bleeding from prolonged DAPT 
than younger patients.
Impact on daily practice
Elderly status conveys a higher risk of both ischaemic and 
bleeding events. Although dual antiplatelet therapy increases 
the risk of bleeding in both elderly and non-elderly patients, the 
former group incurs a substantially higher event rate. The effi-
cacy of prolonged dual antiplatelet therapy for the prevention of 
ischaemic events is not influenced by elderly status.
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Impact of Chronic Kidney Disease on 2-Year Clinical
Outcomes in Patients Treated with 6-Month or
24-Month DAPT Duration: An Analysis from the
PRODIGY Trial
Giuseppe Gargiulo,1,2 MD, Andrea Santucci,1 MD, Raffaele Piccolo,1 MD,
Anna Franzone,1 MD, Sara Ariotti,1,3 MD, Andrea Baldo,1 MD, Giovanni Esposito,2 MD, PhD,
Aris Moschovitis,1 MD, Stephan Windecker,1 MD, and Marco Valgimigli,1,3* MD, PhD
Objectives: To assess whether moderate-to-severe CKD is a treatment modifier for
benefit or harm in patients randomly allocated to 24-month versus 6-month DAPT.
Background: It is still unclear whether chronic kidney disease CKD should impact on
the decision-making on optimal duration of dual antiplatelet therapy (DAPT) after per-
cutaneous coronary intervention (PCI). Methods and Results: PRODIGY trial random-
ized 1970 all-comer patients at 24-month versus 6-month DAPT after PCI. Patients with
moderate-to-severe CKD (n5 604; 30.7%) were older, more likely to be women, to have
hypertension, diabetes, prior MI or PCI, with higher severity of coronary artery disease
(CAD), but were less frequently smokers or presenting with stable CAD. After adjustment,
the 2-year rates of primary endpoint (composite of death, myocardial infarction and cere-
brovascular accident), as well as bleeding and net adverse clinical events were higher in
patients with moderate-to-severe CKD. DAPT prolongation at 24-month did not reduce
the primary endpoint in both CKD (adj. HR: 0.957; 95% CI 0.652–1.407; P50.825) and no-
CKD (adj. HR: 1.341; 95% CI 0.861–2.086; P5 0.194) groups (Pint5 0.249), but increased
bleeding in both groups (CKD: adj. HR: 1.999; 95% CI 1.100–3.632; P5 0.023; no-CKD: adj.
HR: 2.880; 95% CI 1.558–5.326; P5 0.001; Pint50.407). Conclusions: Moderate-to-severe
CKD did not modify the effect of a prolonged or shortened DAPT duration in largely
unselected patients undergoing stent implantation. Our analysis suggests that CKD
should not be a major driver in the decision-making on the duration of DAPT after stent
implantation. This exploratory study is underpowered and should be considered
hypothesis-generating only. VC 2017 Wiley Periodicals, Inc.
Key words: chronic kidney disease (CKD); clopidogrel; DAPT; cardiovascular events;
bleeding
INTRODUCTION
Dual antiplatelet therapy (DAPT) is the antithrom-
botic of choice in patients with coronary artery disease
(CAD) undergoing percutaneous coronary intervention
(PCI) with stent implantation. However, its optimal
duration is a matter of ongoing debate [1–9]. Guide-
lines recommend at least 6-12 months in patients with
acute coronary syndrome (ACS) [1,2,9], but the evi-
dence for this is weak, and some randomized
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controlled trials suggested that the risks of prolonging
DAPT beyond 6 to 12 months outweigh the potential
benefits [10–12]. On the other hand, a recent trial on
DAPT duration has shown a relevant reduction in rates
of stent thrombosis (ST) and myocardial infarction
(MI) in patients free from bleeding or ischemic events
in the 30-month versus 12-month DAPT duration
groups [13].
It is still unknown whether the presence of CKD
should drive the decision-making on optimal DAPT
duration. CKD patients are at increased risk for both
ischemic and bleeding complications [14–16], mak-
ing the equation between possible ischemic benefits
and bleeding risks more challenging. A recent study
has suggested that clopidogrel prolongation over 12
months could be favorable in CKD patients receiving
first-generation drug-eluting stent (DES) in terms
of a significant reduction of death or myocardial
infarction (MI), and no increase of severe bleeding
[17,18].
We assessed whether moderate-to-severe CKD is a
treatment modifier for benefit or harm in patients ran-
domly allocated to 24-month versus 6-month DAPT.
METHODS
The design and main findings of the PRODIGY (Pro-
longing Dual- Antiplatelet Treatment After Grading Stent-
Induced Intimal Hyperplasia Study; NCT00611286) have
been previously reported [12,19,20]. Briefly, all-comer
PCI patients receiving a balanced mixture of stents with
varying anti-intimal hyperplasia potency and belonging to
both first- and second-generation DES at three Italian sites
were randomly allocated at 30 days to either 6 or 24
months of DAPT. Selection criteria were broad, reflecting
routine clinical practice. Randomization to 6- or 24-month
DAPT was stratified by center, ongoing ST-segment-
elevation myocardial infarction (STEMI), presence of
diabetes mellitus, and need for intervening for at least one
in-stent restenotic lesion. The study was conducted in
accordance with the principles of the Declaration of Hel-
sinki. The Ethics Committees of the three participating
centers independently approved the protocol, and all par-
ticipants gave written informed consent.
Treatment Protocol
All patients received aspirin (80–160 mg orally indefi-
nitely) and clopidogrel (75 mg/day) according to the ran-
domization scheme as follows: for either 6 months in the
short DAPT arm or 24 months in the prolonged DAPT
arm irrespective of the previously implanted stent type or
indication for PCI.
Follow-Up
The randomized patients returned for study visits at 30
days, and then every 6 months up to 2 years. During follow-
up visits, patients were examined and assessed for adverse
events, asked for the antiplatelet therapy compliance and
12-lead electrocardiogram recordings were obtained.
Study Endpoints
The primary efficacy endpoint of the PRODIGY trial
was the composite of death, MI, or cerebrovascular acci-
dent (CVA), while the key safety endpoint included
Bleeding Academic Research Consortium (BARC) type 2,
3, or 5 bleeding. The net effect on the combined ischemic
and bleeding complications was obtained by two net
adverse clinical event (NACE) endpoints that were gener-
ated by combining the primary efficacy endpoint of death,
MI, or CVA with either the primary safety endpoint of
BARC type 2, 3, or 5 bleeding or with BARC type 3 or 5
events. Other endpoints included each component of the
primary efficacy endpoint, cardiovascular death, stent
thrombosis (ST) defined on the basis of the Academic
Research Consortium criteria, and BARC type 3 or 5
bleeding. Other safety endpoints included bleeding events
adjudicated according to the TIMI and GUSTO scales. All
study endpoint definitions were previously reported.
All endpoints were confirmed on the basis of docu-
mentation collected at each hospital and were centrally
adjudicated by the clinical events committee, whose
members were unaware of the patients’ treatment-group
assignments. The time frame of interest for the primary
endpoint was from 30 days (i.e., after the primary end-
point randomization) to 24 months.
Renal Function Assessment
For this analysis, patients were divided into two groups
according to their estimated creatinine clearance (Cockroft-
Gault formula). Patients were defined as “Moderate-to-
severe CKD” if having an estimated creatinine clearance
<60 ml/min, while defined as “No/mild CKD” if creatinine
clearance was >60 ml/min. As sensitivity analysis, the
modification of diet in renal disease (MDRD) formula was
also used to estimate glomerular filtration rate (eGFR) and
CKD was defined if eGRF <60ml/min/1.73 m2 (Supple-
mentary Table I).
Statistical Analysis
The PRODIGY trial was designed to enroll at least
1700 patients to detect a 40% reduction in the relative
risk of the primary endpoint in the 24-month clopidogrel
group compared with 6-month duration of clopidogrel
therapy, with statistical power of >80% at a 2-sided sig-
nificance level of 0.05. The planned sample size was
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finally increased up to 2000 to allow for fatalities occur-
ring within the first 30 days, noncompliance, and loss to
follow-up as previously described [12].
Categorical variables were expressed as frequency (per-
centage), whereas continuous variables were expressed as
mean (standard deviation) and median (interquartile range).
Continuous variables were compared between randomized
groups using the Wilcoxon’s rank sums test, whereas for
binary variables the v2 test was used. Multiple imputations
were used for missing values of creatinine levels (n5 21)
and ejection fraction (n5 136).
Hazard ratios (HRs) with 95% confidence intervals
(CIs) were calculated for moderate-to-severe CKD ver-
sus no/mild CKD (i.e., values >1 indicated increased
hazard in the CKD group) and 24-month versus
6-month DAPT (i.e., values >1 indicated increased
hazard in the 24-month DAPT) with a proportional
hazards model. Cox-regression was used for multivari-
ate analysis. Clinical and angiographic characteristics
that were imbalanced at a nominal 5% significance lev-
el between the two groups were identified and included
the final adjusted model; these included age, gender,
body mass index (BMI), diabetes, hypertension, smok-
ing, prior myocardial infarction (MI), left ventricular
ejection fraction (LVEF), clinical presentation, multives-
sel intervention and total ACC/AHA score. Interaction
testing was performed to determine whether the effect of
TABLE I. Baseline Characteristics in Patients with or Without Moderate-to-Severe CKD
Characteristic
Moderate-to-severe
CKD (N5 604)
No/Mild CKD
(N5 1366) P value
Age (yr) 76.96 8.0
77.5 (73.3–82.3)
63.96 10.1
64.7 (57.2–71.4)
<0.0001
Male (n) 63.1% (381) 82.7% (1130) <0.0001
Body Mass Index (kg/m2) 25.66 3.4
25.3 (23.5–27.5)
28.66 13.0
27.4 (25.2–29.9)
<0.0001
Diabetes 27.6% (167) 22.7% (310) 0.018
Insulin-dependent 6.5% (39) 5.5% (75)
Hypertension 79.8% (482) 68.2% (932) <0.0001
Hyperlipidemia 51.8% (313) 56.0% (765) 0.086
Current cigarette use 11.4% (69) 29.3% (400) <0.0001
Creatinine levels (mg/dl) 1.56 1.2
1.3 (1.0–1.5)
0.96 0.2
0.9 (0.8–1.1)
<0.0001
Creatinine Clearance (ml/min) 45.46 11.9
48.3 (38.7–54.9)
93.16 34.2
87.8 (72.8–105.3)
<0.0001
Prior myocardial infarction 33.9% (205) 23.5% (321) <0.0001
Prior PCI 20.5% (124) 17.2% (235) 0.078
LVEF 48.36 10.8
50.0 (40–56)
51.86 9.9
55 (45–60)
<0.0001
Clinical presentation
Stable angina pectoris 20.2% (122) 28.0% (383) <0.0001
Acute Coronary Syndrome 79.8% (482) 72.0% (983)
STEMI 29.1% (176) 34.6% (472) 0.018
NSTEMI 30.0% (181) 19.7% (269) <0.0001
Unstable Angina 20.7% (125) 17.7% (242) 0.117
Multivessel Disease 77.3% (467) 66.8% (912) <0.0001
No. of treated lesions 1.546 0.8
1 (1–2)
1.546 0.9
1 (1–2)
0.996
!2 treated lesions 40.7% (246) 35.9% (490) 0.040
!3 treated lesions 11.1% (67) 11.4% (156) 0.832
Multivessel intervention 30.1% (182) 25.2% (344) 0.022
At least one complex lesion
(Type B2 or C)a
69.5% (420) 64.9% (886) 0.043
Total ACC/AHA scoreb 4.06 2.2
3 (3–5)
3.86 2.3
3 (2–4)
0.014
Aspirin 100% (604) 100% (1366) >0.999
Clopidogrel 99.5% (601) 100.0% (1366) 0.009
Statin 85.3% (505) 92.8% (1259) <0.0001
ACC5American College of Cardiology; AHA5American Heart Association; CABG5Coronary Artery Bypass Graft; LVEF5Left Ventricle
Ejection Fraction; NSTEMI5Non-ST-Elevation Myocardial Infarction; PCI5Percutaneous Coronary Intervention; STEMI5 ST-Elevation Myocardial
Infarction.
aAccording to the ACC/AHA coronary lesion classification.
bType A stenoses were coded 1 point, type B1 stenoses 2 points, type B2 stenoses 3 points, and type C stenoses 4 points.
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DAPT duration was consistent irrespective of CKD
severity on the primary and secondary endpoints of the
study. This was performed with likelihood ratio tests of
the null hypothesis that the interaction coefficient was
zero. Finally, the interaction between treatment effect
and renal function, modeled as a continuous variable,
was analyzed with a fractional polynomial interaction, as
proposed by Royston and Sauerbrei, and the best fit for
the interaction models was chosen according to the
Akaike information criteria. A two-sided probability
value of <0.05 was considered significant. All analyses
were based on the intention-to-treat principle, and were
performed with SPSS, version 21.0 (SPSS Inc., Chicago,
IL, USA) and Stata Statistical Software, release 13
(StataCorp LP, College Station, Texas, US).
RESULTS
Among 1,970 patients randomized to 6 versus
24-month DAPT at 30 days from the PCI, 1366 (69.3%)
had a creatinine clearance >60 ml/min and 604 (30.7%)
had moderate-to-severe CKD, including 65 patients with
creatinine clearance "30 ml/min. Baseline characteris-
tics are summarized in Table I. Characteristics of patients
randomized to 24-month or 6-month DAPT stratified for
CKD are reported in Table II. Compared with no/mild
CKD, patients with moderate-to-severe CKD were older,
more likely to be women, to have hypertension, diabetes,
prior MI or PCI, but had lower BMI, lower LVEF, and
were less frequently smokers. They had a higher exten-
sion and severity of CAD, with increased need for multi-
vessel intervention. Among CKD patients, PCI was more
frequently indicated by non-ST-segment elevation ACS
TABLE II. Baseline Characteristics in Patients with or Without Moderate-to-Severe CKD According to the Randomization for
DAPT Duration
Characteristic
Moderate-to-Severe CKD (N5 604) No/Mild CKD (N5 1366)
24-Month
Clopidogrel
(N5 312)
6-Month
Clopidogrel
(N5 292) P value
24-Month
Clopidogrel
(N5 675)
6-Month
Clopidogrel
(N5 691) P Value
Age (year) 77.0 (73.3–81.7) 78.3 (73.3–83.2) 0.194 64.6 (57.2–71.5) 64.8 (57.2–71.3) 0.824
Male 65.1% (203) 61.0% (178) 0.296 83.1% (561) 82.3% (569) 0.708
Body Mass Index (kg/m2) 25.5 (23.5–27.7) 25.3 (23.4–27.4) 0.960 27.4 (25.3–30.4) 27.3 (24.8–29.7) 0.597
Diabetes 28.2% (88) 27.1% (79) 0.752 23.1% (156) 22.3% (154) 0.716
Insulin-dependent 5.8% (18) 7.2% (21) 6.1% (41) 4.9% (34)
Hypertension 82.1% (256) 77.4% (226) 0.155 68.9% (465) 67.6% (467) 0.604
Hyperlipidemia 53.5% (167) 50.0% (146) 0.386 57.2% (386) 54.8% (379) 0.384
Current cigarette use 11.2% (35) 11.6% (34) 0.869 27.7% (187) 30.8% (213) 0.205
Creatinine levels (mg/dl) 1.3 (1.1–1.5) 1.2 (1–1.4) 0.152 0.9 (0.8–1.1) 1.0 (0.8–1.1) 0.578
Creatinine Clearance (ml/min) 48.1 (37.7–55.4) 48.6 (39.9–54.7) 0.433 88.0 (73.1–108) 87.7 (72.2–101.4) 0.026
Prior myocardial infarction 33.7% (105) 34.2% (100) 0.878 24.4% (165) 22.6% (156) 0.415
Prior PCI 21.8% (68) 19.2% (56) 0.426 17.9% (121) 16.5% (114) 0.484
LVEF 50.0 (40.4–56.1) 50.0 (40–55) 0.180 55.0 (45–60) 55.0 (45–60) 0.547
Clinical presentation
Stable angina pectoris 20.5% (64) 19.9% (58) 0.842 28.3% (191) 27.9% (192) 0.834
Acute Coronary Syndrome 79.5% (248) 80.1% (234) 0.842 71.7% (484) 72.2% (499) 0.834
STEMI 27.6% (86) 30.8% (90) 0.379 34.8% (235) 34.3% (237) 0.841
NSTEMI 30.8% (96) 29.1% (86) 0.656 19.3% (130) 20.1% (139) 0.691
Unstable Angina 21.2% (66) 20.2% (59) 0.774 17.6% (119) 17.8% (123) 0.934
Multivessel Disease 78.2% (244) 76.4% (223) 0.590 66.8% (451) 66.7% (461) 0.969
No. of treated lesions 1 (1–2) 1 (1–2) 0.028 1 (1–2) 1 (1–2) 0.557
!2 treated lesions 37.8% (118) 43.8% (128) 0.133 36.6% (247) 35.2% (243) 0.583
!3 treated lesions 10.3% (32) 12.0% (35) 0.499 11.3% (76) 11.6% (80) 0.853
Multivessel intervention 26.9% (84) 33.6% (98) 0.076 25.0% (169) 25.3% (175) 0.902
At least one complex lesion
(Type B2 or C)a
65.1% (203) 74.3% (217) 0.014 65.0% (439) 64.7% (447) 0.893
Total ACC/AHA scoreb 3 (2–4) 4 (3–6) 0.010 3 (2–4) 3 (2–4) 0.606
Aspirin 100% (312) 100% (292) >0.999 100% (675) 100% (691) >0.999
Clopidogrel 99.4% (310) 99.7% (291) >0.999 100.0% (675) 100.0% (691) 0.602
Statin 83.4% (257) 87.5% (248) 0.183 92.5% (621) 93.0% (638) 0.746
ACC5American College of Cardiology; AHA5American Heart Association; CABG5Coronary Artery Bypass Graft; LVEF5Left Ventricle Ejec-
tion Fraction; NSTEMI5Non-ST-Elevation Myocardial Infarction; PCI5 Percutaneous Coronary Intervention; STEMI5 ST-Elevation Myocardial
Infarction.
aAccording to the ACC/AHA coronary lesion classification.
bType A stenoses were coded 1 point, type B1 stenoses 2 points, type B2 stenoses 3 points, and type C stenoses 4 points.
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(NSTE-ACS) and less frequently by ST-segment eleva-
tion MI (STEMI) compared with no/mild CKD (Table I).
Baseline characteristics were well balanced in ran-
domized DAPT arms in both moderate-to-severe CKD
and no/mild CKD (Table II).
At 2-year, crude events and unadjusted HR sug-
gested higher ischemic and bleeding risks in patients
with moderate-to-severe CKD (Table III). The primary
efficacy endpoint (death, MI or CVA) occurred in 112
(18.5%) of moderate-to-severe CKD and 86 (6.3%) of
no/mild CKD. After adjustment, the primary efficacy
endpoint was increased by roughly 50% in those with
as compared to those without CKD (adj. HR:1.512;
95% confidence interval [CI] 1.042–2.194; P5 0.029;
Table III). Similarly, bleeding and NACE were signifi-
cantly higher in patients with CKD (Table III).
In both randomized groups of DAPT regimen (24 and
6-month DAPT), the primary endpoint was nonsignifi-
cantly increased in patients with CKD (24-month DAPT:
adj. HR:1.497; 95% CI 0.901–2.488; P5 0.120; 6-month
DAPT: adj. HR:1.427; 95% CI 0.814–2.501; P5 0.214;
p for interaction5 0.249; Table IV, Fig. 1). Similarly, the
risk of the primary efficacy endpoint did not differ with
respect to DAPT duration in both moderate-to-severe
CKD (17.6% in the 24-month vs. 19.5% in the 6-month
DAPT arms; adj. HR:0.957; 95% CI 0.652–1.407;
P5 0.825; Figs. 1 and 2, Table V, Supplementary Table
I) and no/mild CKD patients (6.7% in the 24-month vs.
5.9% in the 6-month DAPT arms; adj. HR:1.341; 95%
CI 0.861–2.086; P5 0.194; Figs. 1 and 2, Table V,
Supplementary Table I). The absence of interaction
between CKD and DAPT duration was further confirmed
by analyzing renal function as a continuous variable with
fractional polynomial analyses (P 50.558; Supplementary
Figure 1).
The key safety endpoint of BARC type 2, 3 or 5
bleeding occurred in 53 (8.8%) and 54 (4.0%) CKD
and no-mild CKD respectively. Patients treated with
longer DAPT experienced higher rate of bleeding
events in both groups (CKD: adj. HR:1.999; 95% CI
1.100–3.632; P5 0.023; no/mild CKD: adj. HR:2.880;
95% CI 1.558–5.326; P5 0.001; Fig. 3, Table V,
TABLE III. Clinical Outcomes in Patients with or Without Moderate-to-Severe CKD
Moderate-to-Severe
CKD (N5 604)
No/Mild
CKD (N5 1366)
Unadjusted Hazard
Ratio (95%CI) P value
Adjusted Hazard
Ratio (95% CI) P Value
Primary Efficacy Endpoint
Death for any cause, MI or CVA 112 (18.5) 86 (6.3) 3.172 (2.395–4.202) <0.0001 1.512 (1.042–2.194) 0.029
Secondary Efficacy Endpoints
Death for any cause or MI 104 (17.2) 78 (5.7) 3.230 (2.408–4.333) <0.0001 1.540 (1.044–2.273) 0.030
Death for any cause 79 (13.1) 51 (3.7) 3.819 (2.469–5.907) <0.0001 1.153 (0.651–2.040) 0.626
Death for cardiovascular cause 46 (7.6) 27 (2.0) 4.034 (2.508–6.489) <0.0001 1.268 (0.687–2.341) 0.447
Stroke or TIA 20 (3.3) 12 (0.9) 3.873 (1.893–7.923) <0.0001 1.965 (0.785–4.918) 0.149
MI 44 (7.3) 36 (2.6) 2.872 (1.849–4.461) <0.0001 1.454 (0.815–2.592) 0.205
Definite ST 7 (1.2) 8 (0.6) 2.094 (0.759–5.774) 0.153 2.004 (0.470–8.539) 0.347
Definite or Probable ST 9 (1.5) 19 (1.4) 1.078 (0.488–2.382) 0.853 0.552 (0.208–1.467) 0.234
Definite, Probable or Possible ST 50 (8.3) 34 (2.5) 3.512 (2.272–5.431) <0.0001 1.349 (0.758–2.402) 0.308
Safety Endpoints
BARC classification
Key safety endpoint (Type 2, 3 or 5) 53 (8.8) 54 (4.0) 2.379 (1.628–3.475) <0.0001 1.677 (1.025–2.743) 0.039
Type 3 or 5 33 (5.5) 20 (1.5) 3.971 (2.278–6.920) <0.0001 2.373 (1.147–4.908) 0.020
TIMI classification
Minor 11 (1.8) 9 (0.7) 2.956 (1.225–7.135) 0.016 2.199 (0.660–7.330) 0.200
Major 13 (2.2) 9 (0.7) 3.418 (1.461–7.997) 0.005 1.529 (0.514–4.550) 0.445
Minor or major 24 (4.0) 18 (1.3) 3.196 (0.734–5.888) <0.0001 1.757 (0.782–3.949) 0.172
GUSTO classification
Moderate 18 (3.0) 9 (0.7) 4.836 (2.173–10.766) <0.0001 4.154 (1.437–12.011) 0.009
Severe 15 (2.5) 10 (0.7) 3.553 (1.596–7.909) 0.002 2.023 (0.734–5.578) 0.173
Moderate or severe 32 (5.3) 19 (1.4) 4.051 (2.296–7.148) <0.0001 2.714 (1.293–5.694) 0.008
Net Clinical Adverse Events (NACE)
Death for any cause, MI,
CVA or BARC 2,
3 or 5 Bleeding
139 (23.0) 130 (9.5) 2.630 (2.071–3.341) <0.0001 1.488 (1.087–2.036) 0.013
Death for any cause, MI,
CVA or BARC
3 or 5 Bleeding
126 (20.9) 96 (7.0) 3.225 (2.473–4.206) <0.0001 1.601 (1.128–2.274) 0.008
BARC5Bleeding Academic Research Consortium; CVA5Cerebrovascular Accident; GUSTO5 Global Use of Strategies to Open Occluded Coro-
nary Arteries; MI5Myocardial Infarction; ST5 Stent Thrombosis; TIA5Transient Ischemic Attack; TIMI5Thrombolysis in Myocardial
Infarction.
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Supplementary Table I), without significant interaction
between CKD and bleeding outcomes (p for inter-
action5 0.407). This latter observation remained con-
sistent when considering renal function as a continuous
variable (P 50.476; Supplementary Figure 2).
When bleeding was restricted to BARC 3 or 5, the
increased rate of bleeding with prolonged DAPT as com-
pared with short-DAPT was higher in CKD patients
(CKD: adj. HR:2.278; 95% CI 1.066–4.869; P5 0.034)
but not in those with no/mild CKD: adj. HR:1.250; 95%
CI 0.489–3.196; P5 0.641; Figs. 2 and 3, Table V,
Supplementary Table I). Interaction testing however was
negative between CKD and moderate-to-severe bleeding
(p for interaction5 0.310).
The risk of NACE, consisting of death, MI, CVA or
BARC 2, 3 or 5 bleeding, was similar between 24-month
versus 6-month DAPT in CKD (adj. HR:1.162; 95% CI
0.822–1.643; P5 0.395; Fig. 4, Table V, Supplementary
Table I), but significantly increased in no/mild CKD
group (adj. HR:1.765; 95% CI 1.226–2.540; P5 0.002;
Fig. 4, Table V, Supplementary Table I), with negative
quantitative interaction testing (p for interaction5
0.085). When BARC 3 or 5 were used for NACE, there
were no significant differences between 24-month versus
6-month DAPT in both groups (CKD: adj. HR:1.117;
Fig. 1. Survival free from ischemic events according to CKD
presence. Cox proportional model plot for the primary
endpoint of all-cause death, myocardial infarction, and
cerebrovascular accident.
Fig. 2. Interaction between CKD and impact of randomiza-
tion to 24-month or 6-month DAPT on 2-year clinical out-
comes. CKD and no CKD subgroups are shown, with hazard
ratios and 95% confidence intervals, for the primary endpoint
of death for any cause, myocardial infarction (MI), or
cerebrovascular accident (CVA), death for any cause, cardio-
vascular death, myocardial infarction, definite or probable
stent thrombosis, BARC type 3 or 5 bleeding and net adverse
clinical events (NACE) among patients randomly assigned to
either the 6-month or the 24-month dual-antiplatelet therapy.
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95% CI 0.777–1.607; P5 0.549; no/mild CKD: adj.
HR:1.266; 95% CI 0.834–1.922; P5 0.269; p for inter-
action5 0.591; Figs. 2 and 4, Table V, Supplementary
Table I).
DISCUSSION
This sub-analysis from the PRODIGY randomized
trial assessed the impact of CKD on clinical outcomes
in all-comer patients undergoing PCI and receiving
DAPT with clopidogrel and aspirin. The main findings
are as follows:
1. CKD was confirmed to be a risk factor for both
ischemic and bleeding events;
2. Although patients with moderate-to-severe CKD had
higher rates of ischemic events than those with
no-mild CKD, DAPT prolongation at 24-month as
compared with 6-month DAPT was not associated
with ischemic benefits in both CKD and no-mild
CKD sub-groups, which is a consistent observation
with the overall results of the PRODIGY trial;
3. Patients with or without CKD experienced a significant
increase of bleeding events when undergoing prolonged
DAPT duration according to the key safety endpoint of
the study, consisting of BARC 2, 3 or 5. When more
stringent criteria for bleeding were applied (excluding
BARC 2 events), only those with CKD had a signifi-
cantly higher rate of bleeding events with DAPT pro-
longation; However, interaction testing was negative
suggesting that CKD per se did not emerge as treatment
modifier with respect to the risk of bleeding when a
prolonged DAPT regimen is implemented.
The optimal DAPT duration after coronary stenting
remains an ongoing matter of debate, but the more fre-
quently suggested approach is tailoring therapy based on
patient characteristics and avoiding prolonged DAPT
regimens due to emerging risks in terms of bleeding and
mortality [4,5,12].
Many studies have focused on the association
between renal dysfunction and risk of ischemic events
after PCI [17,21–23]. CKD patients are characterized
by more frequent high platelet reactivity and higher
rate of poor responsiveness to this drug have been pre-
viously observed [24–27].
However, a large body of evidence also supports the
concept that CKD patients are also at higher bleeding risks
after PCI [15,22,28,29]. Consistent with these observa-
tions, renal function is frequently taken into account in
previously developed bleeding risk scores, including
CRUSADE, HAS-BLEED and ACUITY.
The evidence from studies that specifically addressed
the impact of DAPT regimen stratified for renal func-
tion is limited. To our knowledge, the current study is
Fig. 3. Survival free from bleeding events according to CKD
presence. Cox proportional model plot for BARC 2, 3, or 5
bleeding events.
Fig. 4. Survival free from net clinical adverse events accord-
ing to CKD presence. Cox proportional model plot for NACE
including BARC 2, 3, or 5 bleeding events.
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the first dedicated CKD sub-analysis from a random-
ized trial comparing a short versus a prolonged DAPT
regimen. In a retrospective analysis from Siddiqui
et al, clopidogrel prolongation was found to be associ-
ated with reduction of MI and death in the absence of
significant increase in severe bleeding [17,18]. Howev-
er, that study suffered from important limitations,
including the bleeding definition [18]. Conversely, our
study prospectively collected baseline and follow-up
information in the setting of a randomized clinical
study specifically investigating the role of two different
regimens of DAPT after stent implantation [12]. In the
PEGASUS-TIMI 54 trial, there was no significant
interaction between renal function and clinical ische-
mic events with both CKD and no-CKD patients hav-
ing benefits from ticagrelor therapy, even if those with
CKD had a higher risk of MACE and a higher absolute
risk reduction [30].
Differently from previous suggestions, our findings
support the concept that the presence of moderate-to-
severe CKD should be considered as a condition in
which bleeding risk outweighs ischemic risk, rather than
the opposite [14,16,17]. Therefore, these patients would
benefit more if not prolonging DAPT over the recom-
mended period after PCI, although this decision should
always be tailored at an individual level. Consequently,
it seems plausible to extend the results generally
observed by randomized trials (DAPT prolongation
increases risks of bleeding and mortality, while a short
course of DAPT was associated with a significant reduc-
tion in major bleeding without significant differences in
ischemic or thrombotic outcomes) also to patients with
CKD.
Limitations
This sub-analysis of the PRODIGY trial was not pre-
specified. This study was not designed or powered to
specifically investigate on CKD differences, but it is
an exploratory analysis that should be considered
hypothesis generating and needs to be confirmed in
further trials.
CONCLUSIONS
The present study suggests that in the setting of an unse-
lected PCI population receiving a balanced distribution of
coronary stents, including first and newer generation DES,
CKD does not appear a treatment modifier with respect to
the benefit or harm of a prolonged DAPT regimen. More-
over, CKD patients are exposed to a sizable bleeding risk
when treated with a 24-month as compared with 6-month
DAPT duration. Hence, our analysis does not suggest that
CKD should be a major driver in the decision-making on
the duration of DAPT after stent implantation.
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Invited Commentary
Deciding on the Duration of Dual Antiplatelet Therapy—
When the Choice Between 2 Evils Is Still Evil
Marco Valgimigli, MD, PhD; Giuseppe Gargiulo, MD
TheDualAntiplateletTherapy (DAPT) Study1wasan interna-
tional, blinded, placebo-controlled, randomized trial compar-
ing 2 durations of thienopyridine therapy to prevent stent
thrombosis (ST) or the com-
posite end point of mortal-
ity, myocardial infarction
(MI), or stroke among 9961
patients treatedwith drug-eluting stents. The study aimed to
demonstrate that prolonged thienopyridine therapy (ie, for an
additional 18months)wouldbenoninferior tostandardtherapy
duration (ie, 1-year therapy after coronary stenting) with re-
spect tomoderate or severe bleeding as defined by theGlobal
Utilization of Streptokinase and Tissue Plasminogen Activa-
tor for Occluded Arteries (GUSTO) classification.1 A second-
ary cohort consisting of 1687 patients treatedwith baremetal
stents was also included.
Prolonging DAPT for an additional 18months compared
with 1-year therapy in selected patients with no ischemic or
bleeding recurrences at 12 months (in addition to other fea-
tures) reduced the risksofmajor adversecardiovascular events
(4.3% vs 5.9%, P < .001) and ST (0.4% vs 1.4%, P < .001) but
increased the risks of moderate to severe bleeding (2.5% vs
1.6%, P = .001).1While a trade-off between benefits and risks
with continued thienopyridine therapy plus aspirin was an-
ticipated basedonprevious findings,2 an increased risk of all-
cause mortality, a secondary end point, with continuation of
thienopyridine therapy was unexpected and remains a mat-
ter of concern.1 The higher risk of fatalities in the group with
continued thienopyridine therapywas attributable to greater
noncardiovascularmortality (1%vs0.5%,P < .002),while car-
diac death was comparable (0.9% vs 1.0%, P = .98).1
In thePreventionofCardiovascularEvents inPatientsWith
PriorHeartAttackUsingTicagrelorCompared toPlaceboonthe
Background of Aspirin–Thrombolysis in Myocardial
Infarction 54 (PEGASUS TIMI 54) trial,3 patients after MI who
were treatedwith ticagrelor in combinationwith aspirin expe-
rienceda 17%relative reduction incardiovasculardeath,MI, or
strokecomparedwith thosewhowere treatedwithplaceboand
aspirin (4.47%vs5.25%,P = .005). In aprespecifiedanalysisof
thosewhohadnotdiscontinuedP2Y12 inhibitor therapyorhad
only discontinued it within 30 days, the benefit was greatest
(28%relative reduction [4.9%vs6.2%],P = .004).3Yet, consis-
tentwithwhatwaspreviouslyobserved in theDAPTStudy,1 the
ratesofTIMImajorbleedingwerehigherwith ticagrelor (2.60%
with90mgtwicedaily and2.30%with60mgtwicedaily) than
withplacebo (1.06%)(P < .001 foreachdosevsplacebo).3While
cardiovascular death trended lower, noncardiovascular death
was increasedwith ticagrelor therapy.4
Both studies1,3 established the superiority of prolonged
DAPT over aspirin alone in preventing ischemic recurrence in
stabilizedpatientsafterpercutaneouscoronary interventionor
MI.However,despiteapparentlyselectingsubpopulationswith
lowbleeding risk, both trials observed aworrisome increase in
major bleeding with DAPT compared with no DAPT (placebo,
which is aspirin alone), themagnitudeofwhichappeared tobe
comparable to the difference in nonfatal ischemic end points
seen between study arms. Therefore, the decision of whether
DAPT should be continued 1 year from the event or coronary
stenting requires preliminary clarificationof the relative effect
of ischemic and bleeding events onmortality.
In this issue of JAMA Cardiology, Secemsky et al5 present
findings that lend further support to end the one-size-fits-all
era regarding the potency and duration of antithrombotic
agents. Those believing that the DAPT Study1 uncondition-
ally supports the extension of DAPT beyond 1 year in all pa-
tientsaftercoronarystentingshouldreadtheirarticlewitheven
greater attention.6
What are the lessons to be learned by practicing cardiolo-
gists?First, continuingDAPTbeyond 12monthsbasedon theo-
retical concerns about very late ST is unjustified. Even in the
setting of the study by Secemsky et al,5 in which 22.5%of pa-
tients received paclitaxel-eluting stents (which were con-
firmed to be independently associated with higher ischemic
risk), ST was rare (22.5% of ischemic events), while most is-
chemic events were MI not related to ST (61.0% of ischemic
events). Therefore, DAPT should be continued with the chief
aim of preventing spontaneousMI rather than protecting the
few previously stented millimeters of coronary arteries.
Second, the frequency of bleeding events after a pro-
longed course of DAPT, as well as their implications with re-
spect to mortality, is dependent on the applied classification.
The DAPT Study1 prespecified a sensitive definition for recur-
rentMI based on troponin elevation beyond the upper limit of
normal in conjunctionwith any compatible transient ischemia
symptoms. This specification is in keeping with the universal
MI definition (and with the somewhat insensitive GUSTO
classification for bleeding events) that was developed in the
thrombolysis era to compare in-hospital hemorrhagic compli-
cations across different lytic agents. In the study by Secemsky
et al,5 a total of235GUSTOmoderate or severe bleeding events
occurred in232of 11 648patients (2.0%),which is roughly50%
lower than the 502 adjudicated ischemic end points that were
observed in478 (4.1%)of thepatients. Thisobservation led the
authors to conclude that, while ischemic and bleeding events
werebothassociatedwithahighmortality rate, ischemicevents
weremore frequent than bleeding events.
However, delving deeper into the study results by
Secemsky et al5 reveals a broader and (we believe) more
accurate setofobservations.PatientswithspontaneousMIhad
a9.1-fold greater riskofdyingduring the studycomparedwith
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thosewithout spontaneousMI.However,patientswithGUSTO
moderate to severe bleedinghadan 18.1-fold greater probabil-
ity of death comparedwith thosewithout suchGUSTOevents
throughout follow-up. Hence, amore appropriate conclusion
is that, although bleeding events were less frequent than
ischemic events according toprespecified classifications, they
were associated with a 2-fold higher risk of death. Calcula-
tion of the attributable risk helps to factor in both prevalence
and ameasure of association withmortality. By doing so, the
occurrence of spontaneous MI during the study would ex-
plain approximately 17%of theoverallmortality,while theoc-
currence of GUSTO moderate to severe bleeding would ex-
plain as much as 25%. Therefore, prioritizing (to prevent)
ischemic events over bleeding events does not definitively
appear to be the right thing to do.
Third, theBleedingAcademicResearchConsortium(BARC)
classificationappears tobemuchmoresuitable thantheGUSTO
classification to inform clinicians on the safety profile of any
tested antithrombotic treatment in today’s practice. Bleeding
atBARC2,3, or5 (ie, anyactionablebleeding) occurred in4.1%
of the patients in the study by Secemsky et al,5 which corre-
sponds exactly to the event rate observed for ischemic events
and which carried an almost identical risk of mortality com-
pared with ischemic events.
Fourth, the analysis by Secemsky et al5 confirmed previ-
ous observations that even a so-called minor yet actionable
bleeding category, such as BARC 2, is associated with higher
mortality risk.7 This finding by Secemsky et al5 is in agree-
ment with the prior study7 and is paramount because it de-
rives fromananalysis inwhich fatal bleeding events (ie, BARC
5)wereanalyzedseparately insteadofbeingdistributedtoother
classes (ie, BARC 2 or 3) according to initial assessment by the
clinical event committee (ie, before theybecame fatal).Hence,
this scenario hasmost likely resulted in a dilution effect with
respect to the measure of association between BARC 2 and 3
and fatal outcomes.
Fifth, as expected, while ischemic events in the study by
Secemskyet al5weremainly associatedwith an increased risk
of cardiovascular death (78.8% forwith cardiovascular death
among all deaths in patients with ischemic events), bleeding
accounted foramorebalanceddistributionwith respect to type
of fatalities (of deaths after a bleeding event, 53.7%were car-
diovascular and 46.3% were noncardiovascular). This find-
ingpossiblyexplains, at least inpart, theoverall results in terms
of mortality and type thereof across major DAPT studies.3
In summary, choosing between 2 evils occurring at simi-
lar frequencies and carrying comparable prognostic implica-
tions is still evil. Personalized treatment algorithmsmaximiz-
ingbenefitsover risks represent theonly sensibleway forward.
TheDAPTStudy investigators shouldbe commended for their
continued efforts to learn from and teach based on the
powerful database they have amassed.
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Use of the Dual-Antiplatelet Therapy Score to Guide Treatment
Duration After Percutaneous Coronary Intervention
Raffaele Piccolo, MD; Giuseppe Gargiulo, MD; Anna Franzone, MD; Andrea Santucci, MD; Sara Ariotti, MD; Andrea Baldo, MD;
Carlo Tumscitz, MD; Aris Moschovitis, MD; Stephan Windecker, MD; and Marco Valgimigli, MD, PhD
Background: The dual-antiplatelet therapy (DAPT) score was
developed to identify patients more likely to derive harm (score
<2) or benefit (score ≥2) from prolonged DAPT after percutane-
ous coronary intervention (PCI).
Objective: To evaluate the safety and efficacy of DAPT duration
according to DAPT score.
Design: Retrospective assessment of DAPT score–guided treat-
ment duration in a randomized clinical trial. (ClinicalTrials.gov:
NCT00611286)
Setting: PCI patients.
Patients: 1970 patients undergoing PCI.
Intervention: DAPT (aspirin and clopidogrel) for 24 versus 6
months.
Measurements: Primary efficacy outcomes were death, myo-
cardial infarction, or cerebrovascular accident. The primary
safety outcome was type 3 or 5 bleeding according to the Bleed-
ing Academic Research Consortium definition. Outcomes were
assessed between 6 and 24 months.
Results: 884 patients (44.9%) had a DAPT score of at least 2,
and 1086 (55.1%) had a score less than 2. The reduction in the
primary efficacy outcome with 24- versus 6-month DAPT was
greater in patients with high scores (risk difference [RD] for score
≥2,!2.05 percentage points [95% CI,!5.04 to 0.95 percentage
points]; RD for score <2, 2.91 percentage points [CI, !0.43 to
6.25 percentage points]; P = 0.030). However, the difference by
score for the primary efficacy outcome varied by stent type; pro-
longed DAPT with high scores was effective only in patients re-
ceiving paclitaxel-eluting stents (RD, !7.55 percentage points
[CI, !12.85 to !2.25 percentage points]). The increase in the
primary safety outcome with 24- versus 6-month DAPT was
greater in patients with low scores (RD for score ≥2, 0.20 per-
centage point [CI, !1.20 to 1.60 percentage points]; RD for
score <2, 2.58 percentage points [CI, 0.71 to 4.46 percentage
points]; P = 0.046).
Limitation: Retrospective calculation of the DAPT score.
Conclusion: Prolonged DAPT resulted in harm in patients with
low DAPT scores undergoing PCI but reduced risk for ischemic
events in patients with high scores receiving paclitaxel-eluting
stents. Whether prolonged DAPT benefits patients with high
scores treated with contemporary drug-eluting stents requires
further study.
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Dual-antiplatelet therapy (DAPT) with aspirin andoral P2Y12 adenosine diphosphate–receptor inhib-
itors is an evidence-based, guideline-recommended
standard of care in patients with coronary artery dis-
ease undergoing percutaneous coronary intervention
(PCI) (1–3). The pathobiological rationale for DAPT after
PCI is to prevent atherothrombotic manifestations in
the stented coronary segments before arterial healing
and stent endothelialization are complete. However, al-
though guidelines mandate a minimum course of 1 to 6
months after PCI, depending on clinical presentation
and stent type (1, 3), the optimal duration of DAPT in
the long term is controversial because the ischemic
protection afforded by extended DAPT is largely offset
by an increase in bleeding complications (4, 5). Pro-
longed DAPT has been estimated to prevent 8 myocar-
dial infarctions per 1000 persons treated for 1 year, but
at a cost of 6 major bleeding events (6, 7). In view of
this tradeoff between efficacy and safety, as well as a
possible lack of a mortality benefit due to an increase in
noncardiovascular deaths with prolonged DAPT (4, 8),
American and European guidelines recommend indi-
vidualizing the duration of DAPT on the basis of isch-
emic versus bleeding risks (1, 3). This recommendation
is also consistent with the results of a survey assessing
contemporary clinical practice (9).
The DAPT score is a new standardized tool to iden-
tify patients who would derive benefit or harm from
prolonged DAPT (10, 11). However, the efficacy and
safety of DAPT duration as guided by the score have
not been assessed outside the derivation cohort in-
cluded in the DAPT (Dual Antiplatelet Therapy) Study
(ClinicalTrials.gov: NCT00977938), in which all patients
received DAPT for 12 months and were then randomly
assigned to continue thienopyridine treatment or pla-
cebo on a background of aspirin (8). We therefore
sought to apply the DAPT score to PRODIGY (Prolong-
ing Dual-Antiplatelet Treatment After Grading Stent-
Induced Intimal Hyperplasia Study), which enrolled a
broadly inclusive sample of patients randomly assigned
to a prolonged (24 months) versus a short (≤6 months)
DAPT regimen after PCI (12).
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METHODS
Details on study design and primary results of
PRODIGY have been reported elsewhere (12–14).
Briefly, unselected patients undergoing PCI (n = 2013)
were randomly assigned to receive 1 of 4 types of stent
(bare-metal, zotarolimus-eluting, paclitaxel-eluting, or
everolimus-eluting). At 30 days, 1970 patients were
randomly allocated to either 6 or 24 months of DAPT.
Randomization was stratified by center, ongoing ST-
segment elevation myocardial infarction, presence or
absence of diabetes mellitus, and presence or absence
of in-stent restenosis. Selection criteria were broad in
order to reflect routine clinical practice. The main ex-
clusion criteria were known allergy to antiplatelet
drugs, planned surgery within the next 24 months, his-
tory of bleeding diathesis, active bleeding or stroke in
the previous 6 months, need for concomitant oral anti-
coagulation, pregnancy, and life expectancy less than 2
years.
Treatment Protocol
A maintenance dose of clopidogrel (75 mg/d) was
administered for up to 6 or 24 months according to
randomization. A low dose of aspirin (80 to 160 mg/d)
was prescribed indefinitely in all patients.
Study End Points
The primary efficacy end point for this analysis
was the composite of death, myocardial infarction, or
cerebrovascular accident. Other efficacy outcomes in-
cluded each component of the primary efficacy end
point, cardiovascular death, and stent thrombosis ac-
cording to the Academic Research Consortium criteria
(15).
The primary safety end point was a composite of
type 3 or 5 bleeding according to the Bleeding Aca-
demic Research Consortium (BARC) definitions, includ-
ing overt bleeding with a decrease in hemoglobin level
of at least 3 g/dL; bleeding requiring transfusion, intra-
venous vasoactive agents, or surgical intervention for
control; bleeding resulting in cardiac tamponade; and
intracranial or intraocular bleeding. Other safety end
points were BARC type 2, 3, or 5 bleeding as well as
bleeding that met the Thrombolysis in Myocardial In-
farction (TIMI) and the Global Utilization of Streptoki-
nase and Tissue Plasminogen Activator for Occluded
Coronary Arteries (GUSTO) criteria. The BARC, TIMI,
and GUSTO criteria are detailed in Appendix 1 (avail-
able at Annals.org). A clinical events committee
blinded to treatment allocation adjudicated all efficacy
and safety events.
Calculation of the DAPT Score
We calculated the DAPT score for each patient in-
cluded in PRODIGY, as previously reported (10). The
score ranges from !2 to 10 and is calculated by assign-
ing points according to characteristics related to the
patient (0 for age <65 years, !1 for age ≥65 and <75
years, !2 for age ≥75 years, 1 for diabetes mellitus, 1
for current smokers, 1 for prior PCI or myocardial infarc-
tion, and 2 for history of congestive heart failure or left
ventricular ejection fraction <30%) and the index pro-
cedure (1 for acute myocardial infarction at presenta-
tion, 2 for PCI of saphenous vein graft, 1 for implanta-
tion of a paclitaxel-eluting stent, and 1 for stent
diameter <3 mm). Overall, a low score (<2) identifies
patients for whom bleeding risks outweigh ischemic
benefits, and a high score (≥2) identifies patients for
whom ischemic benefits outweigh bleeding risks. A cal-
culator for the score is available at www.daptstudy.org
/for-clinicians/calchome.htm.
Statistical Analysis
For calculation of the DAPT score, missing values
for left ventricular ejection fraction (n = 136) were esti-
mated using multiple imputation (Appendix 2, avail-
able at Annals.org). The reported percentages are
Kaplan–Meier estimates of cumulative incidence at 24
months. Because the randomized treatment between
groups began to diverge at 6 months, a landmark anal-
ysis was performed between 6 and 24 months by cen-
soring patients if they experienced the event of interest,
died, or were lost to follow-up before 6 months (16).
The efficacy and safety of prolonged versus short DAPT
were assessed in categories of high and low DAPT
score. To account for data censoring, the pseudovalue
approach was used to calculate absolute risk differ-
ences (RDs) and 95% CIs between prolonged and short
DAPT (17). The treatment effect of prolonged versus
short DAPT between patients with high and low scores
was compared using a Z test for interaction (18). The
efficacy of prolonged versus short DAPT within the high
and low score groups was also explored across stent
types, with heterogeneity assessed by the Q statistic.
Sensitivity analyses were conducted from 1 to 24
months after patients who received earlier-generation
paclitaxel-eluting stents, which are associated with a
higher risk for stent thrombosis and myocardial infarc-
tion, and those with missing values for left ventricular
ejection fraction were excluded. A sensitivity analysis of
safety outcomes accounting for the competing risk for
death was also conducted (17). All P values were
2-sided, and those less than 0.05 indicated statistical
significance. All analyses were done using Stata, ver-
sion 13 (StataCorp). Further details on the statistical
analysis are provided in Appendix 2.
Institutional Review Board Approval
The ethics committees of the participating centers
independently approved the protocol, and all partici-
pants gave written informed consent.
Role of the Funding Source
This study received no funding.
RESULTS
DAPT Score Distribution and Baseline
Characteristics
Of 1970 patients enrolled in PRODIGY, 884 (44.9%)
had a high DAPT score (≥2) and 1086 (55.1%) had a
low score (<2). The median score was 1 (interquartile
range, 0 to 2; mean, 1.3 [SD, 1.5]) (Appendix Figure 1,
available at Annals.org). Patients with high scores were
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younger and more likely to be male; to be smokers;
and to have diabetes, prior myocardial infarction, prior
coronary revascularization, congestive heart failure or
left ventricular dysfunction, and acute myocardial in-
farction at presentation. They also were less likely to
have arterial hypertension or peripheral artery disease
and had higher estimated glomerular filtration rates
(Table 1). Patients with high scores more frequently had
PCI for saphenous vein graft disease or in-stent reste-
nosis and had a greater mean stent diameter (Table 2).
Baseline and periprocedural characteristics were simi-
lar within high and low score groups between patients
assigned to 24 versus 6 months of DAPT (Appendix
Tables 1 and 2, available at Annals.org).
Efficacy OutcomesWith Prolonged Versus Short
DAPT, by DAPT Score
The reduction in the primary efficacy outcome of
death, myocardial infarction, or cerebrovascular acci-
dent with 24 versus 6 months of DAPT was greater in
patients with high scores than those with low scores (P
for interaction = 0.030) (Figure, top).
Among patients with high scores, the primary isch-
emic outcome occurred in 4.2% randomly assigned to
24-month DAPT compared with 6.2% randomly as-
signed to 6-month DAPT (RD, !2.05 percentage points
[95% CI, !5.04 to 0.95 percentage points]) (Table 3
and Appendix Figure 2, available at Annals.org). Com-
pared with short DAPT, prolonged DAPT was associ-
ated with fewer cardiac deaths and myocardial infarc-
tions (RD, !2.01 percentage points [CI, !4.53 to 0.51
percentage points]). Definite, probable, or possible
stent thrombosis was also significantly reduced in pa-
tients with high scores who received prolonged versus
short DAPT (RD, !2.44 percentage points [CI, !4.70 to
!0.19 percentage points]). Among patients with low
scores, the primary efficacy outcome occurred in 9.8%
randomly assigned to 24-month DAPT compared with
6.8% randomly assigned to 6-month DAPT (RD, 2.91
percentage points [CI, !0.43 to 6.25 percentage
points]) (Table 3 and Appendix Figure 2).
Safety OutcomesWith Prolonged Versus Short
DAPT, by Score
The increase in the primary safety outcome of
BARC type 3 or 5 bleeding with 24- versus 6-month
DAPT was greater in patients with low scores than
those with high scores (P for interaction = 0.046) (Fig-
ure, bottom).
Among patients with high scores, BARC type 3 or 5
bleeding occurred in 1.2% randomly assigned to 24-
month DAPT compared with 1.0% randomly assigned
to 6-month DAPT (RD, 0.20 percentage point [CI,
!1.20 to 1.60 percentage points]) (Table 4 and Appen-
dix Figure 2). Consistently, there were no large differ-
ences between prolonged and short DAPT with regard
Table 1. Baseline Characteristics, by DAPT Score
Characteristic DAPT Score High vs. Low DAPT Score
<0 (n ! 233) 0 (n ! 394) 1 (n ! 459) 2 (n ! 461) >2 (n ! 423) High (>2)
(n ! 884)
Low (<2)
(n ! 1086)
Risk Difference
(95% CI)
Mean age (SD), y 77.9 (5.4) 74.1 (8.2) 69.2 (9.9) 63.7 (10.4) 59.7 (10.6) 61.8 (10.6) 72.8 (9.1) −11.0 (−11.9 to −10.2)
Male, n (%) 155 (66.5) 271 (68.8) 353 (76.9) 375 (81.3) 357 (84.4) 732 (82.8) 779 (71.7) 11.1 (7.3 to 14.8)
Mean BMI (SD), kg/m2 26.5 (3.4) 28.0 (18.8) 27.1 (3.9) 27.8 (10.8) 28.4 (9.6) 28.1 (10.2) 27.3 (11.7) 0.8 (−0.2 to 1.8)
Hypertension, n (%) 184 (79.0) 308 (78.2) 340 (74.1) 313 (67.9) 269 (63.6) 582 (65.8) 832 (76.6) −10.8 (−14.7 to −6.8)
Dyslipidemia, n (%) 122 (52.4) 217 (55.1) 241 (52.5) 257 (55.7) 241 (57.0) 498 (56.3) 580 (53.4) 2.9 (−1.5 to 7.4)
Smoking, n (%) 2 (0.9) 21 (5.3) 75 (16.3) 144 (31.2) 227 (53.7) 371 (42.0) 98 (9.0) 32.9 (29.5 to 36.4)
Diabetes, n (%) 14 (6.0) 70 (17.8) 99 (21.6) 124 (26.9) 170 (40.2) 294 (33.3) 183 (16.9) 16.4 (12.7 to 20.1)
Insulin-treated diabetes,
n (%)
4 (1.7) 15 (3.8) 21 (4.6) 27 (5.9) 47 (11.1) 74 (8.4) 40 (3.7) 4.7 (2.6 to 6.8)
Family history of CAD, n (%) 51 (21.9) 105 (26.6) 126 (27.5) 131 (28.4) 140 (33.1) 271 (30.7) 282 (26.0) 4.7 (0.7 to 8.7)
Previous MI, n (%) 26 (11.2) 81 (20.6) 111 (24.2) 136 (29.5) 172 (40.7) 308 (34.8) 218 (20.1) 14.8 (10.9 to 18.6)
Previous PCI, n (%) 18 (7.7) 54 (13.7) 90 (19.6) 96 (20.8) 101 (23.9) 197 (22.3) 162 (14.9) 7.4 (4.0 to 10.8)
Previous CABG, n (%) 26 (11.2) 42 (10.7) 35 (7.6) 46 (10.0) 64 (15.1) 110 (12.4) 103 (9.5) 3.0 (0.2 to 5.7)
Mean creatinine clearance
(SD),mL/min/1.73 m2*
60.6 (19.1) 65.9 (23.3) 77.0 (50.6) 85.5 (28.8) 94.0 (35.1) 89.6 (32.2) 69.5 (37.4) 20.1 (17.0 to 23.2)
Peripheral artery disease,
n (%)
35 (15.0) 60 (15.2) 64 (13.9) 51 (11.1) 36 (8.5) 87 (9.8) 159 (14.6) −4.8 (−7.7 to −1.9)
Mean LVEF (SD), %† 54.2 (8.6) 52.4 (9.9) 51.1 (9.8) 50.3 (10.1) 47.4 (11.5) 48.9 (10.9) 52.2 (9.7) −3.3 (−4.2 to −2.4)
Congestive heart failure or
left ventricular dysfunction,
n (%)
0 (0) 0 (0) 7 (1.5) 20 (4.3) 53 (12.5) 73 (8.3) 7 (0.6) 7.6 (5.9 to 9.3)
Indication for PCI, n (%)
Stable CAD 91 (39.1) 123 (31.2) 128 (27.9) 108 (23.4) 55 (13.0) 163 (18.4) 342 (31.5) −13.1 (−16.9 to −9.2)
NSTE-ACS 105 (45.1) 179 (45.4) 173 (37.7) 183 (39.7) 177 (41.8) 360 (40.7) 457 (42.1) −1.4 (−5.7 to 3.0)
STEMI 37 (15.9) 92 (23.4) 158 (34.4) 170 (36.9) 191 (45.2) 361 (40.8) 287 (26.4) 14.4 (10.3 to 18.5)
Acute MI at presentation,
n (%)
60 (25.8) 175 (44.4) 246 (53.6) 289 (62.7) 328 (77.5) 617 (69.8) 481 (44.3) 25.5 (21.2 to 29.8)
BMI = body mass index; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DAPT = dual-antiplatelet therapy; LVEF = left
ventricular ejection fraction; MI = myocardial infarction; NSTE-ACS = non–ST-segment elevation acute coronary syndrome; PCI = percutaneous
coronary intervention; STEMI = ST-segment elevation myocardial infarction.
* Missing in 21 patients.
† Missing in 136 patients.
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to GUSTO moderate or severe bleeding (RD, 0.20 per-
centage point [CI, !1.03 to 1.44 percentage points]) or
TIMI minor or major bleeding (RD, 0.20 percentage
point [CI, !1.20 to 1.60 percentage points]). In con-
trast, in the low score group, the risk for BARC type 3 or
5 bleeding was increased among patients randomly as-
signed to 24- versus 6-month DAPT (RD, 2.58 percent-
age points [CI, 0.71 to 4.46 percentage points]) (Table
4 and Appendix Figure 2). The risks for GUSTO mod-
erate or severe bleeding (RD, 2.57 percentage points
[CI, 0.77 to 4.38 percentage points]) or TIMI minor or
major bleeding (RD, 1.97 percentage points [CI, 0.37 to
3.56 percentage points]) were consistently increased in
patients allocated to prolonged versus short DAPT.
Effect of Stent Type and Sensitivity Analysis
For the primary efficacy outcome in patients with
high DAPT scores, risk estimates associated with 24-
versus 6-month DAPT varied by stent type (P for inter-
action = 0.005), driven primarily by a lower risk for
events with prolonged versus short DAPT among pa-
tients who received paclitaxel-eluting stents (RD, !7.55
percentage points [CI, !12.85 to !2.25 percentage
points]) (Figure and Appendix Table 3, available at
Annals.org). After patients with paclitaxel-eluting stents
were excluded, the RDs for the primary ischemic out-
come associated with randomized DAPT duration were
similar in both the high (RD, 1.23 percentage points [CI,
!2.41 to 4.86 percentage points]) and low (RD, 2.38
percentage points [CI, !1.12 to 5.87 percentage
points]) score categories (P for interaction = 0.65) (Fig-
ure and Appendix Tables 4 and 5, available at Annals
.org).
Clinical outcomes between 1 and 24 months ac-
cording to DAPT duration and score category are
shown in Appendix Tables 6 and 7 (available at Annals
.org). For the primary efficacy outcome, RDs between
the high (!1.24 percentage points [CI, !4.95 to 2.47
percentage points]) and low (1.37 percentage points
[CI, !2.40 to 5.14 percentage points]) DAPT score
groups were less pronounced (P for interaction = 0.33).
In contrast, the greater harmful effect of prolonged
DAPT on the primary safety outcome remained more
pronounced in patients with low scores (RD, 2.95 per-
centage points [CI, 0.72 to 5.18 percentage points])
Table 2. Angiographic Characteristics, by DAPT Score*
Characteristic DAPT Score High vs. Low DAPT Score
<0 (n ! 233) 0 (n ! 394) 1 (n ! 459) 2 (n ! 461) >2 (n ! 423) High (>2)
(n ! 884)
Low (<2)
(n ! 1086)
Risk Difference
(95% CI)
Angiographic features, n (%)
Single-vessel disease 66 (28.3) 119 (30.2) 156 (34.0) 127 (27.5) 123 (29.1) 250 (28.3) 341 (31.4) −3.1 (−7.2 to 1.0)
2-vessel disease 82 (35.2) 130 (33.0) 153 (33.3) 184 (39.9) 152 (35.9) 336 (38.0) 365 (33.6) 4.4 (0.1 to 8.7)
3-vessel disease 85 (36.5) 145 (36.8) 150 (32.7) 150 (32.5) 148 (35.0) 298 (33.7) 380 (35.0) −1.3 (−5.5 to 2.9)
Multivessel disease, n (%) 167 (71.7) 275 (69.8) 303 (66.0) 334 (72.5) 300 (70.9) 634 (71.7) 745 (68.6) −2.5 (−6.4 to 1.5)
Multivessel PCI, n (%) 72 (30.9) 115 (29.2) 115 (25.1) 124 (26.9) 100 (23.6) 224 (25.3) 302 (27.8) 0.6 (−3.7 to 4.9)
≥2 treated lesions 91 (39.1) 154 (39.1) 158 (34.4) 174 (37.7) 159 (37.6) 333 (37.7) 403 (37.1) 0.6 (−3.7 to 4.9)
≥3 treated lesions 28 (12.0) 44 (11.2) 48 (10.5) 52 (11.3) 51 (12.1) 103 (11.7) 120 (11.0) 0.6 (−2.2 to 3.4)
≥4 treated lesions 12 (5.2) 16 (4.1) 15 (3.3) 20 (4.3) 19 (4.5) 39 (4.4) 43 (4.0) 0.5 (−1.3 to 2.2)
Treated vessel, n (%)
Left anterior descending
artery
141 (60.5) 209 (53.0) 247 (53.8) 238 (51.6) 201 (47.5) 439 (49.7) 597 (55.0) −5.3 (−9.7 to −0.9)
Left circumflex artery 85 (36.5) 141 (35.8) 137 (29.8) 148 (32.1) 128 (30.3) 276 (31.2) 363 (33.4) −2.2 (−6.4 to 2.0)
Right coronary artery 66 (28.3) 147 (37.3) 158 (34.4) 175 (38.0) 163 (38.5) 338 (38.2) 371 (34.2) 4.1 (−0.2 to 8.3)
Left main artery 15 (6.4) 24 (6.1) 29 (6.3) 24 (5.2) 19 (4.5) 43 (4.9) 68 (6.3) −1.4 (−3.4 to 0.7)
Saphenous vein graft 0 (0) 1 (0.3) 3 (0.7) 6 (1.3) 30 (7.1) 36 (4.1) 4 (0.4) 3.7 (2.5 to 4.9)
>1 type B2/C lesion, n (%) 150 (64.4) 249 (63.2) 317 (69.1) 291 (63.1) 299 (70.7) 590 (66.7) 716 (65.9) 0.8 (−3.4 to 5.0)
>1 restenotic lesion, n (%) 6 (2.6) 8 (2.0) 18 (3.9) 36 (7.8) 25 (5.9) 61 (6.9) 32 (2.9) 4.0 (2.1 to 5.8)
Randomized stent, n (%)
Bare-metal stent 85 (36.5) 130 (33.0) 109 (23.7) 98 (21.3) 70 (16.5) 168 (19.0) 324 (29.8) −10.8 (−14.6 to −7.0)
Paclitaxel-eluting stent 7 (3.0) 42 (10.7) 106 (23.1) 145 (31.5) 190 (44.9) 335 (37.9) 155 (14.3) 23.6 (19.9 to 27.3)
Zotarolimus-eluting stent 71 (30.5) 102 (25.9) 124 (27.0) 119 (25.8) 77 (18.2) 196 (22.2) 297 (27.3) −5.2 (−9.0 to −1.3)
Everolimus-eluting stent 70 (30.0) 120 (30.5) 120 (26.1) 99 (21.5) 86 (20.3) 185 (20.9) 310 (28.5) −7.6 (−11.5 to −3.8)
Mean implanted stents
(SD), n
1.9 (1.2) 1.9 (1.3) 1.8 (1.2) 1.9 (1.2) 1.9 (1.2) 1.9 (1.2) 1.9 (1.3) 0 (−0.1 to 0.1)
Mean overall stent length
(SD),mm
40.2 (28.8) 38.1 (28.4) 38.3 (29.3) 40.9 (31.3) 40.7 (29.0) 40.8 (30.2) 38.6 (28.8) 2.2 (−0.4 to 4.8)
Mean stent diameter (SD),
mm
3.0 (0.4) 3.0 (0.4) 3.0 (0.4) 3.0 (0.4) 3.0 (0.5) 3.0 (0.5) 2.95 (0.4) 0.1 (0 to 0.1)
DAPT = dual-antiplatelet therapy; PCI = percutaneous coronary intervention.
* Percentages may not sum to 100 due to rounding.
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versus high scores (RD, !0.05 percentage point [CI,
!1.86 to 1.76 percentage points]) (P for interaction =
0.040). After patients with missing values for left ven-
tricular ejection fraction were excluded, clinical out-
comes stratified by score and DAPT duration were con-
sistent with the main analyses (Appendix Tables 8 and
9, available at Annals.org). The analysis of safety out-
comes after the competing risk for death was ac-
counted for yielded results consistent with those of the
main analysis (Appendix Table 10, available at Annals
.org).
DISCUSSION
The DAPT score integrates ischemic and bleeding
risk factors to guide patient selection for optimal dura-
tion of therapy in patients free from ischemic or bleed-
ing events who have received DAPT for 1 year after PCI.
Similar to the DAPT Study, patients with high and low
scores were roughly equally represented in PRODIGY
(about 45% and 55%, respectively). We applied the
score to unselected patients undergoing PCI and at an
earlier time point (6 months) than in the DAPT Study
(12 months). Given the findings from PRODIGY, our re-
sults suggest that the score may be useful in identifying
patients who would derive harm from prolonged DAPT
and could therefore be managed with a short course
without incurring a higher risk for ischemic events. In
addition, our findings suggest that the performance of
the DAPT score may vary on the basis of the type of
implanted stent. Prolonged therapy was effective in
preventing ischemic events only among patients with a
high score who received early-generation paclitaxel-
eluting stents. However, prolonged DAPT was safe in
patients with high scores, regardless of the type of
stent received, because it was associated with a risk for
bleeding similar to that of short DAPT.
Figure. Risk–benefit assessment of a DAPT score–guided strategy from 6 to 24 mo for the primary efficacy end point (top) and
the primary safety end point (bottom).
−20 −15 −10 −5 0 5 10 15 20
−20 −15 −10 −5 0 5 10 15 20
Favors 24-mo DAPT
Risk Difference (95% CI), %
Favors ≤6-mo DAPT
Favors 24-mo DAPT Favors ≤6-mo DAPT
P Value for
Interaction
Subgroup
Primary efficacy outcome
Overall (n = 1970)
   High DAPT score
   Low DAPT score
Paclitaxel-eluting stents (n = 490)
   High DAPT score
   Low DAPT score
Other coronary stents (n = 1480)
   High DAPT score
   Low DAPT score
−2.05 (−5.04 to 0.95)
2.91 (−0.43 to 6.25)
−7.55 (−12.85 to −2.25)
7.15 (−3.43 to 17.73)
1.23 (−2.41 to 4.86)
2.38 (−1.12 to 5.87)
Primary safety outcome
Overall (n = 1970)
   High DAPT score
   Low DAPT score
Paclitaxel-eluting stents (n = 490)
   High DAPT score
   Low DAPT score
Other coronary stents (n = 1480)
   High DAPT score 
   Low DAPT score
0.20 (−1.20 to 1.60)
2.58 (0.71 to 4.46)
−0.25 (−3.27 to 2.77)
6.68 (−0.36 to 13.72)
0.40 (−0.91 to 1.72)
2.00 (0.11 to 3.89)
0.030
0.015
0.65
0.046
0.076
0.174
DAPT = dual-antiplatelet therapy.
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In the DAPT Study, patients with high scores who
were randomly assigned to continue therapy had fewer
myocardial infarctions or stent thrombosis events (2.7%
vs. 5.7%; P < 0.001) without incurring a significantly in-
creased risk for GUSTO moderate or severe bleeding
(1.8% vs. 1.4%; P = 0.26). In this high-risk category, pro-
longed DAPT was also associated with a significant re-
duction in the risk for myocardial infarction or death
(2.7% vs. 5.7%; P < 0.001) and in the composite of
death, myocardial infarction, or stroke (4.9% vs. 7.6%;
P < 0.001) (10). Conversely, patients with low scores
randomly assigned to prolonged DAPT had a higher
risk for moderate or severe bleeding (3.0% vs. 1.4%;
P < 0.001) without deriving significant benefit in the
prevention of myocardial infarction or stent thrombosis
(1.7% vs. 2.3%; P = 0.07) (10). The test for heterogene-
ity of the treatment effect yielded a significant interac-
tion for the primary ischemic end point of myocardial
infarction or stent thrombosis (P for interaction < 0.001)
and GUSTO moderate or severe bleeding (P for inter-
action = 0.02) (10).
The present study provides additional evidence on
use of the DAPT score in a less selective PCI popula-
tion, in which randomization to DAPT duration was per-
formed at 1 month without a priori knowledge about
tolerability of a 12-month DAPT course (as was the case
in the DAPT Study). In addition, although the DAPT
Study excluded patients who had a major ischemic
or bleeding event during the first year after PCI (8),
PRODIGY had few exclusion criteria.
Long-term management of patients with estab-
lished coronary artery disease should be targeted not
only to secondary prevention of ischemic events but
also to bleeding prevention given its independent as-
sociation with mortality. An analysis of the ADAPT-DES
(Assessment of Dual Antiplatelet Therapy with Drug-
Eluting Stents) study showed that bleeding after hospi-
tal discharge occurs in nearly 7% of patients undergo-
ing PCI within 2 years and is associated with a 5-fold
increase in the adjusted risk for all-cause death (19).
The primary safety outcome of this study was BARC
type 3 or 5 bleeding, which has the potential to capture
a greater proportion of clinically significant bleeding
events than the GUSTO and TIMI criteria while main-
taining the same prognostic value of bleeding on mor-
tality (20). We found that DAPT for 6 months in patients
with low scores was associated with an absolute differ-
ence of approximately 2.5 percentage points in BARC
type 3 or 5 bleeding, with consistent findings when
the GUSTO and TIMI criteria were applied. Dual-
antiplatelet therapy for 6 instead of 24 months did not
increase the risk for ischemic events in patients with
low, suggesting that it could be implemented earlier
(such as 6 months) to identify patients at high bleeding
risk (score <2) in whom DAPT can be safely interrupted.
Such a strategy could apply to a relevant proportion of
patients undergoing PCI because at least 50% of pa-
tients included in the DAPT Study and PRODIGY had a
low DAPT score, and roughly 20% of patients had been
Table 3. Efficacy Outcomes With Prolonged Versus Short DAPT, by DAPT Score
Outcome DAPT* Risk Difference (95% CI),
percentage points
24 mo (n ! 450) <6 mo (n ! 434)
High DAPT score (>2)
Death, MI, or CVA 18 (4.2) 26 (6.2) −2.05 (−5.04 to 0.95)
Death 10 (2.3) 16 (3.8) −1.50 (−3.81 to 0.81)
Cardiac death 4 (0.9) 9 (2.1) −1.22 (−2.89 to 0.44)
MI 10 (2.3) 12 (2.9) −0.59 (−2.72 to 1.54)
Cardiac death, MI, or CVA 12 (2.8) 20 (4.8) −2.00 (−4.60 to 0.60)
Death or MI 17 (3.9) 25 (6.0) −2.05 (−4.98 to 0.88)
Cardiac death or MI 11 (2.6) 19 (4.6) −2.01 (−4.53 to 0.51)
Definite ST 4 (0.9) 5 (1.2) −0.29 (−1.68 to 1.11)
Definite or probable ST 5 (1.2) 8 (1.9) −0.79 (−2.47 to 0.89)
Definite, probable, or possible ST 7 (1.6) 17 (4.1) −2.44 (−4.70 to −0.19)
MI or definite/probable ST 10 (2.3) 12 (2.9) −0.60 (−2.78 to 1.58)
DAPT*
24 mo (n ! 537) <6 mo (n ! 549)
Low DAPT score (<2)
Death, MI, or CVA 51 (9.8) 36 (6.8) 2.91 (−0.43 to 6.25)
Death 33 (6.3) 27 (5.0) 1.22 (−1.55 to 4.00)
Cardiac death 14 (2.7) 13 (2.5) 0.24 (−1.68 to 2.16)
MI 17 (3.2) 11 (2.1) 1.17 (−0.78 to 3.11)
Cardiac death, MI, or CVA 38 (7.4) 26 (5.0) 2.36 (−0.57 to 5.29)
Death or MI 42 (8.0) 35 (6.6) 1.39 (−1.76 to 4.54)
Cardiac death or MI 26 (5.0) 22 (4.2) 0.80 (−1.75 to 3.36)
Definite ST 1 (0.2) 1 (0.2) 0.01 (−0.52 to 0.53)
Definite or probable ST 3 (0.6) 2 (0.4) 0.20 (−0.63 to 1.04)
Definite, probable, or possible ST 13 (2.5) 15 (2.8) −0.32 (−2.27 to 1.64)
MI or definite/probable ST 17 (3.3) 11 (2.1) 1.17 (−0.81 to 3.14)
CVA = cerebrovascular accident; DAPT = dual-antiplatelet therapy; MI = myocardial infarction; ST = stent thrombosis.
* Values are numbers of first events and percentages (Kaplan–Meier estimates of cumulative incidence at 24 mo).
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excluded from the DAPT Study due to an intercurrent
bleeding event before 12 months.
Among patients with high scores, our findings on
the safety profile of DAPT are in line with the DAPT
Study, as no increased bleeding risk was observed with
prolonged DAPT. Of note, the cumulative incidence of
BARC type 3 or 5 bleeding at 24 months was about 1%
in both the prolonged and the short DAPT groups, sug-
gesting that patients with high scores may be less sus-
ceptible to bleeding complications, regardless of
DAPT duration. However, we believe that the issue
of whether prolonged DAPT is beneficial in the sub-
group of patients with high scores requires further
investigation.
When analyzing the efficacy of prolonged DAPT in
patients with high scores, we found evidence for an
interaction between duration and the type of stent im-
planted. Prolonged DAPT in patients treated with
paclitaxel-eluting stents resulted in significant absolute
reductions of 7.55 percentage points in the risk for the
primary ischemic outcome and 6.85 percentage points
in the composite outcome of cardiac death or myocar-
dial infarction. In contrast, there was no sign of a ben-
eficial effect of prolonged DAPT for other types of cor-
onary stents, even though CIs were wide. Paclitaxel-
eluting stents are no longer used in clinical practice
and have been superseded by new-generation drug-
eluting stents because of safety concerns. Several trials
and meta-analyses have shown a higher risk for stent
thrombosis and myocardial infarction with paclitaxel-
eluting stents than with bare-metal stents and new-
generation drug-eluting stents (21–23). When data
were analyzed after patients allocated to receive
paclitaxel-eluting stents were excluded, interaction
testing between DAPT duration and score categories
was no longer significant for ischemic outcomes. This is
consistent with a sensitivity analysis performed within
the DAPT Study, where interaction testing for myocar-
dial infarction or stent thrombosis was also no longer
significant when only patients treated with new-
generation everolimus-eluting stents were evaluated
(10).
The results of this study should be interpreted in
view of several limitations. First, although all variables
included in the DAPT score were prospectively col-
lected, the score was not available at enrollment and
was therefore retrospectively calculated. Second, few
ischemic events occurred and risk estimates were im-
Table 4. Safety Outcomes With Prolonged Versus Short DAPT, by DAPT Score
Outcome DAPT* Risk Difference (95% CI),
percentage points
24 mo (n ! 450) <6 mo (n ! 434)
High DAPT score (>2)
BARC criteria
Type 3 or 5 bleeding 5 (1.2) 4 (1.0) 0.20 (−1.20 to 1.60)
Type 2 bleeding 11 (2.6) 4 (1.0) 1.59 (−0.20 to 3.38)
Type 3 bleeding 5 (1.2) 4 (1.0) 0.20 (−1.20 to 1.60)
Type 2 or 3 bleeding 16 (3.8) 8 (2.0) 1.79 (−0.47 to 4.06)
Type 2, 3, or 5 bleeding 16 (3.8) 8 (2.0) 1.79 (−0.48 to 4.05)
TIMI criteria
Minor or major bleeding 5 (1.2) 4 (1.0) 0.20 (−1.20 to 1.60)
Minor bleeding 5 (1.2) 4 (1.0) 0.21 (−1.19 to 1.60)
Major bleeding 0 (0) 0 (0) −0.01 (−0.02 to 0)
GUSTO criteria
Moderate or severe bleeding 4 (0.9) 3 (0.7) 0.20 (−1.03 to 1.44)
Moderate bleeding 5 (1.2) 3 (0.7) 0.44 (−0.88 to 1.76)
Severe bleeding 0 (0) 0 (0) −0.01 (−0.02 to 0)
DAPT*
24 mo (n ! 537) <6 mo (n ! 549)
Low DAPT score (<2)
BARC criteria
Type 3 or 5 bleeding 19 (3.7) 6 (1.1) 2.58 (0.71 to 4.46)
Type 2 bleeding 18 (3.6) 6 (1.1) 2.42 (0.58 to 4.26)
Type 3 bleeding 13 (2.6) 5 (0.9) 1.61 (0.01 to 3.21)
Type 2 or 3 bleeding 31 (6.2) 11 (2.1) 4.10 (1.67 to 6.53)
Type 2, 3, or 5 bleeding 37 (7.4) 12 (2.3) 5.07 (2.46 to 7.69)
TIMI criteria
Minor or major bleeding 14 (2.7) 4 (0.8) 1.97 (0.37 to 3.56)
Minor bleeding 4 (0.8) 3 (0.6) 0.21 (−0.79 to 1.20)
Major bleeding 10 (2.0) 1 (0.2) 1.76 (0.50 to 3.01)
GUSTO criteria
Moderate or severe bleeding 18 (3.5) 5 (1.0) 2.57 (0.77 to 4.38)
Moderate bleeding 8 (1.6) 3 (0.6) 1.00 (−0.25 to 2.25)
Severe bleeding 10 (2.0) 2 (0.4) 1.57 (0.26 to 2.88)
BARC = Bleeding Academic Research Consortium; DAPT = dual-antiplatelet therapy; GUSTO = Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries; TIMI = Thrombolysis in Myocardial Infarction.
* Values are numbers of first events and percentages (Kaplan–Meier estimates of cumulative incidence at 24 mo).
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precise. Third, several differences exist with respect to
study design between PRODIGY and the DAPT Study.
Patients included in the DAPT Study had to demon-
strate the ability to tolerate 12 months of therapy with-
out ischemic or bleeding complications, whereas ran-
domization to DAPT in PRODIGY occurred 1 month
after PCI and inclusion criteria were less restrictive.
Moreover, duration differed between the trials—the
DAPT Study randomly assigned patients to 12- versus
30-month DAPT, whereas PRODIGY randomly assigned
patients to 6- versus 24-month DAPT. Despite these dif-
ferences, evaluation of the score in a different popula-
tion may support expanding the clinical application of
this tool by adding novel information on its external
validity. Fourth, although the interaction by stent type
should be carefully interpreted because of the rela-
tively small number of patients included in each stra-
tum, in PRODIGY, unlike the DAPT Study, the type of
stent was as per random allocation. Fifth, the applica-
bility of the DAPT score to patients with high bleeding
risk who may have been excluded from both trials re-
mains unclear. Finally, left ventricular ejection fraction
was imputed for 136 patients; however, a sensitivity
analysis that excluded these patients showed consis-
tent results.
In conclusion, our study supports the use of the
DAPT score for unselected patients undergoing PCI to
identify those who are at higher risk for bleeding and
concomitantly less likely to derive benefit from pro-
longed therapy. The DAPT score correctly identified
patients deriving benefit and no harm from prolonged
therapy when patients receiving a paclitaxel-eluting
stent were evaluated, but not when they were excluded
in a sensitivity analysis. Further validation of the DAPT
score is therefore needed in a large contemporary co-
hort of patients treated with newer-generation drug-
eluting stents.
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EDITORIAL COMMENT
DAPT Duration After
Drug-Eluting Stent Implantation
No News Is Good News*
Marco Valgimigli, MD, PHD,a Giuseppe Gargiulo, MDa,b
T his year, percutaneous coronary intervention(PCI) is living its 40th anniversary, whichindicates the coming of age of a technique
that has achieved low procedural risks and excellent
clinical outcomes, providing similar (if not superior)
results as compared with conventional coronary
bypass surgery in many patient/lesion subsets.
The advent of coronary stents greatly contributed
to make the results of PCI predictable, satisfactory,
and durable. The risk of thrombotic stent occlusion
led to the development of dual antiplatelet therapy
(DAPT), which was originally conceived as a dedi-
cated treatment regimen to prevent stent thrombosis
(ST), a serious limitation of stent implantation.
Twenty years after the first study ascertained the
efficacy of DAPT for ST prevention (1), and roughly
10 years after durable DAPT was mandated by
consensus to avert the risks of very-late ST (2), DAPT
investigations have reached a mature state, to which
the 2-year results of the ITALIC (Is There a Life for
Drug Eluting Stent (DES) After Discontinuation of
Clopidogrel) study nicely contributes (3). The current
evidence shows that there can be safe drug-eluting
stent (DES) implantation without prolonged DAPT
and that there is value for prolonged DAPT in some
cases of DES implantation (Table 1).
Trials have explored the potential to safely reduce
DAPT duration to 3 to 6 months and showed the
noninferiority of this approach compared with 12
months DAPT (4). Recently, in high bleeding-risk
patients, even 1-month DAPT was shown to be safe
and effective after new-generation DES implantation
as compared with bare-metal stents (5,6). By contrast,
other randomized clinical trials have shown benefits,
even if at greater bleeding risk, of a DAPT regimen
longer than 12 months (ranging from 18 to 48 months)
as compared with 6- or 12-month therapy (4).
The ITALIC trial adds fuel to this complex pano-
rama, suggesting that 6-month DAPT is noninferior
to longer DAPT. The trial was designed and powered
to demonstrate the noninferiority of 6- versus 12-
month DAPT at 1 year for the primary net composite
endpoint of all-cause mortality, myocardial infarction
(MI), target vessel revascularization, stroke, or major
bleeding, and indeed supported that rates of bleeding
and thrombotic events at 1 year were much the same
in both treatment groups (7).
In this issue of JACC: Cardiovascular Interventions,
Didier et al. (3) present the 2-year clinical outcomes
in aspirin-responsive patients treated with 6- or
24-month DAPT after second-generation DES in the
ITALIC trial. Therefore, this study adds new, clini-
cally relevant findings. The investigators report that
the composite endpoint, as well as individual rates of
MI and stroke, were similar between the groups,
though there were nonsignificant trends toward
lower ST (0.3% vs. 0.6%; p ¼ 0.33) and target vessel
revascularization (0.3% vs. 1.0%; p ¼ 0.10) at costs of
higher mortality (2.2% vs. 1.2%; p ¼ 0.11) and major
bleeding (0.4% vs. 0%) in the 24-month group.
Importantly, whereas patients were randomly
allocated to the 2 DAPT durations at the time of PCI,
SEE PAGE 1202
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only those event-free at 6 months from PCI entered
the study. Although direct randomization at 6
months would have been preferable from a method-
ological standpoint, this study design excludes the
confounding or chance effect eventually observed in
the first 6 months, when all patients receive the same
antiplatelet regimen.
Overall, the noninferiority of shorter DAPT and
absence of benefits with longer DAPT should be
interpreted in the context of the study itself.
First, 2-year follow-up was performed in 94% of
patients, and there was suboptimal adherence to
treatment assignment: in the 6-month DAPT group,
212 patients (23.2%) failed to respect treatment
duration (9 stopped before 6 months; 123 were on
DAPT after 6 months, but not at 24 months; and 80
remained on DAPT after 24 months), whereas in
the 24-month DAPT group, 170 patients (18.7%)
discontinued treatment before 24 months.
Second, the findings reported apply to clopidogrel-
treated patients, not to patients receiving ticagrelor
or prasugrel.
Third, included patients were at low ischemic and
bleeding risk, which could have mitigated benefits
and risks of longer DAPT. Overall, event rates were
low, even more than expected (primary endpoint
at 1 year was postulated to occur in 3%, but was
1.6%). The unique study design (selecting aspirin-
responders) may have contributed to the low event
rates. Although the high-risk acute coronary
syndrome (ACS) subgroup did not show particular
benefit from prolonged DAPT, there was a significant
interaction for the composite endpoint between pa-
tients with or without prior MI (patients with prior MI
showed a borderline significant benefit from
24-month DAPT) that is in agreement with previous
data (8). It should be appreciated that the ACS sub-
group analysis is underpowered, especially consid-
ering the premature treatment interruption and low
event rates. There was a significant interaction in
age-based subgroups, showing that elderly patients
did benefit from shorter DAPT. On the other hand,
patients with diabetes did not benefit from longer
DAPT, as previously shown (9).
The present findings support those previously
observed in PRODIGY (Prolonging Dual Antiplatelet
Treatment in Patients With Coronary Artery Disease
After Graded Stent-Induced Intimal Hyperplasia
Study), which also compared 6- versus 24-month
DAPT but included a population at higher ischemic/
bleeding risk (older age, higher rates of patients with
prior MI, with ACS, with ST-segment elevation MI,
with chronic renal disease) and with higher overall
event rates (net composite 11.3% compared with 3.6%
in the ITALIC trial) (10).
Notably, the authors report a 45% increase of all-
cause death with 24-month DAPT, whereas cardiac
death was similar between groups. This finding is
obviously underpowered and inconclusive. However,
it contributes to the concerning signal previously
TABLE 1 Trials Testing DAPT Regimens Longer Than 12 Months
Trial Name N Treatment Duration, Months Stent Type Primary Endpoint
ARCTIC INTERRUPTION 1,259 17 vs. 12 EES, PES, SES, ZES, other DES Superiority of prolonged DAPT not
demonstrated
DAPT 9,961 30 vs. 12 EES, PES, SES, ZES Superiority of prolonged DAPT
demonstrated
DES-LATE 5,045 12 vs. 36 EES, PES, SES, ZES, other DES Superiority of shorter DAPT not
demonstrated
ITALIC 1,850* 6 vs. 24 EES Noninferiority of shorter DAPT
demonstrated, but prematurely
stopped
NIPPON 3,307† 6 vs. 18 BES Noninferiority of shorter DAPT
demonstrated (preliminary data),
but prematurely stopped
OPTIDUAL 1,385‡ 48 vs. 12 EES, PES, SES, ZES, other DES Superiority of prolonged DAPT not
demonstrated, but prematurely
stopped
PRODIGY 1,970 24 vs. 6 BMS, EES, PES, ZES Superiority of prolonged DAPT not
demonstrated
*Of the 2,475 patients initially planned. †Of the 4,598 patients initially planned. ‡Of the 1,966 patients initially planned.
ARCTIC INTERRUPTION ¼ Assessment by a double Randomisation of a Conventional antiplatelet strategy versus a monitoring-guided strategy for drug-eluting stent
implantation and, of Treatment Interruption versus Continuation 1 year after stenting-Interruption; BES¼ biolimus A9-eluting stent(s); BMS¼ bare-metal stent(s); DAPT¼ dual
antiplatelet therapy; DES ¼ drug-eluting stent(s); DES-LATE ¼ Optimal Duration of Clopidogrel Therapy With Drug Eluting Stents to Reduce Late Coronary Arterial Thrombotic
Events; EES ¼ everolimus-eluting stent(s); ITALIC ¼ Is There a Life for Drug Eluting Stent (DES) After Discontinuation of Clopidogrel; NIPPON ¼ Nobori Dual Antiplatelet
Therapy as Appropriate Duration; OPTIDUAL ¼ Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation; PES ¼ paclitaxel-eluting stent(s);
PRODIGY ¼ Prolonging Dual Antiplatelet Treatment in Patients With Coronary Artery Disease After Graded Stent-Induced Intimal Hyperplasia Study; SES ¼ sirolimus-eluting
stent(s); ZES ¼ zotarolimus-eluting stent(s).
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reported for long-term DAPT, which seems to mainly
affect noncardiac mortality (11,12).
Altogether, the results of the ITALIC trial fit well
with previous evidence and contribute to the current
understand of the benefits and risks of prolonged
DAPT. New-generation DES are associated with a very
low risk of late and very late ST. Therefore, prolong-
ing DAPT because of DES implantation per se does not
seem to be justified in an unselected patient popula-
tion undergoing PCI for stable or unstable coronary
artery disease. In this setting, the risk of major
bleeding associated with prolonged DAPT roughly
equals the benefits in terms of MI prevention, but it
largely exceeds the tiny absolute risk reduction in ST.
Consequently, the real question becomes: in
which patients to prolong DAPT? For this purpose,
2 scores, the DAPT (13) and PRECISE-DAPT
(Predicting Bleeding Complications in Patients
Undergoing Stent Implantation and Subsequent Dual
Antiplatelet Therapy) (14), have been recently
generated and have demonstrated the potential to
support clinicians in this delicate decision making.
The DAPT score aims at maximizing the benefits
over the risks of a prolonged DAPT regimen by
integrating predictors of ischemic events (which
favor a prolonged DAPT duration) and bleeding
(which play against the decision of prolonging
DAPT), and should be calculated after 1 year of
uneventful DAPT therapy, to decide whether to stop
or prolong the treatment. PRECISE-DAPT focuses on
bleeding risk only, should be computed soon after
PCI, and identifies patients who had, not only
bleeding events, but also ischemic recurrences, are
lower if treated with a relatively shorter (i.e., 3 to
6 months) DAPT regimen (14). Although both are
awaiting large-scale prospective validation, these 2
new decision-making tools should raise awareness
in the community on which criteria should influence
treatment duration and which characteristics should
not (Figure 1).
In summary, the 2-year results of the ITALIC study
do not generate news on the delicate tradeoff
between benefits and risks of prolonging DAPT
among DES-treated patients. Because confirmation
and replication of study results are a mainstay of
science, the absence of news is definitively good news
for the interventional community, which is now
confronted with the new challenge to tailor DAPT
duration to patients’ characteristics more than to the
implanted coronary devices’ characteristics.
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EDITORIAL COMMENT
To EncourAGE Individualized
Dual Antiplatelet Therapy Duration
After Drug-Eluting Stent Implantation
A New pAGE of an Intriguing Book*
Giuseppe Gargiulo, MD
D ual antiplatelet therapy (DAPT) is anevidence-based, guideline-recommended,standard-of-care treatment after percuta-
neous coronary intervention (PCI) (1). Nevertheless,
the optimal treatment duration of DAPT remains
controversial (1,2). Although DAPT has showed to be
highly effective in preventing stent thrombosis (ST)
during follow-up, as well as non–stent-related
myocardial infarction (MI) and stroke, the increased
risk of bleeding is not negligible and has relevant
impact on prognosis (1–3). It is now clear that a
“one-size-fits-all” approach to balance ischemic and
bleeding risks is not applicable; therefore, individu-
alization of DAPT therapy is a key measure and in-
cludes the identification of risk factors for ischemic
and bleeding events helping to weigh risks against
the potential benefits of DAPT prolongation (1,2).
Tailored therapy should be based on clinical and
procedural considerations, as well as dedicated, clin-
ical risk scores that might better advise the decision
making in the context of a comprehensive clinical
evaluation. Although some subgroups of patients
undergoing drug-eluting stent (DES) implantation
have shown to benefit from longer DAPT (i.e., prior
MI, acute coronary syndrome [ACS] at presentation,
complex PCI, or peripheral arterial disease), others
may not (i.e., female, diabetic, chronic kidney
disease, elderly, and high-bleeding risk patients)
(1,2,4–6).
Elderly individuals represent a growing proportion
of patients with coronary artery disease undergoing
PCI because of aging of the population with increased
life expectancy. Nonetheless, extrapolating findings
from randomized trials to elderly patients is chal-
lenging because such patients have been under-
represented in these studies and are characterized
by peculiar bleeding or ischemic risks.
In PRODIGY (PROlonging Dual-antiplatelet treat-
ment after Grading stent-induced Intimal hyperplasia
studY) trial, elderly patients experienced a greater
risk of both ischemic and bleeding events, with risk
trajectories proceeding similarly with aging (6). In
both elderly and nonelderly individuals, DAPT pro-
longation (24 months) did not reduce the risk of the
primary efficacy endpoint of death, MI, or cerebro-
vascular accidents, and rather increased the risk of
Bleeding Academic Research Consortium (BARC) type
2, 3, or 5 (the relative magnitude of treatment effect
on bleeding was similar between age subgroups, but
the absolute risk difference with prolonged DAPT was
greater in elderly compared with nonelderly patients)
compared with 6-month DAPT. This suggested that
elderly individuals were probably more prone to
benefit from a shorter DAPT compared with their
younger counterparts. Notably, a treatment by age
heterogeneity for the primary endpoint according to
age has been observed in ISAR-SAFE (Intracoronary
Stenting and Antithrombotic Regimen: Safety And
EFficacy of 6 Months Dual Antiplatelet Therapy After
Drug-Eluting Stenting) (interaction p ¼ 0.03), IVUS-
XPL (Impact of Intravascular Ultrasound Guidance
on Outcomes of Xience Prime Stents in Long Lesions)
(interaction p ¼ 0.051), and ITALIC (Is There A LIfe for
ISSN 1936-8798/$36.00 https://doi.org/10.1016/j.jcin.2017.11.005
*Editorials published in JACC: Cardiovascular Interventions reflect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the Department of Cardiology, Bern University Hospital, University
of Bern, Bern, Switzerland; and the Department of Advanced Biomedical
Sciences, University of Naples Federico II, Naples, Italy. Dr. Gargiulo has
received research grant support from the Cardiopath PhD program.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 1 , N O . 5 , 2 0 1 8
ª 2 0 1 8 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N
P U B L I S H E D B Y E L S E V I E R
DES after discontinuation of Clopidogrel) trials
(interaction p ¼ 0.048 at 2 years) favoring the use of
short-term DAPT in elderly rather than younger pa-
tients (Table 1). It should be noted, however, that the
primary endpoint in these latter trials included a
composite of ischemic and bleeding events, which
makes difficult to completely assess the risk-benefit
ratio associated with DAPT in elderly patients. In
line with this evidence, age is a predominant risk
factor for bleeding in both the PRECISE-DAPT (PRE-
dicting bleeding Complications In patients undergo-
ing Stent implantation and subsEquent Dual Anti
Platelet Therapy) score and the DAPT score, sup-
porting that, in the absence of high ischemic risk, a
shorter DAPT may be desirable (1).
In this issue of JACC: Cardiovascular Interventions,
Lee et al. (7) explored the impact of age in an
individual participant data meta-analysis of random-
ized clinical trials where they compared 3 to 6 month
DAPT versus 12-month DAPT after PCI with DES im-
plantation. The authors pooled 6 trials encompassing
11,473 patients of whom 42% presented with ACS and
90% received newer-generation DES. Overall they
observed that a 3- to 6-month DAPT regimen was as
effective as but safer than 12-month DAPT duration.
When exploring age-based subgroups (using 65 years
of age as cutoff) they observed that shorter DAPT, as
compared with longer DAPT, was noninferior in terms
of the ischemic composite of MI, ST, or stroke in
elderly patients (n ¼ 5,319, 46.4%), but inferior in
younger patients with a significant p value for inter-
action. A shorter DAPT reduced the risk of bleeding
compared with longer DAPT irrespective of age
(negative interaction); however, this benefit was sta-
tistically significant in elderly but not in younger pa-
tients. Thus, the authors concluded that elderly
TABLE 1 Age Subgroups in Randomized Clinical Trials Comparing Short (3–6 Months) Versus Long ($12 Months) DAPT After PCI
Trial Design Primary Endpoint
Mean
Age (yrs) Elderly* Age Subgroups
Interaction
p Value
RESET 3 vs. 12 Cardiovascular death, MI, ST,
ID-TVR, bleeding
62 46% <65 yrs of age: 4.4% vs. 4.5%
$65 yrs of age: 5.1% vs. 4.8%
0.599
OPTIMIZE 3 vs. 12 All-cause death, MI, stroke, major
bleeding
62 NA NA NA
EXCELLENT 6 vs. 12 Cardiac death, MI, ID-TVR 63 47% <65 yrs of age: HR 1.61 (95% CI: 0.78–3.31)
$65 yrs of age: HR 0.83 (95% CI: 0.42–1.65)
0.19
SECURITY 6 vs. 12 Cardiac death, MI, stroke, ST,
BARC 2, 3, or 5 bleeding
65 NA NA
$75 yrs of age was predictor of the primary
endpoint at the multivariable analysis
NA
ISAR-SAFE 6 vs. 12 All-cause death, MI, ST, stroke,
major bleeding
67 50% <67.2 yrs of age: HR 2.02 (95% CI: 0.81–4.99)
$67.2 yrs of age: HR 0.60 (95% CI: 0.31–1.13)
0.03
I-LOVE-IT 2 6 vs. 12 All-cause death, MI, stroke, major
bleeding
60 32% <65 yrs of age: RR 1.02 (95% CI: 0.66–1.60)
$65 yrs of age: RR 1.12 (95% CI: 0.71–1.76)
0.79
IVUS-XPL 6 vs. 12 Cardiac death, MI, stroke, major
bleeding
64 46% #65 yrs of age: HR 6.50 (95% CI: 0.80–52.81)
>65 yrs of age: HR 0.67 (95% CI: 0.28–1.62)
0.051
PRODIGY 24 vs. 6 All-cause death, MI, CVA 68 63%/30% <65 yrs of age: HR 0.57 (95% CI: 0.28–1.16)
$65 yrs of age: HR 1.12 (95% CI: 0.82–1.51)
<75 yrs of age: HR 1.48 (95% CI: 0.95–2.30)
$75 yrs of age: HR 0.80 (95% CI: 0.55–1.16)
0.09/0.036
ITALIC 6 vs. 24 All-cause death, MI, stroke, urgent
TVR, major bleeding
62 14% <75 yrs of age: NA
$75 yrs of age: HR 0.35 (95% CI: 0.11–1.09)
0.048
NIPPON 6 vs. 18 All-cause death, MI, stroke, major
bleeding
67 21% #75 yrs of age: 1.5% vs. 1.5%
>75 yrs of age: 3.8% vs. 1.4%
0.15
DAPT-STEMI† 6 vs. 12 All-cause death, MI, stroke, any
revascularization, major
bleeding
60 NA Not available NA
REDUCE† 3 vs. 12 All-cause death, MI, ST, stroke,
TVR, major bleeding
61 13% <75 yrs of age: OR 0.85 (95% CI: 0.56–1.28)
$75 yrs of age: OR 1.66 (95% CI: 0.71–3.86)
0.16
*Percentage of elderly patients reported is based on the age cutoff used in the study. †Data from TCT 2017 presentations.
BARC ¼ Bleeding Academic Research Consortium; CI ¼ confidence interval; CVA ¼ cerebrovascular accident; DAPT ¼ dual antiplatelet therapy; DAPT-STEMI ¼ Six versus twelve month dual antiplatelet
therapy after drug-eluting stent implantation in ST-elevation myocardial infarction; EXCELLENT¼ Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing; HR¼ hazard ratio; I-LOVE-IT 2 ¼
Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization; ID-TVR ¼ ischemia-driven target vessel revascularization; ISAR-SAFE ¼ Intracoronary
Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting; ITALIC ¼ Is There A LIfe for DES after discontinuation of Clopidogrel; IVUS-XPL ¼
Impact of Intravascular Ultrasound Guidance on Outcomes of Xience Prime Stents in Long Lesions; MI ¼ myocardial infarction; NIPPON ¼ Nobori Dual Antiplatelet Therapy as Appropriate Duration; NA ¼ not
available; OPTIMIZE¼ Optimised Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice; OR¼ odds ratio; PCI¼ percutaneous coronary
intervention; PRODIGY ¼ PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY; REDUCE ¼ Randomized Evaluation of Short-term DUal Anti Platelet Therapy in Patients
With Acute Coronary Syndrome Treated With the COMBO Dual-therapy stEnt; RESET ¼ REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation;
RR ¼ relative risk; SECURITY ¼ Second-generation Drug-eluting Stent Implantation Followed by 6- versus 12-month dual antiplatelet therapy; ST ¼ stent thrombosis.
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patients might be those with the highest advantage of
shortening DAPT within 1 year of PCI.
The authors should be commended for this inter-
esting study, which adds new relevant insights into
the decision making on DAPT duration within 1 year
after DES implantation. In the era where DAPT
duration is going to be individualized more than
generalized, ciphering the impact of specific factors,
such as age, in such a large population from
randomized trials may help clinical practice.
The definition of elderly individuals is not uni-
versal. In LEADERS-FREE (Prospective Randomised
Comparison of the BioFreedom Biolimus A9 Drug-
Coated Stent Versus the Gazelle Bare-Metal Stent in
Patients at High Bleeding Risk) and ongoing MASTER-
DAPT (Management of High Bleeding Risk Patients
Post Bioresorbable Polymer Coated Stent Implanta-
tion With an Abbreviated Versus Prolonged DAPT
Regimen) trials, patients are defined at high bleeding
risk if $75 years of age, and in the ZEUS (Zotarolimus-
eluting Endeavor sprint stent in Uncertain DES can-
didates) trial if >80 years of age, and the age cutoff is
heterogeneous also among different DAPT trials
(Table 1). Regarding the DAPT score, patients with 65
to 74 years of age and $75 years of age have –1 and –2
points, respectively (1). With the PRECISE-DAPT
score, where age is considered continuously, the
greater the age is, and the greater the bleeding risk is.
For example, in a patient with no prior bleeding,
normal values of hemoglobin and white blood cells
and a creatinine clearance of 60 ml/min, 65, 75, 80,
85, and 90 years of age are associated with 17, 22, 24,
27, and 29 points, respectively (1). Here, Lee et al. (7)
used the cutoff of 65 years of age that was the pre-
specified one selected in previous analyses from the
same dataset. Interestingly, the authors also analyzed
the risk of primary outcome (MI, ST, or stroke) with
short-term DAPT according to the quintiles of age,
showing that the risk tended to be reduced with
increasing age, and that 65 years of age was around a
tradeoff point among changes of the risk. They also
provided an additional analysis using the cutoff of 75
years of age (elderly n ¼ 1,716, 15%) where the overall
tendency regarding the differential effect of DAPT
strategy on age remained, but was attenuated and the
significant heterogeneity disappeared (interaction
p ¼ 0.36). However, this was probably attributable to
the mitigation of the effect and power of the main
analysis by moving from the elderly to the younger
group a large proportion of patients (those of 65 to
75 years of age were roughly 30% of the population)
with a different risk of primary endpoint.
One could wonder why the primary endpoint of
this analysis is an uncommon composite of MI, ST, or
stroke, which did not include cardiac or all-cause
death. When looking at numbers, both all-cause and
cardiac death were similar between 3- to 6-month and
12-month DAPT groups in elderly patients, but
significantly reduced by shorter DAPT in nonelderly
patients (being thus in opposition to what observed
for ischemic events and leading to different results if
included in the primary endpoint). This was assumed
to be a chance finding, probably clarifying why com-
posite endpoints with mortality were not analyzed.
The efficacy and safety of shortening DAPT dura-
tion after DES implantation in elderly people is in
agreement with data from LEADERS-FREE and ZEUS
trials (high bleeding risk patients treated with 1-month
DAPT), and with the recent SENIOR (Drug-eluting
stents in elderly patients with coronary artery disease)
trial (elderly: $75 years of age; DAPT 1 month or
6 months in stable or ACS patients, respectively) (8).
As for similar studies, the relevance of these find-
ings and their applicability to daily practice should be
interpreted with caution and in light of the charac-
teristics of the included patients. First, almost all
patients received a clopidogrel-based DAPT, and
hence, these results cannot be extended to prasugrel-
or ticagrelor-treated patients who represent a large
proportion of contemporary PCI patients. Second, the
results cannot be extended to all types of DES
because zotarolimus- and everolimus-eluting stents
were more commonly implanted in this population.
Third, this population was characterized by an overall
low risk of bleeding at 1 year (1.5% and 0.6% of all and
major bleeding, respectively); therefore, the obser-
vation that a 12-month DAPT offers more ischemic
benefits than bleeding risks in younger patients may
not apply to a different population with higher
bleeding risk. Fourth, patients presenting with ACS
were 42% (n ¼ 2,251 among elderly) the majority of
whom (67.0%) had unstable angina, and in a previous
analysis of this population a 3-month DAPT was
associated with higher risk of ischemic events in ACS
but not in stable patients (9); thus, based on the
present study only, a shorter DAPT cannot be
recommended to all elderly patients irrespective of
clinical presentation (particularly if high-risk ACS).
Fifth, definition of some clinical endpoints differed
slightly across trials, potentially introducing effect
modifiers. Last, although the present study includes
individual participant data from a very large popula-
tion, there are some trials missing (Table 1) and the
findings need to be confirmed.
The optimal duration of DAPT after DES implanta-
tion has been extensively investigated but remains
debated. To maximize treatment benefits over risks,
there is currently agreement that DAPT duration
Gargiulo J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 1 , N O . 5 , 2 0 1 8
Age and Individualized DAPT Duration After DES M A R C H 1 2 , 2 0 1 8 : 4 4 4 – 7
446
should be tailored on a patient-by-patient basis taking
into account (dynamically) individual risk factors and
scores. On this scenario, the present study adds a new
step forward, showing that in elderly persons a
short-term DAPT may minimize the risk of bleeding
without increasing the ischemic riskwithin 1year fromPCI.
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Part 3
Trade-off for ischemia and bleeding 
and optimal clinical outcomes during 
and after transcatheter aortic valve 
implantation (TAVI):
Optimal antithrombotic therapy 
during and after TAVI
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Abstract
The clinical and demographic characteristics of patients undergoing TAVI pose unique challenges for devel-
oping and implementing optimal antithrombotic therapy. Ischaemic and bleeding events in the periproce-
dural period and months after TAVI still remain a relevant concern to be faced with optimised antithrombotic 
therapy. Moreover, the antiplatelet and anticoagulant pharmacopeia has evolved significantly in recent years 
with new drugs and multiple possible combinations. Dual antiplatelet therapy (DAPT) is currently recom-
mended after TAVI with oral anticoagulation (OAC) restricted for specific indications. However, atrial 
fibrillation (which is often clinically silent and unrecognised) is common after the procedure and embolic 
material often thrombin-rich. Recent evidence has therefore questioned this approach, suggesting that 
DAPT may be futile compared with aspirin alone and that OAC could be a relevant alternative. Future ran-
domised and appropriately powered trials comparing different regimens of antithrombotic therapy, includ-
ing new antiplatelet and anticoagulant agents, are warranted to increase the available evidence on this topic 
and create appropriate recommendations for this frail population. Meanwhile, it remains rational to adhere 
to current guidelines, with routine DAPT and recourse to OAC when specifically indicated, whilst always 
tailoring therapy on the basis of individual bleeding and thromboembolic risk.
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Pathophysiology
Calcific aortic stenosis (AS) is the most frequent manifestation of 
valvular heart disease in the elderly, and its prevalence continues to 
grow as our population ages. Transcatheter aortic valve implantation 
(TAVI) has become the therapy of choice for patients with severe 
AS who are deemed to be inoperable or at high risk for conven-
tional surgical aortic valve replacement (SAVR). The application of 
TAVI in patients at low to intermediate risk is currently being inves-
tigated and it is therefore feasible that the procedure will be offered 
to an increasing number of patients in the near future.
Like all other vascular interventional or surgical procedures, 
TAVI carries thrombotic stroke, myocardial infarction or systemic 
embolism and periprocedural bleeding risks. Importantly, the throm-
botic risk also extends during follow-up, particularly in the presence 
of atrial fibrillation (AF).
The risk of stroke is highest in the periprocedural period owing to 
the mechanics of valve positioning and implantation1. Indeed, sten-
otic aortic valves, unlike normal aortic valve leaflets, are character-
ised by large amounts of tissue factor and thrombin that increase 
inflammation and thrombogenicity. Unlike SAVR, the diseased 
native valve remains in situ during (and after) TAVI and may be 
mechanically damaged, leading to the exposure and/or embolism of 
valvular components into the arterial circulation. Additionally, inser-
tion of a prosthesis without removal of the diseased aortic valve cre-
ates an irregular zone around the valve frame with modified flow 
patterns that may predispose to thrombus formation, particularly 
in the case of small valve sizes with associated patient–prosthesis 
mismatch. It has been demonstrated that cerebral emboli associ-
ated with TAVI can be composed of thrombotic or calcific athero-
sclerotic material. It remains unclear whether the stroke potential 
of these two subtypes of embolic material is alike. Importantly, 
TAVI patients remain at risk of stroke throughout the first months 
after the procedure. In these patients, mechanisms other than valve 
manipulation seem to be involved, such as aortic wall injury, post-
traumatic surface exposure with consequent activation of the hae-
mostatic system, turbulence or local blood stasis. In addition to the 
prothrombotic environment related to valve implantation and proce-
dure-related aortic damage, roughly one third of TAVI patients have 
pre-existing AF and a further variable percentage (ranging from 
1-30%) experience new-onset post-procedural AF, which is known 
to increase the risk of thrombotic complications further2.
The choice of antithrombotic therapy
Against this background, establishing the optimal antithrombotic 
therapy for TAVI patients remains a challenge, largely due to the lack 
of properly powered studies to inform practice. Unfractionated hepa-
rin (UFH) is the most common method of anticoagulation during the 
procedure. In the PARTNER study, UFH was administered as a par-
enteral bolus of 5,000 IU followed by additional doses to achieve an 
activated clotting time (ACT) ≥250 s. A subsequent American con-
sensus document recommended a target ACT ≥300 s with reversal 
of UFH following the procedure with protamine sulphate at a milli-
gram-to-milligram neutralisation dose. The role of bivalirudin instead 
of UFH remains unclear and is currently being investigated in the 
ongoing multicentre open-label pilot study BRAVO 2/3 (Effect of 
Bivalirudin on Aortic Valve Intervention Outcomes 2/3), randomis-
ing 870 patients to bivalirudin or UFH (NCT01651780).
Adequately powered studies addressing the optimal antithrom-
botic therapy after TAVI are non-existent. It may be reasonable to 
speculate that TAVI patients may benefit from similar antithrombotic 
treatment as currently used after SAVR with a biological prosthesis. 
However, it is relevant to emphasise that percutaneous valves have 
leaflets composed of biological material and a metallic frame similar 
to vascular stents. Moreover, there is little evidence to demonstrate 
the ideal antithrombotic regimen after SAVR with biological pros-
theses and no uniformity amongst guidelines: a) European guidelines 
support use of aspirin (IIa recommendation) or vitamin K antagonists 
(VKA, IIb recommendation) for three months; b) AHA/ACC guide-
lines recommend long-term low-dose aspirin (IIa recommendation; 
level of evidence [LOE] B) while VKA are considered reasonable for 
the first three months (IIb recommendation, LOE C); c) ACCP guide-
lines support low-dose aspirin over VKA (Grade 2C). Therefore, 
some but not all guidelines recommend VKA in the first 3-6 months 
after SAVR whereas aspirin may be a preferred long-term treatment.
In TAVI patients, secondary prevention regimes based on anti-
platelet therapy have been the most widely accepted treatment 
option. Given the increased thrombotic risks related to TAVI valve 
structure, dual antiplatelet therapy (DAPT) with aspirin (indefi-
nitely) and clopidogrel (3-6 months) – in the absence of an indica-
tion for anticoagulation – is a widely accepted empirical strategy 
which has been incorporated into practice guidelines (Table 1). 
DAPT is also important for the many TAVI patients with concomi-
tant coronary artery disease (CAD) who undergo stenting.
Nevertheless, the benefits of DAPT have been questioned, and 
recent observations that the addition of clopidogrel to aspirin does 
not seem to improve efficacy and safety may trigger a paradigm 
shift in the choice of optimal antithrombotic therapy after TAVI. 
Pooled analysis of individual patient data from 672 participants 
comparing aspirin alone versus DAPT after TAVI showed no differ-
ence in the rate of 30-day net adverse clinical and cerebral events, 
but a trend towards less life-threatening and major bleeding was 
observed in favour of aspirin alone3. Conversely, it should be con-
sidered that: a) only four studies based on small numbers of patients 
and events are available and in only two of them was treatment 
randomly allocated; b) high on-treatment platelet reactivity associ-
ated with clopidogrel or aspirin can also occur in TAVI patients4, 
although its clinical correlations remain unclear; c) the impact of old 
versus newer percutaneous valve technologies remains elusive – for 
example, inclusion of an additional skirt to reduce the frequency of 
paravalvular leak may potentially increase thrombogenicity.
Forthcoming studies
Further evidence is therefore needed to conclude firmly that DAPT 
is futile compared with aspirin alone: ongoing trials will help to 
clarify this debated issue. The Aspirin Versus Aspirin+ClopidogRel 
Following Transcatheter Aortic Valve Implantation (ARTE) pilot 
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trial (NCT01559298) assesses the efficacy of aspirin alone (80 mg/
day for at least six months) versus aspirin (80 mg/day for at least 
six months)+clopidogrel (75 mg/day for three months) in pre-
venting death, myocardial infarction, ischaemic stroke/transient 
ischaemic attack (TIA) or life-threatening/major bleeding (primary 
endpoint) at one year in 200 patients with no indication to OAC. 
The Dual Antiplatelet Therapy Versus Oral Anticoagulation for 
a Short Time to Prevent Cerebral Embolism After TAVI (AUREA) 
trial (NCT01642134) assesses the efficacy of DuoPlavin (aspirin 
80 mg/day+clopidogrel 75 mg/day, for three months) compared 
with acenocumarol in preventing cerebral thromboembolism identi-
fied using magnetic resonance (primary endpoint) at three months 
in 124 patients with no indication to OAC. The Antiplatelet Therapy 
for Patients Undergoing Transcatheter Aortic Valve Implantation 
(POPular-TAVI) trial (NCT02247128) hypothesises that omitting 
clopidogrel in the first three months after TAVI has similar efficacy and 
greater safety compared with adding clopidogrel to aspirin or OAC. 
This is a multicentre open-label randomised all-comers trial compar-
ing safety, net clinical benefit and efficacy of clopidogrel omission 
compared to aspirin (100 mg/day for at least one year)+clopidogrel 
(75 mg/day for three months) (cohort A) or OAC+clopidogrel (cohort 
B) in 1,000 patients over one year of follow-up. Future studies will 
also need to address multiple outstanding issues including the role of 
clopidogrel monotherapy, the need for a loading dose and the poten-
tial role of newer P2Y12 antagonists, prasugrel or ticagrelor.
The role of anticoagulation
Whether thrombi produced during and after TAVI have a platelet- or 
thrombin-based origin remains uncertain. Hence, antiplatelet-based 
strategies alone may still be suboptimal. Moreover, the need for 
OAC is also supported by the high burden of pre-existing and new-
onset AF in TAVI patients, particularly since the large majority of 
these patients have a high CHA2DS2-VASc score. OAC in this con-
text has great relevance in thrombosis prevention because new-onset 
and recurrent paroxysmal AF may be silent, clinically unrecognised 
and high risk unless specifically investigated2. Transcatheter valve 
thrombosis is rare but dangerous and may result in elevated trans-
valvular gradients requiring OAC. A recent study reviewed a total of 
18 published cases (SAPIEN=17, CoreValve=1) and reported four 
new cases (SAPIEN=1, CoreValve=3)4, while a larger multicen-
tre retrospective study analysed 4,266 patients, reporting 26 cases 
of transcatheter valve thrombosis (mean follow-up six months; 
SAPIEN=20, CoreValve=6)5. Clinical presentation was principally 
with dyspnoea and increased gradients, and anticoagulation therapy 
was effective in reducing gradients in the majority of patients within 
two months of treatment. The frequency of transcatheter valve 
thrombosis may be underestimated, however, since clinical signs 
and symptoms can be masked by comorbidities, and early follow-up 
echocardiography is not uniformly performed. Nonetheless, pannus 
formation or thrombosis should be suspected in patients with sudden 
elevation in valve gradient, prompting further investigation and ther-
apy with OAC plus single antiplatelet therapy (SAPT) or DAPT. In 
case of failure, valve-in-valve TAVI or SAVR could be considered.
The concept that OAC could be important in TAVI patients was 
also discussed at EuroPCR 2015. Neumann presented the results 
of systematic computed tomography (CT) five days after TAVI 
(SAPIEN 3 prosthesis), demonstrating clinically silent valve leaflet 
thickening in 16/156 patients. Full OAC (INR 2.5-3.5) resulted in 
regression of these findings in 11 patients who underwent follow-up 
CT (mean 77 days). In the same session, Sondergaard presented data 
concerning valve leaflet motion assessed with CT approximately 
three months after TAVI (n=47) or SAVR (n=15), demonstrating 
that the frequency of reduced leaflet motion was similar with dif-
ferent types of valve (and procedure), and that the phenomenon 
was not associated with clinical events. Whilst these preliminary 
underpowered data findings await confirmation and more rigorous 
evaluation, they may open new perspectives on the post-procedural 
management of TAVI patients, underlining the need to consider 
a more liberal approach to the use of OAC after TAVI, even in the 
absence of known indications (AF, mechanic valves), and the utility 
of CT imaging during follow-up. Conversely, the necessity of this 
approach remains the subject of discussion since all patients were 
asymptomatic and no clinical events were reported or prevented.
Bleeding risks
A crucial aspect to be considered in the management of TAVI 
patients is the risk of bleeding – a frequent periprocedural com-
plication after TAVI associated with worse prognosis1. However, 
major late bleeding events (>30 days) also significantly increase 
mortality in this population and have great clinical relevance6.
The low incidence of transcatheter valve thrombosis and high 
bleeding risk in most TAVI patients may not justify the routine use of 
OAC, but recent evidence supports the importance of OAC in some 
patients and future trials are needed. Accordingly, two multicentre 
randomised trials have recently been designed (Figure 1). GALILEO 
(Global multicenter, open-label, randomized, event-driven, 
Table 1. Recommendations for antithrombotic therapy in TAVI patients.
European guideline 
and consensus
AHA/ACC 
guidelines
ACCF/AATS/SCAI/STS 
consensus
Canadian Society
 position statement
Aspirin Low-dose indefinitely Low-dose (75-100 mg/day) indefinitely 81 mg/day indefinitely Low-dose indefinitely
Additional antiplatelet 
therapy
Thienopyridine early after TAVI Clopidogrel 75 mg/day for 6 months Clopidogrel 75 mg/day for 
3-6 months
Clopidogrel for 1-3 months
Oral anticoagulation VKA alone in patients with AF but no CAD 
(VKA+antiplatelet therapy if AF and recent stent 
implantation, as per CAD guidelines)
VKA if indicated 
(no clopidogrel)
VKA if indicated (avoid triple 
therapy unless definite 
indication)
AF: atrial fibrillation; CAD: coronary artery disease; TAVI: transcatheter aortic valve implantation; triple therapy: dual antiplatelet therapy plus vitamin K antagonist; VKA: vitamin K antagonist
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active-controlled study comparing a rivAroxaban-based antithrom-
botic strategy to an antipLatelet-based strategy after transcatheter 
aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomes) 
will compare rivaroxaban-based (rivaroxaban 10 mg/day long-term 
with aspirin 75-100 mg/day for three months) and antiplatelet-based 
strategies (aspirin 75-100 mg/day long-term with clopidogrel 75 mg/
day for three months) after TAVI in patients without prior indica-
tion for anticoagulation. ATLANTIS (Anti-Thrombotic strategy to 
Lower All cardiovascular and Neurologic ischemic and hemorrhagic 
events after Trans-aortic valve Implantation for aortic Stenosis) will 
compare apixaban (5 mg bd or 2.5 mg bd in specific settings) with 
the standard of care, irrespective of need for oral anticoagulation.
Finally, there is a paucity of data and ongoing controversy con-
cerning the appropriate antithrombotic regimen (and its duration) 
in AF patients undergoing TAVI. There are only individual reports 
concerning the use of triple therapy (DAPT+OAC) and no evi-
dence regarding warfarin with one antiplatelet agent or warfarin 
alone. Indeed, American and Canadian guidelines discourage the 
use of triple therapy (Table 1). In AF patients undergoing stent-
ing, the combination of OAC with one antiplatelet agent was asso-
ciated with better safety outcomes (and no excess of ischaemic 
events) than triple therapy. However, the recent European consen-
sus on AF treatment stated that VKA alone is the preferred option 
in patients undergoing TAVI with AF but no CAD, since the need 
for additional antiplatelet therapy remains uncertain. Conversely, 
patients who have undergone recent PCI should be treated simi-
larly to those receiving stents outwith the context of TAVI, since 
specific robust data for TAVI are lacking and future trials needed.
In conclusion, the justification for currently recommended regimes 
of DAPT after TAVI has recently been questioned, while arguments 
supporting the potential benefits of OAC therapy have now emerged. 
Well designed and appropriately powered trials are strongly warranted.
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GALILEO trial
1,520 patients after successful TAVI procedure
R 1:1
R 1:1 R 1:1
Rivaroxaban 10 mg OD
AND ASA 75-100 mg OD
90 days:
drop ASA
Rivaroxaban 10 mg OD
Clopidogrel 75 mg OD
AND ASA 75-100 mg OD
90 days:
drop clopidogrel
ASA 75-100 mg OD
Primary endpoint is death or first adjudicated thromboembolic event defined 
as the composite of all-cause death and adjudicated any stroke, myocardial
infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein
thrombosis, or non-CNS systemic embolism over follow-up*.
*Follow-up will be approximately 750 days with expected duration of the treatment of 720 and follow-up of 30 days:
the duration of the planned treatment period will depend on the time needed to reach the efficacy cut-off date,
i.e. to collect the predefined number of efficacy endpoints. The expected duration of the treatment is 720 days
but may be adjusted depending upon the rate of subject recruitme nt and efficacy event rates.
ATLANTIS trial
1,509 patients after successful TAVI procedure
Stratum 1
Indication for anticoagulation
Vitamin K antagonist
Apixaban
5 mg* bid
Stratum 2
No indication for anticoagulation
SAPT/DAPT
*2.5 mg bid if creatinine clearance 15-29 mL/min or if two of the following criteria: age ≥80 years, weight ≤60 kg
or creatinine ≥1.5 mg/dL (133 µMol)
Primary endpoint is a composite of death, myocardial infarction, stroke/TIA/
systemic emboli, intracardiac or bioprosthesis thrombus, episode of deep vein
thrombosis or pulmonary embolism, major bleedings over one year of follow-up.
Figure 1. Flow diagram of the GALILEO and ATLANTIS trials.
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alternativa alla procedura chirurgica. La TAVI ha innanzitutto 
permesso di modificare la prognosi infausta e prolungare la 
sopravvivenza ai pazienti giudicati inoperabili. Inoltre la TAVI è 
oggi diffusamente considerata una strategia efficace e sicura 
nei pazienti con SA ad alto rischio chirurgico, come anche 
raccomandato dalle linee guida internazionali. 
La TAVI, similmente ad altre procedure interventistiche o 
chirurgiche, presenta rischi trombotici (ictus, infarto miocardi-
co o embolismo sistemico) e di sanguinamento, soprattutto 
nella fase periprocedurale1-3. Tali rischi tuttavia sono anche 
presenti durante il follow-up, soprattutto nei pazienti con fi-
brillazione atriale (FA). Nonostante i progressi nella tecnologia 
e nell’esperienza con questa procedura, le complicanze ische-
miche ed emorragiche sono ancora frequenti e hanno un 
impatto prognostico negativo in questa categoria di pazienti 
anziani e con frequenti comorbilità. Per tale ragione, l’identi-
ficazione della terapia antitrombotica ottimale che possa bi-
lanciare appropriatamente il rischio ischemico ed emorragico 
è un obiettivo di diffuso interesse.
RISCHIO DI ICTUS E SANGUINAMENTI
Il rischio di ictus è particolarmente elevato nel periodo peri-
procedurale in relazione al posizionamento ed impianto del 
nuovo dispositivo1-3. Infatti, la valvola aortica stenotica pre-
senta una grande quota di fattore tissutale e di trombina che 
contribuiscono all’infiammazione e alla trombogenicità. Du-
rante la TAVI, a differenza dell’intervento chirurgico, la valvola 
nativa malata resta in situ e viene manipolata durante la fase 
di impianto della nuova valvola potendo comportare espo-
sizione e/o embolizzazione dei suoi componenti nel circolo 
arterioso. Inoltre, la sovrapposizione del nuovo dispositivo 
INTRODUZIONE
La stenosi aortica (SA) è la più frequente valvulopatia cardiaca 
in Europa e Nord America e si presenta principalmente come 
SA calcifica nei soggetti adulti. La prevalenza della patologia 
aumenta all’aumentare dell’età. La SA è una patologia croni-
ca e progressiva che può rimanere asintomatica per anni. La 
morte improvvisa è una frequente causa di morte, sebbene 
sia rara nei pazienti asintomatici. È ben noto che dall’insor-
genza dei sintomi della patologia, la prognosi è infausta. La 
terapia medica non è in grado di modificare la prognosi di 
questi pazienti, dunque l’unica terapia efficace consiste nella 
sostituzione della valvola aortica stenotica.
Per molti anni, la sostituzione valvolare chirurgica (surgical 
aortic valve replacement, SAVR) è stata l’unica opzione per i 
pazienti sintomatici con SA severa. Tuttavia, questo intervento 
è gravato da un significativo rischio di complicanze e mortalità 
ed inoltre non può essere offerto a tutti in considerazione del 
fatto che spesso i pazienti con SA sono molto anziani e hanno 
comorbilità tali da renderli a rischio chirurgico molto elevato 
o inoperabili. Nel 2002, il Professor Alain Cribier impiantò per 
la prima volta una valvola aortica per via percutanea, proce-
dura oggi nota come TAVI o TAVR (transcatheter aortic valve 
implantation or replacement). Da allora, crescenti evidenze 
hanno dimostrato che la TAVI potesse diventare una valida 
Terapia antitrombotica nei pazienti sottoposti  
a impianto transcatetere di valvola aortica
Giuseppe Gargiulo, Marco Valgimigli
Department of Cardiology, Inselspital, University of Bern, Berna, Svizzera
Transcatheter aortic valve implantation (TAVI) has emerged as a valid alternative to surgical replacement in 
patients with severe aortic stenosis. Bleeding and cerebral ischemic events remain frequent complications 
of this procedure during the periprocedural period and at follow-up with a severe impact on survival. 
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risk profile remains relevant in daily clinical practice. 
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Antitrombotici e TAVI
che ha confrontato UFH e bivalirudina nei pazienti sottoposti 
a TAVI e ha dimostrato che la bivalirudina si associa a simile 
incidenza di eventi clinici maggiori rispetto ad UFH senza es-
sere superiore5. Complessivamente 802 pazienti (bivalirudina 
= 404 e UFH = 398) sono stati randomizzati con due prin-
cipali obiettivi: 1) sanguinamenti maggiori entro 48h dalla 
procedura o prima della dimissione (a seconda di quale si è 
verificato per primo); 2) incidenza a 30 giorni di eventi clinici 
avversi netti (net adverse clinical events, NACE) definiti dal-
la combinazione dei sanguinamenti maggiori con gli eventi 
cardiovascolari avversi maggiori (morte per tutte le cause, 
infarto miocardico o ictus). L’ipotesi principale era che la bi-
valirudina potesse dimostrarsi superiore in termini di sangui-
namenti maggiori, ma la superiorità non è stata dimostrata 
sebbene gli eventi fossero numericamente ridotti nel gruppo 
bivalirudina (sanguinamenti BARC [Bleeding Academic Rese-
arch Consortium] ≥3b: 6.9 vs 9.0% nei gruppi bivalirudina vs 
UFH; p=0.27). L’ipotesi di non inferiorità in termini di NACE 
a 30 giorni invece è stata dimostrata, ma anche in questo 
caso non si è osservata superiorità (14.8 vs 15.9%; p per non 
inferiorità <0.01; p per superiorità =0.66).
Le evidenze sulla terapia antitrombotica ottimale dopo 
TAVI sono scarse. Alcuni sostengono che i pazienti TAVI pos-
sono essere paragonati ai pazienti che ricevono intervento chi-
rurgico con impianto di protesi biologica. Tuttavia, le protesi 
impiantate per via percutanea sono diverse da quelle chirur-
giche perché sono costituite da materiale biologico montato 
su una struttura metallica, simile agli stent coronarici. Inoltre, 
anche nel caso della terapia antitrombotica dopo intervento 
chirurgico di impianto di valvola biologica non c’è uniformità 
tra le varie linee guida internazionali. Infatti: a) le linee guida 
europee raccomandano preferenzialmente la somministra-
zione di aspirina per 3 mesi (classe di raccomandazione IIa) 
rispetto all’anticoagulante orale (IIb); b) le linee guida ameri-
cane AHA/ACC (American Heart Association/American Col-
lege of Cardiology) raccomandano l’uso di aspirina a lungo 
termine (IIa) e l’anticoagulante orale è considerato ragione-
vole nei primi 3 mesi (IIb); c) le linee guida americane ACCP 
(American College of Chest Physicians) supportano preferen-
zialmente l’aspirina rispetto all’anticoagulante orale (grado di 
raccomandazione 2C). 
Nei pazienti sottoposti a TAVI la strategia più diffusa nel 
corso degli anni è stata quella basata sull’impiego della terapia 
antipiastrinica piuttosto che anticoagulante orale. In partico-
lare, in considerazione della struttura della protesi e dell’uni-
formità con i dati ottenuti nei pazienti che ricevono impianto 
di stent coronarico, empiricamente la doppia antiaggregazione 
(dual antiplatelet therapy, DAPT) è divenuta la strategia condi-
visa (Tabella 1). In pazienti senza indicazione a terapia antico-
agulante orale (TAO), generalmente si raccomanda la sommi-
nistrazione di aspirina a lungo termine e di clopidogrel per 3-6 
mesi. Tuttavia questa raccomandazione empirica è stata messa 
in dubbio da recenti evidenze, le quali suggeriscono che l’ag-
giunta di clopidogrel non determina vantaggi clinici. Quattro 
studi hanno confrontato il regime di sola aspirina a quello di 
aspirina + clopidogrel (Tabella 2)6-9 e la metanalisi di questi (2 
randomizzati e 2 osservazionali) ha incluso 672 pazienti e ha 
dimostrato che non ci sono differenze di NACE a 30 giorni tra 
i due gruppi di terapia, ma l’aspirina da sola si associava ad un 
numero inferiore di sanguinamenti maggiori, seppur statisti-
camente non significativo10. Tuttavia bisogna considerare che: 
a) gli studi sono solo 4, con pochi pazienti totali e di questi 
alla valvola nativa può creare zone di turbolenza che possono 
predisporre alla generazione di trombi, soprattutto in caso di 
valvole piccole che possono determinare un “mismatch” val-
vola-paziente. Gli emboli cerebrali durante TAVI si sono dimo-
strati composti da materiale trombotico o calcifico. Durante i 
mesi successivi alla TAVI i pazienti presentano comunque un 
aumentato rischio di ictus, probabilmente correlato a diversi 
meccanismi (danno della parete aortica, attivazione del siste-
ma emostatico, turbolenze e stasi ematica locale, ecc.). Inoltre 
la FA contribuisce in modo rilevante a questo rischio. Una re-
cente metanalisi ha infatti dimostrato che circa il 33% dei pa-
zienti che vengono sottoposti a TAVI presenta una FA preesi-
stente all’intervento, e che un altro 17% può sviluppare una 
nuova FA post-procedurale (il dato può essere sottostimato 
a causa della mancata documentazione di eventuali episodi 
di FA parossistica in pazienti non sottoposti a monitoraggio 
continuo)4.
I sanguinamenti sono complicanze frequenti e rilevanti nei 
pazienti sottoposti a TAVI1-3. In particolare, nella fase peripro-
cedurale il 15-30% dei pazienti può avere un sanguinamen-
to maggiore e nel 5-15% l’emorragia è rischiosa per la vita. 
Questi eventi sono spesso, ma non esclusivamente, correlati a 
complicanze vascolari e dell’accesso utilizzato per la procedu-
ra. Tuttavia, anche sanguinamenti in altre sedi (per esempio 
genitourinari o gastrointestinali) possono presentarsi dopo la 
procedura o durante il follow-up e certamente la terapia an-
titrombotica può avere un ruolo importante in questi eventi. 
Inoltre, molti pazienti sottoposti a TAVI hanno un variabile 
grado di anemia che può predisporre alla necessità di trasfu-
sione in caso di emorragia. 
TERAPIA ANTITROMBOTICA DURANTE E DOPO 
IMPIANTO TRANSCATETERE DI VALVOLA AORTICA: 
ATTUALI EVIDENZE
La terapia antitrombotica ottimale per i pazienti sottoposti a 
TAVI è un argomento molto dibattuto, soprattutto perché esi-
stono pochi dati forniti da studi clinici dedicati.
Durante la procedura, la strategia più utilizzata prevede 
la somministrazione di eparina non frazionata (unfractiona-
ted heparin, UFH). Il protocollo previsto dagli studi PARTNER 
prevede la somministrazione di un bolo di 5000 UI seguito 
da eventuali boli addizionali con l’obiettivo di mantenere il 
tempo di coagulazione attivato (activated clotting time, ACT) 
≥250 s. Un documento di consenso raccomandava come 
obiettivo il mantenimento di un ACT ≥300 s. Entrambi i pro-
tocolli prevedevano l’eventuale uso del solfato di protamina 
per antagonizzare l’UFH. In considerazione della riduzione 
dei sanguinamenti maggiori ottenuta con l’uso di bivaliru-
dina rispetto ad UFH in pazienti trattati con angioplastica 
coronarica, anche nei pazienti TAVI si sta valutando questa 
opzione. Tuttavia, nonostante la bivalirudina abbia una breve 
emivita e la sua azione termini rapidamente dopo la sospen-
sione dell’infusione, bisogna anche considerare che l’UFH 
offre il vantaggio di poter essere antagonizzata immedia-
tamente con solfato di protamina, cosa che può essere ne-
cessaria in caso di complicanze emorragiche potenzialmente 
fatali che avvengono durante la procedura come il tampo-
namento cardiaco, la rottura dell’anulus aortico o di vasi pe-
riferici. Recentemente, sono stati pubblicati i risultati dello 
studio randomizzato BRAVO-3 (Bivalirudin versus Heparin 
Anticoagulation in Transcatheter Aortic Valve Replacement) 
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il tessuto aggiuntivo disegnato per ridurre il leak paravalvola-
re possa aumentare il potenziale trombogenico della protesi. 
Dunque, sulla base di queste considerazioni, è chiaro che sono 
necessarie ulteriori evidenze per chiarire se la monoterapia con 
aspirina sia sufficiente rispetto alla DAPT. 
solo 2 sono randomizzati; b) anche pazienti trattati con TAVI 
possono avere un’elevata reattività piastrinica durante terapia 
con clopidogrel o aspirina11; c) il profilo di sicurezza dei nuovi 
dispositivi resta sconosciuto. Infatti, le nuove protesi valvolari 
presentano un diverso disegno e non è noto se per esempio 
Tabella 1. Raccomandazioni per la terapia antitrombotica nei pazienti sottoposti a impianto transcatetere di valvola aortica.
Linee guida  
e consensus ESC
Linee guida  
AHA/ACC
Consensus  
ACCF/AATS/SCAI/STS
Linee guida  
canadesi
Aspirina Bassa dose  
indefinitamente
Bassa dose  
(75-100 mg/die) 
indefinitamente
81 mg/die  
indefinitamente
Bassa dose  
indefinitamente
Antipiastrinico aggiuntivo Tienopiridina  
precoce dopo TAVI
Clopidogrel 75 mg/die  
per 6 mesi
Clopidogrel 75 mg/die  
per 3-6 mesi
Clopidogrel  
per 1-3 mesi
Anticoagulante orale AVK in monoterapia nei 
pazienti con FA e senza CAD
AVK + antipiastrinici  
se FA e recente impianto di 
stent (come da linee guida 
sulla rivascolarizzazione 
miocardica) 
AVK se indicato  
(senza clopidogrel)
AVK se indicato 
(clopidogrel).  
Evitare tripla terapia 
in assenza di specifica 
indicazione
AATS, American Association for Thoracic Surgery; ACC, American College of Cardiology; ACCF, American College of Cardiology Foundation; 
AHA, America Heart Association; AVK, antagonista della vitamina K; CAD, malattia coronarica; FA, fibrillazione atriale; SCAI, Society for Car-
diovascular Angiography and Interventions; STS, Society of Thoracic Surgeons; TAVI, impianto transcatetere di valvola aortica.
Tabella 2. Caratteristiche degli studi che hanno confrontato aspirina e duplice terapia antiaggregante dopo impianto transcatetere di valvola aortica.
Studi randomizzati Studi osservazionali senza matching
Ussia et al.6 Stabile et al.7 Poliacikova et al.8 Durand et al.9
Aspirina DAPT Aspirina DAPT Aspirina DAPT Aspirina DAPT
N. pazienti 39 40 60 60 91 58 164 128
Procedura (%)
 TF
 TA
 Altro
 CoreValve
 Edwards Sapien 
100
0
0
100
0
95
0
5
100
0
NR
NR
NR
0
100
NR
NR
NR
0
100
NR
NR
NR
0
100
NR
NR
NR
0
100
84
15
1
33
67
77
23
0
0
100
Terapia pre-TAVI
 Aspirina (mg)
 Clopidogrel carico (mg)
 INR
 ACT (s)
100
–
NR
200-250
100
300
NR
200-250
75-160
NR
NR
>250
75-160
NR
NR
>250
300
–
NR
NR
300
300
NR
NR
75
300
<1.5
NR
75
300
<1.5
NR
Terapia post-TAVI
 Aspirina (mg)
 Clopidogrel (mg/mesi)
100
–
100
75/3
75-160
–
75-160
75/6a
75
–
75
75/6
75
–b
75
75/1
Eventi clinici
 Morte a 30 giorni (%)
 Morte a 6 mesi (%)
 IM a 30 giorni (%)
 Ictus a 30 giorni (%) 
 Complicanze vascolari a 30 giorni (%)
 Sanguinamenti minori a 30 giorni (%) 
 Sanguinamenti maggiori a 30 giorni (%)
 Sanguinamenti pericolosi per la vita  
 a 30 giorni (%)
 Tutti i sanguinamenti a 30 giorni (%)
10.0
13.0
0
5.0
NR
10.0
30.0
5.0 
18.0
10.0
10.0
0
3.0
NR
8.0
5.0
5.0 
18.0
3.3
5.0
0
3.3
0
1.7
3.3
5.0 
10.0
1.7
5.0
0
1.7
5.0
5.0
3.3
6.6 
15.0
3.3
NR
NR
2.2
3.3
NR
NR
NR 
8.8
6.9
NR
NR
3.4
5.2
NR
NR
NR 
19.0
7.9
NR
1.2
1.2
5.5
2.4
2.4
3.7
8.5
9.4
NR
0.8
4.7
10.2
5.5
13.3
12.5
31.3
ACT, tempo di coagulazione attivato; DAPT, duplice terapia antiaggregante; IM, infarto miocardico; INR, international normalized ratio; NR, non 
riportato; TA, transapicale; TAVI, impianto transcatetere di valvola aortica; TF, transfemorale. 
ain alternativa: ticlopidina 500 mg bid.
bin alternativa monoterapia con clopidogrel 75 mg/die.
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Tuttavia, l’incidenza di trombosi della protesi valvolare 
può essere un evento sottostimato perché i segni e sintomi 
possono essere sfumati o mascherati dalla presenza di co-
morbilità in questi pazienti e perché l’ecocardiografia preco-
ce non viene eseguita in modo uniforme. Inoltre, un recente 
studio pubblicato sul New England Journal of Medicine ha 
ulteriormente sottolineato la rilevanza della trombosi delle 
bioprotesi aortiche e la sua sottostima clinica supportando 
la necessità della TAO in questi pazienti13. L’ispessimento e 
la ridotta motilità dei lembi protesici sono emersi quali segni 
subclinici di trombosi bioprotesica13. Lo studio PORTICO-IDE 
(Portico Re-sheathable Transcatheter Aortic Valve System US 
Investigational Device Exemption), attualmente in corso, sta 
valutando l’efficacia e la sicurezza della nuova protesi Portico 
e nel protocollo è previsto l’uso della tomografia computeriz-
zata (TC) in un sottogruppo di pazienti per valutare la strut-
tura metallica della protesi. Durante lo studio, si è riscontrato 
alla TC una riduzione della motilità dei lembi bioprotesici in 
un paziente che aveva avuto un ictus e in alcuni altri pazienti 
asintomatici. Da quel momento tutte le immagini TC furono 
rivalutate e si decise di iniziare due registri dedicati a questo 
aspetto, il RESOLVE (Assessment of Transcatheter and Surgi-
cal Aortic Bioprosthetic Valve Thrombosis and Its Treatment 
with Anticoagulation) e il SAVORY (Subclinical Aortic Valve 
Bioprosthesis Thrombosis Assessed with Four-Dimensional 
Computed Tomography). Il manoscritto citato riporta ap-
punto i risultati dell’analisi di 55 pazienti dello studio PRO-
TICO-IDE e di 132 pazienti trattati con TAVI o SAVR nei due 
registri13. La riduzione della motilità dei lembi bioprotesici è 
stata riscontrata in 22 dei 55 pazienti (40%) e in 17 dei 132 
(13%) nei registri. La terapia anticoagulante con warfarin si 
associava a una ridotta incidenza di questo evento rispetto 
alla doppia antiaggregazione (0 vs 55%, p=0.01 nel trial; 0 
vs 29%, p=0.04 nei registri uniti in un singolo database). 
La ripetizione della TC al follow-up dimostrava che la TAO 
si associava al ripristino del normale movimento dei lembi 
bioprotesici (11/11 pazienti) a differenza di chi non riceveva 
la TAO (risoluzione solo in 1/10 pazienti) con differenza si-
gnificativa (p<0.001). L’impatto clinico di questa alterazione 
necessita di un’ulteriore valutazione perché l’incidenza di 
ictus/attacco ischemico transitorio non differiva tra coloro 
che avevano o non avevano la riduzione della motilità nel 
trial (2/22 vs 0/33; p=0.16) ma differiva significativamente 
nei pazienti dei registri (3/17 vs 1/115; p=0.007). Uno studio 
della Mayo Clinic ha dimostrato che la trombosi valvolare 
non è rara anche dopo anni dall’intervento chirurgico e che 
alcune caratteristiche cliniche ed ecocardiografiche possono 
essere utili nel predire e diagnosticare l’evento14. Gli autori 
hanno esplorato il problema della trombosi delle bioprote-
si valvolari impiantate chirurgicamente analizzando i referti 
istopatologici di 397 casi di valvole espiantate e valutando le 
caratteristiche cliniche dei pazienti con trombosi rispetto a 
quelli senza tale complicanza14. La trombosi era presente in 
46 casi (11.6%) di cui 29 erano aortiche. La maggior parte 
dei casi di trombosi si era presentata dopo 2 anni dall’im-
pianto (65%) e i predittori di evento erano: a) aumento del 
gradiente medio eco-Doppler >50% rispetto al basale; b) 
FA parossistica; c) INR sub-terapeutico; d) aumento dello 
spessore delle cuspidi; e) anomala motilità delle cuspidi. La 
contemporanea presenza dei 5 fattori prediceva la trombosi 
bioprotesica con alta sensibilità e specificità14.
STUDI CLINICI IN CORSO
Sono in corso alcuni studi che potranno contribuire a chiarire 
questo aspetto:
UÊ studio ARTE (Aspirin vs Aspirin + Clopidogrel Following 
TAVI Pilot Trial; NCT01559298) che valuta l’efficacia della 
monoterapia con aspirina (80 mg/die per 6 mesi) rispetto 
ad aspirina (80 mg/die per 6 mesi) e clopidogrel (75 mg/
die per 3 mesi). L’endpoint primario sarà valutato in 200 
pazienti (senza indicazione a TAO) ed è costituito dall’in-
cidenza di morte, infarto, ictus/attacco ischemico transi-
torio o sanguinamenti maggiori ad 1 anno di follow-up; 
UÊ studio AUREA (Dual Antiplatelet Therapy Versus Oral An-
ticoagulation for a Short-Time to Prevent Cerebral Embo-
lism After TAVI; NCT01642134) che valuta l’efficacia di 
aspirina 80 mg/die + clopidogrel 75 mg/die per 3 mesi 
rispetto ad acecumarolo nel prevenire eventi tromboem-
bolici cerebrali valutati a 3 mesi con risonanza magnetica 
(endpoint primario) in 124 pazienti senza indicazione a 
TAO;
UÊ studio POPULAR-TAVI (Antiplatelet Therapy for Patients 
Undergoing TAVI; NCT02247128) che ipotizza di dimo-
strare simile efficacia ma migliore sicurezza del non ag-
giungere clopidogrel rispetto ad aggiungere clopidogrel 
(75 mg/die per 3 mesi) ad aspirina (100 mg/die per 1 
anno) o TAO sulla base dell’indicazione (coorte A: assenza 
di FA; coorte B: presenza di FA) in circa 1000 pazienti du-
rante un follow-up di 1 anno.
Studi futuri dovranno esplorare anche il ruolo di altre stra-
tegie, per esempio la monoterapia con clopidogrel, la neces-
sità o meno di una dose di carico post-procedurale e l’uso di 
nuovi antipiastrinici (prasugrel o ticagrelor).
TERAPIA ANTICOAGULANTE:  
RAZIONALE ED EVIDENZE SCIENTIFICHE
Recentemente diverse evidenze hanno suggerito che la TAO 
dopo TAVI potrebbe essere una strategia giustificata per la 
prevenzione di eventi trombotici in questi pazienti. Poiché re-
sta ancora da chiarire se gli eventi trombotici durante e dopo 
TAVI siano di origine piastrinica o trombinica, la sola terapia 
antipiastrinica potrebbe non essere una strategia preventiva 
sufficiente. Inoltre, l’uso della TAO potrebbe anche essere 
supportato dal fatto che molti pazienti TAVI, come preceden-
temente sottolineato, presentano FA al basale o la sviluppano 
dopo la procedura o nel follow-up, anche considerato che 
l’età avanzata e la frequente comorbilità in questa popolazio-
ne li rende spesso ad alto rischio con elevato CHA2DS2-VASc 
score. 
La TAO potrebbe avere un ruolo importante nel prevenire 
eventi trombotici valvolari. La trombosi della protesi valvola-
re aortica è una complicanza rara ma pericolosa. Uno studio 
recente ha analizzato i casi descritti in letteratura (n=18 di 
cui 17 coinvolgevano valvole Sapien e 1 caso era su valvola 
CoreValve) e riportato 4 nuovi casi (1 in Sapien e 3 in Core-
Valve)11. Un altro studio ha effettuato un’analisi multicentrica 
retrospettiva di 4266 pazienti e ha riportato 26 casi di trom-
bosi di protesi percutanea valvolare aortica ad un follow-up 
medio di 6 mesi (Sapien = 20; CoreValve = 6)12. Questi casi 
clinicamente si presentavano principalmente con dispnea ed 
aumento dei gradienti. La maggior parte dei casi mostrava 
riduzione dei gradienti nell’arco di 2 mesi di TAO.
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Studio GALILEO
1520 pazienti sottoposti con successo a TAVI
R 1:1
Rivaroxaban 10 mg/die
e ASA 75‐100 mg/die
Clopidogrel 75 mg/die
e ASA 75‐100 mg/die
Rivaroxaban 10 mg/die ASA 75‐100 mg/die
Endpoint primario: morte o primo evento tromboembolico aggiudicato definito come un 
composito di morte da ogni causa e un qualsiasi evento aggiudicato tra ictus, infarto miocardico, 
trombosi valvolare sintomatica, embolia polmonare, trombosi venosa profonda o 
embolia sistemica non a carico del SNC durante il follow‐upa
Interrompere 
ASA dopo 3 mesi
Interrompere 
clopidogrel dopo 3 mesi
Figura 1. Disegno dello studio GALILEO.
ASA, aspirina; SNC, sistema nervoso centrale; TAVI, impianto transcatetere di valvola 
aortica.
ail follow-up sarà di circa 750 giorni con una durata prevista del trattamento di 720 
giorni e monitoraggio di 30 giorni; la durata del trattamento previsto dipenderà dal 
tempo necessario per raggiungere il cut-off di efficacia, vale a dire il numero predefinito 
di endpoint di efficacia. La durata prevista del trattamento di 720 giorni potrebbe variare 
in funzione del numero di pazienti arruolati e dell’incidenza degli eventi di efficacia.
venza1-3. Inoltre, anche episodi di sanguinamento maggiore 
durante follow-up (oltre 30 giorni dopo la procedura) non 
sono rari e aumentano la mortalità15. 
Dunque, due aspetti complessivamente (l’alto rischio di 
sanguinamento e la bassa frequenza degli eventi tromboti-
Un aspetto cruciale tuttavia da prendere in considerazione 
nel valutare l’uso della TAO in pazienti TAVI riguarda il rischio 
di sanguinamento. Come precedentemente descritto, il san-
guinamento post-procedurale dopo TAVI è una complicanza 
frequente e rilevante con un impatto negativo sulla sopravvi-
Studio ATLANTIS
1509 pazienti sottoposti con successo a TAVI
Strato 1
Indicazione a terapia 
anticoagulante
Strato 2
Nessuna indicazione a 
terapia anticoagulante
AVK SAPT/DAPT
Endpoint primario: composito di morte, infarto miocardico, ictus/TIA/embolia sistemica, 
trombosi intracardiaca o di bioprotesi, trombosi venosa profonda o 
embolia polmonare, sanguinamenti maggiori ad 1 anno di follow‐up
Apixaban
5 mga bid
R 1:1 R 1:1
Figura 2. Disegno dello studio ATLANTIS.
AVK, antagonista della vitamina K; DAPT, duplice terapia antiaggregante; TIA, attacco 
ischemico transitorio; SAPT, monoterapia antiaggregante.
a2.5 mg bid in caso di clearance della creatinina 15-29 ml/min o in presenza di due dei 
seguenti criteri: età ≥80 anni, peso ≤60 kg o creatinina ≥1.5 mg/dl (133 µmol).
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questi pazienti così da confermare o suggerire eventuali modi-
fiche delle attuali raccomandazioni. 
CONCLUSIONI
La terapia antitrombotica ottimale nei pazienti con SA seve-
ra trattati mediante TAVI resta ancora dibattuta. Le evidenze 
recenti suggeriscono di rivalutare l’attuale raccomandazione 
di trattare questi pazienti con DAPT per 3-6 mesi (in assenza 
di indicazione specifica ad anticoagulazione). In particolare, 
nuovi dati mostrano i potenziali effetti benefici della TAO 
in questi pazienti. I risultati di nuovi studi contribuiranno a 
chiarire come stabilire la terapia antitrombotica ottimale in 
pazienti sottoposti a TAVI. Nella pratica clinica quotidiana è 
quindi sempre fondamentale avere un approccio individualiz-
zato che tenga conto delle caratteristiche cliniche e procedu-
rali di ogni paziente. 
RIASSUNTO
L’impianto transcatetere di protesi valvolare aortica è una procedu-
ra molto diffusa ed alternativa all’intervento chirurgico per il trat-
tamento della stenosi aortica severa. Gli eventi ischemici cerebrali 
e i sanguinamenti nel periodo periprocedurale e durante follow-up 
rappresentano complicanze frequenti e gravi per la prognosi dei 
pazienti, pertanto, vi è grande interesse nello stabilire la terapia 
antitrombotica ottimale per questi pazienti. La maggior parte delle 
linee guida internazionali supporta l’utilizzo di una doppia terapia 
antipiastrinica dopo la procedura, seppure con alcune differenze 
nella durata e nell’eventuale associazione ad anticoagulante orale 
nel caso di pazienti con specifica indicazione, principalmente colo-
ro con fibrillazione atriale. Recenti evidenze indicano però che la 
doppia antiaggregazione non offre vantaggi, anzi aumenta i rischi 
di sanguinamento, rispetto alla monoterapia con aspirina. Alcuni 
studi recenti hanno mostrato però che la terapia anticoagulante 
potrebbe avere un ruolo molto importante in questi pazienti nel 
prevenire e trattare la trombosi della protesi valvolare aortica, che 
sembra essere spesso subclinica e sottostimata, ma frequente. Di-
versi studi clinici in corso forniranno un importante supporto per le 
future raccomandazioni sulla gestione terapeutica di questi pazien-
ti. Nella pratica clinica quotidiana, la considerazione del profilo di 
rischio di ciascun paziente è fondamentale nella personalizzazione 
della terapia.
Parole chiave. Anticoagulanti; Antiaggreganti; Ictus; Impianto 
transcatetere di valvola aortica; Sanguinamento; Terapia anti-
trombotica.
ci) non permettono ad oggi di considerare la TAO come la 
terapia da raccomandare in tutti i pazienti TAVI in assenza di 
nuove evidenze a supporto di questa strategia. In quest’otti-
ca, un importante trial randomizzato è stato disegnato recen-
temente (Figura 1). Lo studio GALILEO (Global multicenter, 
open-label, randomized, event-driven, active-controlled study 
comparing a rivAroxaban-based antithrombotic strategy to 
an antipLatelet-based strategy after transcatheter aortIc vaL-
ve rEplacement to Optimize clinical outcomes) sarà condotto 
in oltre 100 centri in Europa e Stati Uniti e confronterà una 
strategia anticoagulante con rivaroxaban (10 mg/die a lungo 
termine e aspirina 75-100 mg/die nei primi 3 mesi) ad una 
strategia antipiastrinica (aspirina 75-100 mg/die a lungo ter-
mine e clopidogrel nei primi 3 mesi) in pazienti senza una 
precedente indicazione a TAO. 
Similmente, lo studio multicentrico francese ATLANTIS 
(Anti-Thrombotic Strategy to Lower All Cardiovascular and 
Neurologic Ischemic and Hemorrhagic Events after Trans-Aor-
tic Valve Implantation for Aortic Stenosis) confronterà apixa-
ban (5 mg bid oppure 2.5 mg in specifici contesti clinici) con 
la terapia standard (Figura 2).
PAZIENTI CON FIBRILLAZIONE ATRIALE
Nei pazienti con FA sottoposti a TAVI ci sono ad oggi pochi dati 
in merito a quale possa essere la più appropriata strategia anti-
trombotica e la sua durata. Le linee guida americane e canade-
si scoraggiano l’uso della triplice terapia con TAO più aspirina 
e clopidogrel (Tabella 1). Nei pazienti con FA e con malattia 
aterosclerotica coronarica che ricevono impianto di stent coro-
narico, la combinazione di TAO con un singolo antipiastrinico 
ha dimostrato migliore sicurezza in termini di sanguinamen-
to senza aumento di eventi ischemici rispetto all’uso di una 
triplice terapia. Tuttavia, un recente documento di consenso 
europeo sulla gestione dei pazienti con FA raccomanda di pre-
ferire la singola terapia con warfarin in pazienti sottoposti a 
TAVI senza concomitante coronaropatia significativa piuttosto 
che aggiungere anche un antipiastrinico che aumenterebbe il 
rischio emorragico con dubbio beneficio ischemico. Viceversa, 
nei pazienti con FA e recente impianto di stent coronarico che 
sono sottoposti a TAVI si raccomanda la stessa strategia di co-
loro che non ricevono TAVI poiché ad oggi non ci sono specifici 
e convincenti dati in questa tipologia di pazienti16. Studi futuri 
sono necessari per offrire evidenze scientifiche specifiche per 
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The 2017 marks the 40th anniversary of percutaneous 
coronary intervention (PCI), but also the 15th anniversary 
for transcatheter aortic valve implantation (TAVI) (1). 
For more than 50 years, surgical aortic valve replacement 
(SAVR) has been the standard of care for patients with 
severe symptomatic aortic stenosis, improving outcomes 
and prolonging the lives of these patients. In 1990s the 
transcatheter delivery of a bioprosthetic aortic valve 
was conceptualized and largely tested in animals. The 
first human implantation of a percutaneous implantable 
prosthetic heart valve composed of 3 bovine pericardial 
leaflets mounted within a balloon-expandable stent was 
performed in Rouen on 16 April 2002 in a 57-year-old 
desperately ill man in cardiogenic shock, with critical 
aortic stenosis, subacute leg ischemia deemed inoperable 
due to multiple comorbidities (valve replacement had been 
declined for this patient, and balloon valvuloplasty had been 
performed with nonsustained results) (2).
Since then, TAVI has dramatically evolved, devices and 
procedural techniques have rapidly improved and results of 
randomized clinical trials have revolutionized the current 
treatment of severe aortic stenosis leading today to more 
than 300,000 procedures performed worldwide in more than 
1,000 centers and 65 countries (1). Fifteen years after the 
first-in-man case, we can consider TA7I, with its explosive 
potential, as one of the major medical breakthroughs of 
the past decade in cardiology. Technological improvements 
and favorable clinical outcomes allowed to clearly 
establish the role of TAVI as the recommended strategy 
compared with medical therapy for inoperable patients, 
and alternative to surgery for high-risk patients, reaching 
more recently also the appropriate scientific evidence to 
recommend this procedure in patients at intermediate-
risk (3-7). Furthermore, trials among low-risk patients are 
ongoing and evidence on feasibility and safety of TAVI in 
other clinical settings (treatment of patients with bicuspid 
aortic valve, pure native aortic regurgitation, degenerated 
surgical bioprosthetic valves or those with symptomatic 
moderate aortic stenosis or asymptomatic severe aortic 
stenosis) is being accumulated (3-7). However, ischemic 
and bleeding events soon after or at long-term after TAVI 
remain high, advocating dedicated investigations on optimal 
antithrombotic therapy (Figure 1) (8).
The prevention of ischemic complications during TAVI 
most likely requires full-dose anticoagulation. The most 
frequently used anticoagulant is unfractionated heparin, 
and the only trial comparing this latter with bivalirudin, 
the BRAVO 3 (Effect of Bivalirudin on Aortic Valve 
Intervention Outcomes 3), showed that bivalirudin did not 
reduce rates of major bleeding at 48 hours or net adverse 
cardiovascular events within 30 days compared with heparin 
(even if the non-inferiority hypothesis was reached for 
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this endpoint) supporting the concept that heparin should 
remain the standard of care in TAVI patients (9). Regarding 
the post-procedural antithrombotic therapy, based on the 
increased thrombotic risks related to TAVI valve structure, 
dual antiplatelet therapy (DAPT) with aspirin (indefinitely) 
and clopidogrel (1 to 6 months)—in the absence of an 
indication for anticoagulation—has been a widely accepted 
empirical treatment, which was incorporated into practice 
guidelines. Differently from surgical interventions, the 
diseased native valve is not removed in TAVI procedures 
and may be mechanically damaged, leading to the exposure 
and/or embolism of valvular components into the arterial 
circulation. Moreover, the insertion of the prosthesis 
into the diseased native valve creates an irregular zone 
around the valve frame with modified flow patterns that 
may predispose to thrombus formation, particularly 
in the case of small valve sizes with associated patient–
prosthesis mismatch. Notably, TAVI patients remain 
at risk for stroke throughout the first months after the 
procedure and mechanisms other than valve manipulation 
seem to be involved (i.e., aortic wall injury, posttraumatic 
surface exposure with consequent activation of the 
hemostatic system, turbulence or local blood stasis, atrial 
fibrillation). For all these reasons, although empirical, the 
recommendation to adopt DAPT has reached widespread 
clinical practice. DAPT is a mainstay therapy for patients 
undergoing PCI compared with aspirin monotherapy, but 
the higher risks of bleeding and the well-known impact 
of bleeding on mortality represent a crucial aspect to be 
taken into account when deciding on its duration (10-16). 
In TAVI patients, two important considerations should be 
done: (I) TAVI patients are often old, frail and with multiple 
comorbidities leading to high risk of bleeding. Hence 
the balance between preventing ischemic complications 
at acceptable costs for bleeding remains a challenge in 
this population; (II) the benefits of DAPT over aspirin 
monotherapy have been questioned by recent evidence (17). 
Indeed, the evidence from 2 small randomized trials, some 
small observational studies and meta-analyses does not 
support the use of DAPT compared with aspirin alone 
due to increased risk of bleeding in the absence of sizable 
beneficial effects on ischemic endpoints (17).
Recently, a third randomized clinical trial has been 
published (18). This is a prospective, randomized, open-
label multicenter clinical trial including 222 patients 
undergoing TAVI with a balloon-expandable Edwards 
SAPIEN XT (92.3%) or SAPIEN 3 (7.7%) valves, 
with no indication to oral anticoagulation (OAC), who 
have been randomized to aspirin or DAPT. Overall, the 
patient population was old (mean age was 79 years) and 
the mean Society of Thoracic Surgeons score was 6.3. 
The investigators observed a significantly higher rate of 
major or life-threatening bleeding events in the DAPT 
group (10.8% vs. 3.6%; P=0.038). Notably, the excess of 
Figure 1 Rates of myocardial infarction, stroke and major bleeding 30 days after TAVI in main randomized clinical trials. Data on major 
bleeding were not available for STACCATO trial. The rate of myocardial infarction was 0% in STACCATO, PARTNER 1A and 1B. MI, 
myocardial infarction.
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
MI Stroke Major Bleeding
Staccato Partner 1A Partner 1B US Corevalve Notion Partner 2A Surtavi Choice Bravo 3
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bleeding events occurred within 30 days, the majority of 
which was post-procedurally and mainly included vascular 
or access-site complications or gastrointestinal bleeding. 
This increased risk of bleeding was the major driver for 
the higher (despite statistically borderline: 15.3% vs. 7.2%; 
P=0.065) rate of the primary endpoint, consisting of death, 
myocardial infarction, transient ischemic attack/ischemic 
stroke, or major/life-threatening bleeding 3 months after 
TAVI. Individual ischemic endpoints and mortality did not 
different between the 2 regimens, although numerically 
higher in the DAPT group. These findings represent an 
important step forward in the field.
The study was prematurely stopped due to slow 
recruitment and lack of financial support. Overall 222 
patients of the 300 planned were included. However, it is 
important to note that even the requirement of 300 patients 
only was established for exploratory purposes without 
a formal sample size assumption. Therefore, ARTE, as 
all previous studies, lacks sufficient study power and its 
findings should be interpreted with caution and considered 
hypothesis-generating only.
Even when pooling together the three available 
randomized trials available, DAPT does not offer ischemic 
benefits rather bleeding harms (1). Yet, the overall number 
of patients remains limited and uncertainty around the 
point estimates for ischemic endpoints remain considerable 
and do entail the possibility that DAPT may offer greater 
protection than aspirin monotherapy. Additionally, no 
data is currently available in patients receiving more 
contemporary TAVI devices (e.g., it is unknown if the 
additional skirt aimed at reducing post-implantation 
paravalvular leak may potentially increase thrombogenicity). 
The impact of the high on-treatment platelet reactivity 
associated with clopidogrel or aspirin (which seems more 
frequent in TAVI patients) is yet to be understood. 
Five of the 16 severe bleeds observed in the ARTE 
trial were gastro-intestinal. Despite the claim of the 
investigators that proton-pump inhibitors (PPI) were not 
specifically recommended in patients included in the trial, 
one wonders if and how much the preventive use of PPI 
would have impacted that risk. The use of PPI is currently 
recommended in all DAPT patients, even if the risk of GI 
complications a prior is not high (20,21).
Stroke mainly occurs in the acute phase after TAVI and 
cerebral protection devices have been proposed to integrate 
pharmacologic therapy to prevent such complications. 
Recent studies support benefits of embolic protection 
during TAVI, indirectly providing further evidence for 
the importance of embolic debris in periprocedural stroke 
events (22,23).
While ARTE and the two prior trials investigated the 
concomitant use of clopidogrel in TAVI patients (18), 
there are arguments supporting the preferential use of 
OAC therapy instead of antiplatelet agents. First, there 
is still uncertainties regarding the exact mechanisms 
causing thrombotic events after TAVI and currently we 
cannot exclude that thrombin is the major driver or a 
co-driver of such complications. Second, the rates of 
pre-existing atrial fibrillation and new-onset atrial 
fibrillation are relevant in TA7I population and significantly 
impact on stroke and mortality (24,25). Third, there is 
evidence that leaflet thrombosis of transcatheter heart 
valves could be a relatively novel and important mechanism 
of transcatheter heart valve-related thrombotic events or 
even valve failure. Data from two registries, the SAVORY 
(Subclinical Aortic Valve Bioprosthesis Thrombosis 
Assessed with Four-Dimensional Computed Tomography) 
and the RESOLVE (Assessment of Transcatheter and 
Surgical Aortic Bioprosthetic Valve Thrombosis and Its 
Treatment with Anticoagulation), suggest that subclinical 
leaflet thrombosis, represented by leaflet thickening on 
computed tomography, is more common with transcatheter 
valves compared with bioprosthetic surgical valves, and 
is associated with increased rates of stroke or TIA (26). 
Importantly, anticoagulation (both novel OACs and 
warfarin), but not DAPT, was effective in the prevention or 
treatment of subclinical leaflet thrombosis (26), providing 
the rationale for investigating OAC use in TAVI patients (27). 
However, the natural history and clinical significance of 
asymptomatic leaflet thrombosis remains unclear. Assuming 
OAC therapy to be the solution, does starting it earlier 
rather than later make any difference and for how long 
should it be prescribed? Considering the OAC-related 
bleeding risks, it seems logical for the time being, in the 
absence of compelling evidence that the decision on which 
antithrombotic therapy should be individualized, after with 
careful consideration of the risLbenefit profile. 
Current ly,  the  complex  puzzle  of  the  opt imal 
antithrombotic therapy after TAVI remains intriguing but 
unsolved. Clinical trials are ongoing (Table 1) and their 
results will hopefully add the missing pieces in this complex 
puzzle of optimal antithrombotic therapy after TAVI. 
Acknowledgements
None.
4263Journal of Thoracic Disease, Vol 9, No 11 November 2017
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(11):4260-4265jtd.amegroups.com
T
ab
le
 1
 O
ng
oi
ng
 tr
ia
ls
 o
n 
th
e 
an
tit
hr
om
bo
tic
 tr
ea
tm
en
t a
ft
er
 T
AV
I
Tr
ia
ls
AT
LA
N
TI
S
A
U
R
EA
AV
AT
A
R
EN
VI
S
A
G
E-
TA
VI
G
A
LI
LE
O
P
O
P
U
LA
R
-T
AV
I
C
LO
E
C
lin
ic
al
Tr
ia
ls
.
go
v 
ID
N
C
T0
26
64
64
9
N
C
T0
16
42
13
4
N
C
T0
27
35
90
2
N
C
T0
29
43
78
5
N
C
T0
25
56
20
3
N
C
T0
22
47
12
8
A
nn
ou
nc
ed
P
at
ie
nt
s
1,
51
0
12
4
17
0
1,
40
0
1,
52
0
1,
00
0
N
A
In
di
ca
tio
n 
to
 
O
A
C
Ye
s
N
o
Ye
s
Ye
s
N
o
Ye
s 
(c
oh
or
t B
)
Ye
s
C
om
pa
ris
on
A
pi
xa
ba
n 
vs
.  
S
A
P
T/
D
A
P
T 
 
(n
o 
O
A
C
 in
di
ca
tio
n)
 o
r 
VK
A
 (O
A
C
 in
di
ca
tio
n)
D
A
P
T 
vs
. V
K
A
VK
A
 v
s.
 A
S
A
 +
 
VK
A
Ed
ox
ab
an
 v
s.
 V
K
A
. 
A
P
T 
pe
r l
oc
al
 p
ra
c-
tic
e
R
iv
ar
ox
ab
an
 +
 A
S
A
 v
s.
 
D
A
P
T 
fo
r 3
 m
 th
en
  
riv
ar
ox
ab
an
 v
s.
 A
S
A
A
S
A
 v
s.
 D
A
P
T 
(c
oh
or
t A
) o
r C
lo
p 
+ 
VK
A
 v
s.
 V
K
A
 (c
oh
or
t 
B
)
A
S
A
 v
s.
 D
A
P
T 
or
 c
lo
p 
+ 
VK
A
 
vs
. V
K
A
Fo
llo
w
-u
p 
(m
on
th
s)
U
p 
to
 1
3
3
12
36
U
p 
to
 2
5
12
N
A
P
rim
ar
y 
 
en
dp
oi
nt
C
om
po
si
te
 o
f d
ea
th
, 
M
I, 
st
ro
ke
, S
EE
,  
in
tr
ac
ar
di
ac
 o
r  
bi
op
ro
st
he
si
s 
 
th
ro
m
bu
s,
 a
ny
 D
VT
 
or
 P
E,
 li
fe
-t
hr
ea
te
ni
ng
 
or
 d
is
ab
lin
g 
or
 m
aj
or
 
VA
R
C
-2
 b
le
ed
in
g
P
re
ve
nt
io
n 
of
 c
er
eb
ra
l 
th
ro
m
bo
em
bo
lis
m
 b
y 
th
e 
de
te
ct
io
n 
of
 n
ew
 a
re
as
 
of
 c
er
eb
ra
l i
nf
ar
ct
io
n 
by
 
M
R
I a
t 3
 m
on
th
s 
C
om
po
si
te
 o
f  
al
l-c
au
se
 d
ea
th
, 
M
I, 
st
ro
ke
 a
ll 
ca
us
es
, v
al
ve
 
th
ro
m
bo
si
s 
an
d 
he
m
or
rh
ag
e 
≥2
 
as
 d
efi
ne
d 
by
 th
e 
VA
R
C
-2
C
om
po
si
te
 o
f  
al
l-c
au
se
 d
ea
th
, M
I, 
is
ch
em
ic
 s
tr
ok
e,
 S
EE
, 
va
lv
e 
th
ro
m
bo
si
s,
 
an
d 
IS
TH
 m
aj
or
  
bl
ee
di
ng
C
om
po
si
te
 o
f a
ll-
ca
us
e 
de
at
h 
an
d 
ad
ju
di
ca
te
d 
an
y 
st
ro
ke
, M
I, 
 
sy
m
pt
om
at
ic
 v
al
ve
 
th
ro
m
bo
si
s,
 P
E,
 D
VT
,  
or
 n
on
-C
N
S
-S
E
Fr
ee
do
m
 o
f a
ll 
B
A
R
C
 b
le
ed
in
g 
at
 
1 
y.
 T
he
 c
o-
pr
im
ar
y 
ou
tc
om
e 
is
 fr
ee
do
m
 
of
 n
on
-p
ro
ce
du
re
 
re
la
te
d 
B
A
R
C
 
bl
ee
di
ng
 a
t 1
 y
N
A
AT
LA
N
TI
S
, 
A
nt
i-T
hr
om
bo
tic
 S
tr
at
eg
y 
A
fte
r 
Tr
an
s-
A
or
tic
 V
al
ve
 I
m
pl
an
ta
tio
n 
fo
r 
A
or
tic
 S
te
no
si
s;
 A
P
T,
 a
nt
ip
la
te
le
t 
th
er
ap
y;
 A
S
A
, 
as
pi
rin
; 
A
U
R
EA
, 
D
ua
l A
nt
ip
la
te
le
t 
Th
er
ap
y 
 
Ve
rs
us
 O
ra
l A
nt
ic
oa
gu
la
tio
n 
fo
r 
a 
S
ho
rt
 T
im
e 
to
 P
re
ve
nt
 C
er
eb
ra
l E
m
bo
lis
m
 A
ft
er
 T
AV
I; 
AV
AT
A
R
, 
A
nt
ic
oa
gu
la
tio
n 
A
lo
ne
 V
er
su
s 
A
nt
ic
oa
gu
la
tio
n 
an
d 
A
sp
iri
n 
Fo
llo
w
in
g 
 
Tr
an
sc
at
he
te
r 
A
or
tic
 V
al
ve
 I
nt
er
ve
nt
io
ns
; 
B
A
R
C
, 
B
le
ed
in
g 
A
ca
de
m
ic
 R
es
ea
rc
h 
C
on
so
rt
iu
m
; 
no
n-
C
N
S
-S
E,
 N
on
-c
en
tr
al
 n
er
vo
us
 s
ys
te
m
-s
ys
te
m
ic
 e
m
bo
lis
m
; 
D
A
P
T,
 d
ua
l 
an
tip
la
te
le
t 
th
er
ap
y;
 D
VT
, 
de
ep
 v
ei
n 
th
ro
m
bo
si
s;
 E
N
VI
S
A
G
E 
TA
VI
, 
Ed
ox
ab
an
 C
om
pa
re
d 
to
 S
ta
nd
ar
d 
C
ar
e 
A
ft
er
 H
ea
rt
 V
al
ve
 R
ep
la
ce
m
en
t 
U
si
ng
 a
 C
at
he
te
r 
in
 P
at
ie
nt
s 
W
ith
 A
tr
ia
l F
ib
ril
la
tio
n;
 G
A
LI
LE
O
, 
G
lo
ba
l S
tu
dy
 C
om
pa
rin
g 
a 
riv
ar
ox
ab
an
-b
as
ed
 A
nt
ith
ro
m
bo
tic
 S
tr
at
eg
y 
to
 a
n 
an
tip
la
te
le
t-
ba
se
d 
S
tr
at
eg
y 
A
fte
r 
Tr
an
sc
at
he
te
r 
ao
rt
ic
 v
al
ve
  
re
pl
ac
em
en
t 
to
 O
pt
im
iz
e 
C
lin
ic
al
 O
ut
co
m
es
; 
IS
TH
, 
In
te
rn
at
io
na
l S
oc
ie
ty
 o
n 
Th
ro
m
bo
si
s 
an
d 
H
ae
m
os
ta
si
s;
 M
I, 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 M
R
I, 
M
ag
ne
tic
 R
es
on
an
ce
 I
m
ag
in
g;
 
N
A
, n
ot
 a
va
ila
bl
e;
 O
A
C
, o
ra
l a
nt
ic
oa
gu
la
tio
n;
 P
E,
 p
ul
m
on
ar
y 
em
bo
lis
m
; P
op
ul
ar
-T
AV
I, 
A
nt
ip
la
te
le
t 
Th
er
ap
y 
fo
r 
P
at
ie
nt
s 
U
nd
er
go
in
g 
Tr
an
sc
at
he
te
r 
A
or
tic
 V
al
ve
 Im
pl
an
ta
tio
n;
 
S
EE
, s
ys
te
m
ic
 e
m
bo
lic
 e
ve
nt
s;
 V
A
R
C
, V
al
ve
 A
ca
de
m
ic
 R
es
ea
rc
h 
C
on
so
rt
iu
m
; V
K
A
, v
ita
m
in
 K
 a
nt
ag
on
is
t.
4264 Gargiulo and Valgimigli. Optimal antithrombotic regimen after TAVI
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(11):4260-4265jtd.amegroups.com
Footnote 
Conflicts of Interest: The authors have no conflicts of interest 
to declare.
References
1. Cribier A. Commemorating the 15-year anniversary 
of TAVI: insights into the early stages of development, 
from concept to human application, and perspectives. 
EuroIntervention 2017;13:29-37. 
2. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous 
transcatheter implantation of an aortic valve prosthesis 
for calcific aortic stenosis: first human case description. 
Circulation 2002;106:3006-8.
3. Gargiulo G, Sannino A, Capodanno D, et al. Transcatheter 
Aortic Valve Implantation Versus Surgical Aortic Valve 
Replacement: A Systematic Review and Meta-analysis. 
Ann Intern Med 2016;165:334-44. 
4. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS 
Guidelines for the management of valvular heart disease: 
The Task Force for the Management of Valvular Heart 
Disease of the European Society of Cardiology (ESC) and 
the European Association for Cardio-Thoracic Surgery 
(EACTS). Eur Heart J 2017. [Epub ahead of print].
5. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or 
Surgical Aortic-Valve Replacement in Intermediate-Risk 
Patients. N Engl J Med 2016;374:1609-20.
6. Reardon MJ, Van Mieghem NM, Popma JJ, et al. 
Surgical or Transcatheter Aortic-Valve Replacement 
in Intermediate-Risk Patients. N Engl J Med 
2017;376:1321-31. 
7. Thourani VH, Kodali S, Makkar RR, et al. Transcatheter 
aortic valve replacement versus surgical valve replacement 
in intermediate-risk patients: a propensity score analysis. 
Lancet 2016;387:2218-25. 
8. Gargiulo G, Collet JP, Valgimigli M. Antithrombotic 
therapy in TAVI patients: changing concepts. 
EuroIntervention 2015;11 Suppl W:W92-5.
9. Dangas GD, Lefèvre T, Kupatt C, et al. Bivalirudin Versus 
Heparin Anticoagulation in Transcatheter Aortic Valve 
Replacement: The Randomized BRAVO-3 Trial. J Am 
Coll Cardiol 2015;66:2860-8.
10. Gargiulo G, Valgimigli M, Capodanno D, et al. State 
of the art: duration of dual antiplatelet therapy after 
percutaneous coronary intervention and coronary stent 
implantation - past, present and future perspectives. 
EuroIntervention 2017;13:717-33.
11. Gargiulo G, Windecker S, Vranckx P, et al. A Critical 
Appraisal of Aspirin in Secondary Prevention: Is Less 
More? Circulation 2016;134:1881-906.
12. Capodanno D, Gargiulo G, Buccheri S, et al. Meta-
Analyses of Dual Antiplatelet Therapy Following Drug-
Eluting Stent Implantation: Do Bleeding and Stent 
Thrombosis Weigh Similar on Mortality? J Am Coll 
Cardiol 2015;66:1639-40. 
13. Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of 
myocardial infarction vs. bleeding types on mortality after 
acute coronary syndrome: lessons from the Thrombin 
Receptor Antagonist for Clinical Event Reduction in 
Acute Coronary Syndrome (TRACER) randomized trial. 
Eur Heart J 2017;38:804-10. 
14. Costa F, van Klaveren D, James S, et al. Derivation and 
validation of the predicting bleeding complications in 
patients undergoing stent implantation and subsequent 
dual antiplatelet therapy (PRECISE-DAPT) score: a 
pooled analysis of individual-patient datasets from clinical 
trials. Lancet 2017;389:1025-34. 
15. Gargiulo G, Windecker S, da Costa BR, et al. Short 
term versus long term dual antiplatelet therapy after 
implantation of drug eluting stent in patients with or 
without diabetes: systematic review and meta-analysis of 
individual participant data from randomised trials. BMJ 
2016;355:i5483.
16. Gargiulo G, Ariotti S, Santucci A, et al. Impact of Sex 
on 2-Year Clinical Outcomes in Patients Treated With 
6-Month or 24-Month Dual-Antiplatelet Therapy 
Duration: A Pre-Specified Analysis From the PRODIGY 
Trial. JACC Cardiovasc Interv 2016;9:1780-9. 
17. Hassell ME, Hildick-Smith D, Durand E, et al. 
Antiplatelet therapy following transcatheter aortic valve 
implantation. Heart 2015;101:1118-25.
18. Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin 
Versus Aspirin Plus Clopidogrel as Antithrombotic 
Treatment Following Transcatheter Aortic Valve 
Replacement With a Balloon-Expandable Valve: The 
ARTE (Aspirin Versus Aspirin + Clopidogrel Following 
Transcatheter Aortic Valve Implantation) Randomized 
Clinical Trial. JACC Cardiovasc Interv 2017;10:1357-65.
19. Capodanno D, Angiolillo DJ. Antithrombotic Therapy 
for Prevention of Cerebral Thromboembolic Events 
After Transcatheter Aortic Valve Replacement: Evolving 
Paradigms and Ongoing Directions. JACC Cardiovasc 
Interv 2017;10:1366-9.
20. Valgimigli M, Bueno H, Byrne RA, et al.2017 ESC focused 
update on dual antiplatelet therapy in coronary artery 
4265Journal of Thoracic Disease, Vol 9, No 11 November 2017
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(11):4260-4265jtd.amegroups.com
disease developed in collaboration with EACTS: The 
Task Force for dual antiplatelet therapy in coronary artery 
disease of the European Society of Cardiology (ESC) and 
of the European Association for Cardio-Thoracic Surgery 
(EACTS). Eur Heart J 2017. [Epub ahead of print].
21. Gargiulo G, Costa F, Ariotti S, et al. Impact of proton 
pump inhibitors on clinical outcomes in patients treated 
with a 6- or 24-month dual-antiplatelet therapy duration: 
Insights from the PROlonging Dual-antiplatelet treatment 
after Grading stent-induced Intimal hyperplasia studY 
trial. Am Heart J 2016;174:95-102. 
22. Haussig S, Mangner N, Dwyer MG, et al. Effect of a 
Cerebral Protection Device on Brain Lesions Following 
Transcatheter Aortic Valve Implantation in Patients With 
Severe Aortic Stenosis: The CLEAN-TAVI Randomized 
Clinical Trial. JAMA 2016;316:592-601.
23. Kapadia SR, Kodali S, Makkar R, et al. Protection Against 
Cerebral Embolism During Transcatheter Aortic Valve 
Replacement. J Am Coll Cardiol 2017;69:367-77. 
24. Gargiulo G, Capodanno D, Sannino A, et al. New-onset 
atrial fibrillation and increased mortality after transcatheter 
aortic valve implantation: A causal or spurious association? 
Int J Cardiol 2016;203:264-6.
25. Sannino A, Gargiulo G, Schiattarella GG, et al. A meta-
analysis of the impact of pre-existing and new-onset atrial 
fibrillation on clinical outcomes in patients undergoing 
transcatheter aortic valve implantation. EuroIntervention 
2016;12:e1047-56. 
26. Chakravarty T, Søndergaard L, Friedman J, et al. 
Subclinical leaflet thrombosis in surgical and transcatheter 
bioprosthetic aortic valves: an observational study. Lancet 
2017;389:2383-92.
27. Windecker S, Tijssen J, Giustino G, et al. Trial design: 
Rivaroxaban for the prevention of major cardiovascular 
events after transcatheter aortic valve replacement: 
Rationale and design of the GALILEO study. Am Heart J 
2017;184:81-7.
Cite this article as: Gargiulo G, Valgimigli M. Antithrombotic 
therapy after transcatheter aortic valve implantation: a new piece 
of the still unresolved puzzle. J Thorac Dis 2017;9(11):4260-
4265. doi: 10.21037/jtd.2017.10.28
Part 3
Trade-off for ischemia and bleeding 
and optimal clinical outcomes during 
and after transcatheter aortic valve 
implantation (TAVI):
Risk stratification and optimization of 
clinical outcomes in patients 
undergoing TAVI
Transcatheter Aortic Valve Implantation Versus Surgical Aortic
Valve Replacement
A Systematic Review andMeta-analysis
Giuseppe Gargiulo, MD; Anna Sannino, MD; Davide Capodanno, MD, PhD; Marco Barbanti, MD; Sergio Buccheri, MD;
Cinzia Perrino, MD, PhD; Piera Capranzano, MD; Ciro Indolfi, MD, PhD; Bruno Trimarco, MD; Corrado Tamburino, MD, PhD; and
Giovanni Esposito, MD, PhD
Purpose: To compare clinical outcomes, including early (≤30-
day) and midterm (≤1-year) mortality, in adults with severe aortic
stenosis undergoing either transapical aortic valve implantation
(TAVI) or surgical aortic valve replacement (SAVR).
Data Sources: MEDLINE, Cochrane, and Scopus databases
(without language restrictions) from April 2002 to 5 April
2016; multiple registries and Web sites; scientific meeting
presentations.
Study Selection: Five randomized trials and 31 observational
matched studies comparing mortality outcomes after TAVI or
SAVR.
Data Extraction: Two investigators independently extracted
study data and rated risk of bias.
Data Synthesis: A total of 16 638 patients were analyzed. Over-
all, there was no statistically significant difference between TAVI
and SAVR in early (odds ratio [OR], 1.01 [95%CI, 0.81 to 1.26]) or
midterm (OR, 0.96 [CI, 0.81 to 1.14]) all-cause mortality. Analyses
restricted to trials (early: OR, 0.80 [CI, 0.51 to 1.25]; midterm: OR,
0.90 [CI, 0.64 to 1.26]) were inconclusive, with wide CIs, whereas
analyses of matched studies were similar to the overall results.
Transfemoral TAVI provided mortality benefits over SAVR in tri-
als. Analyses restricted to studies of patients at low to intermedi-
ate risk showed statistically nonsignificant reductions in early
(OR, 0.67 [CI, 0.42 to 1.07]) and midterm (OR, 0.91 [CI, 0.67 to
1.23]) mortality with TAVI. Incidence of periprocedural myocar-
dial infarction, major bleeding, acute kidney injury, and new-
onset atrial fibrillation was lower with TAVI, but risk for pace-
maker implantation, vascular complications, and paravalvular
leak increased. Overall, there was a statistically nonsignificant in-
creased risk in long-term (2- to 5-year) all-cause mortality with
TAVI (OR, 1.28 [CI, 0.97 to 1.69]), whereas long-term mortality
outcomes in patients at low to intermediate risk were inconclu-
sive, with wide CIs (OR, 1.06 [CI, 0.59 to 1.91]).
Limitation: The number of trials was limited, and study designs
and patient characteristics were heterogeneous.
Conclusion: Compared with SAVR, TAVI may have similar or
better early and midterm outcomes for adults with aortic steno-
sis, including those at low to intermediate risk.
Primary Funding Source: None.
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For decades, surgical aortic valve replacement(SAVR) was the standard of care to alleviate symp-
toms and improve survival in patients with severe aortic
stenosis (1). Recently, transcatheter aortic valve implan-
tation (TAVI) emerged as a better option than either
medical therapy or balloon aortic valvuloplasty for
adult patients who cannot undergo SAVR and as a rea-
sonable alternative to SAVR for those considered at
high surgical risk (1–4).
Similar clinical outcomes at 5 years between TAVI
with the Sapien balloon-expandable prosthesis (Ed-
wards Lifesciences) and SAVR have been reported in
high-risk surgical candidates from the PARTNER (Place-
ment of Aortic Transcatheter Valves) trial (5). Compared
with SAVR, TAVI with the CoreValve self-expanding
prosthesis (Medtronic) showed benefits at 3 years in
the U.S. CoreValve High Risk Study (6–8). As evidence
supporting TAVI in patients at high risk consolidates,
interest is increasing in comparative studies of TAVI
and SAVR in patients at low or intermediate surgical risk
(9–17). In the all-comers NOTION (Nordic Aortic Valve
Intervention) trial, in which approximately 80% of pa-
tients were considered low risk, TAVI was not found to
be superior to SAVR for the composite outcome of
death from any cause, stroke, or myocardial infarction
at 1 year (13.1% vs. 16.3%; P for superiority = 0.43) (9,
10). PARTNER 2A, a recent trial in intermediate-risk pa-
tients, also showed no statistically significant differ-
ences between TAVI and SAVR for the primary end
point of death or disabling stroke at 2 years (11).
Given several recent studies, extended follow-up of
previous studies, and some conflicting results, we con-
ducted an updated meta-analysis comparing clinical
outcomes, including short- and midterm mortality, of
adult patients with severe aortic stenosis undergoing
either TAVI or SAVR.
METHODS
Protocol
We developed and followed a protocol (Supple-
ment 1, available at www.annals.org) and followed
PRISMA (Preferred Reporting Items for Systematic Re-
views and Meta-Analyses) reporting guidelines (18).
See also:
Web-Only
Supplement
Annals of Internal Medicine REVIEW
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Data Sources and Searches
MEDLINE,Cochrane, and Scopus databaseswere
searched, without language restrictions, for articles
published from April 2002 (first-in-human TAVI date)
until5April2016.Thesearchstrategyusedacombina-
tionofterms,suchas“transcatheteraorticvalveimplan-
tation” or “transcatheter aortic valve replacement” or
“TAVI”or“TAVR”and“versus”and“surgicalaorticvalve
replacement” or “SAVR” (Supplement 2, available at
www.annals.org). Additional sources searched from
January2015to5April2016includedwww.clinicaltrials
.gov, www.clinicaltrialresults.org, www.tctmd.com,
www.cardiosource.RUJ, www.theheart.org,
www.escardio.org, Google Scholar, and abstracts/
presentations from major cardiovascular meetings.
Reference lists of relevant studies, reviews, editorials,
andlettersalsowerescrutinized.
Study Selection
Citations were screened at the title and abstract
level by 2 independent reviewers, and full text was re-
trieved for those reporting outcome data. Discrepan-
cies, if any, were resolved by consensus. Randomized
or observational matched studies were included if they
reported mortality data of adult patients with severe
aortic stenosis treated with TAVI versus SAVR. Matched
studies had to have TAVI and SAVR groups matched for
propensity score or preoperative variables to minimize
the effect of baseline confounding factors. A study was
excluded if any of the following criteria applied: It
reported observational unmatched data (no type of
matching was used to account for differences in preop-
erative characteristics); it was a duplicate publication;
or the mortality outcome was not reported or could not
be derived from the published results.
Data Extraction and Study Quality
The most up-to-date or inclusive data for a given
study were chosen for abstraction. Two investigators
independently identified studies, extracted data, and
rated the risk of bias at the study level. The quality of
randomized and observational matched studies in-
cluded in the meta-analysis was appraised, respec-
tively, by using Cochrane methods (selection bias, per-
formance bias, detection bias, attrition bias, reporting
bias, and other bias) and Newcastle–Ottawa Scale (se-
lection, comparability, and outcome) criteria as previ-
ously described (19–21).
Study Outcomes
Main outcomes of interest in this study were early
(≤30-day) and midterm (≤1-year) all-cause mortality.
Secondary outcomes of interest included long-term
(>1-year) all-cause mortality; 30-day and midterm
stroke; and an array of periprocedural complications,
including 30-day cardiovascular mortality, myocardial
infarction, permanent pacemaker implantation, major
bleeding, vascular complication, acute kidney injury,
new-onset atrial fibrillation, and moderate to severe
paravalvular leak.
Data Synthesis and Analysis
Effect sizes were calculated with the Knapp–
Hartung random-effects estimator and expressed as
odds ratios (ORs) and 95% CIs, as previously reported
(22). Heterogeneity was assessed by I2 tests, with sub-
stantial heterogeneity defined as I2 greater than 50%.
Mortality outcomes were stratified by study design (ran-
domized or matched) and TAVI access. Multiple sensi-
tivity analyses were performed to investigate potential
sources of inconsistency, including removal of the fol-
lowing: individual studies at each time, non–propensity-
matched studies, studies including fewer than 100 pa-
tients, studies recruiting patients at low to intermediate
risk, studies performing TAVI by transapical approach
only, studies that did not use standardized definitions
(Valve Academic Research Consortium [VARC]/VARC2
and VARC/VARC2-like criteria), and studies with mod-
erate to high risk of bias. A subgroup analysis restricted
to patients at lower (low to intermediate) surgical risk
also was performed that included only studies that pre-
specified inclusion of patients at lower risk. Mortality
data from post hoc analyses of the U.S. CoreValve (pa-
tients with Society of Thoracic Surgery [STS] score <7%)
and PARTNER (patients with STS score <11%) trials did
not contribute to this subanalysis because the entry cri-
terion of these trials was “high risk” as defined by clini-
cians on the basis of STS score and other clinical vari-
ables not included in the STS score algorithm.
Exploratory metaregressions also were done to investi-
gate the influence of baseline characteristics as poten-
tial effect modifiers. Publication bias was assessed by
using funnel plots, Begg tests, Egger tests, and the
trim-and-fill method. Data were analyzed by using the
metafor package for R (R Foundation for Statistical
Computing), Reviewer Manager (RevMan, version 5.2;
Cochrane), and ProMeta (version 2; Internovi) software
(22–25).
Role of the Funding Source
No external funding was received.
RESULTS
Search Results and Study Details
Of 444 articles initially identified, 80 were retrieved
for detailed evaluation and 36 met inclusion criteria
(Supplement Figure 1, available at www.annals.org).
Five studies were randomized trials (5, 6, 9, 11, 26), and
31 were observational matched designs (12–17, 27–51).
Propensity score matching was used in 25 studies,
whereas 6 were matched on the basis of selected clin-
ical characteristics. All studies provided data on short-
or midterm all-cause mortality, whereas long-term mor-
tality data (ranging from 2 to 5 years; mean, 33 months)
were available for 4 randomized (5, 8, 10, 11) and 6
matched (15, 37, 42, 44, 45, 51) studies. The risk of bias
in studies mostly was low, although the interventions
were unavoidably unblinded (Supplement Tables 1
and 2, available at www.annals.org). Among random-
ized trials, STACCATO (A Prospective, Randomised
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Trial of Transapical Transcatheter Aortic Valve Implan-
tation Versus Surgical Aortic Valve Replacement in Op-
erable Elderly Patients With Aortic Stenosis) had a high
risk of bias because of underpowered results and was
terminated prematurely after accruing only 70 of the
200 planned patients.
Patient Characteristics
A total of 16 638 patients undergoing TAVI (n =
7732) or SAVR (n = 8906) were analyzed. Although
most studies involved patients at high surgical risk, 2
randomized trials (9, 11) and 6 matched studies (12–17)
included patients at low to intermediate risk. The
NOTION trial included patients across the full spectrum
of risk, with most considered low risk (mean STS score,
3.0%) (9), whereas the PARTNER 2A trial involved
intermediate-risk patients (mean STS score, 5.8%) (11).
The mean age of patients enrolled in all the included
studies ranged from 70 to 84 years. Most patients were
in New York Heart Association functional class III or IV.
Comorbid conditions varied across studies, and some
studies focused on selected scenarios or patients. Four
focused on redo procedures; of these, 1 included pa-
tients with prior coronary artery bypass grafting and 3
included those with prior cardiac surgery (39, 43, 44,
50). One study analyzed only patients with liver disease
(47) and another only those on dialysis (40). In most
cases, TAVI patients received a first-generation valve,
except those in 1 study that used the latest-generation
balloon-expandable Sapien 3 valve (17). Transfemoral
access was the predominant approach, although 7
studies focused exclusively on transapical procedures
(26, 31, 36, 37, 43, 44, 49). In most studies, SAVR was
done conventionally, with 4 studies using a sutureless
approach (29, 31, 42, 45). Detailed characteristics of
the studies are reported in the Table and in Supple-
ment Tables 3 to 6 (available at www.annals.org).
Main Outcomes: Early and Midterm All-Cause
Mortality
There was no statistically significant difference in
early all-cause mortality between TAVI and SAVR (35
studies, 16 386 patients; OR, 1.01 [95% CI, 0.81 to
1.26]) (Figure 1). The lack of statistically significant dif-
ferences was consistent across multiple sensitivity anal-
yses (Supplement Tables 7 and 8, available at www
.annals.org). The stratified analysis showed a statisti-
cally nonsignificant 20% risk reduction with TAVI com-
pared with SAVR (5 studies, 3822 patients; OR, 0.80 [CI,
0.51 to 1.25]) in randomized trials and no apparent dif-
ference in matched studies (30 studies, 6372 patients;
OR, 1.08 [CI, 0.84 to 1.38]) without significant subgroup
interaction (interaction P = 0.14) (Figure 1). In explor-
atory metaregression analyses, statistically significant
treatment modifiers were age, coronary artery disease,
previous percutaneous coronary intervention, and
valve type. Older age, greater prevalence of coronary
artery disease, previous percutaneous coronary inter-
vention, and use of the Sapien valve were associated
with an improved 30-day treatment effect of TAVI,
whereas use of the CoreValve was associated with
worse 30-day outcomes (Supplement Figure 2 and
Supplement Table 9, available at www.annals.org).
Funnel plots, the Begg test (P = 0.56), the Egger test
(P = 0.76), and the trim-and-fill method (1 study
trimmed; OR, 1.00 [CI, 0.81 to 1.25]) did not highlight
any significant publication bias.
Table. Characteristics of the Randomized Trials*
Characteristic NOTION (9, 10) PARTNER (3–5) PARTNER 2A (11) STACCATO (26) U.S. CoreValve (6–8)
End of enrollment 2013 2009 2013 2011 2012
Year of
publication
2015 2011 2016 2012 2014
Patients randomly
assigned, n
280 699 2031 72 795
Country Denmark (2 sites),
Sweden
(1 site)
United States (22 sites),
Canada (2 sites),
Germany (1 site)
United States (55
sites), Canada
(2 sites)
Denmark (2 sites) United States (45 sites)
Randomization TAVI vs. SAVR Transfemoral TAVI vs.
SAVR
Transapical TAVI vs.
SAVR
Transfemoral TAVI vs.
SAVR
Transapical/transaortic
TAVI vs. SAVR
Transapical TAVI
vs. SAVR
TAVI vs. SAVR
Valve type CoreValve (Medtronic) Sapien (Edwards) Sapien XT Sapien CoreValve
Design Superiority Noninferiority Noninferiority Superiority Noninferiority and superiority
Primary end point Death from any cause,
stroke, or myocardial
infarction at 1 y
Death from any cause
at 1 y
Death from any cause
or disabling stroke at
2 y
Death from any
cause or
cerebral stroke
and/or renal
failure requiring
hemodialysis at
30 d
Death from any cause at 1 y
Result Superiority not shown Noninferiority shown Noninferiority shown Inconclusive due
to premature
termination
Noninferiority and superiority
shown
NOTION = Nordic Aortic Valve Intervention; PARTNER = Placement of Aortic Transcatheter Valves; SAVR = surgical aortic valve replacement;
STACCATO = A Prospective, Randomised Trial of Transapical Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in
Operable Elderly Patients with Aortic Stenosis; TAVI = transcatheter aortic valve implantation.
* Values in parentheses in column headings are reference numbers.
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Figure 1. Forest plot for early all-cause mortality in the overall population.
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      Random-effects model
      Heterogeneity: l2 = 0%, tau-squared = 0, P = 0.4571
Matched studies
   Ailawadi et al (27)
   Appel et al (28)
   Biancari et al (29)
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   Guarracino et al (34)
   Hannan et al (35)
   Higgins et al (36)
   Holzhey et al (37)
   Johansson et al (38)
   Jones et al (39)
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   Minutello et al (41)
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   Stöhr et al (46)
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Midterm all-cause mortality did not differ between
TAVI and SAVR (23 studies, 11 222 patients; OR, 0.96
[CI, 0.81 to 1.14]) (Figure 2). The lack of statistically
significant differences was consistent in multiple sensi-
tivity analyses (Supplement Tables 7 and 8) and in the
subgroups of randomized trials (5 studies, 3822 pa-
tients; OR, 0.90 [CI, 0.64 to 1.26]) (Figure 2) and
matched studies (18 studies, 7400 patients; OR, 1.00
[CI, 0.81 to 1.24]; interaction P = 0.48) (Figure 2). In
exploratory metaregression analyses, statistically signif-
icant treatment modifiers were age, male sex, and cor-
onary artery disease; older age and a higher percent-
age of men or patients with coronary artery disease
were associated with an improved treatment effect of
TAVI at 1 year (Supplement Figure 3 and Supplement
Table 9, available at www.annals.org). No other factors
modified the treatment effect of TAVI, including the
type of prosthesis implanted (Sapien or CoreValve).
Funnel plots, the Begg test (P = 0.75), the Egger test
(P = 0.27), and the trim-and-fill method (2 studies
trimmed; OR, 0.95 [CI, 0.81 to 1.12]) did not suggest
significant publication bias.
Figure 2. Forest plot for midterm all-cause mortality in the overall population.
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Effect of TAVI Approach
When early all-cause mortality in randomized trials
was stratified by TAVI approach, lower mortality was
observed in patients who received transfemoral TAVI
than in those who underwent SAVR (4 studies, 3063
patients; OR, 0.68 [CI, 0.53 to 0.87]) (Supplement Fig-
ure 4, available at www.annals.org) but was not seen in
those who had transapical TAVI (3 studies, 759 pa-
tients; OR, 1.27 [CI, 0.15 to 10.9]) (Supplement Figure
4). This finding also was observed for midterm mortality
(transfemoral: 4 studies, 3063 patients; OR, 0.80 [CI,
0.68 to 0.93]; transapical: 3 studies, 759 patients; OR,
1.41 [CI 0.51 to 3.86]; test for interaction P = 0.02) (Sup-
plement Figure 5, available at www.annals.org).
Patients at Low to Intermediate Risk
Analyses of the subgroup of studies with patients at
low to intermediate risk showed a statistically nonsignif-
icant reduction in early (8 studies, 6875 patients; OR,
0.67 [CI, 0.42 to 1.07]) and midterm (8 studies, 6779
patients; OR, 0.91 [CI, 0.67 to 1.23]) mortality with TAVI
compared with SAVR (Figure 3).
Figure 3. Forest plots for all-cause mortality in the low- to intermediate-risk population.
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Secondary Outcomes
There was a statistically nonsignificant increased
risk in long-term all-cause mortality between TAVI and
SAVR overall (10 studies, 5505 patients; OR, 1.28 [CI,
0.97 to 1.69]) (Supplement Figure 6, available at www
.annals.org). In the analysis stratified by study design,
no statistically significant differences were noted in the
randomized studies, whereas SAVR was better than
TAVI in matched studies, with significant interaction be-
tween these subgroups (interaction P = 0.008) (Supple-
ment Figure 6). Long-term mortality stratified by the
TAVI approach in randomized trials showed that TAVI
was better than SAVR in the transfemoral subgroup,
with the opposite result in the transapical subgroup
and significant interaction between subgroups (interac-
tion P < 0.001) (Supplement Figure 7, available at www
.annals.org). Long-term mortality was similar for TAVI
and SAVR in patients at low to intermediate risk (3 stud-
ies, 2738 patients; OR, 1.06 [CI, 0.59 to 1.91])
(Figure 3).
Other secondary outcomes are displayed in Figure
4 and the Supplemental Material (available at www
.annals.org). No statistically significant differences were
apparent between TAVI and SAVR in early cardiovascu-
lar death (10 studies, 6656 patients; OR, 0.73 [CI, 0.45
to 1.19]) (Supplement Figure 8, available at www
.annals.org) or stroke (early: 30 studies, 14 236 pa-
tients; OR, 0.84 [CI, 0.64 to 1.09]; midterm: 9 studies,
7433 patients; OR, 0.92 [CI, 0.62 to 1.35]) (Supplement
Figures 9 and 10, available at www.annals.org). Myo-
cardial infarction was reduced by 49% in patients un-
dergoing TAVI (19 studies, 11 835 patients; OR, 0.51
[CI, 0.38 to 0.69]) (Supplement Figure 11, available at
www.annals.org), with consistency in randomized and
matched studies (interaction P = 0.33). Permanent
pacemaker implantation (Supplement Figure 12, avail-
able at www.annals.org), vascular complications (Sup-
plement Figure 13, available at www.annals.org), and
moderate to severe paravalvular leak (Supplement Fig-
ure 14, available at www.annals.org) were more fre-
quent after TAVI, whereas major bleeding (Supplement
Figure 15, available at www.annals.org), acute kidney
injury (Supplement Figure 16, available at www.annals
.org), and new-onset atrial fibrillation (Supplement Fig-
ure 17, available at www.annals.org) were more fre-
quent after SAVR (Figure 4).
Figure 4. Forest plot for all outcomes of the meta-analysis.
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DISCUSSION
This meta-analysis highlights several key points.
Compared with SAVR, TAVI may have similar or re-
ducedearlyandmidtermall-causemortalityoutcomes
in patients with high and low to intermediate risk.
Transfemoral TAVI provides mortality benefits over
SAVR.ComparedwithSAVR,TAVI reducesearlymyo-
cardial infarction,but itsbenefitsonearlycardiovascu-
lardeathand stroke remainunclear.Acute kidney in-
jury,major bleeding, and new-onset atrial fibrillation
occurlessoftenafterTAVIthanafterSAVR.Pacemaker
implantation, vascular complications, and paravalvular
leak occurmore often after 7$9, than after 6$95. Ef-
fects of TAVI on long-term mortality are unclear but
maydependon thepatient'sunderlying risk leveland
theTAVIapproachused.
These findings, which apply to adults with severe
aortic stenosis, consolidate the role of TAVI as an alter-
native to SAVR. Since the first percutaneous aortic valve
implantation in a human in 2002, TAVI has attracted
growing interest. Patients undergoing TAVI typically
are older adults who have clinically relevant comorbid
conditions that preclude SAVR (1, 2). It originally
emerged as a treatment option for patients who were
judged inoperable due to prohibitive surgical risk and
referred to medical therapy. During the past decade,
clinical practice guideline committees have reviewed
accumulating evidence and have recognized TAVI as a
reasonable alternative to SAVR for patients at high sur-
gical risk (1, 2). As experience with TAVI increased and
the outcomes improved, 2 important clinical questions
arose: First, is TAVI similar to or better than SAVR in
patients at high risk? Second, is the adoption of TAVI
justified for patients at lower surgical risk?
We tried to address these questions by summariz-
ing the available comparisons of TAVI and SAVR in the
literature. We elected all-cause mortality as the most
relevant outcome for many reasons, including its clini-
cal implications, frequent reporting, and indisputable
definition. In our analysis of the 5 available randomized
trials, early and midterm all-cause mortality was nonsig-
nificantly reduced with TAVI, but the treatment effect of
TAVI was greater (although it did not reach formal sta-
tistical significance) when we excluded the STACCATO
trial, a study with well-known limitations that did not
replicate contemporary practice or outcomes of TAVI
(26), and became statistically significant when we re-
stricted the analysis to studies in which TAVI was done
transfemorally, in line with the most recent evidence
(11, 52). Among the observational matched studies,
there also was no difference between TAVI and SAVR,
resulting in no significant interaction across subgroups
defined by study design, although randomized studies
remain the best evidence to guide inference and inter-
pretation. Other studies (with increased available total
information size) are needed to provide definitive re-
sults regarding long-term mortality, which was found to
be nonsignificantly increased in TAVI patients (a sec-
ondary end point in our study because of the limited
number of studies), although this result was driven
mainly by matched studies. Long-term follow-up infor-
mation currently is being provided by 4 randomized
trials (PARTNER, U.S. CoreValve, PARTNER 2A, and NO-
TION, with 5, 3, 2, and 2 years of follow-up, respec-
tively) and so far has shown no significant difference
between TAVI and SAVR (Supplement Figure 6). How-
ever, the matched studies showed lower long-term
mortality for SAVR, and a significant interaction by
study design was observed. In the aggregate, long-
term results were available from 10 studies with a mean
follow-up of 33 months; thus, more evidence is war-
ranted in this regard, particularly concerning the sus-
tained durability of TAVI prostheses. However, increas-
ing expertise, new-generation TAVI devices, and the
transfemoral approach might lead to better long-term
comparative results from TAVI in the near future, as
suggested by the most recent studies (11, 17). Indeed,
TAVI techniques continue to improve, newer valves ad-
dress the issue of paravalvular leak, the percentage of
persons with pacemakers is decreasing, and the rate of
vascular complications is expected to decline as the re-
sult of smaller sheaths and improved procedural tech-
niques. Future mortality studies will assess the net ef-
fects of emerging technical improvements and
potential long-term clinical gains versus a possible in-
crease in the late adverse consequences of paravalvu-
lar leak and pacemaker implantation.
Interestingly, exploratory metaregressions suggest
that TAVI may be more beneficial than SAVR in elderly
patients and those with coronary artery disease, prob-
ably because these groups might represent markers of
heightened risk favoring less invasive approaches. No-
tably, TAVI showed greater benefit regarding early
mortality when the Sapien valve rather than the
CoreValve was implanted, but this finding is guided
mainly by the large study by Thourani and colleagues
(17) (showing superiority of TAVI with the new Sapien 3
valve) and did not emerge at midterm follow-up. Future
studies directly comparing these valves, as well as
new devices, would overcome the limitations of this
analysis.
Although the potential benefits of TAVI versus
SAVR in terms of early cardiovascular mortality and
stroke remain unclear, TAVI was associated with signif-
icantly less risk for myocardial infarction than SAVR;
however, a sound mechanistic explanation cannot be
drawn from our data. That the observed reduction in
myocardial infarction might be responsible for the non-
significant lower cardiac death rate is intriguing and
warrants further investigation. TAVI was also associated
with significant reductions in major bleeding, acute kid-
ney injury, and new-onset atrial fibrillation compared
with SAVR, but the need for pacemaker implantation,
vascular complications (related mainly to the access
site), and paravalvular leak were significantly less with
SAVR (Figure 4).
To our knowledge, this is the largest meta-analysis
of TAVI versus SAVR that includes randomized trials
and explores the effect of the TAVI approach (trans-
femoral or transapical) (53–57). Unlike the authors of a
recent study, we investigated the risk for death in the
REVIEW Systematic Review and Meta-analysis of TAVI Versus SAVR
8 Annals of Internal Medicine www.annals.org
Downloaded From: http://annals.org/ on 06/10/2016
subgroup of patients at low to intermediate risk, ex-
tending our observation to mid- and long-term mortal-
ity and not considering the U.S. CoreValve or STAC-
CATO trials in this subgroup because, regardless of the
mean STS score, they enrolled high-risk patients in ac-
cordance with their inclusion criteria (58). To improve
the power and reliability of our results while minimizing
the risk of bias, we also included observational studies
but applied a restriction to those with matched popu-
lations. Indeed, we excluded many available observa-
tional studies that compared the 2 procedures in unbal-
anced populations, namely TAVI in inoperable or
high-risk patients (according to evidence and guide-
lines) and SAVR in lower-risk cohorts.
Ongoing trials comparing TAVI and SAVR will pro-
vide additional data (Supplement Tables 10 and 11,
available at www.annals.org). The results of the
SURTAVI (Surgical Replacement and Transcatheter Aor-
tic Valve Implantation) trial (NCT01586910) will shed
light on patients at intermediate risk, whereas 2 re-
cently announced trials will explore the safety and ef-
fectiveness of TAVI in low-risk patients: PARTNER 3
(NCT02675114), using the Sapien 3 device, and a
Medtronic study (NCT02701283) using the CoreValve/
Evolut R system.
Several limitations of this review and of the under-
lying evidence merit careful consideration. There were
few trials and, in some instances, few events. Confi-
dence bounds around some of the summary estimates
of effect were too wide to rule out potentially important
benefits or harms from TAVI versus SAVR. Definitions of
clinical outcomes, other than mortality, varied across
studies (Supplement Table 5). Because baseline char-
acteristics were not reported uniformly, results of
metaregression analyses were mainly exploratory (Sup-
plement Tables 3, 4, and 9). Long-term data were lim-
ited, which is a particularly critical limitation because
valve durability is a major unknown of TAVI and an im-
portant issue when the procedure is being considered
for younger or lower-risk patients. Mean age of patients
in the included studies ranged from 70 to 84 years, and
findings cannot be extended to younger or older pa-
tients. It was not possible to analyze mortality after ex-
cluding patients with paravalvular leak. A post hoc anal-
ysis from the PARTNER trial demonstrated that the
mortality of patients with postprocedural paravalvular
leak was greater than that of patients without this com-
plication (4). If patients with paravalvular leak are re-
moved from the mortality analyses (a plausible scenario
in the future, considering the very low rate of paraval-
vular regurgitation with new-generation TAVI devices)
(59, 60), the results might turn in favor of TAVI, but this
has to be demonstrated. The definition of “low” or “in-
termediate” risk is based on the definition used in the
original studies, which is not standardized. Some stud-
ies were based on STS score and others on Euro-
SCORE; however, surgical risk scores alone do not ac-
count for the clinical characteristics and comorbid
conditions that may have increased the level of patient
risk perceived by the local heart teams.
Compared with SAVR, TAVI may lead to similar or
lower early and midterm mortality rates in adults with
aortic stenosis, including those at low to intermediate
risk. There was a significant interaction between TAVI
approach and mortality, with transfemoral TAVI being
more beneficial than SAVR. At long-term follow-up, the
effects on mortality remain unclear but may depend on
the underlying risk level of the patient or procedural
approach.
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Abstract
Aims: Little is known about the prognostic role of pre-existing atrial fibrillation (AF) and new-onset AF 
(NOAF) in transcatheter aortic valve implantation (TAVI). Therefore, the aim of this meta-analysis was 
to compare the short- and long-term clinical outcomes of patients undergoing TAVI with and without pre-
existing and new-onset AF.
Methods and results: Twenty-six studies, enrolling 14,078 patients undergoing TAVI, of whom 33.4% 
had pre-existing AF and 17.5% had NOAF, were analysed for early and long-term all-cause mortality, car-
diovascular mortality and cerebrovascular events (CVE). In patients with pre-existing AF, 30-day all-cause 
mortality was similar to patients in sinus rhythm (SR). Conversely, long-term all-cause and cardiovascu-
lar mortality were significantly greater in pre-existing AF patients than in patients with SR (20 studies; 
8,743 patients; HR: 1.68; p<0.00001, and three studies; 1,138 patients; HR: 2.07; p=0.01, respectively). 
Pre-existing AF was not a predictor of CVE at long-term follow-up. NOAF patients showed similar short- 
and long-term all-cause mortality when compared to patients in SR, whereas they experienced a signifi-
cantly higher incidence of CVE at short-term follow-up (six studies; 2,025 patients; HR: 2.86; p<0.00001). 
A non-significant increase in the incidence of CVE was observed at long-term follow-up.
Conclusions: Pre-existing AF is a predictor of all-cause mortality in patients undergoing TAVI. NOAF is 
related to the occurrence of CVE at short-term follow-up. Similarly to surgical aortic valve replacement 
(SAVR), the optimal management and risk stratification of these patients should be further investigated.
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Abbreviations
AF atrial fibrillation
AS aortic stenosis
CI confidence interval
CVE cerebrovascular events
HR hazard ratio
NOAF new-onset atrial fibrillation
SAVR surgical aortic valve replacement
SR sinus rhythm
TAVI transcatheter aortic valve implantation
Introduction
Atrial fibrillation (AF) is the most common arrhythmia in the gen-
eral population, with a higher prevalence in the elderly as well as 
in patients with severe aortic stenosis (AS)1. AF and AS coexist in 
almost 30% of patients, with a prevalence that varies from 16% 
to 40%2. New-onset AF (NOAF) post transcatheter aortic valve 
implantation (TAVI), however, occurs in approximately 13% of 
patients, ranging from 0.7% to 31.9%3.
Pre-existing AF and NOAF significantly affect cardiovascular 
physiology, due to loss of atrioventricular synchrony and irregular-
ity of ventricular contraction resulting in reduced cardiac output and 
increased filling pressures, which may be further accentuated by the 
presence of severe AS and myocardial hypertrophy4. Additionally, 
the left ventricular outflow obstruction provoked by AS results in 
left ventricular hypertrophy and diastolic dysfunction, which may 
itself precipitate AF due to increased left atrial pressures4.
AF has an important impact on cardiovascular morbidity and 
mortality5. Population-based studies have indicated an increased risk 
of stroke and systemic embolism as well as impaired long-term sur-
vival of individuals with AF compared to those with normal sinus 
rhythm (SR)6. In the general population, AF is estimated to increase 
the risk of death 1.5-fold among men and 1.9-fold among women5. 
Moreover, it has been shown previously that, after surgical aortic 
valve replacement (SAVR), AF represents an independent predictor 
of late adverse cardiac and cerebrovascular events (CVE), including 
congestive heart failure, stroke, and mortality7,8. Similarly, NOAF 
is associated with overall and late mortality after coronary artery 
bypass graft surgery and perioperative complications, and 30-day 
mortality and CVE in post-myocardial infarction patients9.
In the last decade, TAVI has become the treatment of choice for 
inoperable or high-risk patients with severe, symptomatic AS, but 
the indication might be expanded in the near future. In the subset 
of patients with indications for TAVI, sparse and partly contrasting 
evidence exists regarding the impact of AF on morbidity and mor-
tality. Some studies have indicated the absence of any significant 
impact of AF on prognosis10-18, whilst others have shown increased 
mortality among patients with AF undergoing TAVI19-30. Moreover, 
a recent meta-analysis did not mention AF among predictors of 
all-cause mortality in patients undergoing TAVI31.
Therefore, the aim of this meta-analysis was to compare the 
short- and long-term clinical outcomes of patients undergoing 
TAVI with and without pre-existing and new-onset AF.
Methods
The study was designed according to PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) 
requirements32,33. MEDLINE, Cochrane, ISI Web of Science and 
SCOPUS databases were searched for articles published from 
April 200234 (first-in-human TAVI date) until January 2015. 
Studies were identified using the major medical subject heading 
“transcatheter aortic valve implantation OR transcatheter aortic 
valve replacement OR TAVI OR TAVR” combined with “clini-
cal outcome or mortality” and “atrial fibrillation”. Citations were 
screened at the title and abstract level by two independent review-
ers and retrieved as a full report if they reported data on outcomes 
after TAVI, based on the presence/absence of AF and/or if AF was 
considered as a predictor of mortality in their regression models. 
No language limitations were applied. The full texts and bibliog-
raphies of all potential articles were also retrieved in detail to seek 
additional relevant studies.
Studies were included if: 1) TAVI was performed in high surgi-
cal risk or inoperable patients (as defined by a logistic EuroSCORE 
>20 or by the presence of contraindications to surgery such as por-
celain aorta, severe respiratory failure, unfavourable anatomy for 
sternotomy) with symptomatic, severe AS (defined as an aortic 
valve area <1 cm2, or an indexed aortic valve area <0.6 cm2/m2); 
2) they reported data of mortality outcomes according to the pres-
ence of pre-existing AF or NOAF.
Studies were excluded if any of the following criteria applied: 
1) duplicate publication; 2) lack of data on pre-existing AF before 
TAVI or NOAF after the procedure; 3) the outcome of interest was 
not clearly reported or was impossible to extract or calculate from 
the published results.
Two reviewers independently screened articles for fulfilment of 
inclusion criteria. Reviewers compared selected trials and discrepan-
cies were resolved by consensus. Baseline characteristics, AF at base-
line and outcomes, including mortality outcomes, were abstracted.
The primary endpoint evaluated was the incidence of early and 
long-term all-cause mortality in patients with baseline or new-
onset AF undergoing TAVI. Secondary endpoints of interest were 
the cardiovascular mortality and the incidence of CVE in the same 
population. Long-term follow-up included a time frame ranging 
from six months to five years from the procedure. Short-term fol-
low-up corresponded to 30-day follow-up.
Of 1,424 articles identified by the initial search, 45 were 
retrieved for more detailed evaluation and 26 trials were included 
in the study (Appendix Figure 1).
The number of events, participants, hazard ratios (HR) and con-
fidence intervals (CI) were abstracted. Pooled measures were cal-
culated assuming a random effects model using inverse variance 
weighting, and used the adjusted HR. The results were also con-
firmed with a fixed effects model; however, the random effects 
model was prioritised in case of significant heterogeneity. Statistical 
VLJQLILFDQFH ZDV VHW DW S WZRWDLOHG +HWHURJHQHLW\ ZDV
assessed by a Q-statistic and I2 test. Significant heterogeneity was 
considered present for p-values <0.10 or an I2 >50%.
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Meta-regressions were performed to test the influence of base-
line characteristics included in Table 1 as potential effect modifi-
HUVVLJQLILFDQFHDWS
Publication bias was assessed using funnel plots and Egger’s test, 
consisting of a linear regression of the intervention effect estimates 
on their standard errors, weighting by 1/(variance of the intervention 
effect estimate)35. If there was some evidence of publication bias, the 
trim and fill method, which estimates the number and results of poten-
tial missing studies resulting from publication bias, was applied36.
All data analyses were performed using Prometa Software, Ver-
sion 2 (Internovi, Cesena, Italy), and Review Manager (RevMan), Ver-
sion 5.2 (The Cochrane Collaboration, London, United Kingdom)37-41.
Results
Of the 1,424 articles identified in the initial search, 45 were 
retrieved for more detailed evaluation. Nineteen studies were subse-
quently excluded. Therefore, 26 studies, enrolling 14,078 patients, 
were finally included in the analyses (Table 1, Appendix Table 1, 
Appendix Figure 1)10-30,42-46.
Pre-existing AF is common among patients with symptomatic 
severe aortic stenosis undergoing TAVI, with an average prevalence 
of 33.4±9.6% in our meta-population (23 studies; 13,241 patients; 
3,824 pre-existing AF). NOAF incidence after TAVI was, on the 
other hand, 17.5±8.7% (nine studies; 4,749 patients; 831 NOAF).
In patients with pre-existing AF, the overall mortality risk post 
TAVI was not significantly increased at 30-day follow-up (eight 
studies, 3,329 patients, HR: 1.12, 95% confidence interval [CI]: 0.95 
to 1.33; p=0.19, I2=25%) (Figure 1A, Appendix Table 2, Appendix 
Table 3). Conversely, it was significantly increased at long-term fol-
low-up (20 studies, 8,743 patients, HR: 1.68, 95% CI: 1.45 to 1.96; 
p<0.00001, I2=54%) (Figure 1B, Appendix Table 2, Appendix Table 3).
Cardiovascular mortality at long-term follow-up was signifi-
cantly increased in patients with pre-existing AF when compared 
to patients with baseline SR (three studies, 1,138 patients, HR: 
2.07, 95% CI: 1.17 to 3.65; p=0.01, I2=53%) (Figure 2A, Appendix 
Table 2, Appendix Table 3).
Additionally, the presence of pre-existing AF in patients under-
going TAVI did not predict CVE at long-term follow-up (five 
studies, 4,604 patients, HR: 1.68, 95% CI: 0.86 to 3.30; p=0.13, 
I2=75%) (Figure 2B, Appendix Table 2-Appendix Table 4). All 
these results were confirmed with fixed effect models (Appendix 
Figure 2 and Appendix Figure 3).
Table 1. Studies included in the meta-analysis.
Publication year Number of patients FU (months) Type of study
Alassar et al29 2013 119  16 Observational prospective, single-centre
Allende et al24 2014 619  12 Observational prospective, multicentre (9 centres)
Amat-Santos et al44 2012 138  12 Observational prospective, single-centre
Auffret et al14 2014 163  6 Observational prospective, single-centre
Barbash et al30 2015 371  1 12 Observational prospective, single-centre
Elhmidi et al27 2013 373  12 Observational prospective, single-centre
Gotzmann et al26 2013 202  18 Observational prospective, single-centre
Lange et al12 2012 420  1 6 Observational prospective, single-centre
LeVen et al21 2013 639  12 Observational retrospective, multicentre (2 centres)
Maan et al 46 2014 137  12 Observational prospective, single-centre
Nombela-Franco et al22 2012 1,061  12 Observational prospective, multicentre (5 centres)
Nuis et al28 2012 995  1 12 Observational prospective, multicentre (7 centres)
Nuis et al42 2012 214  13 Observational prospective, single-centre
Ribeiro et al13 2014 333  20 Observational prospective, single-centre
Rodés-Cabau et al20 2010 339  1 42 Observational prospective, multicentre (6 centres)
Sabaté et al25 2014 1,416  12 Observational prospective, single-centre
Salinas et al11 2012 34  1 10.4 Observational prospective, single-centre
Seiffert et al43 2013 326  12 Observational prospective, single-centre
Stortecky et al19 2014 389  12 Observational prospective, single-centre
Tamburino et al16 2011 663  12 Observational prospective, multicentre (14 centres)
Tay et al 10 2011 253  12 Observational prospective, single-centre
Tchetche et al17 2014 3,191  6 Observational prospective, multicentre (34 centres)
Toggweiler et al15 2013 88  60 Observational prospective, single-centre
Unbehaun et al23 2014 730  12 Observational prospective, single-centre
Urena et al45 2015 485  1 Observational prospective, multicentre (6 centres)
Yankelson et al18 2014 380  1 12 Observational retrospective, single-centre
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Patients with and without NOAF did not show significant dif-
ferences of 30-day (four studies, 971 patients, HR: 1.41, 95% 
CI: 0.85 to 2.34; p=0.18, I2=0%) (Figure 3A, Appendix Table 2, 
Appendix Table 3) or long-term all-cause mortality (four stud-
ies, 971 patients, HR: 1.43, 95% CI: 0.96 to 2.14; p=0.08, I2=0%) 
(Figure 3B, Appendix Table 2, Appendix Table 3).
On the other hand, NOAF proved to be a significant predic-
tor of CVE at short-term follow-up (six studies, 2,025 patients, 
HR: 2.86, 95% CI: 1.88 to 4.34; p<0.00001, I2=0%) (Figure 4A, 
Appendix Table 2-Appendix Table 4), while there was a non-signif-
icant increase in the incidence of CVE at long-term follow-up (five 
studies, 3,997 patients, HR: 1.44, 95% CI: 0.50 to 4.10; p=0.50, 
I2=79%) (Figure 4B, Appendix Table 2-Appendix Table 4).
Meta-regression analysis showed no relationship between all 
the analysed effect modifiers and the outcomes of interest (all 
p-values >0.05) (Appendix Table 5, Appendix Table 6).
The funnel plots (Appendix Figure 4-Appendix Figure 7), 
Egger’s test (Appendix Table 2) and the trim and fill method did 
not show any publication bias, in all the analyses performed.
Discussion
The present meta-analysis demonstrated that AF is common 
among high-risk elderly patients undergoing TAVI, with a preva-
lence of 33.4% in this patient population, and that AF is associated 
with a significantly increased risk of all-cause mortality at long-
term follow-up. However, the presence of AF at baseline does not 
Favours pre-existing AF Favours SR
0.01 0.1 1 10 100
Favours pre-existing AF Favours SR
0.01 0.1 1 10 100
Pre-AF SR Hazard ratio
Study or subgroup log [hazard ratio] SE total total Weight IV, random, 95% Cl
Hazard ratio
IV, random, 95% Cl
Pre-AF SR Hazard ratio
Study or subgroup log [hazard ratio] SE total total Weight IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
A
B
PRE-EXISTING AF: EARLY ALL-CAUSE MORTALITY
Barbash et al 2014 0.104 0.195 143 182 0.3% 1.11 [0.76, 1.63]
Lange et al 2012 –0.462 0.45 97 323 0.0% 0.63 [0.26, 1.52]
Maan et al 2014 0.788 0.727 67 70 0.0% 2.20 [0.53, 9.14]
Nuis et al 2012 0.378 0.161 265 730 0.4% 1.46 [1.06, 2.00]
Rodés-Cabau et al 201O 0.104 0.369 115 224 0.1% 1.11 [0.54, 2.29]
Salinas et al 2012 0 0.916 17 17 0.0% 1.00 [0.17, 6.02]
Unbehaun et al 2014 0.02 0.01 217 513 99.2% 1.02 [1.00, 1.04]
YankeIson et al 2014 0.829 0.588 118 231 0.0% 2.29 [0.72, 7.25]
Total [95% Cl] 1,039 2,290 100.0% 1.02 [1.00, 1.04]
Heterogeneity: Tau2=0.01; Chi2=9.31, df=7 (p=0.23); I2=25%
Test for overall effect: Z=1.32 (p=0.19)
PRE-EXISTING AF: LONG-TERM ALL-CAUSE MORTALITY
Alassar et al 2013 –0.598 0.777 19 100 0.3% 0.55 [0.12, 2.52]
Allende et al 2014 0.489 0.086 217 513 27.9% 1.63 [1.38, 1.93]
Auffret et al 2014 0.871 0.627 71 92 0.5% 2.39 [0.70, 8.17]
Barbash et al 2014 0.993 0.34 143 182 1.8% 2.70 [1.39, 5.26]
Elhmidi et al 2014 1.144 0.517 83 290 0.8% 3.14 [1.14, 8.65]
Gotzmann et al 2013 0.732 0.324 69 133 2.0% 2.08 [1.10, 3.92]
Lange et al 2012 0.457 0.274 97 323 2.8% 1.58 [0.92, 2.70]
LeVen et al 2013 0.412 0.147 236 40 39.6% 1.51 [1.13, 2.01]
Maan et al 2014 0.626 0.458 67 70 1.0% 1.87 [0.76, 4.59]
Nuis et al 2012 0.336 0.151 265 730 9.1% 1.40 [1.04, 1.88]
Ribeiro et al 2014 0.451 0.214 101 232 4.5% 1.57 [1.03, 2.39]
Rodés-Cabau et al 2010 0.554 0.268 115 224 2.9% 1.74 [1.03, 2.94]
Sabaté et al 2014 0.577 0.147 402 1,014 9.6% 1.78 [1.33, 2.38]
Salinas et al 2012 –0.301 0.78 17 17 0.3% 0.74 [0.16, 3.41]
Seiffert et al 2013 0.131 0.232 106 220 3.8% 1.14 [0.72, 1.80]
Stortecky et al 2012 0.896 0.247 104 258 3.4% 2.45 [1.51, 3.98]
Tamburino et al 2011 0.166 0.268 109 554 2.9% 1.18 [0.70, 2.00]
Toggweiler et al 2013 –0.083 0.25 45 43 3.3% 0.92 [0.56, 1.50]
Unbehaun et al 2014 0.507 0.135 217 513 11.3% 1.66 [1.27, 2.16]
Yankelson et al 2014 1.81 0.299 118 231 2.3% 6.11 [3.40, 10.98]
Total [95% Cl] 2,601 6,142 100.0% 1.64 [1.50, 1.79]
Heterogeneity: Tau2= 0.05; Chi2=40.87, df=19 (p=0.003); I2=54%
Test for overall effect: Z=6.70 (p<0.00001)
Figure 1. Impact of pre-existing AF on early and long-term all-cause mortality. Random effects hazard ratio and 95% confidence interval for 
early (A) and long-term (B) all-cause mortality.
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seem to represent a risk factor for 30-day all-cause mortality or for 
CVE in the long term following TAVI. On the other hand, NOAF 
occurred in 17.5% of patients after TAVI and was not associated 
with increased mortality, but with an increased risk of CVE.
AF is the most common cardiac arrhythmia, and is associ-
ated with structural heart disease, in particular hypertensive heart 
disease, coronary artery disease and valvular heart disease. Due 
to the high prevalence of AF in the elderly population and to the 
similarity of risk factors for both AF and severe degenerative AS, 
both conditions coexist in almost 50% of patients. Similar to the 
general population, in whom AF is estimated to carry a 1.5-fold 
increased risk of death among men and 1.9-fold among women5, 
0.01 0.1 1 10 100
0.10.01 1 10 100
PRE-EXISTING AF: LONG-TERM CARDIOVASCULAR MORTALITY
Pre-AF SR Hazard ratio
Study or subgroup log [hazard ratio] SE total total Weight IV, random, 95% Cl
Hazard ratio
IV, random, 95% Cl
Hazard ratio
IV, random, 95% Cl
LeVen et al 2013 0.405 0.19 236 403 52.8% 1.50 [1.03, 2.18]
Maan et al 2014 2.086 1.084 67 70 6.5% 8.05 [0.96, 67.40]
Stortecky et al 2012 0.928 0.289 104 258 40.7% 2.53 [1.44, 4.46]
Total (95% CI) 407 731 100.0% 2.07 [1.17, 3.65]
Heterogeneity: Tau2=0.12; Chi2=4.22, df=2 (p=0.12); I2=53%
Favours pre-existing AF   Favours SR
Favours pre-existing AF   Favours SR
Test for overall effect: Z=2.51 (p=0.01)
PRE-EXISTING AF: LONG-TERM CEREBROVASCULAR EVENTS
Pre-AF SR Hazard ratio
Study or subgroup log [hazard ratio] SE total total Weight IV, random, 95% CI
Nombela-Franco et al 2012 1.044 0.34 276 658 22.1% 2.84 [1.46, 5.53]
Stortecky et al 2012 –0.163 0.53 104 258 16.9% 0.85 [0.30, 2.40]
Tay et al 2011 0.412 0.438 98 155 19.3% 1.51 [0.64, 3.56]
Tchetche et al 2014 –0.139 0.214 849 1,857 25.4% 0.87 [0.57, 1.32]
Yankelson et al 2014 1.664 0.552 118 231 16.3% 5.28 [1.79, 15.58]
Total (95% CI) 1,445 3,159 100.0% 1.68 [0.86, 3.30]
Heterogeneity: Tau2=0.42; Chi2=15.93, df=4 (p=0.003); l2=75%
Test for overall effect: Z=1.51 (p=0.13)
A
B
Figure 2. Impact of pre-existing AF on long-term cardiovascular mortality and cerebrovascular events. Random effects hazard ratio and 95% 
confidence interval for long-term cardiovascular mortality (A) and long-term cerebrovascular events (B).
NOAF SR Hazard ratio
Study or subgroup log [hazard ratio] SE total total Weight IV, random, 95% Cl
Heterogeneity: Tau2=0.00; Chi2=0.32, df=3 (p=0.96); I2=0%
Test for overall effect: Z=1.33 (p=0.18)
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Study or subgroup log [hazard ratio] SE total total Weight IV, random, 95% CI
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Hazard ratio
IV, random, 95% CI
Heterogeneity: Tau2=0.00; Chi2=2.44, df=3 (p=0.49); I2=0%
Test for overall effect: Z=1.76 (p<0.08)
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NEW-ONSET AF: EARLY ALL-CAUSE MORTALITY
Amat-Santos et al 2012 0.385 0.685 44 94 14.2% 1.47 [0.38, 5.63]
Barbash et al 2O14 0.378 0.299 46 182 74.5% 1.46 [0.81, 2.62]
Stortecky et al 2012 –0.236 1.057 27 285 6.0% 0.79 [0.10, 6.27]
Yankelson et al 2O14 0.412 1.113 31 262 5.4% 1.51 [0.17, 13.38]
Total (95% CI) 148 823 100.0% 1.41 [0.85, 2.34]
NEW-ONSET AF: LONG-TERM ALL-CAUSE MORTALITY
Amat-Santos et al 2012 –0.236 0.441 44 94 21.4% 0.79 [0.33, 1.87]
Barbash et al 2O14 0.457 0.299 46 182 46.6% 1.58 [0.88, 2.84]
Stortecky et al 2012 0.647 0.457 27 285 20.0% 1.91 [0.78, 4.68]
Yankelson et al 2O14 0.56 0.59 31 262 12.0% 1.75 [0.55, 5.56]
Total (95% Cl) 148 823 100.0% 1.43 [0.96, 2.14]
Figure 3. Impact of NOAF on early and long-term all-cause mortality. Figure showing random effects hazard ratio and 95% confidence interval 
for early (A) and long-term (B) all-cause mortality. Note: fixed effects estimates for early (four studies, 971 patients, HR: 1.41, 95% CI: 0.85 to 
2.34; p=0.18, I2=0%) and long-term all-cause mortality (four studies, 971 patients, HR: 1.43, 95% CI: 0.96 to 2.14; p=0.08, I2=0%).
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our meta-regression analysis confirms these data also for patients 
undergoing TAVI, with a higher HR for all-cause mortality.
The observed differences in outcome among patients in SR and 
patients with baseline AF are not surprising and may be attribut-
able to a worsening in heart failure from decreased ventricular 
filling secondary to loss of atrial systolic contraction, tachycar-
dia-induced cardiomyopathy and/or complications associated 
with systemic embolisation, all conditions also contributing to 
all-cause mortality37,47. Indeed, heart failure might be precipitated 
in hypertrophied left ventricles with a lower ejection fraction 
because of the sudden loss of the Frank-Starling mechanism in 
cardiac reserve compensating in part for the reduced left ventri-
cle contractility. This is particularly relevant in pressure-overload 
left ventricular hypertrophy, when geometry is often concentric 
and myocardial mechanics are substantially depressed due to 
structural modifications. As far as NOAF is concerned, although 
inflammatory components have been shown to be responsible 
for its occurrence after cardiac surgery48, the mechanisms lead-
ing to the arrhythmia after TAVI have still to be clarified. No 
hypothetical differences between different types of valve or pro-
cedure have emerged up to now. Indeed, the results of our meta-
regression analysis did not evidence any significant difference 
between the CoreValve® (Medtronic, Minneapolis, MN, USA) 
and the Edwards SAPIEN (Edwards Lifesciences, Irvine, CA, 
USA) valve, or between transfemoral and transapical implanta-
tion in terms of the incidence of NOAF.
The results of this meta-analysis demonstrate that pre-existing 
AF is a predictor of all-cause mortality in the long term following 
TAVI. This provides clarification to the current literature, since, 
even in recent publications, AF was not identified as a predictor of 
all-cause mortality31.
It is important to underline that patients undergoing TAVI exhibit 
an incidence of stroke which is not negligible49: this is principally 
due to manipulation of large catheters in atherosclerotic and calci-
fied aortas and to embolisation after valvuloplasty or valve implan-
tation. On the other hand, AF itself represents a risk factor for 
stroke. Interestingly, the result of this meta-analysis, although com-
ing from a pooled analysis of only five studies with a limited num-
ber of patients (4,604), clarifies that patients with pre-existing AF 
did not experience a higher incidence of new CVE when compared 
to patients in SR. These data, probably corroborating what has been 
previously shown, might support the concept that the main causes 
of stroke following TAVI are technical. However, in the subset ana-
lysed in this meta-analysis, we were not able to reach a statisti-
cal significance on this outcome. This might be due to a variety of 
issues. First, the total number of CVE is generally low and the num-
ber of studies/patients for this analysis is relatively low to draw con-
sistent and final conclusions. Second, it has to be taken into account 
that, both in patients with pre-existing AF and in those with NOAF, 
drug therapy was administered. Unfortunately, we were not able to 
consider the effects of drugs on CVE because often these data were 
not reported in the primary studies. Conversely, the occurrence of 
NOAF SR Hazard ratio
Study or subgroup log [hazard ratio] SE total total Weight IV, random, 95% Cl
Favours NOAF Favours SR
Favours NOAF Favours SR
NOAF SR Hazard ratio
Study or subgroup log [hazard ratio] SE total total Weight IV, random, 95% CI
Hazard ratio
IV, random, 95% Cl
Hazard ratio
IV, random, 95% CI
0.01 0.1 1 10 100
0.01 0.1 1 10 100
A
B
Amat-Santos et al 2012 1.358 0.754 44 94 8.0% 3.89 [0.89, 17.04]
Barbash et al 2O14 –0.139 0.803 46 182 7.1% 0.87 [0.18, 4.20]
Nombela-Franco et al 2012 0.82 0.347 127 785 37.9% 2.27 [1.15, 4.48]
Nuis et al 2012 1.482 0.654 22 166 10.7% 4.40 [1.22, 15.86]
Urena et al 2015 1.278 0.366 28 238 34.1% 3.59 [1.75, 7.35]
Yankelson et al 2O14 2.037 1.426 31 262 2.2% 7.67 [0.47, 125.45]
Total (95% CI) 298 1,727 100.0% 2.86 [1.88, 4.34]
Heterogeneity: Tau2=0.00; Chi2=4.10, df=5 (p=0.53); I2=0%
Test for overall effect: Z=4.91 (p<0.00001)
Amat-Santos et al 2012 1.452 0.707 44 94 21.0% 4.27 [1.07, 17.08]
Nombela-Franco et al 2012 0.928 0.285 127 785 30.3% 2.53 [1.45, 4.42]
Stortecky et al 2012 –3.507 2.323 27 285 4.6% 0.03 [0.00, 2.85]
Tchetche et al 2014 –0.478 0.257 485 1,857 30.8% 0.62 [0.37, 1.03]
Yankelson et al 2O14 0.637 1.141 31 262 13.2% 1.89 [0.20, 17.70]
Total (95% Cl) 714 3,283 100.0% 1.44 [0.50, 4.10]
Heterogeneity: Tau2=0.86; Chi2=19.29, df=4 (p=0.0007); I2=79%
Test for overall effect: Z=0.68 (p=0.50)
NEW-ONSET AF: EARLY CEREBROVASCULAR EVENTS
NEW-ONSET AF: LONG-TERM CEREBROVASCULAR EVENTS 
Figure 4. Impact of NOAF on early and long-term cerebrovascular events. Figure showing random effects hazard ratio and 95% confidence 
interval for early (A) and long-term cerebrovascular events (B). Note: fixed effects estimates for early (six studies, 2,025 patients, HR: 2.86, 
95% CI: 1.88 to 4.34, p<0.00001, I2=0%) and long-term cerebrovascular events (five studies; 971 patients, HR: 0.26, 95% CI: 0.88 to 1.79; 
p=0.21, I2=79%).
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NOAF seemed to be linked to a higher incidence of CVE, particu-
larly at short-term follow-up.
However, while pre-existing AF analysis demonstrating 
increased mortality was obtained in up to 8,000 patients, the results 
in NOAF were observed in fewer than 1,000 patients. Therefore, 
we cannot exclude an impact of NOAF on mortality, and future 
studies in larger populations of NOAF are needed.
Certainly, these results might have been induced by the different 
therapeutic strategies adopted in AF patients when compared to 
patients in SR. Unfortunately, the absence of the use of a standard-
ised therapy in the available trials made it impossible to analyse, in 
this meta-analysis, the effect of different antithrombotic regimens 
on outcome after TAVI, in particular in AF patients. Therefore, 
future randomised studies are needed to determine the most appro-
priate antithrombotic therapy in arrhythmic TAVI patients. In addi-
tion, this meta-analysis is limited by the inclusion of observational 
studies not directly comparing AF and non-AF patients, except in 
one case. The limitations of this study are mainly related to dif-
ferences in the studies included, as is the case for all meta-analy-
ses. All the studies were observational and the data reported were 
not sufficient to analyse the role of AF subtypes or AF clinical 
management. Due to incomplete/unequal reporting of data, not all 
studies were analysed for all outcomes.
Long-term CVE for both pre-existing AF and NOAF showed 
a high heterogeneity (>70%) not explained by analysis of poten-
tial modifiers or publication bias. Therefore, the results should be 
considered with caution. However, this heterogeneity reflects the 
contrasting results among the studies included on this issue, sup-
porting the need for a meta-analysis and future larger studies.
Finally, among the studies included there were no overlapping 
populations (duplicates were excluded in the eligibility screening). 
However, given that many studies are multicentre, a small number 
of overlapping patients cannot be excluded.
Conclusions
In conclusion, pre-existing AF, but not NOAF, is a predictor of 
long-term mortality. NOAF, on the contrary, predicts new CVE 
in the short term after TAVI. Screening patients’ rhythm may help 
to identify a subgroup at higher risk of future major events, while 
preventing NOAF may help to reduce CVE in patients undergoing 
TAVI. Thus, similar to the results with SAVR, AF should be taken 
into account when referring a patient for a TAVI procedure.
Impact on daily practice
Despite the clinical safety of TAVI, mortality and cerebral 
events still occur. New prognostic predictors could be useful 
for future risk scores and for decision making in daily prac-
tice for patients with moderate-to-severe aortic stenosis. These 
findings should be taken into account not only when selecting 
patients for TAVI, but also after treatment in order to reach an 
appropriate diagnosis, to decide on clinical management and to 
reduce clinical events, optimising prognosis after TAVI.
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Dear Editor,
Newly-onset atrial fibrillation (NOAF) has emerged in the last few
years as a potential prognostic factor in patients undergoing transcath-
eter aortic valve implantation (TAVI). NOAF after TAVI could be detri-
mental due to atrio-ventricular dissynchrony resulting in reduced
cardiac output and increased filling pressures. In addition, NOAF could
be responsible for fatal cerebrovascular events (CVE). In the last few
years some studies explored the incidence and the prognostic impact
of NOAF after TAVI [1–5], and recently new large series have added to
our knowledge [6–8]. However, the incidence of NOAF varies signifi-
cantly across registries (around 6–32%), with controversial findings on
its prognostic significance, hence the rationale for a meta-analysis.
We searched MEDLINE, Scopus and Cochrane databases until
September 20, 2015 using Internet-based engines, with no language
restrictions using various keywords including “new-onset atrial fibrilla-
tion” or “NOAF” and “transcatheter aortic valve implantation” or “TAVI”
or “TAVR”. The reference lists of relevant studies and reviews, editorials
and letters were searched. The analysis was restricted to studies
reporting data on mortality and CVE after TAVI stratified by the occur-
rence of NOAF. The most updated or inclusive data for a given study
were selected. All studies were observational and the highest-quality
estimate availablewaspicked for the overallmeta-analysis, with the fol-
lowing ranking: adjusted with propensity score N adjusted with multi-
variable analysis N unadjusted. The number of events, participants,
hazard ratios (HR) and confidence intervals (CI) for all-cause death
and CVE at 30-day and 1-year were abstracted. The results of all studies
were combined using a random-effects model to minimize heterogene-
ity among groups. Statistical heterogeneity was quantified with the I2
test. Systematic bias was explored with funnel plots. A 2-tailed alpha
of 5%was used for hypothesis testing. Statistical analysis was performed
with Review Manager (Version 5.2 Copenhagen).
A total of 8 studies encompassing 4959 patientswere included [1–8].
Overall, the mean incidence of NOAF was 10.1% (499 patients with
NOAF and 4460 patients in sinus rhythm after TAVI). Patients with
NOAF showed a borderline increase of 30-day and a significant increase
in 1-year all-cause death compared with those in sinus rhythm (Fig. 1).
Conversely, CVE were significantly increased at 30-day but non-
significantly albeit numerically increased at 1-year follow-up in NOAF
patients (Fig. 2). The main limitation of this meta-analysis is related to
the differences in NOAF definition across the included studies. We
excluded the study by Tchetche et al. [9] because most recent data
from the FRANCE-2 registry were available [8].
In conclusion, this updated meta-analysis on the role of NOAF
on outcomes after TAVI supports the understanding that NOAF is
associated with clinical events after TAVI. Whether this is a causal or
spurious association demands further research in this field.
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Meta-Analysis of Effect of Body Mass Index on Outcomes
After Transcatheter Aortic Valve Implantation
Anna Sannino, MDa,b, Gabriele Giacomo Schiattarella, MDa,c, Evelina Toscano, MDa,
Giuseppe Gargiulo, MDa, Giuseppe Giugliano, MDa, Maurizio Galderisi, MDa, Maria-Angela Losi, MDa,
Eugenio Stabile, MD, PhDa, Plinio Cirillo, MDa, Massimo Imbriaco, MDa, Paul Artur Grayburn, MDb,
Bruno Trimarco, MDa, and Giovanni Esposito, MD, PhDa,*
Controversial data exist regarding the impact of body mass index (BMI) on TAVI out-
comes. Thirteen TAVI studies were included and analyzed for the incidence of procedural
complications, 30-day, and long-term all-cause mortality. Three comparisons were
executed: (1) underweight versus normal weight, (2) overweight versus normal weight, and
(3) obese versus normal weight patients. Underweight patients (BMI <20 kg/m2) had similar
30-day all-cause mortality compared with the normal, although they displayed a significant
worse survival at long-term follow-up (hazard ratio 1.68, 95% confidence interval (CI) 1.09
to 2.59, p [ 0.02). Underweight patients showed a higher incidence of major and life-
threatening bleedings (2,566 patients, odds ratio 1.64, 95% CI 1.10 to 2.45, p [ 0.02)
and of major vascular complications (2,566 patients, odds ratio 1.86, 95% CI 1.16 to 2.98,
p [ 0.01), compared with normal weight patients. Overweight patients (BMI ‡25 and
<30 kg/m2) display similar 30-day and long-term all-cause mortality, as well as similar
procedural complication rate compared with normal weight patients. Obese patients (BMI
>30 kg/m2) had similar 30-day all-cause mortality rates compared with the normal weight
category, whereas they displayed a significant better survival at long-term (hazard ratio
0.79, 95% CI 0.67 to 0.93, p [ 0.004). Procedural complications did not differ between
obese and normal body weight patients. In conclusion, a low BMI is linked to a significantly
worse prognosis after TAVI. Therefore, BMI represents an important and handily tool that
might be used in the risk prediction of patients to be addressed for TAVI. ! 2016 Elsevier
Inc. All rights reserved. (Am J Cardiol 2017;119:308e316)
Obesity is a major modifiable risk factor for cardiovas-
cular morbidity and mortality.1 Nevertheless, a considerable
number of studies showed better outcomes for overweight
and obese patients after percutaneous and surgical cardio-
vascular interventions in general and after surgical aortic
valve replacement in particular.2 This phenomenon was
termed the “obesity paradox,” given its contrast with the
classical U-shape or U-shapeelike survival hazard curve
attributed to body mass index (BMI) when treated as
continuous variable. Possible mechanisms for this protective
effect include production of the soluble tumor necrosis
factor-a receptor in adipose tissue and subsequent neutral-
ization of the adverse effects of tumor necrosis factor-a on
mortality in patients with chronic inflammation diseases
such as cardiovascular diseases.3 Noteworthy, the relation
between BMI and transcatheter aortic valve implantation
(TAVI) outcome is to date controversial. Some authors re-
ported a protective role of obesity, as opposed to a signifi-
cant higher 30-day and 1-year mortality in patients with low
body weight.4,5 The FRANCE-2 registry data showed better
outcomes in overweight and obese patients than normal
weight ones.6 Others did not confirm the existence of this
obesity paradox, arguing that the obese population is
younger, seeks medical care earlier, is treated medically
more aggressively, and therefore benefits more from medi-
cal and interventional treatment.7,8 However, the real impact
of body weight on survival after TAVI still remains highly
debated. Given these observations, in the present meta-
analysis, we investigated the effect of different BMI cate-
gories on short- and long-term outcomes of elderly high-risk
patients with severe symptomatic aortic valve stenosis un-
dergoing TAVI.
Methods
The study was designed according to Preferred Reporting
Items for Systematic Reviews and Meta-Analyses re-
quirements.9 MEDLINE, Cochrane, ISI Web of Science, and
SCOPUS database were searched for studies published from
April 2002 (first-in-human TAVI date) until April 2016.
Additional sources included www.clinicaltrials.gov, www.
clinicaltrialresults.org, www.tctmd.com, www.cardiosource.
com, and abstracts/presentations from major cardiovascular
meetings. The reference lists of relevant studies, reviews,
aDivision of Cardiology, Department of Advanced Biomedical Sci-
ences, Federico II University, Naples, Italy; bDivision of Cardiology,
Baylor University Medical Center, Dallas, Texas; and cDepartment of In-
ternal Medicine (Cardiology), University of Texas Southwestern Medical
Center, Dallas, Texas. Manuscript received September 13, 2016; revised
manuscript received and accepted September 29, 2016.
Drs. Sannino and Schiattarella equally contributed to this work.
See page 315 for disclosure information.
*Corresponding author: Tel: (þ39) 081-746-3075; fax: (þ39) 081-746-
2223.
E-mail address: espogiov@unina.it (G. Esposito).
0002-9149/16/$ - see front matter ! 2016 Elsevier Inc. All rights reserved. www.ajconline.org
http://dx.doi.org/10.1016/j.amjcard.2016.09.031
editorials, and letters were scrutinized to identify further ci-
tations. Studies were identified using the major medical
subject heading “transcatheter aortic valve implantation or
transcatheter aortic valve replacement or TAVI or TAVR”
combined with “body mass index or body weight or BMI.”
Citations were screened at the title and abstract level by 2
independent reviewers and retrieved as a full report if they
reported data on outcomes after TAVI, when BMI was
considered as a predictor of mortality in their regression
models as a categorical and/or continuous variable. No lan-
guage limitations were applied. The most updated or inclu-
sive data for a given study were chosen for abstraction.
Studies were included if: (1) TAVI was performed in
patients with symptomatic, severe aortic stenosis (defined as
an aortic valve area <1 cm2 or an indexed aortic valve area
<0.6 cm2/m2); (2) outcomes data were reported according to
the BMI values (reported as either categorical or continuous
variable); (3) BMI categories were identified following the
World Health Organization10 or Valve Academic Research
Consortium-2 (VARC-2) definitions.11 Studies were
excluded if any of the following criteria applied: (1) dupli-
cate publication date; (2) lack of data on BMI values and
their impact on TAVI outcomes; (3) the outcome of interest
was not clearly reported or was impossible to extract or
calculate from the published results; (4) number of patients
<100. Two reviewers independently screened studies for
fulfillment of inclusion criteria. Reviewers compared
selected trials and discrepancies were resolved by
consensus. Baseline characteristics, outcomes, including
mortality and procedural complications, were abstracted.
The primary outcomes evaluated were the incidence of
30-day and long-term all-cause mortality in obese, over-
weight, and underweight patients compared with normal
weight patients undergoing TAVI. Secondary outcomes of
interest were the incidence procedural complications in the
same populations (defined as: device success rate, major
vascular complications, major and life-threatening bleed-
ings, cerebrovascular events, myocardial infarction, and
acute kidney injury). A separate analysis on long-term
all-cause mortality was performed including studies report-
ing BMI as a continuous variable.
Weight categories were defined according to accepted
criteria10,11 and specifically: underweight was defined as
BMI <20 kg/m2, normal weight category included BMI
"20 kg/m2 and <25 kg/m2, overweight category included
BMI "25 kg/m2 and <30 kg/m2, and obese was defined as
BMI "30 kg/m2.
The number of events, participants, and percentages as
well as adjusted hazard ratios (HRs) and CIs were abstracted
when available. Highest quality data were prioritized
(adjusted HR >number of events). Estimates of effect were
calculated with a random-effects model and confirmed by a
fixed-effects model and expressed as odds ratio (OR) or HR.
Statistical significance was set at p #0.05 (2 tailed).
Heterogeneity was assessed by a Q-statistic and I2 test.
Significant heterogeneity was considered present for p
values <0.10 or an I2 >50%. In case of significant hetero-
geneity, the random-effects model was prioritized over the
fixed-effects model, and subgroup and sensitivity analyses
were performed to explore sources of inconsistency.
Meta-regressions were performed to test the influence of
baseline characteristics included in Table 1 as potential
effect modifiers (significance at p #0.05).
Publication bias was assessed using funnel plots and
Egger’s test, consisting in a linear regression of the inter-
vention effect estimates on their standard errors, weighting
by 1/(variance of the intervention effect estimate).12 If there
was some evidence of publication bias, the trim and fill
method, which estimates the number and results of potential
missing studies resulting from publication bias, was applied.
All data analyses were performed using Prometa Software
(Version 2, Internovi, Cesena FC, Italy), and Reviewer Man-
ager (RevMan, version 5.2, Copenhagen, Denmark).13e16
Results
Of the 224 studies identified in the initial search, 36 were
retrieved for more detailed evaluation. Twenty-three studies
were subsequently excluded, and therefore, 13 studies were
finally included in the analyses4e8,17e24(Figure 1, Table 1,
and Supplementary Table 1). Studies design and follow-up
definitions are reported in Supplementary Table 2.
Underweight patients (BMI <20 kg/m2) had similar
30-day all-cause mortality compared with the normal weight
category (3 studies; 2,883 patients, HR 1.61, 95% CI 0.57 to
4.53, p ¼ 0.37, I2 ¼ 71%, Figure 2, Table 2), although they
displayed a significant worsening in survival at long-term
follow-up (5 studies; HR 1.68, 95% CI 1.09 to 2.59,
p ¼ 0.02, I2 ¼ 60%, Figure 2, Table 2). As far as procedural
complications regard, underweight patients showed a higher
incidence of major and life-threatening bleedings (5 studies;
2,566 patients, OR 1.64, 95% CI 1.10 to 2.45, p ¼ 0.02,
I2 ¼ 0%, Figure 3, Table 2) and of major vascular com-
plications, as well (5 studies; 2,566 patients, OR 1.86, 95%
CI 1.16 to 2.98, p ¼ 0.01, I2 ¼ 19%, Figure 3, Table 2).
Conversely, device success rate (4 studies; 2,428 patients,
OR 0.94, 95% CI 0.51 to 1.72, p ¼ 0.84, I2 ¼ 0%, Figure 3,
Table 2), incidence of cerebrovascular events (5 studies;
2,565 patients, OR 1.11, 95% CI 0.58 to 2.14, p ¼ 0.75,
I2 ¼ 0%, Figure 3, Table 2), myocardial infarction (3
studies; 2,237 patients, OR 1.31, 95% CI 0.34 to 4.98, p ¼
0.69, I2 ¼ 0%, Figure 3, Table 2) and acute kidney injury
(5 studies; 2,566 patients, OR 0.93, 95% CI 0.51 to 1.69,
p ¼ 0.80, I2 ¼ 0%, Figure 3, Table 2) did not differ
significantly between the 2 groups.
Overweight patients (BMI "25 and <30 kg/m2) display
similar mortality rates both at 30-day (3 studies, 3,769
patients, OR 0.78, 95% CI 0.54 to 1.13, I2 ¼ 37%,
Supplementary Figure 1, Table 3) and at long-term
follow-up (4 studies, HR 0.94, 95% CI 0.77 to 1.16,
I2 ¼ 18%, Supplementary Figure 1, Table 3), compared
with normal weight patients. The 30-day mortality turned
significantly lower for the overweight patients, when the
fixed-effect model was used; however, this is a pooled
analysis of only 3 studies and should therefore be
considered with caution. Similarly, major and life-
threatening bleedings (5 studies; 4,380 patients, OR 1.11,
95% CI 0.89 to 1.39, p ¼ 0.34, I2 ¼ 0%, Supplementary
Figure 1, Table 3), of major vascular complications
(5 studies; 4,380 patients, OR 1.09, 95% CI 0.84 to 1.41,
p ¼ 0.52, I2 ¼ 0%, Supplementary Figure 1, Table 3),
device success rate (4 studies; 4,079 patients, OR 1.03,
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95% CI 0.76 to 1.40, p ¼ 0.86, I2 ¼ 0%, Supplementary
Figure 1), incidence of cerebrovascular events (5 studies;
4,373 patients, OR 1.11, 95% CI 0.58 to 2.14, p ¼ 0.75,
I2 ¼ 0%, Supplementary Figure 1, Table 3), myocardial
infarction (3 studies; 3,769 patients, OR 1.31, 95% CI 0.34
to 4.98, p ¼ 0.69, I2 ¼ 0%, Supplementary Figure 1,
Table 3), and acute kidney injury (5 studies; 4,380 patients,
OR 1.29, 95% CI 0.92 to 1.79, p ¼ 0.80, I2 ¼ 0%,
Supplementary Figure 1, Table 3) did not differ signifi-
cantly between the 2 groups.
Obese patients (BMI "30 kg/m2) had similar 30-day
all-cause mortality ratios compared with the normal
weight category (6 studies; 3,367 patients, HR 0.87, 95% CI
0.65 to 1.16, p ¼ 0.35, I2 ¼ 58%, Figure 4, Table 4),
Figure 1. Meta-analysis flow chart. Flow chart showing study search and selection.
Table 1
Baseline characteristics of selected studies included in meta-analysis
First Author
(Ref.#)
Year n Age
(years)
AF Balloon
expandable
BMI
(kg/m2)
CAD CKD COPD Diabetes Dyslipidemia EF Women Hypertension Logistic
EURO
score
Abramowitz8 2016 805 82 33.5% 91.5% 26.8 64.6% N/A 37.5% 31.8% N/A 56.8% 39.9% 91.3% N/A
Kodali17 2012 348 83.6 40.7% 100% N/A 74.7% 10.8% 43.7% N/A N/A 52.5% 42.2% N/A 29.3%
Koifman(A)19 2015 476 83.5 39.7% N/A 27.5 N/A N/A 30.2% 33.2% N/A N/A 27.1% 89.9% N/A
Koifman(B)5 2016 491 82.9 42.8% 67.4% 27.8 N/A N/A 33.2% 33.4% N/A N/A 49.9% 93.5% N/A
Konigstein18 2015 409 82 30% 25% N/A 59% N/A 19% 34.5% 78% 55.8% 58% 88% 24%
Leon20 2016 1011 81.5 31% 100% 28.6 69.2% 5.0% 31.8% 37.7% N/A 56.2% 45.8% N/A N/A
Mok21 2013 319 80 30.7% 98.7% 26.8 63.9% 60.2% 29.5% 37.3% N/A 54% 53.9% 89% N/A
Seiffert22 2013 326 80.6 33.2% 86.2% N/A 61.6% 8.9% 26.7% N/A N/A N/A 55.5% N/A 22.7%
Seiffert23 2014 845 80.9 33.9% N/A 26.5 44% N/A 28.5% 28.4% N/A N/A 51.1% N/A 20.4%
van der Boon4 2013 940 81 N/A 46.3% 26.2 45% 63% 34% 29% N/A N/A 46% 70% 20.9%
Wenaweser24 2011 200 82.9 26% 35% 25.6 62.5% N/A N/A 25% 58% 51% 80% 77% 24.6%
Yamamoto6 2013 3072 82.8 N/A 66.8% 26 47.8% 10.3% 25.4% 25.5% 48.1% 53.2% 49% 69% 22%
Yamamoto7 2015 777 83.4 N/A 60% 25.8 N/A 63.4% 26.4% 23% 50.8% 50.8% 51.5% 71.4% 22.3%
AF ¼ atrial fibrillation; BMI ¼ body mass index; CAD ¼ coronary arterial disease; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease; EF ¼ ejection
fraction; MI ¼ myocardial infarction; N/A ¼ not applicable (data not shown in the primary study or not obtainable; otherwise, the analysis was conducted only in a subgroup of the
entire study population); NYHA ¼ New York Heart Association; PAD ¼ peripheral arterial disease; PCI ¼ percutaneous coronary interventions; PM¼ pacemaker; STS ¼ Society of
Thoracic Surgeons.
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whereas they displayed a significant improvement in sur-
vival at 1-year follow-up (7 studies; 4,709 patients, HR
0.79, 95% CI 0.67 to 0.93, p ¼ 0.004, I2 ¼ 0%, Figure 4,
Table 4). As far as procedural complications regard, no
differences were found between obese and normal body
weight patients (major and life-threatening bleedings, 5
studies, 4,237 patients, OR 1.05, 95% CI 0.75 to 1.46,
p ¼ 0.79, I2 ¼ 49%, Figure 5, Table 4; major vascular
complications, 6 studies, 4,237 patients, OR 1.14, 95% CI
0.85 to 1.52, p ¼ 0.38, I2 ¼ 11%, Figure 5, Table 4; device
success, 5 studies, 4,003 patients, OR 1.07, 95% CI 0.75 to
1.54, p ¼ 0.70, I2 ¼ 29%, Figure 5, Table 4; cerebrovascular
events, 6 studies, 4,237 patients, OR 1.10, 95% CI 0.63 to
1.94, p ¼ 0.74, I2 ¼ 56%, Figure 5, Table 4; myocardial
infarction, 4 studies, 3,717 patients, OR 0.67, 95% CI 0.33
to 1.39, p ¼ 0.28, I2 ¼ 0%, Figure 5, Table 4; acute kidney
injury, 6 studies, 4,237 patients, OR 1.02, 95% CI 0.77 to
1.36, p ¼ 0.88, I2 ¼ 0%, Figure 5, Table 4).
In addition, when BMI was analyzed as a continuous
variable, each increase in 1 unit of kg/m2 was associated
with a significant reduction in long-term all-cause mortality
(7 studies; 4,677 patients, HR 0.96, 95% CI 0.93 to 1.00,
p ¼ 0.03, I2 ¼ 73%, Supplementary Figure 2, Table 4).
Meta-regression analysis showed no relation between all
the analyzed effect modifiers and the outcomes of interest,
except for diabetes, previous myocardial infarction, and
self-expandable valves in the analysis of long-term all-cause
mortality for the comparison of underweight versus normal
weight patients (Supplementary Figure 3). In the overweight
versus normal weight comparison, coronary arterial disease,
and a transaortic approach were significantly associated with
higher 30-day all-cause mortality (Supplementary Figure 4).
Figure 2. Impact of BMI <20 kg/m2on 30-day and long-term all-cause mortality. Random-effects HR and 95% CI for 30-day (A) and long-term (B) all-cause
mortality.
NYHA
class
III/IV
Obese PAD Prev
Cardiac
Surgery
Prior MI Prior
PCI
Prior
PM
Prior
Stroke
Self
expandable
Smoke STS
score
Subclavian Transaortic Transapical Transfemoral Under
weight
N/A 23.1% 35.3% 26.3% 16.3% N/A 20.9% 21% 8.5% N/A 8.1% 2% 7.4% 4.8% 85.2% 33.3%
94.3% N/A 43.2% 42.5% 26.5% 33.5% 19.8% N/A 0% N/A 11.8% 0% 0% 29.9% 70.1% N/A
89.1% N/A 33.4% 32.1% N/A 28.1% 16.8% 15.3% N/A N/A 10% 0% 0% 25.4% 74.6% N/A
85.7% 28.1% 29.1% 33.4% N/A 29.9% 16.3% 12.2% 24% N/A 11% 0% 0% 0% 100% 8.8%
67% 25% 7% 17% 17% 43% N/A 10% 75% 26% N/A 0% 0% 0% 100% 1%
77.3% N/A 27.9% 23.6% 18.3% 27.1% 11.7% N/A 0% N/A 5.8% 0% 0% 23.3% 76.7% N/A
80.3% N/A 34.8% 38.6% 35.1% N/A N/A 19.1% 1.3% 4.7% 6.3% 0% N/A N/A 39.2% N/A
81.6% 61.7% N/A 19.9% 19.9% 35.3% N/A 19.3% 13.8% N/A 8.3% 0.9% 0% 54.3% 44.8% 5.6%
N/A N/A 36.9% 18.9% 19.3% 36.6% 11.3% N/A N/A N/A 6.4% 0% 0.1% 0% 99.9% N/A
81% 16.9% 25% 22% 17% 30% 11% 16% 53.7% N/A N/A 6% 0.4% 10% 84% 2.7%
N/A N/A 23.5% 20% 20% 22% 11% 9% 65% N/A 6.4% 1.5% 0% 21.5% 77% N/A
65.7% 18.6% 20.6% 20.1% 16% N/A 14% 9.8% 33.2% N/A N/A 6.6% 1.8% 17.8% 74.5% 3.1%
80.4% 51.3% 28.4% 16% 14.4% N/A 15.2% 9.8% 40% N/A 10.9% N/A N/A N/A 65.4% 7.2%
Table 1
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For the obese versus normal weight comparison, there was
an association between chronic obstructive pulmonary
disease and higher long-term all-cause mortality
(Supplementary Figure 5).
The long-term all-cause mortality in the comparison be-
tween underweight and normal weight patients lost the
statistical significance removing the study from Koifman
et al19 (HR 1.64, 95% CI 0.94 to 2.88), Koifman et al5 (HR
1.54, 95% CI 0.94 to 2.53) and Seiffert et al (HR 1.47, 95%
CI 0.97 to 2.25). Similarly, the significant reduction in long-
term all-cause mortality was confirmed for obese patients
when meta-analyses were repeated removing 1 study at the
time; however, when removing Seiffert et al (HR 0.78, 95%
CI 0.66 to 1.93) and Yamamoto et al, 2013 (HR 0.82, 95%
CI 0.67 to 1.01), this result lost its statistical significance.
Additional sensitivity analyses are reported in
Supplementary Tables 6 to 9.
The funnel plots and Egger’s test did not suggest any
significant publication bias for all the analyses performed,
except for the long-term all-cause mortality in the overweight
versus normal weight comparison (HR 0.87, 95% CI 0.70 to
1.07, p ¼ 0.003), although not changing the final result.
Discussion
This meta-analysis of 13 TAVI studies adds to the
current knowledge with the following considerations: (1)
underweight patients (BMI <20 kg/m2) experience a higher
mortality at long term after TAVI, as well as increased rates
of major vascular complications and major and life-
threatening bleedings (VARC-2 definitions) during the
procedure, compared with normal body weight patients; (2)
overweight patients (BMI "25 and <30 kg/m2) display
similar 30-day and long-term all-cause mortality, as well as
Figure 3. Impact of BMI <20 kg/m2on procedural complications. Random-effects OR and 95% CI for major and life-threatening bleedings (A) major vascular
complications, (B) device success, (C) cerebrovascular events, (D) myocardial infarction, and (E) acute kidney injury (F).
Table 2
Outcomes after TAVI in underweight versus normal weight patients
Outcome Studies Patients RE HR/OR
[95% CI]
P Value c2 FE HR/OR
[95% CI]
P Value c2 I2% Egger
Test
Trim and Fill HR
All-cause mortality
30-day 3 2883 1.61[0.57-4.53] 0.37 6.81 1.45[0.91-2.32] 0.12 6.81 71 0.793 1.61[0.57-4.52]
Long-term 5 N/A 1.68[1.09-2.59] 0.02 10.11 1.61[1.23-2.10] 0.0005 10.11 60 0.394 1.68[1.09-2.59]
Major and life-threatening
bleeding
5 2566 1.64[1.10-2.45] 0.02 2.31 1.61[1.07-2.40] 0.02 2.31 0 0.607 1.53[1.04-2.24]
Major Vascular complication 5 2566 1.86[1.16-2.98] 0.01 4.94 1.78[1.20-2.65] 0.004 4.94 19 0.907 1.86[1.16-2.98]
Device Success 4 2428 0.94[0.51-1.72] 0.84 1.51 0.99[0.54-1.81] 0.98 1.51 0 0.497 0.94[0.51-1.72]
Cerebrovascular events 5 2565 1.11[0.58-2.14] 0.75 0.53 1.08[0.56-2.08] 0.81 0.53 0 0.993 1.11[0.58-2.14]
Myocardial Infarction 3 2237 1.31[0.34-4.98] 0.69 1.06 1.10[0.30-4.05] 0.89 1.06 0 0.746 1.31[0.34-4.98]
Acute Kidney Injury 5 2566 0.93[0.51-1.69] 0.80 2.70 0.86[0.47-1.57] 0.62 2.70 0 0.199 0.75[0.43-1.29]
Mortality data are reported as HR; procedural outcomes are reported as OR according to the availability of crude events in the primary studies.
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similar procedural complication rates compared with normal
weight patients; (3) obese patients (BMI "30 kg/m2)
showed lower long-term all-cause mortality and similar rates
of procedural complications compared with normal body
weight patients. These data in aggregate suggest that low
body weight patients are exposed to worse outcomes after
TAVI.
Although not statistically significant, the early, slightly
higher, mortality of the underweight patients could be attrib-
uted to the higher rate of vascular complications andmajor and
life-threatening bleedings in this population, which may result
from similar sized sheath in a smaller peripheral access site in a
smaller patient.25 Late mortality could be explained by frailty
of the low-BMI patients, as suggested in the VARC-2 criteria,
in which a BMI<20 kg/m2 and/or weight loss 5 kg/year have
been included. Previous studies in TAVI cohorts have actually
demonstrated the importance of frailty as an independent
predictor ofmortality, yet its assessment incorporated different
methods, including questionnaires, various gait-speed and
strength tests, and physicians’ subjective assessments, which
can have substantial variance according to method and
observer interpretation.26 Our meta-regression analysis sug-
gested that in underweight patients, the presence of diabetes
and previous myocardial infarction led to an increased risk of
long-term all-cause mortality. Interestingly, for the same
comparison, the lower long-term mortality was reported in
those studies with a higher usage of self-expandable valves.
However, this result came from a pooled analysis of only 4
Figure 4. Impact of BMI "30 kg/m2 on 30-day and long-term all-cause mortality. Random-effects HR and 95% CI for 30-day (A) and long-term (B) all-cause
mortality.
Table 3
Outcomes after TAVI in overweight versus normal weight patients
Outcome Studies Patients RE HR/OR
[95% CI]
P Value c2 FE HR/OR
[95% CI]
P Value c2 I2% Egger Test Trim and
Fill HR
All-cause mortality
30-day 3 3769 0.78[0.54-1.13] 0.19 3.18 0.76[0.60-0.96] 0.02 3.18 37 0.584 0.78[0.54-1.13]
Long-term 4 N/A 0.94[0.77-1.16] 0.58 3.66 0.91[0.77-1.07] 0.25 3.66 18 0.003 0.87[0.70-1.07]
Major and life-threatening
bleeding
5 4380 1.11[0.89-1.39] 0.34 2.98 1.11[0.89-1.39] 0.34 2.98 0 0.932 1.08[0.87-1.35]
Major Vascular complication 5 4380 1.09[0.84-1.41] 0.52 3.97 1.09[0.84-1.41] 0.53 3.97 0 0.692 1.09[0.84-1.41]
Device Success 4 4079 1.03[0.76-1.40] 0.86 0.22 1.03[0.76-1.40] 0.86 0.22 0 0.289 1.03[0.76-1.40]
Cerebrovascular events 5 4373 0.90[0.66-1.24] 0.52 2.80 0.90[0.66-1.23] 0.52 2.80 0 0.948 0.90[0.66-1.24]
Myocardial Infarction 3 3769 0.57[0.30-1.08] 0.09 1.48 0.56[0.30-1.05] 0.07 1.48 0 0.891 0.57[0.30-1.08]
Acute Kidney Injury 5 4380 1.29[0.92-1.79] 0.14 0.88 1.29[0.92-1.80] 0.14 0.88 0 0.981 1.25[0.92-1.70]
Long-term mortality is reported as HR; 30-day mortality and procedural outcomes are reported as OR according to the availability of crude events in the
primary studies.
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studies, not sufficient to draw effective conclusions. As far as
procedural complication regards, the higher incidence ofmajor
and life-threatening bleedings as well as of major vascular
complications might suggest that in underweight patients with
very small peripheral vessels, new devices with progressively
smaller introduction and delivery system should be used to
reduce the risk of vascular complications and bleeding issues.
Indeed, this issue has been previously reported also in small
body sized patients undergoing TAVI.27
Our meta-analysis shows a lower mortality in obese
patients thus corroborating pervious studies demonstrating
the “obesity paradox” in TAVI patients. Actually, even
when BMI was analyzed a continuous variable, each
increase in 1 unit of kg/m2 was linked to a significantly
lower rate in long-term mortality. Obesity was shown to
result in a worse prognosis in general population cohorts,
with BMI conferring a U-shaped curve in relation to mor-
tality, as both obesity and underweight have been found to
have detrimental effects on overall survival.1 However, in
severe aortic stenosis patients undergoing surgical aortic
valve replacement2 or TAVI,6,18,28 BMI was found to have a
protecting effect, with obese patients having a better
outcome than normal weight patients. Some possible ex-
planations can be suggested for the obesity paradox. First,
the obese group often consists of younger subjects, although
age did not emerge as a significant modifier in our analysis.
Figure 5. Impact of BMI "30 kg/m2 on procedural complications. Random-effects OR and 95% CI for major and life-threatening bleedings (A) major vascular
complications, (B) device success, (C) cerebrovascular events, (D) myocardial infarction, (E) acute kidney injury (F).
Table 4
Outcomes after TAVI in obese versus normal weight patients
Outcome Studies Patients RE HR/OR
[95% CI]
P
Value
c2 FE HR/OR
[95% CI]
P Value c2 I2% Egger
Test
Trim and
Fill HR
All-cause mortality
30-day 6 3367 0.87[0.65-1.16] 0.35 11.80 0.97[0.93-1.01] 0.20 11.80 58 0.662 0.82[0.60-1.13]
Long-term 7 4709 0.79[0.67-0.93] 0.004 4.91 0.79[0.67-0.93] 0.004 4.91 0 0.151 0.75[0.63-0.89]
Long-term (for each 1 kg/m2 increase) 7 4677 0.96[0.93-1.00] 0.03 22.54 0.96[0.95-0.98] <0.00001 22.54 73 0.528 0.96[0.93-1.00]
Major and life-threatening bleeding 6 4237 1.05[0.75-1.46] 0.79 9.79 0.99[0.79-1.23] 0.90 9.79 49 0.377 1.05[0.75-1.46]
Major Vascular complication 6 4237 1.14[0.85-1.52] 0.38 5.59 1.14[0.87-1.48] 0.34 5.59 11 0.771 1.14[0.85-1.52]
Device Success 5 4003 1.07[0.75-1.54] 0.70 5.61 1.06[0.79-1.42] 0.70 5.61 29 0.305 0.86[0.58-1.27]
Cerebrovascular events 6 4237 1.10[0.63-1.94] 0.74 11.43 0.98[0.70-1.37] 0.91 11.43 56 0.347 1.10[0.63-1.94]
Myocardial Infarction 4 3717 0.67[0.33-1.39] 0.28 1.00 0.66[0.32-1.34] 0.25 1.00 0 0.868 0.67[0.33-1.39]
Acute Kidney Injury 6 4237 1.29[0.92-1.79] 0.14 0.88 1.29[0.92-1.80] 0.14 0.88 0 0.407 1.29[0.92-1.79]
Mortality data are reported as HR; procedural outcomes are reported as OR according to the availability of crude events in the primary studies.
314 The American Journal of Cardiology (www.ajconline.org)
Second, it is possible that obese patients are treated more
aggressively with cardioprotective drugs that may contribute
to better outcomes.
As of today, BMI is not part of the risk scores ordinarily
used to screen and to predict mortality after TAVI. The
currently used scores (logistic EuroSCORE, Society of
Thoracic Surgeons score, EuroSCORE II, Age, Creatinine,
and Ejection Fraction [ACEF] score, Ambler’s risk score,
OBSERVANT, SURgical replacement and Transcatheter
Aortic Valve Implantation [SURTAVI] model, and survival
post TAVI [STT] score) provide important prognostic in-
formation but still lack calibration and discriminatory po-
wer.29 This is probably because they do not consider a
number of factors that have subsequently emerged in recent
series, as significantly affecting outcome of patients under-
going TAVI. Among those, BMI has not been considered so
far in the risk prediction for patients undergoing TAVI;
however, given the results of this meta-analysis BMI should
definitely be included in new TAVI-oriented risk score
models.
The results of this meta-analysis are affected by limita-
tions and differences of the original included studies them-
selves. All meta-analyses share limitations related to
differences in study design, end point definitions, and
publication bias. Importantly, we found a substantial vari-
ation in the categorization of BMI in the included studies,
which might have led to differences in the reported out-
comes and contributed to the heterogeneity observed.30 The
analysis of 30-day all-cause mortality in the comparison
underweight versus normal weight patients and the analysis
of long-term mortality when BMI was used as a continuous
variable showed a high heterogeneity (>70%) not explained
by analysis of potential modifiers or publication bias.
Therefore, the results should be considered with caution.
However, this heterogeneity reflects the contrasting results
among the studies included on this issue, supporting the
need for a meta-analysis and future larger studies. Although
mortality analyses are based on the highest quality of data
(adjusted HR), patient-level data from TAVI studies pro-
spectively reporting on BMI could be of added value to
confirm our findings and further elucidate this topic.
Moreover, although it might be supposed that people with a
BMI of 45 have a different risk profile compared with
people with a BMI of 31, we were not able to investigate the
differences in outcome, if any, among different grades of
obesity. Actually, the vast majority of obese patients laid in
the grade 1 category and data about morbid obese patients
are usually included (and therefore lost) in a one categori-
zation group. Another limitation is that all the analyses
about the procedural complications were performed on un-
adjusted data, which might suffer the weight of other
covariables (Table 2).
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ABSTRACT
Introduction: Transcatheter aortic valve implantation (TAVI) underwent progressive improvements until
it became the default therapy for inoperable patients, and a recommended therapy in high-risk
operable patients with symptomatic severe aortic stenosis. Recent evidence will further support TAVI
as treatment for a growing number of patients.
Areas covered: This review will discuss on the current knowledge about the role of both pre-
procedural chronic kidney disease (CKD) and post-procedural acute kidney injury (AKI) in adult patients
with severe aortic stenosis undergoing TAVI.
Expert commentary: Pre-procedural CKD is one of the most frequent comorbidities of TAVI patients
and has been found to significantly worsen patients’ prognosis at short and long-term follow-up.
Similarly, post-procedural AKI is a frequent and relevant complication associated with increased
mortality. The risk stratification of the patient, the prevention of complications and the appropriate
post-procedural management are the main focus of the future research aimed at further improving
clinical outcomes of TAVI patients.
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1. Introduction
Transcatheter aortic valve implantation (TAVI) has accumu-
lated growing evidence in the last year supporting the con-
cept that it should now be considered a valid alternative to
surgical aortic valve replacement (SAVR) [1]. Patients under-
going TAVI are commonly very old and have a high preva-
lence of comorbidities. Renal dysfunction is a relevant
medical issue for elderly patients with severe aortic stenosis
(AS) being both a baseline risk factor for increased mortality
and complications after treatment as well as a post-proce-
dural adverse event impacting on the prognosis of patients
undergoing TAVI.
This review will discuss on the current knowledge about
the role of both pre-procedural chronic kidney disease (CKD)
and post-procedural acute kidney injury (AKI) in adult patients
with severe AS undergoing TAVI.
2. Pre-procedural CKD
2.1. Definition and prevalence of baseline CKD
CKD is a growing worldwide public health problem with rele-
vant economic and social repercussions and is a well recog-
nized modifier of the natural history of cardiovascular diseases
being associated with a poorer prognosis in these patients [2].
According to KDIGO (Kidney Disease: Improving Global
Outcomes), CKD is generally classified into five stages: Stage
1 = kidney damage (albuminuria, proteinuria, hematuria) with
normal or higher estimated glomerular filtration rate (eGFR)
(≥90 mL/min/1.73 m2; normal CKD); Stage 2 = kidney damage
(albuminuria, proteinuria, hematuria) with mild eGFR reduc-
tion (60–89 mL/min/1.73 m2; mild CKD); Stage 3 = moderate
eGFR reduction (30–59 mL/min/1.73 m2; moderate CKD,
chronic renal insufficiency, early renal insufficiency); Stage
4 = severe eGFR reduction (15–29 mL/min/1.73 m2, severe
CKD, chronic renal insufficiency, late renal insufficiency);
Stage 5 = renal failure with eGFR<15 mL/min/1.73 m2 or
dialysis (kidney failure, uremia, end-stage renal disease
[ESRD]) [3].
Patients with AS are generally elderly and their renal func-
tion is often reduced. In currently available clinical trials of
TAVI versus SAVR, CKD was not uniformly defined and the
prevalence of preoperative CKD was not so high as in other
trials or registries (Figure 1). In the PARTNER trial, patients with
creatinine levels >2 mg/dL (>177 micromol/L) were 9.0% (TAVI
38/343, SAVR 24/344); in the PARTNER 2 trial, patients with
creatinine levels >2 mg/dL were 5.1% (TAVI 51/1011, SAVR 53/
1021); in the STACCATO trial, patients with creatinine levels
>2.2 mg/dL (200 micromol/L) were 1.4% (TAVI 1/34, SAVR 0/
36); in the US CoreValve trial, patients with CKD 4–5 were
12.7% (TAVI 48/390, SAVR 52/396); in the NOTION trial,
patients with creatinine levels >2 mg/dL were 1.1% (TAVI 2/
145, SAVR 1/135). On the other hand, CKD was present in
24.7% and 54.6% of TAVI patients included in the DEFLECT III
(CKD definition not reported) and BRAVO 3 (CKD defined as
eGFR<60 mL/min) trials, respectively [4,5] and was ranging
from 20% to more than 60% in many real-world registries
[1,6–10].
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2.2. Impact of CKD on outcomes after TAVI
It is well known that baseline CKD increases early and late
mortality in patients undergoing cardiac surgery, particularly
for those with ESRD [11]. On the contrary, this was a debated
issue in patients undergoing TAVI with some contrasting evi-
dence, indeed, some studies found that CKD predicted mor-
tality [6,7,10,12,13], while a large national registry did not
confirm this finding [14]. Moreover, two studies had showed
that only CKD stages 4 and 5 but not stage 3 were associated
with significant increase of mortality [15,16]. On this back-
ground, our group conducted a meta-analysis to explore this
issue including 9 studies with a total of 4992 patients [17]. As
first step, we assessed the impact of overall renal dysfunction
comparing outcomes of patients categorized as CKD stages 3–
5 with those in the stages CKD 1 and 2 (Figure 2); then we
looked for a potential different impact on prognosis related to
the severity of CKD analyzing separately the role of moderate
CKD (stage 3) and severe CKD (stages 4 and 5). We found that
overall CKD (stages 3–5) was associated with significant
increase of early and 1-year all-cause and cardiovascular mor-
tality, early stroke, AKI, AKI 2 to 3, need for dialysis, and length
of stay in the absence of differences in contrast medium
administration, but also that compared with lower degree of
CKD, worse renal impairment (i.e. CKD 4–5 versus CKD 1–2;
CKD 4–5 versus CKD 3; CKD 3 versus 1–2) was associated with
increased all-cause and cardiovascular mortality, stroke, AKI,
AKI 2–3, need for dialysis and bleeding. More importantly,
moderate CKD alone emerged for the first time to significantly
impact on all-cause mortality, stroke, and AKI (Figure 3).
Altogether, these findings support the concept that not only
patients with severe CKD may experience worse prognosis
after TAVI but also those with a moderate degree of renal
dysfunction [17].
After this meta-analysis, a new study exploring the role of
CKD on outcomes according to its severity was published by
the FRANCE2 registry investigators [8]. This study analyzed a
total of 2929 patients of whom 1386, 711, 547, 189, and 96,
respectively, belonged to CKD 1–2, CKD 3a, CKD 3b, CKD 4,
and CKD 5 stages. They confirmed that both 30-day and 1-year
mortality rates were significantly increased and positively cor-
related with CKD severity in all groups [8].
Even after pooling these data with our prior analyses, we
found that CKD (stages 3–5) as well as moderate CKD (only
stage 3) worsened mortality after TAVI [18]. Notably, in the
study by Oguri et al., moderate CKD was further divided into
stage 3a (45–59 mL/min/1.73 m2) and 3b (30–44 mL/min/
Figure 1. Prevalence of pre-operative CKD in randomized trials comparing TAVI
vs SAVR.
Figure 2. Prognostic impact of CKD stages 3 to 5 on clinical outcomes [17].
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1.73 m2) and the authors observed that both CKD 3a and 3b
did not emerge as independent predictor of 30-day mortality,
while at one year, stage 3b (p = 0.045) but not stage 3a
(p = 0.59) significantly predicted mortality [8]. However, this
finding of differential impact between stage 3a and 3b needs
to be further confirmed in larger studies to exclude that it was
driven by underpowered analyses, particularly due to the
observation that the prognostic impact is related to the
degree of renal dysfunction (CKD stages 4–5 worse prognosis
than stage 3). This would be clinically relevant because
patients with CKD 3a represent a large cohort (in the
FRANCE2 24% compared with 19%, 7%, and 3% of stages 3b,
4, and 5, respectively) and because a further stratification of
patient’s risk with significant association to prognosis might
help in decision-making.
Further studies have confirmed the detrimental impact of
CKD on prognosis of patients undergoing TAVI. Ferro et al.
analyzed 3980 patients from the UK TAVI registry and found
that eGFR <45 mL/min/1.73 m2 was significantly associated
with increased mortality, even after adjustment for risk factors
and that for every 10 mL/min/1.73 m2 decrease in eGFR,
cumulative mortality increased by 4.4% at a median follow-
up of 543 days [19]. Interestingly, this study confirmed that the
worse the renal function, the worse is prognosis. Another
meta-analysis explored the role of the pre-procedural renal
dysfunction and confirmed that CKD was associated with
increased mid-term mortality after TAVI with CKD stage 4
being associated with a significantly higher rate of peri-proce-
dural complications and a poorer prognosis [20].
Notably, a study by Dvir et al. has been recently presented
at the international EuroPCR 2016 meeting [21]. The authors
analyzed 378 patients treated with TAVI and with follow-up
longer than 5 years (5-14 years) from St. Paul’s Hospital in
Vancouver, Canada and Hôpital Charles Nicolle in Rouen,
France in order to explore long-term durability of TAVI valves.
Valve degeneration was defined as at least moderate regur-
gitation and/or mean gradient ≥20 mmHg, which did not
appear within 30 days of the procedure and was not related
to endocarditis. This study found that baseline renal failure
(defined as eGFR<60 mL/min) was present in 46.3% of patients
and emerged as the strongest correlate for valve degeneration
(HR = 3.22, CI 1.45–7.15, p = 0.004) in a multivariable model
including age, gender, baseline orifice area, baseline left ven-
tricular ejection fraction, body mass index, renal failure, valve
type, valve size, anticoagulation treatment (i.e. warfarin) after
TAVI [21].
2.3. Outcomes of patients on dialysis
TAVI is emerging as an alternative to SAVR also for patients
with ESRD, even if it is known that the worse is the renal
function the worse is the patient prognosis after TAVI. AS is
common in patients with ESRD and the rate of progression is
faster than in patients without end-stage renal disease.
However, these patients have also a high risk for SAVR with
poor short- and long-term outcomes [22]. A large European
cohort reported that 6.9% of patients undergoing TAVI were
on dialysis [23]. TAVI might be therefore a promising alterna-
tive to SAVR in this setting of patients but they are often
excluded by trials and few data are currently available on
their outcomes. In the large multicenter Italian OBservational
Study of Effectiveness of AVR—TAVI procedures for severe
Aortic steNosis Treatment (OBSERVANT) Registry, 44 of the
Figure 3. Prognostic impact of moderate CKD (stages 3) on clinical outcomes [17].
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1911 consecutive patients (2.3%) enrolled between 2010 and
2012 were on dialysis [24]. They were more commonly men
(74%), severely symptomatic (NYHA III/IV 70%) and mean age
was 78 years. The majority underwent transfemoral TAVI (77%)
and 64% received the third-generation self-expanding trans-
catheter heart valve (CoreValve ReValving System) while 36%
the balloon-expandable valve (Edwards Sapien XT) [24].
Regarding procedural outcomes, moderate-to-severe paravalv-
ular regurgitation and new permanent pacemaker implanta-
tion were reported in 12% and 20% of the patients,
respectively. Mortality rates were 4.5% in-hospital, 9.1% at 30
day and 34.1% at 1 year whereas the composite of major
adverse cardiac and cerebrovascular events was 36.4% at
1 year and rehospitalization was reported in 47.7% of patients.
In the multicenter study by Allende et al. [16], 67 of 2075
patients (3.2%) were defined as stage 5 CKD (eGFR <15 or on
dialysis). In this study, dialysis was an independent predictor of
mortality as was atrial fibrillation as in other studies [25,26].
The 30-day pacemaker implantation and moderate-to-severe
aortic regurgitation were observed in 12.1% and 11.9%,
respectively. AKI occurred in 30% of those not on dialysis
and major or life-threatening bleeding events were reported
in 10.4% of patients while no cerebrovascular events occurred.
Mortality was 11.9% at 30-day and 50.7% at mid-term follow-
up (median follow-up of 15 months).
In the 4-center collaborative analysis by Dumonteil et al.
(PRAGMATIC-Plus), 33 of 942 patients (3.5%) were on dialysis
and showed the following outcomes at 30 day after TAVI:
death 15.2%, myocardial infarction 6.2%, stroke 6.1%, major
bleeding 24.2%, AKI stage III 31.2%, and new permanent pace-
maker implantation 12.5%. At 1 year, mortality was approxi-
mately 45% [27].
In the study by Goebel et al., 15 of 270 patients (5.6%) were
on dialysis of whom 20% needed pacemaker implantation
after TAVI, and mortality was 20% at 30 day [28].
Although further data are needed for this complex setting
of patients, these preliminary findings suggest favorable safety
and efficacy at short- and mid-term follow-up of TAVI in
patients with severe symptomatic AS and chronic dialysis.
However, many efforts should be provided to optimize their
outcomes, indeed the subtle equilibrium between thrombotic
and hemorrhagic events and the implications for antithrom-
botic treatment have been well recognized in TAVI patients
[29,30]. Severe CKD patients are particularly challenging and
should be carefully managed avoiding antithrombotic over-
treatment to reduce risks of complications after TAVI.
3. Post-procedural AKI
3.1. Definition
AKI has a great clinical relevance due to several reasons: (i) AKI
is common; (ii) it is associated with a heavy burden of illness
(morbidity and mortality); (iii) it is associated with high cost of
managing; (iv) it is amenable to early detection and potential
prevention; (v) there is considerable variability in practice to
prevent, diagnose, treat, and achieve outcomes of AKI.
The Acute Dialysis Quality Initiative (ADQI) group devel-
oped a system for diagnosis and classification of a broad
range of acute impairment of kidney function through a
broad consensus of experts (Table 1) [31]. The acronym RIFLE
stands for the increasing severity classes Risk, Injury, and
Failure; and the two outcome classes, Loss and ESRD. The
three severity grades are defined on the basis of the changes
in serum creatinine (sCr) or urine output where the worst of
each criterion is used, while the two outcome criteria, Loss and
ESRD, are defined by the duration of loss of kidney function.
To define AKI and its stages after TAVI, the first document
by VARC proposed to adopt serum creatinine criteria from the
‘modified’ RIFLE classification [32]. Two important changes
were applied to modify the original RIFLE classification includ-
ing (i) smaller changes in serum creatinine (0.3 mg/dL) are
included in stage 1 (Risk); (ii) the ‘Loss’ and ‘ESRD’ categories
have been removed due to a lack of uniform indications and
timing of renal replacement therapy (RRT) and variability in
RRT resources in different countries. A timing of 72 h from the
index procedure was selected for diagnosing AKI based on
evidence that adverse outcomes were observed when the
elevation occurred within 24 -48 h of the procedure and to
ensure that the process was both acute and related to the
procedure itself rather than as a consequence of post-proce-
dure multiorgan system failure. RIFLE classification also under-
lined the predictive value of urine output criteria in defining
AKI, but first VARC criteria did not include this measure in the
definition of AKI since urine outputs may not be measured
accurately or routinely in all cases. VARC proposed to adopt
the modified RIFLE classification to (i) capture even the earliest
stages of AKI (stage 1) on case report forms, (ii) define AKI as
Table 1. RIFLE and AKIN diagnostic criteria for acute kidney injury.
Class output Criteria: GFR/sCr Criteria: urine
RIFLE criteria (7days)
R-Risk Increase sCr × 1.5 or GFR decrease >25% <0.5 mL/kg/h for >6 h but <12 h
I-Injury Increase sCr × 2 or GFR decrease >25% <0.5 mL/kg/h for >12 h but <24 h
F-Failure Increase sCr × 3 or GFR decrease >75% or sCr ≥4 mg/dL,
Acute rise 0.5 mg/dL
<0.3 mL/kg/h for ≥24 h or anuria for ≥12 h
L-Loss Persistent kidney failure >4 weeks
E-ESKD Terminal kidney injury >3 months
Stage output
AKIN criteria (48 h)
Stage 1 Increase of sCr × 1.5 or ≥0.3 mg/dL <0.5 mL/kg/h for >6 h but <12 h
Stage 2 Increase of sCr × 2 <0.5 mL/kg/h for >12 h but <24 h
Stage 3* Increase of sCr × 3 or ≥4 mg/dL <0.3 mL/kg/h for ≥24 h or anuria for ≥12 h
AKIN: acute kidney injury; ESKD: end-stage kidney disease; GFR: glomerular filtration rate; sCr: serum creatinine.
*Patients receiving renal replacement therapy are considered to meet stage 3 criteria irrespective of other criteria.
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either stage 2 or 3, and (iii) report any case of RRT (hemodia-
lysis, peritoneal dialysis, or hemofiltration) occurring during
the index hospitalization or within 30 days after the index
procedure. In addition, based on the well-recognized dama-
ging impact of contrast media on renal function, VARC also
recommended reporting the volume and type of contrast
medium used during the index procedure [32]. The subse-
quent VARC-2 document [33] recommended using the AKIN
system (Table 1) [34], which is a modified version of RIFLE that
has been adopted by many in the nephrology community,
including the KDIGO initiative [33]. Consequently, AKI was to
be diagnosed also according to urine output measures
(Table 1). Furthermore, the timing for the diagnosis of AKI
was extended from 72 h to 7 days and it was recommended
that patients who experience AKI should have follow-up renal
function assessments after 7 days until stabilization [33].
3.2. Pathophysiology of AKI
Renal dysfunction in patients undergoing TAVI is usually multi-
factorial: the commonest cause is acute tubular necrosis as a
result of hypoxic damage to nephrons in the medullary region
of the kidney secondary to hypotension, hypovolemia, and/or
dehydration, that can occur fairly often during and after the
procedure [31]. The contrast media increases intra-renal vaso-
constriction and osmotic load, decreasing medullary blood
supply and leading to an increased oxygen requirement in
the presence of an already low tissue oxygen tension. In
addition, the hypovolemia plays a key role in the development
of AKI, by activating series of vasoconstrictor, salt-retaining
neurohumoral systems (these include the sympathoadrenal
system, angiotensin, aldosterone, and antidiuretic hormone).
The initial response to a contracted extracellular fluid volume
is a decrease in both the GFR and the filtered solute load.
3.3. AKI incidence and impact on outcomes after TAVI
Differently from percutaneous coronary intervention in which
AKI is mainly related to contrast-induced damage, TAVI
patients might develop kidney injury after the procedure for
several factors including contrast agent administration, con-
comitant drugs, need for rapid pacing with resulting hypoten-
sion, and renal hypoperfusion, blood loss, embolization during
the implantation due to patient’s age and frequent coexis-
tence of atherosclerosis, and postoperative severe inflamma-
tory response syndrome [35].
The incidence of AKI after TAVI is widely ranging. In the
currently available randomized trials of TAVI versus SAVR, the
AKI incidence is quite low compared to registries (Figure 4). In
the PARTNER trial, all patients with AKI were 1.1% (TAVI 4/348,
SAVR 4/351); in the PARTNER 2 trial, patients with AKI were 2.2%
(TAVI 13/1011, SAVR 31/1021); in the US CoreValve trial, patients
with AKI were 10.3% (TAVI 23/390, SAVR 54/357); in the NOTION
trial, patients with AKI were 5.7% (TAVI 1/139, SAVR 9/135); in
the STACCATO trial, AKI was not assessed, but 1 patient in the
TAVI group required permanent hemodialysis after the proce-
dure. Conversely, data from real-world registries reported that
AKI might occur also in higher than 40% of patients. A recent
meta-analysis has explored the impact of AKI on outcomes in 24
studies including 5,971 and found that the mean incidence of
AKI in this population was 22.1%±11.2 (Table 2) [35]. More
importantly, this meta-analysis contributed to clarify the prog-
nostic role of AKI after TAVI. Whereas it was clear that AKI
worsened outcomes after SAVR [36,37], there was still conflicting
and debated evidence for TAVI patients with some studies
showing no significant impact of AKI on mortality [38–41] com-
pared with other studies [42–45]. As compared with no-AKI, AKI
was found to significantly increase early and 1-year all-cause and
cardiovascular mortality as well as early myocardial infarction,
life-threatening bleeding, need for transfusion, need for dialysis
(Figure 5) with a nonsignificant increase of stroke, length of
hospitalization (mean difference [MD] 1.73; 95% CI, 20.31 to
3.77), and contrast medium received (MD 4.74; 95% CI, 22.33
to 11.81) [35]. Furthermore, meta-regression analyses showed
that the presence of coronary artery disease and a lower ejection
fraction at baseline were significantly associated with worse 1-
year all-cause mortality in accordance with prior studies [46–48].
Figure 4. Incidence of AKI in randomized trials comparing TAVI vs SAVR.
Table 2. AKI incidence in observational studies included in the meta-analysis by
Gargiulo et al. [35].
Authors Year
Age
(years)
All
patients
AKI
patients
AKI incidence
(%)
Aregger et al. 2009 83.0 58 15 25.9
Bagur et al. 2010 82.0 213 25 11.7
Barbanti et al. 2014 82.0 1157 231 20.0
Barbash et al. 2012 85.0 165 24 14.5
Elhmidi et al. 2011 81.0 234 46 19.7
Garcìa-Lara et al. 2014 80.8 131 17 13.0
Gebauer et al. 2012 82.0 140 28 20.0
Généreux et al. 2013 85.4 218 18 8.3
Goebel et al. 2013 81.6 270 41 15.2
Johansson et al. 2013 80.0 64 21 32.8
Keles et al. 2013 77.6 70 5 7.1
Khawaja et al. 2012 82.2 248 89 35.9
Kong et al. 2012 84.0 52 15 28.8
Konigstein et al. 2013 83.2 251 42 16.7
Nuis et al. 2011 82.0 118 22 18.6
Nuis et al. 2012 82.0 995 206 20.7
Pilgrim et al. 2013 82.5 389 64 16.5
Saia et al. 2013 83.7 102 42 41.2
Sinning et al. 2010 80.8 77 20 26.0
Sinning et al. 2014 80.9 132 30 22.7
Strauch et al. 2010 82.1 28 16 57.1
Van Linden et al. 2011 82.0 261 42 16.1
Wessely et al. 2012 81.1 183 49 26.8
Yamamoto et al. 2013 83.6 415 63 15.2
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Anyway, this complication and its impact should not limit
indication to TAVI procedure, indeed, even if frequent, AKI is
significantly reduced with TAVI compared with SAVR [1].
These findings support the clinical relevance of AKI and the
need for future studies to address the preoperative risk eva-
luation, strategies for AKI prevention and the postoperative
patient management of these patients to improve their out-
comes. However, future studies should also take into account
the current management of TAVI patients; indeed, the
improvement of assistance and outcomes has led to reduction
in length of hospitalization and this might be a potential issue
to be considered for the timing required for AKI diagnosis
[49–51].
3.4. AKI prevention
AKI prevention is a relevant aim for the future research
because AKI has detrimental effects on prognosis as previously
discussed, but also because we do not have yet large scientific
evidence regarding risk factors and the role of preventive
strategies in this setting of patients compared with patients
undergoing coronary angiography or intervention. As for
these latter patients, the contrast amount received is a rele-
vant risk factor for AKI [45], but we also recognized above that
the pathophysiology of AKI after TAVI is not exclusively related
to contrast administration. Therefore, the identification of spe-
cific risk factors for TAVI patients is fundamental. As under-
lined before, pre-operative CKD, particularly if more severe, is
a critical factor increasing the risk of AKI after TAVI
[16,17,42,52], but also other factors were found to indepen-
dently predict AKI including female gender, general anesthe-
sia, heart failure, transfusion (≥3 red blood cell units), major
bleeding, peripheral vascular disease, maximum leukocyte
count (within 72 h), and logistic EuroSCORE [42,45,53,54].
Many trials have explored several prevention strategies
with conflicting results for patients undergoing coronary
angiography or intervention, but few data are available for
TAVI patients. Even if hydration is fundamental for all patients,
it should be considered that in patients with impaired left
ventricular function and left side valvular heart diseases,
hydration is usually suboptimal due to the perceived risk of
overhydration and pulmonary edema. In line with this, hydra-
tion has been combined with diuretic agents in order to
increase urine output and prevent overhydration. Indeed, the
RenalGuard System is a device delivering intravenous fluids
matched to the urine output that emerged as an alternative
strategy for AKI prevention.
The recent PROphylactic effecT of furosEmide-induCed
diuresis with matched isotonic intravenous hydraTion in
Transcatheter Aortic Valve Implantation (PROTECT-TAVI) has
evaluated for the first time in a randomized trial the role of
RenalGuard System in the prevention of AKI in patients under-
going TAVI [55]. The PROTECT-TAVI was a single-center, pro-
spective, open-label, registry-based randomized study that
used the TAVI institutional registry of the Ferrarotto Hospital
in Catania, Italy, as the platform for randomization, data col-
lection, and follow-up assessment. Overall, 112 consecutive
TAVI patients were randomized to hydration with normal
saline solution controlled by the RenalGuard System and fur-
osemide (RenalGuard group = 56) or normal saline solution
(Control group = 56). The primary end point was the incidence
of AKI in the first 72 h after the procedure according to the
VARC definition [55]. Three patients (5.4%) developed AKI
stage I in the RenalGuard group while no AKI stages II–III
were observed. In the control group, AKI stage I and stage III
Figure 5. Prognostic impact of post-procedural AKI on clinical outcomes [33].
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occurred in 13 (23.2%) and 1 (1.8%), respectively. Therefore,
AKI overall was significantly lower in RenalGuard group com-
pared with control (5.4% vs. 25.0%, p = 0.014). No patient
required in-hospital dialysis due to renal failure and no sig-
nificant differences were reported at 30 days in terms of
mortality, cerebrovascular events, bleeding, and hospitaliza-
tion for heart failure [55].
A further experience on the role of RenalGuard System has
recently added to this study [56]. This prospective nonrando-
mized study included 48 patients with CKD that were assigned
to: (1) hydration with sodium bicarbonate solution (154 mEq/L
of sodium bicarbonate in dextrose and H2O plus
N-acetylcysteine at a high dose) (control group = 26), or (2)
hydration with RenalGuard System in order to achieve an
optimal urine flow of ≥300 mL/h (RenalGuard group = 22).
Criteria for treating the patients with the RenalGuard System
were: (a) eGFR ≤30 mL/min/1.73 m2, or (b) a predicted risk for
AKI ≥50%. All patients received CoreValve System by transfe-
moral approach. The primary end point was the occurrence of
AKI defined as an increase of ≥0.3 mg/dL in the serum creati-
nine concentration at 7 days. AKI occurred in 10/26 (38.5%)
patients in the control group and in 1/22 (4.5%) patients in the
RenalGuard group (p = 0.005). RenalGuard demonstrated to
protect against AKI (OR 0.71, 95% CI: 0.07–0.775, p = 0.026),
while post-procedural hypotension defined as peri-procedural
mean blood pressure <55 mmHg (OR 3.88, 95% CI: 1.06–14.24,
p = 0.040), and contrast media volume (OR 3.65, 95% CI: 1.15–
5.75, p = 0.043) were found to significantly increase the risk of
AKI [56].
4. Expert commentary
We believe that the evidence discussed here should serve as
basis to plan future research and offer the better quality in
daily assistance to patients in order to improve their quality of
life and prognosis. The advances in our current knowledge will
translate into advances in patients’ care.
TAVI patients with baseline CKD have a higher risk of
experiencing further deterioration of renal function as well as
other negative outcomes including mortality and long-term
valve deterioration during follow-up. Due to the high preva-
lence of these patients among those undergoing TAVI and to
this poor prognosis, it will be pivotal to focus clinical and
research efforts to appropriately manage these patients and
their complications.
Even if risky, TAVI is an important alternative for such
patients, particularly those with ESRD, and a close follow-up
as well accurate and specific pharmacological management is
required to optimize the risk/benefit ratio of TAVI in these
patients.
It is also important to underline that patients with severe
CKD should not be deprived a priori of the opportunity to
receive TAVI, indeed, some data show that TAVI may also be
beneficial for renal function in some patients due to improve-
ment in functional status (New York Heart Association class)
and absence of valve hemodynamic anomalies [16,57].
AKI remains one of the most frequent complications after
TAVI, and its prevention still needs to be adequately
addressed. Therapeutic efforts not to exceed the threshold
value of contrast medium administration may reduce the risk
of AKI after TAVI. Similarly, prevention of bleeding and need
for transfusion would be also important to decrease AKI inci-
dence. The trends in shortening of hospitalization length
should carefully consider the AKI definition and occurrence
in the days after the procedure. All patients developing AKI
should receive careful monitoring to prevent further compli-
cations and improve their prognosis.
5. Five-year view
TAVI has dramatically changed the clinical practice offering a
life-saving therapy for inoperable patients as well as a valid
alternative for high-risk patients [1]. Pre-procedural CKD and
post-procedural AKI are frequently observed in patients under-
going TAVI and need to be further addressed due to their
detrimental impact on prognosis, particularly because in the
near future TAVI is going to be extended worldwide to inter-
mediate- and low-risk patients in whom all efforts should be
provided in order to achieve optimal outcomes [1].
Key issues
● CKD is frequent in patients undergoing TAVI and is a rele-
vant factor increasing pre-procedural risk
● Baseline CKD predicts short- and long-term mortality, as
well as other relevant outcomes, including long-term
valve deterioration
● In addition to severe pre-procedural CKD, also moderate CKD
was found to significantly reduce survival of TAVI patients
● The presence of CKD at baseline also increases the risk of
30-day stroke, AKI, need for dialysis, and length of
hospitalization
● AKI remains a frequent complication after TAVI and has a
significant negative impact on the prognosis increasing
mortality, myocardial infarction, need for dialysis, and life-
threatening bleeding
● Furosemide-induced diuresis with matched isotonic intra-
venous hydration using the RenalGuard system is an effec-
tive therapeutic tool to reduce the occurrence of AKI in
patients undergoing TAVI
● There is the need for studies on risk stratification, preven-
tion strategies and postoperative management of trans-
catheter aortic valve implantation patients with baseline
CKD or developing AKI
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Impact of Renal Dysfunction on Results of Transcatheter
Aortic Valve Replacement Outcomes in a Large
Multicenter Cohort
Pablo Codner, MDa,b, Amos Levi, MDa,b, Giuseppe Gargiulo, MDc,d, Fabien Praz, MDd,
Kentaro Hayashida, MD, PhDe, Yusuke Watanabe, MDf, Darren Mylotte, BCh, MDg,
Nicolas Debry, MDh, Marco Barbanti, MDi, Thierry Lefèvre, MDf, Thomas Modine, MD, PhD, MBAh,
Johan Bosmans, MD, PhDj, Stephan Windecker, MDd, Israel Barbash, MDk, Jan-Malte Sinning, MDl,
Georg Nickenig, MDl, Alon Barsheshet, MDa,b, and Ran Kornowski, MDa,b,*
Patients with advanced chronic renal dysfunction were excluded from randomized trials of
transcatheter aortic valve replacement (TAVR). The potential impact of chronic renal
disease on TAVR prognosis is not fully understood. We aim to evaluate outcomes within a
large cohort of patients who underwent TAVR distinguished by renal function. Baseline
characteristics, procedural data, and clinical follow-up findings were collected from 10 high-
volume TAVR centers in Europe, Israel, and Japan. Data were analyzed according to renal
function. Patients (n[ 1,204) were divided into 4 groups according to pre-TAVR-estimated
glomerular filtration rate (eGFR): group I (eGFR >60), n [ 288 (female 45%), group II
(eGFR 31 to 60), n[ 452 (female 61%), group III (eGFR £30), n[ 398 (female 61%), and
group IV (dialysis), n [ 66 (female 31%). Mean Society of Thoracic Surgeons score was
higher in patients with lower preprocedural eGFR. All-cause mortality at 1 year was higher
in patients with lower eGFR (9.0%, 12.1%, 24.3%, and 24.2% for group I, II, III, and IV,
respectively, p <0.001). Multivariate analysis demonstrated that eGFR £30, but not eGFR
31 to 60, was associated with increased risk of death (odds ratio 3), bleeding (odds ratio 5.2),
and device implantation failure (hazard ratio 2.28). For each 10 ml/min decrease in eGFR,
there was an associated relative increase in the risk of death (35%; p <0.001), cardiovascular
death (14%; p [ 0.018), major bleeding 35% (p <0.001), and transcatheter valve failure
(16%; p[ 0.007). Renal dysfunction was not associated with stroke or need for pacemaker
implantation. In conclusion, among patients who underwent TAVR, baseline renal
dysfunction is an important independent predictor of morbidity and mortality. ! 2016
Elsevier Inc. All rights reserved. (Am J Cardiol 2016;118:1888e1896)
Transcatheter aortic valve replacement (TAVR) has been
consolidated as the treatment of choice for inoperable patients
with severe symptomatic aortic stenosis (AS) and as an
alternative for those at high surgical risk.1e4 Patients who
underwent TAVR are, thus, commonly very old and have a
high prevalence of co-morbidities.5,6 Population aging, hy-
pertension, and the diabetesmellitus pandemic account for the
increased prevalence of chronic kidney disease (CKD).7,8
Renal insufficiency modifies the natural history of cardio-
vascular diseases, and the presence of CKD has been asso-
ciated with poor prognosis in patients diagnosed with heart
failure, coronary artery or valvular heart disease, and in those
who underwent cardiac interventions.9,10 The association
between AS and renal dysfunction has been established.11,12
Furthermore, patients with renal dysfunction who under-
went surgical aortic valve replacement have higher rates of
bleeding, postsurgical infections, and highermortality rates.13
Advanced and end-stage CKD has been found to be an in-
dependent predictor for all-cause and cardiovascular mortal-
ity post-TAVR.14 However, controversy exists as to whether
milder CKD is a predictor of worse outcomes as well. This
multicenter international collaboration study sought to assess
the implications of baseline estimated glomerular filtration
rate (eGFR) and dialysis therapy on the periprocedural and 1-
year clinical outcomes from a large cohort of patients with
severe symptomatic AS who underwent TAVR.
Methods
A total of 1,204 consecutive patients with severe symp-
tomatic AS who underwent TAVR from 2006 to 2015 with
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and without CKD were enrolled from 10 centers in Europe
(Ferrarotto Hospital, Catania, Italy; Inselspital University
Hospital, Bern, Switzerland; Institute Cardiovasculaire Paris
Sud, Massy, France; Galway University Hospital, Galway
Ireland; CHRU, Lille, France; University Hospital, Ant-
werp, Belgium; Bonn University Hospital, Bonn, Germany),
Japan (Keio University Hospital, Keio), and Israel (Rabin
Medical Center, Petach Tikva and Sheba Medical Center,
Ramat Gan). Treatment assignments, device selection, and
access approach were determined by each center according
to local practice. All treated patients were evaluated by their
local heart team and found suitable for TAVR because of
high or prohibitive surgical risk. Each center submitted a
dedicated database detailing patient baseline demographic
and clinical characteristics, echocardiographic and/or mul-
tislice computed tomographic data, procedural information,
and follow-up data. Prospective data collection was per-
formed in all centers. Outcomes and events were adjudicated
according to Valvular academic research consortium 2
(VARC-2) criteria.15 Baseline creatinine values were
available for all patients. The eGFR rate was calculated
using the modified diet on renal disease formula.16 Patients
were divided into 4 groups according to their preprocedural
eGFR: >60 ml/min/1.73 m2 (normal-mild CKD, group I),
31 to 60 ml/min/1.73 m2 (moderate CKD, group II),
"30 ml/min/1.73 m2 (advanced CKD, group III), and
dialysis (group IV).17 Data for all eGFR groups were ob-
tained from 3 centers, whereas the 7 remaining centers
submitted data for patients with eGFR "30. Acute kidney
injury (AKI) after TAVR was adjudicated using the modi-
fied Risk, Injury, Failure, Loss of kidney function, and End-
stage kidney disease (RIFLE) classification criteria using the
highest post-TAVR in hospital creatinine value.18 Categor-
ical data are presented as frequencies and percentages and
continuous variables are presented as mean # SD or median
(interquartile range), according to distribution. Baseline
characteristics of study patients were compared using the
Kruskal-Wallis test, chi-square, or Fisher’s exact tests, as
appropriate. The probabilities of all-cause mortality and
cardiovascular mortality by eGFR and dialysis groups were
graphically displayed using Kaplan-Meier curves, which
were compared by the log-rank test. Univariate logistic
regression analysis was used to evaluate the association
between eGFR (assessed both as a categorical and as a
continuous variable) and mortality. The best subsets
regression procedure was used to identify significant vari-
ables to be included in the multivariable regression models.
Multivariable logistic regression analysis was used to eval-
uate the association between eGFR and dialysis groups and
mortality adjusting for the following variables: gender, de-
vice implanted, New York Heart Association functional
class, median Society of Thoracic Surgeons (STS) score,
peak gradient across the valve, and left ventricular ejection
fraction. An eGFR (continuous)-by-eGFR group interaction
term was used to estimate the mortality risk associated with
eGFR decrease in patients with eGFR <30 versus eGFR
>30 ml/min. Separate multivariable models were con-
structed using logistic regression analysis for the following
end points: major bleeding, major vascular complications,
device failure, new permanent pacemaker implantation,
and inhospital cerebrovascular accident. An additional
sensitivity analysis was performed to examine the consis-
tency of results in the 3 centers that provided eGFR data on
all patients who underwent TAVR (Rabin Medical Center,
Ferrarotto Hospital, and Sheba Medical Center). All statis-
tical tests were 2 sided, and a p value of <0.05 was
considered statistically significant. All analyses were con-
ducted using the SAS Statistical Package, version 9.4 (SAS
Institute, Inc., Cary, North Carolina).
Results
Of the 1,204 patients, 288 were included in group I
(eGFR >60 ml/min), 458 in group II (eGFR 31 to 60 ml/
min), 452 in group III (eGFR "30 ml/min), and 66 in group
IV (dialysis). Baseline characteristics of the study popula-
tion according to CKD severity are listed in Table 1. Mean
age increased with decreasing eGFR in patients who did not
undergo dialysis, whereas patients in the dialysis group were
the youngest (p <0.001). Mean STS score increased with
decreasing eGFR (p <0.001). Baseline echocardiography
demonstrated lower ejection fraction, lower mean, and peak
transvalvular gradients and larger aortic valve area in pa-
tients with lower baseline eGFR. Procedural characteristics
are described in Table 2.
At 12 months of follow-up, Kaplan-Meier survival ana-
lyses demonstrated a direct relation between poor renal
function and all-cause mortality and cardiovascular mortal-
ity (Figure 1, p <0.001). Rates of all-cause mortality, car-
diovascular mortality, major bleeding events, and vascular
complications at 1-year follow-up were higher for patients
with lower preprocedural eGFR, with 1-year all-cause death
reaching almost a quarter of the patients in groups III and IV
(Figure 2). Clinical status pre- and post-TAVR was assessed
using the New York Heart Association functional class
classification (Figure 3). The echocardiographic transaortic
valve gradients at follow-up are presented in Figure 4.
The results of the multivariable analyses evaluating the
predictors of adverse events are listed in Table 3. In com-
parison with group I (eGFR >60 ml/min), group III (eGFR
"30) was associated with a threefold increase (odds ratio
[OR] 3.01, 95% confidence interval [CI] 1.72 to 5.26;
p<0.001) of 1-year all-cause mortality, a twofold increase of
1-year cardiovascular mortality (OR 2.22, 95% CI 1.95 to
4.14; p¼ 0.12), a fivefold increase (OR 5.19, 95% CI 2.43 to
11.1; p<0.001) of inhospital major/life-threatening bleeding,
and more than twofold increase in unsuccessful valve im-
plantation (OR 2.28, 95% CI 1.22 to 4.25; p ¼ 0.01). Strik-
ingly, dialysiswas associatedwith eightfold increase (OR7.9,
95% CI 2.76 to 22.59; p <0.001) in 30-day major/life-
threatening bleeding. When analyzing eGFR as a contin-
uous variable, multivariable analysis demonstrated that every
10 ml/min decrease in eGFRwas associated with a respective
19% (p<0.001), 14% (p¼ 0.018), 35% (p<0.001), and 16%
(p¼ 0.007) increase in the risk of death, cardiovascular death,
major bleeding, and valve failure, respectively. It should be
noted that the association between low eGFR and increased
mortality risk was mainly driven by eGFR <30. Conse-
quently, in patients with an eGFR <30 every 10 ml/min
decrease in eGFRwas associatedwith a twofold increase in 1-
year mortality (OR 2.24, 95% CI 1.22 to 4.12; p ¼ 0.010),
whereas in patients with eGFR%30 every 10ml/min decrease
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in eGFR was not associated with a significant increase in 1-
year mortality. The p value for interaction (GFR decrease
by GFR group) was 0.022. Renal dysfunction was not asso-
ciated with an increased risk of stroke or requirement for new
pacemaker implantation. A sensitivity analysis including only
patients enrolled in the centers that provided eGFR data for all
patients who underwent TAVR showed consistent results in
which every 10ml/min decrease in eGFRwas associated with
Table 2
Procedural characteristics
N Dialysis
(n ¼ 66)
GFR "30 ml/min/1.72 m2
(n ¼ 398)
GFR 31-60 ml/min/1.72 m2
(n ¼ 452)
GFR >60 ml/min/1.72 m2
(n ¼ 288)
p-Value
Device type
Corevalve 790 39 (59%) 236 (60%) 317 (71%) 198 (69%) 0.073
Edward XT 376 24 (36%) 144 (36%) 126 (28%) 82 (28%)
Edwards Sapien 3 12 2 (3%) 7 (2%) 1 (0.2%) 2 (0.7%)
Lotus Valve 11 0 3 (1%) 4 (0.9%) 4 (1%)
Corevalve Evolut R 4 0 0 2 (0.4%) 2 (0.7%)
Other 11 1 8 (2%) 2 (0.4%) 0
Access
Transfemoral 1092 53 (80%) 367 (92%) 417 (93%) 255 (89%) 0.002
Trans-apical 70 9 (14%) 25 (6%) 18 (4%) 18 (6%)
Trans-axillary 36 3 (5%) 8 (2%) 13 (3%) 12 (4%)
Other 6 1 (1%) 0 3 (0.7%) 2 (0.7 %)
Hospitalization length (in days)
1204 7 (IQR 5.5 e 11) 7 (IQR 5-9) 5 (IQR 4-7) 5 (IQR 4-6) <0.001
Variables are expressed as n (%) or median (Interquartile).
GFR ¼ glomerular filtration rate.
Table 1
Baseline and echocardiographic characteristics of the study population
Dialysis
(n ¼ 66)
GFR
"30 ml/min/1.72 m2
(n ¼ 398)
GFR
31-60 ml/min/1.72 m2 (n ¼ 452)
GFR >60 ml/min/1.72 m2
(n ¼ 288)
p-Value
Age (years) 76.1 #7.5 83.8 #5.1 82.3 #4.9 78.5 #7.5 <0.001
Men 70% 39% 39% 55% <0.001
Smoker 17% 19% 15% 16% 0.541
Chronic obstructive
lung disease
15% 25% 28% 26% 0.153
Diabetes Mellitus 38% 29% 31% 35% 0.163
Hypertension 85% 86% 97% 93% <0.001
Previous myocardial
infarction
20% 15% 14% 13% 0.451
Previous coronary artery
bypass graft surgery
23% 14% 15% 22% 0.01
Atrial fibrillation 28% 24% 9% 9% <0.001
“Porcelain” aorta 15% 7% 6% 6% 0.117
Baseline Pacemaker 17% 13% 8% 10% 0.035
Pre/Periprocedural
Coronary Angiography
79% 85% 98% 98% <0.001
Transesophageal
Echocardiogram
83% 74% 89% 90% <0.001
Gated Cardiac Computed
tomography
56% 38% 34% 39% 0.007
Society of thoracic
surgeons score
10.1 (7.7-16) 8.8 (6.0-12.6) 6 (4.3-9) 5.4 (3.7-7.1) <0.001
Hemoglobin (gr/dl) 11 (10.1- 12.1) 11.3 (10.1-12.3) 11.7 (10.5-12.7) 12.2 (11-13.5) <0.001
Echocardiographic variables
Left ventricular ejection
fraction (%)
49.2#13.6 51.2#13.8 51.7#10.6 53.7#10.6 0.013
Peak gradient (mmHg) 72.2#26.1 77.7#26.2 82.5#23.6 78.3#23.2 <0.001
Mean gradient (mmHg) 42.0#15.5 47.2#17.6 51.4#16.1 48.8#15.3 <0.001
Aortic valve area (cm2) 0.7 (0.6-0.8) 0.6 (0.5-0.7) 0.6 (0.5-0.7) 0.6 (0.5-0.8) <0.001
Variables are expressed as n (%), mean # standard deviation or median (interquartile).
GFR ¼ Glomerular filtration rate.
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a 13% increase in 1-year mortality (OR 1.13, 95% CI 1.02 to
2.26; p ¼ 0.019).
AKI and need for dialysis after TAVR are presented in
Table 4. AKI occurred in 378 patients (33%) after TAVR
and was classified as stage 1 in 305 patients (26.8%), stage 2
in 33 patients (2.9%), and stage 3 in 40 patients (3.5%).
Although 1 patient with baseline advanced CKD deterio-
rated to end-stage renal disease requiring permanent dialysis
therapy, 28 patients (2.5%) required a single dialysis and 7
patients (0.6%) required temporary dialysis. The occurrence
of AKI and the need for dialysis were significantly related to
lower baseline eGFR (p <0.001 for both). The association
between AKI and all-cause mortality at 1-year follow-up is
presented in Table 5.
Discussion
In this large multicenter analysis of patients who under-
went TAVR for the treatment of severe symptomatic AS,
renal dysfunctionwas associated with poor clinical outcomes.
Figure 1. Kaplan-Meier curve for all cause death (A) and cardiovascular death (B) with respect to the eGFR group.
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All-cause and cardiovascular mortality rates during the
follow-up period increased with decreasing renal function.
Importantly, a eGFR "30 ml/min was identified as an inde-
pendent predictor for all-cause and cardiovascular mortality.
There is a broad agreement that TAVR outcomes are
negatively influenced by advanced and end-stage renal
dysfunction (stage 4/5 CKD).19 However, the effect of
moderate renal dysfunction (stage 3 CKD) on TAVR
Figure 2. Outcomes with respect to the eGFR group.
Figure 3. The distribution of baseline and 1-year New York Heart Association functional class with respect to the eGFR group.
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outcomes is still debatable. Although several trials showed
that stage 3 CKD was not predictive of all-cause and car-
diovascular mortality after TAVR,20 other data are contra-
dictory.21,22 In the present study, moderate renal
dysfunction was not an independent predictor for adverse
events in the current trial. Moreover, when analyzed as a
continuous variable, eGFR decrease was associated with an
increase in 1-year mortality in patients with eGFR <30 but
not in those with eGFR %30. The precise reasons for
increased morbidity and mortality after TAVR in patients
with renal dysfunction are unclear but are likely to be
multifactorial and complex and related to higher baseline
risk profile. Median STS score increased with decreasing
eGFR, reflecting the impact of renal function on STS score
calculation. Patients with an STS score >10% for periop-
erative mortality are considered very high-risk surgical
candidates in most TAVR trials and registries.1,4e6 In our
experience, only the group of patients on dialysis fits this
definition (median STS score of 10.1 [7.7 to 16]), whereas
patients with advanced moderate and mild CKD were at
high to intermediate risk (8.8 [6.0 to 12.6, 6 [4.3 to 9], and
5.4 [3.7 to 7.1], respectively). This finding is consistent with
contemporary TAVR practice, where most treated patients
belong to the category of moderate risk.23,24
Atrial fibrillation was pointed out as a strong predictor of
mortality in patients with advanced kidney disease who
underwent TAVR.25,26 In the present study, patients with
advanced and end-stage renal disease had a higher
prevalence of atrial fibrillation possibly contributing to the
increased mortality and morbidity in this group.
Renal dysfunction also carries a higher risk of bleeding.
Bleeding diathesis in patients with CKD is because of
impaired platelet activation and aggregation, anemia,
frequent need for antiplatelet drugs, anticoagulants, and
invasive procedures.27 Major bleeding was fivefold and
eightfold more common in patients with advanced and end-
stage renal disease, respectively, in comparison with those
with a GFR >60. Moreover, the increased risk for vascular
complications with eGFR decrease poses these patients at an
exceedingly higher risk for extended hospital stay,
morbidity, and overall mortality.
Finally, patients with decreased renal function are at an
increased risk for AKI and CKD after TAVR.28,29 Contrast
media administration, sudden hemodynamic changes during
the procedure (rapid pacing, balloon valvuloplasty, valve
deployment, and postdilation), and manipulation of large
catheters in the aorta are all considered contributing factors.
AKI has an important prognostic significance after TAVR as it
is associatedwith higher rates ofmortality,major bleeding, and
vascular complications after TAVR.30 In our experience, pa-
tients with moderate and advanced CKD showed higher rates
of moderate and severe post-TAVR AKI according to the RI-
FLE classification and greater requirements for temporary and
permanent renal replacement therapy, respectively.
Our data have several limitations. First, this is a registry-
based study with the inherent limitations of an observational
Figure 4. Mean transaortic valve gradient (mm Hg) at baseline, discharge, and at 1-year follow-up with respect to the eGFR group.
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study design. Indications to proceed to a TAVR procedure
rather than surgical aortic valve replacement or conservative
treatment were established by each local institutional heart
team. Outcomes and adverse events were adjudicated
individually by each center without external validation from
a core laboratory. There was a small number of patients
in the dialysis group, which may have accounted for the
lack of statistical significance for all-cause mortality and
Table 3
Multivariate logistic regression analysis
Outcome Odds Ratio 95% Confidence Interval p Value
All cause death
eGFR 31-60 1.66 0.95 e 2.9 0.075
eGFR " 30 3.01 1.72 e 5.26 <0.001
Dialysis 2.25 0.93 e 5.44 0.072
eGFR Continuous per 10 ml/min/1.72m2 decline 1.35 1.18 e 1.54 <0.001
Cardiovascular Death
eGFR 31-60 1.12 0.59 e 2.11 0.734
eGFR " 30 2.22 1.95 e 4.13 0.012
Dialysis 1.01 0.31 e 3.31 0.980
eGFR Continuous per 10 ml/min/1.72m2 decline 1.14 1.02 -1.27 0.018
Bleeding
eGFR 31-60 1.66 0.75 e 3.7 0.21
eGFR " 30 5.19 2.43 e 11.1 <0.001
Dialysis 7.9 2.76 e 22.59 <0.001
eGFR Continuous per 10 ml/min/1.72m2 decline 1.35 1.18 e 1.54 <0.001
Major Vascular complications
eGFR 31-60 1.15 0.51 e 2.58 0.750
eGFR " 30 2.14 0.95 e 4.82 0.065
Dialysis 0.76 0.091 e 6.36 0.802
eGFR Continuous per 10 ml/min/1.72m2 decline 1.18 1.02 e 1.37 0.026
Device failure
eGFR 31-60 1.29 0.74-2.25 0.368
eGFR " 30 2.28 1.22e 4.25 0.010
Dialysis 2.49 0.90 e 9.96 0.080
eGFR Continuous per 10 ml/min/1.72m2 decline 1.16 1.04 e 1.29 0.007
Pacemaker implantation
eGFR 31-60 1.05 0.65 e 1.70 0.856
eGFR " 30 1.47 0.86e 2.52 0.156
Dialysis 1.72 0.59 e 5.03 0.320
eGFR Continuous per 10 ml/min/1.72m2 decline 1.07 0.97 e 1.1 0.088
In hospital CVA
eGFR 31-60 1.12 0.50 e 2.54 0.783
eGFR " 30 1.09 0.45 e 2.65 0.839
Dialysis NA NA NA
eGFR Continuous per 10 ml/min/1.72m2 decline 1.08 0.94e 1.24 0.272
CVA ¼ cerebrovascular accident; eGFR ¼estimated glomerular filtration rate in ml/min/1.72 m2.
Table 4
Acute kidney injury according to the RIFLE criteria and the need for renal replacement therapy after transcatheter aortic valve replacement in respect to
glomerular filtration rate groups (for all patients not on dialysis at baseline)
RIFLE Acute Kidney Injury Class Baseline Estimated Glomerular Filtration Rate (ml/min/1.72m2) p-Value
"30 (n ¼ 398) 31 -60 (n ¼ 452) >60 (n ¼ 288)
0 255 (64%) 326 (72%) 178 (62%) <0.001
1 105 (26%) 113 (25%) 87 (30%)
2 13 (3.3%) 11 (2%) 9 (3%)
3 24 (6%) 2 (0.4%) 14 (5%)
4 1 (0.2%) 0 0
Renal replacement therapy
Not needed 373 (94%) 449 (99%) 280 (97%) <0.001
Preformed once 18 (4%) 3 (0.6%) 7 (2%)
Preformed temporarily 6 (1%) 0 1 (0.3%)
Permanent 1 (0.2%) 0 0 (0%)
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cardiovascular mortality in this group. Finally, the data for
patients with eGFR >30 were only collected only from 3
centers. The current cohort should, therefore, not be inter-
preted as representative of the entire TAVR population but
rather as a platform for comparison between patients in
different CKD groups. A sensitivity analysis including only
patients enrolled in the centers that provided eGFR data for
all patients was preformed to mitigate concerns of a possible
selection bias, yielding consistent results.
In conclusion, among patients who underwent TAVR,
advanced CKD and dialysis are associated with increased
rates of all-cause and cardiovascular mortality, major and
life-threatening bleeding, and vascular complications. CKD
should, therefore, be considered as an important factor
during preprocedural risk stratification.
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Predictors of 1-Year Mortality After Transcatheter
Aortic Valve Implantation in Patients With and
Without Advanced Chronic Kidney Disease
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Advanced chronic kidney disease (CKD) is an independent predictor of mortality in pa-
tients undergoing transcatheter aortic valve implantation (TAVI). We aimed to identify
predictors of 1-year mortality in patients after TAVI stratified by the presence or absence
of advanced CKD (defined as estimated glomerular filtration rate ≤30 ml/min/1.73 m2 or
permanent renal replacement therapy). Patients (n = 1204) from 10 centers in Europe, Japan,
and Israel were included: 464 with and 740 without advanced CKD. Advanced CKD was
associated with a 2-fold increase in the adjusted risk of 1-year all-cause death (p <0.001),
and a 1.9-fold increase in cardiovascular death (p = 0.016). Interaction-term analysis was
used to identify and compare independent predictors of 1-year mortality in both groups.
Impaired left ventricular ejection fraction and poor functional class were predictive of death
in the advanced CKD group (odds ratio [OR] 2.27, p = 0.002 and OR 3.87, p = 0.003, re-
spectively) but not in patients without advanced CKD (p for interaction = 0.035 and 0.039,
respectively), whereas bleeding was a predictor of mortality in the nonadvanced CKD group
(OR 3.2, p = 0.005) but not in advanced CKD (p for interaction = 0.006). Atrial fibrillation
was associated with a 2.2-fold increase (p = 0.032) in the risk of cardiovascular death in
the advanced CKD group but not in the absence of advanced CKD (p for interac-
tion = 0.022). In conclusion, the coexistence of advanced CKD and either reduced left
ventricular ejection fraction or poor functional class has an incremental effect on the risk
of death after TAVI. In contrast, bleeding had a greater effect on risk of death in
patients without advanced CKD. © 2017 Elsevier Inc. All rights reserved. (Am J Cardiol
2017;120:2025–2030)
Transcatheter aortic valve implantation (TAVI) has emerged
as the treatment of choice for patients with severe symptom-
atic aortic stenosis (AS) at prohibitive risk for surgical aortic
valve replacement and is an established alternative to surgery
for patients at high and intermediate risk.1–4 Chronic kidney
disease (CKD) frequently accompanies severe AS and is known
to have a negative prognostic effect on the course of valvular
heart disease and on the outcomes of cardiovascular
interventions.5,6 In a study recently published by our group,
we analyzed the outcomes of 1,204 patients with TAVI
distinguished by renal function. In our experience, ad-
vanced CKD (defined as estimated glomerular filtration rate
[eGFR] ≤ 30 ml/min/1.73 m2 or permanent renal replace-
ment therapy), emerged as a potent independent predictor of
peri- and postprocedural morbidity and mortality.7 However,
little is known about the comparative performance of pre-
dictors of death after TAVI in patients with advanced CKD
and patients without advanced CKD. We therefore aimed to
estimate the interaction between advanced CKD and known
risk factors of death 1 year after TAVI.
Methods
Most of our methods have been previously described in
detail.7 Briefly, 1,204 patients with severe symptomatic AS
undergoing TAVI in 10 high-volume centers in Europe,
Japan, and Israel were included. Three centers provided
data of all consecutive patients with TAVI, whereas the re-
maining 7 centers submitted data of patients with
eGRF ≤ 30 ml/min/1.73 m2. Our dedicated database in-
cluded patients’ demographic, clinical, and preprocedural
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characteristics. eGFR was calculated for each patient using
the modified diet on renal disease formula.8 Based on pre-
vious studies that identified CKD stages 4 and 5 as a potent
independent predictor of adverse outcomes, patients were dis-
tinguished by the presence or absence of advanced CKD,
defined as eGFR ≤30 ml/min/1.73 m2 or permanent renal re-
placement therapy.7,9 Outcomes were adjudicated according
to the Valvular Academic Research Consortium 2 criteria
definitions,10 and reported for 1-year follow-up period. Cat-
egorical data are presented as frequencies and percentages,
and continuous variables are presented as mean ± standard
deviation or median (interquartile range), according to dis-
tribution. Baseline characteristics of the study patients were
compared using the Student t, Mann-Whitney U, chi-square,
or Fisher’s exact tests, as appropriate.
The following method was applied to examine and compare
predictors of 1-year mortality and cardiovascular mortality
in patients with and without advanced CKD. First, potential
variables were selected based on clinical and statistical sig-
nificance and evaluated by univariate analysis. The cumulative
probability of death in the CKD groups distinguished by bleed-
ing (major or life-threatening), Society of Thoracic Surgeons
(STS) score, atrial fibrillation, age, left ventricular ejection
fraction (LVEF), and New York Heart Association (NYHA)
FC were graphically displayed using Kaplan-Meier (KM)
curves and compared by the log-rank test. Categorical cutoff
values for STS score, Hb, and age were chosen to be 7%, 12
md/dl, and 82 years, respectively, based on median values of
these variables in our dataset.
To compare predictors of 1-year all-cause and cardiovas-
cular mortality in the 2 groups, a multivariable logistic
regression model was constructed for each dichotomous risk
factor adjusting for gender, age (≥82 vs <82), NYHA func-
tional class (I or II vs III/ or IV), previous myocardial
infarction, STS score (≤7 vs >7), peak Doppler wave veloc-
ity across the stenotic valve (≤4 m/s vs >4 m/s), LVEF (<50%
vs ≥50%), bleeding (severe or life-threatening), chronic ob-
structive pulmonary disease, and atrial fibrillation with the
addition of a “risk factor”-by-“renal function group” inter-
action term. A significant interaction implies that the adjusted
odds ratio (OR) for high risk versus low risk (e.g., LVEF <50%
vs ≥50%) in the advanced CKD group is significantly dif-
ferent from the adjusted OR of high risk versus low risk in
the patients without advanced CKD.
Data collection was approved in each of the 10 centers in-
dividually by the institutional human research committee. All
statistical tests were 2-sided, a p value of <0.05 was consid-
ered statistically significant. All analyses were conducted using
the SAS statistical package version 9.4 (SAS Institute, Inc.,
Cary, NC).
Results
Baseline demographic and clinical characteristics are pre-
sented in Table 1. Patients with advanced CKD were older,
had higher rates of peripheral vascular disease, higher STS
score, and lower gradients across the aortic valve compared
with their counterparts without advanced CKD (p <0.001 for
all). Procedural characteristics and short-term clinical out-
comes are presented in the supplementary material. Although
no significant difference in 30-day all-cause death, 30-day
cardiovascular death, or in-hospital stroke rate was ob-
served between the groups, bleeding and vascular
complications occurred more often in patients with ad-
vanced CKD (22.2% vs 10.2% p <0.001, and 17.3% vs 15.9%
p = 0.03, respectively).
Compared with patients without advanced CKD, pa-
tients with advanced CKD had a higher 1-year mortality and
cardiovascular mortality (24% vs 11% and 15% vs 8%, re-
spectively; Figure 1, log-rank p <0.001). After adjusting for
multiple risk factors, patients with advanced CKD exhib-
ited a 2-fold increase in the risk of 1-year all-cause mortality
(p = 0.001), and 1.9-fold (p = 0.016) increase in the risk of
cardiovascular mortality, compared with their counterparts
without advanced CKD.
One-year KM estimates of death in patients with and
without advanced CKD in selected subgroups are presented
in the supplementary material, and the KM plots for bleed-
ing, LVEF, and FC are presented in Figure 2. Severe or life-
threatening bleeding was associated with comparable death
rate to no or mild bleeding in patients with advanced CKD
(24% vs 23%, respectively, p = 0.68), but with a consider-
ably higher death rate (22% vs 10%, respectively, p = 0.001)
in patients without advanced CKD. Although patients with
LVEF <50%, STS score ≥7%, and NYHA FC III or IV had
Table 1
Baseline demographic, clinical, and echocardiographic characteristics
Advanced Kidney Disease
Variable Yes
(n = 464)
No
(n = 740)
p-value
Age (years) 82.8 ± 6.1 80.8 ± 6.4 <0.001
Men 56.9% 54.5% 0.42
Smoker 14.7% 15.6% 0.18
Chronic lung disease 23.8% 27.3% 0.16
Diabetes mellitus 29.4% 32.8% 0.31
Dyslipidemia 58.8% 69.6% <0.001
Hypertension 86.1% 95.4% <0.001
Body mass index (Kg/m2) 24.8 ± 4.1 27.4 ± 4.8 <0.001
Previous myocardial infarction 16.0% 13.4% 0.21
Previous coronary bypass surgery 15.3% 17.9% 0.334
Previous stroke 12.3% 14.6% 0.26
Peripheral vascular disease 20.9% 10.7% <0.001
Atrial fibrillation 13.3% 25.3% 0.01
“Porcelain” aorta 7.1% 6.1% 0.23
Baseline Pacemaker 13.4% 8.6% 0.013
Society of thoracic surgeons score 11 ± 7.6 7.2 ± 5.2 <0.001
New York heart association FC III-IV 80.4% 84.1% 0.11
Log Euro Score 26.7 ± 16.8 18.3 ± 12.7 <0.001
Hemoglobin (gr/dL) 11.2 ± 1.6 11.8 ± 1.7 0.04
Preprocedural assessment
Coronary angiography 93.5% 98.9% <0.001
Gated cardiac computerized
tomography
40.8% 36.4% 0.14
Echocardiographic variables
Left ventricular ejection
fraction (%)
50.9 ± 13.7 52.5 ± 10.7 0.03
Peak gradient (mmHg) 77 ± 26.1 80.9 ± 23.5 0.009
Mean gradient (mmHg) 46.5 ± 17.2 50.4 ± 15.9 <0.001
Aortic valve area (cm2) 0.64 ± 0.19 0.64 ± 0.18 0.65
Variables are expressed as n (%), mean ± standard deviation, or median
(interquartile).
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an increased rate of 1-year demise compared with their lower
risk counterparts in the advanced CKD group (p <0.05 for
all), there was no such association in patients without CKD.
Independent predictors of 1-year all-cause mortality dis-
tinguished by CKD groups and interaction analysis are
presented in Table 2. Severe or life-threatening bleeding during
hospitalization was predictive of a 3-fold (95% CI 1.42 to 7.34,
p = 0.005) and 0.78-fold (95% CI 0.36 to 1.67, p = 0.53) in-
crease in the OR of death in the nonadvanced and advanced
CKD groups, respectively (p for interaction = 0.014). Im-
paired baseline LVEF was predictive of 2.27-fold (95% CI
1.23 to 4.19, p = 0.002) and 1.05-fold (95% CI 0.61 to 1.80,
p = 0.614) increase in the OR of death in the advanced and
nonadvanced CKD groups respectively (p for interac-
tion = 0.035). The OR for death in the poor versus mildly
impaired FC was 3.87 (95% CI 1.52 to 9.83, p = 0.004) and
1.10 (95% CI 0.51 to 2.38, p = 0.316) in the advanced and
nonadvanced CKD groups, respectively (p for interac-
tion = 0.039). Predictors of 1-year cardiovascular mortality
(presented in the supplementary material) demonstrated a
similar trend as in all-cause mortality and included bleed-
ing in the nonadvanced CKD group (OR 3.85, 95% CI 1.44
to 9.19, p = 0.004) and poor FC (OR 3.06, 95% CI 1.14 to
10.8, p = 0.045) coupled by impaired LVEF (OR 2.02, 95%
CI 1 to 4.1, p = 0.05) in the advanced CKD group. Addition-
ally, preexisting atrial fibrillation emerged as an independent
predictor of cardiovascular death in the advanced CKD group
(OR 2.21, 95% CI 1.05 to 4.54, p = 0.032), but not in the
nonadvanced CKD group (p for interaction = 0.022).
Discussion
In the current analysis, we compared predictors of 1-year
mortality in patients after TAVI distinguished by the pres-
ence or absence of advanced CKD. Our major findings are
as follows: (1) the presence of advanced CKD was indepen-
dently associated with 2-fold increase in the risk of 1-year
death compared with the absence of advanced CKD; (2) poor
FC and impaired LVEF were independently associated with
an increased risk of death in the presence of advanced CKD
but not in its absence; (3) the presence of preexisting atrial
fibrillation was predictive of increased risk of cardiovascu-
lar death in the advanced CKD group; and (4) periprocedural
severe or life-threatening bleeding was more common in pa-
tients with advanced CKD, but had a greater negative effect
on survival in the absence of advanced CKD.
Even though previous trials have identified impaired
LVEF,11,12 poor FC,13 atrial fibrillation,14 and advanced
CKD7,9,13,15–17 as independent predictors of death after TAVI,
Figure 1. Kaplan-Meier curves depicting the cumulative probability of 1-year
all-cause death (A) and cardiovascular death (B) in the advanced chronic kidney
disease (CKD) group versus the nonadvanced CKD group.
Table 2
Predictors of 1-year mortality (multivariate analyses)
Risk subsets Adjusted odds ratio
(95% CI)
p for interaction
Bleeding yes vs. no
Advanced kidney disease 0.78 (0.36–1.67) 0.014
Non-advanced kidney disease 3.2 (1.42–7.34)
Age ≥82 vs. <82 years
Advanced kidney disease 0.52 (0.28–0.95) 0.128
Non-advanced kidney disease 0.97 (0.56–1.66)
Female vs. male gender
Advanced kidney disease 0.69 (0.37–1.25) 0.686
Non-advanced kidney disease 0.58 (0.33–1.01)
LV ejection fraction <50% vs. ≥50%
Advanced kidney disease 2.27 (1.23–4.19) 0.035
Non-advanced kidney disease 1.05 (0.61–1.80)
Functional class III/IV vs. I/II
Advanced kidney disease 3.87 (1.52–9.83) 0.039
Non-advanced kidney disease 1.10 (0.51–2.38)
Chronic lung disease yes vs. no
Advanced kidney disease 1.06 (0.55–1.97) 0.894
Non-advanced kidney disease 1 (0.5–1.75)
Atrial fibrillation yes vs. no
Advanced kidney disease 1.32 (0.76–2.53) 0.067
Non-advanced kidney disease 0.44 (0.15–1.1)
STS score ≥7% vs. < 7%
Advanced kidney disease 2.09 (1.07–4.07) 0.437
Non-advanced kidney disease 1.48 (0.75–2.90)
Hemoglobin <12 vs. ≥12 g/dL
Advanced kidney disease 1.07 (0.54–2.11) 0.493
Non-advanced kidney disease 1.46 (0.83–2.56)
Peak velocity ≥ m/s vs. < 4 m/s
Advanced kidney disease 0.58 (0.30–1.11) 0.479
Non-advanced kidney disease 0.79 (0.45–1.36)
Post-procedural pacemaker
Advanced kidney disease 0.53 (0.22–1.26) 0.150
Non-advanced kidney disease 1.19 (0.59–2.39)
Odds ratio (95% confidence interval) for every risk subset was calcu-
lated after adjustment to multiple clinical, laboratory, and echocardiographic
variables (see Methods section).
CI = confidence interval; LV = left ventricular; STS = Society of Tho-
racic Surgeons.
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Figure 2. Kaplan-Meier curves depicting the cumulative probability of 1-year all-cause death in the advanced chronic kidney disease (CKD) group (left column),
and in the nonadvanced CKD group (right column) of patients with high versus low left ventricular ejection fraction (LVEF ≥50% and <50%, A1 and A2),
major periprocedural bleeding versus no bleeding (B1 and B2), and at functional class I or II versus III or IV (C1 and C2).
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data regarding the predictors of mortality in patients with TAVI
distinguished by renal function is lacking. In our experi-
ence, poor FC was predictive of 3.87-fold increase and
impaired LVEF of 2.27-fold increase in 1-year mortality in
patients with advanced CKD, but not in patients without ad-
vanced CKD. KM curves for poor versus normal or mildly
decreased FC in the advanced CKD group separated early and
continued to diverge during the first year after TAVI, sug-
gesting that differences between the groups were related both
to periprocedural and late death. Indeed, patients with ad-
vanced CKD and poor FC represent a high-risk subgroup and
are prone to periprocedural complications including mechani-
cal ventilation, longer hospitalization intervals, higher rates
of acute kidney injury and dialysis, and nosocomial infec-
tions, and are therefore at higher risk of periprocedural death.
Additional research is required to further characterize this sub-
group and to ascertain whether intervention is warranted earlier
in the clinical course of patients with severe AS with con-
comitant advanced CKD.
Our observation of increased mortality in patients with base-
line CKD and impaired LVEF reinforces the well-established
correlation between impaired renal function and risk of death
and cardiac decompensation in patients with heart failure.18
Previous studies have shown that patients with severe LV dys-
function enjoy significant improvement in LVEF after TAVI
both in the immediate postprocedural period because of acute
decrease of afterload,19 and in the intermediate and late period,
mediated by regression of LV hypertrophy,20,21 causing an im-
provement in FC22 and possibly prolonging survival.23 However,
patients with advanced CKD are at risk of ventricular dys-
function and dilatation,24 and may not gain a similar
improvement in LVEF, functional capacity, and survival.
Severe or life-threatening bleeding events were more fre-
quent in the advanced CKD group (15.1% vs 6.8%, p <0.001),
but were a stronger predictor of mortality in the patients
without advanced CKD. Several explanations may apply: (1)
bleeding was more common in patients with advanced CKD,
but more often classified life-threatening in the nonadvanced
CKD group (38% vs 50% respectively), probably reflecting
bleeding diathesis and higher rate of “trivial” nonproc-
edural bleeding (i.e., gastrointestinal bleeding, genitourinary
bleeding, or no obvious source) in contrast to higher rate of
catastrophic procedural-related bleeding, associated with
greater morbidity, when occurring in patients without ad-
vanced CKD; (2) because patients with advanced CKD were
at an increased risk of death compared with patients without
advanced CKD even in absence of bleeding (1-year unad-
justed death risk 24% vs 10%), the addition of a fixed absolute
risk inflicted by bleeding would translate to a lower relative
risk increase than in patients without advanced CKD; (3) as
per the Valvular Academic Research Consortium 2 defini-
tion, Hg drop of ≥3 gr/dl and the administration of >1 units
of packed blood cells define major bleeding or life-threatening
bleeding. Patients with advanced CKD were more often anemic
(mean baseline hemoglobin 11.8 vs 11.2 gr/dl, p = 0.04), and
at greater risk of receiving >1 blood transfusions (8.4% vs
2.9%, p <0.001), thus at higher risk of complying with the
definition of major or life-threatening bleeding even if ef-
fectively having a minor bleeding.
In our experience, the presence of a preexisting atrial fi-
brillation doubled the risk of cardiovascular death after TAVI
in patients with advanced CKD but did not affect risk in pa-
tients without advanced CKD. This observation is in line with
a previous trial reporting the predictors of death in a small
cohort of patients with advanced CKD,15 but in disagree-
ment with a previous publication from the France 2 registry
reporting an increased risk of death in patients with preex-
isting atrial fibrillation regardless of kidney function.25
Our study has several limitations. First, it was a multi-
center international collaboration, based on institutional
registries without a central core laboratory or data valida-
tion system. Data of patients with eGFR >30 ml/min were
available only from 3 centers. However, a sensitivity analy-
sis that included only patients enrolled in the centers that
provided data for all unselected patients with TAVI showed
consistent results with regard to mortality and cardiovascu-
lar mortality by eGFR.7 Second, data on paravalvular leak were
not available. Finally, this was a subgroup analysis study, with
its well-known inherent limitations. Nevertheless, the impor-
tance of the current study lies in the preliminarity of our
findings and our big multicenter cohort of large-volume centers.
In conclusion, patients with and without severe CKD have
different predictors of mortality, which call for different con-
siderations in the patient selection and management. Although
poor FC, impaired LVEF, and atrial fibrillation were stron-
ger predictors of mortality in patients with advanced CKD,
major or life-threatening bleeding was a harbinger of death
regardless of renal function.
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Summary and Conclusions 
- In medio stat virtus (“virtue stands in the middle”), scholastic philosophers of the Middle ages 
- “Virtue is the balance point between a deficiency in a trait and an excess of a trait; virtue must vary 
and reflect the intermediate and best condition at the right times, about the right things, towards the 
right people, for the right end, and in the right way”, Aristotle’s Nicomachean Ethics  
- Est modus in rebus (“there is an optimal condition in all things: everything in proportion”), Horace’s 
Satires 
- Medio tutissimus ibis (“you will go most safely by the middle course”), Ovid’s Metamorphoses 
 
In the last years there was a radical change in the perception of the ischemia/bleeding balance in patients 
undergoing PCI, which was reflected in both guidelines and the community. Although more potent and 
prolonged treatments to reduce ischemic recurrences have been traditionally the main focus of clinical research, 
recent data pointed the attention towards the risk of increasing bleeding events, which in turn even negatively 
affect patient prognosis. In patients managed with antithrombotics after an ACS, the impact of major bleeding 
as compared to recurrent myocardial infarction appeared similar or even greater in particular cases. This data 
reinforces the concept that clinicians should prevent both ischemia and bleeding and should perform a careful 
assessment of the ischemia/bleeding risk when deciding the treatment management of a single patient.  
 
Many pharmacological and mechanical strategies have been proposed to reduce bleeding and ischemia during 
PCI as well as early and late after the procedure.  
During PCI, unfractionated heparin (UFH) has the main advantages of being cheap and antagonizable by means 
of intravenous protamine sulfate, thus it remains the most widely used anticoagulant agent during PCI. 
However, UFH has a poorly predictable effect on the coagulation cascade and a relatively narrow therapeutic 
window. Additionally, despite the measurement of activated clotting time (ACT) at the time of PCI has been 
advocated to mitigate both ischemic and bleeding events during or soon after intervention, there is limited 
evidence from prospective studies, there is no full agreement on cut-offs to be used and ACT is not routinely 
used to adjust UFH dosing in many centres (Chapter 1.6). Bivalirudin has emerged to be a valid alternative to 
UFH (Chapters 1.1 to 1.8). Despite most recent trials, including MATRIX trial, failed to demonstrate the 
superiority of bivalirudin over UFH in terms of composite ischemic/bleeding endpoints and most recent 
guidelines have slightly downgraded their recommendations on its use in ACS patients, there is large evidence 
from single trials and pooled analyses that bivalirudin use is associated with reduction of bleeding 
complications (Chapter 1.1 and 1.5). While the bleeding benefit observed in previous studies was probably 
attributable to the fact that the comparator group was UFH plus GPI, which notoriously increase the risk of 
bleeding, in the MATRIX trial, bivalirudin significantly reduced bleeding complications, mainly those not 
related to access site, irrespective of planned use of GPI (Chapter 1.5). Yet, the optimal regimen of bivalirudin 
after PCI and whether this differs across ACS with or without ST-segment elevation is unknown, but after 
adjustment, the full post-PCI bivalirudin dose was associated to improved efficacy and safety outcomes when 
compared to the low post-PCI bivalirudin regimen, no post-PCI infusion or unfractionated heparin groups 
(Chapter 1.8). 
 
The use of the radial artery rather than femoral artery reduces access site bleeding and mortality in ACS patients 
undergoing invasive management (Chapters 1.9 to 1.11). These advantages that led to recommend radial 
approach in European guidelines have been observed in studies in which operators were properly trained and 
must have sufficient expertise in both radial and femoral access (Chapter 1.9). Interestingly, women are 
generally characterized by higher risk of severe bleeding and access site complications, and have smaller radial 
arteries that are more prone to spasm as well as shorter aortic roots than men, which adds to the operative 
difficulty and may undermine the efficacy of radial access in this population. However radial access 
demonstrated to be an effective method to reduce these complications as well as composite ischemic and 
ischemic or bleeding endpoints (Chapter 1.10). More importantly, the benefit of radial over femoral access in 
ACS patients undergoing invasive management has been found to be also related to prevention of acute kidney 
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	injury (AKI), indeed, radial access was associated with a reduced risk of AKI compared with FA (Chapter 
1.11). Additionally, AKI is a relevant complication of PCI still today due to both its frequency and negative 
impact on prognosis, and several pharmacologic strategies have been proposed to be used to prevent such 
important complication but there is great debate on the real effectiveness of all of them. Statin administration 
was found to be associated with a marked and consistent reduction in the risk of AKI compared with saline, 
while for other strategies, including xanthine, N-acetylcysteine (NAC), sodium bicarbonate (NaHCO3), 
NAC+NaHCO3, ischemic preconditioning, and natriuretic peptide, although some nephroprotective effects have 
been described, data are not consistent and conclusive to support their use (Chapter 1.17). 
 
In more than 40 years from its birth, PCI has evolved significantly and procedural aspects have played an 
important role in the optimization of outcomes related to this treatment (Chapters 1.12 to 1.16). In-stent 
restenosis has been for years one of the weakness of PCI and the use of more recent strategies, including drug-
coated balloons (DCB) and new generation drug-eluting stents (DES) have been found to provide better efficacy 
compared to older strategies (i.e. plain balloons, bare-metal stents (BMS), brachytherapy, rotational 
atherectomy, and cutting balloons) (Chapter 1.12). DES in particular, have demonstrated to be superior to BMS 
in several settings, also leading PCI to become a valid alternative to CABG characterized by equivalent rates of 
hard endpoints for patients with left main coronary artery disease (Chapter 1.14). Coronary stent selection has 
been traditionally considered a major determinant of post-procedural antithrombotic treatment duration, hence 
impacting bleeding/ischemia balance. Based on preliminary evidence coming from first-generation DES, DES 
have traditionally been considered more thrombogenic leading to the common practice to provide longer DAPT 
treatments to patients treated with DES as compared to BMS. Consequently, patients deemed at high bleeding 
risk, which would not tolerate prolonged DAPT courses, have been more commonly selected for BMS 
implantation, however, current evidence suggests that DES is superior and recommended over BMS in all 
clinical settings irrespective of coronary complexity, operator experience or patient bleeding risk and that a 
short DAPT is plausible and safe with new-generation DES (Chapters 1.15 and 1.16).  
 
In order to optimize PCI outcomes, an adequate platelet inhibition should be obtained and even the optimization 
of the concomitant therapy (i.e. use of proton pump inhibitors in all patients undergoing DAPT to reduce the 
bleeding risk; use of beta-blockers, ACE-inhibitors and ARB in patients with acute myocardial infarction to 
reduce ischemic complications and mortality) has a crucial role (Chapters 2.1 to 2.4). 
Despite the fact that adverse event rate is relatively higher during the first month after the procedure, the vast 
majority of ischemic and bleeding complications occur late after revascularization, and might be modulated by 
adjusting DAPT duration. Therefore, the selection of optimal DAPT duration after PCI has a central role in the 
balance of ischemic/bleeding risk (Chapters 2.5 to 2.17). Longer DAPT duration has been associated with a 
consistent reduction of major adverse cardiovascular events (MACE) and stent thrombosis, but also with an 
increase in major bleeding and a worrisome increase in mortality (Chapter 2.5), which raised concern in the 
community. The large and sometimes contrasting evidence accumulated in the last 25 years in the field of 
DAPT type and duration has generated great debate on the optimal regimen of DAPT to adopt after PCI. What 
we have learned from this huge discussion is that probably we cannot apply a “one-size fits all” approach, rather 
we should shift to a new paradigm of “personalized medicine” able to select the optimal treatment in the 
individual patient.  
 
In last 10-15 years, the optimization of ischemic and bleeding outcomes has been a focus of great interest even 
for patient undergoing TAVI. In few years TAVI has dramatically evolved, devices and procedural techniques 
have rapidly improved and results of randomized clinical trials have revolutionized the current treatment of 
severe aortic stenosis. A large body of evidence has demonstrated that TAVI is non-inferior to SAVR, or even 
superior when performed transfemorally (rather than through transthoracic access) in terms of all-cause 
mortality in high-risk patients as well as patients deemed at low-to-intermediate risk (Chapter 3.4). Yet, 
compared with SAVR, TAVI is associated with similar rates of early stroke, reduces early myocardial 
infarction, AKI, major bleeding, and new-onset atrial fibrillation, while is associated with higher rates of 
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	pacemaker implantation, vascular complications, and paravalvular leak (Chapter 3.4). Effects of TAVI on long-
term mortality and device durability over long time are still unclear and remain the focus of current and future 
studies. Although there are risk scores used in daily practice to help guiding the Heart-Team clinicians in the 
decision-making in patients with severe AS, these scores have important limitations, were mainly generated in 
outdated studies of surgery and cannot account for all risk factors. Many studies have assessed specific risk 
factors trying to identify patients at higher risk of complications and death after TAVI. For example, in large 
TAVI populations a low BMI was linked to a significantly worse prognosis after TAVI, thus suggesting that 
BMI could represent an important and handily tool in the risk prediction of patients to be addressed for TAVI 
(Chapter 3.7). Similarly, pre-procedural renal dysfunction (even moderate CKD) has been found to be one of 
the most frequent comorbidities of TAVI patients and to significantly worsen patients’ prognosis at short and 
long-term follow-up (Chapters 3.8 to 3.10). Another important comorbidity that significantly impacts on TAVI 
patients’ prognosis in atrial fibrillation (AF). Both pre-existing and new onset AF are very frequent and are 
associated with worse prognosis (Chapters 3.5 and 3.6). The presence of this comorbidity or its occurrence, 
often silent, after the procedure also contribute to make complex the decision regarding the optimal 
antithrombotic therapy in patients undergoing TAVI. From one side TAVI patients are exposed to 
ischemic/thrombotic risks (i.e. stroke, transient ischemic attack, myocardial infarction related to possible 
comorbidities such as CAD or leaflet thrombosis), while on the other side they have bleeding risks related to the 
procedure and to the antithrombotic therapy (Chapters 3.1 to 3.3). A DAPT regimen is often recommend, but 
compared with single antiplatelet therapy it has been found to increase bleeding risks without significantly 
prevent thrombotic complications. The use of oral anticoagulation, particularly of novel and safer non-vitamin 
K antagonists, in all patients, irrespective of AF, has been advocated to prevent thrombotic complications of the 
implanted devise, however, to date we have no sufficient evidence for such an approach. Consequently, the 
complex puzzle of the optimal antithrombotic therapy after TAVI remains intriguing but still unsolved. Clinical 
trials are ongoing and their results will hopefully add the missing pieces in this complex puzzle. Thus, as for 
PCI patients, even in TAVI patients the careful risk evaluation and selection of antithrombotic regimen during 
and after the procedure should be individualized based on the factors influencing ischemic and bleeding risks 
and aiming at balancing these risks.  
 
More than 2,400 years ago, Hippocrates, the father of western medicine, recognized the individuality of each 
patient and the importance of adapting treatment accordingly saying that “It is more important to know what 
sort of person has a disease than to know what sort of disease a person has.” Since than, clinicians struggled 
understanding patients’ characteristics that predict a different response to treatment. Adjusting treatment based 
on baseline characteristics, biohumoral or genomic markers is the premise of Precision Medicine, which aims to 
the construction of an evidence-based medical model for customized decision-making based on single patient 
characteristics. In conclusion, choosing between 2 evils (ischemia or bleeding) occurring at similar frequencies 
and carrying comparable prognostic implications is still evil. Personalized treatment algorithms maximizing 
benefits over risks represent the only sensible way forward. 
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In the Greek mythology, the Chimera was a monstrous fire-
breathing hybrid creature of Lycia in Asia Minor, composed of 
the parts of more than one animal (usually depicted as a lion, 
with the head of a goat arising from its back, and a tail of snake). 
Homer's brief description in the Iliad is the earliest surviving 
literary reference. The term Chimera has come to describe any 
mythical or fictional animal with parts taken from various 
animals, or to describe anything composed of very disparate 
parts, or perceived as wildly imaginative, implausible, difficult to 
realize or utopian.  
Bellerophon was the hero who fought and killed the Chimera. When he arrived in Lycia, 
the Chimera was truly ferocious, and he could not harm the monster even while riding on 
Pegasus. He felt the heat of the breath the Chimera expelled, and was struck with an idea. 
He got a large block of lead and mounted it on his spear. Then he flew head-on towards 
the Chimera, holding out the spear as far as he could. Before he broke off his attack, he 
managed to lodge the block of lead inside the Chimera's throat. The beast's firebreath 
melted the lead, and blocked its air passage. The Chimera suffocated, and Bellerophon 
returned victorious to King Iobates.  
Percutaneous cardiovascular interventions are the cornerstone treatment of cardiovascular 
diseases. Antithrombotic therapy during and after these interventions is fundamental to 
prevent ischemic recurrences, but has the risk to increase bleeding complications. To find 
the optimal strategy to prevent ischemia without affecting bleeding in all patients is 
matter of ongoing discussion and research, and probably remains a chimera. Like 
Bellerophon searching for and fighting with the Chimera, clinicians should be aware of 
the trade-off of both bleeding and ischemia and their impact on patients’ health, thus 
searching for the optimal therapy which has not to face with a single animal (ischemia or 
bleeding), rather must account and balance for the effects on both these entities. In such a 
context, personalized medicine characterized by individualization of therapies patient-by-
patient based on the individual risk/benefit profile appears to be a promising approach 
that clinicians might adopt to kill this nightmare. 
	
